{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "14675901-ca51-44d1-a3c0-7ba69622ad8d",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#ANALYSIS OF CLINICAL TRIAL DATA BY PAMELA YUSUF @00646995"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "d2e6e000-45c0-4208-849f-1f60ce6c83b5",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "##DATAFRAME IMPLEMENTATION"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "52892d26-8b55-4b9c-a467-b6970d934301",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Python interpreter will be restarted.\n",
       "Collecting bokeh\n",
       "  Downloading bokeh-2.4.2-py3-none-any.whl (18.5 MB)\n",
       "Collecting PyYAML>=3.10\n",
       "  Downloading PyYAML-6.0-cp38-cp38-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_12_x86_64.manylinux2010_x86_64.whl (701 kB)\n",
       "Requirement already satisfied: pillow>=7.1.0 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (8.2.0)\n",
       "Requirement already satisfied: tornado>=5.1 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (6.1)\n",
       "Collecting typing-extensions>=3.10.0\n",
       "  Downloading typing_extensions-4.2.0-py3-none-any.whl (24 kB)\n",
       "Requirement already satisfied: packaging>=16.8 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (20.9)\n",
       "Requirement already satisfied: numpy>=1.11.3 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (1.20.1)\n",
       "Requirement already satisfied: Jinja2>=2.9 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (2.11.3)\n",
       "Requirement already satisfied: MarkupSafe>=0.23 in /databricks/python3/lib/python3.8/site-packages (from Jinja2>=2.9->bokeh) (2.0.1)\n",
       "Requirement already satisfied: pyparsing>=2.0.2 in /databricks/python3/lib/python3.8/site-packages (from packaging>=16.8->bokeh) (2.4.7)\n",
       "Installing collected packages: typing-extensions, PyYAML, bokeh\n",
       "Successfully installed PyYAML-6.0 bokeh-2.4.2 typing-extensions-4.2.0\n",
       "Python interpreter will be restarted.\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Python interpreter will be restarted.\nCollecting bokeh\n  Downloading bokeh-2.4.2-py3-none-any.whl (18.5 MB)\nCollecting PyYAML>=3.10\n  Downloading PyYAML-6.0-cp38-cp38-manylinux_2_5_x86_64.manylinux1_x86_64.manylinux_2_12_x86_64.manylinux2010_x86_64.whl (701 kB)\nRequirement already satisfied: pillow>=7.1.0 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (8.2.0)\nRequirement already satisfied: tornado>=5.1 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (6.1)\nCollecting typing-extensions>=3.10.0\n  Downloading typing_extensions-4.2.0-py3-none-any.whl (24 kB)\nRequirement already satisfied: packaging>=16.8 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (20.9)\nRequirement already satisfied: numpy>=1.11.3 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (1.20.1)\nRequirement already satisfied: Jinja2>=2.9 in /databricks/python3/lib/python3.8/site-packages (from bokeh) (2.11.3)\nRequirement already satisfied: MarkupSafe>=0.23 in /databricks/python3/lib/python3.8/site-packages (from Jinja2>=2.9->bokeh) (2.0.1)\nRequirement already satisfied: pyparsing>=2.0.2 in /databricks/python3/lib/python3.8/site-packages (from packaging>=16.8->bokeh) (2.4.7)\nInstalling collected packages: typing-extensions, PyYAML, bokeh\nSuccessfully installed PyYAML-6.0 bokeh-2.4.2 typing-extensions-4.2.0\nPython interpreter will be restarted.\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#installing necessary visualization software\n",
    "%pip install bokeh"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "ec122bd6-ce12-44a2-aab8-0edadce8bd12",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Python interpreter will be restarted.\n",
       "Collecting wordcloud\n",
       "  Downloading wordcloud-1.8.1-cp38-cp38-manylinux1_x86_64.whl (371 kB)\n",
       "Requirement already satisfied: numpy>=1.6.1 in /databricks/python3/lib/python3.8/site-packages (from wordcloud) (1.20.1)\n",
       "Requirement already satisfied: pillow in /databricks/python3/lib/python3.8/site-packages (from wordcloud) (8.2.0)\n",
       "Requirement already satisfied: matplotlib in /databricks/python3/lib/python3.8/site-packages (from wordcloud) (3.4.2)\n",
       "Requirement already satisfied: kiwisolver>=1.0.1 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (1.3.1)\n",
       "Requirement already satisfied: cycler>=0.10 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (0.10.0)\n",
       "Requirement already satisfied: pyparsing>=2.2.1 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (2.4.7)\n",
       "Requirement already satisfied: python-dateutil>=2.7 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (2.8.1)\n",
       "Requirement already satisfied: six in /databricks/python3/lib/python3.8/site-packages (from cycler>=0.10->matplotlib->wordcloud) (1.15.0)\n",
       "Installing collected packages: wordcloud\n",
       "Successfully installed wordcloud-1.8.1\n",
       "Python interpreter will be restarted.\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Python interpreter will be restarted.\nCollecting wordcloud\n  Downloading wordcloud-1.8.1-cp38-cp38-manylinux1_x86_64.whl (371 kB)\nRequirement already satisfied: numpy>=1.6.1 in /databricks/python3/lib/python3.8/site-packages (from wordcloud) (1.20.1)\nRequirement already satisfied: pillow in /databricks/python3/lib/python3.8/site-packages (from wordcloud) (8.2.0)\nRequirement already satisfied: matplotlib in /databricks/python3/lib/python3.8/site-packages (from wordcloud) (3.4.2)\nRequirement already satisfied: kiwisolver>=1.0.1 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (1.3.1)\nRequirement already satisfied: cycler>=0.10 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (0.10.0)\nRequirement already satisfied: pyparsing>=2.2.1 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (2.4.7)\nRequirement already satisfied: python-dateutil>=2.7 in /databricks/python3/lib/python3.8/site-packages (from matplotlib->wordcloud) (2.8.1)\nRequirement already satisfied: six in /databricks/python3/lib/python3.8/site-packages (from cycler>=0.10->matplotlib->wordcloud) (1.15.0)\nInstalling collected packages: wordcloud\nSuccessfully installed wordcloud-1.8.1\nPython interpreter will be restarted.\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "%pip install wordcloud"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "206781ed-89fc-4fd2-acb6-6065c85bdb27",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[1]: [FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1647902342000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1651321833000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1651321813000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1651321741000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/devicestatus-1.txt', name='devicestatus-1.txt', size=64124001, modificationTime=1645542732000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/devicestatus.zip', name='devicestatus.zip', size=23873574, modificationTime=1645537804000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/json_activations-1.zip', name='json_activations-1.zip', size=8411369, modificationTime=1645473471000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/json_activations.zip', name='json_activations.zip', size=8411369, modificationTime=1645012412000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/letter_frequencies.txt', name='letter_frequencies.txt', size=2637452, modificationTime=1646061097000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1645028419000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1651320830000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1651320835000),\n",
       " FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1646219298000)]"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[1]: [FileInfo(path='dbfs:/FileStore/tables/accounts.zip', name='accounts.zip', size=5297592, modificationTime=1647902342000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2019.csv', name='clinicaltrial_2019.csv', size=42400056, modificationTime=1651321833000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2020.csv', name='clinicaltrial_2020.csv', size=46318151, modificationTime=1651321813000),\n FileInfo(path='dbfs:/FileStore/tables/clinicaltrial_2021.csv', name='clinicaltrial_2021.csv', size=50359696, modificationTime=1651321741000),\n FileInfo(path='dbfs:/FileStore/tables/devicestatus-1.txt', name='devicestatus-1.txt', size=64124001, modificationTime=1645542732000),\n FileInfo(path='dbfs:/FileStore/tables/devicestatus.zip', name='devicestatus.zip', size=23873574, modificationTime=1645537804000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations-1.zip', name='json_activations-1.zip', size=8411369, modificationTime=1645473471000),\n FileInfo(path='dbfs:/FileStore/tables/json_activations.zip', name='json_activations.zip', size=8411369, modificationTime=1645012412000),\n FileInfo(path='dbfs:/FileStore/tables/letter_frequencies.txt', name='letter_frequencies.txt', size=2637452, modificationTime=1646061097000),\n FileInfo(path='dbfs:/FileStore/tables/logs.zip', name='logs.zip', size=18168065, modificationTime=1645028419000),\n FileInfo(path='dbfs:/FileStore/tables/mesh.csv', name='mesh.csv', size=5295548, modificationTime=1651320830000),\n FileInfo(path='dbfs:/FileStore/tables/pharma.csv', name='pharma.csv', size=678999, modificationTime=1651320835000),\n FileInfo(path='dbfs:/FileStore/tables/webpage.zip', name='webpage.zip', size=1582, modificationTime=1646219298000)]",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Confirming that files were unzipped and copied successfully\n",
    "dbutils.fs.ls(\"FileStore/tables\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "3e89a9bc-ab13-4f36-a1c7-876e09b61db4",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "####Loading the Clinical Trial Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "a32053e0-a796-4fd1-aab0-58fb025f0d1e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "year = 2021"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "f3d8d0bc-1f3f-4c6c-8501-ad92ffca3dd7",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "# storing the clinial trial data in a variable to aid reusability \n",
    "clinical_filepath = \"/FileStore/tables/clinicaltrial_\"+ str(year) + \".csv\""
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "59ec4335-dda6-493a-a3f5-57843567189a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Truncated to first 65536 bytes]\n",
       "Out[4]: \"Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\\r\\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\\r\\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\\r\\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\\r\\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\\r\\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\\r\\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\\r\\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\\r\\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\\r\\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\\r\\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\\r\\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\\r\\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\\r\\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\\r\\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\\r\\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\\r\\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\\r\\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\\r\\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\\r\\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\\r\\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\\r\\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\\r\\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\\r\\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\\r\\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\\r\\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\\r\\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\\r\\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\\r\\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\\r\\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\\r\\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\\r\\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\\r\\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\\r\\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\\r\\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\\r\\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\\r\\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\\r\\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\\r\\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\\r\\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\\r\\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\\r\\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\\r\\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\\r\\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\\r\\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\\r\\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\\r\\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\\r\\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\\r\\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\\r\\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\\r\\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\\r\\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\\r\\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\\r\\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\\r\\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\\r\\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\\r\\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\\r\\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\\r\\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\\r\\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\\r\\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\\r\\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\\r\\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\\r\\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\\r\\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\\r\\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\\r\\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\\r\\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\\r\\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\\r\\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\\r\\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\\r\\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\\r\\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\\r\\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\\r\\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\\r\\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\\r\\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\\r\\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\\r\\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\\r\\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\\r\\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\\r\\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\\r\\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\\r\\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\\r\\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\\r\\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\\r\\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\\r\\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\\r\\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\\r\\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\\r\\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\\r\\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\\r\\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\\r\\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\\r\\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\\r\\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\\r\\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\\r\\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\\r\\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\\r\\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\\r\\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\\r\\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\\r\\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\\r\\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\\r\\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\\r\\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\\r\\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\\r\\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\\r\\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\\r\\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\\r\\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\\r\\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\\r\\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\\r\\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\\r\\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\\r\\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\\r\\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\\r\\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\\r\\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\\r\\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\\r\\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\\r\\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\\r\\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\\r\\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\\r\\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\\r\\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\\r\\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\\r\\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\\r\\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\\r\\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\\r\\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\\r\\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\\r\\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\\r\\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\\r\\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\\r\\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\\r\\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\\r\\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\\r\\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\\r\\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\\r\\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\\r\\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\\r\\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\\r\\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\\r\\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\\r\\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\\r\\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\\r\\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\\r\\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\\r\\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\\r\\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\\r\\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\\r\\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\\r\\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\\r\\nNCT02757170|All India In\n",
       "\n",
       "*** WARNING: max output size exceeded, skipping output. ***\n",
       "\n",
       "ional|Apr 2016||\\r\\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\\r\\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\\r\\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\\r\\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\\r\\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\\r\\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\\r\\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\\r\\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\\r\\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\\r\\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\\r\\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\\r\\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\\r\\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\\r\\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\\r\\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\\r\\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\\r\\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\\r\\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\\r\\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\\r\\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\\r\\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\\r\\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\\r\\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\\r\\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\\r\\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\\r\\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\\r\\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\\r\\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\\r\\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\\r\\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\\r\\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\\r\\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\\r\\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\\r\\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\\r\\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\\r\\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\\r\\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\\r\\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\\r\\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\\r\\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\\r\\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\\r\\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\\r\\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\\r\\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\\r\\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\\r\\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\\r\\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\\r\\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\\r\\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\\r\\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\\r\\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\\r\\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\\r\\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\\r\\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\\r\\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\\r\\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\\r\\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\\r\\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\\r\\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\\r\\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\\r\\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\\r\\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\\r\\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\\r\\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\\r\\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\\r\\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\\r\\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\\r\\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\\r\\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\\r\\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\\r\\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\\r\\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\\r\\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\\r\\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\\r\\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\\r\\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\\r\\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\\r\\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\\r\\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\\r\\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\\r\\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\\r\\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\\r\\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\\r\\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\\r\\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\\r\\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\\r\\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\\r\\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\\r\\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\\r\\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\\r\\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\\r\\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\\r\\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\\r\\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\\r\\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\\r\\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\\r\\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\\r\\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\\r\\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\\r\\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\\r\\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\\r\\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\\r\\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\\r\\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\\r\\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\\r\\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\\r\\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\\r\\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\\r\\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\\r\\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\\r\\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\\r\\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\\r\\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\\r\\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\\r\\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\\r\\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\\r\\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\\r\\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\\r\\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\\r\\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\\r\\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\\r\\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\\r\\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\\r\\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\\r\\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\\r\\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\\r\\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\\r\\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\\r\\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\\r\\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\\r\\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\\r\\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\\r\\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\\r\\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\\r\\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\\r\\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\\r\\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\\r\\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\\r\\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\\r\\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\\r\\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\\r\\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\\r\\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\\r\\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\\r\\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\\r\\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\\r\\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\\r\\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\\r\\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\\r\\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\\r\\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\\r\\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\\r\\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\\r\\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\\r\\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\\r\\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\\r\\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\""
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "[Truncated to first 65536 bytes]\nOut[4]: \"Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\\r\\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\\r\\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\\r\\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\\r\\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\\r\\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\\r\\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\\r\\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\\r\\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\\r\\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\\r\\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\\r\\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\\r\\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\\r\\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\\r\\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\\r\\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\\r\\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\\r\\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\\r\\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\\r\\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\\r\\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\\r\\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\\r\\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\\r\\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\\r\\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\\r\\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\\r\\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\\r\\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\\r\\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\\r\\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\\r\\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\\r\\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\\r\\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\\r\\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\\r\\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\\r\\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\\r\\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\\r\\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\\r\\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\\r\\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\\r\\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\\r\\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\\r\\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\\r\\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\\r\\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\\r\\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\\r\\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\\r\\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\\r\\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\\r\\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\\r\\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\\r\\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\\r\\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\\r\\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\\r\\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\\r\\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\\r\\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\\r\\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\\r\\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\\r\\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\\r\\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\\r\\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\\r\\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\\r\\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\\r\\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\\r\\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\\r\\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\\r\\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\\r\\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\\r\\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\\r\\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\\r\\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\\r\\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\\r\\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\\r\\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\\r\\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\\r\\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\\r\\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\\r\\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\\r\\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\\r\\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\\r\\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\\r\\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\\r\\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\\r\\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\\r\\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\\r\\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\\r\\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\\r\\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\\r\\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\\r\\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\\r\\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\\r\\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\\r\\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\\r\\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\\r\\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\\r\\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\\r\\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\\r\\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\\r\\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\\r\\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\\r\\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\\r\\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\\r\\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\\r\\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\\r\\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\\r\\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\\r\\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\\r\\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\\r\\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\\r\\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\\r\\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\\r\\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\\r\\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\\r\\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\\r\\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\\r\\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\\r\\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\\r\\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\\r\\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\\r\\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\\r\\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\\r\\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\\r\\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\\r\\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\\r\\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\\r\\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\\r\\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\\r\\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\\r\\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\\r\\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\\r\\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\\r\\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\\r\\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\\r\\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\\r\\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\\r\\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\\r\\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\\r\\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\\r\\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\\r\\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\\r\\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\\r\\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\\r\\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\\r\\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\\r\\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\\r\\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\\r\\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\\r\\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\\r\\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\\r\\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\\r\\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\\r\\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\\r\\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\\r\\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\\r\\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\\r\\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\\r\\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\\r\\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\\r\\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\\r\\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\\r\\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\\r\\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\\r\\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\\r\\nNCT02757170|All India In\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nional|Apr 2016||\\r\\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\\r\\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\\r\\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\\r\\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\\r\\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\\r\\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\\r\\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\\r\\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\\r\\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\\r\\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\\r\\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\\r\\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\\r\\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\\r\\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\\r\\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\\r\\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\\r\\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\\r\\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\\r\\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\\r\\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\\r\\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\\r\\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\\r\\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\\r\\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\\r\\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\\r\\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\\r\\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\\r\\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\\r\\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\\r\\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\\r\\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\\r\\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\\r\\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\\r\\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\\r\\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\\r\\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\\r\\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\\r\\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\\r\\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\\r\\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\\r\\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\\r\\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\\r\\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\\r\\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\\r\\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\\r\\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\\r\\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\\r\\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\\r\\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\\r\\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\\r\\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\\r\\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\\r\\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\\r\\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\\r\\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\\r\\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\\r\\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\\r\\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\\r\\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\\r\\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\\r\\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\\r\\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\\r\\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\\r\\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\\r\\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\\r\\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\\r\\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\\r\\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\\r\\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\\r\\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\\r\\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\\r\\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\\r\\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\\r\\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\\r\\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\\r\\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\\r\\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\\r\\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\\r\\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\\r\\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\\r\\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\\r\\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\\r\\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\\r\\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\\r\\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\\r\\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\\r\\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\\r\\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\\r\\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\\r\\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\\r\\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\\r\\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\\r\\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\\r\\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\\r\\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\\r\\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\\r\\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\\r\\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\\r\\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\\r\\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\\r\\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\\r\\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\\r\\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\\r\\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\\r\\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\\r\\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\\r\\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\\r\\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\\r\\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\\r\\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\\r\\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\\r\\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\\r\\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\\r\\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\\r\\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\\r\\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\\r\\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\\r\\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\\r\\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\\r\\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\\r\\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\\r\\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\\r\\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\\r\\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\\r\\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\\r\\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\\r\\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\\r\\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\\r\\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\\r\\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\\r\\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\\r\\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\\r\\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\\r\\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\\r\\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\\r\\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\\r\\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\\r\\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\\r\\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\\r\\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\\r\\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\\r\\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\\r\\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\\r\\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\\r\\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\\r\\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\\r\\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\\r\\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\\r\\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\\r\\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\\r\\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\\r\\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\\r\\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\\r\\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\\r\\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\\r\\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\\r\\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\\r\\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\\r\\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\\r\\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\\r\\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\\r\\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\\r\\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\\r\\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\\r\\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\\r\\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\\r\\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\\r\\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\\r\\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\\r\\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\\r\\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\\r\\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\\r\\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\\r\\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\\r\\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\\r\\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\\r\\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\\r\\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\\r\\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\\r\\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\\r\\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\"",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#viewing the first few lines of the file\n",
    "dbutils.fs.head(clinical_filepath)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "3729814e-332c-4b93-993e-bea11d673666",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Truncated to first 65536 bytes]\n",
       "Id|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\n",
       "NCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\n",
       "NCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\n",
       "NCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\n",
       "NCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\n",
       "NCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\n",
       "NCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\n",
       "NCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\n",
       "NCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\n",
       "NCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\n",
       "NCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\n",
       "NCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\n",
       "NCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\n",
       "NCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\n",
       "NCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\n",
       "NCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\n",
       "NCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\n",
       "NCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\n",
       "NCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\n",
       "NCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\n",
       "NCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\n",
       "NCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\n",
       "NCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\n",
       "NCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\n",
       "NCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\n",
       "NCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\n",
       "NCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\n",
       "NCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\n",
       "NCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\n",
       "NCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\n",
       "NCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\n",
       "NCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\n",
       "NCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\n",
       "NCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\n",
       "NCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\n",
       "NCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\n",
       "NCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\n",
       "NCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\n",
       "NCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\n",
       "NCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\n",
       "NCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\n",
       "NCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\n",
       "NCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\n",
       "NCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\n",
       "NCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\n",
       "NCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\n",
       "NCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\n",
       "NCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\n",
       "NCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\n",
       "NCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\n",
       "NCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\n",
       "NCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\n",
       "NCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\n",
       "NCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\n",
       "NCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\n",
       "NCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\n",
       "NCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\n",
       "NCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\n",
       "NCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\n",
       "NCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\n",
       "NCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\n",
       "NCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\n",
       "NCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\n",
       "NCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\n",
       "NCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\n",
       "NCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\n",
       "NCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\n",
       "NCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\n",
       "NCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\n",
       "NCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\n",
       "NCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\n",
       "NCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\n",
       "NCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\n",
       "NCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\n",
       "NCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\n",
       "NCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\n",
       "NCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\n",
       "NCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\n",
       "NCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\n",
       "NCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\n",
       "NCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\n",
       "NCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\n",
       "NCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\n",
       "NCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\n",
       "NCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\n",
       "NCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\n",
       "NCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\n",
       "NCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\n",
       "NCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\n",
       "NCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\n",
       "NCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\n",
       "NCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\n",
       "NCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\n",
       "NCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\n",
       "NCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\n",
       "NCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\n",
       "NCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\n",
       "NCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\n",
       "NCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\n",
       "NCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\n",
       "NCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\n",
       "NCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\n",
       "NCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\n",
       "NCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\n",
       "NCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\n",
       "NCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\n",
       "NCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\n",
       "NCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\n",
       "NCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\n",
       "NCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\n",
       "NCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\n",
       "NCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\n",
       "NCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\n",
       "NCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\n",
       "NCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\n",
       "NCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\n",
       "NCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\n",
       "NCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\n",
       "NCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\n",
       "NCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\n",
       "NCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\n",
       "NCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\n",
       "NCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\n",
       "NCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\n",
       "NCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\n",
       "NCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\n",
       "NCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\n",
       "NCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\n",
       "NCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\n",
       "NCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\n",
       "NCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\n",
       "NCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\n",
       "NCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\n",
       "NCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\n",
       "NCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\n",
       "NCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\n",
       "NCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\n",
       "NCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\n",
       "NCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\n",
       "NCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\n",
       "NCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\n",
       "NCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\n",
       "NCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\n",
       "NCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\n",
       "NCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\n",
       "NCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\n",
       "NCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\n",
       "NCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\n",
       "NCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\n",
       "NCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\n",
       "NCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\n",
       "NCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\n",
       "NCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\n",
       "NCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\n",
       "NCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\n",
       "NCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\n",
       "NCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\n",
       "NCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\n",
       "NCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\n",
       "NCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\n",
       "NCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\n",
       "NCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\n",
       "NCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\n",
       "NCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\n",
       "NCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\n",
       "NCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\n",
       "NCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\n",
       "NCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\n",
       "NCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\n",
       "NCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\n",
       "NCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\n",
       "NCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\n",
       "NCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\n",
       "NCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\n",
       "NCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\n",
       "NCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\n",
       "NCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\n",
       "NCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\n",
       "NCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\n",
       "NCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\n",
       "NCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\n",
       "NCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\n",
       "NCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\n",
       "NCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\n",
       "NCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\n",
       "NCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\n",
       "NCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\n",
       "NCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\n",
       "NCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\n",
       "NCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\n",
       "NCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\n",
       "NCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\n",
       "NCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\n",
       "NCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\n",
       "NCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\n",
       "NCT02757170|All India Institute of Medical Sciences, New Delhi|Unknown status|Jul 2015|Jul 2016|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency,End Stage Liver Disease,Acute-On-Chronic Liver Failure|\n",
       "NCT02757625|Pfizer|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Dexmedetomidine\n",
       "NCT02752347|Riyadh Colleges of Dentistry and Pharmacy|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Malocclusion|\n",
       "NCT02756468|University of Roma La Sapienza|Unknown status|Jan 2015|Dec 2016|Observational [Patient Registry]|Apr 2016|Pancreatic Neoplasms|\n",
       "NCT02750410|Eli Lilly and Company|Completed|Aug 2016|\n",
       "\n",
       "*** WARNING: max output size exceeded, skipping output. ***\n",
       "\n",
       "st Neoplasms|\n",
       "NCT02758990|Verifomics LLC|Terminated|Mar 2016|Nov 2016|Interventional|Apr 2016|Rhinitis,Arthralgia,Dyspnea,Sleep Deprivation,Migraine Disorders,Sleep Initiation and Maintenance Disorders,Disease,Headache,Respiratory Sounds|Vitamin D,Cholecalciferol,Vitamins,Ascorbic Acid,Vitamin E,Tocopherols,Vitamin A,Niacinamide,Niacin,Nicotinic Acids,Pyridoxine,Pyridoxal,Vitamin B 6,Caffeine\n",
       "NCT02754193|Central Hospital, Nancy, France|Completed|Oct 2016|Nov 2019|Interventional|Apr 2016|Shock,Hypothermia|\n",
       "NCT02758613|Eli Lilly and Company|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\n",
       "NCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\n",
       "NCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\n",
       "NCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\n",
       "NCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\n",
       "NCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\n",
       "NCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\n",
       "NCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\n",
       "NCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\n",
       "NCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\n",
       "NCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\n",
       "NCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\n",
       "NCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\n",
       "NCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\n",
       "NCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\n",
       "NCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\n",
       "NCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\n",
       "NCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\n",
       "NCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\n",
       "NCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\n",
       "NCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\n",
       "NCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\n",
       "NCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\n",
       "NCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\n",
       "NCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\n",
       "NCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\n",
       "NCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\n",
       "NCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\n",
       "NCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\n",
       "NCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\n",
       "NCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\n",
       "NCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\n",
       "NCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\n",
       "NCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\n",
       "NCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\n",
       "NCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\n",
       "NCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\n",
       "NCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\n",
       "NCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\n",
       "NCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\n",
       "NCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\n",
       "NCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\n",
       "NCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\n",
       "NCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\n",
       "NCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\n",
       "NCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\n",
       "NCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\n",
       "NCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\n",
       "NCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\n",
       "NCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\n",
       "NCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\n",
       "NCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\n",
       "NCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\n",
       "NCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\n",
       "NCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\n",
       "NCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\n",
       "NCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\n",
       "NCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\n",
       "NCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\n",
       "NCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\n",
       "NCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\n",
       "NCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\n",
       "NCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\n",
       "NCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\n",
       "NCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\n",
       "NCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\n",
       "NCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\n",
       "NCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\n",
       "NCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\n",
       "NCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\n",
       "NCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\n",
       "NCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\n",
       "NCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\n",
       "NCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\n",
       "NCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\n",
       "NCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\n",
       "NCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\n",
       "NCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\n",
       "NCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\n",
       "NCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\n",
       "NCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\n",
       "NCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\n",
       "NCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\n",
       "NCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\n",
       "NCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\n",
       "NCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\n",
       "NCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\n",
       "NCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\n",
       "NCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\n",
       "NCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\n",
       "NCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\n",
       "NCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\n",
       "NCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\n",
       "NCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\n",
       "NCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\n",
       "NCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\n",
       "NCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\n",
       "NCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\n",
       "NCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\n",
       "NCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\n",
       "NCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\n",
       "NCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\n",
       "NCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\n",
       "NCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\n",
       "NCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\n",
       "NCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\n",
       "NCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\n",
       "NCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\n",
       "NCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\n",
       "NCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\n",
       "NCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\n",
       "NCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\n",
       "NCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\n",
       "NCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\n",
       "NCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\n",
       "NCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\n",
       "NCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\n",
       "NCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\n",
       "NCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\n",
       "NCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\n",
       "NCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\n",
       "NCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\n",
       "NCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\n",
       "NCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\n",
       "NCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\n",
       "NCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\n",
       "NCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\n",
       "NCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\n",
       "NCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\n",
       "NCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\n",
       "NCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\n",
       "NCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\n",
       "NCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\n",
       "NCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\n",
       "NCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\n",
       "NCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\n",
       "NCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\n",
       "NCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\n",
       "NCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\n",
       "NCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\n",
       "NCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\n",
       "NCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\n",
       "NCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\n",
       "NCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\n",
       "NCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\n",
       "NCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\n",
       "NCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\n",
       "NCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\n",
       "NCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\n",
       "NCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\n",
       "NCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\n",
       "NCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\n",
       "NCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\n",
       "NCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\n",
       "NCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\n",
       "NCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\n",
       "NCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\n",
       "NCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\n",
       "NCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\n",
       "NCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\n",
       "NCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\n",
       "NCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\n",
       "NCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\n",
       "NCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\n",
       "NCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\n",
       "NCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\n",
       "NCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\n",
       "NCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\n",
       "NCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\n",
       "NCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\n",
       "NCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\n",
       "NCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\n",
       "NCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\n",
       "NCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\n",
       "NCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\n",
       "NCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\n",
       "NCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\n",
       "NCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\n",
       "NCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\n",
       "NCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\n",
       "NCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\n",
       "NCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\n",
       "NCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\n",
       "NCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\n",
       "NCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\n",
       "NCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\n",
       "NCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\n",
       "NCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\n",
       "NCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\n",
       "NCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\n",
       "NCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\n",
       "NCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\n",
       "NCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\n",
       "NCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\n",
       "NCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "[Truncated to first 65536 bytes]\nId|Sponsor|Status|Start|Completion|Type|Submission|Conditions|Interventions\nNCT02758028|The University of Hong Kong|Recruiting|Aug 2005|Nov 2021|Interventional|Apr 2016||\nNCT02751957|Duke University|Completed|Jul 2016|Jul 2020|Interventional|Apr 2016|Autistic Disorder,Autism Spectrum Disorder|\nNCT02758483|Universidade Federal do Rio de Janeiro|Completed|Mar 2017|Jan 2018|Interventional|Apr 2016|Diabetes Mellitus|\nNCT02759848|Istanbul Medeniyet University|Completed|Jan 2012|Dec 2014|Observational|May 2016|Tuberculosis,Lung Diseases,Pulmonary Disease|\nNCT02758860|University of Roma La Sapienza|Active, not recruiting|Jun 2016|Sep 2020|Observational [Patient Registry]|Apr 2016|Diverticular Diseases,Diverticulum,Diverticulosis|\nNCT02757209|Consorzio Futuro in Ricerca|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate\nNCT02752438|Ankara University|Unknown status|May 2016|Jul 2017|Observational [Patient Registry]|Apr 2016|Hypoventilation|\nNCT02753543|Ruijin Hospital|Unknown status|Nov 2015|Nov 2019|Interventional|Apr 2016|Lymphoma|\nNCT02757508|Washington University School of Medicine|Completed|Mar 2016|Jul 2017|Interventional|Apr 2016||Vitamins\nNCT02753530|Orphazyme|Completed|Aug 2017|Jan 2021|Interventional|Apr 2016|Myositis|\nNCT02754817|Novo Nordisk A/S|Completed|Apr 2016|Oct 2016|Observational|Apr 2016|Diabetes Mellitus|Liraglutide,Xultophy\nNCT02759276|Daniel Alexandre Bottino|Completed|May 2015|Dec 2015|Observational|Apr 2016|Hypertension|\nNCT02750956|Bulent Ecevit University|Completed|Jun 2015|Mar 2016|Observational|Apr 2016|Periodontal Diseases|\nNCT02752113|Institut für Pharmakologie und Präventive Medizin|Completed|Apr 2016|May 2019|Interventional|Apr 2016|Diabetes Mellitus|Metformin,Empagliflozin,Linagliptin\nNCT02752698|The Third Xiangya Hospital of Central South University|Active, not recruiting|Jan 2015|Dec 2021|Interventional|Jun 2015|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones|\nNCT02755779|Tel Aviv Medical Center|Unknown status|Jun 2016|Jun 2017|Observational|Apr 2016||\nNCT02750384|Medicines for Malaria Venture|Terminated|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02754609|James Cook University, Queensland, Australia|Completed|Sep 2016|Oct 2019|Interventional|Apr 2016|Hookworm Infections,Celiac Disease|\nNCT02755701|Soonchunhyang University Hospital|Unknown status|Jul 2016|Dec 2018|Interventional|Apr 2016|Ascites|\nNCT02751762|Member Companies of the Opioid PMR Consortium|Recruiting|Nov 2017|Oct 2022|Observational|Apr 2016|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\nNCT02756299|Marmara University|Completed|Jun 2014|Apr 2015|Interventional|Apr 2016|Sleep Apnea Syndromes,Sleep Apnea|\nNCT02750709|Cycle Pharmaceuticals Ltd.|Completed|Oct 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\nNCT02753907|Yonsei University|Completed|Jun 2015||Interventional|Apr 2016||\nNCT02755467|Cutera Inc.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Hemangioma|\nNCT02755298|University of Zurich|Completed|Oct 2016|Nov 2020|Interventional|Mar 2016|Hypertension|Acetazolamide\nNCT02759614|Guangdong Association of Clinical Trials|Unknown status|Apr 2016|Jun 2019|Interventional|Mar 2016|Carcinoma|Bevacizumab,Erlotinib Hydrochloride\nNCT02752815|Ruijin Hospital|Unknown status|Apr 2016|Jun 2020|Interventional|Apr 2016|Lymphoma|Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin\nNCT02757131|The Cleveland Clinic|Completed|Jul 2016|Jul 2017|Interventional|Apr 2016|Iatrogenic Disease|\nNCT02758704|St. Justine's Hospital|Completed|Oct 2015|Jun 2021|Interventional|Apr 2016||\nNCT02750501|Alcresta Therapeutics, Inc.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\nNCT02759913|Iron Horse Diagnostics, Inc.|Unknown status|Jan 2015|Dec 2016|Observational|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\nNCT02752724|VA Puget Sound Health Care System|Completed|Mar 2016|Apr 2018|Interventional|Mar 2016|Depressive Disorder,Depression|Ketamine,Methohexital\nNCT02758444|University of Colorado, Denver|Completed|Nov 2015|Feb 2019|Interventional|Apr 2016||Micronutrients,Trace Elements\nNCT02758067|H. Lundbeck A/S|Withdrawn|Jun 2016||Interventional|Apr 2016|Schizophrenia|Risperidone,Brexpiprazole\nNCT02759341|Ospedale San Giovanni Bellinzona|Completed|Feb 2016|Nov 2017|Interventional|Apr 2016|Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction|\nNCT02753803|Dong-A ST Co., Ltd.|Completed|Jul 2016|Mar 2017|Interventional|Apr 2016||Pioglitazone\nNCT02752490|The University of Texas Health Science Center, Houston|Completed|Apr 2016|Jul 2016|Interventional|Apr 2016||\nNCT02759562|Gilead Sciences|Terminated|Nov 2016|Jul 2017|Interventional|Apr 2016|Cystic Fibrosis,Fibrosis|\nNCT02758262|Laval University|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Hyperphagia|\nNCT02754258|Children's Hospital of Eastern Ontario|Unknown status|Jan 2017|Dec 2018|Interventional|Apr 2016||Methylphenidate\nNCT02755207|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Apr 2016|Dec 2020|Observational|Mar 2016|Acute Coronary Syndrome,Syndrome|\nNCT02759900|The Skin Center Dermatology Group|Recruiting|Jan 2016|Jan 2023|Interventional|Apr 2016|Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases|\nNCT02752581|Mert Özcan|Completed|Jan 2009|Apr 2013|Interventional|Apr 2016|Hemarthrosis|\nNCT02759796|Instituto de Investigación Hospital Universitario La Paz|Completed|Nov 2015|Apr 2017|Interventional|Apr 2016|Necrosis,Neovascularization,Fat Necrosis|\nNCT02754063|University Hospital, Grenoble|Active, not recruiting|Jun 2016|Apr 2022|Interventional|Apr 2016|Brain Injuries,Wounds and Injuries|3\nNCT02750917|Foisor Orthopedics Clinical Hospital|Completed|Sep 2014|Mar 2015|Interventional|Feb 2016|Pain|Etoricoxib,Lornoxicam\nNCT02753569|Institute of Cancer Research, United Kingdom|Completed|May 2016|May 2020|Observational|Apr 2016||\nNCT02751255|VU University Medical Center|Active, not recruiting|Jul 2016|Mar 2022|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Tretinoin\nNCT02751528|NantBioScience, Inc.|Unknown status|Dec 2016|Dec 2020|Interventional|Apr 2016|Breast Neoplasms|Vaccines\nNCT02751619|University of Campania Luigi Vanvitelli|Completed|Jan 2013|Dec 2015|Interventional|Apr 2016|Pain|Lidocaine\nNCT02757833|Lawson Health Research Institute|Withdrawn|Feb 2019|Feb 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\nNCT02750761|Merck Sharp & Dohme Corp.|Completed|May 2016|Dec 2018|Interventional|Apr 2016|Infections,Bacterial Infections,Gram-Positive Bacterial Infections|Tedizolid phosphate,Tedizolid,Oxazolidinones\nNCT02752594|Sharda University|Completed|Apr 2015|Apr 2015|Interventional|Apr 2016|Dental Caries|\nNCT02753452|Holland Bloorview Kids Rehabilitation Hospital|Unknown status|May 2015|Mar 2020|Interventional|Apr 2016||\nNCT02752763|Niğde State Hospital|Completed|Oct 2015|Mar 2016|Interventional|Mar 2016|Dry Eye Syndromes,Keratoconjunctivitis Sicca|Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops\nNCT02753816|Spectrum Health Hospitals|Terminated|Apr 2016|Dec 2019|Interventional|Apr 2016|Burns|Tranexamic Acid\nNCT02751294|GlaxoSmithKline|Completed|May 2016|Aug 2016|Interventional|Apr 2016|Malaria|Tafenoquine\nNCT02756429|Hospices Civils de Lyon|Completed|Feb 2014|Jan 2018|Interventional|Apr 2016|Atrial Fibrillation|\nNCT02750163|Università Politecnica delle Marche|Completed|Jul 2017|Jun 2019|Observational|Apr 2016|Shock|Acetaminophen\nNCT02751905|Biogen|Completed|Apr 2016|May 2016|Interventional|Apr 2016|Neuralgia|\nNCT02753153|University of Liege|Completed|May 2011|May 2015|Interventional|Apr 2016|Tooth Loss|\nNCT02750891|Sumitomo Dainippon Pharma Co., Ltd.|Completed|Apr 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma|\nNCT02751073|Mayo Clinic|Completed|Feb 2016|Jul 2018|Observational|Feb 2016|Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse|\nNCT02753114|University of British Columbia|Completed|Nov 2017|May 2018|Interventional|Apr 2016|Acute Pain|Ketamine\nNCT02752516|Chia Tai Tianqing Pharmaceutical Group Co., Ltd.|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016||\nNCT02752269|Medical University of Graz|Completed|Oct 2014|Jun 2019|Observational|Nov 2015|Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome|\nNCT02754713|Hippocration General Hospital|Recruiting|Sep 2009|Dec 2025|Observational|Apr 2016|Pericarditis|\nNCT02759770|Beijing Anzhen Hospital|Completed|Jul 2017|Sep 2017|Observational|Apr 2016|Respiratory Distress Syndrome,Acute Lung Injury|\nNCT02755129|Medtronic BRC|Completed|Sep 2016|Jul 2017|Interventional|Mar 2016|Frailty|\nNCT02754674|Samsung Medical Center|Completed|May 2014|Dec 2017|Interventional|Feb 2015|Rupture|\nNCT02757521|Washington University School of Medicine|Terminated|Mar 2016|Dec 2016|Interventional|Apr 2016|Disease,Depression,Depressive Disorder,Bipolar Disorder|Nitrous Oxide\nNCT02750774|University of Modena and Reggio Emilia|Unknown status|Dec 2015|Dec 2016|Interventional|Apr 2016|Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight|\nNCT02754739|Samsung Medical Center|Completed|Apr 2014|Aug 2017|Interventional|Apr 2016|Diabetes Mellitus,Prediabetic State|Pravastatin\nNCT02758808|University of Michigan|Recruiting|Mar 2016|Oct 2023|Observational [Patient Registry]|Apr 2016|Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\nNCT02751840|Tel Hai College|Completed|Oct 2014|Apr 2016|Interventional|Apr 2016|Asymptomatic Diseases|Caffeine\nNCT02752451|University of Arizona|Completed|Mar 2015|Apr 2015|Interventional|Apr 2016||\nNCT02757599|Rigshospitalet, Denmark|Completed|Aug 2016|Jun 2017|Interventional|Apr 2016||\nNCT02753894|Astellas Pharma Inc|Completed|Jan 2008|Jun 2008|Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency,Hyperphosphatemia|\nNCT02757638|Texas A&M University|Active, not recruiting|Oct 2015|Oct 2021|Interventional|Feb 2016|Weight Loss|\nNCT02757378|Kevin Farrell|Completed|May 2015|Sep 2015|Interventional|Apr 2016|Back Pain,Low Back Pain|\nNCT02751489|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|\nNCT02759315|Merck Sharp & Dohme Corp.|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Uprifosbuvir,Ruzasvir\nNCT02754895|Massachusetts General Hospital|Completed|Oct 2014|May 2017|Interventional|Apr 2016|Acute Coronary Syndrome,Syndrome|\nNCT02750475|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\nNCT02755064|Adil Bharucha|Completed|Jun 2010|Nov 2013|Interventional|Apr 2016|Diabetes Mellitus|Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate\nNCT02758002|University of California, San Diego|Withdrawn|Jan 2016|Dec 2018|Interventional|Apr 2016|Atrial Fibrillation|\nNCT02755142|medac GmbH|Completed|Feb 2000|Jun 2001|Interventional|Apr 2016|Glioma,Brain Neoplasms|Aminolevulinic Acid\nNCT02756364|Millennium Pharmaceuticals, Inc.|Completed|Jul 2016|Nov 2019|Interventional|Apr 2016|Breast Neoplasms|Fulvestrant\nNCT02759484|Rush University Medical Center|Unknown status|Mar 2015|Mar 2019|Interventional|Dec 2015|Hypertension,Diabetes Mellitus,Hyperglycemia|\nNCT02752061|Harvard School of Public Health (HSPH)|Completed|May 2016|Jul 2020|Interventional|Apr 2016||\nNCT02756598|Aarhus University Hospital|Completed|Jan 2015|Jun 2018|Interventional|Dec 2015||Sufentanil,Dsuvia,Propofol\nNCT02755727|Royal Devon and Exeter NHS Foundation Trust|Completed|Mar 2016|Sep 2017|Interventional|Apr 2016|Tennis Elbow|\nNCT02754882|Samsung Bioepis Co., Ltd.|Completed|Jul 2016|Oct 2018|Interventional|Mar 2016|Lung Neoplasms,Carcinoma|Paclitaxel,Bevacizumab,Carboplatin\nNCT02754778|Martin-Luther-Universität Halle-Wittenberg|Completed|Apr 2016|Mar 2021|Interventional|Apr 2016|Pre-Eclampsia,HELLP Syndrome,Syndrome|\nNCT02758171|Boehringer Ingelheim|Completed|May 2016|Aug 2016|Interventional|Apr 2016||Empagliflozin,Linagliptin\nNCT02755376|Samsung Medical Center|Completed|Jan 2014|Dec 2018|Interventional|Feb 2015||Hyaluronic Acid\nNCT02759016|Boehringer Ingelheim|Completed|Jun 2016|Jul 2019|Interventional|Apr 2016|Leukemia|BI 836826\nNCT02758457|University of Bologna|Completed|Jan 2008|Apr 2015|Interventional|Apr 2016||\nNCT02755519|Chongqing Medical University|Completed|May 2014|Oct 2016|Observational|Apr 2016|Hyperaldosteronism|\nNCT02758782|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2021|Interventional|Apr 2016|Spondylitis|Celecoxib,Golimumab\nNCT02756806|Cutera Inc.|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016||\nNCT02756156|Kahramanmaras Sutcu Imam University|Unknown status|Apr 2016|Aug 2016|Observational|Mar 2016|Humeral Fractures|\nNCT02759458|Rush University Medical Center|Completed|Nov 2013|Jan 2017|Interventional|Apr 2016|Rotator Cuff Injuries|\nNCT02750982|Brown, Theodore R., M.D., MPH|Completed|Jul 2016|Aug 2018|Interventional|Apr 2016|Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries|\nNCT02751502|NYU Langone Health|Terminated|Jan 2017|Feb 2021|Interventional|Apr 2016|Hemiplegia|\nNCT02752087|Eli Lilly and Company|Completed|Apr 2016|May 2016|Interventional|Apr 2016||\nNCT02756858|Anavex Life Sciences Corp.|Completed|Mar 2016|Nov 2020|Interventional|Mar 2016|Alzheimer Disease|\nNCT02758249|Konkuk University Medical Center|Completed|Jan 2016|Jan 2016|Interventional|Feb 2016||Propofol,Sevoflurane\nNCT02754570|University of Colorado, Denver|Completed|Jul 2016|Feb 2018|Interventional|Apr 2016|Glaucoma,Ocular Hypertension,Hypertension|Pilocarpine\nNCT02754102|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016|Dermatitis|Sunscreening Agents\nNCT02751593|Peking University People's Hospital|Unknown status|Jan 2016|Dec 2017|Interventional|Apr 2016|Thrombocytopenia,Purpura|Dexamethasone\nNCT02757014|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\nNCT02753062|Asan Medical Center|Recruiting|Aug 2015|Aug 2023|Interventional|Apr 2016|Lymphoma|Rituximab,Bendamustine Hydrochloride\nNCT02752425|Hospices Civils de Lyon|Completed|May 2016|May 2018|Interventional|Apr 2016|Speech Disorders|\nNCT02757300|Marienhospital Osnabrück|Unknown status|May 2016|Jul 2017|Interventional|Apr 2016|Pharyngitis|\nNCT02754180|Peking Union Medical College Hospital|Unknown status|Mar 2016|Mar 2021|Interventional|Apr 2016|Adenocarcinoma,Pancreatic Neoplasms|Gemcitabine\nNCT02752321|Northwell Health|Terminated|Aug 2016|Dec 2017|Interventional|Apr 2016||\nNCT02753595|Eisai Inc.|Terminated|Jul 2016|Aug 2019|Interventional|Apr 2016|Breast Neoplasms|\nNCT02755246|Charite University, Berlin, Germany|Completed|Apr 2016|Sep 2016|Interventional|Apr 2016|Cognitive Dysfunction|\nNCT02754115|Tata Memorial Centre|Recruiting|Apr 2016|Jan 2022|Observational|Mar 2016|Peritoneal Diseases|\nNCT02756897|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2024|Interventional|Apr 2016|Lymphoma,Leukemia|Venetoclax\nNCT02752334|Magrabi Eye & Ear Hospital|Completed|Sep 2015|Mar 2019|Interventional|Mar 2016||Magnesium Sulfate,Bupivacaine\nNCT02754791|Shaare Zedek Medical Center|Unknown status|May 2016|May 2017|Interventional|Apr 2016||\nNCT02754128|Holland Bloorview Kids Rehabilitation Hospital|Completed|Jun 2016|Oct 2017|Interventional|Apr 2016|Cerebral Palsy|\nNCT02751190|Umeå University|Completed|Sep 2013|Feb 2017|Observational [Patient Registry]|Apr 2016|Chronic Pain,Hernia|\nNCT02751645|Oregon Health and Science University|Unknown status|Jun 2016|May 2020|Interventional|Apr 2016||\nNCT02758184|Duke University|Terminated|Jun 2016|May 2018|Interventional|Apr 2016||\nNCT02751892|University of East Anglia|Completed|Oct 2013|Sep 2014|Interventional|Apr 2016|Colorectal Neoplasms|\nNCT02755324|Leiden University|Completed|Oct 2016|Jan 2019|Interventional|Apr 2016|Schistosomiasis|\nNCT02758886|Washington State University|Completed|Apr 2014||Interventional|Apr 2016|Stress|\nNCT02750072|Fraser Orthopaedic Research Society|Active, not recruiting|Sep 2016|Apr 2023|Interventional|Apr 2016|Patellofemoral Pain Syndrome,Fractures,Tibial Fractures|\nNCT02750332|Cycle Pharmaceuticals Ltd.|Completed|Nov 2015|Jan 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\nNCT02752529|Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine|Unknown status|Mar 2016||Interventional|Mar 2016|Liver Cirrhosis|Tacrolimus\nNCT02759939|Dartmouth-Hitchcock Medical Center|Completed|Jul 2016|Jul 2017|Interventional|Feb 2016||\nNCT02757157|European Respiratory Society|Terminated|Oct 2016|Jan 2020|Interventional|Apr 2016|Lung Diseases,Pulmonary Disease|\nNCT02759627|Istanbul University|Completed|Nov 2014|Mar 2016|Interventional|Apr 2016|Stroke|\nNCT02752412|Sanofi|Completed|May 2016|Oct 2018|Interventional|Apr 2016|Diabetes Mellitus|Insulin,Metformin,Insulin Glargine,Lixisenatide\nNCT02756988|Bayer|Completed|Oct 2015|Oct 2015|Interventional|Apr 2016||\nNCT02751203|Lara McKenzie|Completed|Apr 2016|Dec 2017|Interventional|Mar 2016||\nNCT02753946|Nabriva Therapeutics AG|Completed|Apr 2016|May 2017|Interventional|Apr 2016|Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis|Tazobactam,Piperacillin,Fosfomycin\nNCT02755480|University Health Network, Toronto|Terminated|Feb 2015|Feb 2017|Interventional|Mar 2015||\nNCT02753257|Valtari Bio|Unknown status|Sep 2016|Dec 2019|Observational|Apr 2016|Stroke|\nNCT02758691|Virginia Polytechnic Institute and State University|Completed|Dec 2015|May 2017|Interventional|Apr 2016||Insulin\nNCT02755623|Centre hospitalier de Ville-Evrard, France|Unknown status|May 2015|Dec 2018|Interventional|Apr 2016|Hallucinations,Schizophrenia|\nNCT02756234|Lancaster General Hospital|Completed|May 2016|Aug 2018|Observational|Apr 2016|Coronary Artery Disease|\nNCT02756091|University Hospital Inselspital, Berne|Recruiting|Aug 2016|May 2022|Observational [Patient Registry]|Apr 2016|Cerebrovascular Disorders|\nNCT02753491|Marmara University|Completed|Oct 2015|Mar 2016|Interventional|Apr 2016||\nNCT02752737|Medtronic Cardiac Rhythm and Heart Failure|Recruiting|May 2016|Dec 2024|Observational [Patient Registry]|Apr 2016|Atrial Fibrillation|\nNCT02758925|University Hospital, Caen|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Lymphoma|Cytarabine,Rituximab,Bendamustine Hydrochloride\nNCT02751723|Florian Lordick, MD|Unknown status|Sep 2014|Oct 2019|Observational|Apr 2016||\nNCT02751931|Astellas Pharma Europe B.V.|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Urinary Bladder|Mirabegron\nNCT02758847|Rabih A. Chaer|Recruiting|Sep 2016|Dec 2022|Interventional|Apr 2016|Ischemia|Paclitaxel,Albumin-Bound Paclitaxel\nNCT02757807|Eco Fusion|Unknown status|Jul 2016|Dec 2016|Interventional|Apr 2016|Erectile Dysfunction|\nNCT02755220|Shanghai Cingularbio Co. Ltd|Completed|Jan 2016|Apr 2019|Interventional|Apr 2016||\nNCT02758548|Novartis Pharmaceuticals|Completed|Mar 2016|May 2016|Interventional|Mar 2016||\nNCT02756845|Amgen|Recruiting|Aug 2017|Jun 2024|Interventional|Dec 2015|Neoplasms|Talimogene laherparepvec\nNCT02750605|Skane University Hospital|Active, not recruiting|Feb 2016|Dec 2021|Interventional|Jan 2016|Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia|\nNCT02756702|Aesculap AG|Active, not recruiting|Mar 2016|Dec 2022|Observational|Apr 2016|Osteoarthritis|\nNCT02752945|King's College London|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Depression,Depressive Disorder,Anxiety Disorders|\nNCT02759952|STZ eyetrial|Enrolling by invitation|Jan 2013|Dec 2025|Observational|Apr 2016|Retinitis,Retinitis Pigmentosa|\nNCT02754661|Medtronic - MITG|Completed|Sep 2016|Aug 2018|Interventional|Apr 2016|Colorectal Neoplasms|\nNCT02755441|Nils Hoyer|Recruiting|Apr 2016|Dec 2024|Observational|Apr 2016|Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis|\nNCT02750098|Sheba Medical Center|Unknown status|May 2016|Mar 2018|Interventional|Apr 2016|Diabetes Mellitus|\nNCT02753179|Hospices Civils de Lyon|Completed|May 2016|Jan 2017|Interventional|Apr 2016|Vestibular Diseases|\nNCT02758509|Parc de Salut Mar|Completed|Jan 2010|Oct 2017|Observational|Apr 2016|Hepatitis C,Hepatitis|Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir\nNCT02751970|Universidad de Valparaiso|Unknown status|Apr 2014|Apr 2018|Interventional|Apr 2016|Dental Caries|\nNCT02753712|Mundipharma Research Limited|Completed|Jun 2016|Aug 2017|Interventional|Apr 2016|Asthma|Fluticasone,Xhance,Formoterol Fumarate\nNCT02751151|Inova Health Care Services|Completed|Feb 2016|May 2021|Interventional|Mar 2016|Skin Neoplasms|Aminolevulinic Acid\nNCT02757716|Sana Klinikum Offenbach|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Behavior|\nNCT02758652|Tampere University Hospital|Active, not recruiting|May 2016|May 2026|Observational|Apr 2016|Ovarian Neoplasms,Carcinoma|\nNCT02754206|Southern Methodist University|Terminated|Jan 2016|Sep 2021|Observational|Apr 2016|Post-Concussion Syndrome,Brain Concussion|\nNCT02752243|Peter Bader|Active, not recruiting|Mar 2016|Mar 2022|Interventional|Mar 2016|Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease|\nNCT02754856|M.D. Anderson Cancer Center|Active, not recruiting|Jul 2016|Jul 2021|Interventional|Apr 2016|Colorectal Neoplasms|Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G\nNCT02759861|University of Nebraska|Active, not recruiting|Aug 2016|Aug 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis|Sofosbuvir,Ledipasvir\nNCT02759679|Haukeland University Hospital|Unknown status|May 2016|Dec 2019|Interventional|Mar 2016|Lung Neoplasms|\nNCT02752932|Lawson Health Research Institute|Completed|Nov 2015|Oct 2017|Interventional|Feb 2016|Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms|\nNCT02759445|RWTH Aachen University|Unknown status|Apr 2016|Oct 2016|Observational|Nov 2015||\nNCT02754622|Guy's and St Thomas' NHS Foundation Trust|Completed|Jul 2016|Dec 2016|Observational|Apr 2016|Critical Illness|\nNCT02756611|AbbVie|Active, not recruiting|Jun 2016|Sep 2022|Interventional|Apr 2016|Leukemia|Venetoclax\nNCT02758223|Wuerzburg University Hospital|Active, not recruiting|Apr 2016|Jun 2021|Interventional|Feb 2016|Leukemia,Myelodysplastic Syndromes|\nNCT02757079|Nobelpharma|Completed|Jun 2016|Jul 2018|Interventional|Apr 2016|Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders|Melatonin\nNCT02754219|Dong-A ST Co., Ltd.|Completed|Sep 2016|Jan 2018|Interventional|Apr 2016|Liver Diseases|\nNCT02753101|Stanford University|Completed|Feb 2016|Feb 2017|Interventional|Apr 2016|Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica|\nNCT02759003|Fondazione Salvatore Maugeri|Completed|Mar 2011|Mar 2014|Interventional|Apr 2016|Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis|\nNCT02752659|University of British Columbia|Completed|Jun 2016|Jun 2017|Interventional|Apr 2016|Breast Neoplasms,Lymphedema|\nNCT02758912|Burnasyan Federal Medical Biophysical Center|Completed|Nov 2016|Oct 2019|Interventional|Apr 2016|Stroke,Angina Pectoris,Infarction,Hemorrhage|\nNCT02754388|National Taiwan University Hospital|Completed|Feb 2016|Dec 2019|Observational [Patient Registry]|Apr 2016|Lung Neoplasms|\nNCT02759666|Atridia Pty Ltd.|Completed|Jun 2016|Apr 2019|Interventional|Apr 2016|Neoplasms|\nNCT02750241|The University of Texas Medical Branch, Galveston|Completed|Apr 2016|Jan 2019|Interventional|Apr 2016|Breast Neoplasms|\nNCT02752568|Kasr El Aini Hospital|Unknown status|May 2016|Dec 2016|Interventional|Apr 2016||\nNCT02758015|University of California, San Francisco|Completed|Jun 2016|Mar 2018|Interventional|Apr 2016||Betaine\nNCT02756884|Arkansas Heart Hospital|Completed|Jun 2015|Jan 2019|Interventional|Apr 2016|Peripheral Arterial Disease,Peripheral Vascular Diseases|\nNCT02758353|JSI Research & Training Institute, Inc.|Completed|Apr 2015|Nov 2015|Interventional|Apr 2016|Malaria,Stillbirth|\nNCT02753751|Yale University|Completed|Mar 2018|Jan 2020|Interventional|Apr 2016|Acute Kidney Injury,Wounds and Injuries|\nNCT02757170|All India Institute of Medical Sciences, New Delhi|Unknown status|Jul 2015|Jul 2016|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency,End Stage Liver Disease,Acute-On-Chronic Liver Failure|\nNCT02757625|Pfizer|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Dexmedetomidine\nNCT02752347|Riyadh Colleges of Dentistry and Pharmacy|Unknown status|Apr 2016|Dec 2017|Interventional|Apr 2016|Malocclusion|\nNCT02756468|University of Roma La Sapienza|Unknown status|Jan 2015|Dec 2016|Observational [Patient Registry]|Apr 2016|Pancreatic Neoplasms|\nNCT02750410|Eli Lilly and Company|Completed|Aug 2016|\n\n*** WARNING: max output size exceeded, skipping output. ***\n\nst Neoplasms|\nNCT02758990|Verifomics LLC|Terminated|Mar 2016|Nov 2016|Interventional|Apr 2016|Rhinitis,Arthralgia,Dyspnea,Sleep Deprivation,Migraine Disorders,Sleep Initiation and Maintenance Disorders,Disease,Headache,Respiratory Sounds|Vitamin D,Cholecalciferol,Vitamins,Ascorbic Acid,Vitamin E,Tocopherols,Vitamin A,Niacinamide,Niacin,Nicotinic Acids,Pyridoxine,Pyridoxal,Vitamin B 6,Caffeine\nNCT02754193|Central Hospital, Nancy, France|Completed|Oct 2016|Nov 2019|Interventional|Apr 2016|Shock,Hypothermia|\nNCT02758613|Eli Lilly and Company|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02751047|Seoul National University Hospital|Completed|May 2016|Jan 2017|Interventional|Apr 2016||\nNCT02758197|Ottawa Hospital Research Institute|Completed|Jul 2016|Oct 2020|Interventional|Apr 2016|Neuralgia,Chronic Pain|\nNCT02753270|University of Sao Paulo|Completed|Dec 2014|Apr 2017|Interventional|Apr 2016|Varicose Veins|\nNCT02750839|Azienda Ospedaliera Bolognini di Seriate Bergamo|Unknown status|Apr 2016|Apr 2016|Observational|Apr 2016|Osteoporosis,Fractures,Humeral Fractures|\nNCT02750488|Bayer|Completed|May 2016|Jul 2016|Interventional|Apr 2016|Dermatitis|\nNCT02752958|GlaxoSmithKline|Completed|May 2016|Feb 2017|Interventional|Apr 2016|Dentin Sensitivity,Hypersensitivity|Fluorides,Tin Fluorides\nNCT02753322|The Queen Elizabeth Hospital|Unknown status|Apr 2016|Mar 2018|Interventional|Apr 2016|Stroke|\nNCT02757261|University of Nove de Julho|Unknown status|Jun 2016|Mar 2017|Interventional|Apr 2016|Bruxism,Sleep Bruxism|Salicylic Acid\nNCT02754427|University of British Columbia|Completed|Feb 2013|Aug 2015|Interventional|Apr 2016|Breast Neoplasms|\nNCT02758366|Meyer Children's Hospital|Terminated|Feb 2016|Jan 2020|Interventional|Apr 2016|Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms|Doxorubicin\nNCT02755402|Centre hospitalier de l'Université de Montréal (CHUM)|Completed|Jan 2017|May 2021|Interventional|Apr 2016|Hepatitis C|\nNCT02754453|The Cleveland Clinic|Withdrawn|Jul 2013|Oct 2015|Interventional|Sep 2013|Body Weight,Weight Loss|\nNCT02755103|Medical University of South Carolina|Active, not recruiting|Jun 2016|Oct 2021|Interventional|Apr 2016|Disease,Substance-Related Disorders,Stress Disorders|\nNCT02758834|Università Politecnica delle Marche|Completed|Jan 2014|Apr 2016|Observational|Apr 2016|Liver Diseases|\nNCT02759146|Michigan State University|Completed|May 2016|Nov 2019|Interventional|Apr 2016||\nNCT02754414|Bloodworks|Unknown status|Apr 2016|Jan 2019|Interventional|Apr 2016||\nNCT02759783|Royal Marsden NHS Foundation Trust|Active, not recruiting|Nov 2016|Oct 2024|Interventional|Apr 2016|Carcinoma|\nNCT02756923|Weill Medical College of Cornell University|Suspended|Apr 2012|Dec 2025|Observational|Apr 2016|Infertility|\nNCT02759237|Medtronic Cardiovascular|Terminated|Feb 2016|May 2017|Observational|Apr 2016|Aortic Valve Stenosis|\nNCT02757391|M.D. Anderson Cancer Center|Terminated|Aug 2019|Oct 2020|Interventional|Apr 2016|Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma|Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors\nNCT02750904|Fred Hutchinson Cancer Research Center|Completed|Apr 2017|May 2019|Interventional|Mar 2016|Disease,Bipolar Disorder|Nicotine\nNCT02758418|Universitat Jaume I|Unknown status|Apr 2016|Jul 2019|Interventional|Apr 2016|Adjustment Disorders|\nNCT02756039|AstraZeneca|Completed|May 2016|Aug 2018|Observational|Apr 2016||\nNCT02755077|Massachusetts General Hospital|Completed|Jul 2014|Jan 2016|Interventional|Apr 2016||\nNCT02751801|Sheffield Teaching Hospitals NHS Foundation Trust|Completed|Nov 2016|Dec 2017|Observational|Apr 2016|Hypophosphatasia|\nNCT02751177|Institut de Cancérologie de Lorraine|Completed|Mar 2016|May 2017|Interventional|Mar 2016|Colorectal Neoplasms|\nNCT02758574|University of Pittsburgh|Completed|May 2016|Aug 2021|Interventional|Mar 2016|Pulmonary Embolism,Embolism|\nNCT02758587|NHS Greater Glasgow and Clyde|Recruiting|Jul 2017|Dec 2021|Interventional|Apr 2016|Mesothelioma,Carcinoma,Pancreatic Neoplasms|Pembrolizumab\nNCT02752100|Third Military Medical University|Unknown status|Mar 2016|May 2020|Interventional|Mar 2016|Arterial Occlusive Diseases|\nNCT02755818|University of California, Davis|Terminated|Oct 2008|Feb 2019|Observational|Mar 2016|Insulin Resistance|Heparin,Calcium heparin\nNCT02752906|Sanofi Pasteur, a Sanofi Company|Completed|Apr 2016|Dec 2016|Interventional|Apr 2016|Meningococcal Infections,Meningitis|Vaccines\nNCT02750371|University Hospital, Bordeaux|Active, not recruiting|Jul 2016|Oct 2021|Interventional|Apr 2016|Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases|\nNCT02751125|University of Bergen|Completed|Jun 2014|Mar 2020|Interventional|Mar 2016|Atrophy|\nNCT02754700|High Point University|Completed|Apr 2016|Feb 2019|Interventional|Apr 2016|Knee Injuries|\nNCT02756442|Assistance Publique Hopitaux De Marseille|Unknown status|Apr 2016|Apr 2019|Interventional|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Diabetes|\nNCT02756637|Abramson Cancer Center of the University of Pennsylvania|Completed|Apr 2016|Nov 2016|Observational|Apr 2016|Urinary Bladder Neoplasms|\nNCT02755688|Royal Brompton & Harefield NHS Foundation Trust|Unknown status|Jun 2015|Mar 2020|Interventional|Apr 2016|Atrial Fibrillation|\nNCT02753387|Rennes University Hospital|Completed|May 2016|Sep 2018|Interventional|Apr 2016|Bacterial Infections,Head and Neck Neoplasms|Chlorhexidine\nNCT02758470|University of British Columbia|Completed|Nov 2016|Jun 2017|Interventional|Apr 2016|Fatigue,Hypoxia|Acetazolamide,Methazolamide\nNCT02754375|Centre Hospitalier Universitaire de Nice|Unknown status|May 2016|May 2019|Interventional|Apr 2016|Depression,Depressive Disorder|\nNCT02758756|University of Rochester|Completed|Jun 2016|May 2019|Interventional|Apr 2016|Fatigue|\nNCT02750787|Abbott Nutrition|Completed|Aug 2016|Jul 2017|Interventional|Apr 2016|Malabsorption Syndromes|\nNCT02757339|Mclean Hospital|Enrolling by invitation|Jun 2015|May 2022|Observational|Mar 2016|Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder|\nNCT02753959|Guy's and St Thomas' NHS Foundation Trust|Completed|Aug 2016|Sep 2019|Interventional|Apr 2016|Neuromuscular Diseases|\nNCT02753426|University of California, San Francisco|Completed|Apr 2016|Jan 2018|Interventional|Apr 2016|Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome|Doxycycline\nNCT02757183|AnalyticsPlus, Inc.|Unknown status|Apr 2016|Mar 2017|Observational|Apr 2016||\nNCT02750293|University of Tromso|Completed|Jun 2015|Sep 2017|Interventional|Apr 2016|Vitamin D Deficiency|Cholecalciferol\nNCT02757274|European Association of Urology Research Foundation|Recruiting|Feb 2017|Jul 2027|Observational [Patient Registry]|Apr 2016|Urinary Incontinence,Enuresis|\nNCT02756741|All India Institute of Medical Sciences, New Delhi|Completed|Apr 2014|Jul 2015|Interventional|Apr 2016|Peritonitis,Fibrosis|\nNCT02758964|Charite University, Berlin, Germany|Completed|Sep 2016|Jan 2019|Observational|Apr 2016|Intracranial Embolism,Embolism,Aortic Valve Stenosis|\nNCT02753439|The Baruch Padeh Medical Center, Poriya|Unknown status|Feb 2017|Feb 2019|Interventional|Mar 2016|Tooth|\nNCT02751281|Isfahan University of Medical Sciences|Completed|Dec 2014|Apr 2016|Interventional|Apr 2016|Kidney Calculi,Nephrolithiasis|\nNCT02756676|Ospedale Generale Di Zona Moriggia-Pelascini|Completed|Apr 2015|Dec 2016|Interventional|Apr 2016|Parkinson Disease|\nNCT02750215|Massachusetts General Hospital|Completed|May 2016|May 2021|Interventional|Apr 2016|Lung Neoplasms|\nNCT02755935|Cochlear|Completed|May 2016|Sep 2017|Interventional|Apr 2016|Hearing Loss|\nNCT02759523|Penn State University|Completed|Jul 2013|Dec 2015|Observational|Apr 2016|Pediatric Obesity|\nNCT02756533|University Hospital, Grenoble|Recruiting|Aug 2016|Aug 2021|Interventional|Mar 2016|Lung Diseases,Pulmonary Disease,Signs and Symptoms|\nNCT02752841|Brown University|Terminated|May 2016|May 2019|Interventional|Apr 2016|Kidney Calculi,Calculi|Vitamin D\nNCT02758392|Janssen Research & Development, LLC|Completed|Apr 2016|Jan 2017|Interventional|Apr 2016||\nNCT02755870|Clene Nanomedicine|Completed|Apr 2015|Oct 2016|Interventional|Apr 2016||\nNCT02752464|Boston Medical Center|Completed|Sep 2016|Jun 2018|Interventional|Apr 2016||\nNCT02756780|Royal Marsden NHS Foundation Trust|Unknown status|Apr 2016|Apr 2018|Interventional|Apr 2016||\nNCT02753998|Assistance Publique - Hôpitaux de Paris|Active, not recruiting|Dec 2016|Sep 2021|Interventional|Apr 2016|Arteriovenous Fistula,Constriction,Fistula|Paclitaxel\nNCT02751307|Taipei Medical University WanFang Hospital|Completed|May 2013|Jan 2015|Interventional|Apr 2016|Congenital Abnormalities,Metabolic Syndrome,Schizophrenia|Metformin,Clozapine\nNCT02757755|Armata Pharmaceuticals, Inc.|Completed|May 2016|Aug 2016|Interventional|Apr 2016||\nNCT02753972|University of New Mexico|Completed|Aug 2006|Jan 2008|Interventional|Apr 2016||\nNCT02751853|University of Luebeck|Unknown status|Dec 2016|Aug 2020|Interventional|Apr 2016|Heart Failure|\nNCT02752971|Hospital Central Dr. Luis Ortega|Completed|Feb 2015||Interventional|Mar 2016|Pain|Diclofenac,Bupivacaine\nNCT02755012|McGill University|Completed|Jun 2012|Nov 2013|Observational|Apr 2016|Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress|\nNCT02751996|F-star Therapeutics, Inc.|Completed|May 2016|Feb 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis B,Hepatitis|Tenofovir\nNCT02752893|Dartmouth-Hitchcock Medical Center|Completed|Jan 2017|Apr 2019|Observational|Apr 2016|Breast Neoplasms|\nNCT02753842|Global Protection Corp.|Completed|May 2016|Jul 2017|Interventional|Apr 2016||\nNCT02757040|Peking University People's Hospital|Unknown status|Dec 2016|Dec 2018|Interventional|Apr 2016|Leukemia|Arsenic Trioxide\nNCT02751606|Radboud University|Unknown status|Jun 2015|Nov 2019|Interventional|Nov 2014|Neoplasms,Breast Neoplasms,Rectal Neoplasms|\nNCT02751372|Bayer|Completed|May 2016|May 2016|Interventional|Apr 2016||\nNCT02753764|National Jewish Health|Completed|Jan 2017|Feb 2019|Interventional|Apr 2016|Asthma|Prednisone,AZD7624\nNCT02758938|University of Wisconsin, Madison|Completed|Jun 2016|Sep 2018|Interventional|Dec 2015|Lower Urinary Tract Symptoms|\nNCT02752399|Federal University of São Paulo|Unknown status|Apr 2016|Jun 2017|Observational|Apr 2016|Hypertension,Heart Defects,Eisenmenger Complex|\nNCT02753296|University of Sheffield|Unknown status|May 2016|Jun 2018|Observational|Apr 2016||\nNCT02759432|Teesside University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02750137|KK Women's and Children's Hospital|Completed|Aug 2014|May 2015|Observational|Apr 2016|Drug-Related Side Effects and Adverse Reactions|Tetracaine\nNCT02754466|University of Brasilia|Terminated|May 2017|Sep 2021|Interventional|Apr 2016|Dental Caries|\nNCT02752191|Paul Finn|Recruiting|Apr 2016|Apr 2021|Interventional|Apr 2016|Heart Diseases,Heart Defects|Ferrosoferric Oxide\nNCT02753517|University Hospital, Lille|Recruiting|Dec 2015|Nov 2023|Interventional|Apr 2016|Liver Failure,Hepatic Insufficiency|\nNCT02758054|University of Texas Southwestern Medical Center|Active, not recruiting|Jun 2017|Mar 2023|Interventional|Apr 2016|Carcinoma|\nNCT02757573|Tampere University Hospital|Active, not recruiting|Apr 2016|Dec 2022|Interventional|Apr 2016|Hypercapnia|\nNCT02752789|National Institute of Allergy and Infectious Diseases (NIAID)|Completed|Jul 2014|Nov 2019|Observational|Apr 2016||\nNCT02756416|University of Nottingham|Unknown status|Jul 2016|May 2017|Interventional|Mar 2016|Syndrome|\nNCT02758106|Chung Shan Medical University|Completed|Feb 2014|Nov 2015|Interventional|Apr 2016|Respiratory Insufficiency|\nNCT02759159|Xuanwu Hospital, Beijing|Unknown status|Jun 2016|Dec 2018|Interventional|Apr 2016|Alzheimer Disease|\nNCT02753777|University of Pennsylvania|Recruiting|Apr 2016|Dec 2025|Observational [Patient Registry]|Apr 2016|Pemphigoid,Pemphigus|\nNCT02754245|Baylor Research Institute|Unknown status|Nov 2016|Jul 2017|Observational|Apr 2016|Emergencies|\nNCT02754687|Health Decisions|Unknown status|Apr 2016|Jan 2020|Interventional|Mar 2016||Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate\nNCT02755337|Dr. Soetomo General Hospital|Unknown status|Jan 2016|Dec 2016|Observational|Apr 2016|Lung Neoplasms|\nNCT02755090|University of New Mexico|Completed|Jul 2016|May 2017|Interventional|Apr 2016||Nitrous Oxide\nNCT02751437|Liverpool Women's NHS Foundation Trust|Completed|Aug 2016|Mar 2018|Interventional|Mar 2016|Premature Birth|\nNCT02757950|GlaxoSmithKline|Completed|Jul 2016|May 2017|Observational|Apr 2016|Diphtheria|\nNCT02756754|University Hospital, Toulouse|Completed|Nov 2016|May 2019|Interventional|Apr 2016|Adenoma,Adrenocortical Adenoma,Hyperaldosteronism|\nNCT02754726|HonorHealth Research Institute|Active, not recruiting|Apr 2016|Jun 2022|Interventional|Apr 2016|Adenocarcinoma|Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel\nNCT02759549|Emory University|Withdrawn|Sep 2015||Interventional|Apr 2016|Breast Neoplasms|\nNCT02755714|Haukeland University Hospital|Completed|Jun 2016|Oct 2020|Interventional|Apr 2016||Bromides,Ipratropium\nNCT02750358|Memorial Sloan Kettering Cancer Center|Active, not recruiting|May 2016|May 2022|Interventional|Apr 2016|Breast Neoplasms,Triple Negative Breast Neoplasms|\nNCT02754921|Mohamed Sayed Mohamed Abbas|Completed|Jan 2013||Interventional|Apr 2016||\nNCT02755259|University of Zurich|Completed|Jan 2017|Apr 2019|Interventional|Mar 2016|Hypertension|Acetazolamide\nNCT02759081|Dalin Tzu Chi General Hospital|Completed|Jan 2015||Interventional|Apr 2016||\nNCT02755155|University Hospital, Strasbourg, France|Terminated|Sep 2016|Aug 2019|Interventional|Apr 2016|Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome|\nNCT02758119|Ilumens|Completed|Jun 2016|Oct 2016|Interventional|Apr 2016|Heart Arrest,Out-of-Hospital Cardiac Arrest|\nNCT02755415|China Medical University Hospital|Unknown status|May 2016|Dec 2017|Interventional|Apr 2016|Stroke|\nNCT02751268|Armed Forces Hampyeong Hospital|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Psychomotor Agitation,Emergence Delirium|Ropivacaine\nNCT02756572|University of Washington|Completed|Sep 2016|Jul 2020|Interventional|Apr 2016|Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome|Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim\nNCT02756871|Institute of Child Health|Completed|Jul 2015|Feb 2017|Interventional|Apr 2016||\nNCT02750618|Ultragenyx Pharmaceutical Inc|Completed|May 2016|Sep 2019|Interventional|Dec 2015|Familial Hypophosphatemic Rickets,Hypophosphatemia|\nNCT02757196|Peking University People's Hospital|Unknown status|May 2016|Dec 2018|Interventional|Apr 2016|Thrombocytopenia,Purpura|Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate\nNCT02758093|University of Alabama at Birmingham|Completed|Sep 2016|Mar 2020|Interventional|Mar 2016||\nNCT02750943|GlaxoSmithKline|Completed|Nov 2015|Mar 2016|Interventional|Nov 2015|Gingivitis|Fluorides,Tin Fluorides,Fluorophosphate\nNCT02754908|The University of Hong Kong|Completed|Jan 2016|Jun 2018|Interventional|Apr 2016|Brain Neoplasms|\nNCT02750514|Bristol-Myers Squibb|Terminated|May 2016|Jan 2020|Interventional|Apr 2016|Carcinoma|Nivolumab,Ipilimumab,Dasatinib,Linrodostat\nNCT02755350|LVCT Health|Unknown status|Aug 2015|Apr 2017|Interventional|Nov 2015||Emtricitabine\nNCT02753374|Beijing Children's Hospital|Not yet recruiting|May 2016|Jul 2030|Observational|Apr 2016|Cystic Fibrosis,Fibrosis|\nNCT02759419|Bayer|Recruiting|Jun 2016|Dec 2023|Interventional|Apr 2016|Pulmonary Arterial Hypertension,Hypertension|Riociguat\nNCT02757612|Universidad de Murcia|Completed|Jun 2015|Jul 2016|Interventional|Apr 2016|Burning Mouth Syndrome,Syndrome,Burns|\nNCT02754297|CHU de Quebec-Universite Laval|Recruiting|Apr 2016|Dec 2026|Interventional|Mar 2016|Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma|Lutetium Lu 177 dotatate\nNCT02758665|University of Ulm|Active, not recruiting|Sep 2016|Mar 2022|Interventional|Apr 2016|Leukemia|Venetoclax,Obinutuzumab\nNCT02755285|Fujifilm Medical Systems USA, Inc.|Completed|Aug 2016|Oct 2016|Interventional|Apr 2016||\nNCT02757690|Asan Medical Center|Completed|Jan 2015|Feb 2016|Interventional|Apr 2016|Neoplasms,Brain Neoplasms|\nNCT02753218|LEO Pharma|Terminated|Apr 2016|May 2016|Interventional|Apr 2016|Psoriasis|Midazolam\nNCT02754986|University of Hyogo|Completed|Mar 2015||Interventional|Mar 2016|Kidney Diseases,Renal Insufficiency|\nNCT02752048|Taiho Pharmaceutical Co., Ltd.|Completed|May 2016|Oct 2017|Interventional|Apr 2016|Muscular Dystrophies,Muscular Dystrophy|\nNCT02752256|University of Iowa|Completed|Oct 2015|Oct 2017|Observational|Apr 2016||Plasminogen,Tissue Plasminogen Activator\nNCT02756936|Genuine Research Center, Egypt|Completed|Feb 2016|Mar 2016|Interventional|Apr 2016||\nNCT02756000|Clinical Hospital Center Zemun|Unknown status|Jan 2016|Jul 2018|Interventional|Apr 2016|Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction|Dobutamine\nNCT02754492|Terumo BCT|Completed|Apr 2016|Feb 2017|Interventional|Apr 2016||\nNCT02757677|Swiss Vision Network|Unknown status|Dec 2015|Dec 2019|Observational|Apr 2016|Glaucoma|\nNCT02752373|Brain Sentinel|Terminated|May 2016|Feb 2017|Observational|Mar 2016|Epilepsy,Seizures|\nNCT02752230|Kettering Health Network|Withdrawn|Nov 2016|Jun 2021|Interventional|Mar 2016|Pain|\nNCT02756728|BioInvent International AB|Terminated|May 2016|Dec 2016|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Melphalan\nNCT02751658|University Hospital, Montpellier|Completed|Nov 2016|Jul 2019|Interventional|Mar 2016|Otorhinolaryngologic Diseases|\nNCT02754518|University of Chicago|Completed|Apr 2016|Apr 2019|Interventional|Apr 2016|Heart Failure|Valsartan,Sacubitril and valsartan sodium hydrate drug combination\nNCT02759380|Sahlgrenska University Hospital, Sweden|Recruiting|Mar 2016|Oct 2022|Interventional|Apr 2016|Prostatic Neoplasms|Phytoestrogens\nNCT02755649|Regeneron Pharmaceuticals|Completed|Jan 2016|Mar 2017|Interventional|Mar 2016|Dermatitis,Eczema|\nNCT02751827|Institut Bergonié|Completed|Feb 2016|Nov 2019|Observational|Apr 2016||\nNCT02755545|Galderma Laboratories, L.P.|Completed|May 2016|Apr 2017|Interventional|Apr 2016|Acne Vulgaris|Salicylic Acid,Adapalene,Salicylates\nNCT02750345|Cycle Pharmaceuticals Ltd.|Completed|Mar 2016|May 2016|Interventional|Apr 2016|Tyrosinemias|Nitisinone\nNCT02755532|Federal University of São Paulo|Completed|Jan 2014|Oct 2015|Interventional|Apr 2016||Bupivacaine\nNCT02758743|Biohit Oyj|Completed|Apr 2016|May 2017|Interventional|Apr 2016||\nNCT02754947|Nationwide Children's Hospital|Completed|Feb 2015|Mar 2016|Observational|Apr 2016|Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases|\nNCT02750280|Calvary Hospital, Bronx, NY|Completed|Jun 2015|Dec 2015|Interventional|Apr 2016|Diabetic Foot,Foot Ulcer,Ulcer|\nNCT02756325|NYU Langone Health|Withdrawn|Jun 2016|Jan 2019|Interventional|Apr 2016|Infertility|\nNCT02758717|Academic and Community Cancer Research United|Active, not recruiting|May 2016|May 2024|Interventional|Apr 2016|Lymphoma,Hodgkin Disease|Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates\nNCT02751034|Medy-Tox|Completed|Jun 2013|Jan 2014|Interventional|Apr 2015||Lidocaine\nNCT02751476|Action Contre la Faim|Unknown status|Apr 2016|Mar 2017|Interventional|Apr 2016|Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition|Disinfectants\nNCT02755454|University Health Network, Toronto|Completed|Oct 2013|Nov 2018|Interventional|Mar 2016|Lung Neoplasms|\nNCT02752867|Dongfang Hospital Beijing University of Chinese Medicine|Unknown status|Dec 2016|Nov 2019|Interventional|Mar 2016|Cerebral Infarction,Infarction,Cognitive Dysfunction|\nNCT02754830|Eli Lilly and Company|Completed|Apr 2016|Jul 2018|Interventional|Apr 2016|Alzheimer Disease|\nNCT02753738|Medical University of Vienna|Unknown status|Aug 2016||Interventional|Apr 2016||Citalopram\nNCT02750267|University of Virginia|Completed|May 2016|May 2016|Interventional|Apr 2016|Diabetes Mellitus|\nNCT02754999|Prolong Pharmaceuticals|Completed|Mar 2016|May 2017|Interventional|Apr 2016|Anemia|\nNCT02754843|Sonova AG|Completed|Oct 2015||Interventional|Oct 2015|Hearing Loss|\nNCT02759055|HealthPartners Institute|Completed|Oct 2016|Dec 2019|Interventional|Apr 2016|Prediabetic State,Glucose Intolerance|\nNCT02753673|Memorial Sloan Kettering Cancer Center|Completed|Apr 2016|Apr 2020|Observational|Apr 2016||\nNCT02754531|Indonesia University|Completed|May 2016|Jul 2016|Interventional|Apr 2016||\nNCT02750033|Seton Healthcare Family|Withdrawn|Oct 2016|Mar 2017|Observational|Apr 2016|Carcinoma|\nNCT02759133|Centre Antoine Lacassagne|Recruiting|Jun 2016|Nov 2022|Interventional|Apr 2016|Breast Neoplasms|\nNCT02756650|Novartis Pharmaceuticals|Completed|Jun 2016|Jan 2019|Interventional|Mar 2016|Behcet Syndrome|\nNCT02752152|Institut de Recherche pour le Developpement|Completed|Dec 2015|Oct 2020|Interventional|Apr 2016|Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis|\nNCT02751385|Boehringer Ingelheim|Terminated|May 2016|Nov 2017|Interventional|Apr 2016|Carcinoma|Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination\nNCT02751879|Boehringer Ingelheim|Completed|Nov 2016|Sep 2017|Observational|Apr 2016|Carcinoma|\nNCT02756663|Novartis Pharmaceuticals|Withdrawn|Dec 2016|Feb 2021|Interventional|Apr 2016|Multiple Myeloma,Neoplasms|Dexamethasone,Panobinostat\nNCT02756273|Centre Hospitalier Universitaire, Amiens|Recruiting|May 2016|May 2022|Interventional|Apr 2016||\nNCT02755974|Imperial College London|Unknown status|Jan 2009|Apr 2021|Observational|Apr 2016|Lung Diseases,Pulmonary Disease|\nNCT02756507|Babes-Bolyai University|Completed|Jun 2016|Jun 2018|Interventional|Apr 2016|Disease,Depression,Anxiety Disorders,Panic Disorder|\nNCT02750553|Jiangsu HengRui Medicine Co., Ltd.|Completed|Jan 2015||Interventional|Apr 2016||\nNCT02750228|Mednax Center for Research, Education, Quality and Safety|Completed|May 2016|Jun 2020|Observational|Mar 2016|Ductus Arteriosus|\nNCT02751710|Ontario Clinical Oncology Group (OCOG)|Recruiting|Dec 2016|Dec 2022|Interventional|Apr 2016|Breast Neoplasms|\nNCT02753361|Suez Canal University|Completed|May 2016|Dec 2016|Interventional|Apr 2016|Lipoma|\nNCT02753634|Lawson Health Research Institute|Completed|Apr 2015|Jun 2016|Interventional|Mar 2016|Osteoarthritis|\nNCT02759250|argenx|Completed|Feb 2015|Jun 2018|Interventional|Apr 2016|Nasopharyngeal Carcinoma|\nNCT02757482|Celal Bayar University|Completed|Sep 2014|Jun 2015|Interventional|Apr 2016||\nNCT02757105|RedHill Biopharma Limited|Completed|May 2016|Jul 2017|Interventional|Apr 2016|Irritable Bowel Syndrome,Syndrome,Diarrhea|Ondansetron\nNCT02756520|Fresenius Kabi|Completed|Sep 2016|Oct 2018|Observational|Apr 2016|Kidney Diseases,Renal Insufficiency|\nNCT02753309|The University of Texas Health Science Center at San Antonio|Completed|Jun 2016|Mar 2021|Interventional|Apr 2016|Urinary Bladder Neoplasms|Sirolimus\nNCT02756832|Takeda|Completed|Sep 2016|Apr 2018|Observational|Apr 2016|Diabetes Mellitus|Alogliptin\nNCT02758158|University Health Network, Toronto|Completed|Jan 2016|Feb 2017|Interventional|Mar 2016|Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases|\nNCT02752360|Beijing Friendship Hospital|Unknown status|Apr 2016|Dec 2018|Interventional|Apr 2016|Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis|\nNCT02757794|Assistance Publique Hopitaux De Marseille|Recruiting|Nov 2016|Jun 2022|Interventional|Apr 2016|Memory Disorders|\nNCT02751346|Washington University School of Medicine|Completed|Jan 2016|Feb 2017|Observational|Apr 2016|Pain|\nNCT02757027|Konkuk University Medical Center|Unknown status|May 2016|Jan 2017|Interventional|Apr 2016||\nNCT02756689|University of Alabama at Birmingham|Completed|Mar 2016|Oct 2017|Interventional|Apr 2016||\nNCT02751164|Intensive Care National Audit & Research Centre|Completed|Apr 2013|May 2016|Observational|Apr 2016|Critical Illness|\nNCT02754765|Médecins Sans Frontières, France|Recruiting|Dec 2016|Aug 2023|Interventional|Apr 2016|Tuberculosis,Bacterial Infections|Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine\nNCT02757729|Amorepacific Corporation|Completed|Oct 2015||Interventional|Apr 2016|Dermatitis,Eczema|\nNCT02751866|University of Cincinnati|Recruiting|Jan 2016|Jul 2023|Interventional|Apr 2016|Overweight,Hyperphagia|\nNCT02759068|Hospices Civils de Lyon|Completed|Nov 2014|May 2017|Interventional|Apr 2016|Consciousness Disorders|\nNCT02752503|Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|Un\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Taking a clearer look at the data\n",
    "for line in dbutils.fs.head(clinical_filepath).splitlines():\n",
    "    print(line)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "97cdeb29-29a5-4272-a42c-0af9f7c56328",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n",
       "|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n",
       "|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n",
       "|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n",
       "|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n",
       "|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n",
       "|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "only showing top 10 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 10 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#reading the clinial trial data into a dataframe and checking to see if it was read in correctly\n",
    "clinical_df = spark.read.option(\"delimiter\", \"|\").option(\"header\" , \"True\").option(\"inferSchema\" ,\"True\").csv(clinical_filepath)\n",
    "clinical_df.show(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "40a2d699-bb10-4349-9c26-71f72ef370a8",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "root\n",
       " |-- Id: string (nullable = true)\n",
       " |-- Sponsor: string (nullable = true)\n",
       " |-- Status: string (nullable = true)\n",
       " |-- Start: string (nullable = true)\n",
       " |-- Completion: string (nullable = true)\n",
       " |-- Type: string (nullable = true)\n",
       " |-- Submission: string (nullable = true)\n",
       " |-- Conditions: string (nullable = true)\n",
       " |-- Interventions: string (nullable = true)\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "root\n |-- Id: string (nullable = true)\n |-- Sponsor: string (nullable = true)\n |-- Status: string (nullable = true)\n |-- Start: string (nullable = true)\n |-- Completion: string (nullable = true)\n |-- Type: string (nullable = true)\n |-- Submission: string (nullable = true)\n |-- Conditions: string (nullable = true)\n |-- Interventions: string (nullable = true)\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "clinical_df.printSchema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "4a076572-e944-4fcc-9b93-c45af9d12bac",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style scoped>\n",
       "  .table-result-container {\n",
       "    max-height: 300px;\n",
       "    overflow: auto;\n",
       "  }\n",
       "  table, th, td {\n",
       "    border: 1px solid black;\n",
       "    border-collapse: collapse;\n",
       "  }\n",
       "  th, td {\n",
       "    padding: 5px;\n",
       "  }\n",
       "  th {\n",
       "    text-align: left;\n",
       "  }\n",
       "</style><div class='table-result-container'><table class='table-result'><thead style='background-color: white'><tr><th>Id</th><th>Sponsor</th><th>Status</th><th>Start</th><th>Completion</th><th>Type</th><th>Submission</th><th>Conditions</th><th>Interventions</th></tr></thead><tbody><tr><td>NCT02758028</td><td>The University of Hong Kong</td><td>Recruiting</td><td>Aug 2005</td><td>Nov 2021</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751957</td><td>Duke University</td><td>Completed</td><td>Jul 2016</td><td>Jul 2020</td><td>Interventional</td><td>Apr 2016</td><td>Autistic Disorder,Autism Spectrum Disorder</td><td>null</td></tr><tr><td>NCT02758483</td><td>Universidade Federal do Rio de Janeiro</td><td>Completed</td><td>Mar 2017</td><td>Jan 2018</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02759848</td><td>Istanbul Medeniyet University</td><td>Completed</td><td>Jan 2012</td><td>Dec 2014</td><td>Observational</td><td>May 2016</td><td>Tuberculosis,Lung Diseases,Pulmonary Disease</td><td>null</td></tr><tr><td>NCT02758860</td><td>University of Roma La Sapienza</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Sep 2020</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Diverticular Diseases,Diverticulum,Diverticulosis</td><td>null</td></tr><tr><td>NCT02757209</td><td>Consorzio Futuro in Ricerca</td><td>Completed</td><td>Apr 2016</td><td>Jan 2018</td><td>Interventional</td><td>Apr 2016</td><td>Asthma</td><td>Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate</td></tr><tr><td>NCT02752438</td><td>Ankara University</td><td>Unknown status</td><td>May 2016</td><td>Jul 2017</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Hypoventilation</td><td>null</td></tr><tr><td>NCT02753543</td><td>Ruijin Hospital</td><td>Unknown status</td><td>Nov 2015</td><td>Nov 2019</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>null</td></tr><tr><td>NCT02757508</td><td>Washington University School of Medicine</td><td>Completed</td><td>Mar 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Vitamins</td></tr><tr><td>NCT02753530</td><td>Orphazyme</td><td>Completed</td><td>Aug 2017</td><td>Jan 2021</td><td>Interventional</td><td>Apr 2016</td><td>Myositis</td><td>null</td></tr><tr><td>NCT02754817</td><td>Novo Nordisk A/S</td><td>Completed</td><td>Apr 2016</td><td>Oct 2016</td><td>Observational</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Liraglutide,Xultophy</td></tr><tr><td>NCT02759276</td><td>Daniel Alexandre Bottino</td><td>Completed</td><td>May 2015</td><td>Dec 2015</td><td>Observational</td><td>Apr 2016</td><td>Hypertension</td><td>null</td></tr><tr><td>NCT02750956</td><td>Bulent Ecevit University</td><td>Completed</td><td>Jun 2015</td><td>Mar 2016</td><td>Observational</td><td>Apr 2016</td><td>Periodontal Diseases</td><td>null</td></tr><tr><td>NCT02752113</td><td>Institut für Pharmakologie und Präventive Medizin</td><td>Completed</td><td>Apr 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Metformin,Empagliflozin,Linagliptin</td></tr><tr><td>NCT02752698</td><td>The Third Xiangya Hospital of Central South University</td><td>Active, not recruiting</td><td>Jan 2015</td><td>Dec 2021</td><td>Interventional</td><td>Jun 2015</td><td>Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones</td><td>null</td></tr><tr><td>NCT02755779</td><td>Tel Aviv Medical Center</td><td>Unknown status</td><td>Jun 2016</td><td>Jun 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750384</td><td>Medicines for Malaria Venture</td><td>Terminated</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754609</td><td>James Cook University, Queensland, Australia</td><td>Completed</td><td>Sep 2016</td><td>Oct 2019</td><td>Interventional</td><td>Apr 2016</td><td>Hookworm Infections,Celiac Disease</td><td>null</td></tr><tr><td>NCT02755701</td><td>Soonchunhyang University Hospital</td><td>Unknown status</td><td>Jul 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Ascites</td><td>null</td></tr><tr><td>NCT02751762</td><td>Member Companies of the Opioid PMR Consortium</td><td>Recruiting</td><td>Nov 2017</td><td>Oct 2022</td><td>Observational</td><td>Apr 2016</td><td>Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior</td><td>null</td></tr><tr><td>NCT02756299</td><td>Marmara University</td><td>Completed</td><td>Jun 2014</td><td>Apr 2015</td><td>Interventional</td><td>Apr 2016</td><td>Sleep Apnea Syndromes,Sleep Apnea</td><td>null</td></tr><tr><td>NCT02750709</td><td>Cycle Pharmaceuticals Ltd.</td><td>Completed</td><td>Oct 2015</td><td>Jan 2016</td><td>Interventional</td><td>Apr 2016</td><td>Tyrosinemias</td><td>Nitisinone</td></tr><tr><td>NCT02753907</td><td>Yonsei University</td><td>Completed</td><td>Jun 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755467</td><td>Cutera Inc.</td><td>Completed</td><td>May 2016</td><td>Apr 2017</td><td>Interventional</td><td>Apr 2016</td><td>Hemangioma</td><td>null</td></tr><tr><td>NCT02755298</td><td>University of Zurich</td><td>Completed</td><td>Oct 2016</td><td>Nov 2020</td><td>Interventional</td><td>Mar 2016</td><td>Hypertension</td><td>Acetazolamide</td></tr><tr><td>NCT02759614</td><td>Guangdong Association of Clinical Trials</td><td>Unknown status</td><td>Apr 2016</td><td>Jun 2019</td><td>Interventional</td><td>Mar 2016</td><td>Carcinoma</td><td>Bevacizumab,Erlotinib Hydrochloride</td></tr><tr><td>NCT02752815</td><td>Ruijin Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Jun 2020</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin</td></tr><tr><td>NCT02757131</td><td>The Cleveland Clinic</td><td>Completed</td><td>Jul 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Iatrogenic Disease</td><td>null</td></tr><tr><td>NCT02758704</td><td>St. Justine's Hospital</td><td>Completed</td><td>Oct 2015</td><td>Jun 2021</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750501</td><td>Alcresta Therapeutics, Inc.</td><td>Completed</td><td>Jul 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Cystic Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT02759913</td><td>Iron Horse Diagnostics, Inc.</td><td>Unknown status</td><td>Jan 2015</td><td>Dec 2016</td><td>Observational</td><td>Apr 2016</td><td>Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis</td><td>null</td></tr><tr><td>NCT02752724</td><td>VA Puget Sound Health Care System</td><td>Completed</td><td>Mar 2016</td><td>Apr 2018</td><td>Interventional</td><td>Mar 2016</td><td>Depressive Disorder,Depression</td><td>Ketamine,Methohexital</td></tr><tr><td>NCT02758444</td><td>University of Colorado, Denver</td><td>Completed</td><td>Nov 2015</td><td>Feb 2019</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Micronutrients,Trace Elements</td></tr><tr><td>NCT02758067</td><td>H. Lundbeck A/S</td><td>Withdrawn</td><td>Jun 2016</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Schizophrenia</td><td>Risperidone,Brexpiprazole</td></tr><tr><td>NCT02759341</td><td>Ospedale San Giovanni Bellinzona</td><td>Completed</td><td>Feb 2016</td><td>Nov 2017</td><td>Interventional</td><td>Apr 2016</td><td>Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction</td><td>null</td></tr><tr><td>NCT02753803</td><td>Dong-A ST Co., Ltd.</td><td>Completed</td><td>Jul 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Pioglitazone</td></tr><tr><td>NCT02752490</td><td>The University of Texas Health Science Center, Houston</td><td>Completed</td><td>Apr 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759562</td><td>Gilead Sciences</td><td>Terminated</td><td>Nov 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Cystic Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT02758262</td><td>Laval University</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Hyperphagia</td><td>null</td></tr><tr><td>NCT02754258</td><td>Children's Hospital of Eastern Ontario</td><td>Unknown status</td><td>Jan 2017</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Methylphenidate</td></tr><tr><td>NCT02755207</td><td>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2020</td><td>Observational</td><td>Mar 2016</td><td>Acute Coronary Syndrome,Syndrome</td><td>null</td></tr><tr><td>NCT02759900</td><td>The Skin Center Dermatology Group</td><td>Recruiting</td><td>Jan 2016</td><td>Jan 2023</td><td>Interventional</td><td>Apr 2016</td><td>Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases</td><td>null</td></tr><tr><td>NCT02752581</td><td>Mert Özcan</td><td>Completed</td><td>Jan 2009</td><td>Apr 2013</td><td>Interventional</td><td>Apr 2016</td><td>Hemarthrosis</td><td>null</td></tr><tr><td>NCT02759796</td><td>Instituto de Investigación Hospital Universitario La Paz</td><td>Completed</td><td>Nov 2015</td><td>Apr 2017</td><td>Interventional</td><td>Apr 2016</td><td>Necrosis,Neovascularization,Fat Necrosis</td><td>null</td></tr><tr><td>NCT02754063</td><td>University Hospital, Grenoble</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Apr 2022</td><td>Interventional</td><td>Apr 2016</td><td>Brain Injuries,Wounds and Injuries</td><td>3</td></tr><tr><td>NCT02750917</td><td>Foisor Orthopedics Clinical Hospital</td><td>Completed</td><td>Sep 2014</td><td>Mar 2015</td><td>Interventional</td><td>Feb 2016</td><td>Pain</td><td>Etoricoxib,Lornoxicam</td></tr><tr><td>NCT02753569</td><td>Institute of Cancer Research, United Kingdom</td><td>Completed</td><td>May 2016</td><td>May 2020</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751255</td><td>VU University Medical Center</td><td>Active, not recruiting</td><td>Jul 2016</td><td>Mar 2022</td><td>Interventional</td><td>Apr 2016</td><td>Multiple Myeloma,Neoplasms</td><td>Tretinoin</td></tr><tr><td>NCT02751528</td><td>NantBioScience, Inc.</td><td>Unknown status</td><td>Dec 2016</td><td>Dec 2020</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>Vaccines</td></tr><tr><td>NCT02751619</td><td>University of Campania Luigi Vanvitelli</td><td>Completed</td><td>Jan 2013</td><td>Dec 2015</td><td>Interventional</td><td>Apr 2016</td><td>Pain</td><td>Lidocaine</td></tr><tr><td>NCT02757833</td><td>Lawson Health Research Institute</td><td>Withdrawn</td><td>Feb 2019</td><td>Feb 2019</td><td>Interventional</td><td>Apr 2016</td><td>Depression,Depressive Disorder</td><td>null</td></tr><tr><td>NCT02750761</td><td>Merck Sharp & Dohme Corp.</td><td>Completed</td><td>May 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Infections,Bacterial Infections,Gram-Positive Bacterial Infections</td><td>Tedizolid phosphate,Tedizolid,Oxazolidinones</td></tr><tr><td>NCT02752594</td><td>Sharda University</td><td>Completed</td><td>Apr 2015</td><td>Apr 2015</td><td>Interventional</td><td>Apr 2016</td><td>Dental Caries</td><td>null</td></tr><tr><td>NCT02753452</td><td>Holland Bloorview Kids Rehabilitation Hospital</td><td>Unknown status</td><td>May 2015</td><td>Mar 2020</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752763</td><td>Niğde State Hospital</td><td>Completed</td><td>Oct 2015</td><td>Mar 2016</td><td>Interventional</td><td>Mar 2016</td><td>Dry Eye Syndromes,Keratoconjunctivitis Sicca</td><td>Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops</td></tr><tr><td>NCT02753816</td><td>Spectrum Health Hospitals</td><td>Terminated</td><td>Apr 2016</td><td>Dec 2019</td><td>Interventional</td><td>Apr 2016</td><td>Burns</td><td>Tranexamic Acid</td></tr><tr><td>NCT02751294</td><td>GlaxoSmithKline</td><td>Completed</td><td>May 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Malaria</td><td>Tafenoquine</td></tr><tr><td>NCT02756429</td><td>Hospices Civils de Lyon</td><td>Completed</td><td>Feb 2014</td><td>Jan 2018</td><td>Interventional</td><td>Apr 2016</td><td>Atrial Fibrillation</td><td>null</td></tr><tr><td>NCT02750163</td><td>Università Politecnica delle Marche</td><td>Completed</td><td>Jul 2017</td><td>Jun 2019</td><td>Observational</td><td>Apr 2016</td><td>Shock</td><td>Acetaminophen</td></tr><tr><td>NCT02751905</td><td>Biogen</td><td>Completed</td><td>Apr 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Neuralgia</td><td>null</td></tr><tr><td>NCT02753153</td><td>University of Liege</td><td>Completed</td><td>May 2011</td><td>May 2015</td><td>Interventional</td><td>Apr 2016</td><td>Tooth Loss</td><td>null</td></tr><tr><td>NCT02750891</td><td>Sumitomo Dainippon Pharma Co., Ltd.</td><td>Completed</td><td>Apr 2016</td><td>Jan 2020</td><td>Interventional</td><td>Apr 2016</td><td>Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma</td><td>null</td></tr><tr><td>NCT02751073</td><td>Mayo Clinic</td><td>Completed</td><td>Feb 2016</td><td>Jul 2018</td><td>Observational</td><td>Feb 2016</td><td>Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse</td><td>null</td></tr><tr><td>NCT02753114</td><td>University of British Columbia</td><td>Completed</td><td>Nov 2017</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>Acute Pain</td><td>Ketamine</td></tr><tr><td>NCT02752516</td><td>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752269</td><td>Medical University of Graz</td><td>Completed</td><td>Oct 2014</td><td>Jun 2019</td><td>Observational</td><td>Nov 2015</td><td>Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome</td><td>null</td></tr><tr><td>NCT02754713</td><td>Hippocration General Hospital</td><td>Recruiting</td><td>Sep 2009</td><td>Dec 2025</td><td>Observational</td><td>Apr 2016</td><td>Pericarditis</td><td>null</td></tr><tr><td>NCT02759770</td><td>Beijing Anzhen Hospital</td><td>Completed</td><td>Jul 2017</td><td>Sep 2017</td><td>Observational</td><td>Apr 2016</td><td>Respiratory Distress Syndrome,Acute Lung Injury</td><td>null</td></tr><tr><td>NCT02755129</td><td>Medtronic BRC</td><td>Completed</td><td>Sep 2016</td><td>Jul 2017</td><td>Interventional</td><td>Mar 2016</td><td>Frailty</td><td>null</td></tr><tr><td>NCT02754674</td><td>Samsung Medical Center</td><td>Completed</td><td>May 2014</td><td>Dec 2017</td><td>Interventional</td><td>Feb 2015</td><td>Rupture</td><td>null</td></tr><tr><td>NCT02757521</td><td>Washington University School of Medicine</td><td>Terminated</td><td>Mar 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Depression,Depressive Disorder,Bipolar Disorder</td><td>Nitrous Oxide</td></tr><tr><td>NCT02750774</td><td>University of Modena and Reggio Emilia</td><td>Unknown status</td><td>Dec 2015</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight</td><td>null</td></tr><tr><td>NCT02754739</td><td>Samsung Medical Center</td><td>Completed</td><td>Apr 2014</td><td>Aug 2017</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus,Prediabetic State</td><td>Pravastatin</td></tr><tr><td>NCT02758808</td><td>University of Michigan</td><td>Recruiting</td><td>Mar 2016</td><td>Oct 2023</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT02751840</td><td>Tel Hai College</td><td>Completed</td><td>Oct 2014</td><td>Apr 2016</td><td>Interventional</td><td>Apr 2016</td><td>Asymptomatic Diseases</td><td>Caffeine</td></tr><tr><td>NCT02752451</td><td>University of Arizona</td><td>Completed</td><td>Mar 2015</td><td>Apr 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757599</td><td>Rigshospitalet, Denmark</td><td>Completed</td><td>Aug 2016</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753894</td><td>Astellas Pharma Inc</td><td>Completed</td><td>Jan 2008</td><td>Jun 2008</td><td>Interventional</td><td>Mar 2016</td><td>Kidney Diseases,Renal Insufficiency,Hyperphosphatemia</td><td>null</td></tr><tr><td>NCT02757638</td><td>Texas A&M University</td><td>Active, not recruiting</td><td>Oct 2015</td><td>Oct 2021</td><td>Interventional</td><td>Feb 2016</td><td>Weight Loss</td><td>null</td></tr><tr><td>NCT02757378</td><td>Kevin Farrell</td><td>Completed</td><td>May 2015</td><td>Sep 2015</td><td>Interventional</td><td>Apr 2016</td><td>Back Pain,Low Back Pain</td><td>null</td></tr><tr><td>NCT02751489</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>null</td></tr><tr><td>NCT02759315</td><td>Merck Sharp & Dohme Corp.</td><td>Terminated</td><td>May 2016</td><td>Nov 2017</td><td>Interventional</td><td>Apr 2016</td><td>Hepatitis A,Hepatitis C,Hepatitis</td><td>Uprifosbuvir,Ruzasvir</td></tr><tr><td>NCT02754895</td><td>Massachusetts General Hospital</td><td>Completed</td><td>Oct 2014</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Acute Coronary Syndrome,Syndrome</td><td>null</td></tr><tr><td>NCT02750475</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>Sunscreening Agents</td></tr><tr><td>NCT02755064</td><td>Adil Bharucha</td><td>Completed</td><td>Jun 2010</td><td>Nov 2013</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate</td></tr><tr><td>NCT02758002</td><td>University of California, San Diego</td><td>Withdrawn</td><td>Jan 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Atrial Fibrillation</td><td>null</td></tr><tr><td>NCT02755142</td><td>medac GmbH</td><td>Completed</td><td>Feb 2000</td><td>Jun 2001</td><td>Interventional</td><td>Apr 2016</td><td>Glioma,Brain Neoplasms</td><td>Aminolevulinic Acid</td></tr><tr><td>NCT02756364</td><td>Millennium Pharmaceuticals, Inc.</td><td>Completed</td><td>Jul 2016</td><td>Nov 2019</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>Fulvestrant</td></tr><tr><td>NCT02759484</td><td>Rush University Medical Center</td><td>Unknown status</td><td>Mar 2015</td><td>Mar 2019</td><td>Interventional</td><td>Dec 2015</td><td>Hypertension,Diabetes Mellitus,Hyperglycemia</td><td>null</td></tr><tr><td>NCT02752061</td><td>Harvard School of Public Health (HSPH)</td><td>Completed</td><td>May 2016</td><td>Jul 2020</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756598</td><td>Aarhus University Hospital</td><td>Completed</td><td>Jan 2015</td><td>Jun 2018</td><td>Interventional</td><td>Dec 2015</td><td>null</td><td>Sufentanil,Dsuvia,Propofol</td></tr><tr><td>NCT02755727</td><td>Royal Devon and Exeter NHS Foundation Trust</td><td>Completed</td><td>Mar 2016</td><td>Sep 2017</td><td>Interventional</td><td>Apr 2016</td><td>Tennis Elbow</td><td>null</td></tr><tr><td>NCT02754882</td><td>Samsung Bioepis Co., Ltd.</td><td>Completed</td><td>Jul 2016</td><td>Oct 2018</td><td>Interventional</td><td>Mar 2016</td><td>Lung Neoplasms,Carcinoma</td><td>Paclitaxel,Bevacizumab,Carboplatin</td></tr><tr><td>NCT02754778</td><td>Martin-Luther-Universität Halle-Wittenberg</td><td>Completed</td><td>Apr 2016</td><td>Mar 2021</td><td>Interventional</td><td>Apr 2016</td><td>Pre-Eclampsia,HELLP Syndrome,Syndrome</td><td>null</td></tr><tr><td>NCT02758171</td><td>Boehringer Ingelheim</td><td>Completed</td><td>May 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Empagliflozin,Linagliptin</td></tr><tr><td>NCT02755376</td><td>Samsung Medical Center</td><td>Completed</td><td>Jan 2014</td><td>Dec 2018</td><td>Interventional</td><td>Feb 2015</td><td>null</td><td>Hyaluronic Acid</td></tr><tr><td>NCT02759016</td><td>Boehringer Ingelheim</td><td>Completed</td><td>Jun 2016</td><td>Jul 2019</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia</td><td>BI 836826</td></tr><tr><td>NCT02758457</td><td>University of Bologna</td><td>Completed</td><td>Jan 2008</td><td>Apr 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755519</td><td>Chongqing Medical University</td><td>Completed</td><td>May 2014</td><td>Oct 2016</td><td>Observational</td><td>Apr 2016</td><td>Hyperaldosteronism</td><td>null</td></tr><tr><td>NCT02758782</td><td>Charite University, Berlin, Germany</td><td>Completed</td><td>Sep 2016</td><td>Jan 2021</td><td>Interventional</td><td>Apr 2016</td><td>Spondylitis</td><td>Celecoxib,Golimumab</td></tr><tr><td>NCT02756806</td><td>Cutera Inc.</td><td>Completed</td><td>Apr 2016</td><td>Sep 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756156</td><td>Kahramanmaras Sutcu Imam University</td><td>Unknown status</td><td>Apr 2016</td><td>Aug 2016</td><td>Observational</td><td>Mar 2016</td><td>Humeral Fractures</td><td>null</td></tr><tr><td>NCT02759458</td><td>Rush University Medical Center</td><td>Completed</td><td>Nov 2013</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>Rotator Cuff Injuries</td><td>null</td></tr><tr><td>NCT02750982</td><td>Brown, Theodore R., M.D., MPH</td><td>Completed</td><td>Jul 2016</td><td>Aug 2018</td><td>Interventional</td><td>Apr 2016</td><td>Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT02751502</td><td>NYU Langone Health</td><td>Terminated</td><td>Jan 2017</td><td>Feb 2021</td><td>Interventional</td><td>Apr 2016</td><td>Hemiplegia</td><td>null</td></tr><tr><td>NCT02752087</td><td>Eli Lilly and Company</td><td>Completed</td><td>Apr 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756858</td><td>Anavex Life Sciences Corp.</td><td>Completed</td><td>Mar 2016</td><td>Nov 2020</td><td>Interventional</td><td>Mar 2016</td><td>Alzheimer Disease</td><td>null</td></tr><tr><td>NCT02758249</td><td>Konkuk University Medical Center</td><td>Completed</td><td>Jan 2016</td><td>Jan 2016</td><td>Interventional</td><td>Feb 2016</td><td>null</td><td>Propofol,Sevoflurane</td></tr><tr><td>NCT02754570</td><td>University of Colorado, Denver</td><td>Completed</td><td>Jul 2016</td><td>Feb 2018</td><td>Interventional</td><td>Apr 2016</td><td>Glaucoma,Ocular Hypertension,Hypertension</td><td>Pilocarpine</td></tr><tr><td>NCT02754102</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>Sunscreening Agents</td></tr><tr><td>NCT02751593</td><td>Peking University People's Hospital</td><td>Unknown status</td><td>Jan 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Thrombocytopenia,Purpura</td><td>Dexamethasone</td></tr><tr><td>NCT02757014</td><td>Bayer</td><td>Completed</td><td>Oct 2015</td><td>Oct 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753062</td><td>Asan Medical Center</td><td>Recruiting</td><td>Aug 2015</td><td>Aug 2023</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>Rituximab,Bendamustine Hydrochloride</td></tr><tr><td>NCT02752425</td><td>Hospices Civils de Lyon</td><td>Completed</td><td>May 2016</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>Speech Disorders</td><td>null</td></tr><tr><td>NCT02757300</td><td>Marienhospital Osnabrück</td><td>Unknown status</td><td>May 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Pharyngitis</td><td>null</td></tr><tr><td>NCT02754180</td><td>Peking Union Medical College Hospital</td><td>Unknown status</td><td>Mar 2016</td><td>Mar 2021</td><td>Interventional</td><td>Apr 2016</td><td>Adenocarcinoma,Pancreatic Neoplasms</td><td>Gemcitabine</td></tr><tr><td>NCT02752321</td><td>Northwell Health</td><td>Terminated</td><td>Aug 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753595</td><td>Eisai Inc.</td><td>Terminated</td><td>Jul 2016</td><td>Aug 2019</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02755246</td><td>Charite University, Berlin, Germany</td><td>Completed</td><td>Apr 2016</td><td>Sep 2016</td><td>Interventional</td><td>Apr 2016</td><td>Cognitive Dysfunction</td><td>null</td></tr><tr><td>NCT02754115</td><td>Tata Memorial Centre</td><td>Recruiting</td><td>Apr 2016</td><td>Jan 2022</td><td>Observational</td><td>Mar 2016</td><td>Peritoneal Diseases</td><td>null</td></tr><tr><td>NCT02756897</td><td>M.D. Anderson Cancer Center</td><td>Active, not recruiting</td><td>Jul 2016</td><td>Jul 2024</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma,Leukemia</td><td>Venetoclax</td></tr><tr><td>NCT02752334</td><td>Magrabi Eye & Ear Hospital</td><td>Completed</td><td>Sep 2015</td><td>Mar 2019</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>Magnesium Sulfate,Bupivacaine</td></tr><tr><td>NCT02754791</td><td>Shaare Zedek Medical Center</td><td>Unknown status</td><td>May 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754128</td><td>Holland Bloorview Kids Rehabilitation Hospital</td><td>Completed</td><td>Jun 2016</td><td>Oct 2017</td><td>Interventional</td><td>Apr 2016</td><td>Cerebral Palsy</td><td>null</td></tr><tr><td>NCT02751190</td><td>Umeå University</td><td>Completed</td><td>Sep 2013</td><td>Feb 2017</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Chronic Pain,Hernia</td><td>null</td></tr><tr><td>NCT02751645</td><td>Oregon Health and Science University</td><td>Unknown status</td><td>Jun 2016</td><td>May 2020</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758184</td><td>Duke University</td><td>Terminated</td><td>Jun 2016</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751892</td><td>University of East Anglia</td><td>Completed</td><td>Oct 2013</td><td>Sep 2014</td><td>Interventional</td><td>Apr 2016</td><td>Colorectal Neoplasms</td><td>null</td></tr><tr><td>NCT02755324</td><td>Leiden University</td><td>Completed</td><td>Oct 2016</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Schistosomiasis</td><td>null</td></tr><tr><td>NCT02758886</td><td>Washington State University</td><td>Completed</td><td>Apr 2014</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Stress</td><td>null</td></tr><tr><td>NCT02750072</td><td>Fraser Orthopaedic Research Society</td><td>Active, not recruiting</td><td>Sep 2016</td><td>Apr 2023</td><td>Interventional</td><td>Apr 2016</td><td>Patellofemoral Pain Syndrome,Fractures,Tibial Fractures</td><td>null</td></tr><tr><td>NCT02750332</td><td>Cycle Pharmaceuticals Ltd.</td><td>Completed</td><td>Nov 2015</td><td>Jan 2016</td><td>Interventional</td><td>Apr 2016</td><td>Tyrosinemias</td><td>Nitisinone</td></tr><tr><td>NCT02752529</td><td>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</td><td>Unknown status</td><td>Mar 2016</td><td>null</td><td>Interventional</td><td>Mar 2016</td><td>Liver Cirrhosis</td><td>Tacrolimus</td></tr><tr><td>NCT02759939</td><td>Dartmouth-Hitchcock Medical Center</td><td>Completed</td><td>Jul 2016</td><td>Jul 2017</td><td>Interventional</td><td>Feb 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757157</td><td>European Respiratory Society</td><td>Terminated</td><td>Oct 2016</td><td>Jan 2020</td><td>Interventional</td><td>Apr 2016</td><td>Lung Diseases,Pulmonary Disease</td><td>null</td></tr><tr><td>NCT02759627</td><td>Istanbul University</td><td>Completed</td><td>Nov 2014</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>Stroke</td><td>null</td></tr><tr><td>NCT02752412</td><td>Sanofi</td><td>Completed</td><td>May 2016</td><td>Oct 2018</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Insulin,Metformin,Insulin Glargine,Lixisenatide</td></tr><tr><td>NCT02756988</td><td>Bayer</td><td>Completed</td><td>Oct 2015</td><td>Oct 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751203</td><td>Lara McKenzie</td><td>Completed</td><td>Apr 2016</td><td>Dec 2017</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753946</td><td>Nabriva Therapeutics AG</td><td>Completed</td><td>Apr 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis</td><td>Tazobactam,Piperacillin,Fosfomycin</td></tr><tr><td>NCT02755480</td><td>University Health Network, Toronto</td><td>Terminated</td><td>Feb 2015</td><td>Feb 2017</td><td>Interventional</td><td>Mar 2015</td><td>null</td><td>null</td></tr><tr><td>NCT02753257</td><td>Valtari Bio</td><td>Unknown status</td><td>Sep 2016</td><td>Dec 2019</td><td>Observational</td><td>Apr 2016</td><td>Stroke</td><td>null</td></tr><tr><td>NCT02758691</td><td>Virginia Polytechnic Institute and State University</td><td>Completed</td><td>Dec 2015</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Insulin</td></tr><tr><td>NCT02755623</td><td>Centre hospitalier de Ville-Evrard, France</td><td>Unknown status</td><td>May 2015</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Hallucinations,Schizophrenia</td><td>null</td></tr><tr><td>NCT02756234</td><td>Lancaster General Hospital</td><td>Completed</td><td>May 2016</td><td>Aug 2018</td><td>Observational</td><td>Apr 2016</td><td>Coronary Artery Disease</td><td>null</td></tr><tr><td>NCT02756091</td><td>University Hospital Inselspital, Berne</td><td>Recruiting</td><td>Aug 2016</td><td>May 2022</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Cerebrovascular Disorders</td><td>null</td></tr><tr><td>NCT02753491</td><td>Marmara University</td><td>Completed</td><td>Oct 2015</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752737</td><td>Medtronic Cardiac Rhythm and Heart Failure</td><td>Recruiting</td><td>May 2016</td><td>Dec 2024</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Atrial Fibrillation</td><td>null</td></tr><tr><td>NCT02758925</td><td>University Hospital, Caen</td><td>Unknown status</td><td>Jun 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>Cytarabine,Rituximab,Bendamustine Hydrochloride</td></tr><tr><td>NCT02751723</td><td>Florian Lordick, MD</td><td>Unknown status</td><td>Sep 2014</td><td>Oct 2019</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751931</td><td>Astellas Pharma Europe B.V.</td><td>Completed</td><td>Jun 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Urinary Bladder</td><td>Mirabegron</td></tr><tr><td>NCT02758847</td><td>Rabih A. Chaer</td><td>Recruiting</td><td>Sep 2016</td><td>Dec 2022</td><td>Interventional</td><td>Apr 2016</td><td>Ischemia</td><td>Paclitaxel,Albumin-Bound Paclitaxel</td></tr><tr><td>NCT02757807</td><td>Eco Fusion</td><td>Unknown status</td><td>Jul 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Erectile Dysfunction</td><td>null</td></tr><tr><td>NCT02755220</td><td>Shanghai Cingularbio Co. Ltd</td><td>Completed</td><td>Jan 2016</td><td>Apr 2019</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758548</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Mar 2016</td><td>May 2016</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756845</td><td>Amgen</td><td>Recruiting</td><td>Aug 2017</td><td>Jun 2024</td><td>Interventional</td><td>Dec 2015</td><td>Neoplasms</td><td>Talimogene laherparepvec</td></tr><tr><td>NCT02750605</td><td>Skane University Hospital</td><td>Active, not recruiting</td><td>Feb 2016</td><td>Dec 2021</td><td>Interventional</td><td>Jan 2016</td><td>Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia</td><td>null</td></tr><tr><td>NCT02756702</td><td>Aesculap AG</td><td>Active, not recruiting</td><td>Mar 2016</td><td>Dec 2022</td><td>Observational</td><td>Apr 2016</td><td>Osteoarthritis</td><td>null</td></tr><tr><td>NCT02752945</td><td>King's College London</td><td>Completed</td><td>Apr 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Depression,Depressive Disorder,Anxiety Disorders</td><td>null</td></tr><tr><td>NCT02759952</td><td>STZ eyetrial</td><td>Enrolling by invitation</td><td>Jan 2013</td><td>Dec 2025</td><td>Observational</td><td>Apr 2016</td><td>Retinitis,Retinitis Pigmentosa</td><td>null</td></tr><tr><td>NCT02754661</td><td>Medtronic - MITG</td><td>Completed</td><td>Sep 2016</td><td>Aug 2018</td><td>Interventional</td><td>Apr 2016</td><td>Colorectal Neoplasms</td><td>null</td></tr><tr><td>NCT02755441</td><td>Nils Hoyer</td><td>Recruiting</td><td>Apr 2016</td><td>Dec 2024</td><td>Observational</td><td>Apr 2016</td><td>Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT02750098</td><td>Sheba Medical Center</td><td>Unknown status</td><td>May 2016</td><td>Mar 2018</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02753179</td><td>Hospices Civils de Lyon</td><td>Completed</td><td>May 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>Vestibular Diseases</td><td>null</td></tr><tr><td>NCT02758509</td><td>Parc de Salut Mar</td><td>Completed</td><td>Jan 2010</td><td>Oct 2017</td><td>Observational</td><td>Apr 2016</td><td>Hepatitis C,Hepatitis</td><td>Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir</td></tr><tr><td>NCT02751970</td><td>Universidad de Valparaiso</td><td>Unknown status</td><td>Apr 2014</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>Dental Caries</td><td>null</td></tr><tr><td>NCT02753712</td><td>Mundipharma Research Limited</td><td>Completed</td><td>Jun 2016</td><td>Aug 2017</td><td>Interventional</td><td>Apr 2016</td><td>Asthma</td><td>Fluticasone,Xhance,Formoterol Fumarate</td></tr><tr><td>NCT02751151</td><td>Inova Health Care Services</td><td>Completed</td><td>Feb 2016</td><td>May 2021</td><td>Interventional</td><td>Mar 2016</td><td>Skin Neoplasms</td><td>Aminolevulinic Acid</td></tr><tr><td>NCT02757716</td><td>Sana Klinikum Offenbach</td><td>Completed</td><td>Apr 2016</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Behavior</td><td>null</td></tr><tr><td>NCT02758652</td><td>Tampere University Hospital</td><td>Active, not recruiting</td><td>May 2016</td><td>May 2026</td><td>Observational</td><td>Apr 2016</td><td>Ovarian Neoplasms,Carcinoma</td><td>null</td></tr><tr><td>NCT02754206</td><td>Southern Methodist University</td><td>Terminated</td><td>Jan 2016</td><td>Sep 2021</td><td>Observational</td><td>Apr 2016</td><td>Post-Concussion Syndrome,Brain Concussion</td><td>null</td></tr><tr><td>NCT02752243</td><td>Peter Bader</td><td>Active, not recruiting</td><td>Mar 2016</td><td>Mar 2022</td><td>Interventional</td><td>Mar 2016</td><td>Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease</td><td>null</td></tr><tr><td>NCT02754856</td><td>M.D. Anderson Cancer Center</td><td>Active, not recruiting</td><td>Jul 2016</td><td>Jul 2021</td><td>Interventional</td><td>Apr 2016</td><td>Colorectal Neoplasms</td><td>Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G</td></tr><tr><td>NCT02759861</td><td>University of Nebraska</td><td>Active, not recruiting</td><td>Aug 2016</td><td>Aug 2020</td><td>Interventional</td><td>Apr 2016</td><td>Hepatitis A,Hepatitis C,Hepatitis</td><td>Sofosbuvir,Ledipasvir</td></tr><tr><td>NCT02759679</td><td>Haukeland University Hospital</td><td>Unknown status</td><td>May 2016</td><td>Dec 2019</td><td>Interventional</td><td>Mar 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02752932</td><td>Lawson Health Research Institute</td><td>Completed</td><td>Nov 2015</td><td>Oct 2017</td><td>Interventional</td><td>Feb 2016</td><td>Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms</td><td>null</td></tr><tr><td>NCT02759445</td><td>RWTH Aachen University</td><td>Unknown status</td><td>Apr 2016</td><td>Oct 2016</td><td>Observational</td><td>Nov 2015</td><td>null</td><td>null</td></tr><tr><td>NCT02754622</td><td>Guy's and St Thomas' NHS Foundation Trust</td><td>Completed</td><td>Jul 2016</td><td>Dec 2016</td><td>Observational</td><td>Apr 2016</td><td>Critical Illness</td><td>null</td></tr><tr><td>NCT02756611</td><td>AbbVie</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Sep 2022</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia</td><td>Venetoclax</td></tr><tr><td>NCT02758223</td><td>Wuerzburg University Hospital</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Jun 2021</td><td>Interventional</td><td>Feb 2016</td><td>Leukemia,Myelodysplastic Syndromes</td><td>null</td></tr><tr><td>NCT02757079</td><td>Nobelpharma</td><td>Completed</td><td>Jun 2016</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders</td><td>Melatonin</td></tr><tr><td>NCT02754219</td><td>Dong-A ST Co., Ltd.</td><td>Completed</td><td>Sep 2016</td><td>Jan 2018</td><td>Interventional</td><td>Apr 2016</td><td>Liver Diseases</td><td>null</td></tr><tr><td>NCT02753101</td><td>Stanford University</td><td>Completed</td><td>Feb 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica</td><td>null</td></tr><tr><td>NCT02759003</td><td>Fondazione Salvatore Maugeri</td><td>Completed</td><td>Mar 2011</td><td>Mar 2014</td><td>Interventional</td><td>Apr 2016</td><td>Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis</td><td>null</td></tr><tr><td>NCT02752659</td><td>University of British Columbia</td><td>Completed</td><td>Jun 2016</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms,Lymphedema</td><td>null</td></tr><tr><td>NCT02758912</td><td>Burnasyan Federal Medical Biophysical Center</td><td>Completed</td><td>Nov 2016</td><td>Oct 2019</td><td>Interventional</td><td>Apr 2016</td><td>Stroke,Angina Pectoris,Infarction,Hemorrhage</td><td>null</td></tr><tr><td>NCT02754388</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Feb 2016</td><td>Dec 2019</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02759666</td><td>Atridia Pty Ltd.</td><td>Completed</td><td>Jun 2016</td><td>Apr 2019</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms</td><td>null</td></tr><tr><td>NCT02750241</td><td>The University of Texas Medical Branch, Galveston</td><td>Completed</td><td>Apr 2016</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02752568</td><td>Kasr El Aini Hospital</td><td>Unknown status</td><td>May 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758015</td><td>University of California, San Francisco</td><td>Completed</td><td>Jun 2016</td><td>Mar 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Betaine</td></tr><tr><td>NCT02756884</td><td>Arkansas Heart Hospital</td><td>Completed</td><td>Jun 2015</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Peripheral Arterial Disease,Peripheral Vascular Diseases</td><td>null</td></tr><tr><td>NCT02758353</td><td>JSI Research & Training Institute, Inc.</td><td>Completed</td><td>Apr 2015</td><td>Nov 2015</td><td>Interventional</td><td>Apr 2016</td><td>Malaria,Stillbirth</td><td>null</td></tr><tr><td>NCT02753751</td><td>Yale University</td><td>Completed</td><td>Mar 2018</td><td>Jan 2020</td><td>Interventional</td><td>Apr 2016</td><td>Acute Kidney Injury,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT02757170</td><td>All India Institute of Medical Sciences, New Delhi</td><td>Unknown status</td><td>Jul 2015</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Liver Failure,Hepatic Insufficiency,End Stage Liver Disease,Acute-On-Chronic Liver Failure</td><td>null</td></tr><tr><td>NCT02757625</td><td>Pfizer</td><td>Completed</td><td>Jul 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Dexmedetomidine</td></tr><tr><td>NCT02752347</td><td>Riyadh Colleges of Dentistry and Pharmacy</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Malocclusion</td><td>null</td></tr><tr><td>NCT02756468</td><td>University of Roma La Sapienza</td><td>Unknown status</td><td>Jan 2015</td><td>Dec 2016</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Pancreatic Neoplasms</td><td>null</td></tr><tr><td>NCT02750410</td><td>Eli Lilly and Company</td><td>Completed</td><td>Aug 2016</td><td>Jun 2018</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Dulaglutide</td></tr><tr><td>NCT02755389</td><td>Nova Scotia Health Authority</td><td>Completed</td><td>Sep 2016</td><td>Jun 2018</td><td>Interventional</td><td>Apr 2016</td><td>Apnea</td><td>null</td></tr><tr><td>NCT02755168</td><td>Assiut University</td><td>Unknown status</td><td>May 2017</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751567</td><td>Bayer</td><td>Withdrawn</td><td>May 2016</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>null</td></tr><tr><td>NCT02755558</td><td>Penn State University</td><td>Completed</td><td>Sep 2014</td><td>May 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757547</td><td>Electrical Geodesics, Inc.</td><td>Terminated</td><td>Sep 2015</td><td>Nov 2017</td><td>Interventional</td><td>Apr 2016</td><td>Epilepsy</td><td>null</td></tr><tr><td>NCT02752828</td><td>Sanofi</td><td>Completed</td><td>May 2016</td><td>Mar 2018</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Insulin,Insulin Glargine,Lixisenatide,Hypoglycemic Agents</td></tr><tr><td>NCT02756715</td><td>Konkuk University Medical Center</td><td>Completed</td><td>May 2016</td><td>Feb 2020</td><td>Interventional</td><td>Apr 2016</td><td>Vascular System Injuries,Ischemia</td><td>Propofol,Desflurane</td></tr><tr><td>NCT02756117</td><td>Vanderbilt University</td><td>Completed</td><td>May 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>Prediabetic State</td><td>null</td></tr><tr><td>NCT02753205</td><td>Gachon University Gil Medical Center</td><td>Withdrawn</td><td>Apr 2016</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>Intracranial Hypertension</td><td>Dexmedetomidine</td></tr><tr><td>NCT02756221</td><td>Tel Hai College</td><td>Completed</td><td>Mar 2016</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>Respiratory Tract Infections,Gastroenteritis</td><td>null</td></tr><tr><td>NCT02755675</td><td>Rigshospitalet, Denmark</td><td>Recruiting</td><td>Apr 2016</td><td>Oct 2023</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma,Lung Neoplasms,Mesothelioma</td><td>null</td></tr><tr><td>NCT02754037</td><td>University of California, Davis</td><td>Recruiting</td><td>Apr 2016</td><td>Jun 2024</td><td>Observational</td><td>Apr 2016</td><td>Liver Diseases,Fatty Liver,Non-alcoholic Fatty Liver Disease,Inflammation</td><td>Fluorodeoxyglucose F18</td></tr><tr><td>NCT02750306</td><td>Merck Sharp & Dohme Corp.</td><td>Completed</td><td>May 2016</td><td>Sep 2018</td><td>Interventional</td><td>Apr 2016</td><td>Alzheimer Disease,Sleep Initiation and Maintenance Disorders</td><td>Suvorexant</td></tr><tr><td>NCT02756403</td><td>Medstar Health Research Institute</td><td>Completed</td><td>Mar 2016</td><td>Jul 2017</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>Azithromycin,Metronidazole,Doxycycline</td></tr><tr><td>NCT02759653</td><td>Haukeland University Hospital</td><td>Completed</td><td>May 2016</td><td>Dec 2018</td><td>Observational</td><td>Apr 2016</td><td>Stroke,Ischemic Stroke,Carotid Artery Diseases,Embolic Stroke</td><td>null</td></tr><tr><td>NCT02753920</td><td>Northwell Health</td><td>Completed</td><td>Mar 2016</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>Prolapse</td><td>null</td></tr><tr><td>NCT02759367</td><td>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</td><td>Completed</td><td>Mar 2008</td><td>Jun 2015</td><td>Interventional</td><td>Dec 2015</td><td>Hypertension</td><td>null</td></tr><tr><td>NCT02752997</td><td>Mayo Clinic</td><td>Completed</td><td>Dec 2015</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT02750059</td><td>South East Asia Research Collaboration with Hawaii</td><td>Completed</td><td>Jan 2015</td><td>Feb 2018</td><td>Interventional</td><td>May 2015</td><td>Infections,Communicable Diseases,HIV Infections,Acquired Immunodeficiency Syndrome</td><td>Tenofovir,Lamivudine,Efavirenz,Telmisartan</td></tr><tr><td>NCT02754505</td><td>Danube Hospital</td><td>Completed</td><td>Feb 2008</td><td>Dec 2011</td><td>Interventional</td><td>Mar 2016</td><td>Critical Illness</td><td>null</td></tr><tr><td>NCT02751736</td><td>Seoul National University Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Rectal Neoplasms</td><td>null</td></tr><tr><td>NCT02750930</td><td>GlaxoSmithKline</td><td>Terminated</td><td>Oct 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>rGLP-1 protein</td></tr><tr><td>NCT02753582</td><td>Indonesia University</td><td>Unknown status</td><td>Apr 2016</td><td>Apr 2017</td><td>Interventional</td><td>Apr 2016</td><td>Frailty</td><td>null</td></tr><tr><td>NCT02750722</td><td>University of Zurich</td><td>Completed</td><td>May 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>Cystic Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT02756793</td><td>Lawson Health Research Institute</td><td>Active, not recruiting</td><td>Oct 2016</td><td>Jun 2026</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasm Metastasis,Neoplasms</td><td>null</td></tr><tr><td>NCT02750436</td><td>Montreal General Hospital</td><td>Completed</td><td>Apr 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Back Pain</td><td>null</td></tr><tr><td>NCT02755922</td><td>Instituto Mexicano del Seguro Social</td><td>Completed</td><td>Apr 2010</td><td>Dec 2010</td><td>Interventional</td><td>Apr 2016</td><td>Mandibular Fractures</td><td>null</td></tr><tr><td>NCT02755493</td><td>Brigham and Women's Hospital</td><td>Completed</td><td>Apr 2016</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>Sleep Deprivation</td><td>null</td></tr><tr><td>NCT02750397</td><td>Massachusetts General Hospital</td><td>Active, not recruiting</td><td>Aug 2016</td><td>Dec 2024</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753621</td><td>Johns Hopkins University</td><td>Completed</td><td>Dec 2015</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Parkinson Disease</td><td>null</td></tr><tr><td>NCT02754154</td><td>Bristol-Myers Squibb</td><td>Unknown status</td><td>Dec 2014</td><td>Feb 2019</td><td>Observational</td><td>Apr 2016</td><td>Atrial Fibrillation</td><td>Warfarin,Rivaroxaban,Dabigatran,Apixaban</td></tr><tr><td>NCT02753049</td><td>New York University</td><td>Unknown status</td><td>Nov 2016</td><td>Aug 2018</td><td>Interventional</td><td>Apr 2016</td><td>HIV Infections,Acquired Immunodeficiency Syndrome</td><td>null</td></tr><tr><td>NCT02750813</td><td>Alcon, a Novartis Company</td><td>Completed</td><td>Apr 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Refractive Errors</td><td>null</td></tr><tr><td>NCT02756975</td><td>Modarres Hospital</td><td>Completed</td><td>Dec 2014</td><td>Dec 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759601</td><td>Queen Mary University of London</td><td>Unknown status</td><td>Jan 2013</td><td>Dec 2018</td><td>Interventional</td><td>Oct 2014</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02757326</td><td>RedHill Biopharma Limited</td><td>Terminated</td><td>Dec 2016</td><td>May 2019</td><td>Interventional</td><td>Mar 2016</td><td>Multiple Myeloma,Neoplasms</td><td>null</td></tr><tr><td>NCT02758236</td><td>Ina-Respond</td><td>Active, not recruiting</td><td>Feb 2017</td><td>Dec 2021</td><td>Observational</td><td>Apr 2016</td><td>Tuberculosis</td><td>null</td></tr><tr><td>NCT02754804</td><td>University Hospital, Angers</td><td>Completed</td><td>Jul 2016</td><td>Mar 2020</td><td>Observational</td><td>Apr 2016</td><td>Peripheral Arterial Disease</td><td>null</td></tr><tr><td>NCT02756065</td><td>Washington University Early Recognition Center</td><td>Completed</td><td>Sep 2014</td><td>Aug 2019</td><td>Observational</td><td>Jun 2015</td><td>Schizophrenia,Bipolar Disorder</td><td>null</td></tr><tr><td>NCT02756247</td><td>Memorial Sloan Kettering Cancer Center</td><td>Active, not recruiting</td><td>May 2016</td><td>May 2022</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>null</td></tr><tr><td>NCT02755857</td><td>Mayne Pharma International Pty Ltd</td><td>Completed</td><td>Jul 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>Neutropenia</td><td>Itraconazole</td></tr><tr><td>NCT02750111</td><td>Dr. Orit Hamiel</td><td>Unknown status</td><td>May 2016</td><td>May 2018</td><td>Observational</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02755948</td><td>Imperial College London</td><td>Recruiting</td><td>Apr 2012</td><td>Mar 2023</td><td>Interventional</td><td>Apr 2016</td><td>Influenza,Virus Diseases,Respiratory Syncytial Virus Infections</td><td>null</td></tr><tr><td>NCT02754089</td><td>Shiraz University of Medical Sciences</td><td>Completed</td><td>May 2016</td><td>Sep 2016</td><td>Interventional</td><td>Apr 2016</td><td>Body Weight</td><td>null</td></tr><tr><td>NCT02756169</td><td>Universidad Iberoamericana A.C., Mexico</td><td>Completed</td><td>Jul 2016</td><td>Feb 2018</td><td>Interventional</td><td>Apr 2016</td><td>Obesity</td><td>null</td></tr><tr><td>NCT02757664</td><td>Federal University of São Paulo</td><td>Completed</td><td>Feb 2017</td><td>Jun 2020</td><td>Interventional</td><td>Apr 2016</td><td>Tendinopathy</td><td>null</td></tr><tr><td>NCT02757989</td><td>Groupe Francophone des Myelodysplasies</td><td>Active, not recruiting</td><td>May 2016</td><td>Jun 2024</td><td>Interventional</td><td>Mar 2016</td><td>Preleukemia,Myelodysplastic Syndromes</td><td>null</td></tr><tr><td>NCT02755038</td><td>Bnai Zion Medical Center</td><td>Unknown status</td><td>Mar 2016</td><td>Mar 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759354</td><td>MCM Vaccines B.V.</td><td>Completed</td><td>Apr 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Hepatitis A,Hepatitis B,Whooping Cough,Hepatitis</td><td>null</td></tr><tr><td>NCT02750254</td><td>Washington University School of Medicine</td><td>Terminated</td><td>Jun 2016</td><td>Oct 2020</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic Syndromes</td><td>Plerixafor,Cyclophosphamide,Melphalan,Busulfan,Fludarabine,Azacitidine,Lenograstim,Sargramostim</td></tr><tr><td>NCT02755025</td><td>Mayo Clinic</td><td>Completed</td><td>Jul 2016</td><td>Aug 2016</td><td>Observational</td><td>Mar 2016</td><td>Sepsis</td><td>null</td></tr><tr><td>NCT02757703</td><td>Kaohsiung Veterans General Hospital.</td><td>Completed</td><td>May 2010</td><td>Jan 2015</td><td>Interventional</td><td>Apr 2016</td><td>Hemorrhage</td><td>Terlipressin,Pantoprazole,Somatostatin</td></tr><tr><td>NCT02758899</td><td>Washington University School of Medicine</td><td>Terminated</td><td>Mar 2014</td><td>Aug 2016</td><td>Observational</td><td>Apr 2016</td><td>Spondylosis,Spinal Cord Diseases,Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02751450</td><td>GlaxoSmithKline</td><td>Completed</td><td>Feb 2016</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dentin Sensitivity,Hypersensitivity</td><td>Fluorides,Tin Fluorides,Fluorophosphate</td></tr><tr><td>NCT02759497</td><td>Tanta University</td><td>Unknown status</td><td>Mar 2016</td><td>Nov 2020</td><td>Observational</td><td>May 2016</td><td>Peritonitis</td><td>null</td></tr><tr><td>NCT02750826</td><td>Alliance for Clinical Trials in Oncology</td><td>Active, not recruiting</td><td>Aug 2016</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms,Weight Loss</td><td>null</td></tr><tr><td>NCT02750631</td><td>New York State Psychiatric Institute</td><td>Completed</td><td>Apr 2014</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Depression,Depressive Disorder</td><td>null</td></tr><tr><td>NCT02756182</td><td>Laborie Medical Technologies Inc.</td><td>Completed</td><td>Apr 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754583</td><td>University of California, San Francisco</td><td>Recruiting</td><td>Dec 2015</td><td>Aug 2024</td><td>Interventional</td><td>Oct 2015</td><td>Trachoma</td><td>Azithromycin,Tetracycline</td></tr><tr><td>NCT02750020</td><td>The University of Hong Kong</td><td>Completed</td><td>Feb 2016</td><td>Sep 2016</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759978</td><td>University Medical Center Groningen</td><td>Recruiting</td><td>May 2016</td><td>May 2023</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Endocarditis</td><td>null</td></tr><tr><td>NCT02759575</td><td>Vinita Takiar</td><td>Completed</td><td>Apr 2016</td><td>Feb 2021</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma,Squamous Cell Carcinoma of Head and Neck</td><td>Pembrolizumab</td></tr><tr><td>NCT02750878</td><td>Boston Urogynecology Associates</td><td>Unknown status</td><td>Nov 2015</td><td>Jul 2020</td><td>Interventional</td><td>Apr 2016</td><td>Urinary Incontinence,Enuresis</td><td>null</td></tr><tr><td>NCT02758600</td><td>Federal University of São Paulo</td><td>Unknown status</td><td>Mar 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Myocardial Infarction,Infarction</td><td>null</td></tr><tr><td>NCT02750657</td><td>University Health Network, Toronto</td><td>Active, not recruiting</td><td>Dec 2015</td><td>Dec 2021</td><td>Observational</td><td>Jan 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02750007</td><td>Jiangsu Hansoh Pharmaceutical Co., Ltd.</td><td>Unknown status</td><td>Dec 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02750462</td><td>University Hospital Schleswig-Holstein</td><td>Completed</td><td>Nov 2016</td><td>Sep 2019</td><td>Interventional</td><td>Apr 2016</td><td>Heart Arrest,Out-of-Hospital Cardiac Arrest</td><td>null</td></tr><tr><td>NCT02755597</td><td>AbbVie</td><td>Suspended</td><td>Jul 2016</td><td>Feb 2022</td><td>Interventional</td><td>Apr 2016</td><td>Multiple Myeloma,Neoplasms</td><td>Dexamethasone,Bortezomib,Venetoclax</td></tr><tr><td>NCT02754232</td><td>Odense University Hospital</td><td>Withdrawn</td><td>Aug 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Pulmonary Disease,Chronic Disease</td><td>null</td></tr><tr><td>NCT02751515</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>null</td></tr><tr><td>NCT02758080</td><td>Seoul National University Hospital</td><td>Unknown status</td><td>Jan 2016</td><td>Jun 2019</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms,Hematologic Neoplasms</td><td>null</td></tr><tr><td>NCT02756312</td><td>Beijing Tiantan Hospital</td><td>Not yet recruiting</td><td>Oct 2020</td><td>Dec 2022</td><td>Interventional</td><td>Apr 2016</td><td>Glioma</td><td>Anesthetics</td></tr><tr><td>NCT02759107</td><td>Eli Lilly and Company</td><td>Completed</td><td>May 2016</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Dulaglutide,Tirzepatide</td></tr><tr><td>NCT02758795</td><td>University of Limerick</td><td>Completed</td><td>Feb 2016</td><td>Apr 2017</td><td>Interventional</td><td>Feb 2016</td><td>Inflammation</td><td>null</td></tr><tr><td>NCT02757859</td><td>Sidney Kimmel Cancer Center at Thomas Jefferson University</td><td>Recruiting</td><td>Apr 2016</td><td>Jan 2022</td><td>Interventional</td><td>Apr 2016</td><td>Adenocarcinoma,Cholangiocarcinoma,Carcinoma,Pancreatic Intraductal Neoplasms</td><td>Pancrelipase,Pancreatin</td></tr><tr><td>NCT02750800</td><td>AbbVie</td><td>Completed</td><td>Apr 2016</td><td>Apr 2018</td><td>Observational</td><td>Apr 2016</td><td>Spondylitis,Arthritis,Crohn Disease,Colitis,Inflammatory Bowel Diseases,Psoriasis</td><td>Adalimumab</td></tr><tr><td>NCT02754167</td><td>Pieris Pharmaceuticals GmbH</td><td>Unknown status</td><td>Jun 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Diseases,Renal Insufficiency</td><td>null</td></tr><tr><td>NCT02758379</td><td>Shockwave Medical, Inc.</td><td>Completed</td><td>Jul 2014</td><td>Mar 2016</td><td>Interventional</td><td>Jan 2015</td><td>Coronary Stenosis</td><td>null</td></tr><tr><td>NCT02755740</td><td>The University of Hong Kong</td><td>Completed</td><td>Jul 2015</td><td>Aug 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751008</td><td>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</td><td>Completed</td><td>Apr 2016</td><td>Jun 2018</td><td>Observational</td><td>Apr 2016</td><td>Osteoporosis</td><td>null</td></tr><tr><td>NCT02756390</td><td>Dana-Farber Cancer Institute</td><td>Completed</td><td>Dec 2015</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>Sleep Initiation and Maintenance Disorders</td><td>null</td></tr><tr><td>NCT02753075</td><td>GlaxoSmithKline</td><td>Completed</td><td>Sep 2015</td><td>Dec 2015</td><td>Interventional</td><td>Apr 2016</td><td>Dentin Sensitivity,Hypersensitivity</td><td>Fluorides</td></tr><tr><td>NCT02753465</td><td>Fudan University</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2019</td><td>Interventional</td><td>Apr 2016</td><td>Rectal Neoplasms</td><td>null</td></tr><tr><td>NCT02750852</td><td>Azienda Ospedaliera Bolognini di Seriate Bergamo</td><td>Unknown status</td><td>Apr 2016</td><td>May 2016</td><td>Observational</td><td>Apr 2016</td><td>Hemorrhage</td><td>null</td></tr><tr><td>NCT02753088</td><td>Biocad</td><td>Completed</td><td>Oct 2013</td><td>Nov 2015</td><td>Interventional</td><td>Apr 2016</td><td>Multiple Sclerosis,Sclerosis</td><td>Glatiramer Acetate,Mannitol,(T</td></tr><tr><td>NCT02758626</td><td>NYU Langone Health</td><td>Completed</td><td>Nov 2016</td><td>Feb 2021</td><td>Interventional</td><td>Apr 2016</td><td>Epilepsy,Epilepsies</td><td>null</td></tr><tr><td>NCT02757222</td><td>Tata Medical Center</td><td>Recruiting</td><td>Jan 2016</td><td>Dec 2022</td><td>Interventional</td><td>Mar 2016</td><td>Neoplasms,Oropharyngeal Neoplasms,Hypopharyngeal Neoplasms,Laryngeal Neoplasms,Laryngeal Diseases</td><td>null</td></tr><tr><td>NCT02750150</td><td>University Hospital, Lille</td><td>Completed</td><td>Jul 2013</td><td>Jan 2016</td><td>Interventional</td><td>Apr 2016</td><td>Hemostatic Disorders,Blood Coagulation Disorders,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT02752776</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Mar 2016</td><td>Mar 2018</td><td>Interventional</td><td>Feb 2016</td><td>Psoriasis</td><td>null</td></tr><tr><td>NCT02752984</td><td>IRCCS Policlinico S. Matteo</td><td>Unknown status</td><td>Apr 2016</td><td>Jun 2018</td><td>Observational</td><td>Apr 2016</td><td>Thrombosis,Venous Thrombosis</td><td>null</td></tr><tr><td>NCT02755272</td><td>Fox Chase Cancer Center</td><td>Recruiting</td><td>May 2016</td><td>Apr 2024</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms,Triple Negative Breast Neoplasms</td><td>Gemcitabine,Carboplatin,Pembrolizumab</td></tr><tr><td>NCT02753192</td><td>Centre National de la Recherche Scientifique, France</td><td>Unknown status</td><td>Jan 2014</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Parkinson Disease,Dysarthria,Disease Progression</td><td>null</td></tr><tr><td>NCT02750189</td><td>Konkuk University Medical Center</td><td>Completed</td><td>Sep 2015</td><td>Jan 2017</td><td>Observational</td><td>Mar 2016</td><td>Lung Diseases,Pulmonary Disease</td><td>null</td></tr><tr><td>NCT02756338</td><td>Biotronik, Inc.</td><td>Completed</td><td>Jun 2016</td><td>Jul 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759809</td><td>The Hospital for Sick Children</td><td>Completed</td><td>Jun 2016</td><td>Jul 2018</td><td>Observational</td><td>Apr 2016</td><td>Birth Weight</td><td>null</td></tr><tr><td>NCT02758431</td><td>University of Colorado, Denver</td><td>Recruiting</td><td>Feb 2016</td><td>Nov 2022</td><td>Interventional</td><td>Apr 2016</td><td>Hypogonadism</td><td>Methyltestosterone,Anastrozole,Testosterone,Testosterone undecanoate,Testosterone enanthate,Testosterone 17 beta-cypionate,Aromatase Inhibitors,Acyline,Hormone Antagonists</td></tr><tr><td>NCT02756962</td><td>Washington University School of Medicine</td><td>Recruiting</td><td>Jul 2016</td><td>Jul 2024</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Cytarabine</td></tr><tr><td>NCT02752919</td><td>Eli Lilly and Company</td><td>Completed</td><td>Apr 2016</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759705</td><td>Hospices Civils de Lyon</td><td>Withdrawn</td><td>Sep 2017</td><td>May 2018</td><td>Observational</td><td>Apr 2016</td><td>Bladder Exstrophy</td><td>null</td></tr><tr><td>NCT02753478</td><td>Catharina Ziekenhuis Eindhoven</td><td>Completed</td><td>Jun 2016</td><td>Nov 2016</td><td>Interventional</td><td>Apr 2016</td><td>Myocardial Infarction,Infarction,Hypothermia</td><td>null</td></tr><tr><td>NCT02753413</td><td>GlaxoSmithKline</td><td>Completed</td><td>Apr 2016</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>Respiratory Syncytial Virus Infections</td><td>null</td></tr><tr><td>NCT02759510</td><td>RenJi Hospital</td><td>Unknown status</td><td>Jun 2016</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>Cardiac Output</td><td>Phenylephrine,Oxymetazoline,Norepinephrine</td></tr><tr><td>NCT02756130</td><td>Jonsson Comprehensive Cancer Center</td><td>Withdrawn</td><td>Aug 2018</td><td>Feb 2021</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma,Adenocarcinoma,Ovarian Neoplasms,Cystadenocarcinoma</td><td>Carboplatin</td></tr><tr><td>NCT02750124</td><td>Karolinska Institutet</td><td>Active, not recruiting</td><td>Mar 2016</td><td>Dec 2021</td><td>Interventional</td><td>Mar 2016</td><td>Uterine Cervical Neoplasms</td><td>null</td></tr><tr><td>NCT02755610</td><td>Chulalongkorn University</td><td>Unknown status</td><td>May 2016</td><td>Apr 2019</td><td>Interventional</td><td>Feb 2016</td><td>Peritonitis,Kidney Diseases,Kidney Failure</td><td>null</td></tr><tr><td>NCT02759328</td><td>Ankara University</td><td>Completed</td><td>Dec 2012</td><td>Mar 2014</td><td>Interventional</td><td>Apr 2016</td><td>Stroke</td><td>null</td></tr><tr><td>NCT02753608</td><td>Jena University Hospital</td><td>Completed</td><td>Jun 2016</td><td>Mar 2018</td><td>Interventional</td><td>Mar 2016</td><td>Pneumonia</td><td>null</td></tr><tr><td>NCT02751944</td><td>ESM Technologies, LLC</td><td>Completed</td><td>Dec 2015</td><td>Jan 2016</td><td>Interventional</td><td>Apr 2016</td><td>Arthralgia</td><td>null</td></tr><tr><td>NCT02750748</td><td>National Institute on Drug Abuse (NIDA)</td><td>Completed</td><td>Jul 2016</td><td>Sep 2016</td><td>Interventional</td><td>Apr 2016</td><td>Opioid-Related Disorders</td><td>Naltrexone</td></tr><tr><td>NCT02758405</td><td>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</td><td>Completed</td><td>May 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Labor Pain</td><td>Fentanyl,Bupivacaine</td></tr><tr><td>NCT02753829</td><td>Ágata Sofia da Silva Vieira</td><td>Completed</td><td>Sep 2013</td><td>Jul 2015</td><td>Interventional</td><td>Apr 2016</td><td>Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Heart Diseases,Infarction</td><td>null</td></tr><tr><td>NCT02751788</td><td>Pennington Biomedical Research Center</td><td>Completed</td><td>Apr 2016</td><td>Jun 2018</td><td>Observational</td><td>Apr 2016</td><td>Pediatric Obesity</td><td>null</td></tr><tr><td>NCT02753010</td><td>Uppsala University</td><td>Completed</td><td>Mar 2011</td><td>Mar 2016</td><td>Observational</td><td>Apr 2016</td><td>Gastroparesis,Fractures,Hip Fractures</td><td>null</td></tr><tr><td>NCT02750969</td><td>HaEmek Medical Center, Israel</td><td>Unknown status</td><td>Apr 2016</td><td>Feb 2019</td><td>Interventional</td><td>Mar 2016</td><td>Tinnitus</td><td>Lidocaine</td></tr><tr><td>NCT02755831</td><td>United States Naval Medical Center, San Diego</td><td>Completed</td><td>Feb 2017</td><td>Oct 2019</td><td>Interventional</td><td>Mar 2016</td><td>Apnea,Sleep Apnea Syndromes,Sleep Apnea</td><td>null</td></tr><tr><td>NCT02752009</td><td>Dana-Farber Cancer Institute</td><td>Withdrawn</td><td>Apr 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02758990</td><td>Verifomics LLC</td><td>Terminated</td><td>Mar 2016</td><td>Nov 2016</td><td>Interventional</td><td>Apr 2016</td><td>Rhinitis,Arthralgia,Dyspnea,Sleep Deprivation,Migraine Disorders,Sleep Initiation and Maintenance Disorders,Disease,Headache,Respiratory Sounds</td><td>Vitamin D,Cholecalciferol,Vitamins,Ascorbic Acid,Vitamin E,Tocopherols,Vitamin A,Niacinamide,Niacin,Nicotinic Acids,Pyridoxine,Pyridoxal,Vitamin B 6,Caffeine</td></tr><tr><td>NCT02754193</td><td>Central Hospital, Nancy, France</td><td>Completed</td><td>Oct 2016</td><td>Nov 2019</td><td>Interventional</td><td>Apr 2016</td><td>Shock,Hypothermia</td><td>null</td></tr><tr><td>NCT02758613</td><td>Eli Lilly and Company</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751047</td><td>Seoul National University Hospital</td><td>Completed</td><td>May 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758197</td><td>Ottawa Hospital Research Institute</td><td>Completed</td><td>Jul 2016</td><td>Oct 2020</td><td>Interventional</td><td>Apr 2016</td><td>Neuralgia,Chronic Pain</td><td>null</td></tr><tr><td>NCT02753270</td><td>University of Sao Paulo</td><td>Completed</td><td>Dec 2014</td><td>Apr 2017</td><td>Interventional</td><td>Apr 2016</td><td>Varicose Veins</td><td>null</td></tr><tr><td>NCT02750839</td><td>Azienda Ospedaliera Bolognini di Seriate Bergamo</td><td>Unknown status</td><td>Apr 2016</td><td>Apr 2016</td><td>Observational</td><td>Apr 2016</td><td>Osteoporosis,Fractures,Humeral Fractures</td><td>null</td></tr><tr><td>NCT02750488</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>null</td></tr><tr><td>NCT02752958</td><td>GlaxoSmithKline</td><td>Completed</td><td>May 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Dentin Sensitivity,Hypersensitivity</td><td>Fluorides,Tin Fluorides</td></tr><tr><td>NCT02753322</td><td>The Queen Elizabeth Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Mar 2018</td><td>Interventional</td><td>Apr 2016</td><td>Stroke</td><td>null</td></tr><tr><td>NCT02757261</td><td>University of Nove de Julho</td><td>Unknown status</td><td>Jun 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Bruxism,Sleep Bruxism</td><td>Salicylic Acid</td></tr><tr><td>NCT02754427</td><td>University of British Columbia</td><td>Completed</td><td>Feb 2013</td><td>Aug 2015</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02758366</td><td>Meyer Children's Hospital</td><td>Terminated</td><td>Feb 2016</td><td>Jan 2020</td><td>Interventional</td><td>Apr 2016</td><td>Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms</td><td>Doxorubicin</td></tr><tr><td>NCT02755402</td><td>Centre hospitalier de l'Université de Montréal (CHUM)</td><td>Completed</td><td>Jan 2017</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Hepatitis C</td><td>null</td></tr><tr><td>NCT02754453</td><td>The Cleveland Clinic</td><td>Withdrawn</td><td>Jul 2013</td><td>Oct 2015</td><td>Interventional</td><td>Sep 2013</td><td>Body Weight,Weight Loss</td><td>null</td></tr><tr><td>NCT02755103</td><td>Medical University of South Carolina</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Oct 2021</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Substance-Related Disorders,Stress Disorders</td><td>null</td></tr><tr><td>NCT02758834</td><td>Università Politecnica delle Marche</td><td>Completed</td><td>Jan 2014</td><td>Apr 2016</td><td>Observational</td><td>Apr 2016</td><td>Liver Diseases</td><td>null</td></tr><tr><td>NCT02759146</td><td>Michigan State University</td><td>Completed</td><td>May 2016</td><td>Nov 2019</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754414</td><td>Bloodworks</td><td>Unknown status</td><td>Apr 2016</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759783</td><td>Royal Marsden NHS Foundation Trust</td><td>Active, not recruiting</td><td>Nov 2016</td><td>Oct 2024</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02756923</td><td>Weill Medical College of Cornell University</td><td>Suspended</td><td>Apr 2012</td><td>Dec 2025</td><td>Observational</td><td>Apr 2016</td><td>Infertility</td><td>null</td></tr><tr><td>NCT02759237</td><td>Medtronic Cardiovascular</td><td>Terminated</td><td>Feb 2016</td><td>May 2017</td><td>Observational</td><td>Apr 2016</td><td>Aortic Valve Stenosis</td><td>null</td></tr><tr><td>NCT02757391</td><td>M.D. Anderson Cancer Center</td><td>Terminated</td><td>Aug 2019</td><td>Oct 2020</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma</td><td>Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors</td></tr><tr><td>NCT02750904</td><td>Fred Hutchinson Cancer Research Center</td><td>Completed</td><td>Apr 2017</td><td>May 2019</td><td>Interventional</td><td>Mar 2016</td><td>Disease,Bipolar Disorder</td><td>Nicotine</td></tr><tr><td>NCT02758418</td><td>Universitat Jaume I</td><td>Unknown status</td><td>Apr 2016</td><td>Jul 2019</td><td>Interventional</td><td>Apr 2016</td><td>Adjustment Disorders</td><td>null</td></tr><tr><td>NCT02756039</td><td>AstraZeneca</td><td>Completed</td><td>May 2016</td><td>Aug 2018</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755077</td><td>Massachusetts General Hospital</td><td>Completed</td><td>Jul 2014</td><td>Jan 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751801</td><td>Sheffield Teaching Hospitals NHS Foundation Trust</td><td>Completed</td><td>Nov 2016</td><td>Dec 2017</td><td>Observational</td><td>Apr 2016</td><td>Hypophosphatasia</td><td>null</td></tr><tr><td>NCT02751177</td><td>Institut de Cancérologie de Lorraine</td><td>Completed</td><td>Mar 2016</td><td>May 2017</td><td>Interventional</td><td>Mar 2016</td><td>Colorectal Neoplasms</td><td>null</td></tr><tr><td>NCT02758574</td><td>University of Pittsburgh</td><td>Completed</td><td>May 2016</td><td>Aug 2021</td><td>Interventional</td><td>Mar 2016</td><td>Pulmonary Embolism,Embolism</td><td>null</td></tr><tr><td>NCT02758587</td><td>NHS Greater Glasgow and Clyde</td><td>Recruiting</td><td>Jul 2017</td><td>Dec 2021</td><td>Interventional</td><td>Apr 2016</td><td>Mesothelioma,Carcinoma,Pancreatic Neoplasms</td><td>Pembrolizumab</td></tr><tr><td>NCT02752100</td><td>Third Military Medical University</td><td>Unknown status</td><td>Mar 2016</td><td>May 2020</td><td>Interventional</td><td>Mar 2016</td><td>Arterial Occlusive Diseases</td><td>null</td></tr><tr><td>NCT02755818</td><td>University of California, Davis</td><td>Terminated</td><td>Oct 2008</td><td>Feb 2019</td><td>Observational</td><td>Mar 2016</td><td>Insulin Resistance</td><td>Heparin,Calcium heparin</td></tr><tr><td>NCT02752906</td><td>Sanofi Pasteur, a Sanofi Company</td><td>Completed</td><td>Apr 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Meningococcal Infections,Meningitis</td><td>Vaccines</td></tr><tr><td>NCT02750371</td><td>University Hospital, Bordeaux</td><td>Active, not recruiting</td><td>Jul 2016</td><td>Oct 2021</td><td>Interventional</td><td>Apr 2016</td><td>Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases</td><td>null</td></tr><tr><td>NCT02751125</td><td>University of Bergen</td><td>Completed</td><td>Jun 2014</td><td>Mar 2020</td><td>Interventional</td><td>Mar 2016</td><td>Atrophy</td><td>null</td></tr><tr><td>NCT02754700</td><td>High Point University</td><td>Completed</td><td>Apr 2016</td><td>Feb 2019</td><td>Interventional</td><td>Apr 2016</td><td>Knee Injuries</td><td>null</td></tr><tr><td>NCT02756442</td><td>Assistance Publique Hopitaux De Marseille</td><td>Unknown status</td><td>Apr 2016</td><td>Apr 2019</td><td>Interventional</td><td>Apr 2016</td><td>Respiration Disorders,Respiratory Tract Diseases,Diabetes</td><td>null</td></tr><tr><td>NCT02756637</td><td>Abramson Cancer Center of the University of Pennsylvania</td><td>Completed</td><td>Apr 2016</td><td>Nov 2016</td><td>Observational</td><td>Apr 2016</td><td>Urinary Bladder Neoplasms</td><td>null</td></tr><tr><td>NCT02755688</td><td>Royal Brompton & Harefield NHS Foundation Trust</td><td>Unknown status</td><td>Jun 2015</td><td>Mar 2020</td><td>Interventional</td><td>Apr 2016</td><td>Atrial Fibrillation</td><td>null</td></tr><tr><td>NCT02753387</td><td>Rennes University Hospital</td><td>Completed</td><td>May 2016</td><td>Sep 2018</td><td>Interventional</td><td>Apr 2016</td><td>Bacterial Infections,Head and Neck Neoplasms</td><td>Chlorhexidine</td></tr><tr><td>NCT02758470</td><td>University of British Columbia</td><td>Completed</td><td>Nov 2016</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>Fatigue,Hypoxia</td><td>Acetazolamide,Methazolamide</td></tr><tr><td>NCT02754375</td><td>Centre Hospitalier Universitaire de Nice</td><td>Unknown status</td><td>May 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Depression,Depressive Disorder</td><td>null</td></tr><tr><td>NCT02758756</td><td>University of Rochester</td><td>Completed</td><td>Jun 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Fatigue</td><td>null</td></tr><tr><td>NCT02750787</td><td>Abbott Nutrition</td><td>Completed</td><td>Aug 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Malabsorption Syndromes</td><td>null</td></tr><tr><td>NCT02757339</td><td>Mclean Hospital</td><td>Enrolling by invitation</td><td>Jun 2015</td><td>May 2022</td><td>Observational</td><td>Mar 2016</td><td>Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder</td><td>null</td></tr><tr><td>NCT02753959</td><td>Guy's and St Thomas' NHS Foundation Trust</td><td>Completed</td><td>Aug 2016</td><td>Sep 2019</td><td>Interventional</td><td>Apr 2016</td><td>Neuromuscular Diseases</td><td>null</td></tr><tr><td>NCT02753426</td><td>University of California, San Francisco</td><td>Completed</td><td>Apr 2016</td><td>Jan 2018</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome</td><td>Doxycycline</td></tr><tr><td>NCT02757183</td><td>AnalyticsPlus, Inc.</td><td>Unknown status</td><td>Apr 2016</td><td>Mar 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750293</td><td>University of Tromso</td><td>Completed</td><td>Jun 2015</td><td>Sep 2017</td><td>Interventional</td><td>Apr 2016</td><td>Vitamin D Deficiency</td><td>Cholecalciferol</td></tr><tr><td>NCT02757274</td><td>European Association of Urology Research Foundation</td><td>Recruiting</td><td>Feb 2017</td><td>Jul 2027</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Urinary Incontinence,Enuresis</td><td>null</td></tr><tr><td>NCT02756741</td><td>All India Institute of Medical Sciences, New Delhi</td><td>Completed</td><td>Apr 2014</td><td>Jul 2015</td><td>Interventional</td><td>Apr 2016</td><td>Peritonitis,Fibrosis</td><td>null</td></tr><tr><td>NCT02758964</td><td>Charite University, Berlin, Germany</td><td>Completed</td><td>Sep 2016</td><td>Jan 2019</td><td>Observational</td><td>Apr 2016</td><td>Intracranial Embolism,Embolism,Aortic Valve Stenosis</td><td>null</td></tr><tr><td>NCT02753439</td><td>The Baruch Padeh Medical Center, Poriya</td><td>Unknown status</td><td>Feb 2017</td><td>Feb 2019</td><td>Interventional</td><td>Mar 2016</td><td>Tooth</td><td>null</td></tr><tr><td>NCT02751281</td><td>Isfahan University of Medical Sciences</td><td>Completed</td><td>Dec 2014</td><td>Apr 2016</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Calculi,Nephrolithiasis</td><td>null</td></tr><tr><td>NCT02756676</td><td>Ospedale Generale Di Zona Moriggia-Pelascini</td><td>Completed</td><td>Apr 2015</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Parkinson Disease</td><td>null</td></tr><tr><td>NCT02750215</td><td>Massachusetts General Hospital</td><td>Completed</td><td>May 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02755935</td><td>Cochlear</td><td>Completed</td><td>May 2016</td><td>Sep 2017</td><td>Interventional</td><td>Apr 2016</td><td>Hearing Loss</td><td>null</td></tr><tr><td>NCT02759523</td><td>Penn State University</td><td>Completed</td><td>Jul 2013</td><td>Dec 2015</td><td>Observational</td><td>Apr 2016</td><td>Pediatric Obesity</td><td>null</td></tr><tr><td>NCT02756533</td><td>University Hospital, Grenoble</td><td>Recruiting</td><td>Aug 2016</td><td>Aug 2021</td><td>Interventional</td><td>Mar 2016</td><td>Lung Diseases,Pulmonary Disease,Signs and Symptoms</td><td>null</td></tr><tr><td>NCT02752841</td><td>Brown University</td><td>Terminated</td><td>May 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Calculi,Calculi</td><td>Vitamin D</td></tr><tr><td>NCT02758392</td><td>Janssen Research & Development, LLC</td><td>Completed</td><td>Apr 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755870</td><td>Clene Nanomedicine</td><td>Completed</td><td>Apr 2015</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752464</td><td>Boston Medical Center</td><td>Completed</td><td>Sep 2016</td><td>Jun 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756780</td><td>Royal Marsden NHS Foundation Trust</td><td>Unknown status</td><td>Apr 2016</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753998</td><td>Assistance Publique - Hôpitaux de Paris</td><td>Active, not recruiting</td><td>Dec 2016</td><td>Sep 2021</td><td>Interventional</td><td>Apr 2016</td><td>Arteriovenous Fistula,Constriction,Fistula</td><td>Paclitaxel</td></tr><tr><td>NCT02751307</td><td>Taipei Medical University WanFang Hospital</td><td>Completed</td><td>May 2013</td><td>Jan 2015</td><td>Interventional</td><td>Apr 2016</td><td>Congenital Abnormalities,Metabolic Syndrome,Schizophrenia</td><td>Metformin,Clozapine</td></tr><tr><td>NCT02757755</td><td>Armata Pharmaceuticals, Inc.</td><td>Completed</td><td>May 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753972</td><td>University of New Mexico</td><td>Completed</td><td>Aug 2006</td><td>Jan 2008</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751853</td><td>University of Luebeck</td><td>Unknown status</td><td>Dec 2016</td><td>Aug 2020</td><td>Interventional</td><td>Apr 2016</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT02752971</td><td>Hospital Central Dr. Luis Ortega</td><td>Completed</td><td>Feb 2015</td><td>null</td><td>Interventional</td><td>Mar 2016</td><td>Pain</td><td>Diclofenac,Bupivacaine</td></tr><tr><td>NCT02755012</td><td>McGill University</td><td>Completed</td><td>Jun 2012</td><td>Nov 2013</td><td>Observational</td><td>Apr 2016</td><td>Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress</td><td>null</td></tr><tr><td>NCT02751996</td><td>F-star Therapeutics, Inc.</td><td>Completed</td><td>May 2016</td><td>Feb 2020</td><td>Interventional</td><td>Apr 2016</td><td>Hepatitis A,Hepatitis B,Hepatitis</td><td>Tenofovir</td></tr><tr><td>NCT02752893</td><td>Dartmouth-Hitchcock Medical Center</td><td>Completed</td><td>Jan 2017</td><td>Apr 2019</td><td>Observational</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02753842</td><td>Global Protection Corp.</td><td>Completed</td><td>May 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757040</td><td>Peking University People's Hospital</td><td>Unknown status</td><td>Dec 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia</td><td>Arsenic Trioxide</td></tr><tr><td>NCT02751606</td><td>Radboud University</td><td>Unknown status</td><td>Jun 2015</td><td>Nov 2019</td><td>Interventional</td><td>Nov 2014</td><td>Neoplasms,Breast Neoplasms,Rectal Neoplasms</td><td>null</td></tr><tr><td>NCT02751372</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753764</td><td>National Jewish Health</td><td>Completed</td><td>Jan 2017</td><td>Feb 2019</td><td>Interventional</td><td>Apr 2016</td><td>Asthma</td><td>Prednisone,AZD7624</td></tr><tr><td>NCT02758938</td><td>University of Wisconsin, Madison</td><td>Completed</td><td>Jun 2016</td><td>Sep 2018</td><td>Interventional</td><td>Dec 2015</td><td>Lower Urinary Tract Symptoms</td><td>null</td></tr><tr><td>NCT02752399</td><td>Federal University of São Paulo</td><td>Unknown status</td><td>Apr 2016</td><td>Jun 2017</td><td>Observational</td><td>Apr 2016</td><td>Hypertension,Heart Defects,Eisenmenger Complex</td><td>null</td></tr><tr><td>NCT02753296</td><td>University of Sheffield</td><td>Unknown status</td><td>May 2016</td><td>Jun 2018</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759432</td><td>Teesside University</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750137</td><td>KK Women's and Children's Hospital</td><td>Completed</td><td>Aug 2014</td><td>May 2015</td><td>Observational</td><td>Apr 2016</td><td>Drug-Related Side Effects and Adverse Reactions</td><td>Tetracaine</td></tr><tr><td>NCT02754466</td><td>University of Brasilia</td><td>Terminated</td><td>May 2017</td><td>Sep 2021</td><td>Interventional</td><td>Apr 2016</td><td>Dental Caries</td><td>null</td></tr><tr><td>NCT02752191</td><td>Paul Finn</td><td>Recruiting</td><td>Apr 2016</td><td>Apr 2021</td><td>Interventional</td><td>Apr 2016</td><td>Heart Diseases,Heart Defects</td><td>Ferrosoferric Oxide</td></tr><tr><td>NCT02753517</td><td>University Hospital, Lille</td><td>Recruiting</td><td>Dec 2015</td><td>Nov 2023</td><td>Interventional</td><td>Apr 2016</td><td>Liver Failure,Hepatic Insufficiency</td><td>null</td></tr><tr><td>NCT02758054</td><td>University of Texas Southwestern Medical Center</td><td>Active, not recruiting</td><td>Jun 2017</td><td>Mar 2023</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02757573</td><td>Tampere University Hospital</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Dec 2022</td><td>Interventional</td><td>Apr 2016</td><td>Hypercapnia</td><td>null</td></tr><tr><td>NCT02752789</td><td>National Institute of Allergy and Infectious Diseases (NIAID)</td><td>Completed</td><td>Jul 2014</td><td>Nov 2019</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756416</td><td>University of Nottingham</td><td>Unknown status</td><td>Jul 2016</td><td>May 2017</td><td>Interventional</td><td>Mar 2016</td><td>Syndrome</td><td>null</td></tr><tr><td>NCT02758106</td><td>Chung Shan Medical University</td><td>Completed</td><td>Feb 2014</td><td>Nov 2015</td><td>Interventional</td><td>Apr 2016</td><td>Respiratory Insufficiency</td><td>null</td></tr><tr><td>NCT02759159</td><td>Xuanwu Hospital, Beijing</td><td>Unknown status</td><td>Jun 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Alzheimer Disease</td><td>null</td></tr><tr><td>NCT02753777</td><td>University of Pennsylvania</td><td>Recruiting</td><td>Apr 2016</td><td>Dec 2025</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Pemphigoid,Pemphigus</td><td>null</td></tr><tr><td>NCT02754245</td><td>Baylor Research Institute</td><td>Unknown status</td><td>Nov 2016</td><td>Jul 2017</td><td>Observational</td><td>Apr 2016</td><td>Emergencies</td><td>null</td></tr><tr><td>NCT02754687</td><td>Health Decisions</td><td>Unknown status</td><td>Apr 2016</td><td>Jan 2020</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate</td></tr><tr><td>NCT02755337</td><td>Dr. Soetomo General Hospital</td><td>Unknown status</td><td>Jan 2016</td><td>Dec 2016</td><td>Observational</td><td>Apr 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02755090</td><td>University of New Mexico</td><td>Completed</td><td>Jul 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Nitrous Oxide</td></tr><tr><td>NCT02751437</td><td>Liverpool Women's NHS Foundation Trust</td><td>Completed</td><td>Aug 2016</td><td>Mar 2018</td><td>Interventional</td><td>Mar 2016</td><td>Premature Birth</td><td>null</td></tr><tr><td>NCT02757950</td><td>GlaxoSmithKline</td><td>Completed</td><td>Jul 2016</td><td>May 2017</td><td>Observational</td><td>Apr 2016</td><td>Diphtheria</td><td>null</td></tr><tr><td>NCT02756754</td><td>University Hospital, Toulouse</td><td>Completed</td><td>Nov 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Adenoma,Adrenocortical Adenoma,Hyperaldosteronism</td><td>null</td></tr><tr><td>NCT02754726</td><td>HonorHealth Research Institute</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Jun 2022</td><td>Interventional</td><td>Apr 2016</td><td>Adenocarcinoma</td><td>Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel</td></tr><tr><td>NCT02759549</td><td>Emory University</td><td>Withdrawn</td><td>Sep 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02755714</td><td>Haukeland University Hospital</td><td>Completed</td><td>Jun 2016</td><td>Oct 2020</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Bromides,Ipratropium</td></tr><tr><td>NCT02750358</td><td>Memorial Sloan Kettering Cancer Center</td><td>Active, not recruiting</td><td>May 2016</td><td>May 2022</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms,Triple Negative Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02754921</td><td>Mohamed Sayed Mohamed Abbas</td><td>Completed</td><td>Jan 2013</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755259</td><td>University of Zurich</td><td>Completed</td><td>Jan 2017</td><td>Apr 2019</td><td>Interventional</td><td>Mar 2016</td><td>Hypertension</td><td>Acetazolamide</td></tr><tr><td>NCT02759081</td><td>Dalin Tzu Chi General Hospital</td><td>Completed</td><td>Jan 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755155</td><td>University Hospital, Strasbourg, France</td><td>Terminated</td><td>Sep 2016</td><td>Aug 2019</td><td>Interventional</td><td>Apr 2016</td><td>Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome</td><td>null</td></tr><tr><td>NCT02758119</td><td>Ilumens</td><td>Completed</td><td>Jun 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>Heart Arrest,Out-of-Hospital Cardiac Arrest</td><td>null</td></tr><tr><td>NCT02755415</td><td>China Medical University Hospital</td><td>Unknown status</td><td>May 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Stroke</td><td>null</td></tr><tr><td>NCT02751268</td><td>Armed Forces Hampyeong Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Psychomotor Agitation,Emergence Delirium</td><td>Ropivacaine</td></tr><tr><td>NCT02756572</td><td>University of Washington</td><td>Completed</td><td>Sep 2016</td><td>Jul 2020</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome</td><td>Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim</td></tr><tr><td>NCT02756871</td><td>Institute of Child Health</td><td>Completed</td><td>Jul 2015</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750618</td><td>Ultragenyx Pharmaceutical Inc</td><td>Completed</td><td>May 2016</td><td>Sep 2019</td><td>Interventional</td><td>Dec 2015</td><td>Familial Hypophosphatemic Rickets,Hypophosphatemia</td><td>null</td></tr><tr><td>NCT02757196</td><td>Peking University People's Hospital</td><td>Unknown status</td><td>May 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Thrombocytopenia,Purpura</td><td>Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate</td></tr><tr><td>NCT02758093</td><td>University of Alabama at Birmingham</td><td>Completed</td><td>Sep 2016</td><td>Mar 2020</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750943</td><td>GlaxoSmithKline</td><td>Completed</td><td>Nov 2015</td><td>Mar 2016</td><td>Interventional</td><td>Nov 2015</td><td>Gingivitis</td><td>Fluorides,Tin Fluorides,Fluorophosphate</td></tr><tr><td>NCT02754908</td><td>The University of Hong Kong</td><td>Completed</td><td>Jan 2016</td><td>Jun 2018</td><td>Interventional</td><td>Apr 2016</td><td>Brain Neoplasms</td><td>null</td></tr><tr><td>NCT02750514</td><td>Bristol-Myers Squibb</td><td>Terminated</td><td>May 2016</td><td>Jan 2020</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma</td><td>Nivolumab,Ipilimumab,Dasatinib,Linrodostat</td></tr><tr><td>NCT02755350</td><td>LVCT Health</td><td>Unknown status</td><td>Aug 2015</td><td>Apr 2017</td><td>Interventional</td><td>Nov 2015</td><td>null</td><td>Emtricitabine</td></tr><tr><td>NCT02753374</td><td>Beijing Children's Hospital</td><td>Not yet recruiting</td><td>May 2016</td><td>Jul 2030</td><td>Observational</td><td>Apr 2016</td><td>Cystic Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT02759419</td><td>Bayer</td><td>Recruiting</td><td>Jun 2016</td><td>Dec 2023</td><td>Interventional</td><td>Apr 2016</td><td>Pulmonary Arterial Hypertension,Hypertension</td><td>Riociguat</td></tr><tr><td>NCT02757612</td><td>Universidad de Murcia</td><td>Completed</td><td>Jun 2015</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Burning Mouth Syndrome,Syndrome,Burns</td><td>null</td></tr><tr><td>NCT02754297</td><td>CHU de Quebec-Universite Laval</td><td>Recruiting</td><td>Apr 2016</td><td>Dec 2026</td><td>Interventional</td><td>Mar 2016</td><td>Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma</td><td>Lutetium Lu 177 dotatate</td></tr><tr><td>NCT02758665</td><td>University of Ulm</td><td>Active, not recruiting</td><td>Sep 2016</td><td>Mar 2022</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia</td><td>Venetoclax,Obinutuzumab</td></tr><tr><td>NCT02755285</td><td>Fujifilm Medical Systems USA, Inc.</td><td>Completed</td><td>Aug 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757690</td><td>Asan Medical Center</td><td>Completed</td><td>Jan 2015</td><td>Feb 2016</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms,Brain Neoplasms</td><td>null</td></tr><tr><td>NCT02753218</td><td>LEO Pharma</td><td>Terminated</td><td>Apr 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Psoriasis</td><td>Midazolam</td></tr><tr><td>NCT02754986</td><td>University of Hyogo</td><td>Completed</td><td>Mar 2015</td><td>null</td><td>Interventional</td><td>Mar 2016</td><td>Kidney Diseases,Renal Insufficiency</td><td>null</td></tr><tr><td>NCT02752048</td><td>Taiho Pharmaceutical Co., Ltd.</td><td>Completed</td><td>May 2016</td><td>Oct 2017</td><td>Interventional</td><td>Apr 2016</td><td>Muscular Dystrophies,Muscular Dystrophy</td><td>null</td></tr><tr><td>NCT02752256</td><td>University of Iowa</td><td>Completed</td><td>Oct 2015</td><td>Oct 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>Plasminogen,Tissue Plasminogen Activator</td></tr><tr><td>NCT02756936</td><td>Genuine Research Center, Egypt</td><td>Completed</td><td>Feb 2016</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756000</td><td>Clinical Hospital Center Zemun</td><td>Unknown status</td><td>Jan 2016</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction</td><td>Dobutamine</td></tr><tr><td>NCT02754492</td><td>Terumo BCT</td><td>Completed</td><td>Apr 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757677</td><td>Swiss Vision Network</td><td>Unknown status</td><td>Dec 2015</td><td>Dec 2019</td><td>Observational</td><td>Apr 2016</td><td>Glaucoma</td><td>null</td></tr><tr><td>NCT02752373</td><td>Brain Sentinel</td><td>Terminated</td><td>May 2016</td><td>Feb 2017</td><td>Observational</td><td>Mar 2016</td><td>Epilepsy,Seizures</td><td>null</td></tr><tr><td>NCT02752230</td><td>Kettering Health Network</td><td>Withdrawn</td><td>Nov 2016</td><td>Jun 2021</td><td>Interventional</td><td>Mar 2016</td><td>Pain</td><td>null</td></tr><tr><td>NCT02756728</td><td>BioInvent International AB</td><td>Terminated</td><td>May 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Multiple Myeloma,Neoplasms</td><td>Melphalan</td></tr><tr><td>NCT02751658</td><td>University Hospital, Montpellier</td><td>Completed</td><td>Nov 2016</td><td>Jul 2019</td><td>Interventional</td><td>Mar 2016</td><td>Otorhinolaryngologic Diseases</td><td>null</td></tr><tr><td>NCT02754518</td><td>University of Chicago</td><td>Completed</td><td>Apr 2016</td><td>Apr 2019</td><td>Interventional</td><td>Apr 2016</td><td>Heart Failure</td><td>Valsartan,Sacubitril and valsartan sodium hydrate drug combination</td></tr><tr><td>NCT02759380</td><td>Sahlgrenska University Hospital, Sweden</td><td>Recruiting</td><td>Mar 2016</td><td>Oct 2022</td><td>Interventional</td><td>Apr 2016</td><td>Prostatic Neoplasms</td><td>Phytoestrogens</td></tr><tr><td>NCT02755649</td><td>Regeneron Pharmaceuticals</td><td>Completed</td><td>Jan 2016</td><td>Mar 2017</td><td>Interventional</td><td>Mar 2016</td><td>Dermatitis,Eczema</td><td>null</td></tr><tr><td>NCT02751827</td><td>Institut Bergonié</td><td>Completed</td><td>Feb 2016</td><td>Nov 2019</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755545</td><td>Galderma Laboratories, L.P.</td><td>Completed</td><td>May 2016</td><td>Apr 2017</td><td>Interventional</td><td>Apr 2016</td><td>Acne Vulgaris</td><td>Salicylic Acid,Adapalene,Salicylates</td></tr><tr><td>NCT02750345</td><td>Cycle Pharmaceuticals Ltd.</td><td>Completed</td><td>Mar 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Tyrosinemias</td><td>Nitisinone</td></tr><tr><td>NCT02755532</td><td>Federal University of São Paulo</td><td>Completed</td><td>Jan 2014</td><td>Oct 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Bupivacaine</td></tr><tr><td>NCT02758743</td><td>Biohit Oyj</td><td>Completed</td><td>Apr 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754947</td><td>Nationwide Children's Hospital</td><td>Completed</td><td>Feb 2015</td><td>Mar 2016</td><td>Observational</td><td>Apr 2016</td><td>Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases</td><td>null</td></tr><tr><td>NCT02750280</td><td>Calvary Hospital, Bronx, NY</td><td>Completed</td><td>Jun 2015</td><td>Dec 2015</td><td>Interventional</td><td>Apr 2016</td><td>Diabetic Foot,Foot Ulcer,Ulcer</td><td>null</td></tr><tr><td>NCT02756325</td><td>NYU Langone Health</td><td>Withdrawn</td><td>Jun 2016</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Infertility</td><td>null</td></tr><tr><td>NCT02758717</td><td>Academic and Community Cancer Research United</td><td>Active, not recruiting</td><td>May 2016</td><td>May 2024</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma,Hodgkin Disease</td><td>Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates</td></tr><tr><td>NCT02751034</td><td>Medy-Tox</td><td>Completed</td><td>Jun 2013</td><td>Jan 2014</td><td>Interventional</td><td>Apr 2015</td><td>null</td><td>Lidocaine</td></tr><tr><td>NCT02751476</td><td>Action Contre la Faim</td><td>Unknown status</td><td>Apr 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition</td><td>Disinfectants</td></tr><tr><td>NCT02755454</td><td>University Health Network, Toronto</td><td>Completed</td><td>Oct 2013</td><td>Nov 2018</td><td>Interventional</td><td>Mar 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02752867</td><td>Dongfang Hospital Beijing University of Chinese Medicine</td><td>Unknown status</td><td>Dec 2016</td><td>Nov 2019</td><td>Interventional</td><td>Mar 2016</td><td>Cerebral Infarction,Infarction,Cognitive Dysfunction</td><td>null</td></tr><tr><td>NCT02754830</td><td>Eli Lilly and Company</td><td>Completed</td><td>Apr 2016</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>Alzheimer Disease</td><td>null</td></tr><tr><td>NCT02753738</td><td>Medical University of Vienna</td><td>Unknown status</td><td>Aug 2016</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Citalopram</td></tr><tr><td>NCT02750267</td><td>University of Virginia</td><td>Completed</td><td>May 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02754999</td><td>Prolong Pharmaceuticals</td><td>Completed</td><td>Mar 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Anemia</td><td>null</td></tr><tr><td>NCT02754843</td><td>Sonova AG</td><td>Completed</td><td>Oct 2015</td><td>null</td><td>Interventional</td><td>Oct 2015</td><td>Hearing Loss</td><td>null</td></tr><tr><td>NCT02759055</td><td>HealthPartners Institute</td><td>Completed</td><td>Oct 2016</td><td>Dec 2019</td><td>Interventional</td><td>Apr 2016</td><td>Prediabetic State,Glucose Intolerance</td><td>null</td></tr><tr><td>NCT02753673</td><td>Memorial Sloan Kettering Cancer Center</td><td>Completed</td><td>Apr 2016</td><td>Apr 2020</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754531</td><td>Indonesia University</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750033</td><td>Seton Healthcare Family</td><td>Withdrawn</td><td>Oct 2016</td><td>Mar 2017</td><td>Observational</td><td>Apr 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02759133</td><td>Centre Antoine Lacassagne</td><td>Recruiting</td><td>Jun 2016</td><td>Nov 2022</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02756650</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Jun 2016</td><td>Jan 2019</td><td>Interventional</td><td>Mar 2016</td><td>Behcet Syndrome</td><td>null</td></tr><tr><td>NCT02752152</td><td>Institut de Recherche pour le Developpement</td><td>Completed</td><td>Dec 2015</td><td>Oct 2020</td><td>Interventional</td><td>Apr 2016</td><td>Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis</td><td>null</td></tr><tr><td>NCT02751385</td><td>Boehringer Ingelheim</td><td>Terminated</td><td>May 2016</td><td>Nov 2017</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma</td><td>Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination</td></tr><tr><td>NCT02751879</td><td>Boehringer Ingelheim</td><td>Completed</td><td>Nov 2016</td><td>Sep 2017</td><td>Observational</td><td>Apr 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02756663</td><td>Novartis Pharmaceuticals</td><td>Withdrawn</td><td>Dec 2016</td><td>Feb 2021</td><td>Interventional</td><td>Apr 2016</td><td>Multiple Myeloma,Neoplasms</td><td>Dexamethasone,Panobinostat</td></tr><tr><td>NCT02756273</td><td>Centre Hospitalier Universitaire, Amiens</td><td>Recruiting</td><td>May 2016</td><td>May 2022</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755974</td><td>Imperial College London</td><td>Unknown status</td><td>Jan 2009</td><td>Apr 2021</td><td>Observational</td><td>Apr 2016</td><td>Lung Diseases,Pulmonary Disease</td><td>null</td></tr><tr><td>NCT02756507</td><td>Babes-Bolyai University</td><td>Completed</td><td>Jun 2016</td><td>Jun 2018</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Depression,Anxiety Disorders,Panic Disorder</td><td>null</td></tr><tr><td>NCT02750553</td><td>Jiangsu HengRui Medicine Co., Ltd.</td><td>Completed</td><td>Jan 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750228</td><td>Mednax Center for Research, Education, Quality and Safety</td><td>Completed</td><td>May 2016</td><td>Jun 2020</td><td>Observational</td><td>Mar 2016</td><td>Ductus Arteriosus</td><td>null</td></tr><tr><td>NCT02751710</td><td>Ontario Clinical Oncology Group (OCOG)</td><td>Recruiting</td><td>Dec 2016</td><td>Dec 2022</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT02753361</td><td>Suez Canal University</td><td>Completed</td><td>May 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Lipoma</td><td>null</td></tr><tr><td>NCT02753634</td><td>Lawson Health Research Institute</td><td>Completed</td><td>Apr 2015</td><td>Jun 2016</td><td>Interventional</td><td>Mar 2016</td><td>Osteoarthritis</td><td>null</td></tr><tr><td>NCT02759250</td><td>argenx</td><td>Completed</td><td>Feb 2015</td><td>Jun 2018</td><td>Interventional</td><td>Apr 2016</td><td>Nasopharyngeal Carcinoma</td><td>null</td></tr><tr><td>NCT02757482</td><td>Celal Bayar University</td><td>Completed</td><td>Sep 2014</td><td>Jun 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757105</td><td>RedHill Biopharma Limited</td><td>Completed</td><td>May 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Irritable Bowel Syndrome,Syndrome,Diarrhea</td><td>Ondansetron</td></tr><tr><td>NCT02756520</td><td>Fresenius Kabi</td><td>Completed</td><td>Sep 2016</td><td>Oct 2018</td><td>Observational</td><td>Apr 2016</td><td>Kidney Diseases,Renal Insufficiency</td><td>null</td></tr><tr><td>NCT02753309</td><td>The University of Texas Health Science Center at San Antonio</td><td>Completed</td><td>Jun 2016</td><td>Mar 2021</td><td>Interventional</td><td>Apr 2016</td><td>Urinary Bladder Neoplasms</td><td>Sirolimus</td></tr><tr><td>NCT02756832</td><td>Takeda</td><td>Completed</td><td>Sep 2016</td><td>Apr 2018</td><td>Observational</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Alogliptin</td></tr><tr><td>NCT02758158</td><td>University Health Network, Toronto</td><td>Completed</td><td>Jan 2016</td><td>Feb 2017</td><td>Interventional</td><td>Mar 2016</td><td>Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases</td><td>null</td></tr><tr><td>NCT02752360</td><td>Beijing Friendship Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis</td><td>null</td></tr><tr><td>NCT02757794</td><td>Assistance Publique Hopitaux De Marseille</td><td>Recruiting</td><td>Nov 2016</td><td>Jun 2022</td><td>Interventional</td><td>Apr 2016</td><td>Memory Disorders</td><td>null</td></tr><tr><td>NCT02751346</td><td>Washington University School of Medicine</td><td>Completed</td><td>Jan 2016</td><td>Feb 2017</td><td>Observational</td><td>Apr 2016</td><td>Pain</td><td>null</td></tr><tr><td>NCT02757027</td><td>Konkuk University Medical Center</td><td>Unknown status</td><td>May 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756689</td><td>University of Alabama at Birmingham</td><td>Completed</td><td>Mar 2016</td><td>Oct 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751164</td><td>Intensive Care National Audit & Research Centre</td><td>Completed</td><td>Apr 2013</td><td>May 2016</td><td>Observational</td><td>Apr 2016</td><td>Critical Illness</td><td>null</td></tr><tr><td>NCT02754765</td><td>Médecins Sans Frontières, France</td><td>Recruiting</td><td>Dec 2016</td><td>Aug 2023</td><td>Interventional</td><td>Apr 2016</td><td>Tuberculosis,Bacterial Infections</td><td>Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine</td></tr><tr><td>NCT02757729</td><td>Amorepacific Corporation</td><td>Completed</td><td>Oct 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis,Eczema</td><td>null</td></tr><tr><td>NCT02751866</td><td>University of Cincinnati</td><td>Recruiting</td><td>Jan 2016</td><td>Jul 2023</td><td>Interventional</td><td>Apr 2016</td><td>Overweight,Hyperphagia</td><td>null</td></tr><tr><td>NCT02759068</td><td>Hospices Civils de Lyon</td><td>Completed</td><td>Nov 2014</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Consciousness Disorders</td><td>null</td></tr><tr><td>NCT02752503</td><td>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</td><td>Unknown status</td><td>Mar 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Alcoholism,Alcohol Drinking,Personality Disorders,Borderline Personality Disorder</td><td>Nalmefene</td></tr><tr><td>NCT02750592</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Mar 2016</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>Spondylitis</td><td>null</td></tr><tr><td>NCT02754440</td><td>Terumo BCT</td><td>Completed</td><td>Apr 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750670</td><td>University Health Network, Toronto</td><td>Completed</td><td>Mar 2017</td><td>Feb 2021</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>Gemcitabine,Dexamethasone,Obinutuzumab</td></tr><tr><td>NCT02753400</td><td>Kubota Vision Inc.</td><td>Completed</td><td>May 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Retinal Diseases,Diabetic Retinopathy</td><td>null</td></tr><tr><td>NCT02754310</td><td>Ilumens</td><td>Completed</td><td>May 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758275</td><td>Universidad Industrial de Santander</td><td>Completed</td><td>Apr 2016</td><td>Sep 2017</td><td>Interventional</td><td>Apr 2016</td><td>Hypertension,Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02757417</td><td>University Hospitals Cleveland Medical Center</td><td>Unknown status</td><td>Jul 2016</td><td>Dec 2019</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753725</td><td>University of Nairobi</td><td>Completed</td><td>Apr 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Delirium,Emergence Delirium</td><td>Fentanyl</td></tr><tr><td>NCT02752646</td><td>MDbackline, LLC</td><td>Completed</td><td>Apr 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Cataract</td><td>Ketorolac,Nepafenac</td></tr><tr><td>NCT02750566</td><td>New York Institute of Technology</td><td>Recruiting</td><td>Nov 2015</td><td>Dec 2021</td><td>Interventional</td><td>Dec 2015</td><td>Post-Concussion Syndrome</td><td>null</td></tr><tr><td>NCT02753335</td><td>University of Tromso</td><td>Recruiting</td><td>Sep 2016</td><td>Dec 2022</td><td>Interventional</td><td>Mar 2016</td><td>Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Syndrome</td><td>null</td></tr><tr><td>NCT02754544</td><td>M.D. Anderson Cancer Center</td><td>Recruiting</td><td>Jul 2016</td><td>Aug 2020</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms,Brain Neoplasms</td><td>null</td></tr><tr><td>NCT02751112</td><td>Imagine Institute</td><td>Terminated</td><td>Nov 2015</td><td>Aug 2017</td><td>Interventional</td><td>Apr 2016</td><td>Graft vs Host Disease</td><td>null</td></tr><tr><td>NCT02751320</td><td>GlaxoSmithKline</td><td>Completed</td><td>Feb 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dental Caries</td><td>Citric Acid,Sodium Citrate</td></tr><tr><td>NCT02753036</td><td>Charite University, Berlin, Germany</td><td>Active, not recruiting</td><td>Jan 2016</td><td>Jun 2023</td><td>Observational</td><td>Apr 2016</td><td>Polyneuropathies,Cognition Disorders</td><td>null</td></tr><tr><td>NCT02759198</td><td>Yuhan Corporation</td><td>Completed</td><td>May 2016</td><td>Sep 2017</td><td>Interventional</td><td>Apr 2016</td><td>Osteoarthritis</td><td>Celecoxib</td></tr><tr><td>NCT02752802</td><td>Osprey Medical, Inc</td><td>Completed</td><td>Apr 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757586</td><td>Peking University People's Hospital</td><td>Unknown status</td><td>Dec 2016</td><td>Dec 2019</td><td>Observational</td><td>Apr 2016</td><td>Leukemia</td><td>null</td></tr><tr><td>NCT02755961</td><td>Ajou University School of Medicine</td><td>Completed</td><td>Jul 2015</td><td>Oct 2015</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Diseases,Kidney Failure,Hyperphosphatemia</td><td>null</td></tr><tr><td>NCT02759263</td><td>Boston Children's Hospital</td><td>Completed</td><td>Jun 2016</td><td>Oct 2018</td><td>Interventional</td><td>Apr 2016</td><td>Heart Diseases,Heart Defects</td><td>null</td></tr><tr><td>NCT02754271</td><td>Toronto Rehabilitation Institute</td><td>Unknown status</td><td>Apr 2014</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Failure</td><td>null</td></tr><tr><td>NCT02756195</td><td>Vanderbilt University</td><td>Recruiting</td><td>Nov 2016</td><td>Jan 2022</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754336</td><td>Helse Stavanger HF</td><td>Completed</td><td>Oct 2014</td><td>Jun 2015</td><td>Interventional</td><td>Nov 2015</td><td>null</td><td>null</td></tr><tr><td>NCT02758639</td><td>University of Texas at Austin</td><td>Completed</td><td>Sep 2015</td><td>Aug 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759185</td><td>Multidisciplinary Association for Psychedelic Studies</td><td>Completed</td><td>Jan 2017</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Marijuana Abuse,Stress Disorders</td><td>Dronabinol,Cannabidiol</td></tr><tr><td>NCT02758145</td><td>Service de Médecine Préventive Hospitalière</td><td>Completed</td><td>Apr 2016</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>Influenza</td><td>Vaccines</td></tr><tr><td>NCT02756455</td><td>University of Roma La Sapienza</td><td>Unknown status</td><td>Jan 2015</td><td>Dec 2016</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Stomach Neoplasms</td><td>null</td></tr><tr><td>NCT02757118</td><td>Konkuk University Medical Center</td><td>Unknown status</td><td>May 2016</td><td>Jan 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756819</td><td>Takeda</td><td>Completed</td><td>Jul 2016</td><td>May 2018</td><td>Observational</td><td>Apr 2016</td><td>Hypertension,Overweight</td><td>Azilsartan medoxomil</td></tr><tr><td>NCT02754362</td><td>NYU Langone Health</td><td>Withdrawn</td><td>Nov 2016</td><td>Jun 2019</td><td>Interventional</td><td>Apr 2016</td><td>Glioblastoma</td><td>Bevacizumab,Poly ICLC,Keyhole-limpet hemocyanin,Adjuvants</td></tr><tr><td>NCT02752711</td><td>Nantes University Hospital</td><td>Completed</td><td>May 2013</td><td>Dec 2015</td><td>Observational</td><td>Apr 2016</td><td>Craniocerebral Trauma</td><td>null</td></tr><tr><td>NCT02756494</td><td>Beijing Chao Yang Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2018</td><td>Observational</td><td>Apr 2016</td><td>Stroke,Ischemic Stroke,Cerebral Infarction,Ischemia</td><td>null</td></tr><tr><td>NCT02753855</td><td>University of Illinois at Chicago</td><td>Completed</td><td>Apr 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Telavancin</td></tr><tr><td>NCT02756013</td><td>Case Comprehensive Cancer Center</td><td>Terminated</td><td>Apr 2016</td><td>Jan 2019</td><td>Interventional</td><td>Apr 2016</td><td>Overweight</td><td>Paclitaxel,Carboplatin</td></tr><tr><td>NCT02756949</td><td>World Bank</td><td>Completed</td><td>Oct 2015</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>HIV Infections</td><td>null</td></tr><tr><td>NCT02757885</td><td>Emory University</td><td>Recruiting</td><td>Apr 2016</td><td>Jul 2023</td><td>Interventional</td><td>Apr 2016</td><td>Anemia</td><td>Cyclophosphamide,Thiotepa,Fludarabine,Fludarabine phosphate,Hydroxyurea,Antilymphocyte Serum,Thymoglobulin</td></tr><tr><td>NCT02758340</td><td>Karachi Medical and Dental College</td><td>Completed</td><td>Apr 2016</td><td>Nov 2016</td><td>Interventional</td><td>Apr 2016</td><td>Labor Pain</td><td>Misoprostol</td></tr><tr><td>NCT02753933</td><td>Guy's and St Thomas' NHS Foundation Trust</td><td>Unknown status</td><td>Apr 2016</td><td>Dec 2018</td><td>Observational</td><td>Apr 2016</td><td>Headache Disorders,Headache</td><td>null</td></tr><tr><td>NCT02756624</td><td>Nicox Ophthalmics, Inc.</td><td>Completed</td><td>Apr 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Cetirizine</td></tr><tr><td>NCT02759393</td><td>National Cheng-Kung University Hospital</td><td>Unknown status</td><td>Oct 2015</td><td>Sep 2017</td><td>Interventional</td><td>Apr 2016</td><td>Gastroesophageal Reflux,Esophagitis</td><td>Lansoprazole,Dexlansoprazole</td></tr><tr><td>NCT02757820</td><td>Assiut University</td><td>Completed</td><td>Jun 2016</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754141</td><td>Bristol-Myers Squibb</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Feb 2023</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Nivolumab</td></tr><tr><td>NCT02753985</td><td>Abramson Cancer Center of the University of Pennsylvania</td><td>Completed</td><td>Jul 2014</td><td>Apr 2016</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757768</td><td>Astellas Pharma Global Development, Inc.</td><td>Completed</td><td>Jun 2016</td><td>Sep 2018</td><td>Interventional</td><td>Apr 2016</td><td>Urinary Bladder,Prostatic Hyperplasia,Hyperplasia,Lower Urinary Tract Symptoms</td><td>Tamsulosin,Mirabegron</td></tr><tr><td>NCT02753348</td><td>Henning Bundgaard</td><td>Completed</td><td>Apr 2016</td><td>Nov 2018</td><td>Observational</td><td>Apr 2016</td><td>Heart Diseases,Heart Defects</td><td>null</td></tr><tr><td>NCT02759718</td><td>Asan Medical Center</td><td>Unknown status</td><td>Jun 2012</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Neuroendocrine Tumors,Endocrine Gland Neoplasms,Adenoma</td><td>null</td></tr><tr><td>NCT02755181</td><td>Boehringer Ingelheim</td><td>Completed</td><td>Jul 2016</td><td>May 2018</td><td>Observational</td><td>Apr 2016</td><td>Disease,Personality Disorders,Borderline Personality Disorder,Impulsive Behavior,Disruptive</td><td>null</td></tr><tr><td>NCT02759926</td><td>Universitaire Ziekenhuizen Leuven</td><td>Unknown status</td><td>Aug 2011</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Obesity</td><td>Quinine,Denatonium</td></tr><tr><td>NCT02756286</td><td>Think Now Incorporated</td><td>Completed</td><td>Jan 2017</td><td>Jul 2018</td><td>Observational</td><td>Nov 2015</td><td>Attention Deficit Disorder with Hyperactivity</td><td>null</td></tr><tr><td>NCT02752126</td><td>Lawson Health Research Institute</td><td>Completed</td><td>Jun 2016</td><td>Sep 2020</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02752035</td><td>Astellas Pharma Global Development, Inc.</td><td>Active, not recruiting</td><td>Aug 2016</td><td>Aug 2023</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia</td><td>Azacitidine</td></tr><tr><td>NCT02750865</td><td>Boston Medical Center</td><td>Recruiting</td><td>Aug 2017</td><td>Dec 2022</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752165</td><td>University of Rochester</td><td>Recruiting</td><td>Aug 2016</td><td>Feb 2023</td><td>Interventional</td><td>Mar 2016</td><td>Asthma,Emergencies</td><td>null</td></tr><tr><td>NCT02755792</td><td>The Hong Kong Polytechnic University</td><td>Completed</td><td>Jul 2012</td><td>Apr 2016</td><td>Interventional</td><td>Apr 2016</td><td>Cognitive Dysfunction</td><td>null</td></tr><tr><td>NCT02757898</td><td>Emory University</td><td>Recruiting</td><td>Jan 2017</td><td>Dec 2021</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Biotin</td></tr><tr><td>NCT02758678</td><td>Science and Technology Park, Center of Innovation Technologies for Human Health</td><td>Completed</td><td>Nov 2015</td><td>Oct 2016</td><td>Observational</td><td>Apr 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02751424</td><td>GlaxoSmithKline</td><td>Terminated</td><td>Jun 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Bacterial Infections</td><td>null</td></tr><tr><td>NCT02750319</td><td>Memorial Sloan Kettering Cancer Center</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Apr 2022</td><td>Interventional</td><td>Apr 2016</td><td>Atrial Fibrillation</td><td>Acetylcysteine,Amiodarone,N-monoacetylcystine</td></tr><tr><td>NCT02757495</td><td>Suez Canal University</td><td>Completed</td><td>Apr 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Psychomotor Agitation,Emergence Delirium,Delayed Emergence from Anesthesia</td><td>Dexmedetomidine</td></tr><tr><td>NCT02752607</td><td>Dr. Vicky Tagalakis</td><td>Terminated</td><td>May 2016</td><td>Nov 2018</td><td>Observational</td><td>Apr 2016</td><td>Thrombosis,Venous Thrombosis</td><td>null</td></tr><tr><td>NCT02757911</td><td>Genethon</td><td>Active, not recruiting</td><td>Mar 2016</td><td>Jun 2024</td><td>Interventional</td><td>Apr 2016</td><td>Granuloma,Granulomatous Disease</td><td>null</td></tr><tr><td>NCT02759224</td><td>Boryung Pharmaceutical Co., Ltd</td><td>Completed</td><td>Apr 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>Stomach Ulcer</td><td>Irsogladine,Lafutidine</td></tr><tr><td>NCT02756351</td><td>CytaCoat AB</td><td>Completed</td><td>Apr 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Cross Infection,Pneumonia</td><td>null</td></tr><tr><td>NCT02751359</td><td>University of California, Los Angeles</td><td>Completed</td><td>Jul 2016</td><td>Apr 2020</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Cannabidiol</td></tr><tr><td>NCT02756585</td><td>Nova Scotia Health Authority</td><td>Unknown status</td><td>Sep 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Brain Injuries,Craniocerebral Trauma,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT02751411</td><td>Aboca Spa Societa' Agricola</td><td>Completed</td><td>Apr 2016</td><td>Mar 2020</td><td>Interventional</td><td>Apr 2016</td><td>Constipation</td><td>null</td></tr><tr><td>NCT02750735</td><td>University of Palermo</td><td>Completed</td><td>Jan 2001</td><td>Mar 2016</td><td>Observational</td><td>Apr 2016</td><td>Hypersensitivity</td><td>null</td></tr><tr><td>NCT02753868</td><td>University of Illinois at Urbana-Champaign</td><td>Completed</td><td>Feb 2016</td><td>Feb 2017</td><td>Interventional</td><td>Feb 2016</td><td>Renal Insufficiency</td><td>null</td></tr><tr><td>NCT02755844</td><td>Hospices Civils de Lyon</td><td>Active, not recruiting</td><td>Sep 2016</td><td>Apr 2022</td><td>Interventional</td><td>Apr 2016</td><td>Endometrial Neoplasms</td><td>Metformin,Cyclophosphamide,Olaparib</td></tr><tr><td>NCT02758301</td><td>Medtronic Cardiac Rhythm and Heart Failure</td><td>Completed</td><td>Jun 2016</td><td>Dec 2018</td><td>Observational</td><td>Apr 2016</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT02751463</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>null</td></tr><tr><td>NCT02752633</td><td>Landspitali University Hospital</td><td>Completed</td><td>May 2013</td><td>May 2015</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Allopurinol,Febuxostat</td></tr><tr><td>NCT02755909</td><td>Indonesia University</td><td>Completed</td><td>Dec 2015</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>Anxiety Disorders</td><td>Anesthetics</td></tr><tr><td>NCT02752620</td><td>Rio de Janeiro State University</td><td>Completed</td><td>May 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>Back Pain,Low Back Pain</td><td>null</td></tr><tr><td>NCT02759965</td><td>Karolinska University Hospital</td><td>Completed</td><td>Sep 2014</td><td>Dec 2018</td><td>Observational</td><td>Nov 2014</td><td>Acute-Phase Reaction,Cognitive Dysfunction</td><td>null</td></tr><tr><td>NCT02754752</td><td>M.D. Anderson Cancer Center</td><td>Recruiting</td><td>Sep 2016</td><td>Sep 2023</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms,Chronic Pain</td><td>null</td></tr><tr><td>NCT02754349</td><td>Onze Lieve Vrouw Hospital</td><td>Completed</td><td>Feb 2015</td><td>May 2016</td><td>Interventional</td><td>Mar 2016</td><td>Atrial Fibrillation</td><td>null</td></tr><tr><td>NCT02754479</td><td>Cutera Inc.</td><td>Completed</td><td>Apr 2016</td><td>Mar 2017</td><td>Interventional</td><td>Apr 2016</td><td>Telangiectasis</td><td>null</td></tr><tr><td>NCT02753790</td><td>New Mexico Cancer Care Alliance</td><td>Active, not recruiting</td><td>Feb 2016</td><td>Mar 2023</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasm Metastasis,Neoplasms,Brain Neoplasms</td><td>null</td></tr><tr><td>NCT02757248</td><td>Anne Beaven, MD</td><td>Withdrawn</td><td>Nov 2016</td><td>Nov 2016</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>Romidepsin</td></tr><tr><td>NCT02759991</td><td>Norwegian Institute of Public Health</td><td>Completed</td><td>Oct 2017</td><td>Sep 2019</td><td>Interventional</td><td>Mar 2016</td><td>Infections,Hepatitis A,Hepatitis E,Hepatitis</td><td>Vaccines</td></tr><tr><td>NCT02758561</td><td>Ottawa Hospital Research Institute</td><td>Completed</td><td>May 2016</td><td>Nov 2017</td><td>Interventional</td><td>Dec 2015</td><td>Urinary Incontinence,Enuresis,Pelvic Floor Disorders,Prolapse</td><td>null</td></tr><tr><td>NCT02753504</td><td>Chong Kun Dang Pharmaceutical</td><td>Completed</td><td>Apr 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dyslipidemias</td><td>null</td></tr><tr><td>NCT02758821</td><td>University of Oxford</td><td>Completed</td><td>Jun 2016</td><td>Sep 2017</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757430</td><td>Abbott Medical Devices</td><td>Completed</td><td>Aug 2016</td><td>Jul 2017</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Arrhythmias</td><td>null</td></tr><tr><td>NCT02754024</td><td>Werner Anderl</td><td>Active, not recruiting</td><td>Sep 2005</td><td>Sep 2025</td><td>Observational</td><td>Apr 2016</td><td>Osteoarthritis,Necrosis</td><td>null</td></tr><tr><td>NCT02757651</td><td>Institute of Cancer Research, United Kingdom</td><td>Completed</td><td>Jan 2017</td><td>Nov 2020</td><td>Interventional</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>Hydrogen Peroxide</td></tr><tr><td>NCT02758769</td><td>Bristol-Myers Squibb</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Oct 2023</td><td>Observational</td><td>Apr 2016</td><td>Arthritis</td><td>Abatacept</td></tr><tr><td>NCT02755896</td><td>Weill Medical College of Cornell University</td><td>Recruiting</td><td>Jul 2015</td><td>Jul 2024</td><td>Interventional</td><td>Aug 2015</td><td>Neoplasms,Breast Neoplasms,Radiation Pneumonitis</td><td>null</td></tr><tr><td>NCT02753699</td><td>Debiopharm International SA</td><td>Completed</td><td>Dec 2011</td><td>May 2015</td><td>Interventional</td><td>Mar 2016</td><td>Hepatitis A,Hepatitis C,Hepatitis</td><td>null</td></tr><tr><td>NCT02754323</td><td>Centre Hospitalier Universitaire de Nice</td><td>Unknown status</td><td>May 2016</td><td>Dec 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753881</td><td>Yale University</td><td>Completed</td><td>Nov 2015</td><td>Dec 2019</td><td>Interventional</td><td>Mar 2016</td><td>Liver Neoplasms</td><td>Doxorubicin,Liposomal doxorubicin</td></tr><tr><td>NCT02752074</td><td>Incyte Corporation</td><td>Completed</td><td>Jun 2016</td><td>Aug 2019</td><td>Interventional</td><td>Apr 2016</td><td>Melanoma</td><td>Pembrolizumab</td></tr><tr><td>NCT02753244</td><td>Intendu Ltd.</td><td>Unknown status</td><td>Apr 2015</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Brain Injuries,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT02752672</td><td>Medical University of Graz</td><td>Completed</td><td>Mar 2016</td><td>Nov 2016</td><td>Observational</td><td>Apr 2016</td><td>Psoriasis</td><td>null</td></tr><tr><td>NCT02759029</td><td>Gangnam Severance Hospital</td><td>Unknown status</td><td>Mar 2016</td><td>Feb 2018</td><td>Interventional</td><td>Apr 2016</td><td>Disease Susceptibility</td><td>null</td></tr><tr><td>NCT02750202</td><td>University of Pretoria</td><td>Recruiting</td><td>Jul 2018</td><td>Jul 2023</td><td>Interventional</td><td>Apr 2016</td><td>Warts,Condylomata Acuminata,Recurrence</td><td>Vaccines</td></tr><tr><td>NCT02753686</td><td>Novartis Pharmaceuticals</td><td>Active, not recruiting</td><td>Mar 2016</td><td>Aug 2022</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>Tamoxifen,Everolimus,Letrozole,Fulvestrant,Anastrozole,Exemestane</td></tr><tr><td>NCT02752217</td><td>Khon Kaen University</td><td>Unknown status</td><td>Mar 2016</td><td>Sep 2018</td><td>Interventional</td><td>Apr 2016</td><td>Hypertension</td><td>null</td></tr><tr><td>NCT02755662</td><td>ResMed</td><td>Completed</td><td>May 2016</td><td>Jul 2017</td><td>Interventional</td><td>Apr 2016</td><td>Apnea,Sleep Apnea Syndromes,Sleep Apnea,Syndrome</td><td>null</td></tr><tr><td>NCT02751671</td><td>St. Justine's Hospital</td><td>Completed</td><td>Aug 2016</td><td>Jun 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752880</td><td>Chang Gung Memorial Hospital</td><td>Completed</td><td>Jun 2016</td><td>Feb 2018</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02751632</td><td>Orygen</td><td>Active, not recruiting</td><td>Apr 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Psychotic Disorders,Mental Disorders,Personality Disorders</td><td>Fluoxetine</td></tr><tr><td>NCT02750527</td><td>Kinderkrankenhaus auf der Bult</td><td>Completed</td><td>Sep 2016</td><td>Dec 2020</td><td>Observational</td><td>Apr 2016</td><td>Hyperlipoproteinemia Type II,Diabetes Mellitus,Hypercholesterolemia</td><td>null</td></tr><tr><td>NCT02751242</td><td>Vanderbilt University</td><td>Completed</td><td>Aug 2016</td><td>Jul 2017</td><td>Observational</td><td>Apr 2016</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT02755363</td><td>Medical University of Warsaw</td><td>Unknown status</td><td>Apr 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Lung Diseases,Pulmonary Disease</td><td>null</td></tr><tr><td>NCT02751775</td><td>Pennington Biomedical Research Center</td><td>Completed</td><td>Jun 2016</td><td>Jun 2017</td><td>Observational</td><td>Apr 2016</td><td>Pediatric Obesity</td><td>null</td></tr><tr><td>NCT02757976</td><td>Lawson Health Research Institute</td><td>Terminated</td><td>Mar 2018</td><td>Jun 2019</td><td>Interventional</td><td>Apr 2016</td><td>Heart Failure,Ventricular Dysfunction</td><td>null</td></tr><tr><td>NCT02752386</td><td>University of Tulsa</td><td>Completed</td><td>Feb 2016</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756143</td><td>University Hospital of Torrejon</td><td>Completed</td><td>Nov 2014</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754648</td><td>Ain Shams University</td><td>Unknown status</td><td>Sep 2015</td><td>Sep 2016</td><td>Interventional</td><td>Mar 2016</td><td>Endometriosis</td><td>null</td></tr><tr><td>NCT02751138</td><td>University of Ulm</td><td>Recruiting</td><td>Mar 2016</td><td>Sep 2024</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Glioblastoma</td><td>null</td></tr><tr><td>NCT02753231</td><td>Universidad Santo Tomas</td><td>Completed</td><td>Jan 2017</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Metabolic Syndrome,Metabolic Diseases,Lipid Metabolism Disorders,Overweight</td><td>null</td></tr><tr><td>NCT02759588</td><td>Genelux Corporation</td><td>Active, not recruiting</td><td>May 2016</td><td>May 2022</td><td>Interventional</td><td>Apr 2016</td><td>Ovarian Neoplasms,Carcinoma,Fallopian Tube Neoplasms,Peritoneal Neoplasms</td><td>Bevacizumab</td></tr><tr><td>NCT02757352</td><td>Eli Lilly and Company</td><td>Completed</td><td>Aug 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>Spondylarthritis</td><td>Ixekizumab</td></tr><tr><td>NCT02752022</td><td>St George's, University of London</td><td>Unknown status</td><td>Sep 2016</td><td>Apr 2019</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754973</td><td>The University of Hong Kong</td><td>Completed</td><td>May 2015</td><td>Nov 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755506</td><td>Chinese PLA General Hospital</td><td>Unknown status</td><td>Oct 2015</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>Aneurysm</td><td>null</td></tr><tr><td>NCT02751216</td><td>Moens Maarten</td><td>Completed</td><td>May 2016</td><td>Jan 2018</td><td>Interventional</td><td>Apr 2016</td><td>Syndrome,Failed Back Surgery Syndrome</td><td>null</td></tr><tr><td>NCT02756559</td><td>Lixin Xie</td><td>Unknown status</td><td>Jan 2014</td><td>Dec 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754557</td><td>Emory University</td><td>Recruiting</td><td>Mar 2016</td><td>Dec 2021</td><td>Interventional</td><td>Apr 2016</td><td>Stress Disorders</td><td>null</td></tr><tr><td>NCT02758496</td><td>Wave Neuroscience</td><td>Completed</td><td>Apr 2016</td><td>Apr 2017</td><td>Observational</td><td>Apr 2016</td><td>Autistic Disorder</td><td>null</td></tr><tr><td>NCT02757066</td><td>Nobelpharma</td><td>Completed</td><td>Jun 2016</td><td>Sep 2018</td><td>Interventional</td><td>Apr 2016</td><td>Sleep Wake Disorders,Parasomnias,Disease,Autistic Disorder,Autism Spectrum Disorder,Child Development Disorders</td><td>Melatonin</td></tr><tr><td>NCT02756104</td><td>University Hospital, Montpellier</td><td>Completed</td><td>Jun 2016</td><td>May 2020</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Vitamin D</td></tr><tr><td>NCT02751814</td><td>Pennington Biomedical Research Center</td><td>Completed</td><td>Apr 2016</td><td>Jun 2018</td><td>Observational</td><td>Apr 2016</td><td>Pediatric Obesity</td><td>null</td></tr><tr><td>NCT02751749</td><td>Örebro University, Sweden</td><td>Completed</td><td>Dec 2015</td><td>Sep 2016</td><td>Interventional</td><td>Apr 2016</td><td>Chronic Pain</td><td>null</td></tr><tr><td>NCT02756052</td><td>University of Calgary</td><td>Completed</td><td>Mar 2016</td><td>Aug 2016</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753647</td><td>Ruijin Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Apr 2019</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>Prednisone,Cyclophosphamide,Rituximab,Doxorubicin,Vincristine</td></tr><tr><td>NCT02756910</td><td>Peking Union Medical College Hospital</td><td>Completed</td><td>May 2016</td><td>Sep 2016</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02756208</td><td>University of Maryland, College Park</td><td>Completed</td><td>Nov 2015</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>HIV Infections</td><td>Vaccines</td></tr><tr><td>NCT02757443</td><td>Meshalkin Research Institute of Pathology of Circulation</td><td>Completed</td><td>Jun 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Phosphocreatine,Anesthetics</td></tr><tr><td>NCT02759744</td><td>National Institutes of Health Clinical Center (CC)</td><td>Enrolling by invitation</td><td>Oct 2017</td><td>Jan 2026</td><td>Interventional</td><td>Apr 2016</td><td>Prostatic Neoplasms</td><td>null</td></tr><tr><td>NCT02753140</td><td>Daping Hospital and the Research Institute of Surgery of the Third Military Medical University</td><td>Unknown status</td><td>Apr 2016</td><td>Sep 2018</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma,Squamous Cell Carcinoma of Head and Neck</td><td>Docetaxel,Cetuximab</td></tr><tr><td>NCT02759536</td><td>The Third Xiangya Hospital of Central South University</td><td>Unknown status</td><td>Jul 2013</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Melanoma</td><td>null</td></tr><tr><td>NCT02750449</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>null</td></tr><tr><td>NCT02759211</td><td>Mount Sinai Rehabilitation Hospital</td><td>Unknown status</td><td>Apr 2016</td><td>Feb 2018</td><td>Interventional</td><td>Mar 2016</td><td>Multiple Sclerosis,Sclerosis</td><td>null</td></tr><tr><td>NCT02752477</td><td>Ben Lim</td><td>Active, not recruiting</td><td>Aug 2016</td><td>Sep 2020</td><td>Interventional</td><td>Mar 2016</td><td>Pain,Chronic Pain</td><td>Anesthetics</td></tr><tr><td>NCT02759835</td><td>National Cancer Institute (NCI)</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Sep 2022</td><td>Interventional</td><td>Apr 2016</td><td>Lung Neoplasms,Adenocarcinoma of Lung</td><td>Osimertinib</td></tr><tr><td>NCT02754596</td><td>Glaukos Corporation</td><td>Active, not recruiting</td><td>Mar 2016</td><td>Dec 2021</td><td>Interventional</td><td>Mar 2016</td><td>Glaucoma</td><td>Timolol,Travoprost,Ophthalmic Solutions</td></tr><tr><td>NCT02757846</td><td>Chinese Academy of Sciences</td><td>Enrolling by invitation</td><td>Apr 2017</td><td>Mar 2022</td><td>Observational</td><td>Apr 2016</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT02750085</td><td>Victor Blanchette</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Dec 2020</td><td>Observational</td><td>Apr 2016</td><td>Hemophilia A</td><td>null</td></tr><tr><td>NCT02759692</td><td>Johnson & Johnson Vision Care, Inc.</td><td>Completed</td><td>Apr 2016</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02752750</td><td>Medical University of Graz</td><td>Enrolling by invitation</td><td>May 2016</td><td>May 2022</td><td>Observational</td><td>Apr 2016</td><td>Alzheimer Disease</td><td>null</td></tr><tr><td>NCT02757781</td><td>Avedis Donabedian Research Institute</td><td>Unknown status</td><td>Jul 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Chronic Disease</td><td>null</td></tr><tr><td>NCT02757924</td><td>Abbott Nutrition</td><td>Completed</td><td>May 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759887</td><td>St. Joseph's Hospital and Medical Center, Phoenix</td><td>Completed</td><td>Nov 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Dementia,Down Syndrome,Alzheimer Disease,Syndrome</td><td>Fluorodeoxyglucose F18</td></tr><tr><td>NCT02758977</td><td>University of Zurich</td><td>Unknown status</td><td>May 2016</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms,Neoplasm Metastasis,Liver Neoplasms,Colorectal Neoplasms,Liver Diseases</td><td>null</td></tr><tr><td>NCT02751580</td><td>Sidney Kimmel Cancer Center at Thomas Jefferson University</td><td>Completed</td><td>Mar 2016</td><td>Aug 2018</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms</td><td>null</td></tr><tr><td>NCT02751333</td><td>Johns Hopkins University</td><td>Withdrawn</td><td>Mar 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Esophageal Stenosis,Esophageal Fistula,Esophageal Perforation,Fistula,Constriction</td><td>null</td></tr><tr><td>NCT02759731</td><td>National Cancer Institute (NCI)</td><td>Recruiting</td><td>Nov 2016</td><td>Jun 2022</td><td>Interventional</td><td>Apr 2016</td><td>Graft vs Host Disease</td><td>null</td></tr><tr><td>NCT02758288</td><td>Loma Linda University</td><td>Withdrawn</td><td>Sep 2015</td><td>Jul 2022</td><td>Observational</td><td>Mar 2016</td><td>Virus Diseases,Kidney Diseases</td><td>null</td></tr><tr><td>NCT02756546</td><td>Cairo University</td><td>Completed</td><td>Sep 2014</td><td>Dec 2015</td><td>Interventional</td><td>Apr 2016</td><td>Lupus Erythematosus</td><td>Hydroxychloroquine,Hydrocortisone,Cyclophosphamide</td></tr><tr><td>NCT02759094</td><td>Implantica CE & Production Ltd</td><td>Unknown status</td><td>Dec 2016</td><td>Feb 2018</td><td>Interventional</td><td>Apr 2016</td><td>Gastroesophageal Reflux</td><td>null</td></tr><tr><td>NCT02757313</td><td>Yale University</td><td>Completed</td><td>Oct 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Marijuana Abuse</td><td>Dronabinol</td></tr><tr><td>NCT02754011</td><td>UNICANCER</td><td>Recruiting</td><td>Jan 2017</td><td>Dec 2021</td><td>Interventional</td><td>Feb 2016</td><td>Breast Neoplasms</td><td>Capecitabine</td></tr><tr><td>NCT02755805</td><td>University of Pittsburgh</td><td>Completed</td><td>Jul 2009</td><td>Dec 2012</td><td>Interventional</td><td>Apr 2016</td><td>Stroke</td><td>null</td></tr><tr><td>NCT02755428</td><td>Chinese Academy of Sciences</td><td>Unknown status</td><td>Jan 2018</td><td>Dec 2020</td><td>Interventional</td><td>Mar 2016</td><td>Macular Degeneration</td><td>null</td></tr><tr><td>NCT02752555</td><td>Benha University</td><td>Unknown status</td><td>Apr 2016</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Oligospermia</td><td>Antioxidants</td></tr><tr><td>NCT02751398</td><td>Yonsei University</td><td>Completed</td><td>Aug 2016</td><td>Jun 2020</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>Dapagliflozin</td></tr><tr><td>NCT02758951</td><td>Koen Rovers</td><td>Recruiting</td><td>Jun 2017</td><td>Aug 2026</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms,Colorectal Neoplasms,Neoplasm Metastasis,Carcinoma,Peritoneal Neoplasms</td><td>Bevacizumab</td></tr><tr><td>NCT02750176</td><td>University of Southern California</td><td>Completed</td><td>Apr 2016</td><td>Jul 2018</td><td>Interventional</td><td>Apr 2016</td><td>Rotator Cuff Injuries</td><td>null</td></tr><tr><td>NCT02750696</td><td>Federal University of Rio Grande do Sul</td><td>Completed</td><td>Apr 2013</td><td>Apr 2015</td><td>Interventional</td><td>Apr 2016</td><td>Abscess,Periapical Abscess</td><td>Acetaminophen,Tramadol,Codeine</td></tr><tr><td>NCT02757963</td><td>GlaxoSmithKline</td><td>Completed</td><td>May 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Prostatic Hyperplasia,Hyperplasia</td><td>null</td></tr><tr><td>NCT02756026</td><td>USDA, Western Human Nutrition Research Center</td><td>Completed</td><td>Sep 2013</td><td>Feb 2014</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Micronutrients,Trace Elements</td></tr><tr><td>NCT02756481</td><td>Bristol-Myers Squibb</td><td>Completed</td><td>Oct 2013</td><td>Nov 2014</td><td>Observational</td><td>Oct 2015</td><td>Atrial Fibrillation</td><td>null</td></tr><tr><td>NCT02751060</td><td>Tongji Hospital</td><td>Enrolling by invitation</td><td>Apr 2016</td><td>Dec 2022</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Heart Diseases,Coronary Disease,Coronary Artery Disease,Myocardial Ischemia</td><td>null</td></tr><tr><td>NCT02753127</td><td>Sumitomo Dainippon Pharma Oncology, Inc</td><td>Completed</td><td>Jun 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Colorectal Neoplasms</td><td>Leucovorin,Bevacizumab,Fluorouracil,Irinotecan</td></tr><tr><td>NCT02755051</td><td>University of Missouri-Columbia</td><td>Completed</td><td>Jul 2016</td><td>Mar 2018</td><td>Interventional</td><td>Mar 2016</td><td>Sleep Initiation and Maintenance Disorders,Autistic Disorder,Autism Spectrum Disorder,Child Development Disorders</td><td>null</td></tr><tr><td>NCT02757560</td><td>Phoenix VA Health Care System</td><td>Unknown status</td><td>Feb 2012</td><td>Dec 2020</td><td>Interventional</td><td>Aug 2015</td><td>Insulin Resistance</td><td>null</td></tr><tr><td>NCT02754076</td><td>Allievex Corporation</td><td>Completed</td><td>Apr 2016</td><td>Jul 2020</td><td>Interventional</td><td>Feb 2016</td><td>Mucopolysaccharidoses,Mucopolysaccharidosis III</td><td>null</td></tr><tr><td>NCT02752282</td><td>University of Washington</td><td>Unknown status</td><td>Mar 2016</td><td>Dec 2019</td><td>Interventional</td><td>Apr 2016</td><td>Uterine Hemorrhage</td><td>null</td></tr><tr><td>NCT02751021</td><td>University Hospital, Caen</td><td>Completed</td><td>Jun 2016</td><td>Jun 2019</td><td>Interventional</td><td>Apr 2016</td><td>Apnea,Sleep Apnea Syndromes,Arrhythmias,Hyperaldosteronism</td><td>null</td></tr><tr><td>NCT02759471</td><td>Coopervision, Inc.</td><td>Completed</td><td>Apr 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Myopia</td><td>null</td></tr><tr><td>NCT02752854</td><td>Taif University</td><td>Unknown status</td><td>Apr 2015</td><td>May 2016</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02759822</td><td>Leonardo Javier Arcuri</td><td>Unknown status</td><td>Apr 2016</td><td>null</td><td>Observational</td><td>Apr 2016</td><td>Leukemia,Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>null</td></tr><tr><td>NCT02752139</td><td>Yi Yang</td><td>Completed</td><td>May 2016</td><td>Oct 2018</td><td>Observational [Patient Registry]</td><td>Mar 2016</td><td>Sleep Wake Disorders,Parasomnias,Sleep Disorders,Disease</td><td>null</td></tr><tr><td>NCT02752295</td><td>Medical University of Vienna</td><td>Completed</td><td>May 2015</td><td>Jul 2016</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Inflammation,Anxiety Disorders,Mood Disorders,Stress</td><td>null</td></tr><tr><td>NCT02753023</td><td>University of Sao Paulo General Hospital</td><td>Unknown status</td><td>May 2015</td><td>May 2020</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>Pulmonary Embolism,Pulmonary Edema,Syncope,Aneurysm,Acute Coronary Syndrome,Embolism,Aortic Aneurysm,Emergencies,Chest Pain</td><td>null</td></tr><tr><td>NCT02757365</td><td>West China Hospital</td><td>Unknown status</td><td>Apr 2014</td><td>Apr 2019</td><td>Interventional</td><td>Apr 2016</td><td>Prostatic Neoplasms</td><td>Aspirin,Levofloxacin,Ofloxacin</td></tr><tr><td>NCT02757092</td><td>Chang Gung Memorial Hospital</td><td>Completed</td><td>Mar 2016</td><td>May 2017</td><td>Interventional</td><td>Apr 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02758327</td><td>Koffler Vision Group</td><td>Completed</td><td>Oct 2015</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dry Eye Syndromes</td><td>Carboxymethylcellulose Sodium,Ophthalmic Solutions,Lubricant Eye Drops</td></tr><tr><td>NCT02757404</td><td>Medy-Tox</td><td>Completed</td><td>May 2016</td><td>Aug 2016</td><td>Interventional</td><td>Apr 2016</td><td>Muscle Spasticity</td><td>Botulinum Toxins</td></tr><tr><td>NCT02757469</td><td>Navy General Hospital, Beijing</td><td>Unknown status</td><td>May 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Premature Birth,Infertility,Primary Ovarian Insufficiency,Menopause</td><td>Drospirenone,Ethinyl Estradiol,Drospirenone and ethinyl estradiol combination,Estradiol</td></tr><tr><td>NCT02759172</td><td>Michigan State University</td><td>Unknown status</td><td>Apr 2016</td><td>null</td><td>Interventional</td><td>Apr 2016</td><td>Suicide</td><td>null</td></tr><tr><td>NCT02758041</td><td>Sebacia, Inc.</td><td>Completed</td><td>Feb 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Acne Vulgaris</td><td>null</td></tr><tr><td>NCT02755116</td><td>Jaime B Hyman</td><td>Completed</td><td>Apr 2016</td><td>Sep 2019</td><td>Interventional</td><td>Apr 2016</td><td>Nausea,Vomiting,Postoperative Nausea and Vomiting</td><td>Olanzapine</td></tr><tr><td>NCT02755584</td><td>National Institute on Aging (NIA)</td><td>Completed</td><td>Jun 2016</td><td>Apr 2021</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750540</td><td>Johns Hopkins University</td><td>Completed</td><td>Oct 2016</td><td>May 2019</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Tenofovir</td></tr><tr><td>NCT02751918</td><td>Bayer</td><td>Completed</td><td>Jun 2016</td><td>Oct 2019</td><td>Interventional</td><td>Apr 2016</td><td>Ovarian Neoplasms</td><td>Doxorubicin,Liposomal doxorubicin,Maytansine</td></tr><tr><td>NCT02751541</td><td>Bayer</td><td>Completed</td><td>May 2016</td><td>May 2016</td><td>Interventional</td><td>Apr 2016</td><td>Dermatitis</td><td>Sunscreening Agents</td></tr><tr><td>NCT02755883</td><td>Weill Medical College of Cornell University</td><td>Completed</td><td>Apr 2016</td><td>Oct 2017</td><td>Interventional</td><td>Apr 2016</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT02751229</td><td>University of Ulm</td><td>Completed</td><td>May 2016</td><td>May 2017</td><td>Interventional</td><td>Mar 2016</td><td>Mental Disorders</td><td>null</td></tr><tr><td>NCT02759640</td><td>Atridia Pty Ltd.</td><td>Completed</td><td>Sep 2016</td><td>May 2018</td><td>Interventional</td><td>Apr 2016</td><td>Neoplasms</td><td>null</td></tr><tr><td>NCT02750683</td><td>Hopital Antoine Beclere</td><td>Completed</td><td>Oct 2014</td><td>Jan 2016</td><td>Observational</td><td>Apr 2016</td><td>Shock</td><td>null</td></tr><tr><td>NCT02758132</td><td>University of Hawaii</td><td>Terminated</td><td>Mar 2016</td><td>Sep 2016</td><td>Interventional</td><td>Apr 2016</td><td>Prostatic Neoplasms,Neoplasm Metastasis</td><td>Denosumab,Prednisone</td></tr><tr><td>NCT02757001</td><td>Group of Research in Minimally Invasive Techniques</td><td>Completed</td><td>Jun 2016</td><td>Jul 2019</td><td>Observational [Patient Registry]</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02757235</td><td>Sahlgrenska University Hospital, Sweden</td><td>Unknown status</td><td>Mar 2016</td><td>Jun 2020</td><td>Interventional</td><td>Apr 2016</td><td>Hematoma</td><td>null</td></tr><tr><td>NCT02754869</td><td>University College, London</td><td>Unknown status</td><td>Feb 2011</td><td>Aug 2018</td><td>Observational</td><td>Feb 2016</td><td>Intestinal Diseases</td><td>null</td></tr><tr><td>NCT02759406</td><td>Palmaz Scientific</td><td>Completed</td><td>Sep 2013</td><td>Jun 2015</td><td>Interventional</td><td>Apr 2016</td><td>Heart Diseases,Myocardial Ischemia,Coronary Artery Disease,Ischemia</td><td>null</td></tr><tr><td>NCT02758522</td><td>Hospital Universitario Dr. Jose E. Gonzalez</td><td>Completed</td><td>Oct 2013</td><td>Oct 2015</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus,Hyperglycemia</td><td>Insulin</td></tr><tr><td>NCT02750046</td><td>Second Affiliated Hospital of Soochow University</td><td>Unknown status</td><td>Mar 2016</td><td>Feb 2018</td><td>Interventional</td><td>Mar 2016</td><td>Fractures,Femoral Neck Fractures</td><td>null</td></tr><tr><td>NCT02755233</td><td>University of Zurich</td><td>Completed</td><td>Jan 2014</td><td>Mar 2016</td><td>Observational</td><td>Apr 2016</td><td>Melanoma</td><td>null</td></tr><tr><td>NCT02750423</td><td>Emory University</td><td>Completed</td><td>Apr 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754050</td><td>Tandem Technologies LTD</td><td>Unknown status</td><td>Sep 2016</td><td>Oct 2018</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02754284</td><td>Chinese Academy of Sciences</td><td>Completed</td><td>Dec 2015</td><td>Jun 2020</td><td>Interventional</td><td>Apr 2016</td><td>Vocal Cord Dysfunction</td><td>null</td></tr><tr><td>NCT02756078</td><td>Johnson & Johnson Vision Care, Inc.</td><td>Completed</td><td>Apr 2016</td><td>Oct 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02750995</td><td>Daniel El Fassi</td><td>Completed</td><td>Apr 2016</td><td>Jun 2019</td><td>Interventional</td><td>Apr 2016</td><td>Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome</td><td>Azacitidine</td></tr><tr><td>NCT02759302</td><td>Rigshospitalet, Denmark</td><td>Completed</td><td>Apr 2016</td><td>Apr 2017</td><td>Observational</td><td>Apr 2016</td><td>Muscular Dystrophies</td><td>null</td></tr><tr><td>NCT02759874</td><td>Institute of Health Economics, Canada</td><td>Unknown status</td><td>Nov 2015</td><td>Nov 2018</td><td>Interventional</td><td>Apr 2016</td><td>Fetal Alcohol Spectrum Disorders,Alcoholism</td><td>null</td></tr><tr><td>NCT02758535</td><td>Modarres Hospital</td><td>Completed</td><td>Mar 2015</td><td>Mar 2016</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755636</td><td>Pro-Change Behavior Systems</td><td>Unknown status</td><td>May 2016</td><td>Jul 2017</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758873</td><td>University of Sussex</td><td>Completed</td><td>Feb 2016</td><td>Jul 2019</td><td>Interventional</td><td>Apr 2016</td><td>Asthma</td><td>Salmeterol Xinafoate,Montelukast</td></tr><tr><td>NCT02753166</td><td>NYU Langone Health</td><td>Withdrawn</td><td>Jan 2017</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>Dexamethasone</td></tr><tr><td>NCT02755766</td><td>Shriners Hospitals for Children</td><td>Completed</td><td>May 2015</td><td>Jul 2019</td><td>Observational</td><td>Mar 2016</td><td>Scoliosis,Clubfoot,Talipes,Equinus Deformity</td><td>null</td></tr><tr><td>NCT02751983</td><td>VA Office of Research and Development</td><td>Completed</td><td>Nov 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Suicide</td><td>null</td></tr><tr><td>NCT02754960</td><td>Shanghai Jiao Tong University School of Medicine</td><td>Withdrawn</td><td>Mar 2010</td><td>Sep 2014</td><td>Interventional</td><td>Apr 2016</td><td>Gastrointestinal Hemorrhage,Vascular Malformations,Congenital Abnormalities,Hemorrhage</td><td>Thalidomide</td></tr><tr><td>NCT02751086</td><td>International Study Group on Minimally Invasive Surgery for Gastric Cancer</td><td>Recruiting</td><td>Apr 2016</td><td>Dec 2024</td><td>Observational</td><td>Apr 2016</td><td>Stomach Neoplasms</td><td>null</td></tr><tr><td>NCT02755753</td><td>YongChan Lee</td><td>Completed</td><td>Jan 2014</td><td>Apr 2016</td><td>Interventional</td><td>Sep 2015</td><td>Gastroesophageal Reflux,Esophagitis</td><td>Lansoprazole,Dexlansoprazole,Rebamipide</td></tr><tr><td>NCT02757872</td><td>Albert Einstein College of Medicine</td><td>Active, not recruiting</td><td>Apr 2016</td><td>Nov 2021</td><td>Interventional</td><td>Apr 2016</td><td>Kidney Diseases,Hypertension</td><td>Vitamin D,Ergocalciferols,Cholecalciferol,Vitamins</td></tr><tr><td>NCT02756767</td><td>Abramson Cancer Center of the University of Pennsylvania</td><td>Completed</td><td>Apr 2016</td><td>Apr 2021</td><td>Observational</td><td>Apr 2016</td><td>Neoplasms</td><td>null</td></tr><tr><td>NCT02757937</td><td>Children's Hospital of Philadelphia</td><td>Completed</td><td>May 2016</td><td>Dec 2017</td><td>Interventional</td><td>Apr 2016</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT02753660</td><td>Indonesia University</td><td>Completed</td><td>Aug 2014</td><td>Oct 2014</td><td>Interventional</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02751684</td><td>Universitätsklinikum Köln</td><td>Completed</td><td>Mar 2017</td><td>May 2017</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02753556</td><td>Dimagi Inc.</td><td>Completed</td><td>Sep 2015</td><td>Jun 2016</td><td>Observational</td><td>Apr 2016</td><td>Lung Diseases,Pulmonary Disease</td><td>null</td></tr><tr><td>NCT02757287</td><td>Institut Universitari Dexeus</td><td>Withdrawn</td><td>May 2016</td><td>Dec 2018</td><td>Interventional</td><td>Apr 2016</td><td>Infertility</td><td>Desogestrel</td></tr><tr><td>NCT02752308</td><td>Isfahan University of Medical Sciences</td><td>Completed</td><td>Sep 2014</td><td>Mar 2015</td><td>Interventional</td><td>Apr 2016</td><td>Hypospadias</td><td>Atropine,Epinephrine,Fentanyl,Bupivacaine,Neostigmine</td></tr><tr><td>NCT02758314</td><td>Instituto Nacional de Cancerologia de Mexico</td><td>Unknown status</td><td>Mar 2017</td><td>Dec 2018</td><td>Observational</td><td>Apr 2016</td><td>Lung Neoplasms,Carcinoma</td><td>null</td></tr><tr><td>NCT02752685</td><td>NYU Langone Health</td><td>Recruiting</td><td>Jun 2016</td><td>Dec 2021</td><td>Observational</td><td>Apr 2016</td><td>Breast Neoplasms</td><td>Paclitaxel,Pembrolizumab</td></tr><tr><td>NCT02759289</td><td>NYU Langone Health</td><td>Completed</td><td>Nov 2015</td><td>Sep 2020</td><td>Observational</td><td>Apr 2016</td><td>Atherosclerosis</td><td>null</td></tr><tr><td>NCT02759120</td><td>Weill Medical College of Cornell University</td><td>Terminated</td><td>Mar 2017</td><td>Mar 2020</td><td>Interventional</td><td>Apr 2016</td><td>Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis</td><td>Doxycycline,Anti-Bacterial Agents,Trimethoprim,Anti-Infective Agents</td></tr><tr><td>NCT02754401</td><td>Renatus, Antonio Renatus, Dent., M.Sc</td><td>Completed</td><td>Jan 2014</td><td>Jul 2014</td><td>Interventional</td><td>Apr 2016</td><td>Periodontitis</td><td>null</td></tr><tr><td>NCT02759757</td><td>Leandro Pires</td><td>Unknown status</td><td>May 2016</td><td>Feb 2017</td><td>Interventional</td><td>Apr 2016</td><td>Back Pain,Low Back Pain</td><td>null</td></tr><tr><td>NCT02750579</td><td>Assistance Publique Hopitaux De Marseille</td><td>Completed</td><td>Sep 2016</td><td>Apr 2018</td><td>Interventional</td><td>Apr 2016</td><td>Acute Coronary Syndrome,Syndrome</td><td>null</td></tr><tr><td>NCT02752204</td><td>University of Birmingham</td><td>Completed</td><td>Oct 2015</td><td>Feb 2020</td><td>Interventional</td><td>Apr 2016</td><td>Lymphoma</td><td>Rituximab</td></tr><tr><td>NCT02757053</td><td>Mosaic Life Care</td><td>Terminated</td><td>Apr 2016</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>Brain Injuries,Brain Concussion,Diffuse Axonal Injury,Wounds and Injuries,Athletic Injuries</td><td>null</td></tr><tr><td>NCT02752542</td><td>Nova Scotia Health Authority</td><td>Unknown status</td><td>Oct 2016</td><td>May 2021</td><td>Interventional</td><td>Apr 2016</td><td>Disease,Depressive Disorder,Depression</td><td>null</td></tr><tr><td>NCT02753283</td><td>Susan L. Greenspan</td><td>Active, not recruiting</td><td>Jun 2016</td><td>Sep 2023</td><td>Interventional</td><td>Apr 2016</td><td>Osteoporosis,Osteoporotic Fractures</td><td>Vitamin D,Zoledronic Acid,Denosumab,Calcium</td></tr><tr><td>NCT02754934</td><td>Balgrist University Hospital</td><td>Completed</td><td>Nov 2014</td><td>Nov 2016</td><td>Observational</td><td>Apr 2016</td><td>Neck Pain</td><td>null</td></tr><tr><td>NCT02755194</td><td>The Hospital for Sick Children</td><td>Terminated</td><td>Sep 2014</td><td>Sep 2019</td><td>Observational</td><td>Apr 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02758210</td><td>Emory University</td><td>Completed</td><td>Apr 2016</td><td>Oct 2016</td><td>Interventional</td><td>Apr 2016</td><td>Bradycardia,Tachycardia</td><td>null</td></tr><tr><td>NCT02757456</td><td>Sameena Iqbal</td><td>Completed</td><td>Feb 2015</td><td>Feb 2016</td><td>Interventional</td><td>Nov 2012</td><td>Cardiovascular Diseases</td><td>null</td></tr><tr><td>NCT02756377</td><td>Islamic Azad University, Tehran</td><td>Completed</td><td>May 2014</td><td>Jun 2015</td><td>Interventional</td><td>Apr 2016</td><td>Periodontal Diseases</td><td>Chlorhexidine,Chlorhexidine gluconate,Cetylpyridinium</td></tr><tr><td>NCT02751099</td><td>Centro Hospitalar de Lisboa Central</td><td>Unknown status</td><td>Nov 2015</td><td>Dec 2018</td><td>Observational</td><td>Apr 2016</td><td>Bone Diseases,Renal Insufficiency,Vascular Diseases</td><td>null</td></tr><tr><td>NCT02752178</td><td>University of Cambridge</td><td>Completed</td><td>Jun 2015</td><td>Sep 2018</td><td>Observational</td><td>Mar 2016</td><td>Depressive Disorder,Depression</td><td>null</td></tr><tr><td>NCT02757144</td><td>Daewoong Pharmaceutical Co. LTD.</td><td>Completed</td><td>Mar 2016</td><td>Feb 2017</td><td>Interventional</td><td>Mar 2016</td><td>null</td><td>Esomeprazole</td></tr><tr><td>NCT02757742</td><td>Fu Wai Hospital, Beijing, China</td><td>Completed</td><td>Dec 2010</td><td>Aug 2016</td><td>Observational</td><td>Apr 2016</td><td>Cardiomyopathies</td><td>null</td></tr><tr><td>NCT02750644</td><td>Joaquin de Haro, M.D.</td><td>Completed</td><td>Jan 2005</td><td>Apr 2016</td><td>Observational</td><td>Apr 2016</td><td>Carotid Artery Diseases</td><td>null</td></tr><tr><td>NCT02754635</td><td>HaEmek Medical Center, Israel</td><td>Unknown status</td><td>Mar 2016</td><td>Jul 2018</td><td>Interventional</td><td>Feb 2016</td><td>null</td><td>null</td></tr><tr><td>NCT02755311</td><td>Sun Yat-sen University</td><td>Unknown status</td><td>Mar 2014</td><td>Jun 2016</td><td>Interventional</td><td>Apr 2016</td><td>Carcinoma</td><td>Cisplatin,Carboplatin,Fluorouracil,Epirubicin,Ethiodized Oil,Pirarubicin,Doxorubicin,Gelatin Sponge</td></tr><tr><td>NCT00170053</td><td>Mayo Clinic</td><td>Completed</td><td>Jun 2005</td><td>Sep 2008</td><td>Interventional</td><td>Sep 2005</td><td>Kidney Diseases</td><td>Sirolimus</td></tr><tr><td>NCT00175396</td><td>University of British Columbia</td><td>Unknown status</td><td>May 2004</td><td>Jun 2014</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms</td><td>Ascorbic Acid,Leuprolide,Methyltestosterone,Flutamide,Bicalutamide,Nilutamide,Buserelin,Androgens,Estrogens</td></tr><tr><td>NCT00179647</td><td>Celgene Corporation</td><td>Completed</td><td>Sep 2005</td><td>Apr 2009</td><td>Interventional</td><td>Sep 2005</td><td>Multiple Myeloma,Neoplasms</td><td>Dexamethasone,Lenalidomide</td></tr><tr><td>NCT00172523</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Oct 2004</td><td>Aug 2005</td><td>Observational</td><td>Sep 2005</td><td>Polycystic Ovary Syndrome,Syndrome</td><td>null</td></tr><tr><td>NCT00174785</td><td>Sanofi</td><td>Completed</td><td>Jun 2005</td><td>Mar 2008</td><td>Interventional</td><td>Sep 2005</td><td>Atrial Fibrillation,Atrial Flutter</td><td>Dronedarone</td></tr><tr><td>NCT00175058</td><td>TherOx</td><td>Completed</td><td>Aug 2005</td><td>May 2008</td><td>Interventional</td><td>Sep 2005</td><td>Myocardial Infarction,Infarction</td><td>null</td></tr><tr><td>NCT00177541</td><td>University of Pittsburgh</td><td>Completed</td><td>Feb 2004</td><td>Sep 2016</td><td>Interventional</td><td>Sep 2005</td><td>Urinary Incontinence</td><td>null</td></tr><tr><td>NCT00176215</td><td>Heidelberg University</td><td>Unknown status</td><td>May 2003</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Tooth Abrasion</td><td>null</td></tr><tr><td>NCT00178529</td><td>The University of Texas Health Science Center, Houston</td><td>Completed</td><td>Jul 2001</td><td>Sep 2005</td><td>Interventional</td><td>Sep 2005</td><td>Stroke</td><td>null</td></tr><tr><td>NCT00172367</td><td>National Taiwan University Hospital</td><td>Withdrawn</td><td>Jan 2006</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Carcinoma</td><td>Lycopene</td></tr><tr><td>NCT00173875</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Mar 2005</td><td>Jul 2007</td><td>Interventional</td><td>Sep 2005</td><td>Lung Neoplasms,Carcinoma</td><td>Gefitinib</td></tr><tr><td>NCT00174668</td><td>Sanofi</td><td>Completed</td><td>Nov 2004</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Diabetes Mellitus</td><td>Insulin,Insulin Glargine,Insulin glulisine</td></tr><tr><td>NCT00173927</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Mar 2004</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Atherosclerosis</td><td>null</td></tr><tr><td>NCT00179933</td><td>Ann & Robert H Lurie Children's Hospital of Chicago</td><td>Terminated</td><td>Sep 2005</td><td>Feb 2007</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00176878</td><td>Masonic Cancer Center, University of Minnesota</td><td>Completed</td><td>Jun 2000</td><td>Mar 2009</td><td>Interventional</td><td>Sep 2005</td><td>Shwachman-Diamond Syndrome,Neutropenia,Bone Marrow Failure Disorders,Pancytopenia,Anemia,Syndrome</td><td>Fludarabine,Fludarabine phosphate,Busulfan,Antilymphocyte Serum</td></tr><tr><td>NCT00172653</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00177645</td><td>University of Pittsburgh</td><td>Completed</td><td>Mar 2002</td><td>Dec 2006</td><td>Interventional</td><td>Sep 2005</td><td>Cystic Fibrosis,Fibrosis</td><td>null</td></tr><tr><td>NCT00176475</td><td>University of Medicine and Dentistry of New Jersey</td><td>Terminated</td><td>Jan 2005</td><td>Feb 2008</td><td>Interventional</td><td>Sep 2005</td><td>Lymphoma,Leukemia,Multiple Myeloma,Neoplasms,Plasmacytoma</td><td>Rituximab</td></tr><tr><td>NCT00178087</td><td>University of Pittsburgh</td><td>Completed</td><td>Aug 2005</td><td>Aug 2011</td><td>Observational</td><td>Sep 2005</td><td>Depression,Depressive Disorder</td><td>null</td></tr><tr><td>NCT00178854</td><td>Vanderbilt University Medical Center</td><td>Withdrawn</td><td>May 2004</td><td>Mar 2006</td><td>Interventional</td><td>Sep 2005</td><td>Depressive Disorder</td><td>Risperidone</td></tr><tr><td>NCT00178503</td><td>The University of Texas Health Science Center, Houston</td><td>Completed</td><td>Sep 2005</td><td>May 2011</td><td>Interventional</td><td>Sep 2005</td><td>Hyperkinesis,Autistic Disorder,Attention Deficit Disorder with Hyperactivity</td><td>Methylphenidate</td></tr><tr><td>NCT00176410</td><td>University of Leipzig</td><td>Unknown status</td><td>Jan 2003</td><td>Dec 2009</td><td>Interventional</td><td>Sep 2005</td><td>Aortic Valve Stenosis,Constriction</td><td>null</td></tr><tr><td>NCT00179166</td><td>Vanderbilt University</td><td>Terminated</td><td>Jun 2004</td><td>Jul 2005</td><td>Interventional</td><td>Sep 2005</td><td>Renal Insufficiency,Acute Kidney Injury</td><td>null</td></tr><tr><td>NCT00171054</td><td>Novartis</td><td>Completed</td><td>Sep 2003</td><td>Oct 2007</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Amlodipine,Valsartan,Hydrochlorothiazide</td></tr><tr><td>NCT00170300</td><td>Medtronic Bakken Research Center</td><td>Completed</td><td>Jan 2001</td><td>May 2005</td><td>Interventional</td><td>Sep 2005</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT00177619</td><td>University of Pittsburgh</td><td>Completed</td><td>May 2002</td><td>Dec 2005</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms,Osteoporosis</td><td>Alendronate</td></tr><tr><td>NCT00178139</td><td>University of Rochester</td><td>Completed</td><td>Apr 2004</td><td>Jul 2006</td><td>Interventional</td><td>Sep 2005</td><td>Respiratory Insufficiency,Pulmonary Valve Insufficiency</td><td>null</td></tr><tr><td>NCT00175799</td><td>University of British Columbia</td><td>Completed</td><td>Sep 2007</td><td>Jul 2013</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00172874</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Jan 1998</td><td>Dec 2008</td><td>Observational</td><td>Sep 2005</td><td>Feeding and Eating Disorders</td><td>null</td></tr><tr><td>NCT00179985</td><td>Ann & Robert H Lurie Children's Hospital of Chicago</td><td>Completed</td><td>Dec 2004</td><td>Jul 2011</td><td>Observational</td><td>Sep 2005</td><td>Hypersensitivity</td><td>null</td></tr><tr><td>NCT00176384</td><td>University of Leipzig</td><td>Completed</td><td>Mar 2003</td><td>Dec 2006</td><td>Interventional</td><td>Sep 2005</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT00176644</td><td>University of Medicine and Dentistry of New Jersey</td><td>Terminated</td><td>May 2005</td><td>Dec 2008</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms</td><td>Estradiol</td></tr><tr><td>NCT00174070</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>Feb 2006</td><td>Observational</td><td>Sep 2005</td><td>Respiratory Insufficiency</td><td>null</td></tr><tr><td>NCT00173472</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jul 2002</td><td>Jul 2005</td><td>Observational</td><td>Sep 2005</td><td>Colorectal Neoplasms</td><td>null</td></tr><tr><td>NCT00172640</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Carcinoma</td><td>null</td></tr><tr><td>NCT00174967</td><td>Takeda</td><td>Completed</td><td>Jan 2001</td><td>Jul 2001</td><td>Interventional</td><td>Sep 2005</td><td>Gout</td><td>Febuxostat</td></tr><tr><td>NCT00171028</td><td>Novartis</td><td>Completed</td><td>Dec 2003</td><td>Nov 2006</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Valsartan</td></tr><tr><td>NCT00175344</td><td>University of British Columbia</td><td>Completed</td><td>Feb 2004</td><td>Apr 2006</td><td>Interventional</td><td>Sep 2005</td><td>Breast Neoplasms,Pain</td><td>null</td></tr><tr><td>NCT00173368</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Jan 2003</td><td>Mar 2005</td><td>Observational</td><td>Sep 2005</td><td>Choledocholithiasis</td><td>null</td></tr><tr><td>NCT00174629</td><td>Sanofi</td><td>Completed</td><td>Jun 2001</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Lung Neoplasms</td><td>Gemcitabine,Docetaxel</td></tr><tr><td>NCT00179231</td><td>Vanderbilt University</td><td>Completed</td><td>May 2000</td><td>Feb 2004</td><td>Interventional</td><td>Sep 2005</td><td>Schizophrenia,Psychotic Disorders</td><td>Olanzapine,Clozapine</td></tr><tr><td>NCT00173693</td><td>National Taiwan University Hospital</td><td>Withdrawn</td><td>Jan 2006</td><td>Dec 2010</td><td>Interventional</td><td>Sep 2005</td><td>Osteoporosis,Bone Diseases</td><td>null</td></tr><tr><td>NCT00171093</td><td>Novartis</td><td>Completed</td><td>Sep 2004</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension,Hypercholesterolemia</td><td>Valsartan,Simvastatin</td></tr><tr><td>NCT00179348</td><td>Albert Einstein College of Medicine</td><td>Completed</td><td>Feb 2001</td><td>Jul 2016</td><td>Interventional</td><td>Sep 2005</td><td>Carcinoma,Breast Neoplasms,Colorectal Neoplasms,Sleep Wake Disorders,Alopecia,Vomiting</td><td>null</td></tr><tr><td>NCT00172133</td><td>Shire</td><td>Completed</td><td>Oct 2001</td><td>Apr 2005</td><td>Interventional</td><td>Sep 2005</td><td>Osteoporosis</td><td>null</td></tr><tr><td>NCT00170508</td><td>National Institute of Allergy and Infectious Diseases (NIAID)</td><td>Completed</td><td>Jun 2005</td><td>Aug 2005</td><td>Interventional</td><td>Sep 2005</td><td>Influenza</td><td>null</td></tr><tr><td>NCT00179543</td><td>Beth Israel Deaconess Medical Center</td><td>Completed</td><td>Aug 2001</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>null</td></tr><tr><td>NCT00177216</td><td>University of Pittsburgh</td><td>Completed</td><td>Feb 2002</td><td>May 2008</td><td>Interventional</td><td>Sep 2005</td><td>Sleep Initiation and Maintenance Disorders,Sleep Wake Disorders</td><td>Zolpidem,Citalopram</td></tr><tr><td>NCT00176813</td><td>University of Michigan Rogel Cancer Center</td><td>Completed</td><td>Mar 2003</td><td>Nov 2006</td><td>Interventional</td><td>Sep 2005</td><td>Pancreatic Neoplasms</td><td>Gemcitabine,Celecoxib</td></tr><tr><td>NCT00170131</td><td>Mayo Clinic</td><td>Completed</td><td>Sep 2002</td><td>Jul 2007</td><td>Observational</td><td>Sep 2005</td><td>Infections,Hepatitis C</td><td>null</td></tr><tr><td>NCT00174551</td><td>Rainier Associates</td><td>Unknown status</td><td>Nov 2003</td><td>Nov 2005</td><td>Interventional</td><td>Sep 2005</td><td>Stress Disorders</td><td>Prazosin</td></tr><tr><td>NCT00170755</td><td>Novartis</td><td>Completed</td><td>Apr 2002</td><td>Jan 2005</td><td>Interventional</td><td>Sep 2005</td><td>Urinary Bladder</td><td>Darifenacin</td></tr><tr><td>NCT00174200</td><td>Pfizer</td><td>Completed</td><td>Dec 2004</td><td>May 2006</td><td>Interventional</td><td>Sep 2005</td><td>Schizophrenia,Mental Disorders,Psychotic Disorders</td><td>Risperidone</td></tr><tr><td>NCT00178698</td><td>The University of Texas Health Science Center, Houston</td><td>Unknown status</td><td>Jul 2002</td><td>Jun 2014</td><td>Interventional</td><td>Sep 2005</td><td>Lung Neoplasms,Stomach Neoplasms,Small Cell Lung Carcinoma,Carcinoma</td><td>Gemcitabine,Interferons</td></tr><tr><td>NCT00178516</td><td>University of Rochester</td><td>Completed</td><td>Jun 2004</td><td>Dec 2005</td><td>Observational</td><td>Sep 2005</td><td>Infertility</td><td>null</td></tr><tr><td>NCT00172289</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2004</td><td>Dec 2006</td><td>Observational</td><td>Sep 2005</td><td>Spinal Cord Injuries,Stroke,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT00172718</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Mar 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Jaw,Mouth</td><td>null</td></tr><tr><td>NCT00174239</td><td>Pfizer</td><td>Terminated</td><td>Jul 2004</td><td>Sep 2005</td><td>Interventional</td><td>Sep 2005</td><td>Parkinson Disease</td><td>Levodopa,Carbidopa,Cabergoline</td></tr><tr><td>NCT00178620</td><td>The University of Texas Health Science Center, Houston</td><td>Completed</td><td>Nov 2003</td><td>Mar 2014</td><td>Interventional</td><td>Sep 2005</td><td>Myocardial Infarction,Heart Diseases,Infarction</td><td>Reteplase</td></tr><tr><td>NCT00177112</td><td>University of Minnesota</td><td>Completed</td><td>Jun 2005</td><td>Oct 2007</td><td>Interventional</td><td>Sep 2005</td><td>Infections,Communicable Diseases,Urinary Tract Infections</td><td>null</td></tr><tr><td>NCT00173108</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Jan 2006</td><td>Oct 2010</td><td>Interventional</td><td>Sep 2005</td><td>Premature Birth</td><td>null</td></tr><tr><td>NCT00170404</td><td>National Institute of Allergy and Infectious Diseases (NIAID)</td><td>Completed</td><td>Jun 2000</td><td>Oct 2005</td><td>Interventional</td><td>Sep 2005</td><td>Tuberculosis</td><td>Vitamins,Folic Acid,Vitamin A,Thiamine,Selenium,Micronutrients,Trace Elements</td></tr><tr><td>NCT00176280</td><td>University of Kentucky</td><td>Withdrawn</td><td>Sep 2005</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Carcinoma</td><td>Dexamethasone,Sargramostim</td></tr><tr><td>NCT00175123</td><td>University of Aarhus</td><td>Unknown status</td><td>May 2005</td><td>Jun 2008</td><td>Interventional</td><td>Sep 2005</td><td>Urinary Bladder,Meningomyelocele,Spina Bifida Cystica</td><td>Botulinum Toxins,abobotulinumtoxinA</td></tr><tr><td>NCT00170924</td><td>Novartis</td><td>Completed</td><td>Aug 2004</td><td>Jun 2006</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Valsartan</td></tr><tr><td>NCT00170222</td><td>Medical Center Alkmaar</td><td>Completed</td><td>Jul 2002</td><td>Aug 2008</td><td>Interventional</td><td>Sep 2005</td><td>Lung Diseases,Pulmonary Disease</td><td>Doxycycline</td></tr><tr><td>NCT00172042</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Mar 2005</td><td>Jun 2010</td><td>Interventional</td><td>Sep 2005</td><td>Lung Neoplasms,Carcinoma,Neoplasm Metastasis</td><td>Zoledronic Acid</td></tr><tr><td>NCT00170690</td><td>North Eastern German Society of Gynaecological Oncology</td><td>Completed</td><td>Aug 2004</td><td>Apr 2012</td><td>Interventional</td><td>Sep 2005</td><td>Ovarian Neoplasms,Carcinoma</td><td>Treosulfan,Busulfan</td></tr><tr><td>NCT00176904</td><td>Masonic Cancer Center, University of Minnesota</td><td>Completed</td><td>Jan 1995</td><td>Jun 2010</td><td>Interventional</td><td>Sep 2005</td><td>Gaucher Disease,Adrenoleukodystrophy,Pick Disease of the Brain,Gangliosidoses,Leukodystrophy,Niemann-Pick Diseases,Niemann-Pick Disease,Neuronal Ceroid-Lipofuscinoses,Tay-Sachs Disease,Gangliosidosis,Sandhoff Disease,Fucosidosis,Metabolism,Wolman Disease</td><td>Cyclophosphamide,Busulfan,Antilymphocyte Serum</td></tr><tr><td>NCT00178204</td><td>University of Rochester</td><td>Completed</td><td>Nov 2004</td><td>Dec 2011</td><td>Observational</td><td>Sep 2005</td><td>Fatigue</td><td>null</td></tr><tr><td>NCT00176345</td><td>University of Leipzig</td><td>Unknown status</td><td>Jan 2001</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Coronary Artery Disease,Myocardial Ischemia,Coronary Disease</td><td>null</td></tr><tr><td>NCT00178711</td><td>The University of Texas Health Science Center, Houston</td><td>Terminated</td><td>Nov 2005</td><td>Dec 2009</td><td>Interventional</td><td>Sep 2005</td><td>Brain Injuries,Hypothermia,Wounds and Injuries</td><td>null</td></tr><tr><td>NCT00173680</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT00170417</td><td>NHS Greater Glasgow and Clyde</td><td>Completed</td><td>Dec 2000</td><td>May 2003</td><td>Interventional</td><td>Sep 2005</td><td>Sleep Initiation and Maintenance Disorders</td><td>null</td></tr><tr><td>NCT00173485</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>Jun 2009</td><td>Observational</td><td>Sep 2005</td><td>Peritonitis,Renal Insufficiency</td><td>null</td></tr><tr><td>NCT00178269</td><td>University of Rochester</td><td>Completed</td><td>Jan 2005</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Uterine Cervical Neoplasms</td><td>Docetaxel</td></tr><tr><td>NCT00171301</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Jun 2005</td><td>May 2008</td><td>Interventional</td><td>Sep 2005</td><td>Thalassemia,beta-Thalassemia,Iron Overload,Hemosiderosis</td><td>Deferasirox</td></tr><tr><td>NCT00171782</td><td>Novartis</td><td>Completed</td><td>Feb 2004</td><td>Dec 2004</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Valsartan,Hydrochlorothiazide</td></tr><tr><td>NCT00176566</td><td>University of Medicine and Dentistry of New Jersey</td><td>Terminated</td><td>Sep 2003</td><td>Nov 2006</td><td>Interventional</td><td>Sep 2005</td><td>Leukoplakia</td><td>null</td></tr><tr><td>NCT00170846</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Feb 2005</td><td>Oct 2009</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>Everolimus,Azathioprine,Calcineurin Inhibitors</td></tr><tr><td>NCT00173836</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Aug 2003</td><td>Aug 2006</td><td>Observational</td><td>Sep 2005</td><td>Nasopharyngeal Carcinoma,Nasopharyngeal Neoplasms</td><td>null</td></tr><tr><td>NCT00174005</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Dec 1994</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00176527</td><td>University of Medicine and Dentistry of New Jersey</td><td>Terminated</td><td>Nov 2002</td><td>Aug 2007</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms</td><td>Interferons,Interferon-alpha,Interferon alpha-2,Docetaxel,Estramustine,Isotretinoin</td></tr><tr><td>NCT00171314</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Mar 2004</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Breast Neoplasms</td><td>Zoledronic Acid,Letrozole</td></tr><tr><td>NCT00175409</td><td>University of British Columbia</td><td>Completed</td><td>Jan 2008</td><td>Jun 2010</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00177190</td><td>University of Pittsburgh</td><td>Completed</td><td>Jun 2002</td><td>Jan 2006</td><td>Observational</td><td>Sep 2005</td><td>Mycoses,Lymphoma,Mycosis Fungoides,Sezary Syndrome</td><td>null</td></tr><tr><td>NCT00179101</td><td>Vanderbilt University</td><td>Completed</td><td>Apr 2004</td><td>Nov 2005</td><td>Observational</td><td>Sep 2005</td><td>Parkinson Disease,Depression</td><td>null</td></tr><tr><td>NCT00175526</td><td>University of British Columbia</td><td>Completed</td><td>Sep 2005</td><td>Dec 2010</td><td>Observational</td><td>Sep 2005</td><td>Toxemia,Sepsis</td><td>null</td></tr><tr><td>NCT00176293</td><td>University of Kentucky</td><td>Terminated</td><td>Oct 2005</td><td>Feb 2007</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms</td><td>Dexamethasone,Doxorubicin</td></tr><tr><td>NCT00178347</td><td>University of Rochester</td><td>Terminated</td><td>Dec 2004</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00171964</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>May 2002</td><td>Dec 2008</td><td>Interventional</td><td>Sep 2005</td><td>Neoplasm Metastasis</td><td>Zoledronic Acid</td></tr><tr><td>NCT00178945</td><td>Vanderbilt University</td><td>Completed</td><td>Mar 2004</td><td>Mar 2006</td><td>Interventional</td><td>Sep 2005</td><td>Myofascial Pain Syndromes,Fibromyalgia,Dystonia,Dystonic Disorders,Syndrome,Torticollis</td><td>Botulinum Toxins,abobotulinumtoxinA</td></tr><tr><td>NCT00172965</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2004</td><td>Jun 2005</td><td>Observational</td><td>Sep 2005</td><td>Mouth Neoplasms</td><td>null</td></tr><tr><td>NCT00179764</td><td>Ann & Robert H Lurie Children's Hospital of Chicago</td><td>Completed</td><td>Mar 2000</td><td>Jan 2014</td><td>Interventional</td><td>Sep 2005</td><td>Leukemia,Melanoma,Neoplasms,Hematologic Neoplasms,Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>Busulfan</td></tr><tr><td>NCT00170612</td><td>University of Melbourne</td><td>Completed</td><td>Nov 2005</td><td>Aug 2008</td><td>Interventional</td><td>Sep 2005</td><td>Pneumococcal Infections</td><td>Heptavalent Pneumococcal Conjugate Vaccine</td></tr><tr><td>NCT00172627</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Stomach Neoplasms</td><td>null</td></tr><tr><td>NCT00170872</td><td>Novartis</td><td>Completed</td><td>Nov 2004</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Arthritis,Osteoarthritis</td><td>Lumiracoxib</td></tr><tr><td>NCT00172770</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2004</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>Schizophrenia</td><td>null</td></tr><tr><td>NCT00173849</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2006</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>Mouth Neoplasms</td><td>null</td></tr><tr><td>NCT00175682</td><td>University of British Columbia</td><td>Completed</td><td>Dec 2004</td><td>Jul 2011</td><td>Interventional</td><td>Sep 2005</td><td>Spinal Cord Injuries,Autonomic Dysreflexia</td><td>Prazosin</td></tr><tr><td>NCT00179127</td><td>Vanderbilt University Medical Center</td><td>Completed</td><td>Aug 2004</td><td>Sep 2012</td><td>Interventional</td><td>Sep 2005</td><td>Ketosis,Acidosis,Diabetic Ketoacidosis</td><td>Insulin Glargine</td></tr><tr><td>NCT00178113</td><td>University of Pittsburgh</td><td>Completed</td><td>Jul 2003</td><td>Jul 2004</td><td>Interventional</td><td>Sep 2005</td><td>Neoplasms,Carcinoma in Situ,Prostatic Intraepithelial Neoplasia</td><td>Lycopene</td></tr><tr><td>NCT00170560</td><td>National Institute of Allergy and Infectious Diseases (NIAID)</td><td>Completed</td><td>Oct 2001</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Infections</td><td>null</td></tr><tr><td>NCT00178022</td><td>University of Pittsburgh</td><td>Completed</td><td>Feb 2005</td><td>Sep 2006</td><td>Interventional</td><td>Sep 2005</td><td>Brain Injuries,Wounds and Injuries,Depression,Anxiety Disorders</td><td>null</td></tr><tr><td>NCT00178425</td><td>University of Rochester</td><td>Completed</td><td>Jan 2005</td><td>Jun 2006</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00178438</td><td>University of Rochester</td><td>Withdrawn</td><td>Jun 2005</td><td>Jun 2006</td><td>Interventional</td><td>Sep 2005</td><td>Crohn Disease</td><td>null</td></tr><tr><td>NCT00173173</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Aug 2003</td><td>Jul 2004</td><td>Observational</td><td>Sep 2005</td><td>Disease,Feeding and Eating Disorders</td><td>null</td></tr><tr><td>NCT00177294</td><td>University of Pittsburgh</td><td>Completed</td><td>Apr 2004</td><td>Aug 2009</td><td>Interventional</td><td>Sep 2005</td><td>Depression,Depressive Disorder</td><td>Citalopram</td></tr><tr><td>NCT00175461</td><td>University of British Columbia</td><td>Completed</td><td>Sep 2005</td><td>Aug 2011</td><td>Interventional</td><td>Sep 2005</td><td>Osteoarthritis</td><td>null</td></tr><tr><td>NCT00179062</td><td>Vanderbilt University</td><td>Completed</td><td>Feb 2000</td><td>Jun 2007</td><td>Interventional</td><td>Sep 2005</td><td>Disease,Schizophrenia,Depressive Disorder,Bipolar Disorder,Psychotic Disorders</td><td>Olanzapine,Risperidone</td></tr><tr><td>NCT00173550</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2004</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Premature Birth,Menopause,Primary Ovarian Insufficiency</td><td>null</td></tr><tr><td>NCT00177385</td><td>University of Pittsburgh</td><td>Completed</td><td>Jun 2003</td><td>Sep 2011</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00171002</td><td>Novartis</td><td>Completed</td><td>Nov 2004</td><td>Jun 2005</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Amlodipine,Valsartan</td></tr><tr><td>NCT00177125</td><td>University of Minnesota</td><td>Completed</td><td>Jan 2004</td><td>Jan 2004</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms</td><td>null</td></tr><tr><td>NCT00172861</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Stomach Neoplasms</td><td>null</td></tr><tr><td>NCT00174798</td><td>Sanofi</td><td>Completed</td><td>May 2005</td><td>May 2006</td><td>Interventional</td><td>Sep 2005</td><td>Urinary Incontinence,Enuresis,Urinary Bladder</td><td>Tolterodine Tartrate</td></tr><tr><td>NCT00177892</td><td>National Institute on Aging (NIA)</td><td>Unknown status</td><td>Sep 2003</td><td>Aug 2008</td><td>Interventional</td><td>Sep 2005</td><td>Apnea,Sleep Apnea Syndromes,Sleep Apnea,Metabolic Syndrome,Syndrome</td><td>null</td></tr><tr><td>NCT00176761</td><td>University of Michigan Rogel Cancer Center</td><td>Terminated</td><td>Mar 2000</td><td>May 2006</td><td>Interventional</td><td>Sep 2005</td><td>Colorectal Neoplasms</td><td>Interleukin-2</td></tr><tr><td>NCT00176319</td><td>University of Leipzig</td><td>Completed</td><td>May 2005</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Heart Failure</td><td>null</td></tr><tr><td>NCT00177203</td><td>University of Pittsburgh</td><td>Completed</td><td>Jun 2003</td><td>Jan 2009</td><td>Interventional</td><td>Sep 2005</td><td>Sleep Initiation and Maintenance Disorders</td><td>null</td></tr><tr><td>NCT00174993</td><td>Takeda</td><td>Completed</td><td>May 2001</td><td>Jan 2005</td><td>Interventional</td><td>Sep 2005</td><td>Diabetes Mellitus</td><td>Pioglitazone</td></tr><tr><td>NCT00177658</td><td>University of Pittsburgh</td><td>Completed</td><td>Mar 2006</td><td>Jun 2017</td><td>Observational</td><td>Sep 2005</td><td>Salmonella Infections</td><td>null</td></tr><tr><td>NCT00174928</td><td>Takeda</td><td>Completed</td><td>May 2005</td><td>Aug 2005</td><td>Interventional</td><td>Sep 2005</td><td>Gastroesophageal Reflux,Esophagitis</td><td>Lansoprazole,Dexlansoprazole</td></tr><tr><td>NCT00170677</td><td>North Eastern German Society of Gynaecological Oncology</td><td>Completed</td><td>Sep 2005</td><td>Jan 2013</td><td>Interventional</td><td>Sep 2005</td><td>Ovarian Neoplasms,Carcinoma</td><td>Topotecan</td></tr><tr><td>NCT00178295</td><td>University of Rochester</td><td>Completed</td><td>Nov 1999</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Brain Neoplasms,Trauma</td><td>null</td></tr><tr><td>NCT00176449</td><td>University of Maryland, Baltimore</td><td>Completed</td><td>Apr 2001</td><td>Dec 2005</td><td>Interventional</td><td>Sep 2005</td><td>Tobacco Use Disorder</td><td>Bupropion</td></tr><tr><td>NCT00179751</td><td>Celgene Corporation</td><td>Terminated</td><td>Apr 2005</td><td>Aug 2006</td><td>Interventional</td><td>Sep 2005</td><td>Pancreatic Neoplasms</td><td>Gemcitabine,Lenalidomide</td></tr><tr><td>NCT00172744</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Apr 2005</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00177255</td><td>University of Pittsburgh</td><td>Terminated</td><td>Apr 2005</td><td>Dec 2008</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>Docetaxel,Capecitabine</td></tr><tr><td>NCT00171925</td><td>Novartis Pharmaceuticals</td><td>Terminated</td><td>Aug 2000</td><td>Nov 2008</td><td>Interventional</td><td>Sep 2005</td><td>Multiple Myeloma,Neoplasms</td><td>Vitamin D,Zoledronic Acid,Calcium</td></tr><tr><td>NCT00177307</td><td>University of Pittsburgh</td><td>Completed</td><td>Jan 2005</td><td>Feb 2012</td><td>Interventional</td><td>Sep 2005</td><td>Colorectal Neoplasms</td><td>Bevacizumab,Capecitabine,Oxaliplatin</td></tr><tr><td>NCT00173862</td><td>National Taiwan University Hospital</td><td>Completed</td><td>May 2000</td><td>Jun 2006</td><td>Interventional</td><td>Jun 2005</td><td>Carcinoma</td><td>Gemcitabine,Ifosfamide</td></tr><tr><td>NCT00171990</td><td>Novartis</td><td>Completed</td><td>Jan 2003</td><td>Feb 2006</td><td>Interventional</td><td>Sep 2005</td><td>Herpes Genitalis</td><td>Famciclovir</td></tr><tr><td>NCT00177060</td><td>Hordinsky, Maria K., MD</td><td>Terminated</td><td>Oct 2003</td><td>May 2007</td><td>Interventional</td><td>Sep 2005</td><td>Wounds and Injuries</td><td>Hydromorphone</td></tr><tr><td>NCT00173043</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Oct 2004</td><td>Aug 2005</td><td>Observational</td><td>Sep 2005</td><td>Polycystic Ovary Syndrome,Insulin Resistance,Syndrome</td><td>null</td></tr><tr><td>NCT00171769</td><td>Novartis</td><td>Completed</td><td>Apr 2005</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Atrial Fibrillation</td><td>Certoparin</td></tr><tr><td>NCT00171951</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Aug 2004</td><td>Jul 2013</td><td>Interventional</td><td>Sep 2005</td><td>ACTH-Secreting Pituitary Adenoma,Pituitary ACTH Hypersecretion</td><td>Pasireotide</td></tr><tr><td>NCT00174850</td><td>State University of New York - Upstate Medical University</td><td>Completed</td><td>Jul 2004</td><td>May 2005</td><td>Interventional</td><td>Sep 2005</td><td>Anxiety Disorders</td><td>null</td></tr><tr><td>NCT00177970</td><td>University of Pittsburgh</td><td>Terminated</td><td>Oct 2003</td><td>Apr 2008</td><td>Interventional</td><td>Sep 2005</td><td>Diarrhea</td><td>Immunoglobulins,Antibodies,Immunoglobulin G,gamma-Globulins,Rho(D) Immune Globulin</td></tr><tr><td>NCT00171834</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Aug 2003</td><td>Sep 2008</td><td>Interventional</td><td>Sep 2005</td><td>Lung Neoplasms,Carcinoma</td><td>Epothilones,Epothilone B</td></tr><tr><td>NCT00172601</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Bursitis</td><td>null</td></tr><tr><td>NCT00176254</td><td>Susanne Arnold</td><td>Completed</td><td>May 2000</td><td>Oct 2012</td><td>Interventional</td><td>Sep 2005</td><td>Carcinoma,Head and Neck Neoplasms</td><td>Paclitaxel,Carboplatin</td></tr><tr><td>NCT00176553</td><td>University of Medicine and Dentistry of New Jersey</td><td>Terminated</td><td>Mar 2003</td><td>May 2007</td><td>Interventional</td><td>Sep 2005</td><td>Neurotoxicity Syndromes</td><td>Dextromethorphan</td></tr><tr><td>NCT00171405</td><td>Novartis</td><td>Completed</td><td>Jun 2005</td><td>Feb 2006</td><td>Interventional</td><td>Aug 2005</td><td>Hypertension</td><td>null</td></tr><tr><td>NCT00177814</td><td>University of Pittsburgh</td><td>Completed</td><td>Sep 2005</td><td>Jun 2017</td><td>Observational</td><td>Sep 2005</td><td>Bacterial Infections,Gram-Negative Bacterial Infections</td><td>null</td></tr><tr><td>NCT00174122</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jul 2005</td><td>Jun 2006</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00179608</td><td>Celgene</td><td>Completed</td><td>Sep 2005</td><td>Jun 2007</td><td>Interventional</td><td>Sep 2005</td><td>Melanoma</td><td>Lenalidomide</td></tr><tr><td>NCT00173394</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>Dec 2008</td><td>Observational</td><td>Sep 2005</td><td>Ovarian Neoplasms,Carcinoma</td><td>null</td></tr><tr><td>NCT00170001</td><td>Mayo Clinic</td><td>Completed</td><td>Apr 2005</td><td>Aug 2006</td><td>Interventional</td><td>Sep 2005</td><td>Gastroesophageal Reflux</td><td>Esomeprazole</td></tr><tr><td>NCT00170963</td><td>Novartis</td><td>Completed</td><td>Oct 2004</td><td>Jun 2005</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Amlodipine,Valsartan</td></tr><tr><td>NCT00170365</td><td>Hennepin Healthcare Research Institute</td><td>Completed</td><td>Jul 2004</td><td>Mar 2005</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00173810</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>Apr 2007</td><td>Observational</td><td>Sep 2005</td><td>Stroke</td><td>null</td></tr><tr><td>NCT00179335</td><td>Albert Einstein College of Medicine</td><td>Completed</td><td>Aug 2003</td><td>Sep 2006</td><td>Observational</td><td>Sep 2005</td><td>HIV Infections</td><td>null</td></tr><tr><td>NCT00178256</td><td>University of Rochester</td><td>Completed</td><td>Jun 1998</td><td>Dec 2012</td><td>Interventional</td><td>Sep 2005</td><td>Carcinoma</td><td>Paclitaxel</td></tr><tr><td>NCT00178035</td><td>University of Pittsburgh</td><td>Completed</td><td>Dec 1999</td><td>Aug 2003</td><td>Interventional</td><td>Sep 2005</td><td>Depression,Depressive Disorder</td><td>Paroxetine</td></tr><tr><td>NCT00177567</td><td>University of Pittsburgh</td><td>Completed</td><td>Jul 2001</td><td>Jan 2004</td><td>Interventional</td><td>Sep 2005</td><td>Disease,Bipolar Disorder,Mood Disorders</td><td>Lamotrigine,Valproic Acid,Olanzapine,Risperidone,Lithium Carbonate,Mirtazapine,Tranylcypromine,Bupropion,Paroxetine,Venlafaxine Hydrochloride</td></tr><tr><td>NCT00172666</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Aug 2005</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>Arthritis,Lupus Erythematosus</td><td>null</td></tr><tr><td>NCT00172731</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Mar 2005</td><td>Jun 2005</td><td>Observational</td><td>Sep 2005</td><td>Schizophrenia</td><td>null</td></tr><tr><td>NCT00171873</td><td>Carmen Schade-Brittinger</td><td>Completed</td><td>Sep 2001</td><td>Dec 2013</td><td>Interventional</td><td>Sep 2005</td><td>Neuroendocrine Tumors,Neoplasm Metastasis</td><td>Octreotide</td></tr><tr><td>NCT00173355</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>Aug 2005</td><td>Observational</td><td>Sep 2005</td><td>Dermatofibrosarcoma,Soft Tissue Neoplasms</td><td>null</td></tr><tr><td>NCT00176111</td><td>Heidelberg University</td><td>Terminated</td><td>Jan 2004</td><td>Jan 2005</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00170274</td><td>Medtronic Bakken Research Center</td><td>Completed</td><td>Aug 2000</td><td>Oct 2014</td><td>Interventional</td><td>Sep 2005</td><td>Arrhythmias,Tachycardia</td><td>null</td></tr><tr><td>NCT00172250</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Sep 2003</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Coronary Artery Disease</td><td>null</td></tr><tr><td>NCT00174356</td><td>Pfizer</td><td>Completed</td><td>Dec 2002</td><td>Oct 2005</td><td>Interventional</td><td>Sep 2005</td><td>Carcinoma</td><td>Paclitaxel,Carboplatin</td></tr><tr><td>NCT00170989</td><td>Novartis</td><td>Completed</td><td>Sep 2004</td><td>Jul 2005</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Valsartan,Hydrochlorothiazide</td></tr><tr><td>NCT00179569</td><td>Beth Israel Deaconess Medical Center</td><td>Completed</td><td>Aug 2005</td><td>Sep 2007</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00172796</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Apr 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Metabolic Syndrome,Prediabetic State</td><td>null</td></tr><tr><td>NCT00178126</td><td>University of Pittsburgh</td><td>Completed</td><td>Mar 2004</td><td>Oct 2008</td><td>Interventional</td><td>Sep 2005</td><td>Pressure Ulcer,Ulcer</td><td>null</td></tr><tr><td>NCT00172029</td><td>Novartis</td><td>Completed</td><td>Apr 2003</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Breast Neoplasms,Bone Diseases</td><td>Zoledronic Acid</td></tr><tr><td>NCT00176696</td><td>University of Medicine and Dentistry of New Jersey</td><td>Terminated</td><td>Aug 2005</td><td>Apr 2007</td><td>Observational</td><td>Sep 2005</td><td>Pain</td><td>Anesthetics</td></tr><tr><td>NCT00177788</td><td>University of Pittsburgh</td><td>Completed</td><td>Sep 2005</td><td>Aug 2012</td><td>Observational</td><td>Sep 2005</td><td>Mycoses,Fungemia</td><td>null</td></tr><tr><td>NCT00171938</td><td>Novartis</td><td>Terminated</td><td>Apr 2004</td><td>Jun 2006</td><td>Interventional</td><td>Sep 2005</td><td>Glioblastoma</td><td>Imatinib Mesylate</td></tr><tr><td>NCT00177359</td><td>University of Pittsburgh</td><td>Completed</td><td>Nov 2005</td><td>Jun 2007</td><td>Interventional</td><td>Sep 2005</td><td>Mobility Limitation</td><td>null</td></tr><tr><td>NCT00171860</td><td>Novartis Pharmaceuticals</td><td>Terminated</td><td>Sep 2002</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Hypereosinophilic Syndrome,Syndrome</td><td>Imatinib Mesylate</td></tr><tr><td>NCT00171717</td><td>Novartis</td><td>Completed</td><td>Feb 2004</td><td>Dec 2005</td><td>Interventional</td><td>Sep 2005</td><td>Diabetes Mellitus</td><td>Cyclosporine,Cyclosporins</td></tr><tr><td>NCT00176748</td><td>University of Michigan Rogel Cancer Center</td><td>Completed</td><td>Jul 2005</td><td>Jun 2009</td><td>Interventional</td><td>Sep 2005</td><td>Thyroid Neoplasms,Thyroid Diseases</td><td>null</td></tr><tr><td>NCT00175084</td><td>Tufts University</td><td>Completed</td><td>Oct 2004</td><td>Dec 2012</td><td>Interventional</td><td>Sep 2005</td><td>Cardiovascular Diseases,Metabolic Syndrome,Hyperlipidemias</td><td>null</td></tr><tr><td>NCT00178334</td><td>University of Rochester</td><td>Completed</td><td>Mar 2006</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>Urinary Incontinence,Enuresis</td><td>null</td></tr><tr><td>NCT00172822</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2003</td><td>Jun 2005</td><td>Observational</td><td>Sep 2005</td><td>Appendicitis</td><td>null</td></tr><tr><td>NCT00170885</td><td>Novartis</td><td>Completed</td><td>May 2005</td><td>Jul 2007</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>Everolimus</td></tr><tr><td>NCT00177684</td><td>University of Pittsburgh</td><td>Completed</td><td>Sep 2004</td><td>Sep 2005</td><td>Interventional</td><td>Sep 2005</td><td>Mycoses</td><td>Amphotericin B,Liposomal amphotericin B</td></tr><tr><td>NCT00178672</td><td>The University of Texas Health Science Center, Houston</td><td>Completed</td><td>Nov 2002</td><td>Aug 2007</td><td>Interventional</td><td>Sep 2005</td><td>Carotid Stenosis,Carotid Artery Diseases,Stroke,Heart Diseases</td><td>null</td></tr><tr><td>NCT00171080</td><td>Novartis</td><td>Completed</td><td>Apr 2004</td><td>Mar 2006</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Valsartan,Irbesartan</td></tr><tr><td>NCT00176891</td><td>Masonic Cancer Center, University of Minnesota</td><td>Completed</td><td>Mar 2004</td><td>Nov 2012</td><td>Interventional</td><td>Sep 2005</td><td>Mucopolysaccharidoses,Mucopolysaccharidosis I,Syndrome</td><td>null</td></tr><tr><td>NCT00172107</td><td>Shire</td><td>Completed</td><td>May 1995</td><td>Mar 1997</td><td>Interventional</td><td>Sep 2005</td><td>Osteoporosis</td><td>Parathyroid Hormone</td></tr><tr><td>NCT00177827</td><td>University of Pittsburgh</td><td>Completed</td><td>Mar 2004</td><td>Mar 2006</td><td>Observational</td><td>Sep 2005</td><td>Aspergillosis</td><td>null</td></tr><tr><td>NCT00177502</td><td>University of Pittsburgh</td><td>Completed</td><td>Jan 2003</td><td>Dec 2006</td><td>Interventional</td><td>Sep 2005</td><td>Body Weight,Weight Loss,Weight Gain</td><td>null</td></tr><tr><td>NCT00175045</td><td>Takeda</td><td>Completed</td><td>Jun 2003</td><td>Oct 2003</td><td>Interventional</td><td>Sep 2005</td><td>Esophagitis</td><td>Lansoprazole,Dexlansoprazole</td></tr><tr><td>NCT00175981</td><td>Heidelberg University</td><td>Completed</td><td>Feb 2003</td><td>Nov 2004</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>Sildenafil Citrate,Fluvoxamine</td></tr><tr><td>NCT00177983</td><td>University of Pittsburgh</td><td>Completed</td><td>Jan 2003</td><td>Jan 2005</td><td>Interventional</td><td>Sep 2005</td><td>Recurrence</td><td>null</td></tr><tr><td>NCT00179699</td><td>Celgene Corporation</td><td>Terminated</td><td>Sep 2005</td><td>Nov 2006</td><td>Interventional</td><td>Sep 2005</td><td>Lung Neoplasms,Carcinoma</td><td>Pemetrexed,Lenalidomide</td></tr><tr><td>NCT00175383</td><td>University of British Columbia</td><td>Unknown status</td><td>Jun 2004</td><td>Dec 2013</td><td>Interventional</td><td>Sep 2005</td><td>Prostatic Neoplasms</td><td>Hormones,Prolactin Release-Inhibiting Factors</td></tr><tr><td>NCT00178230</td><td>University of Rochester</td><td>Completed</td><td>Mar 1996</td><td>Nov 2013</td><td>Observational</td><td>Sep 2005</td><td>Lung Neoplasms</td><td>null</td></tr><tr><td>NCT00170859</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Aug 2004</td><td>Dec 2006</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>Everolimus</td></tr><tr><td>NCT00179465</td><td>Beth Israel Deaconess Medical Center</td><td>Active, not recruiting</td><td>Nov 2003</td><td>Sep 2022</td><td>Interventional</td><td>Sep 2005</td><td>Schizophrenia</td><td>Tiagabine,Antipsychotic Agents</td></tr><tr><td>NCT00173732</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Sep 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00170976</td><td>Novartis</td><td>Completed</td><td>Apr 2004</td><td>Jun 2005</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Amlodipine,Valsartan</td></tr><tr><td>NCT00173641</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Sep 2005</td><td>Aug 2006</td><td>Observational</td><td>Sep 2005</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT00173342</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Bundle-Branch Block,Heart Block</td><td>null</td></tr><tr><td>NCT00174148</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jul 2005</td><td>Jul 2006</td><td>Observational</td><td>Sep 2005</td><td>Neck Pain</td><td>null</td></tr><tr><td>NCT00170144</td><td>Mayo Clinic</td><td>Completed</td><td>Sep 2005</td><td>Jun 2007</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00170469</td><td>PharmAthene UK Limited</td><td>Completed</td><td>Mar 2005</td><td>Feb 2007</td><td>Interventional</td><td>Sep 2005</td><td>Anthrax</td><td>Aluminum Hydroxide</td></tr><tr><td>NCT00179634</td><td>Beth Israel Deaconess Medical Center</td><td>Terminated</td><td>Mar 2005</td><td>Mar 2008</td><td>Interventional</td><td>Sep 2005</td><td>Breast Neoplasms</td><td>null</td></tr><tr><td>NCT00175318</td><td>University of British Columbia</td><td>Completed</td><td>Apr 2005</td><td>Feb 2011</td><td>Interventional</td><td>Sep 2005</td><td>Dental Caries</td><td>null</td></tr><tr><td>NCT00175812</td><td>University of Bergen</td><td>Completed</td><td>Nov 2004</td><td>Nov 2009</td><td>Interventional</td><td>Sep 2005</td><td>Leukemia</td><td>Tretinoin,Theophylline,Valproic Acid</td></tr><tr><td>NCT00178906</td><td>Vanderbilt University</td><td>Completed</td><td>Dec 1999</td><td>Apr 2008</td><td>Observational</td><td>Sep 2005</td><td>Depression</td><td>null</td></tr><tr><td>NCT00175448</td><td>University of British Columbia</td><td>Completed</td><td>Sep 2005</td><td>Dec 2007</td><td>Interventional</td><td>Sep 2005</td><td>Arthritis</td><td>null</td></tr><tr><td>NCT00173069</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2006</td><td>Dec 2010</td><td>Observational</td><td>Sep 2005</td><td>Schizophrenia</td><td>null</td></tr><tr><td>NCT00176956</td><td>Hordinsky, Maria K., MD</td><td>Terminated</td><td>Nov 2002</td><td>Jan 2007</td><td>Interventional</td><td>Sep 2005</td><td>Dermatitis,Skin Diseases</td><td>null</td></tr><tr><td>NCT00173095</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2005</td><td>Jan 2008</td><td>Observational</td><td>Sep 2005</td><td>Subarachnoid Hemorrhage,Hemorrhage</td><td>null</td></tr><tr><td>NCT00177424</td><td>University of Pittsburgh</td><td>Terminated</td><td>Jul 2004</td><td>Oct 2007</td><td>Interventional</td><td>Sep 2005</td><td>Stroke,Depression,Depressive Disorder</td><td>Sertraline</td></tr><tr><td>NCT00172783</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>Dec 2005</td><td>Observational</td><td>Sep 2005</td><td>Tuberculosis</td><td>null</td></tr><tr><td>NCT00176917</td><td>Masonic Cancer Center, University of Minnesota</td><td>Completed</td><td>May 1999</td><td>May 2010</td><td>Interventional</td><td>Sep 2005</td><td>Mucolipidoses,Mucopolysaccharidoses,Mucopolysaccharidosis I,Mannosidase Deficiency Diseases,alpha-Mannosidosis,Mucopolysaccharidosis VI</td><td>Cyclophosphamide,Busulfan,Thymoglobulin</td></tr><tr><td>NCT00176839</td><td>Masonic Cancer Center, University of Minnesota</td><td>Terminated</td><td>Jun 2000</td><td>Feb 2012</td><td>Interventional</td><td>Sep 2005</td><td>Neoplasms,Hematologic Neoplasms,Leukemia,Precursor Cell Lymphoblastic Leukemia-Lymphoma</td><td>Cyclophosphamide,Melphalan,Busulfan,Antilymphocyte Serum,Lenograstim,Sargramostim</td></tr><tr><td>NCT00179322</td><td>National Institute on Deafness and Other Communication Disorders (NIDCD)</td><td>Completed</td><td>Sep 2005</td><td>Sep 2016</td><td>Observational</td><td>Sep 2005</td><td>Sleep Deprivation</td><td>null</td></tr><tr><td>NCT00170664</td><td>North Eastern German Society of Gynaecological Oncology</td><td>Completed</td><td>Jan 1999</td><td>Sep 2004</td><td>Interventional</td><td>Sep 2005</td><td>Ovarian Neoplasms,Carcinoma</td><td>Paclitaxel,Carboplatin</td></tr><tr><td>NCT00172003</td><td>Novartis Pharmaceuticals</td><td>Completed</td><td>Sep 2004</td><td>Jul 2009</td><td>Interventional</td><td>Sep 2005</td><td>Neoplasm Metastasis,Neoplasms,Carcinoma</td><td>Zoledronic Acid</td></tr><tr><td>NCT00170261</td><td>Medtronic Bakken Research Center</td><td>Completed</td><td>Apr 2002</td><td>Sep 2006</td><td>Interventional</td><td>Sep 2005</td><td>Syncope</td><td>null</td></tr><tr><td>NCT00179075</td><td>Vanderbilt University</td><td>Completed</td><td>Apr 2003</td><td>Apr 2008</td><td>Observational</td><td>Sep 2005</td><td>Graft vs Host Disease</td><td>null</td></tr><tr><td>NCT00179777</td><td>University of Helsinki</td><td>Completed</td><td>May 2002</td><td>Sep 2017</td><td>Interventional</td><td>Sep 2005</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT00174018</td><td>National Taiwan University Hospital</td><td>Completed</td><td>Sep 1993</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>Shoulder Impingement Syndrome</td><td>null</td></tr><tr><td>NCT00171535</td><td>Novartis</td><td>Completed</td><td>Oct 2004</td><td>Apr 2005</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Amlodipine,Valsartan</td></tr><tr><td>NCT00173914</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Mar 2003</td><td>null</td><td>Observational</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00175825</td><td>UCB Pharma</td><td>Completed</td><td>Nov 2005</td><td>Jun 2006</td><td>Interventional</td><td>Sep 2005</td><td>Epilepsy,Seizures</td><td>Brivaracetam</td></tr><tr><td>NCT00172198</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Mar 2005</td><td>Mar 2007</td><td>Interventional</td><td>Sep 2005</td><td>null</td><td>null</td></tr><tr><td>NCT00171366</td><td>Novartis</td><td>Completed</td><td>Jul 2004</td><td>Jul 2005</td><td>Interventional</td><td>Sep 2005</td><td>Hypertension</td><td>Amlodipine,Benazepril</td></tr><tr><td>NCT00170287</td><td>Medtronic Bakken Research Center</td><td>Completed</td><td>May 2002</td><td>Aug 2011</td><td>Interventional</td><td>Sep 2005</td><td>Tachycardia</td><td>null</td></tr><tr><td>NCT00170729</td><td>Novartis</td><td>Completed</td><td>Aug 2004</td><td>Feb 2005</td><td>Interventional</td><td>Sep 2005</td><td>Cataract,Capsule Opacification,Uveitis,Inflammation</td><td>Prednisolone,Methylprednisolone Acetate,Methylprednisolone,Methylprednisolone Hemisuccinate,Prednisolone acetate,Prednisolone hemisuccinate,Prednisolone phosphate</td></tr><tr><td>NCT00173225</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>Jun 2005</td><td>Observational</td><td>Sep 2005</td><td>Asthma,Cough</td><td>null</td></tr><tr><td>NCT00178100</td><td>University of Pittsburgh</td><td>Completed</td><td>Mar 1999</td><td>Aug 2005</td><td>Interventional</td><td>Sep 2005</td><td>Depression,Depressive Disorder</td><td>Paroxetine</td></tr><tr><td>NCT00176397</td><td>University of Leipzig</td><td>Unknown status</td><td>Aug 2003</td><td>null</td><td>Interventional</td><td>Sep 2005</td><td>Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Coronary Stenosis,Constriction</td><td>null</td></tr><tr><td>NCT00177333</td><td>University of Pittsburgh</td><td>Completed</td><td>Sep 2005</td><td>May 2006</td><td>Interventional</td><td>Sep 2005</td><td>Vomiting</td><td>Doxycycline</td></tr><tr><td>NCT00175643</td><td>University of British Columbia</td><td>Completed</td><td>Feb 2005</td><td>Nov 2005</td><td>Interventional</td><td>Sep 2005</td><td>Keratosis</td><td>Imiquimod</td></tr><tr><td>NCT00172913</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>Jul 2008</td><td>Observational</td><td>Sep 2005</td><td>Myopia</td><td>null</td></tr><tr><td>NCT00173628</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 1990</td><td>Dec 2006</td><td>Observational</td><td>Sep 2005</td><td>Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT00172757</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jan 2002</td><td>Jun 2005</td><td>Observational</td><td>Sep 2005</td><td>Colorectal Neoplasms,Diabetes Mellitus</td><td>null</td></tr><tr><td>NCT00174512</td><td>Pfizer</td><td>Completed</td><td>Mar 2005</td><td>Jun 2006</td><td>Interventional</td><td>Sep 2005</td><td>Heart Diseases,Myocardial Ischemia,Coronary Artery Disease</td><td>Moxifloxacin</td></tr><tr><td>NCT00172939</td><td>National Taiwan University Hospital</td><td>Unknown status</td><td>Jun 2005</td><td>Jan 2008</td><td>Interventional</td><td>Sep 2005</td><td>Vitiligo</td><td>null</td></tr><tr><td>NCT00176995</td><td>Hordinsky, Maria K., MD</td><td>Completed</td><td>Mar 1999</td><td>Oct 2000</td><td>Interventional</td><td>Sep 2005</td><td>Hair Diseases</td><td>Eflornithine</td></tr></tbody></table>Showing the first 1000 rows.</div>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "aggData": [],
       "aggError": "",
       "aggOverflow": false,
       "aggSchema": [],
       "aggSeriesLimitReached": false,
       "aggType": "",
       "arguments": {},
       "columnCustomDisplayInfos": {},
       "data": [
        [
         "NCT02758028",
         "The University of Hong Kong",
         "Recruiting",
         "Aug 2005",
         "Nov 2021",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751957",
         "Duke University",
         "Completed",
         "Jul 2016",
         "Jul 2020",
         "Interventional",
         "Apr 2016",
         "Autistic Disorder,Autism Spectrum Disorder",
         null
        ],
        [
         "NCT02758483",
         "Universidade Federal do Rio de Janeiro",
         "Completed",
         "Mar 2017",
         "Jan 2018",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02759848",
         "Istanbul Medeniyet University",
         "Completed",
         "Jan 2012",
         "Dec 2014",
         "Observational",
         "May 2016",
         "Tuberculosis,Lung Diseases,Pulmonary Disease",
         null
        ],
        [
         "NCT02758860",
         "University of Roma La Sapienza",
         "Active, not recruiting",
         "Jun 2016",
         "Sep 2020",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Diverticular Diseases,Diverticulum,Diverticulosis",
         null
        ],
        [
         "NCT02757209",
         "Consorzio Futuro in Ricerca",
         "Completed",
         "Apr 2016",
         "Jan 2018",
         "Interventional",
         "Apr 2016",
         "Asthma",
         "Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate"
        ],
        [
         "NCT02752438",
         "Ankara University",
         "Unknown status",
         "May 2016",
         "Jul 2017",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Hypoventilation",
         null
        ],
        [
         "NCT02753543",
         "Ruijin Hospital",
         "Unknown status",
         "Nov 2015",
         "Nov 2019",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         null
        ],
        [
         "NCT02757508",
         "Washington University School of Medicine",
         "Completed",
         "Mar 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         null,
         "Vitamins"
        ],
        [
         "NCT02753530",
         "Orphazyme",
         "Completed",
         "Aug 2017",
         "Jan 2021",
         "Interventional",
         "Apr 2016",
         "Myositis",
         null
        ],
        [
         "NCT02754817",
         "Novo Nordisk A/S",
         "Completed",
         "Apr 2016",
         "Oct 2016",
         "Observational",
         "Apr 2016",
         "Diabetes Mellitus",
         "Liraglutide,Xultophy"
        ],
        [
         "NCT02759276",
         "Daniel Alexandre Bottino",
         "Completed",
         "May 2015",
         "Dec 2015",
         "Observational",
         "Apr 2016",
         "Hypertension",
         null
        ],
        [
         "NCT02750956",
         "Bulent Ecevit University",
         "Completed",
         "Jun 2015",
         "Mar 2016",
         "Observational",
         "Apr 2016",
         "Periodontal Diseases",
         null
        ],
        [
         "NCT02752113",
         "Institut für Pharmakologie und Präventive Medizin",
         "Completed",
         "Apr 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Metformin,Empagliflozin,Linagliptin"
        ],
        [
         "NCT02752698",
         "The Third Xiangya Hospital of Central South University",
         "Active, not recruiting",
         "Jan 2015",
         "Dec 2021",
         "Interventional",
         "Jun 2015",
         "Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones",
         null
        ],
        [
         "NCT02755779",
         "Tel Aviv Medical Center",
         "Unknown status",
         "Jun 2016",
         "Jun 2017",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750384",
         "Medicines for Malaria Venture",
         "Terminated",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754609",
         "James Cook University, Queensland, Australia",
         "Completed",
         "Sep 2016",
         "Oct 2019",
         "Interventional",
         "Apr 2016",
         "Hookworm Infections,Celiac Disease",
         null
        ],
        [
         "NCT02755701",
         "Soonchunhyang University Hospital",
         "Unknown status",
         "Jul 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Ascites",
         null
        ],
        [
         "NCT02751762",
         "Member Companies of the Opioid PMR Consortium",
         "Recruiting",
         "Nov 2017",
         "Oct 2022",
         "Observational",
         "Apr 2016",
         "Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior",
         null
        ],
        [
         "NCT02756299",
         "Marmara University",
         "Completed",
         "Jun 2014",
         "Apr 2015",
         "Interventional",
         "Apr 2016",
         "Sleep Apnea Syndromes,Sleep Apnea",
         null
        ],
        [
         "NCT02750709",
         "Cycle Pharmaceuticals Ltd.",
         "Completed",
         "Oct 2015",
         "Jan 2016",
         "Interventional",
         "Apr 2016",
         "Tyrosinemias",
         "Nitisinone"
        ],
        [
         "NCT02753907",
         "Yonsei University",
         "Completed",
         "Jun 2015",
         null,
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755467",
         "Cutera Inc.",
         "Completed",
         "May 2016",
         "Apr 2017",
         "Interventional",
         "Apr 2016",
         "Hemangioma",
         null
        ],
        [
         "NCT02755298",
         "University of Zurich",
         "Completed",
         "Oct 2016",
         "Nov 2020",
         "Interventional",
         "Mar 2016",
         "Hypertension",
         "Acetazolamide"
        ],
        [
         "NCT02759614",
         "Guangdong Association of Clinical Trials",
         "Unknown status",
         "Apr 2016",
         "Jun 2019",
         "Interventional",
         "Mar 2016",
         "Carcinoma",
         "Bevacizumab,Erlotinib Hydrochloride"
        ],
        [
         "NCT02752815",
         "Ruijin Hospital",
         "Unknown status",
         "Apr 2016",
         "Jun 2020",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         "Prednisone,Cyclophosphamide,Rituximab,Vincristine,Epirubicin"
        ],
        [
         "NCT02757131",
         "The Cleveland Clinic",
         "Completed",
         "Jul 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Iatrogenic Disease",
         null
        ],
        [
         "NCT02758704",
         "St. Justine's Hospital",
         "Completed",
         "Oct 2015",
         "Jun 2021",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750501",
         "Alcresta Therapeutics, Inc.",
         "Completed",
         "Jul 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Cystic Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT02759913",
         "Iron Horse Diagnostics, Inc.",
         "Unknown status",
         "Jan 2015",
         "Dec 2016",
         "Observational",
         "Apr 2016",
         "Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis",
         null
        ],
        [
         "NCT02752724",
         "VA Puget Sound Health Care System",
         "Completed",
         "Mar 2016",
         "Apr 2018",
         "Interventional",
         "Mar 2016",
         "Depressive Disorder,Depression",
         "Ketamine,Methohexital"
        ],
        [
         "NCT02758444",
         "University of Colorado, Denver",
         "Completed",
         "Nov 2015",
         "Feb 2019",
         "Interventional",
         "Apr 2016",
         null,
         "Micronutrients,Trace Elements"
        ],
        [
         "NCT02758067",
         "H. Lundbeck A/S",
         "Withdrawn",
         "Jun 2016",
         null,
         "Interventional",
         "Apr 2016",
         "Schizophrenia",
         "Risperidone,Brexpiprazole"
        ],
        [
         "NCT02759341",
         "Ospedale San Giovanni Bellinzona",
         "Completed",
         "Feb 2016",
         "Nov 2017",
         "Interventional",
         "Apr 2016",
         "Myocardial Infarction,Cardiomyopathies,Microvascular Angina,Takotsubo Cardiomyopathy,Syndrome,Infarction",
         null
        ],
        [
         "NCT02753803",
         "Dong-A ST Co., Ltd.",
         "Completed",
         "Jul 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         null,
         "Pioglitazone"
        ],
        [
         "NCT02752490",
         "The University of Texas Health Science Center, Houston",
         "Completed",
         "Apr 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759562",
         "Gilead Sciences",
         "Terminated",
         "Nov 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Cystic Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT02758262",
         "Laval University",
         "Unknown status",
         "Apr 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Hyperphagia",
         null
        ],
        [
         "NCT02754258",
         "Children's Hospital of Eastern Ontario",
         "Unknown status",
         "Jan 2017",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         null,
         "Methylphenidate"
        ],
        [
         "NCT02755207",
         "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",
         "Unknown status",
         "Apr 2016",
         "Dec 2020",
         "Observational",
         "Mar 2016",
         "Acute Coronary Syndrome,Syndrome",
         null
        ],
        [
         "NCT02759900",
         "The Skin Center Dermatology Group",
         "Recruiting",
         "Jan 2016",
         "Jan 2023",
         "Interventional",
         "Apr 2016",
         "Molluscum Contagiosum,Keratosis,Bowens Disease,Rosacea,Skin Diseases",
         null
        ],
        [
         "NCT02752581",
         "Mert Özcan",
         "Completed",
         "Jan 2009",
         "Apr 2013",
         "Interventional",
         "Apr 2016",
         "Hemarthrosis",
         null
        ],
        [
         "NCT02759796",
         "Instituto de Investigación Hospital Universitario La Paz",
         "Completed",
         "Nov 2015",
         "Apr 2017",
         "Interventional",
         "Apr 2016",
         "Necrosis,Neovascularization,Fat Necrosis",
         null
        ],
        [
         "NCT02754063",
         "University Hospital, Grenoble",
         "Active, not recruiting",
         "Jun 2016",
         "Apr 2022",
         "Interventional",
         "Apr 2016",
         "Brain Injuries,Wounds and Injuries",
         "3"
        ],
        [
         "NCT02750917",
         "Foisor Orthopedics Clinical Hospital",
         "Completed",
         "Sep 2014",
         "Mar 2015",
         "Interventional",
         "Feb 2016",
         "Pain",
         "Etoricoxib,Lornoxicam"
        ],
        [
         "NCT02753569",
         "Institute of Cancer Research, United Kingdom",
         "Completed",
         "May 2016",
         "May 2020",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751255",
         "VU University Medical Center",
         "Active, not recruiting",
         "Jul 2016",
         "Mar 2022",
         "Interventional",
         "Apr 2016",
         "Multiple Myeloma,Neoplasms",
         "Tretinoin"
        ],
        [
         "NCT02751528",
         "NantBioScience, Inc.",
         "Unknown status",
         "Dec 2016",
         "Dec 2020",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         "Vaccines"
        ],
        [
         "NCT02751619",
         "University of Campania Luigi Vanvitelli",
         "Completed",
         "Jan 2013",
         "Dec 2015",
         "Interventional",
         "Apr 2016",
         "Pain",
         "Lidocaine"
        ],
        [
         "NCT02757833",
         "Lawson Health Research Institute",
         "Withdrawn",
         "Feb 2019",
         "Feb 2019",
         "Interventional",
         "Apr 2016",
         "Depression,Depressive Disorder",
         null
        ],
        [
         "NCT02750761",
         "Merck Sharp & Dohme Corp.",
         "Completed",
         "May 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Infections,Bacterial Infections,Gram-Positive Bacterial Infections",
         "Tedizolid phosphate,Tedizolid,Oxazolidinones"
        ],
        [
         "NCT02752594",
         "Sharda University",
         "Completed",
         "Apr 2015",
         "Apr 2015",
         "Interventional",
         "Apr 2016",
         "Dental Caries",
         null
        ],
        [
         "NCT02753452",
         "Holland Bloorview Kids Rehabilitation Hospital",
         "Unknown status",
         "May 2015",
         "Mar 2020",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02752763",
         "Niğde State Hospital",
         "Completed",
         "Oct 2015",
         "Mar 2016",
         "Interventional",
         "Mar 2016",
         "Dry Eye Syndromes,Keratoconjunctivitis Sicca",
         "Dextrans,Povidone,Ophthalmic Solutions,Lubricant Eye Drops"
        ],
        [
         "NCT02753816",
         "Spectrum Health Hospitals",
         "Terminated",
         "Apr 2016",
         "Dec 2019",
         "Interventional",
         "Apr 2016",
         "Burns",
         "Tranexamic Acid"
        ],
        [
         "NCT02751294",
         "GlaxoSmithKline",
         "Completed",
         "May 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Malaria",
         "Tafenoquine"
        ],
        [
         "NCT02756429",
         "Hospices Civils de Lyon",
         "Completed",
         "Feb 2014",
         "Jan 2018",
         "Interventional",
         "Apr 2016",
         "Atrial Fibrillation",
         null
        ],
        [
         "NCT02750163",
         "Università Politecnica delle Marche",
         "Completed",
         "Jul 2017",
         "Jun 2019",
         "Observational",
         "Apr 2016",
         "Shock",
         "Acetaminophen"
        ],
        [
         "NCT02751905",
         "Biogen",
         "Completed",
         "Apr 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Neuralgia",
         null
        ],
        [
         "NCT02753153",
         "University of Liege",
         "Completed",
         "May 2011",
         "May 2015",
         "Interventional",
         "Apr 2016",
         "Tooth Loss",
         null
        ],
        [
         "NCT02750891",
         "Sumitomo Dainippon Pharma Co., Ltd.",
         "Completed",
         "Apr 2016",
         "Jan 2020",
         "Interventional",
         "Apr 2016",
         "Glioblastoma,Glioma,Diffuse Intrinsic Pontine Glioma",
         null
        ],
        [
         "NCT02751073",
         "Mayo Clinic",
         "Completed",
         "Feb 2016",
         "Jul 2018",
         "Observational",
         "Feb 2016",
         "Infections,Communicable Diseases,Urinary Tract Infections,Prolapse,Pelvic Organ Prolapse",
         null
        ],
        [
         "NCT02753114",
         "University of British Columbia",
         "Completed",
         "Nov 2017",
         "May 2018",
         "Interventional",
         "Apr 2016",
         "Acute Pain",
         "Ketamine"
        ],
        [
         "NCT02752516",
         "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",
         "Unknown status",
         "Apr 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02752269",
         "Medical University of Graz",
         "Completed",
         "Oct 2014",
         "Jun 2019",
         "Observational",
         "Nov 2015",
         "Sjogrens Syndrome,Hypertension,Vascular Diseases,Syndrome",
         null
        ],
        [
         "NCT02754713",
         "Hippocration General Hospital",
         "Recruiting",
         "Sep 2009",
         "Dec 2025",
         "Observational",
         "Apr 2016",
         "Pericarditis",
         null
        ],
        [
         "NCT02759770",
         "Beijing Anzhen Hospital",
         "Completed",
         "Jul 2017",
         "Sep 2017",
         "Observational",
         "Apr 2016",
         "Respiratory Distress Syndrome,Acute Lung Injury",
         null
        ],
        [
         "NCT02755129",
         "Medtronic BRC",
         "Completed",
         "Sep 2016",
         "Jul 2017",
         "Interventional",
         "Mar 2016",
         "Frailty",
         null
        ],
        [
         "NCT02754674",
         "Samsung Medical Center",
         "Completed",
         "May 2014",
         "Dec 2017",
         "Interventional",
         "Feb 2015",
         "Rupture",
         null
        ],
        [
         "NCT02757521",
         "Washington University School of Medicine",
         "Terminated",
         "Mar 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Disease,Depression,Depressive Disorder,Bipolar Disorder",
         "Nitrous Oxide"
        ],
        [
         "NCT02750774",
         "University of Modena and Reggio Emilia",
         "Unknown status",
         "Dec 2015",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Diabetes,Obesity,Pregnancy Complications,Fetal Macrosomia,Overweight,Birth Weight",
         null
        ],
        [
         "NCT02754739",
         "Samsung Medical Center",
         "Completed",
         "Apr 2014",
         "Aug 2017",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus,Prediabetic State",
         "Pravastatin"
        ],
        [
         "NCT02758808",
         "University of Michigan",
         "Recruiting",
         "Mar 2016",
         "Oct 2023",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Lung Diseases,Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT02751840",
         "Tel Hai College",
         "Completed",
         "Oct 2014",
         "Apr 2016",
         "Interventional",
         "Apr 2016",
         "Asymptomatic Diseases",
         "Caffeine"
        ],
        [
         "NCT02752451",
         "University of Arizona",
         "Completed",
         "Mar 2015",
         "Apr 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757599",
         "Rigshospitalet, Denmark",
         "Completed",
         "Aug 2016",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753894",
         "Astellas Pharma Inc",
         "Completed",
         "Jan 2008",
         "Jun 2008",
         "Interventional",
         "Mar 2016",
         "Kidney Diseases,Renal Insufficiency,Hyperphosphatemia",
         null
        ],
        [
         "NCT02757638",
         "Texas A&M University",
         "Active, not recruiting",
         "Oct 2015",
         "Oct 2021",
         "Interventional",
         "Feb 2016",
         "Weight Loss",
         null
        ],
        [
         "NCT02757378",
         "Kevin Farrell",
         "Completed",
         "May 2015",
         "Sep 2015",
         "Interventional",
         "Apr 2016",
         "Back Pain,Low Back Pain",
         null
        ],
        [
         "NCT02751489",
         "Bayer",
         "Completed",
         "May 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         null
        ],
        [
         "NCT02759315",
         "Merck Sharp & Dohme Corp.",
         "Terminated",
         "May 2016",
         "Nov 2017",
         "Interventional",
         "Apr 2016",
         "Hepatitis A,Hepatitis C,Hepatitis",
         "Uprifosbuvir,Ruzasvir"
        ],
        [
         "NCT02754895",
         "Massachusetts General Hospital",
         "Completed",
         "Oct 2014",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Acute Coronary Syndrome,Syndrome",
         null
        ],
        [
         "NCT02750475",
         "Bayer",
         "Completed",
         "May 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         "Sunscreening Agents"
        ],
        [
         "NCT02755064",
         "Adil Bharucha",
         "Completed",
         "Jun 2010",
         "Nov 2013",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Erythromycin,Erythromycin Estolate,Erythromycin Ethylsuccinate,Erythromycin stearate,Erythromycin lactobionate"
        ],
        [
         "NCT02758002",
         "University of California, San Diego",
         "Withdrawn",
         "Jan 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Atrial Fibrillation",
         null
        ],
        [
         "NCT02755142",
         "medac GmbH",
         "Completed",
         "Feb 2000",
         "Jun 2001",
         "Interventional",
         "Apr 2016",
         "Glioma,Brain Neoplasms",
         "Aminolevulinic Acid"
        ],
        [
         "NCT02756364",
         "Millennium Pharmaceuticals, Inc.",
         "Completed",
         "Jul 2016",
         "Nov 2019",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         "Fulvestrant"
        ],
        [
         "NCT02759484",
         "Rush University Medical Center",
         "Unknown status",
         "Mar 2015",
         "Mar 2019",
         "Interventional",
         "Dec 2015",
         "Hypertension,Diabetes Mellitus,Hyperglycemia",
         null
        ],
        [
         "NCT02752061",
         "Harvard School of Public Health (HSPH)",
         "Completed",
         "May 2016",
         "Jul 2020",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756598",
         "Aarhus University Hospital",
         "Completed",
         "Jan 2015",
         "Jun 2018",
         "Interventional",
         "Dec 2015",
         null,
         "Sufentanil,Dsuvia,Propofol"
        ],
        [
         "NCT02755727",
         "Royal Devon and Exeter NHS Foundation Trust",
         "Completed",
         "Mar 2016",
         "Sep 2017",
         "Interventional",
         "Apr 2016",
         "Tennis Elbow",
         null
        ],
        [
         "NCT02754882",
         "Samsung Bioepis Co., Ltd.",
         "Completed",
         "Jul 2016",
         "Oct 2018",
         "Interventional",
         "Mar 2016",
         "Lung Neoplasms,Carcinoma",
         "Paclitaxel,Bevacizumab,Carboplatin"
        ],
        [
         "NCT02754778",
         "Martin-Luther-Universität Halle-Wittenberg",
         "Completed",
         "Apr 2016",
         "Mar 2021",
         "Interventional",
         "Apr 2016",
         "Pre-Eclampsia,HELLP Syndrome,Syndrome",
         null
        ],
        [
         "NCT02758171",
         "Boehringer Ingelheim",
         "Completed",
         "May 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         null,
         "Empagliflozin,Linagliptin"
        ],
        [
         "NCT02755376",
         "Samsung Medical Center",
         "Completed",
         "Jan 2014",
         "Dec 2018",
         "Interventional",
         "Feb 2015",
         null,
         "Hyaluronic Acid"
        ],
        [
         "NCT02759016",
         "Boehringer Ingelheim",
         "Completed",
         "Jun 2016",
         "Jul 2019",
         "Interventional",
         "Apr 2016",
         "Leukemia",
         "BI 836826"
        ],
        [
         "NCT02758457",
         "University of Bologna",
         "Completed",
         "Jan 2008",
         "Apr 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755519",
         "Chongqing Medical University",
         "Completed",
         "May 2014",
         "Oct 2016",
         "Observational",
         "Apr 2016",
         "Hyperaldosteronism",
         null
        ],
        [
         "NCT02758782",
         "Charite University, Berlin, Germany",
         "Completed",
         "Sep 2016",
         "Jan 2021",
         "Interventional",
         "Apr 2016",
         "Spondylitis",
         "Celecoxib,Golimumab"
        ],
        [
         "NCT02756806",
         "Cutera Inc.",
         "Completed",
         "Apr 2016",
         "Sep 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756156",
         "Kahramanmaras Sutcu Imam University",
         "Unknown status",
         "Apr 2016",
         "Aug 2016",
         "Observational",
         "Mar 2016",
         "Humeral Fractures",
         null
        ],
        [
         "NCT02759458",
         "Rush University Medical Center",
         "Completed",
         "Nov 2013",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         "Rotator Cuff Injuries",
         null
        ],
        [
         "NCT02750982",
         "Brown, Theodore R., M.D., MPH",
         "Completed",
         "Jul 2016",
         "Aug 2018",
         "Interventional",
         "Apr 2016",
         "Parkinson Disease,Multiple Sclerosis,Alzheimer Disease,Brain Injuries,Spinal Cord Injuries,Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Huntington Disease,Sclerosis,Wounds and Injuries",
         null
        ],
        [
         "NCT02751502",
         "NYU Langone Health",
         "Terminated",
         "Jan 2017",
         "Feb 2021",
         "Interventional",
         "Apr 2016",
         "Hemiplegia",
         null
        ],
        [
         "NCT02752087",
         "Eli Lilly and Company",
         "Completed",
         "Apr 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756858",
         "Anavex Life Sciences Corp.",
         "Completed",
         "Mar 2016",
         "Nov 2020",
         "Interventional",
         "Mar 2016",
         "Alzheimer Disease",
         null
        ],
        [
         "NCT02758249",
         "Konkuk University Medical Center",
         "Completed",
         "Jan 2016",
         "Jan 2016",
         "Interventional",
         "Feb 2016",
         null,
         "Propofol,Sevoflurane"
        ],
        [
         "NCT02754570",
         "University of Colorado, Denver",
         "Completed",
         "Jul 2016",
         "Feb 2018",
         "Interventional",
         "Apr 2016",
         "Glaucoma,Ocular Hypertension,Hypertension",
         "Pilocarpine"
        ],
        [
         "NCT02754102",
         "Bayer",
         "Completed",
         "May 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         "Sunscreening Agents"
        ],
        [
         "NCT02751593",
         "Peking University People's Hospital",
         "Unknown status",
         "Jan 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Thrombocytopenia,Purpura",
         "Dexamethasone"
        ],
        [
         "NCT02757014",
         "Bayer",
         "Completed",
         "Oct 2015",
         "Oct 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753062",
         "Asan Medical Center",
         "Recruiting",
         "Aug 2015",
         "Aug 2023",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         "Rituximab,Bendamustine Hydrochloride"
        ],
        [
         "NCT02752425",
         "Hospices Civils de Lyon",
         "Completed",
         "May 2016",
         "May 2018",
         "Interventional",
         "Apr 2016",
         "Speech Disorders",
         null
        ],
        [
         "NCT02757300",
         "Marienhospital Osnabrück",
         "Unknown status",
         "May 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Pharyngitis",
         null
        ],
        [
         "NCT02754180",
         "Peking Union Medical College Hospital",
         "Unknown status",
         "Mar 2016",
         "Mar 2021",
         "Interventional",
         "Apr 2016",
         "Adenocarcinoma,Pancreatic Neoplasms",
         "Gemcitabine"
        ],
        [
         "NCT02752321",
         "Northwell Health",
         "Terminated",
         "Aug 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753595",
         "Eisai Inc.",
         "Terminated",
         "Jul 2016",
         "Aug 2019",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02755246",
         "Charite University, Berlin, Germany",
         "Completed",
         "Apr 2016",
         "Sep 2016",
         "Interventional",
         "Apr 2016",
         "Cognitive Dysfunction",
         null
        ],
        [
         "NCT02754115",
         "Tata Memorial Centre",
         "Recruiting",
         "Apr 2016",
         "Jan 2022",
         "Observational",
         "Mar 2016",
         "Peritoneal Diseases",
         null
        ],
        [
         "NCT02756897",
         "M.D. Anderson Cancer Center",
         "Active, not recruiting",
         "Jul 2016",
         "Jul 2024",
         "Interventional",
         "Apr 2016",
         "Lymphoma,Leukemia",
         "Venetoclax"
        ],
        [
         "NCT02752334",
         "Magrabi Eye & Ear Hospital",
         "Completed",
         "Sep 2015",
         "Mar 2019",
         "Interventional",
         "Mar 2016",
         null,
         "Magnesium Sulfate,Bupivacaine"
        ],
        [
         "NCT02754791",
         "Shaare Zedek Medical Center",
         "Unknown status",
         "May 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754128",
         "Holland Bloorview Kids Rehabilitation Hospital",
         "Completed",
         "Jun 2016",
         "Oct 2017",
         "Interventional",
         "Apr 2016",
         "Cerebral Palsy",
         null
        ],
        [
         "NCT02751190",
         "Umeå University",
         "Completed",
         "Sep 2013",
         "Feb 2017",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Chronic Pain,Hernia",
         null
        ],
        [
         "NCT02751645",
         "Oregon Health and Science University",
         "Unknown status",
         "Jun 2016",
         "May 2020",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02758184",
         "Duke University",
         "Terminated",
         "Jun 2016",
         "May 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751892",
         "University of East Anglia",
         "Completed",
         "Oct 2013",
         "Sep 2014",
         "Interventional",
         "Apr 2016",
         "Colorectal Neoplasms",
         null
        ],
        [
         "NCT02755324",
         "Leiden University",
         "Completed",
         "Oct 2016",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Schistosomiasis",
         null
        ],
        [
         "NCT02758886",
         "Washington State University",
         "Completed",
         "Apr 2014",
         null,
         "Interventional",
         "Apr 2016",
         "Stress",
         null
        ],
        [
         "NCT02750072",
         "Fraser Orthopaedic Research Society",
         "Active, not recruiting",
         "Sep 2016",
         "Apr 2023",
         "Interventional",
         "Apr 2016",
         "Patellofemoral Pain Syndrome,Fractures,Tibial Fractures",
         null
        ],
        [
         "NCT02750332",
         "Cycle Pharmaceuticals Ltd.",
         "Completed",
         "Nov 2015",
         "Jan 2016",
         "Interventional",
         "Apr 2016",
         "Tyrosinemias",
         "Nitisinone"
        ],
        [
         "NCT02752529",
         "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",
         "Unknown status",
         "Mar 2016",
         null,
         "Interventional",
         "Mar 2016",
         "Liver Cirrhosis",
         "Tacrolimus"
        ],
        [
         "NCT02759939",
         "Dartmouth-Hitchcock Medical Center",
         "Completed",
         "Jul 2016",
         "Jul 2017",
         "Interventional",
         "Feb 2016",
         null,
         null
        ],
        [
         "NCT02757157",
         "European Respiratory Society",
         "Terminated",
         "Oct 2016",
         "Jan 2020",
         "Interventional",
         "Apr 2016",
         "Lung Diseases,Pulmonary Disease",
         null
        ],
        [
         "NCT02759627",
         "Istanbul University",
         "Completed",
         "Nov 2014",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         "Stroke",
         null
        ],
        [
         "NCT02752412",
         "Sanofi",
         "Completed",
         "May 2016",
         "Oct 2018",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Insulin,Metformin,Insulin Glargine,Lixisenatide"
        ],
        [
         "NCT02756988",
         "Bayer",
         "Completed",
         "Oct 2015",
         "Oct 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751203",
         "Lara McKenzie",
         "Completed",
         "Apr 2016",
         "Dec 2017",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02753946",
         "Nabriva Therapeutics AG",
         "Completed",
         "Apr 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Infections,Communicable Diseases,Urinary Tract Infections,Pyelonephritis",
         "Tazobactam,Piperacillin,Fosfomycin"
        ],
        [
         "NCT02755480",
         "University Health Network, Toronto",
         "Terminated",
         "Feb 2015",
         "Feb 2017",
         "Interventional",
         "Mar 2015",
         null,
         null
        ],
        [
         "NCT02753257",
         "Valtari Bio",
         "Unknown status",
         "Sep 2016",
         "Dec 2019",
         "Observational",
         "Apr 2016",
         "Stroke",
         null
        ],
        [
         "NCT02758691",
         "Virginia Polytechnic Institute and State University",
         "Completed",
         "Dec 2015",
         "May 2017",
         "Interventional",
         "Apr 2016",
         null,
         "Insulin"
        ],
        [
         "NCT02755623",
         "Centre hospitalier de Ville-Evrard, France",
         "Unknown status",
         "May 2015",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Hallucinations,Schizophrenia",
         null
        ],
        [
         "NCT02756234",
         "Lancaster General Hospital",
         "Completed",
         "May 2016",
         "Aug 2018",
         "Observational",
         "Apr 2016",
         "Coronary Artery Disease",
         null
        ],
        [
         "NCT02756091",
         "University Hospital Inselspital, Berne",
         "Recruiting",
         "Aug 2016",
         "May 2022",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Cerebrovascular Disorders",
         null
        ],
        [
         "NCT02753491",
         "Marmara University",
         "Completed",
         "Oct 2015",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02752737",
         "Medtronic Cardiac Rhythm and Heart Failure",
         "Recruiting",
         "May 2016",
         "Dec 2024",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Atrial Fibrillation",
         null
        ],
        [
         "NCT02758925",
         "University Hospital, Caen",
         "Unknown status",
         "Jun 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         "Cytarabine,Rituximab,Bendamustine Hydrochloride"
        ],
        [
         "NCT02751723",
         "Florian Lordick, MD",
         "Unknown status",
         "Sep 2014",
         "Oct 2019",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751931",
         "Astellas Pharma Europe B.V.",
         "Completed",
         "Jun 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Urinary Bladder",
         "Mirabegron"
        ],
        [
         "NCT02758847",
         "Rabih A. Chaer",
         "Recruiting",
         "Sep 2016",
         "Dec 2022",
         "Interventional",
         "Apr 2016",
         "Ischemia",
         "Paclitaxel,Albumin-Bound Paclitaxel"
        ],
        [
         "NCT02757807",
         "Eco Fusion",
         "Unknown status",
         "Jul 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Erectile Dysfunction",
         null
        ],
        [
         "NCT02755220",
         "Shanghai Cingularbio Co. Ltd",
         "Completed",
         "Jan 2016",
         "Apr 2019",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02758548",
         "Novartis Pharmaceuticals",
         "Completed",
         "Mar 2016",
         "May 2016",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02756845",
         "Amgen",
         "Recruiting",
         "Aug 2017",
         "Jun 2024",
         "Interventional",
         "Dec 2015",
         "Neoplasms",
         "Talimogene laherparepvec"
        ],
        [
         "NCT02750605",
         "Skane University Hospital",
         "Active, not recruiting",
         "Feb 2016",
         "Dec 2021",
         "Interventional",
         "Jan 2016",
         "Vascular Diseases,Peripheral Vascular Diseases,Peripheral Arterial Disease,Ischemia",
         null
        ],
        [
         "NCT02756702",
         "Aesculap AG",
         "Active, not recruiting",
         "Mar 2016",
         "Dec 2022",
         "Observational",
         "Apr 2016",
         "Osteoarthritis",
         null
        ],
        [
         "NCT02752945",
         "King's College London",
         "Completed",
         "Apr 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Depression,Depressive Disorder,Anxiety Disorders",
         null
        ],
        [
         "NCT02759952",
         "STZ eyetrial",
         "Enrolling by invitation",
         "Jan 2013",
         "Dec 2025",
         "Observational",
         "Apr 2016",
         "Retinitis,Retinitis Pigmentosa",
         null
        ],
        [
         "NCT02754661",
         "Medtronic - MITG",
         "Completed",
         "Sep 2016",
         "Aug 2018",
         "Interventional",
         "Apr 2016",
         "Colorectal Neoplasms",
         null
        ],
        [
         "NCT02755441",
         "Nils Hoyer",
         "Recruiting",
         "Apr 2016",
         "Dec 2024",
         "Observational",
         "Apr 2016",
         "Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT02750098",
         "Sheba Medical Center",
         "Unknown status",
         "May 2016",
         "Mar 2018",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02753179",
         "Hospices Civils de Lyon",
         "Completed",
         "May 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         "Vestibular Diseases",
         null
        ],
        [
         "NCT02758509",
         "Parc de Salut Mar",
         "Completed",
         "Jan 2010",
         "Oct 2017",
         "Observational",
         "Apr 2016",
         "Hepatitis C,Hepatitis",
         "Interferons,Ritonavir,Ribavirin,Interferon-alpha,Interferon alpha-2,Sofosbuvir,Peginterferon alfa-2a,Ledipasvir,Simeprevir"
        ],
        [
         "NCT02751970",
         "Universidad de Valparaiso",
         "Unknown status",
         "Apr 2014",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         "Dental Caries",
         null
        ],
        [
         "NCT02753712",
         "Mundipharma Research Limited",
         "Completed",
         "Jun 2016",
         "Aug 2017",
         "Interventional",
         "Apr 2016",
         "Asthma",
         "Fluticasone,Xhance,Formoterol Fumarate"
        ],
        [
         "NCT02751151",
         "Inova Health Care Services",
         "Completed",
         "Feb 2016",
         "May 2021",
         "Interventional",
         "Mar 2016",
         "Skin Neoplasms",
         "Aminolevulinic Acid"
        ],
        [
         "NCT02757716",
         "Sana Klinikum Offenbach",
         "Completed",
         "Apr 2016",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Behavior",
         null
        ],
        [
         "NCT02758652",
         "Tampere University Hospital",
         "Active, not recruiting",
         "May 2016",
         "May 2026",
         "Observational",
         "Apr 2016",
         "Ovarian Neoplasms,Carcinoma",
         null
        ],
        [
         "NCT02754206",
         "Southern Methodist University",
         "Terminated",
         "Jan 2016",
         "Sep 2021",
         "Observational",
         "Apr 2016",
         "Post-Concussion Syndrome,Brain Concussion",
         null
        ],
        [
         "NCT02752243",
         "Peter Bader",
         "Active, not recruiting",
         "Mar 2016",
         "Mar 2022",
         "Interventional",
         "Mar 2016",
         "Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome,Acute Disease",
         null
        ],
        [
         "NCT02754856",
         "M.D. Anderson Cancer Center",
         "Active, not recruiting",
         "Jul 2016",
         "Jul 2021",
         "Interventional",
         "Apr 2016",
         "Colorectal Neoplasms",
         "Durvalumab,Ipilimumab,Tremelimumab,Immunoglobulins,Antibodies,Immunoglobulin G"
        ],
        [
         "NCT02759861",
         "University of Nebraska",
         "Active, not recruiting",
         "Aug 2016",
         "Aug 2020",
         "Interventional",
         "Apr 2016",
         "Hepatitis A,Hepatitis C,Hepatitis",
         "Sofosbuvir,Ledipasvir"
        ],
        [
         "NCT02759679",
         "Haukeland University Hospital",
         "Unknown status",
         "May 2016",
         "Dec 2019",
         "Interventional",
         "Mar 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02752932",
         "Lawson Health Research Institute",
         "Completed",
         "Nov 2015",
         "Oct 2017",
         "Interventional",
         "Feb 2016",
         "Carcinoma,Squamous Cell Carcinoma of Head and Neck,Neoplasms",
         null
        ],
        [
         "NCT02759445",
         "RWTH Aachen University",
         "Unknown status",
         "Apr 2016",
         "Oct 2016",
         "Observational",
         "Nov 2015",
         null,
         null
        ],
        [
         "NCT02754622",
         "Guy's and St Thomas' NHS Foundation Trust",
         "Completed",
         "Jul 2016",
         "Dec 2016",
         "Observational",
         "Apr 2016",
         "Critical Illness",
         null
        ],
        [
         "NCT02756611",
         "AbbVie",
         "Active, not recruiting",
         "Jun 2016",
         "Sep 2022",
         "Interventional",
         "Apr 2016",
         "Leukemia",
         "Venetoclax"
        ],
        [
         "NCT02758223",
         "Wuerzburg University Hospital",
         "Active, not recruiting",
         "Apr 2016",
         "Jun 2021",
         "Interventional",
         "Feb 2016",
         "Leukemia,Myelodysplastic Syndromes",
         null
        ],
        [
         "NCT02757079",
         "Nobelpharma",
         "Completed",
         "Jun 2016",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         "Sleep Wake Disorders,Parasomnias,Disease,Neurodevelopmental Disorders",
         "Melatonin"
        ],
        [
         "NCT02754219",
         "Dong-A ST Co., Ltd.",
         "Completed",
         "Sep 2016",
         "Jan 2018",
         "Interventional",
         "Apr 2016",
         "Liver Diseases",
         null
        ],
        [
         "NCT02753101",
         "Stanford University",
         "Completed",
         "Feb 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Sciatica",
         null
        ],
        [
         "NCT02759003",
         "Fondazione Salvatore Maugeri",
         "Completed",
         "Mar 2011",
         "Mar 2014",
         "Interventional",
         "Apr 2016",
         "Motor Neuron Disease,Amyotrophic Lateral Sclerosis,Sclerosis",
         null
        ],
        [
         "NCT02752659",
         "University of British Columbia",
         "Completed",
         "Jun 2016",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms,Lymphedema",
         null
        ],
        [
         "NCT02758912",
         "Burnasyan Federal Medical Biophysical Center",
         "Completed",
         "Nov 2016",
         "Oct 2019",
         "Interventional",
         "Apr 2016",
         "Stroke,Angina Pectoris,Infarction,Hemorrhage",
         null
        ],
        [
         "NCT02754388",
         "National Taiwan University Hospital",
         "Completed",
         "Feb 2016",
         "Dec 2019",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02759666",
         "Atridia Pty Ltd.",
         "Completed",
         "Jun 2016",
         "Apr 2019",
         "Interventional",
         "Apr 2016",
         "Neoplasms",
         null
        ],
        [
         "NCT02750241",
         "The University of Texas Medical Branch, Galveston",
         "Completed",
         "Apr 2016",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02752568",
         "Kasr El Aini Hospital",
         "Unknown status",
         "May 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02758015",
         "University of California, San Francisco",
         "Completed",
         "Jun 2016",
         "Mar 2018",
         "Interventional",
         "Apr 2016",
         null,
         "Betaine"
        ],
        [
         "NCT02756884",
         "Arkansas Heart Hospital",
         "Completed",
         "Jun 2015",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Peripheral Arterial Disease,Peripheral Vascular Diseases",
         null
        ],
        [
         "NCT02758353",
         "JSI Research & Training Institute, Inc.",
         "Completed",
         "Apr 2015",
         "Nov 2015",
         "Interventional",
         "Apr 2016",
         "Malaria,Stillbirth",
         null
        ],
        [
         "NCT02753751",
         "Yale University",
         "Completed",
         "Mar 2018",
         "Jan 2020",
         "Interventional",
         "Apr 2016",
         "Acute Kidney Injury,Wounds and Injuries",
         null
        ],
        [
         "NCT02757170",
         "All India Institute of Medical Sciences, New Delhi",
         "Unknown status",
         "Jul 2015",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Liver Failure,Hepatic Insufficiency,End Stage Liver Disease,Acute-On-Chronic Liver Failure",
         null
        ],
        [
         "NCT02757625",
         "Pfizer",
         "Completed",
         "Jul 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         null,
         "Dexmedetomidine"
        ],
        [
         "NCT02752347",
         "Riyadh Colleges of Dentistry and Pharmacy",
         "Unknown status",
         "Apr 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Malocclusion",
         null
        ],
        [
         "NCT02756468",
         "University of Roma La Sapienza",
         "Unknown status",
         "Jan 2015",
         "Dec 2016",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Pancreatic Neoplasms",
         null
        ],
        [
         "NCT02750410",
         "Eli Lilly and Company",
         "Completed",
         "Aug 2016",
         "Jun 2018",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Dulaglutide"
        ],
        [
         "NCT02755389",
         "Nova Scotia Health Authority",
         "Completed",
         "Sep 2016",
         "Jun 2018",
         "Interventional",
         "Apr 2016",
         "Apnea",
         null
        ],
        [
         "NCT02755168",
         "Assiut University",
         "Unknown status",
         "May 2017",
         "May 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751567",
         "Bayer",
         "Withdrawn",
         "May 2016",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         null
        ],
        [
         "NCT02755558",
         "Penn State University",
         "Completed",
         "Sep 2014",
         "May 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757547",
         "Electrical Geodesics, Inc.",
         "Terminated",
         "Sep 2015",
         "Nov 2017",
         "Interventional",
         "Apr 2016",
         "Epilepsy",
         null
        ],
        [
         "NCT02752828",
         "Sanofi",
         "Completed",
         "May 2016",
         "Mar 2018",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Insulin,Insulin Glargine,Lixisenatide,Hypoglycemic Agents"
        ],
        [
         "NCT02756715",
         "Konkuk University Medical Center",
         "Completed",
         "May 2016",
         "Feb 2020",
         "Interventional",
         "Apr 2016",
         "Vascular System Injuries,Ischemia",
         "Propofol,Desflurane"
        ],
        [
         "NCT02756117",
         "Vanderbilt University",
         "Completed",
         "May 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         "Prediabetic State",
         null
        ],
        [
         "NCT02753205",
         "Gachon University Gil Medical Center",
         "Withdrawn",
         "Apr 2016",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         "Intracranial Hypertension",
         "Dexmedetomidine"
        ],
        [
         "NCT02756221",
         "Tel Hai College",
         "Completed",
         "Mar 2016",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         "Respiratory Tract Infections,Gastroenteritis",
         null
        ],
        [
         "NCT02755675",
         "Rigshospitalet, Denmark",
         "Recruiting",
         "Apr 2016",
         "Oct 2023",
         "Interventional",
         "Apr 2016",
         "Carcinoma,Lung Neoplasms,Mesothelioma",
         null
        ],
        [
         "NCT02754037",
         "University of California, Davis",
         "Recruiting",
         "Apr 2016",
         "Jun 2024",
         "Observational",
         "Apr 2016",
         "Liver Diseases,Fatty Liver,Non-alcoholic Fatty Liver Disease,Inflammation",
         "Fluorodeoxyglucose F18"
        ],
        [
         "NCT02750306",
         "Merck Sharp & Dohme Corp.",
         "Completed",
         "May 2016",
         "Sep 2018",
         "Interventional",
         "Apr 2016",
         "Alzheimer Disease,Sleep Initiation and Maintenance Disorders",
         "Suvorexant"
        ],
        [
         "NCT02756403",
         "Medstar Health Research Institute",
         "Completed",
         "Mar 2016",
         "Jul 2017",
         "Interventional",
         "Mar 2016",
         null,
         "Azithromycin,Metronidazole,Doxycycline"
        ],
        [
         "NCT02759653",
         "Haukeland University Hospital",
         "Completed",
         "May 2016",
         "Dec 2018",
         "Observational",
         "Apr 2016",
         "Stroke,Ischemic Stroke,Carotid Artery Diseases,Embolic Stroke",
         null
        ],
        [
         "NCT02753920",
         "Northwell Health",
         "Completed",
         "Mar 2016",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         "Prolapse",
         null
        ],
        [
         "NCT02759367",
         "Samuel Lunenfeld Research Institute, Mount Sinai Hospital",
         "Completed",
         "Mar 2008",
         "Jun 2015",
         "Interventional",
         "Dec 2015",
         "Hypertension",
         null
        ],
        [
         "NCT02752997",
         "Mayo Clinic",
         "Completed",
         "Dec 2015",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         "Heart Failure",
         null
        ],
        [
         "NCT02750059",
         "South East Asia Research Collaboration with Hawaii",
         "Completed",
         "Jan 2015",
         "Feb 2018",
         "Interventional",
         "May 2015",
         "Infections,Communicable Diseases,HIV Infections,Acquired Immunodeficiency Syndrome",
         "Tenofovir,Lamivudine,Efavirenz,Telmisartan"
        ],
        [
         "NCT02754505",
         "Danube Hospital",
         "Completed",
         "Feb 2008",
         "Dec 2011",
         "Interventional",
         "Mar 2016",
         "Critical Illness",
         null
        ],
        [
         "NCT02751736",
         "Seoul National University Hospital",
         "Unknown status",
         "Apr 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Rectal Neoplasms",
         null
        ],
        [
         "NCT02750930",
         "GlaxoSmithKline",
         "Terminated",
         "Oct 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "rGLP-1 protein"
        ],
        [
         "NCT02753582",
         "Indonesia University",
         "Unknown status",
         "Apr 2016",
         "Apr 2017",
         "Interventional",
         "Apr 2016",
         "Frailty",
         null
        ],
        [
         "NCT02750722",
         "University of Zurich",
         "Completed",
         "May 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         "Cystic Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT02756793",
         "Lawson Health Research Institute",
         "Active, not recruiting",
         "Oct 2016",
         "Jun 2026",
         "Interventional",
         "Apr 2016",
         "Neoplasm Metastasis,Neoplasms",
         null
        ],
        [
         "NCT02750436",
         "Montreal General Hospital",
         "Completed",
         "Apr 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Back Pain",
         null
        ],
        [
         "NCT02755922",
         "Instituto Mexicano del Seguro Social",
         "Completed",
         "Apr 2010",
         "Dec 2010",
         "Interventional",
         "Apr 2016",
         "Mandibular Fractures",
         null
        ],
        [
         "NCT02755493",
         "Brigham and Women's Hospital",
         "Completed",
         "Apr 2016",
         "May 2018",
         "Interventional",
         "Apr 2016",
         "Sleep Deprivation",
         null
        ],
        [
         "NCT02750397",
         "Massachusetts General Hospital",
         "Active, not recruiting",
         "Aug 2016",
         "Dec 2024",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753621",
         "Johns Hopkins University",
         "Completed",
         "Dec 2015",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Parkinson Disease",
         null
        ],
        [
         "NCT02754154",
         "Bristol-Myers Squibb",
         "Unknown status",
         "Dec 2014",
         "Feb 2019",
         "Observational",
         "Apr 2016",
         "Atrial Fibrillation",
         "Warfarin,Rivaroxaban,Dabigatran,Apixaban"
        ],
        [
         "NCT02753049",
         "New York University",
         "Unknown status",
         "Nov 2016",
         "Aug 2018",
         "Interventional",
         "Apr 2016",
         "HIV Infections,Acquired Immunodeficiency Syndrome",
         null
        ],
        [
         "NCT02750813",
         "Alcon, a Novartis Company",
         "Completed",
         "Apr 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Refractive Errors",
         null
        ],
        [
         "NCT02756975",
         "Modarres Hospital",
         "Completed",
         "Dec 2014",
         "Dec 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759601",
         "Queen Mary University of London",
         "Unknown status",
         "Jan 2013",
         "Dec 2018",
         "Interventional",
         "Oct 2014",
         "Carcinoma",
         null
        ],
        [
         "NCT02757326",
         "RedHill Biopharma Limited",
         "Terminated",
         "Dec 2016",
         "May 2019",
         "Interventional",
         "Mar 2016",
         "Multiple Myeloma,Neoplasms",
         null
        ],
        [
         "NCT02758236",
         "Ina-Respond",
         "Active, not recruiting",
         "Feb 2017",
         "Dec 2021",
         "Observational",
         "Apr 2016",
         "Tuberculosis",
         null
        ],
        [
         "NCT02754804",
         "University Hospital, Angers",
         "Completed",
         "Jul 2016",
         "Mar 2020",
         "Observational",
         "Apr 2016",
         "Peripheral Arterial Disease",
         null
        ],
        [
         "NCT02756065",
         "Washington University Early Recognition Center",
         "Completed",
         "Sep 2014",
         "Aug 2019",
         "Observational",
         "Jun 2015",
         "Schizophrenia,Bipolar Disorder",
         null
        ],
        [
         "NCT02756247",
         "Memorial Sloan Kettering Cancer Center",
         "Active, not recruiting",
         "May 2016",
         "May 2022",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         null
        ],
        [
         "NCT02755857",
         "Mayne Pharma International Pty Ltd",
         "Completed",
         "Jul 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         "Neutropenia",
         "Itraconazole"
        ],
        [
         "NCT02750111",
         "Dr. Orit Hamiel",
         "Unknown status",
         "May 2016",
         "May 2018",
         "Observational",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02755948",
         "Imperial College London",
         "Recruiting",
         "Apr 2012",
         "Mar 2023",
         "Interventional",
         "Apr 2016",
         "Influenza,Virus Diseases,Respiratory Syncytial Virus Infections",
         null
        ],
        [
         "NCT02754089",
         "Shiraz University of Medical Sciences",
         "Completed",
         "May 2016",
         "Sep 2016",
         "Interventional",
         "Apr 2016",
         "Body Weight",
         null
        ],
        [
         "NCT02756169",
         "Universidad Iberoamericana A.C., Mexico",
         "Completed",
         "Jul 2016",
         "Feb 2018",
         "Interventional",
         "Apr 2016",
         "Obesity",
         null
        ],
        [
         "NCT02757664",
         "Federal University of São Paulo",
         "Completed",
         "Feb 2017",
         "Jun 2020",
         "Interventional",
         "Apr 2016",
         "Tendinopathy",
         null
        ],
        [
         "NCT02757989",
         "Groupe Francophone des Myelodysplasies",
         "Active, not recruiting",
         "May 2016",
         "Jun 2024",
         "Interventional",
         "Mar 2016",
         "Preleukemia,Myelodysplastic Syndromes",
         null
        ],
        [
         "NCT02755038",
         "Bnai Zion Medical Center",
         "Unknown status",
         "Mar 2016",
         "Mar 2017",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759354",
         "MCM Vaccines B.V.",
         "Completed",
         "Apr 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Hepatitis A,Hepatitis B,Whooping Cough,Hepatitis",
         null
        ],
        [
         "NCT02750254",
         "Washington University School of Medicine",
         "Terminated",
         "Jun 2016",
         "Oct 2020",
         "Interventional",
         "Apr 2016",
         "Leukemia,Precursor Cell Lymphoblastic Leukemia-Lymphoma,Myelodysplastic Syndromes",
         "Plerixafor,Cyclophosphamide,Melphalan,Busulfan,Fludarabine,Azacitidine,Lenograstim,Sargramostim"
        ],
        [
         "NCT02755025",
         "Mayo Clinic",
         "Completed",
         "Jul 2016",
         "Aug 2016",
         "Observational",
         "Mar 2016",
         "Sepsis",
         null
        ],
        [
         "NCT02757703",
         "Kaohsiung Veterans General Hospital.",
         "Completed",
         "May 2010",
         "Jan 2015",
         "Interventional",
         "Apr 2016",
         "Hemorrhage",
         "Terlipressin,Pantoprazole,Somatostatin"
        ],
        [
         "NCT02758899",
         "Washington University School of Medicine",
         "Terminated",
         "Mar 2014",
         "Aug 2016",
         "Observational",
         "Apr 2016",
         "Spondylosis,Spinal Cord Diseases,Diabetes Mellitus",
         null
        ],
        [
         "NCT02751450",
         "GlaxoSmithKline",
         "Completed",
         "Feb 2016",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         "Dentin Sensitivity,Hypersensitivity",
         "Fluorides,Tin Fluorides,Fluorophosphate"
        ],
        [
         "NCT02759497",
         "Tanta University",
         "Unknown status",
         "Mar 2016",
         "Nov 2020",
         "Observational",
         "May 2016",
         "Peritonitis",
         null
        ],
        [
         "NCT02750826",
         "Alliance for Clinical Trials in Oncology",
         "Active, not recruiting",
         "Aug 2016",
         null,
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms,Weight Loss",
         null
        ],
        [
         "NCT02750631",
         "New York State Psychiatric Institute",
         "Completed",
         "Apr 2014",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Depression,Depressive Disorder",
         null
        ],
        [
         "NCT02756182",
         "Laborie Medical Technologies Inc.",
         "Completed",
         "Apr 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754583",
         "University of California, San Francisco",
         "Recruiting",
         "Dec 2015",
         "Aug 2024",
         "Interventional",
         "Oct 2015",
         "Trachoma",
         "Azithromycin,Tetracycline"
        ],
        [
         "NCT02750020",
         "The University of Hong Kong",
         "Completed",
         "Feb 2016",
         "Sep 2016",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759978",
         "University Medical Center Groningen",
         "Recruiting",
         "May 2016",
         "May 2023",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Endocarditis",
         null
        ],
        [
         "NCT02759575",
         "Vinita Takiar",
         "Completed",
         "Apr 2016",
         "Feb 2021",
         "Interventional",
         "Apr 2016",
         "Carcinoma,Squamous Cell Carcinoma of Head and Neck",
         "Pembrolizumab"
        ],
        [
         "NCT02750878",
         "Boston Urogynecology Associates",
         "Unknown status",
         "Nov 2015",
         "Jul 2020",
         "Interventional",
         "Apr 2016",
         "Urinary Incontinence,Enuresis",
         null
        ],
        [
         "NCT02758600",
         "Federal University of São Paulo",
         "Unknown status",
         "Mar 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Myocardial Infarction,Infarction",
         null
        ],
        [
         "NCT02750657",
         "University Health Network, Toronto",
         "Active, not recruiting",
         "Dec 2015",
         "Dec 2021",
         "Observational",
         "Jan 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02750007",
         "Jiangsu Hansoh Pharmaceutical Co., Ltd.",
         "Unknown status",
         "Dec 2015",
         null,
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02750462",
         "University Hospital Schleswig-Holstein",
         "Completed",
         "Nov 2016",
         "Sep 2019",
         "Interventional",
         "Apr 2016",
         "Heart Arrest,Out-of-Hospital Cardiac Arrest",
         null
        ],
        [
         "NCT02755597",
         "AbbVie",
         "Suspended",
         "Jul 2016",
         "Feb 2022",
         "Interventional",
         "Apr 2016",
         "Multiple Myeloma,Neoplasms",
         "Dexamethasone,Bortezomib,Venetoclax"
        ],
        [
         "NCT02754232",
         "Odense University Hospital",
         "Withdrawn",
         "Aug 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Pulmonary Disease,Chronic Disease",
         null
        ],
        [
         "NCT02751515",
         "Bayer",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         null
        ],
        [
         "NCT02758080",
         "Seoul National University Hospital",
         "Unknown status",
         "Jan 2016",
         "Jun 2019",
         "Interventional",
         "Apr 2016",
         "Neoplasms,Hematologic Neoplasms",
         null
        ],
        [
         "NCT02756312",
         "Beijing Tiantan Hospital",
         "Not yet recruiting",
         "Oct 2020",
         "Dec 2022",
         "Interventional",
         "Apr 2016",
         "Glioma",
         "Anesthetics"
        ],
        [
         "NCT02759107",
         "Eli Lilly and Company",
         "Completed",
         "May 2016",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Dulaglutide,Tirzepatide"
        ],
        [
         "NCT02758795",
         "University of Limerick",
         "Completed",
         "Feb 2016",
         "Apr 2017",
         "Interventional",
         "Feb 2016",
         "Inflammation",
         null
        ],
        [
         "NCT02757859",
         "Sidney Kimmel Cancer Center at Thomas Jefferson University",
         "Recruiting",
         "Apr 2016",
         "Jan 2022",
         "Interventional",
         "Apr 2016",
         "Adenocarcinoma,Cholangiocarcinoma,Carcinoma,Pancreatic Intraductal Neoplasms",
         "Pancrelipase,Pancreatin"
        ],
        [
         "NCT02750800",
         "AbbVie",
         "Completed",
         "Apr 2016",
         "Apr 2018",
         "Observational",
         "Apr 2016",
         "Spondylitis,Arthritis,Crohn Disease,Colitis,Inflammatory Bowel Diseases,Psoriasis",
         "Adalimumab"
        ],
        [
         "NCT02754167",
         "Pieris Pharmaceuticals GmbH",
         "Unknown status",
         "Jun 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Kidney Diseases,Renal Insufficiency",
         null
        ],
        [
         "NCT02758379",
         "Shockwave Medical, Inc.",
         "Completed",
         "Jul 2014",
         "Mar 2016",
         "Interventional",
         "Jan 2015",
         "Coronary Stenosis",
         null
        ],
        [
         "NCT02755740",
         "The University of Hong Kong",
         "Completed",
         "Jul 2015",
         "Aug 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751008",
         "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",
         "Completed",
         "Apr 2016",
         "Jun 2018",
         "Observational",
         "Apr 2016",
         "Osteoporosis",
         null
        ],
        [
         "NCT02756390",
         "Dana-Farber Cancer Institute",
         "Completed",
         "Dec 2015",
         "May 2018",
         "Interventional",
         "Apr 2016",
         "Sleep Initiation and Maintenance Disorders",
         null
        ],
        [
         "NCT02753075",
         "GlaxoSmithKline",
         "Completed",
         "Sep 2015",
         "Dec 2015",
         "Interventional",
         "Apr 2016",
         "Dentin Sensitivity,Hypersensitivity",
         "Fluorides"
        ],
        [
         "NCT02753465",
         "Fudan University",
         "Unknown status",
         "Apr 2016",
         "Dec 2019",
         "Interventional",
         "Apr 2016",
         "Rectal Neoplasms",
         null
        ],
        [
         "NCT02750852",
         "Azienda Ospedaliera Bolognini di Seriate Bergamo",
         "Unknown status",
         "Apr 2016",
         "May 2016",
         "Observational",
         "Apr 2016",
         "Hemorrhage",
         null
        ],
        [
         "NCT02753088",
         "Biocad",
         "Completed",
         "Oct 2013",
         "Nov 2015",
         "Interventional",
         "Apr 2016",
         "Multiple Sclerosis,Sclerosis",
         "Glatiramer Acetate,Mannitol,(T"
        ],
        [
         "NCT02758626",
         "NYU Langone Health",
         "Completed",
         "Nov 2016",
         "Feb 2021",
         "Interventional",
         "Apr 2016",
         "Epilepsy,Epilepsies",
         null
        ],
        [
         "NCT02757222",
         "Tata Medical Center",
         "Recruiting",
         "Jan 2016",
         "Dec 2022",
         "Interventional",
         "Mar 2016",
         "Neoplasms,Oropharyngeal Neoplasms,Hypopharyngeal Neoplasms,Laryngeal Neoplasms,Laryngeal Diseases",
         null
        ],
        [
         "NCT02750150",
         "University Hospital, Lille",
         "Completed",
         "Jul 2013",
         "Jan 2016",
         "Interventional",
         "Apr 2016",
         "Hemostatic Disorders,Blood Coagulation Disorders,Wounds and Injuries",
         null
        ],
        [
         "NCT02752776",
         "Novartis Pharmaceuticals",
         "Completed",
         "Mar 2016",
         "Mar 2018",
         "Interventional",
         "Feb 2016",
         "Psoriasis",
         null
        ],
        [
         "NCT02752984",
         "IRCCS Policlinico S. Matteo",
         "Unknown status",
         "Apr 2016",
         "Jun 2018",
         "Observational",
         "Apr 2016",
         "Thrombosis,Venous Thrombosis",
         null
        ],
        [
         "NCT02755272",
         "Fox Chase Cancer Center",
         "Recruiting",
         "May 2016",
         "Apr 2024",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms,Triple Negative Breast Neoplasms",
         "Gemcitabine,Carboplatin,Pembrolizumab"
        ],
        [
         "NCT02753192",
         "Centre National de la Recherche Scientifique, France",
         "Unknown status",
         "Jan 2014",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Parkinson Disease,Dysarthria,Disease Progression",
         null
        ],
        [
         "NCT02750189",
         "Konkuk University Medical Center",
         "Completed",
         "Sep 2015",
         "Jan 2017",
         "Observational",
         "Mar 2016",
         "Lung Diseases,Pulmonary Disease",
         null
        ],
        [
         "NCT02756338",
         "Biotronik, Inc.",
         "Completed",
         "Jun 2016",
         "Jul 2017",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759809",
         "The Hospital for Sick Children",
         "Completed",
         "Jun 2016",
         "Jul 2018",
         "Observational",
         "Apr 2016",
         "Birth Weight",
         null
        ],
        [
         "NCT02758431",
         "University of Colorado, Denver",
         "Recruiting",
         "Feb 2016",
         "Nov 2022",
         "Interventional",
         "Apr 2016",
         "Hypogonadism",
         "Methyltestosterone,Anastrozole,Testosterone,Testosterone undecanoate,Testosterone enanthate,Testosterone 17 beta-cypionate,Aromatase Inhibitors,Acyline,Hormone Antagonists"
        ],
        [
         "NCT02756962",
         "Washington University School of Medicine",
         "Recruiting",
         "Jul 2016",
         "Jul 2024",
         "Interventional",
         "Apr 2016",
         null,
         "Cytarabine"
        ],
        [
         "NCT02752919",
         "Eli Lilly and Company",
         "Completed",
         "Apr 2016",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759705",
         "Hospices Civils de Lyon",
         "Withdrawn",
         "Sep 2017",
         "May 2018",
         "Observational",
         "Apr 2016",
         "Bladder Exstrophy",
         null
        ],
        [
         "NCT02753478",
         "Catharina Ziekenhuis Eindhoven",
         "Completed",
         "Jun 2016",
         "Nov 2016",
         "Interventional",
         "Apr 2016",
         "Myocardial Infarction,Infarction,Hypothermia",
         null
        ],
        [
         "NCT02753413",
         "GlaxoSmithKline",
         "Completed",
         "Apr 2016",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         "Respiratory Syncytial Virus Infections",
         null
        ],
        [
         "NCT02759510",
         "RenJi Hospital",
         "Unknown status",
         "Jun 2016",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         "Cardiac Output",
         "Phenylephrine,Oxymetazoline,Norepinephrine"
        ],
        [
         "NCT02756130",
         "Jonsson Comprehensive Cancer Center",
         "Withdrawn",
         "Aug 2018",
         "Feb 2021",
         "Interventional",
         "Apr 2016",
         "Carcinoma,Adenocarcinoma,Ovarian Neoplasms,Cystadenocarcinoma",
         "Carboplatin"
        ],
        [
         "NCT02750124",
         "Karolinska Institutet",
         "Active, not recruiting",
         "Mar 2016",
         "Dec 2021",
         "Interventional",
         "Mar 2016",
         "Uterine Cervical Neoplasms",
         null
        ],
        [
         "NCT02755610",
         "Chulalongkorn University",
         "Unknown status",
         "May 2016",
         "Apr 2019",
         "Interventional",
         "Feb 2016",
         "Peritonitis,Kidney Diseases,Kidney Failure",
         null
        ],
        [
         "NCT02759328",
         "Ankara University",
         "Completed",
         "Dec 2012",
         "Mar 2014",
         "Interventional",
         "Apr 2016",
         "Stroke",
         null
        ],
        [
         "NCT02753608",
         "Jena University Hospital",
         "Completed",
         "Jun 2016",
         "Mar 2018",
         "Interventional",
         "Mar 2016",
         "Pneumonia",
         null
        ],
        [
         "NCT02751944",
         "ESM Technologies, LLC",
         "Completed",
         "Dec 2015",
         "Jan 2016",
         "Interventional",
         "Apr 2016",
         "Arthralgia",
         null
        ],
        [
         "NCT02750748",
         "National Institute on Drug Abuse (NIDA)",
         "Completed",
         "Jul 2016",
         "Sep 2016",
         "Interventional",
         "Apr 2016",
         "Opioid-Related Disorders",
         "Naltrexone"
        ],
        [
         "NCT02758405",
         "Samuel Lunenfeld Research Institute, Mount Sinai Hospital",
         "Completed",
         "May 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Labor Pain",
         "Fentanyl,Bupivacaine"
        ],
        [
         "NCT02753829",
         "Ágata Sofia da Silva Vieira",
         "Completed",
         "Sep 2013",
         "Jul 2015",
         "Interventional",
         "Apr 2016",
         "Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Heart Diseases,Infarction",
         null
        ],
        [
         "NCT02751788",
         "Pennington Biomedical Research Center",
         "Completed",
         "Apr 2016",
         "Jun 2018",
         "Observational",
         "Apr 2016",
         "Pediatric Obesity",
         null
        ],
        [
         "NCT02753010",
         "Uppsala University",
         "Completed",
         "Mar 2011",
         "Mar 2016",
         "Observational",
         "Apr 2016",
         "Gastroparesis,Fractures,Hip Fractures",
         null
        ],
        [
         "NCT02750969",
         "HaEmek Medical Center, Israel",
         "Unknown status",
         "Apr 2016",
         "Feb 2019",
         "Interventional",
         "Mar 2016",
         "Tinnitus",
         "Lidocaine"
        ],
        [
         "NCT02755831",
         "United States Naval Medical Center, San Diego",
         "Completed",
         "Feb 2017",
         "Oct 2019",
         "Interventional",
         "Mar 2016",
         "Apnea,Sleep Apnea Syndromes,Sleep Apnea",
         null
        ],
        [
         "NCT02752009",
         "Dana-Farber Cancer Institute",
         "Withdrawn",
         "Apr 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02758990",
         "Verifomics LLC",
         "Terminated",
         "Mar 2016",
         "Nov 2016",
         "Interventional",
         "Apr 2016",
         "Rhinitis,Arthralgia,Dyspnea,Sleep Deprivation,Migraine Disorders,Sleep Initiation and Maintenance Disorders,Disease,Headache,Respiratory Sounds",
         "Vitamin D,Cholecalciferol,Vitamins,Ascorbic Acid,Vitamin E,Tocopherols,Vitamin A,Niacinamide,Niacin,Nicotinic Acids,Pyridoxine,Pyridoxal,Vitamin B 6,Caffeine"
        ],
        [
         "NCT02754193",
         "Central Hospital, Nancy, France",
         "Completed",
         "Oct 2016",
         "Nov 2019",
         "Interventional",
         "Apr 2016",
         "Shock,Hypothermia",
         null
        ],
        [
         "NCT02758613",
         "Eli Lilly and Company",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751047",
         "Seoul National University Hospital",
         "Completed",
         "May 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02758197",
         "Ottawa Hospital Research Institute",
         "Completed",
         "Jul 2016",
         "Oct 2020",
         "Interventional",
         "Apr 2016",
         "Neuralgia,Chronic Pain",
         null
        ],
        [
         "NCT02753270",
         "University of Sao Paulo",
         "Completed",
         "Dec 2014",
         "Apr 2017",
         "Interventional",
         "Apr 2016",
         "Varicose Veins",
         null
        ],
        [
         "NCT02750839",
         "Azienda Ospedaliera Bolognini di Seriate Bergamo",
         "Unknown status",
         "Apr 2016",
         "Apr 2016",
         "Observational",
         "Apr 2016",
         "Osteoporosis,Fractures,Humeral Fractures",
         null
        ],
        [
         "NCT02750488",
         "Bayer",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         null
        ],
        [
         "NCT02752958",
         "GlaxoSmithKline",
         "Completed",
         "May 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Dentin Sensitivity,Hypersensitivity",
         "Fluorides,Tin Fluorides"
        ],
        [
         "NCT02753322",
         "The Queen Elizabeth Hospital",
         "Unknown status",
         "Apr 2016",
         "Mar 2018",
         "Interventional",
         "Apr 2016",
         "Stroke",
         null
        ],
        [
         "NCT02757261",
         "University of Nove de Julho",
         "Unknown status",
         "Jun 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Bruxism,Sleep Bruxism",
         "Salicylic Acid"
        ],
        [
         "NCT02754427",
         "University of British Columbia",
         "Completed",
         "Feb 2013",
         "Aug 2015",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02758366",
         "Meyer Children's Hospital",
         "Terminated",
         "Feb 2016",
         "Jan 2020",
         "Interventional",
         "Apr 2016",
         "Glioblastoma,Glioma,Astrocytoma,Diffuse Intrinsic Pontine Glioma,Neoplasms",
         "Doxorubicin"
        ],
        [
         "NCT02755402",
         "Centre hospitalier de l'Université de Montréal (CHUM)",
         "Completed",
         "Jan 2017",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Hepatitis C",
         null
        ],
        [
         "NCT02754453",
         "The Cleveland Clinic",
         "Withdrawn",
         "Jul 2013",
         "Oct 2015",
         "Interventional",
         "Sep 2013",
         "Body Weight,Weight Loss",
         null
        ],
        [
         "NCT02755103",
         "Medical University of South Carolina",
         "Active, not recruiting",
         "Jun 2016",
         "Oct 2021",
         "Interventional",
         "Apr 2016",
         "Disease,Substance-Related Disorders,Stress Disorders",
         null
        ],
        [
         "NCT02758834",
         "Università Politecnica delle Marche",
         "Completed",
         "Jan 2014",
         "Apr 2016",
         "Observational",
         "Apr 2016",
         "Liver Diseases",
         null
        ],
        [
         "NCT02759146",
         "Michigan State University",
         "Completed",
         "May 2016",
         "Nov 2019",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754414",
         "Bloodworks",
         "Unknown status",
         "Apr 2016",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759783",
         "Royal Marsden NHS Foundation Trust",
         "Active, not recruiting",
         "Nov 2016",
         "Oct 2024",
         "Interventional",
         "Apr 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02756923",
         "Weill Medical College of Cornell University",
         "Suspended",
         "Apr 2012",
         "Dec 2025",
         "Observational",
         "Apr 2016",
         "Infertility",
         null
        ],
        [
         "NCT02759237",
         "Medtronic Cardiovascular",
         "Terminated",
         "Feb 2016",
         "May 2017",
         "Observational",
         "Apr 2016",
         "Aortic Valve Stenosis",
         null
        ],
        [
         "NCT02757391",
         "M.D. Anderson Cancer Center",
         "Terminated",
         "Aug 2019",
         "Oct 2020",
         "Interventional",
         "Apr 2016",
         "Carcinoma,Colorectal Neoplasms,Adenocarcinoma,Stomach Neoplasms,Esophageal Neoplasms,Cholangiocarcinoma",
         "Aldesleukin,Cyclophosphamide,Pembrolizumab,Interleukin-2,Immunologic Factors"
        ],
        [
         "NCT02750904",
         "Fred Hutchinson Cancer Research Center",
         "Completed",
         "Apr 2017",
         "May 2019",
         "Interventional",
         "Mar 2016",
         "Disease,Bipolar Disorder",
         "Nicotine"
        ],
        [
         "NCT02758418",
         "Universitat Jaume I",
         "Unknown status",
         "Apr 2016",
         "Jul 2019",
         "Interventional",
         "Apr 2016",
         "Adjustment Disorders",
         null
        ],
        [
         "NCT02756039",
         "AstraZeneca",
         "Completed",
         "May 2016",
         "Aug 2018",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755077",
         "Massachusetts General Hospital",
         "Completed",
         "Jul 2014",
         "Jan 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751801",
         "Sheffield Teaching Hospitals NHS Foundation Trust",
         "Completed",
         "Nov 2016",
         "Dec 2017",
         "Observational",
         "Apr 2016",
         "Hypophosphatasia",
         null
        ],
        [
         "NCT02751177",
         "Institut de Cancérologie de Lorraine",
         "Completed",
         "Mar 2016",
         "May 2017",
         "Interventional",
         "Mar 2016",
         "Colorectal Neoplasms",
         null
        ],
        [
         "NCT02758574",
         "University of Pittsburgh",
         "Completed",
         "May 2016",
         "Aug 2021",
         "Interventional",
         "Mar 2016",
         "Pulmonary Embolism,Embolism",
         null
        ],
        [
         "NCT02758587",
         "NHS Greater Glasgow and Clyde",
         "Recruiting",
         "Jul 2017",
         "Dec 2021",
         "Interventional",
         "Apr 2016",
         "Mesothelioma,Carcinoma,Pancreatic Neoplasms",
         "Pembrolizumab"
        ],
        [
         "NCT02752100",
         "Third Military Medical University",
         "Unknown status",
         "Mar 2016",
         "May 2020",
         "Interventional",
         "Mar 2016",
         "Arterial Occlusive Diseases",
         null
        ],
        [
         "NCT02755818",
         "University of California, Davis",
         "Terminated",
         "Oct 2008",
         "Feb 2019",
         "Observational",
         "Mar 2016",
         "Insulin Resistance",
         "Heparin,Calcium heparin"
        ],
        [
         "NCT02752906",
         "Sanofi Pasteur, a Sanofi Company",
         "Completed",
         "Apr 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Meningococcal Infections,Meningitis",
         "Vaccines"
        ],
        [
         "NCT02750371",
         "University Hospital, Bordeaux",
         "Active, not recruiting",
         "Jul 2016",
         "Oct 2021",
         "Interventional",
         "Apr 2016",
         "Adenoma,Meningioma,Pituitary Neoplasms,Pituitary Diseases",
         null
        ],
        [
         "NCT02751125",
         "University of Bergen",
         "Completed",
         "Jun 2014",
         "Mar 2020",
         "Interventional",
         "Mar 2016",
         "Atrophy",
         null
        ],
        [
         "NCT02754700",
         "High Point University",
         "Completed",
         "Apr 2016",
         "Feb 2019",
         "Interventional",
         "Apr 2016",
         "Knee Injuries",
         null
        ],
        [
         "NCT02756442",
         "Assistance Publique Hopitaux De Marseille",
         "Unknown status",
         "Apr 2016",
         "Apr 2019",
         "Interventional",
         "Apr 2016",
         "Respiration Disorders,Respiratory Tract Diseases,Diabetes",
         null
        ],
        [
         "NCT02756637",
         "Abramson Cancer Center of the University of Pennsylvania",
         "Completed",
         "Apr 2016",
         "Nov 2016",
         "Observational",
         "Apr 2016",
         "Urinary Bladder Neoplasms",
         null
        ],
        [
         "NCT02755688",
         "Royal Brompton & Harefield NHS Foundation Trust",
         "Unknown status",
         "Jun 2015",
         "Mar 2020",
         "Interventional",
         "Apr 2016",
         "Atrial Fibrillation",
         null
        ],
        [
         "NCT02753387",
         "Rennes University Hospital",
         "Completed",
         "May 2016",
         "Sep 2018",
         "Interventional",
         "Apr 2016",
         "Bacterial Infections,Head and Neck Neoplasms",
         "Chlorhexidine"
        ],
        [
         "NCT02758470",
         "University of British Columbia",
         "Completed",
         "Nov 2016",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         "Fatigue,Hypoxia",
         "Acetazolamide,Methazolamide"
        ],
        [
         "NCT02754375",
         "Centre Hospitalier Universitaire de Nice",
         "Unknown status",
         "May 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Depression,Depressive Disorder",
         null
        ],
        [
         "NCT02758756",
         "University of Rochester",
         "Completed",
         "Jun 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Fatigue",
         null
        ],
        [
         "NCT02750787",
         "Abbott Nutrition",
         "Completed",
         "Aug 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Malabsorption Syndromes",
         null
        ],
        [
         "NCT02757339",
         "Mclean Hospital",
         "Enrolling by invitation",
         "Jun 2015",
         "May 2022",
         "Observational",
         "Mar 2016",
         "Disease,Stress Disorders,Dissociative Disorders,Dissociative Identity Disorder",
         null
        ],
        [
         "NCT02753959",
         "Guy's and St Thomas' NHS Foundation Trust",
         "Completed",
         "Aug 2016",
         "Sep 2019",
         "Interventional",
         "Apr 2016",
         "Neuromuscular Diseases",
         null
        ],
        [
         "NCT02753426",
         "University of California, San Francisco",
         "Completed",
         "Apr 2016",
         "Jan 2018",
         "Interventional",
         "Apr 2016",
         "Kidney Diseases,Renal Insufficiency,Cardio-Renal Syndrome",
         "Doxycycline"
        ],
        [
         "NCT02757183",
         "AnalyticsPlus, Inc.",
         "Unknown status",
         "Apr 2016",
         "Mar 2017",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750293",
         "University of Tromso",
         "Completed",
         "Jun 2015",
         "Sep 2017",
         "Interventional",
         "Apr 2016",
         "Vitamin D Deficiency",
         "Cholecalciferol"
        ],
        [
         "NCT02757274",
         "European Association of Urology Research Foundation",
         "Recruiting",
         "Feb 2017",
         "Jul 2027",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Urinary Incontinence,Enuresis",
         null
        ],
        [
         "NCT02756741",
         "All India Institute of Medical Sciences, New Delhi",
         "Completed",
         "Apr 2014",
         "Jul 2015",
         "Interventional",
         "Apr 2016",
         "Peritonitis,Fibrosis",
         null
        ],
        [
         "NCT02758964",
         "Charite University, Berlin, Germany",
         "Completed",
         "Sep 2016",
         "Jan 2019",
         "Observational",
         "Apr 2016",
         "Intracranial Embolism,Embolism,Aortic Valve Stenosis",
         null
        ],
        [
         "NCT02753439",
         "The Baruch Padeh Medical Center, Poriya",
         "Unknown status",
         "Feb 2017",
         "Feb 2019",
         "Interventional",
         "Mar 2016",
         "Tooth",
         null
        ],
        [
         "NCT02751281",
         "Isfahan University of Medical Sciences",
         "Completed",
         "Dec 2014",
         "Apr 2016",
         "Interventional",
         "Apr 2016",
         "Kidney Calculi,Nephrolithiasis",
         null
        ],
        [
         "NCT02756676",
         "Ospedale Generale Di Zona Moriggia-Pelascini",
         "Completed",
         "Apr 2015",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Parkinson Disease",
         null
        ],
        [
         "NCT02750215",
         "Massachusetts General Hospital",
         "Completed",
         "May 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02755935",
         "Cochlear",
         "Completed",
         "May 2016",
         "Sep 2017",
         "Interventional",
         "Apr 2016",
         "Hearing Loss",
         null
        ],
        [
         "NCT02759523",
         "Penn State University",
         "Completed",
         "Jul 2013",
         "Dec 2015",
         "Observational",
         "Apr 2016",
         "Pediatric Obesity",
         null
        ],
        [
         "NCT02756533",
         "University Hospital, Grenoble",
         "Recruiting",
         "Aug 2016",
         "Aug 2021",
         "Interventional",
         "Mar 2016",
         "Lung Diseases,Pulmonary Disease,Signs and Symptoms",
         null
        ],
        [
         "NCT02752841",
         "Brown University",
         "Terminated",
         "May 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Kidney Calculi,Calculi",
         "Vitamin D"
        ],
        [
         "NCT02758392",
         "Janssen Research & Development, LLC",
         "Completed",
         "Apr 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755870",
         "Clene Nanomedicine",
         "Completed",
         "Apr 2015",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02752464",
         "Boston Medical Center",
         "Completed",
         "Sep 2016",
         "Jun 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756780",
         "Royal Marsden NHS Foundation Trust",
         "Unknown status",
         "Apr 2016",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753998",
         "Assistance Publique - Hôpitaux de Paris",
         "Active, not recruiting",
         "Dec 2016",
         "Sep 2021",
         "Interventional",
         "Apr 2016",
         "Arteriovenous Fistula,Constriction,Fistula",
         "Paclitaxel"
        ],
        [
         "NCT02751307",
         "Taipei Medical University WanFang Hospital",
         "Completed",
         "May 2013",
         "Jan 2015",
         "Interventional",
         "Apr 2016",
         "Congenital Abnormalities,Metabolic Syndrome,Schizophrenia",
         "Metformin,Clozapine"
        ],
        [
         "NCT02757755",
         "Armata Pharmaceuticals, Inc.",
         "Completed",
         "May 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753972",
         "University of New Mexico",
         "Completed",
         "Aug 2006",
         "Jan 2008",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751853",
         "University of Luebeck",
         "Unknown status",
         "Dec 2016",
         "Aug 2020",
         "Interventional",
         "Apr 2016",
         "Heart Failure",
         null
        ],
        [
         "NCT02752971",
         "Hospital Central Dr. Luis Ortega",
         "Completed",
         "Feb 2015",
         null,
         "Interventional",
         "Mar 2016",
         "Pain",
         "Diclofenac,Bupivacaine"
        ],
        [
         "NCT02755012",
         "McGill University",
         "Completed",
         "Jun 2012",
         "Nov 2013",
         "Observational",
         "Apr 2016",
         "Infections,Mastitis,Malnutrition,Infant Nutrition Disorders,Growth Disorders,Stress",
         null
        ],
        [
         "NCT02751996",
         "F-star Therapeutics, Inc.",
         "Completed",
         "May 2016",
         "Feb 2020",
         "Interventional",
         "Apr 2016",
         "Hepatitis A,Hepatitis B,Hepatitis",
         "Tenofovir"
        ],
        [
         "NCT02752893",
         "Dartmouth-Hitchcock Medical Center",
         "Completed",
         "Jan 2017",
         "Apr 2019",
         "Observational",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02753842",
         "Global Protection Corp.",
         "Completed",
         "May 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757040",
         "Peking University People's Hospital",
         "Unknown status",
         "Dec 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Leukemia",
         "Arsenic Trioxide"
        ],
        [
         "NCT02751606",
         "Radboud University",
         "Unknown status",
         "Jun 2015",
         "Nov 2019",
         "Interventional",
         "Nov 2014",
         "Neoplasms,Breast Neoplasms,Rectal Neoplasms",
         null
        ],
        [
         "NCT02751372",
         "Bayer",
         "Completed",
         "May 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753764",
         "National Jewish Health",
         "Completed",
         "Jan 2017",
         "Feb 2019",
         "Interventional",
         "Apr 2016",
         "Asthma",
         "Prednisone,AZD7624"
        ],
        [
         "NCT02758938",
         "University of Wisconsin, Madison",
         "Completed",
         "Jun 2016",
         "Sep 2018",
         "Interventional",
         "Dec 2015",
         "Lower Urinary Tract Symptoms",
         null
        ],
        [
         "NCT02752399",
         "Federal University of São Paulo",
         "Unknown status",
         "Apr 2016",
         "Jun 2017",
         "Observational",
         "Apr 2016",
         "Hypertension,Heart Defects,Eisenmenger Complex",
         null
        ],
        [
         "NCT02753296",
         "University of Sheffield",
         "Unknown status",
         "May 2016",
         "Jun 2018",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759432",
         "Teesside University",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750137",
         "KK Women's and Children's Hospital",
         "Completed",
         "Aug 2014",
         "May 2015",
         "Observational",
         "Apr 2016",
         "Drug-Related Side Effects and Adverse Reactions",
         "Tetracaine"
        ],
        [
         "NCT02754466",
         "University of Brasilia",
         "Terminated",
         "May 2017",
         "Sep 2021",
         "Interventional",
         "Apr 2016",
         "Dental Caries",
         null
        ],
        [
         "NCT02752191",
         "Paul Finn",
         "Recruiting",
         "Apr 2016",
         "Apr 2021",
         "Interventional",
         "Apr 2016",
         "Heart Diseases,Heart Defects",
         "Ferrosoferric Oxide"
        ],
        [
         "NCT02753517",
         "University Hospital, Lille",
         "Recruiting",
         "Dec 2015",
         "Nov 2023",
         "Interventional",
         "Apr 2016",
         "Liver Failure,Hepatic Insufficiency",
         null
        ],
        [
         "NCT02758054",
         "University of Texas Southwestern Medical Center",
         "Active, not recruiting",
         "Jun 2017",
         "Mar 2023",
         "Interventional",
         "Apr 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02757573",
         "Tampere University Hospital",
         "Active, not recruiting",
         "Apr 2016",
         "Dec 2022",
         "Interventional",
         "Apr 2016",
         "Hypercapnia",
         null
        ],
        [
         "NCT02752789",
         "National Institute of Allergy and Infectious Diseases (NIAID)",
         "Completed",
         "Jul 2014",
         "Nov 2019",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756416",
         "University of Nottingham",
         "Unknown status",
         "Jul 2016",
         "May 2017",
         "Interventional",
         "Mar 2016",
         "Syndrome",
         null
        ],
        [
         "NCT02758106",
         "Chung Shan Medical University",
         "Completed",
         "Feb 2014",
         "Nov 2015",
         "Interventional",
         "Apr 2016",
         "Respiratory Insufficiency",
         null
        ],
        [
         "NCT02759159",
         "Xuanwu Hospital, Beijing",
         "Unknown status",
         "Jun 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Alzheimer Disease",
         null
        ],
        [
         "NCT02753777",
         "University of Pennsylvania",
         "Recruiting",
         "Apr 2016",
         "Dec 2025",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Pemphigoid,Pemphigus",
         null
        ],
        [
         "NCT02754245",
         "Baylor Research Institute",
         "Unknown status",
         "Nov 2016",
         "Jul 2017",
         "Observational",
         "Apr 2016",
         "Emergencies",
         null
        ],
        [
         "NCT02754687",
         "Health Decisions",
         "Unknown status",
         "Apr 2016",
         "Jan 2020",
         "Interventional",
         "Mar 2016",
         null,
         "Nandrolone Decanoate,Nandrolone,Nandrolone phenpropionate"
        ],
        [
         "NCT02755337",
         "Dr. Soetomo General Hospital",
         "Unknown status",
         "Jan 2016",
         "Dec 2016",
         "Observational",
         "Apr 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02755090",
         "University of New Mexico",
         "Completed",
         "Jul 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         null,
         "Nitrous Oxide"
        ],
        [
         "NCT02751437",
         "Liverpool Women's NHS Foundation Trust",
         "Completed",
         "Aug 2016",
         "Mar 2018",
         "Interventional",
         "Mar 2016",
         "Premature Birth",
         null
        ],
        [
         "NCT02757950",
         "GlaxoSmithKline",
         "Completed",
         "Jul 2016",
         "May 2017",
         "Observational",
         "Apr 2016",
         "Diphtheria",
         null
        ],
        [
         "NCT02756754",
         "University Hospital, Toulouse",
         "Completed",
         "Nov 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Adenoma,Adrenocortical Adenoma,Hyperaldosteronism",
         null
        ],
        [
         "NCT02754726",
         "HonorHealth Research Institute",
         "Active, not recruiting",
         "Apr 2016",
         "Jun 2022",
         "Interventional",
         "Apr 2016",
         "Adenocarcinoma",
         "Gemcitabine,Paclitaxel,Nivolumab,Albumin-Bound Paclitaxel"
        ],
        [
         "NCT02759549",
         "Emory University",
         "Withdrawn",
         "Sep 2015",
         null,
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02755714",
         "Haukeland University Hospital",
         "Completed",
         "Jun 2016",
         "Oct 2020",
         "Interventional",
         "Apr 2016",
         null,
         "Bromides,Ipratropium"
        ],
        [
         "NCT02750358",
         "Memorial Sloan Kettering Cancer Center",
         "Active, not recruiting",
         "May 2016",
         "May 2022",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms,Triple Negative Breast Neoplasms",
         null
        ],
        [
         "NCT02754921",
         "Mohamed Sayed Mohamed Abbas",
         "Completed",
         "Jan 2013",
         null,
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755259",
         "University of Zurich",
         "Completed",
         "Jan 2017",
         "Apr 2019",
         "Interventional",
         "Mar 2016",
         "Hypertension",
         "Acetazolamide"
        ],
        [
         "NCT02759081",
         "Dalin Tzu Chi General Hospital",
         "Completed",
         "Jan 2015",
         null,
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755155",
         "University Hospital, Strasbourg, France",
         "Terminated",
         "Sep 2016",
         "Aug 2019",
         "Interventional",
         "Apr 2016",
         "Hypoalbuminemia,Syndrome,Systemic Inflammatory Response Syndrome",
         null
        ],
        [
         "NCT02758119",
         "Ilumens",
         "Completed",
         "Jun 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         "Heart Arrest,Out-of-Hospital Cardiac Arrest",
         null
        ],
        [
         "NCT02755415",
         "China Medical University Hospital",
         "Unknown status",
         "May 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Stroke",
         null
        ],
        [
         "NCT02751268",
         "Armed Forces Hampyeong Hospital",
         "Unknown status",
         "Apr 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Psychomotor Agitation,Emergence Delirium",
         "Ropivacaine"
        ],
        [
         "NCT02756572",
         "University of Washington",
         "Completed",
         "Sep 2016",
         "Jul 2020",
         "Interventional",
         "Apr 2016",
         "Leukemia,Neoplasms,Preleukemia,Myelodysplastic Syndromes,Anemia,Syndrome",
         "Cytarabine,Cyclosporine,Mycophenolic Acid,Sirolimus,Fludarabine,Fludarabine phosphate,Melphalan,Mechlorethamine,Mitoxantrone,Nitrogen Mustard Compounds,Cladribine,2-chloro-3-deoxyadenosine,Cyclosporins,Lenograstim"
        ],
        [
         "NCT02756871",
         "Institute of Child Health",
         "Completed",
         "Jul 2015",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750618",
         "Ultragenyx Pharmaceutical Inc",
         "Completed",
         "May 2016",
         "Sep 2019",
         "Interventional",
         "Dec 2015",
         "Familial Hypophosphatemic Rickets,Hypophosphatemia",
         null
        ],
        [
         "NCT02757196",
         "Peking University People's Hospital",
         "Unknown status",
         "May 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Thrombocytopenia,Purpura",
         "Methylprednisolone,Methylprednisolone Acetate,Methylprednisolone Hemisuccinate,Prednisolone,Prednisolone acetate,Rituximab,Prednisolone hemisuccinate,Prednisolone phosphate"
        ],
        [
         "NCT02758093",
         "University of Alabama at Birmingham",
         "Completed",
         "Sep 2016",
         "Mar 2020",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02750943",
         "GlaxoSmithKline",
         "Completed",
         "Nov 2015",
         "Mar 2016",
         "Interventional",
         "Nov 2015",
         "Gingivitis",
         "Fluorides,Tin Fluorides,Fluorophosphate"
        ],
        [
         "NCT02754908",
         "The University of Hong Kong",
         "Completed",
         "Jan 2016",
         "Jun 2018",
         "Interventional",
         "Apr 2016",
         "Brain Neoplasms",
         null
        ],
        [
         "NCT02750514",
         "Bristol-Myers Squibb",
         "Terminated",
         "May 2016",
         "Jan 2020",
         "Interventional",
         "Apr 2016",
         "Carcinoma",
         "Nivolumab,Ipilimumab,Dasatinib,Linrodostat"
        ],
        [
         "NCT02755350",
         "LVCT Health",
         "Unknown status",
         "Aug 2015",
         "Apr 2017",
         "Interventional",
         "Nov 2015",
         null,
         "Emtricitabine"
        ],
        [
         "NCT02753374",
         "Beijing Children's Hospital",
         "Not yet recruiting",
         "May 2016",
         "Jul 2030",
         "Observational",
         "Apr 2016",
         "Cystic Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT02759419",
         "Bayer",
         "Recruiting",
         "Jun 2016",
         "Dec 2023",
         "Interventional",
         "Apr 2016",
         "Pulmonary Arterial Hypertension,Hypertension",
         "Riociguat"
        ],
        [
         "NCT02757612",
         "Universidad de Murcia",
         "Completed",
         "Jun 2015",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Burning Mouth Syndrome,Syndrome,Burns",
         null
        ],
        [
         "NCT02754297",
         "CHU de Quebec-Universite Laval",
         "Recruiting",
         "Apr 2016",
         "Dec 2026",
         "Interventional",
         "Mar 2016",
         "Neoplasms,Neuroendocrine Tumors,Carcinoid Tumor,Carcinoma",
         "Lutetium Lu 177 dotatate"
        ],
        [
         "NCT02758665",
         "University of Ulm",
         "Active, not recruiting",
         "Sep 2016",
         "Mar 2022",
         "Interventional",
         "Apr 2016",
         "Leukemia",
         "Venetoclax,Obinutuzumab"
        ],
        [
         "NCT02755285",
         "Fujifilm Medical Systems USA, Inc.",
         "Completed",
         "Aug 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757690",
         "Asan Medical Center",
         "Completed",
         "Jan 2015",
         "Feb 2016",
         "Interventional",
         "Apr 2016",
         "Neoplasms,Brain Neoplasms",
         null
        ],
        [
         "NCT02753218",
         "LEO Pharma",
         "Terminated",
         "Apr 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Psoriasis",
         "Midazolam"
        ],
        [
         "NCT02754986",
         "University of Hyogo",
         "Completed",
         "Mar 2015",
         null,
         "Interventional",
         "Mar 2016",
         "Kidney Diseases,Renal Insufficiency",
         null
        ],
        [
         "NCT02752048",
         "Taiho Pharmaceutical Co., Ltd.",
         "Completed",
         "May 2016",
         "Oct 2017",
         "Interventional",
         "Apr 2016",
         "Muscular Dystrophies,Muscular Dystrophy",
         null
        ],
        [
         "NCT02752256",
         "University of Iowa",
         "Completed",
         "Oct 2015",
         "Oct 2017",
         "Observational",
         "Apr 2016",
         null,
         "Plasminogen,Tissue Plasminogen Activator"
        ],
        [
         "NCT02756936",
         "Genuine Research Center, Egypt",
         "Completed",
         "Feb 2016",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756000",
         "Clinical Hospital Center Zemun",
         "Unknown status",
         "Jan 2016",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         "Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Myocardial Infarction,Infarction",
         "Dobutamine"
        ],
        [
         "NCT02754492",
         "Terumo BCT",
         "Completed",
         "Apr 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757677",
         "Swiss Vision Network",
         "Unknown status",
         "Dec 2015",
         "Dec 2019",
         "Observational",
         "Apr 2016",
         "Glaucoma",
         null
        ],
        [
         "NCT02752373",
         "Brain Sentinel",
         "Terminated",
         "May 2016",
         "Feb 2017",
         "Observational",
         "Mar 2016",
         "Epilepsy,Seizures",
         null
        ],
        [
         "NCT02752230",
         "Kettering Health Network",
         "Withdrawn",
         "Nov 2016",
         "Jun 2021",
         "Interventional",
         "Mar 2016",
         "Pain",
         null
        ],
        [
         "NCT02756728",
         "BioInvent International AB",
         "Terminated",
         "May 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Multiple Myeloma,Neoplasms",
         "Melphalan"
        ],
        [
         "NCT02751658",
         "University Hospital, Montpellier",
         "Completed",
         "Nov 2016",
         "Jul 2019",
         "Interventional",
         "Mar 2016",
         "Otorhinolaryngologic Diseases",
         null
        ],
        [
         "NCT02754518",
         "University of Chicago",
         "Completed",
         "Apr 2016",
         "Apr 2019",
         "Interventional",
         "Apr 2016",
         "Heart Failure",
         "Valsartan,Sacubitril and valsartan sodium hydrate drug combination"
        ],
        [
         "NCT02759380",
         "Sahlgrenska University Hospital, Sweden",
         "Recruiting",
         "Mar 2016",
         "Oct 2022",
         "Interventional",
         "Apr 2016",
         "Prostatic Neoplasms",
         "Phytoestrogens"
        ],
        [
         "NCT02755649",
         "Regeneron Pharmaceuticals",
         "Completed",
         "Jan 2016",
         "Mar 2017",
         "Interventional",
         "Mar 2016",
         "Dermatitis,Eczema",
         null
        ],
        [
         "NCT02751827",
         "Institut Bergonié",
         "Completed",
         "Feb 2016",
         "Nov 2019",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755545",
         "Galderma Laboratories, L.P.",
         "Completed",
         "May 2016",
         "Apr 2017",
         "Interventional",
         "Apr 2016",
         "Acne Vulgaris",
         "Salicylic Acid,Adapalene,Salicylates"
        ],
        [
         "NCT02750345",
         "Cycle Pharmaceuticals Ltd.",
         "Completed",
         "Mar 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Tyrosinemias",
         "Nitisinone"
        ],
        [
         "NCT02755532",
         "Federal University of São Paulo",
         "Completed",
         "Jan 2014",
         "Oct 2015",
         "Interventional",
         "Apr 2016",
         null,
         "Bupivacaine"
        ],
        [
         "NCT02758743",
         "Biohit Oyj",
         "Completed",
         "Apr 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754947",
         "Nationwide Children's Hospital",
         "Completed",
         "Feb 2015",
         "Mar 2016",
         "Observational",
         "Apr 2016",
         "Respiration Disorders,Respiratory Tract Diseases,Nervous System Diseases,Cardiovascular Diseases",
         null
        ],
        [
         "NCT02750280",
         "Calvary Hospital, Bronx, NY",
         "Completed",
         "Jun 2015",
         "Dec 2015",
         "Interventional",
         "Apr 2016",
         "Diabetic Foot,Foot Ulcer,Ulcer",
         null
        ],
        [
         "NCT02756325",
         "NYU Langone Health",
         "Withdrawn",
         "Jun 2016",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Infertility",
         null
        ],
        [
         "NCT02758717",
         "Academic and Community Cancer Research United",
         "Active, not recruiting",
         "May 2016",
         "May 2024",
         "Interventional",
         "Apr 2016",
         "Lymphoma,Hodgkin Disease",
         "Antineoplastic Agents,Nivolumab,Brentuximab Vedotin,Antibodies,Immunoglobulins,Immunoconjugates"
        ],
        [
         "NCT02751034",
         "Medy-Tox",
         "Completed",
         "Jun 2013",
         "Jan 2014",
         "Interventional",
         "Apr 2015",
         null,
         "Lidocaine"
        ],
        [
         "NCT02751476",
         "Action Contre la Faim",
         "Unknown status",
         "Apr 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Malnutrition,Severe Acute Malnutrition,Protein-Energy Malnutrition",
         "Disinfectants"
        ],
        [
         "NCT02755454",
         "University Health Network, Toronto",
         "Completed",
         "Oct 2013",
         "Nov 2018",
         "Interventional",
         "Mar 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02752867",
         "Dongfang Hospital Beijing University of Chinese Medicine",
         "Unknown status",
         "Dec 2016",
         "Nov 2019",
         "Interventional",
         "Mar 2016",
         "Cerebral Infarction,Infarction,Cognitive Dysfunction",
         null
        ],
        [
         "NCT02754830",
         "Eli Lilly and Company",
         "Completed",
         "Apr 2016",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         "Alzheimer Disease",
         null
        ],
        [
         "NCT02753738",
         "Medical University of Vienna",
         "Unknown status",
         "Aug 2016",
         null,
         "Interventional",
         "Apr 2016",
         null,
         "Citalopram"
        ],
        [
         "NCT02750267",
         "University of Virginia",
         "Completed",
         "May 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02754999",
         "Prolong Pharmaceuticals",
         "Completed",
         "Mar 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Anemia",
         null
        ],
        [
         "NCT02754843",
         "Sonova AG",
         "Completed",
         "Oct 2015",
         null,
         "Interventional",
         "Oct 2015",
         "Hearing Loss",
         null
        ],
        [
         "NCT02759055",
         "HealthPartners Institute",
         "Completed",
         "Oct 2016",
         "Dec 2019",
         "Interventional",
         "Apr 2016",
         "Prediabetic State,Glucose Intolerance",
         null
        ],
        [
         "NCT02753673",
         "Memorial Sloan Kettering Cancer Center",
         "Completed",
         "Apr 2016",
         "Apr 2020",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754531",
         "Indonesia University",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750033",
         "Seton Healthcare Family",
         "Withdrawn",
         "Oct 2016",
         "Mar 2017",
         "Observational",
         "Apr 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02759133",
         "Centre Antoine Lacassagne",
         "Recruiting",
         "Jun 2016",
         "Nov 2022",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02756650",
         "Novartis Pharmaceuticals",
         "Completed",
         "Jun 2016",
         "Jan 2019",
         "Interventional",
         "Mar 2016",
         "Behcet Syndrome",
         null
        ],
        [
         "NCT02752152",
         "Institut de Recherche pour le Developpement",
         "Completed",
         "Dec 2015",
         "Oct 2020",
         "Interventional",
         "Apr 2016",
         "Hepatitis A,Hepatitis C,Hepatitis B,Syphilis,Hepatitis",
         null
        ],
        [
         "NCT02751385",
         "Boehringer Ingelheim",
         "Terminated",
         "May 2016",
         "Nov 2017",
         "Interventional",
         "Apr 2016",
         "Carcinoma",
         "Nintedanib,Ethinyl estradiol,Ethinyl Estradiol-Norgestrel Combination"
        ],
        [
         "NCT02751879",
         "Boehringer Ingelheim",
         "Completed",
         "Nov 2016",
         "Sep 2017",
         "Observational",
         "Apr 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02756663",
         "Novartis Pharmaceuticals",
         "Withdrawn",
         "Dec 2016",
         "Feb 2021",
         "Interventional",
         "Apr 2016",
         "Multiple Myeloma,Neoplasms",
         "Dexamethasone,Panobinostat"
        ],
        [
         "NCT02756273",
         "Centre Hospitalier Universitaire, Amiens",
         "Recruiting",
         "May 2016",
         "May 2022",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755974",
         "Imperial College London",
         "Unknown status",
         "Jan 2009",
         "Apr 2021",
         "Observational",
         "Apr 2016",
         "Lung Diseases,Pulmonary Disease",
         null
        ],
        [
         "NCT02756507",
         "Babes-Bolyai University",
         "Completed",
         "Jun 2016",
         "Jun 2018",
         "Interventional",
         "Apr 2016",
         "Disease,Depression,Anxiety Disorders,Panic Disorder",
         null
        ],
        [
         "NCT02750553",
         "Jiangsu HengRui Medicine Co., Ltd.",
         "Completed",
         "Jan 2015",
         null,
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750228",
         "Mednax Center for Research, Education, Quality and Safety",
         "Completed",
         "May 2016",
         "Jun 2020",
         "Observational",
         "Mar 2016",
         "Ductus Arteriosus",
         null
        ],
        [
         "NCT02751710",
         "Ontario Clinical Oncology Group (OCOG)",
         "Recruiting",
         "Dec 2016",
         "Dec 2022",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT02753361",
         "Suez Canal University",
         "Completed",
         "May 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Lipoma",
         null
        ],
        [
         "NCT02753634",
         "Lawson Health Research Institute",
         "Completed",
         "Apr 2015",
         "Jun 2016",
         "Interventional",
         "Mar 2016",
         "Osteoarthritis",
         null
        ],
        [
         "NCT02759250",
         "argenx",
         "Completed",
         "Feb 2015",
         "Jun 2018",
         "Interventional",
         "Apr 2016",
         "Nasopharyngeal Carcinoma",
         null
        ],
        [
         "NCT02757482",
         "Celal Bayar University",
         "Completed",
         "Sep 2014",
         "Jun 2015",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757105",
         "RedHill Biopharma Limited",
         "Completed",
         "May 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Irritable Bowel Syndrome,Syndrome,Diarrhea",
         "Ondansetron"
        ],
        [
         "NCT02756520",
         "Fresenius Kabi",
         "Completed",
         "Sep 2016",
         "Oct 2018",
         "Observational",
         "Apr 2016",
         "Kidney Diseases,Renal Insufficiency",
         null
        ],
        [
         "NCT02753309",
         "The University of Texas Health Science Center at San Antonio",
         "Completed",
         "Jun 2016",
         "Mar 2021",
         "Interventional",
         "Apr 2016",
         "Urinary Bladder Neoplasms",
         "Sirolimus"
        ],
        [
         "NCT02756832",
         "Takeda",
         "Completed",
         "Sep 2016",
         "Apr 2018",
         "Observational",
         "Apr 2016",
         "Diabetes Mellitus",
         "Alogliptin"
        ],
        [
         "NCT02758158",
         "University Health Network, Toronto",
         "Completed",
         "Jan 2016",
         "Feb 2017",
         "Interventional",
         "Mar 2016",
         "Thyroid Neoplasms,Thyroid Nodule,Thyroid Diseases",
         null
        ],
        [
         "NCT02752360",
         "Beijing Friendship Hospital",
         "Unknown status",
         "Apr 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Colonic Neoplasms,Crohn Disease,Diverticulum,Diverticular Diseases,Diverticulosis",
         null
        ],
        [
         "NCT02757794",
         "Assistance Publique Hopitaux De Marseille",
         "Recruiting",
         "Nov 2016",
         "Jun 2022",
         "Interventional",
         "Apr 2016",
         "Memory Disorders",
         null
        ],
        [
         "NCT02751346",
         "Washington University School of Medicine",
         "Completed",
         "Jan 2016",
         "Feb 2017",
         "Observational",
         "Apr 2016",
         "Pain",
         null
        ],
        [
         "NCT02757027",
         "Konkuk University Medical Center",
         "Unknown status",
         "May 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756689",
         "University of Alabama at Birmingham",
         "Completed",
         "Mar 2016",
         "Oct 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751164",
         "Intensive Care National Audit & Research Centre",
         "Completed",
         "Apr 2013",
         "May 2016",
         "Observational",
         "Apr 2016",
         "Critical Illness",
         null
        ],
        [
         "NCT02754765",
         "Médecins Sans Frontières, France",
         "Recruiting",
         "Dec 2016",
         "Aug 2023",
         "Interventional",
         "Apr 2016",
         "Tuberculosis,Bacterial Infections",
         "Moxifloxacin,Levofloxacin,Ofloxacin,Linezolid,Pyrazinamide,Bedaquiline,Clofazimine"
        ],
        [
         "NCT02757729",
         "Amorepacific Corporation",
         "Completed",
         "Oct 2015",
         null,
         "Interventional",
         "Apr 2016",
         "Dermatitis,Eczema",
         null
        ],
        [
         "NCT02751866",
         "University of Cincinnati",
         "Recruiting",
         "Jan 2016",
         "Jul 2023",
         "Interventional",
         "Apr 2016",
         "Overweight,Hyperphagia",
         null
        ],
        [
         "NCT02759068",
         "Hospices Civils de Lyon",
         "Completed",
         "Nov 2014",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Consciousness Disorders",
         null
        ],
        [
         "NCT02752503",
         "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",
         "Unknown status",
         "Mar 2015",
         null,
         "Interventional",
         "Apr 2016",
         "Disease,Alcoholism,Alcohol Drinking,Personality Disorders,Borderline Personality Disorder",
         "Nalmefene"
        ],
        [
         "NCT02750592",
         "Novartis Pharmaceuticals",
         "Completed",
         "Mar 2016",
         "May 2018",
         "Interventional",
         "Apr 2016",
         "Spondylitis",
         null
        ],
        [
         "NCT02754440",
         "Terumo BCT",
         "Completed",
         "Apr 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750670",
         "University Health Network, Toronto",
         "Completed",
         "Mar 2017",
         "Feb 2021",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         "Gemcitabine,Dexamethasone,Obinutuzumab"
        ],
        [
         "NCT02753400",
         "Kubota Vision Inc.",
         "Completed",
         "May 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Retinal Diseases,Diabetic Retinopathy",
         null
        ],
        [
         "NCT02754310",
         "Ilumens",
         "Completed",
         "May 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02758275",
         "Universidad Industrial de Santander",
         "Completed",
         "Apr 2016",
         "Sep 2017",
         "Interventional",
         "Apr 2016",
         "Hypertension,Diabetes Mellitus",
         null
        ],
        [
         "NCT02757417",
         "University Hospitals Cleveland Medical Center",
         "Unknown status",
         "Jul 2016",
         "Dec 2019",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753725",
         "University of Nairobi",
         "Completed",
         "Apr 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Delirium,Emergence Delirium",
         "Fentanyl"
        ],
        [
         "NCT02752646",
         "MDbackline, LLC",
         "Completed",
         "Apr 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Cataract",
         "Ketorolac,Nepafenac"
        ],
        [
         "NCT02750566",
         "New York Institute of Technology",
         "Recruiting",
         "Nov 2015",
         "Dec 2021",
         "Interventional",
         "Dec 2015",
         "Post-Concussion Syndrome",
         null
        ],
        [
         "NCT02753335",
         "University of Tromso",
         "Recruiting",
         "Sep 2016",
         "Dec 2022",
         "Interventional",
         "Mar 2016",
         "Complex Regional Pain Syndromes,Reflex Sympathetic Dystrophy,Syndrome",
         null
        ],
        [
         "NCT02754544",
         "M.D. Anderson Cancer Center",
         "Recruiting",
         "Jul 2016",
         "Aug 2020",
         "Interventional",
         "Apr 2016",
         "Neoplasms,Brain Neoplasms",
         null
        ],
        [
         "NCT02751112",
         "Imagine Institute",
         "Terminated",
         "Nov 2015",
         "Aug 2017",
         "Interventional",
         "Apr 2016",
         "Graft vs Host Disease",
         null
        ],
        [
         "NCT02751320",
         "GlaxoSmithKline",
         "Completed",
         "Feb 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Dental Caries",
         "Citric Acid,Sodium Citrate"
        ],
        [
         "NCT02753036",
         "Charite University, Berlin, Germany",
         "Active, not recruiting",
         "Jan 2016",
         "Jun 2023",
         "Observational",
         "Apr 2016",
         "Polyneuropathies,Cognition Disorders",
         null
        ],
        [
         "NCT02759198",
         "Yuhan Corporation",
         "Completed",
         "May 2016",
         "Sep 2017",
         "Interventional",
         "Apr 2016",
         "Osteoarthritis",
         "Celecoxib"
        ],
        [
         "NCT02752802",
         "Osprey Medical, Inc",
         "Completed",
         "Apr 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757586",
         "Peking University People's Hospital",
         "Unknown status",
         "Dec 2016",
         "Dec 2019",
         "Observational",
         "Apr 2016",
         "Leukemia",
         null
        ],
        [
         "NCT02755961",
         "Ajou University School of Medicine",
         "Completed",
         "Jul 2015",
         "Oct 2015",
         "Interventional",
         "Apr 2016",
         "Kidney Diseases,Kidney Failure,Hyperphosphatemia",
         null
        ],
        [
         "NCT02759263",
         "Boston Children's Hospital",
         "Completed",
         "Jun 2016",
         "Oct 2018",
         "Interventional",
         "Apr 2016",
         "Heart Diseases,Heart Defects",
         null
        ],
        [
         "NCT02754271",
         "Toronto Rehabilitation Institute",
         "Unknown status",
         "Apr 2014",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Kidney Failure",
         null
        ],
        [
         "NCT02756195",
         "Vanderbilt University",
         "Recruiting",
         "Nov 2016",
         "Jan 2022",
         "Observational [Patient Registry]",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754336",
         "Helse Stavanger HF",
         "Completed",
         "Oct 2014",
         "Jun 2015",
         "Interventional",
         "Nov 2015",
         null,
         null
        ],
        [
         "NCT02758639",
         "University of Texas at Austin",
         "Completed",
         "Sep 2015",
         "Aug 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759185",
         "Multidisciplinary Association for Psychedelic Studies",
         "Completed",
         "Jan 2017",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Marijuana Abuse,Stress Disorders",
         "Dronabinol,Cannabidiol"
        ],
        [
         "NCT02758145",
         "Service de Médecine Préventive Hospitalière",
         "Completed",
         "Apr 2016",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         "Influenza",
         "Vaccines"
        ],
        [
         "NCT02756455",
         "University of Roma La Sapienza",
         "Unknown status",
         "Jan 2015",
         "Dec 2016",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Stomach Neoplasms",
         null
        ],
        [
         "NCT02757118",
         "Konkuk University Medical Center",
         "Unknown status",
         "May 2016",
         "Jan 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756819",
         "Takeda",
         "Completed",
         "Jul 2016",
         "May 2018",
         "Observational",
         "Apr 2016",
         "Hypertension,Overweight",
         "Azilsartan medoxomil"
        ],
        [
         "NCT02754362",
         "NYU Langone Health",
         "Withdrawn",
         "Nov 2016",
         "Jun 2019",
         "Interventional",
         "Apr 2016",
         "Glioblastoma",
         "Bevacizumab,Poly ICLC,Keyhole-limpet hemocyanin,Adjuvants"
        ],
        [
         "NCT02752711",
         "Nantes University Hospital",
         "Completed",
         "May 2013",
         "Dec 2015",
         "Observational",
         "Apr 2016",
         "Craniocerebral Trauma",
         null
        ],
        [
         "NCT02756494",
         "Beijing Chao Yang Hospital",
         "Unknown status",
         "Apr 2016",
         "Dec 2018",
         "Observational",
         "Apr 2016",
         "Stroke,Ischemic Stroke,Cerebral Infarction,Ischemia",
         null
        ],
        [
         "NCT02753855",
         "University of Illinois at Chicago",
         "Completed",
         "Apr 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         null,
         "Telavancin"
        ],
        [
         "NCT02756013",
         "Case Comprehensive Cancer Center",
         "Terminated",
         "Apr 2016",
         "Jan 2019",
         "Interventional",
         "Apr 2016",
         "Overweight",
         "Paclitaxel,Carboplatin"
        ],
        [
         "NCT02756949",
         "World Bank",
         "Completed",
         "Oct 2015",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         "HIV Infections",
         null
        ],
        [
         "NCT02757885",
         "Emory University",
         "Recruiting",
         "Apr 2016",
         "Jul 2023",
         "Interventional",
         "Apr 2016",
         "Anemia",
         "Cyclophosphamide,Thiotepa,Fludarabine,Fludarabine phosphate,Hydroxyurea,Antilymphocyte Serum,Thymoglobulin"
        ],
        [
         "NCT02758340",
         "Karachi Medical and Dental College",
         "Completed",
         "Apr 2016",
         "Nov 2016",
         "Interventional",
         "Apr 2016",
         "Labor Pain",
         "Misoprostol"
        ],
        [
         "NCT02753933",
         "Guy's and St Thomas' NHS Foundation Trust",
         "Unknown status",
         "Apr 2016",
         "Dec 2018",
         "Observational",
         "Apr 2016",
         "Headache Disorders,Headache",
         null
        ],
        [
         "NCT02756624",
         "Nicox Ophthalmics, Inc.",
         "Completed",
         "Apr 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         null,
         "Cetirizine"
        ],
        [
         "NCT02759393",
         "National Cheng-Kung University Hospital",
         "Unknown status",
         "Oct 2015",
         "Sep 2017",
         "Interventional",
         "Apr 2016",
         "Gastroesophageal Reflux,Esophagitis",
         "Lansoprazole,Dexlansoprazole"
        ],
        [
         "NCT02757820",
         "Assiut University",
         "Completed",
         "Jun 2016",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754141",
         "Bristol-Myers Squibb",
         "Active, not recruiting",
         "Jun 2016",
         "Feb 2023",
         "Interventional",
         "Apr 2016",
         null,
         "Nivolumab"
        ],
        [
         "NCT02753985",
         "Abramson Cancer Center of the University of Pennsylvania",
         "Completed",
         "Jul 2014",
         "Apr 2016",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757768",
         "Astellas Pharma Global Development, Inc.",
         "Completed",
         "Jun 2016",
         "Sep 2018",
         "Interventional",
         "Apr 2016",
         "Urinary Bladder,Prostatic Hyperplasia,Hyperplasia,Lower Urinary Tract Symptoms",
         "Tamsulosin,Mirabegron"
        ],
        [
         "NCT02753348",
         "Henning Bundgaard",
         "Completed",
         "Apr 2016",
         "Nov 2018",
         "Observational",
         "Apr 2016",
         "Heart Diseases,Heart Defects",
         null
        ],
        [
         "NCT02759718",
         "Asan Medical Center",
         "Unknown status",
         "Jun 2012",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Neuroendocrine Tumors,Endocrine Gland Neoplasms,Adenoma",
         null
        ],
        [
         "NCT02755181",
         "Boehringer Ingelheim",
         "Completed",
         "Jul 2016",
         "May 2018",
         "Observational",
         "Apr 2016",
         "Disease,Personality Disorders,Borderline Personality Disorder,Impulsive Behavior,Disruptive",
         null
        ],
        [
         "NCT02759926",
         "Universitaire Ziekenhuizen Leuven",
         "Unknown status",
         "Aug 2011",
         null,
         "Interventional",
         "Apr 2016",
         "Obesity",
         "Quinine,Denatonium"
        ],
        [
         "NCT02756286",
         "Think Now Incorporated",
         "Completed",
         "Jan 2017",
         "Jul 2018",
         "Observational",
         "Nov 2015",
         "Attention Deficit Disorder with Hyperactivity",
         null
        ],
        [
         "NCT02752126",
         "Lawson Health Research Institute",
         "Completed",
         "Jun 2016",
         "Sep 2020",
         "Interventional",
         "Apr 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02752035",
         "Astellas Pharma Global Development, Inc.",
         "Active, not recruiting",
         "Aug 2016",
         "Aug 2023",
         "Interventional",
         "Apr 2016",
         "Leukemia",
         "Azacitidine"
        ],
        [
         "NCT02750865",
         "Boston Medical Center",
         "Recruiting",
         "Aug 2017",
         "Dec 2022",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02752165",
         "University of Rochester",
         "Recruiting",
         "Aug 2016",
         "Feb 2023",
         "Interventional",
         "Mar 2016",
         "Asthma,Emergencies",
         null
        ],
        [
         "NCT02755792",
         "The Hong Kong Polytechnic University",
         "Completed",
         "Jul 2012",
         "Apr 2016",
         "Interventional",
         "Apr 2016",
         "Cognitive Dysfunction",
         null
        ],
        [
         "NCT02757898",
         "Emory University",
         "Recruiting",
         "Jan 2017",
         "Dec 2021",
         "Interventional",
         "Apr 2016",
         null,
         "Biotin"
        ],
        [
         "NCT02758678",
         "Science and Technology Park, Center of Innovation Technologies for Human Health",
         "Completed",
         "Nov 2015",
         "Oct 2016",
         "Observational",
         "Apr 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02751424",
         "GlaxoSmithKline",
         "Terminated",
         "Jun 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Bacterial Infections",
         null
        ],
        [
         "NCT02750319",
         "Memorial Sloan Kettering Cancer Center",
         "Active, not recruiting",
         "Apr 2016",
         "Apr 2022",
         "Interventional",
         "Apr 2016",
         "Atrial Fibrillation",
         "Acetylcysteine,Amiodarone,N-monoacetylcystine"
        ],
        [
         "NCT02757495",
         "Suez Canal University",
         "Completed",
         "Apr 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Psychomotor Agitation,Emergence Delirium,Delayed Emergence from Anesthesia",
         "Dexmedetomidine"
        ],
        [
         "NCT02752607",
         "Dr. Vicky Tagalakis",
         "Terminated",
         "May 2016",
         "Nov 2018",
         "Observational",
         "Apr 2016",
         "Thrombosis,Venous Thrombosis",
         null
        ],
        [
         "NCT02757911",
         "Genethon",
         "Active, not recruiting",
         "Mar 2016",
         "Jun 2024",
         "Interventional",
         "Apr 2016",
         "Granuloma,Granulomatous Disease",
         null
        ],
        [
         "NCT02759224",
         "Boryung Pharmaceutical Co., Ltd",
         "Completed",
         "Apr 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         "Stomach Ulcer",
         "Irsogladine,Lafutidine"
        ],
        [
         "NCT02756351",
         "CytaCoat AB",
         "Completed",
         "Apr 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Cross Infection,Pneumonia",
         null
        ],
        [
         "NCT02751359",
         "University of California, Los Angeles",
         "Completed",
         "Jul 2016",
         "Apr 2020",
         "Interventional",
         "Apr 2016",
         null,
         "Cannabidiol"
        ],
        [
         "NCT02756585",
         "Nova Scotia Health Authority",
         "Unknown status",
         "Sep 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Brain Injuries,Craniocerebral Trauma,Wounds and Injuries",
         null
        ],
        [
         "NCT02751411",
         "Aboca Spa Societa' Agricola",
         "Completed",
         "Apr 2016",
         "Mar 2020",
         "Interventional",
         "Apr 2016",
         "Constipation",
         null
        ],
        [
         "NCT02750735",
         "University of Palermo",
         "Completed",
         "Jan 2001",
         "Mar 2016",
         "Observational",
         "Apr 2016",
         "Hypersensitivity",
         null
        ],
        [
         "NCT02753868",
         "University of Illinois at Urbana-Champaign",
         "Completed",
         "Feb 2016",
         "Feb 2017",
         "Interventional",
         "Feb 2016",
         "Renal Insufficiency",
         null
        ],
        [
         "NCT02755844",
         "Hospices Civils de Lyon",
         "Active, not recruiting",
         "Sep 2016",
         "Apr 2022",
         "Interventional",
         "Apr 2016",
         "Endometrial Neoplasms",
         "Metformin,Cyclophosphamide,Olaparib"
        ],
        [
         "NCT02758301",
         "Medtronic Cardiac Rhythm and Heart Failure",
         "Completed",
         "Jun 2016",
         "Dec 2018",
         "Observational",
         "Apr 2016",
         "Heart Failure",
         null
        ],
        [
         "NCT02751463",
         "Bayer",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         null
        ],
        [
         "NCT02752633",
         "Landspitali University Hospital",
         "Completed",
         "May 2013",
         "May 2015",
         "Interventional",
         "Apr 2016",
         null,
         "Allopurinol,Febuxostat"
        ],
        [
         "NCT02755909",
         "Indonesia University",
         "Completed",
         "Dec 2015",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         "Anxiety Disorders",
         "Anesthetics"
        ],
        [
         "NCT02752620",
         "Rio de Janeiro State University",
         "Completed",
         "May 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         "Back Pain,Low Back Pain",
         null
        ],
        [
         "NCT02759965",
         "Karolinska University Hospital",
         "Completed",
         "Sep 2014",
         "Dec 2018",
         "Observational",
         "Nov 2014",
         "Acute-Phase Reaction,Cognitive Dysfunction",
         null
        ],
        [
         "NCT02754752",
         "M.D. Anderson Cancer Center",
         "Recruiting",
         "Sep 2016",
         "Sep 2023",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms,Chronic Pain",
         null
        ],
        [
         "NCT02754349",
         "Onze Lieve Vrouw Hospital",
         "Completed",
         "Feb 2015",
         "May 2016",
         "Interventional",
         "Mar 2016",
         "Atrial Fibrillation",
         null
        ],
        [
         "NCT02754479",
         "Cutera Inc.",
         "Completed",
         "Apr 2016",
         "Mar 2017",
         "Interventional",
         "Apr 2016",
         "Telangiectasis",
         null
        ],
        [
         "NCT02753790",
         "New Mexico Cancer Care Alliance",
         "Active, not recruiting",
         "Feb 2016",
         "Mar 2023",
         "Interventional",
         "Apr 2016",
         "Neoplasm Metastasis,Neoplasms,Brain Neoplasms",
         null
        ],
        [
         "NCT02757248",
         "Anne Beaven, MD",
         "Withdrawn",
         "Nov 2016",
         "Nov 2016",
         "Interventional",
         "Mar 2016",
         null,
         "Romidepsin"
        ],
        [
         "NCT02759991",
         "Norwegian Institute of Public Health",
         "Completed",
         "Oct 2017",
         "Sep 2019",
         "Interventional",
         "Mar 2016",
         "Infections,Hepatitis A,Hepatitis E,Hepatitis",
         "Vaccines"
        ],
        [
         "NCT02758561",
         "Ottawa Hospital Research Institute",
         "Completed",
         "May 2016",
         "Nov 2017",
         "Interventional",
         "Dec 2015",
         "Urinary Incontinence,Enuresis,Pelvic Floor Disorders,Prolapse",
         null
        ],
        [
         "NCT02753504",
         "Chong Kun Dang Pharmaceutical",
         "Completed",
         "Apr 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Dyslipidemias",
         null
        ],
        [
         "NCT02758821",
         "University of Oxford",
         "Completed",
         "Jun 2016",
         "Sep 2017",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02757430",
         "Abbott Medical Devices",
         "Completed",
         "Aug 2016",
         "Jul 2017",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Arrhythmias",
         null
        ],
        [
         "NCT02754024",
         "Werner Anderl",
         "Active, not recruiting",
         "Sep 2005",
         "Sep 2025",
         "Observational",
         "Apr 2016",
         "Osteoarthritis,Necrosis",
         null
        ],
        [
         "NCT02757651",
         "Institute of Cancer Research, United Kingdom",
         "Completed",
         "Jan 2017",
         "Nov 2020",
         "Interventional",
         "Apr 2016",
         "Breast Neoplasms",
         "Hydrogen Peroxide"
        ],
        [
         "NCT02758769",
         "Bristol-Myers Squibb",
         "Active, not recruiting",
         "Jun 2016",
         "Oct 2023",
         "Observational",
         "Apr 2016",
         "Arthritis",
         "Abatacept"
        ],
        [
         "NCT02755896",
         "Weill Medical College of Cornell University",
         "Recruiting",
         "Jul 2015",
         "Jul 2024",
         "Interventional",
         "Aug 2015",
         "Neoplasms,Breast Neoplasms,Radiation Pneumonitis",
         null
        ],
        [
         "NCT02753699",
         "Debiopharm International SA",
         "Completed",
         "Dec 2011",
         "May 2015",
         "Interventional",
         "Mar 2016",
         "Hepatitis A,Hepatitis C,Hepatitis",
         null
        ],
        [
         "NCT02754323",
         "Centre Hospitalier Universitaire de Nice",
         "Unknown status",
         "May 2016",
         "Dec 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753881",
         "Yale University",
         "Completed",
         "Nov 2015",
         "Dec 2019",
         "Interventional",
         "Mar 2016",
         "Liver Neoplasms",
         "Doxorubicin,Liposomal doxorubicin"
        ],
        [
         "NCT02752074",
         "Incyte Corporation",
         "Completed",
         "Jun 2016",
         "Aug 2019",
         "Interventional",
         "Apr 2016",
         "Melanoma",
         "Pembrolizumab"
        ],
        [
         "NCT02753244",
         "Intendu Ltd.",
         "Unknown status",
         "Apr 2015",
         null,
         "Interventional",
         "Apr 2016",
         "Brain Injuries,Wounds and Injuries",
         null
        ],
        [
         "NCT02752672",
         "Medical University of Graz",
         "Completed",
         "Mar 2016",
         "Nov 2016",
         "Observational",
         "Apr 2016",
         "Psoriasis",
         null
        ],
        [
         "NCT02759029",
         "Gangnam Severance Hospital",
         "Unknown status",
         "Mar 2016",
         "Feb 2018",
         "Interventional",
         "Apr 2016",
         "Disease Susceptibility",
         null
        ],
        [
         "NCT02750202",
         "University of Pretoria",
         "Recruiting",
         "Jul 2018",
         "Jul 2023",
         "Interventional",
         "Apr 2016",
         "Warts,Condylomata Acuminata,Recurrence",
         "Vaccines"
        ],
        [
         "NCT02753686",
         "Novartis Pharmaceuticals",
         "Active, not recruiting",
         "Mar 2016",
         "Aug 2022",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Breast Neoplasms",
         "Tamoxifen,Everolimus,Letrozole,Fulvestrant,Anastrozole,Exemestane"
        ],
        [
         "NCT02752217",
         "Khon Kaen University",
         "Unknown status",
         "Mar 2016",
         "Sep 2018",
         "Interventional",
         "Apr 2016",
         "Hypertension",
         null
        ],
        [
         "NCT02755662",
         "ResMed",
         "Completed",
         "May 2016",
         "Jul 2017",
         "Interventional",
         "Apr 2016",
         "Apnea,Sleep Apnea Syndromes,Sleep Apnea,Syndrome",
         null
        ],
        [
         "NCT02751671",
         "St. Justine's Hospital",
         "Completed",
         "Aug 2016",
         "Jun 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02752880",
         "Chang Gung Memorial Hospital",
         "Completed",
         "Jun 2016",
         "Feb 2018",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02751632",
         "Orygen",
         "Active, not recruiting",
         "Apr 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Disease,Psychotic Disorders,Mental Disorders,Personality Disorders",
         "Fluoxetine"
        ],
        [
         "NCT02750527",
         "Kinderkrankenhaus auf der Bult",
         "Completed",
         "Sep 2016",
         "Dec 2020",
         "Observational",
         "Apr 2016",
         "Hyperlipoproteinemia Type II,Diabetes Mellitus,Hypercholesterolemia",
         null
        ],
        [
         "NCT02751242",
         "Vanderbilt University",
         "Completed",
         "Aug 2016",
         "Jul 2017",
         "Observational",
         "Apr 2016",
         "Heart Failure",
         null
        ],
        [
         "NCT02755363",
         "Medical University of Warsaw",
         "Unknown status",
         "Apr 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Lung Diseases,Pulmonary Disease",
         null
        ],
        [
         "NCT02751775",
         "Pennington Biomedical Research Center",
         "Completed",
         "Jun 2016",
         "Jun 2017",
         "Observational",
         "Apr 2016",
         "Pediatric Obesity",
         null
        ],
        [
         "NCT02757976",
         "Lawson Health Research Institute",
         "Terminated",
         "Mar 2018",
         "Jun 2019",
         "Interventional",
         "Apr 2016",
         "Heart Failure,Ventricular Dysfunction",
         null
        ],
        [
         "NCT02752386",
         "University of Tulsa",
         "Completed",
         "Feb 2016",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756143",
         "University Hospital of Torrejon",
         "Completed",
         "Nov 2014",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754648",
         "Ain Shams University",
         "Unknown status",
         "Sep 2015",
         "Sep 2016",
         "Interventional",
         "Mar 2016",
         "Endometriosis",
         null
        ],
        [
         "NCT02751138",
         "University of Ulm",
         "Recruiting",
         "Mar 2016",
         "Sep 2024",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Glioblastoma",
         null
        ],
        [
         "NCT02753231",
         "Universidad Santo Tomas",
         "Completed",
         "Jan 2017",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Metabolic Syndrome,Metabolic Diseases,Lipid Metabolism Disorders,Overweight",
         null
        ],
        [
         "NCT02759588",
         "Genelux Corporation",
         "Active, not recruiting",
         "May 2016",
         "May 2022",
         "Interventional",
         "Apr 2016",
         "Ovarian Neoplasms,Carcinoma,Fallopian Tube Neoplasms,Peritoneal Neoplasms",
         "Bevacizumab"
        ],
        [
         "NCT02757352",
         "Eli Lilly and Company",
         "Completed",
         "Aug 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         "Spondylarthritis",
         "Ixekizumab"
        ],
        [
         "NCT02752022",
         "St George's, University of London",
         "Unknown status",
         "Sep 2016",
         "Apr 2019",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754973",
         "The University of Hong Kong",
         "Completed",
         "May 2015",
         "Nov 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755506",
         "Chinese PLA General Hospital",
         "Unknown status",
         "Oct 2015",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         "Aneurysm",
         null
        ],
        [
         "NCT02751216",
         "Moens Maarten",
         "Completed",
         "May 2016",
         "Jan 2018",
         "Interventional",
         "Apr 2016",
         "Syndrome,Failed Back Surgery Syndrome",
         null
        ],
        [
         "NCT02756559",
         "Lixin Xie",
         "Unknown status",
         "Jan 2014",
         "Dec 2017",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754557",
         "Emory University",
         "Recruiting",
         "Mar 2016",
         "Dec 2021",
         "Interventional",
         "Apr 2016",
         "Stress Disorders",
         null
        ],
        [
         "NCT02758496",
         "Wave Neuroscience",
         "Completed",
         "Apr 2016",
         "Apr 2017",
         "Observational",
         "Apr 2016",
         "Autistic Disorder",
         null
        ],
        [
         "NCT02757066",
         "Nobelpharma",
         "Completed",
         "Jun 2016",
         "Sep 2018",
         "Interventional",
         "Apr 2016",
         "Sleep Wake Disorders,Parasomnias,Disease,Autistic Disorder,Autism Spectrum Disorder,Child Development Disorders",
         "Melatonin"
        ],
        [
         "NCT02756104",
         "University Hospital, Montpellier",
         "Completed",
         "Jun 2016",
         "May 2020",
         "Interventional",
         "Apr 2016",
         null,
         "Vitamin D"
        ],
        [
         "NCT02751814",
         "Pennington Biomedical Research Center",
         "Completed",
         "Apr 2016",
         "Jun 2018",
         "Observational",
         "Apr 2016",
         "Pediatric Obesity",
         null
        ],
        [
         "NCT02751749",
         "Örebro University, Sweden",
         "Completed",
         "Dec 2015",
         "Sep 2016",
         "Interventional",
         "Apr 2016",
         "Chronic Pain",
         null
        ],
        [
         "NCT02756052",
         "University of Calgary",
         "Completed",
         "Mar 2016",
         "Aug 2016",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02753647",
         "Ruijin Hospital",
         "Unknown status",
         "Apr 2016",
         "Apr 2019",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         "Prednisone,Cyclophosphamide,Rituximab,Doxorubicin,Vincristine"
        ],
        [
         "NCT02756910",
         "Peking Union Medical College Hospital",
         "Completed",
         "May 2016",
         "Sep 2016",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02756208",
         "University of Maryland, College Park",
         "Completed",
         "Nov 2015",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         "HIV Infections",
         "Vaccines"
        ],
        [
         "NCT02757443",
         "Meshalkin Research Institute of Pathology of Circulation",
         "Completed",
         "Jun 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         null,
         "Phosphocreatine,Anesthetics"
        ],
        [
         "NCT02759744",
         "National Institutes of Health Clinical Center (CC)",
         "Enrolling by invitation",
         "Oct 2017",
         "Jan 2026",
         "Interventional",
         "Apr 2016",
         "Prostatic Neoplasms",
         null
        ],
        [
         "NCT02753140",
         "Daping Hospital and the Research Institute of Surgery of the Third Military Medical University",
         "Unknown status",
         "Apr 2016",
         "Sep 2018",
         "Interventional",
         "Apr 2016",
         "Carcinoma,Squamous Cell Carcinoma of Head and Neck",
         "Docetaxel,Cetuximab"
        ],
        [
         "NCT02759536",
         "The Third Xiangya Hospital of Central South University",
         "Unknown status",
         "Jul 2013",
         null,
         "Interventional",
         "Apr 2016",
         "Melanoma",
         null
        ],
        [
         "NCT02750449",
         "Bayer",
         "Completed",
         "May 2016",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         null
        ],
        [
         "NCT02759211",
         "Mount Sinai Rehabilitation Hospital",
         "Unknown status",
         "Apr 2016",
         "Feb 2018",
         "Interventional",
         "Mar 2016",
         "Multiple Sclerosis,Sclerosis",
         null
        ],
        [
         "NCT02752477",
         "Ben Lim",
         "Active, not recruiting",
         "Aug 2016",
         "Sep 2020",
         "Interventional",
         "Mar 2016",
         "Pain,Chronic Pain",
         "Anesthetics"
        ],
        [
         "NCT02759835",
         "National Cancer Institute (NCI)",
         "Active, not recruiting",
         "Apr 2016",
         "Sep 2022",
         "Interventional",
         "Apr 2016",
         "Lung Neoplasms,Adenocarcinoma of Lung",
         "Osimertinib"
        ],
        [
         "NCT02754596",
         "Glaukos Corporation",
         "Active, not recruiting",
         "Mar 2016",
         "Dec 2021",
         "Interventional",
         "Mar 2016",
         "Glaucoma",
         "Timolol,Travoprost,Ophthalmic Solutions"
        ],
        [
         "NCT02757846",
         "Chinese Academy of Sciences",
         "Enrolling by invitation",
         "Apr 2017",
         "Mar 2022",
         "Observational",
         "Apr 2016",
         "Carcinoma",
         null
        ],
        [
         "NCT02750085",
         "Victor Blanchette",
         "Active, not recruiting",
         "Apr 2016",
         "Dec 2020",
         "Observational",
         "Apr 2016",
         "Hemophilia A",
         null
        ],
        [
         "NCT02759692",
         "Johnson & Johnson Vision Care, Inc.",
         "Completed",
         "Apr 2016",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02752750",
         "Medical University of Graz",
         "Enrolling by invitation",
         "May 2016",
         "May 2022",
         "Observational",
         "Apr 2016",
         "Alzheimer Disease",
         null
        ],
        [
         "NCT02757781",
         "Avedis Donabedian Research Institute",
         "Unknown status",
         "Jul 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Chronic Disease",
         null
        ],
        [
         "NCT02757924",
         "Abbott Nutrition",
         "Completed",
         "May 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759887",
         "St. Joseph's Hospital and Medical Center, Phoenix",
         "Completed",
         "Nov 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Dementia,Down Syndrome,Alzheimer Disease,Syndrome",
         "Fluorodeoxyglucose F18"
        ],
        [
         "NCT02758977",
         "University of Zurich",
         "Unknown status",
         "May 2016",
         null,
         "Interventional",
         "Apr 2016",
         "Neoplasms,Neoplasm Metastasis,Liver Neoplasms,Colorectal Neoplasms,Liver Diseases",
         null
        ],
        [
         "NCT02751580",
         "Sidney Kimmel Cancer Center at Thomas Jefferson University",
         "Completed",
         "Mar 2016",
         "Aug 2018",
         "Interventional",
         "Apr 2016",
         "Neoplasms",
         null
        ],
        [
         "NCT02751333",
         "Johns Hopkins University",
         "Withdrawn",
         "Mar 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Esophageal Stenosis,Esophageal Fistula,Esophageal Perforation,Fistula,Constriction",
         null
        ],
        [
         "NCT02759731",
         "National Cancer Institute (NCI)",
         "Recruiting",
         "Nov 2016",
         "Jun 2022",
         "Interventional",
         "Apr 2016",
         "Graft vs Host Disease",
         null
        ],
        [
         "NCT02758288",
         "Loma Linda University",
         "Withdrawn",
         "Sep 2015",
         "Jul 2022",
         "Observational",
         "Mar 2016",
         "Virus Diseases,Kidney Diseases",
         null
        ],
        [
         "NCT02756546",
         "Cairo University",
         "Completed",
         "Sep 2014",
         "Dec 2015",
         "Interventional",
         "Apr 2016",
         "Lupus Erythematosus",
         "Hydroxychloroquine,Hydrocortisone,Cyclophosphamide"
        ],
        [
         "NCT02759094",
         "Implantica CE & Production Ltd",
         "Unknown status",
         "Dec 2016",
         "Feb 2018",
         "Interventional",
         "Apr 2016",
         "Gastroesophageal Reflux",
         null
        ],
        [
         "NCT02757313",
         "Yale University",
         "Completed",
         "Oct 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Marijuana Abuse",
         "Dronabinol"
        ],
        [
         "NCT02754011",
         "UNICANCER",
         "Recruiting",
         "Jan 2017",
         "Dec 2021",
         "Interventional",
         "Feb 2016",
         "Breast Neoplasms",
         "Capecitabine"
        ],
        [
         "NCT02755805",
         "University of Pittsburgh",
         "Completed",
         "Jul 2009",
         "Dec 2012",
         "Interventional",
         "Apr 2016",
         "Stroke",
         null
        ],
        [
         "NCT02755428",
         "Chinese Academy of Sciences",
         "Unknown status",
         "Jan 2018",
         "Dec 2020",
         "Interventional",
         "Mar 2016",
         "Macular Degeneration",
         null
        ],
        [
         "NCT02752555",
         "Benha University",
         "Unknown status",
         "Apr 2016",
         null,
         "Interventional",
         "Apr 2016",
         "Oligospermia",
         "Antioxidants"
        ],
        [
         "NCT02751398",
         "Yonsei University",
         "Completed",
         "Aug 2016",
         "Jun 2020",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         "Dapagliflozin"
        ],
        [
         "NCT02758951",
         "Koen Rovers",
         "Recruiting",
         "Jun 2017",
         "Aug 2026",
         "Interventional",
         "Apr 2016",
         "Neoplasms,Colorectal Neoplasms,Neoplasm Metastasis,Carcinoma,Peritoneal Neoplasms",
         "Bevacizumab"
        ],
        [
         "NCT02750176",
         "University of Southern California",
         "Completed",
         "Apr 2016",
         "Jul 2018",
         "Interventional",
         "Apr 2016",
         "Rotator Cuff Injuries",
         null
        ],
        [
         "NCT02750696",
         "Federal University of Rio Grande do Sul",
         "Completed",
         "Apr 2013",
         "Apr 2015",
         "Interventional",
         "Apr 2016",
         "Abscess,Periapical Abscess",
         "Acetaminophen,Tramadol,Codeine"
        ],
        [
         "NCT02757963",
         "GlaxoSmithKline",
         "Completed",
         "May 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Prostatic Hyperplasia,Hyperplasia",
         null
        ],
        [
         "NCT02756026",
         "USDA, Western Human Nutrition Research Center",
         "Completed",
         "Sep 2013",
         "Feb 2014",
         "Interventional",
         "Apr 2016",
         null,
         "Micronutrients,Trace Elements"
        ],
        [
         "NCT02756481",
         "Bristol-Myers Squibb",
         "Completed",
         "Oct 2013",
         "Nov 2014",
         "Observational",
         "Oct 2015",
         "Atrial Fibrillation",
         null
        ],
        [
         "NCT02751060",
         "Tongji Hospital",
         "Enrolling by invitation",
         "Apr 2016",
         "Dec 2022",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Heart Diseases,Coronary Disease,Coronary Artery Disease,Myocardial Ischemia",
         null
        ],
        [
         "NCT02753127",
         "Sumitomo Dainippon Pharma Oncology, Inc",
         "Completed",
         "Jun 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Colorectal Neoplasms",
         "Leucovorin,Bevacizumab,Fluorouracil,Irinotecan"
        ],
        [
         "NCT02755051",
         "University of Missouri-Columbia",
         "Completed",
         "Jul 2016",
         "Mar 2018",
         "Interventional",
         "Mar 2016",
         "Sleep Initiation and Maintenance Disorders,Autistic Disorder,Autism Spectrum Disorder,Child Development Disorders",
         null
        ],
        [
         "NCT02757560",
         "Phoenix VA Health Care System",
         "Unknown status",
         "Feb 2012",
         "Dec 2020",
         "Interventional",
         "Aug 2015",
         "Insulin Resistance",
         null
        ],
        [
         "NCT02754076",
         "Allievex Corporation",
         "Completed",
         "Apr 2016",
         "Jul 2020",
         "Interventional",
         "Feb 2016",
         "Mucopolysaccharidoses,Mucopolysaccharidosis III",
         null
        ],
        [
         "NCT02752282",
         "University of Washington",
         "Unknown status",
         "Mar 2016",
         "Dec 2019",
         "Interventional",
         "Apr 2016",
         "Uterine Hemorrhage",
         null
        ],
        [
         "NCT02751021",
         "University Hospital, Caen",
         "Completed",
         "Jun 2016",
         "Jun 2019",
         "Interventional",
         "Apr 2016",
         "Apnea,Sleep Apnea Syndromes,Arrhythmias,Hyperaldosteronism",
         null
        ],
        [
         "NCT02759471",
         "Coopervision, Inc.",
         "Completed",
         "Apr 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Myopia",
         null
        ],
        [
         "NCT02752854",
         "Taif University",
         "Unknown status",
         "Apr 2015",
         "May 2016",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02759822",
         "Leonardo Javier Arcuri",
         "Unknown status",
         "Apr 2016",
         null,
         "Observational",
         "Apr 2016",
         "Leukemia,Precursor Cell Lymphoblastic Leukemia-Lymphoma",
         null
        ],
        [
         "NCT02752139",
         "Yi Yang",
         "Completed",
         "May 2016",
         "Oct 2018",
         "Observational [Patient Registry]",
         "Mar 2016",
         "Sleep Wake Disorders,Parasomnias,Sleep Disorders,Disease",
         null
        ],
        [
         "NCT02752295",
         "Medical University of Vienna",
         "Completed",
         "May 2015",
         "Jul 2016",
         "Interventional",
         "Apr 2016",
         "Disease,Inflammation,Anxiety Disorders,Mood Disorders,Stress",
         null
        ],
        [
         "NCT02753023",
         "University of Sao Paulo General Hospital",
         "Unknown status",
         "May 2015",
         "May 2020",
         "Observational [Patient Registry]",
         "Apr 2016",
         "Pulmonary Embolism,Pulmonary Edema,Syncope,Aneurysm,Acute Coronary Syndrome,Embolism,Aortic Aneurysm,Emergencies,Chest Pain",
         null
        ],
        [
         "NCT02757365",
         "West China Hospital",
         "Unknown status",
         "Apr 2014",
         "Apr 2019",
         "Interventional",
         "Apr 2016",
         "Prostatic Neoplasms",
         "Aspirin,Levofloxacin,Ofloxacin"
        ],
        [
         "NCT02757092",
         "Chang Gung Memorial Hospital",
         "Completed",
         "Mar 2016",
         "May 2017",
         "Interventional",
         "Apr 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02758327",
         "Koffler Vision Group",
         "Completed",
         "Oct 2015",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         "Dry Eye Syndromes",
         "Carboxymethylcellulose Sodium,Ophthalmic Solutions,Lubricant Eye Drops"
        ],
        [
         "NCT02757404",
         "Medy-Tox",
         "Completed",
         "May 2016",
         "Aug 2016",
         "Interventional",
         "Apr 2016",
         "Muscle Spasticity",
         "Botulinum Toxins"
        ],
        [
         "NCT02757469",
         "Navy General Hospital, Beijing",
         "Unknown status",
         "May 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Premature Birth,Infertility,Primary Ovarian Insufficiency,Menopause",
         "Drospirenone,Ethinyl Estradiol,Drospirenone and ethinyl estradiol combination,Estradiol"
        ],
        [
         "NCT02759172",
         "Michigan State University",
         "Unknown status",
         "Apr 2016",
         null,
         "Interventional",
         "Apr 2016",
         "Suicide",
         null
        ],
        [
         "NCT02758041",
         "Sebacia, Inc.",
         "Completed",
         "Feb 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Acne Vulgaris",
         null
        ],
        [
         "NCT02755116",
         "Jaime B Hyman",
         "Completed",
         "Apr 2016",
         "Sep 2019",
         "Interventional",
         "Apr 2016",
         "Nausea,Vomiting,Postoperative Nausea and Vomiting",
         "Olanzapine"
        ],
        [
         "NCT02755584",
         "National Institute on Aging (NIA)",
         "Completed",
         "Jun 2016",
         "Apr 2021",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750540",
         "Johns Hopkins University",
         "Completed",
         "Oct 2016",
         "May 2019",
         "Interventional",
         "Apr 2016",
         null,
         "Tenofovir"
        ],
        [
         "NCT02751918",
         "Bayer",
         "Completed",
         "Jun 2016",
         "Oct 2019",
         "Interventional",
         "Apr 2016",
         "Ovarian Neoplasms",
         "Doxorubicin,Liposomal doxorubicin,Maytansine"
        ],
        [
         "NCT02751541",
         "Bayer",
         "Completed",
         "May 2016",
         "May 2016",
         "Interventional",
         "Apr 2016",
         "Dermatitis",
         "Sunscreening Agents"
        ],
        [
         "NCT02755883",
         "Weill Medical College of Cornell University",
         "Completed",
         "Apr 2016",
         "Oct 2017",
         "Interventional",
         "Apr 2016",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT02751229",
         "University of Ulm",
         "Completed",
         "May 2016",
         "May 2017",
         "Interventional",
         "Mar 2016",
         "Mental Disorders",
         null
        ],
        [
         "NCT02759640",
         "Atridia Pty Ltd.",
         "Completed",
         "Sep 2016",
         "May 2018",
         "Interventional",
         "Apr 2016",
         "Neoplasms",
         null
        ],
        [
         "NCT02750683",
         "Hopital Antoine Beclere",
         "Completed",
         "Oct 2014",
         "Jan 2016",
         "Observational",
         "Apr 2016",
         "Shock",
         null
        ],
        [
         "NCT02758132",
         "University of Hawaii",
         "Terminated",
         "Mar 2016",
         "Sep 2016",
         "Interventional",
         "Apr 2016",
         "Prostatic Neoplasms,Neoplasm Metastasis",
         "Denosumab,Prednisone"
        ],
        [
         "NCT02757001",
         "Group of Research in Minimally Invasive Techniques",
         "Completed",
         "Jun 2016",
         "Jul 2019",
         "Observational [Patient Registry]",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02757235",
         "Sahlgrenska University Hospital, Sweden",
         "Unknown status",
         "Mar 2016",
         "Jun 2020",
         "Interventional",
         "Apr 2016",
         "Hematoma",
         null
        ],
        [
         "NCT02754869",
         "University College, London",
         "Unknown status",
         "Feb 2011",
         "Aug 2018",
         "Observational",
         "Feb 2016",
         "Intestinal Diseases",
         null
        ],
        [
         "NCT02759406",
         "Palmaz Scientific",
         "Completed",
         "Sep 2013",
         "Jun 2015",
         "Interventional",
         "Apr 2016",
         "Heart Diseases,Myocardial Ischemia,Coronary Artery Disease,Ischemia",
         null
        ],
        [
         "NCT02758522",
         "Hospital Universitario Dr. Jose E. Gonzalez",
         "Completed",
         "Oct 2013",
         "Oct 2015",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus,Hyperglycemia",
         "Insulin"
        ],
        [
         "NCT02750046",
         "Second Affiliated Hospital of Soochow University",
         "Unknown status",
         "Mar 2016",
         "Feb 2018",
         "Interventional",
         "Mar 2016",
         "Fractures,Femoral Neck Fractures",
         null
        ],
        [
         "NCT02755233",
         "University of Zurich",
         "Completed",
         "Jan 2014",
         "Mar 2016",
         "Observational",
         "Apr 2016",
         "Melanoma",
         null
        ],
        [
         "NCT02750423",
         "Emory University",
         "Completed",
         "Apr 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754050",
         "Tandem Technologies LTD",
         "Unknown status",
         "Sep 2016",
         "Oct 2018",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02754284",
         "Chinese Academy of Sciences",
         "Completed",
         "Dec 2015",
         "Jun 2020",
         "Interventional",
         "Apr 2016",
         "Vocal Cord Dysfunction",
         null
        ],
        [
         "NCT02756078",
         "Johnson & Johnson Vision Care, Inc.",
         "Completed",
         "Apr 2016",
         "Oct 2017",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02750995",
         "Daniel El Fassi",
         "Completed",
         "Apr 2016",
         "Jun 2019",
         "Interventional",
         "Apr 2016",
         "Leukemia,Preleukemia,Myelodysplastic Syndromes,Syndrome",
         "Azacitidine"
        ],
        [
         "NCT02759302",
         "Rigshospitalet, Denmark",
         "Completed",
         "Apr 2016",
         "Apr 2017",
         "Observational",
         "Apr 2016",
         "Muscular Dystrophies",
         null
        ],
        [
         "NCT02759874",
         "Institute of Health Economics, Canada",
         "Unknown status",
         "Nov 2015",
         "Nov 2018",
         "Interventional",
         "Apr 2016",
         "Fetal Alcohol Spectrum Disorders,Alcoholism",
         null
        ],
        [
         "NCT02758535",
         "Modarres Hospital",
         "Completed",
         "Mar 2015",
         "Mar 2016",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02755636",
         "Pro-Change Behavior Systems",
         "Unknown status",
         "May 2016",
         "Jul 2017",
         "Interventional",
         "Mar 2016",
         null,
         null
        ],
        [
         "NCT02758873",
         "University of Sussex",
         "Completed",
         "Feb 2016",
         "Jul 2019",
         "Interventional",
         "Apr 2016",
         "Asthma",
         "Salmeterol Xinafoate,Montelukast"
        ],
        [
         "NCT02753166",
         "NYU Langone Health",
         "Withdrawn",
         "Jan 2017",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         null,
         "Dexamethasone"
        ],
        [
         "NCT02755766",
         "Shriners Hospitals for Children",
         "Completed",
         "May 2015",
         "Jul 2019",
         "Observational",
         "Mar 2016",
         "Scoliosis,Clubfoot,Talipes,Equinus Deformity",
         null
        ],
        [
         "NCT02751983",
         "VA Office of Research and Development",
         "Completed",
         "Nov 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Suicide",
         null
        ],
        [
         "NCT02754960",
         "Shanghai Jiao Tong University School of Medicine",
         "Withdrawn",
         "Mar 2010",
         "Sep 2014",
         "Interventional",
         "Apr 2016",
         "Gastrointestinal Hemorrhage,Vascular Malformations,Congenital Abnormalities,Hemorrhage",
         "Thalidomide"
        ],
        [
         "NCT02751086",
         "International Study Group on Minimally Invasive Surgery for Gastric Cancer",
         "Recruiting",
         "Apr 2016",
         "Dec 2024",
         "Observational",
         "Apr 2016",
         "Stomach Neoplasms",
         null
        ],
        [
         "NCT02755753",
         "YongChan Lee",
         "Completed",
         "Jan 2014",
         "Apr 2016",
         "Interventional",
         "Sep 2015",
         "Gastroesophageal Reflux,Esophagitis",
         "Lansoprazole,Dexlansoprazole,Rebamipide"
        ],
        [
         "NCT02757872",
         "Albert Einstein College of Medicine",
         "Active, not recruiting",
         "Apr 2016",
         "Nov 2021",
         "Interventional",
         "Apr 2016",
         "Kidney Diseases,Hypertension",
         "Vitamin D,Ergocalciferols,Cholecalciferol,Vitamins"
        ],
        [
         "NCT02756767",
         "Abramson Cancer Center of the University of Pennsylvania",
         "Completed",
         "Apr 2016",
         "Apr 2021",
         "Observational",
         "Apr 2016",
         "Neoplasms",
         null
        ],
        [
         "NCT02757937",
         "Children's Hospital of Philadelphia",
         "Completed",
         "May 2016",
         "Dec 2017",
         "Interventional",
         "Apr 2016",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT02753660",
         "Indonesia University",
         "Completed",
         "Aug 2014",
         "Oct 2014",
         "Interventional",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02751684",
         "Universitätsklinikum Köln",
         "Completed",
         "Mar 2017",
         "May 2017",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02753556",
         "Dimagi Inc.",
         "Completed",
         "Sep 2015",
         "Jun 2016",
         "Observational",
         "Apr 2016",
         "Lung Diseases,Pulmonary Disease",
         null
        ],
        [
         "NCT02757287",
         "Institut Universitari Dexeus",
         "Withdrawn",
         "May 2016",
         "Dec 2018",
         "Interventional",
         "Apr 2016",
         "Infertility",
         "Desogestrel"
        ],
        [
         "NCT02752308",
         "Isfahan University of Medical Sciences",
         "Completed",
         "Sep 2014",
         "Mar 2015",
         "Interventional",
         "Apr 2016",
         "Hypospadias",
         "Atropine,Epinephrine,Fentanyl,Bupivacaine,Neostigmine"
        ],
        [
         "NCT02758314",
         "Instituto Nacional de Cancerologia de Mexico",
         "Unknown status",
         "Mar 2017",
         "Dec 2018",
         "Observational",
         "Apr 2016",
         "Lung Neoplasms,Carcinoma",
         null
        ],
        [
         "NCT02752685",
         "NYU Langone Health",
         "Recruiting",
         "Jun 2016",
         "Dec 2021",
         "Observational",
         "Apr 2016",
         "Breast Neoplasms",
         "Paclitaxel,Pembrolizumab"
        ],
        [
         "NCT02759289",
         "NYU Langone Health",
         "Completed",
         "Nov 2015",
         "Sep 2020",
         "Observational",
         "Apr 2016",
         "Atherosclerosis",
         null
        ],
        [
         "NCT02759120",
         "Weill Medical College of Cornell University",
         "Terminated",
         "Mar 2017",
         "Mar 2020",
         "Interventional",
         "Apr 2016",
         "Pulmonary Fibrosis,Idiopathic Pulmonary Fibrosis,Fibrosis",
         "Doxycycline,Anti-Bacterial Agents,Trimethoprim,Anti-Infective Agents"
        ],
        [
         "NCT02754401",
         "Renatus, Antonio Renatus, Dent., M.Sc",
         "Completed",
         "Jan 2014",
         "Jul 2014",
         "Interventional",
         "Apr 2016",
         "Periodontitis",
         null
        ],
        [
         "NCT02759757",
         "Leandro Pires",
         "Unknown status",
         "May 2016",
         "Feb 2017",
         "Interventional",
         "Apr 2016",
         "Back Pain,Low Back Pain",
         null
        ],
        [
         "NCT02750579",
         "Assistance Publique Hopitaux De Marseille",
         "Completed",
         "Sep 2016",
         "Apr 2018",
         "Interventional",
         "Apr 2016",
         "Acute Coronary Syndrome,Syndrome",
         null
        ],
        [
         "NCT02752204",
         "University of Birmingham",
         "Completed",
         "Oct 2015",
         "Feb 2020",
         "Interventional",
         "Apr 2016",
         "Lymphoma",
         "Rituximab"
        ],
        [
         "NCT02757053",
         "Mosaic Life Care",
         "Terminated",
         "Apr 2016",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         "Brain Injuries,Brain Concussion,Diffuse Axonal Injury,Wounds and Injuries,Athletic Injuries",
         null
        ],
        [
         "NCT02752542",
         "Nova Scotia Health Authority",
         "Unknown status",
         "Oct 2016",
         "May 2021",
         "Interventional",
         "Apr 2016",
         "Disease,Depressive Disorder,Depression",
         null
        ],
        [
         "NCT02753283",
         "Susan L. Greenspan",
         "Active, not recruiting",
         "Jun 2016",
         "Sep 2023",
         "Interventional",
         "Apr 2016",
         "Osteoporosis,Osteoporotic Fractures",
         "Vitamin D,Zoledronic Acid,Denosumab,Calcium"
        ],
        [
         "NCT02754934",
         "Balgrist University Hospital",
         "Completed",
         "Nov 2014",
         "Nov 2016",
         "Observational",
         "Apr 2016",
         "Neck Pain",
         null
        ],
        [
         "NCT02755194",
         "The Hospital for Sick Children",
         "Terminated",
         "Sep 2014",
         "Sep 2019",
         "Observational",
         "Apr 2016",
         null,
         null
        ],
        [
         "NCT02758210",
         "Emory University",
         "Completed",
         "Apr 2016",
         "Oct 2016",
         "Interventional",
         "Apr 2016",
         "Bradycardia,Tachycardia",
         null
        ],
        [
         "NCT02757456",
         "Sameena Iqbal",
         "Completed",
         "Feb 2015",
         "Feb 2016",
         "Interventional",
         "Nov 2012",
         "Cardiovascular Diseases",
         null
        ],
        [
         "NCT02756377",
         "Islamic Azad University, Tehran",
         "Completed",
         "May 2014",
         "Jun 2015",
         "Interventional",
         "Apr 2016",
         "Periodontal Diseases",
         "Chlorhexidine,Chlorhexidine gluconate,Cetylpyridinium"
        ],
        [
         "NCT02751099",
         "Centro Hospitalar de Lisboa Central",
         "Unknown status",
         "Nov 2015",
         "Dec 2018",
         "Observational",
         "Apr 2016",
         "Bone Diseases,Renal Insufficiency,Vascular Diseases",
         null
        ],
        [
         "NCT02752178",
         "University of Cambridge",
         "Completed",
         "Jun 2015",
         "Sep 2018",
         "Observational",
         "Mar 2016",
         "Depressive Disorder,Depression",
         null
        ],
        [
         "NCT02757144",
         "Daewoong Pharmaceutical Co. LTD.",
         "Completed",
         "Mar 2016",
         "Feb 2017",
         "Interventional",
         "Mar 2016",
         null,
         "Esomeprazole"
        ],
        [
         "NCT02757742",
         "Fu Wai Hospital, Beijing, China",
         "Completed",
         "Dec 2010",
         "Aug 2016",
         "Observational",
         "Apr 2016",
         "Cardiomyopathies",
         null
        ],
        [
         "NCT02750644",
         "Joaquin de Haro, M.D.",
         "Completed",
         "Jan 2005",
         "Apr 2016",
         "Observational",
         "Apr 2016",
         "Carotid Artery Diseases",
         null
        ],
        [
         "NCT02754635",
         "HaEmek Medical Center, Israel",
         "Unknown status",
         "Mar 2016",
         "Jul 2018",
         "Interventional",
         "Feb 2016",
         null,
         null
        ],
        [
         "NCT02755311",
         "Sun Yat-sen University",
         "Unknown status",
         "Mar 2014",
         "Jun 2016",
         "Interventional",
         "Apr 2016",
         "Carcinoma",
         "Cisplatin,Carboplatin,Fluorouracil,Epirubicin,Ethiodized Oil,Pirarubicin,Doxorubicin,Gelatin Sponge"
        ],
        [
         "NCT00170053",
         "Mayo Clinic",
         "Completed",
         "Jun 2005",
         "Sep 2008",
         "Interventional",
         "Sep 2005",
         "Kidney Diseases",
         "Sirolimus"
        ],
        [
         "NCT00175396",
         "University of British Columbia",
         "Unknown status",
         "May 2004",
         "Jun 2014",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms",
         "Ascorbic Acid,Leuprolide,Methyltestosterone,Flutamide,Bicalutamide,Nilutamide,Buserelin,Androgens,Estrogens"
        ],
        [
         "NCT00179647",
         "Celgene Corporation",
         "Completed",
         "Sep 2005",
         "Apr 2009",
         "Interventional",
         "Sep 2005",
         "Multiple Myeloma,Neoplasms",
         "Dexamethasone,Lenalidomide"
        ],
        [
         "NCT00172523",
         "National Taiwan University Hospital",
         "Unknown status",
         "Oct 2004",
         "Aug 2005",
         "Observational",
         "Sep 2005",
         "Polycystic Ovary Syndrome,Syndrome",
         null
        ],
        [
         "NCT00174785",
         "Sanofi",
         "Completed",
         "Jun 2005",
         "Mar 2008",
         "Interventional",
         "Sep 2005",
         "Atrial Fibrillation,Atrial Flutter",
         "Dronedarone"
        ],
        [
         "NCT00175058",
         "TherOx",
         "Completed",
         "Aug 2005",
         "May 2008",
         "Interventional",
         "Sep 2005",
         "Myocardial Infarction,Infarction",
         null
        ],
        [
         "NCT00177541",
         "University of Pittsburgh",
         "Completed",
         "Feb 2004",
         "Sep 2016",
         "Interventional",
         "Sep 2005",
         "Urinary Incontinence",
         null
        ],
        [
         "NCT00176215",
         "Heidelberg University",
         "Unknown status",
         "May 2003",
         null,
         "Interventional",
         "Sep 2005",
         "Tooth Abrasion",
         null
        ],
        [
         "NCT00178529",
         "The University of Texas Health Science Center, Houston",
         "Completed",
         "Jul 2001",
         "Sep 2005",
         "Interventional",
         "Sep 2005",
         "Stroke",
         null
        ],
        [
         "NCT00172367",
         "National Taiwan University Hospital",
         "Withdrawn",
         "Jan 2006",
         null,
         "Interventional",
         "Sep 2005",
         "Carcinoma",
         "Lycopene"
        ],
        [
         "NCT00173875",
         "National Taiwan University Hospital",
         "Completed",
         "Mar 2005",
         "Jul 2007",
         "Interventional",
         "Sep 2005",
         "Lung Neoplasms,Carcinoma",
         "Gefitinib"
        ],
        [
         "NCT00174668",
         "Sanofi",
         "Completed",
         "Nov 2004",
         null,
         "Interventional",
         "Sep 2005",
         "Diabetes Mellitus",
         "Insulin,Insulin Glargine,Insulin glulisine"
        ],
        [
         "NCT00173927",
         "National Taiwan University Hospital",
         "Unknown status",
         "Mar 2004",
         null,
         "Observational",
         "Sep 2005",
         "Atherosclerosis",
         null
        ],
        [
         "NCT00179933",
         "Ann & Robert H Lurie Children's Hospital of Chicago",
         "Terminated",
         "Sep 2005",
         "Feb 2007",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00176878",
         "Masonic Cancer Center, University of Minnesota",
         "Completed",
         "Jun 2000",
         "Mar 2009",
         "Interventional",
         "Sep 2005",
         "Shwachman-Diamond Syndrome,Neutropenia,Bone Marrow Failure Disorders,Pancytopenia,Anemia,Syndrome",
         "Fludarabine,Fludarabine phosphate,Busulfan,Antilymphocyte Serum"
        ],
        [
         "NCT00172653",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00177645",
         "University of Pittsburgh",
         "Completed",
         "Mar 2002",
         "Dec 2006",
         "Interventional",
         "Sep 2005",
         "Cystic Fibrosis,Fibrosis",
         null
        ],
        [
         "NCT00176475",
         "University of Medicine and Dentistry of New Jersey",
         "Terminated",
         "Jan 2005",
         "Feb 2008",
         "Interventional",
         "Sep 2005",
         "Lymphoma,Leukemia,Multiple Myeloma,Neoplasms,Plasmacytoma",
         "Rituximab"
        ],
        [
         "NCT00178087",
         "University of Pittsburgh",
         "Completed",
         "Aug 2005",
         "Aug 2011",
         "Observational",
         "Sep 2005",
         "Depression,Depressive Disorder",
         null
        ],
        [
         "NCT00178854",
         "Vanderbilt University Medical Center",
         "Withdrawn",
         "May 2004",
         "Mar 2006",
         "Interventional",
         "Sep 2005",
         "Depressive Disorder",
         "Risperidone"
        ],
        [
         "NCT00178503",
         "The University of Texas Health Science Center, Houston",
         "Completed",
         "Sep 2005",
         "May 2011",
         "Interventional",
         "Sep 2005",
         "Hyperkinesis,Autistic Disorder,Attention Deficit Disorder with Hyperactivity",
         "Methylphenidate"
        ],
        [
         "NCT00176410",
         "University of Leipzig",
         "Unknown status",
         "Jan 2003",
         "Dec 2009",
         "Interventional",
         "Sep 2005",
         "Aortic Valve Stenosis,Constriction",
         null
        ],
        [
         "NCT00179166",
         "Vanderbilt University",
         "Terminated",
         "Jun 2004",
         "Jul 2005",
         "Interventional",
         "Sep 2005",
         "Renal Insufficiency,Acute Kidney Injury",
         null
        ],
        [
         "NCT00171054",
         "Novartis",
         "Completed",
         "Sep 2003",
         "Oct 2007",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Amlodipine,Valsartan,Hydrochlorothiazide"
        ],
        [
         "NCT00170300",
         "Medtronic Bakken Research Center",
         "Completed",
         "Jan 2001",
         "May 2005",
         "Interventional",
         "Sep 2005",
         "Heart Failure",
         null
        ],
        [
         "NCT00177619",
         "University of Pittsburgh",
         "Completed",
         "May 2002",
         "Dec 2005",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms,Osteoporosis",
         "Alendronate"
        ],
        [
         "NCT00178139",
         "University of Rochester",
         "Completed",
         "Apr 2004",
         "Jul 2006",
         "Interventional",
         "Sep 2005",
         "Respiratory Insufficiency,Pulmonary Valve Insufficiency",
         null
        ],
        [
         "NCT00175799",
         "University of British Columbia",
         "Completed",
         "Sep 2007",
         "Jul 2013",
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00172874",
         "National Taiwan University Hospital",
         "Completed",
         "Jan 1998",
         "Dec 2008",
         "Observational",
         "Sep 2005",
         "Feeding and Eating Disorders",
         null
        ],
        [
         "NCT00179985",
         "Ann & Robert H Lurie Children's Hospital of Chicago",
         "Completed",
         "Dec 2004",
         "Jul 2011",
         "Observational",
         "Sep 2005",
         "Hypersensitivity",
         null
        ],
        [
         "NCT00176384",
         "University of Leipzig",
         "Completed",
         "Mar 2003",
         "Dec 2006",
         "Interventional",
         "Sep 2005",
         "Heart Failure",
         null
        ],
        [
         "NCT00176644",
         "University of Medicine and Dentistry of New Jersey",
         "Terminated",
         "May 2005",
         "Dec 2008",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms",
         "Estradiol"
        ],
        [
         "NCT00174070",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         "Feb 2006",
         "Observational",
         "Sep 2005",
         "Respiratory Insufficiency",
         null
        ],
        [
         "NCT00173472",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jul 2002",
         "Jul 2005",
         "Observational",
         "Sep 2005",
         "Colorectal Neoplasms",
         null
        ],
        [
         "NCT00172640",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2005",
         null,
         "Observational",
         "Sep 2005",
         "Carcinoma",
         null
        ],
        [
         "NCT00174967",
         "Takeda",
         "Completed",
         "Jan 2001",
         "Jul 2001",
         "Interventional",
         "Sep 2005",
         "Gout",
         "Febuxostat"
        ],
        [
         "NCT00171028",
         "Novartis",
         "Completed",
         "Dec 2003",
         "Nov 2006",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Valsartan"
        ],
        [
         "NCT00175344",
         "University of British Columbia",
         "Completed",
         "Feb 2004",
         "Apr 2006",
         "Interventional",
         "Sep 2005",
         "Breast Neoplasms,Pain",
         null
        ],
        [
         "NCT00173368",
         "National Taiwan University Hospital",
         "Completed",
         "Jan 2003",
         "Mar 2005",
         "Observational",
         "Sep 2005",
         "Choledocholithiasis",
         null
        ],
        [
         "NCT00174629",
         "Sanofi",
         "Completed",
         "Jun 2001",
         null,
         "Interventional",
         "Sep 2005",
         "Lung Neoplasms",
         "Gemcitabine,Docetaxel"
        ],
        [
         "NCT00179231",
         "Vanderbilt University",
         "Completed",
         "May 2000",
         "Feb 2004",
         "Interventional",
         "Sep 2005",
         "Schizophrenia,Psychotic Disorders",
         "Olanzapine,Clozapine"
        ],
        [
         "NCT00173693",
         "National Taiwan University Hospital",
         "Withdrawn",
         "Jan 2006",
         "Dec 2010",
         "Interventional",
         "Sep 2005",
         "Osteoporosis,Bone Diseases",
         null
        ],
        [
         "NCT00171093",
         "Novartis",
         "Completed",
         "Sep 2004",
         null,
         "Interventional",
         "Sep 2005",
         "Hypertension,Hypercholesterolemia",
         "Valsartan,Simvastatin"
        ],
        [
         "NCT00179348",
         "Albert Einstein College of Medicine",
         "Completed",
         "Feb 2001",
         "Jul 2016",
         "Interventional",
         "Sep 2005",
         "Carcinoma,Breast Neoplasms,Colorectal Neoplasms,Sleep Wake Disorders,Alopecia,Vomiting",
         null
        ],
        [
         "NCT00172133",
         "Shire",
         "Completed",
         "Oct 2001",
         "Apr 2005",
         "Interventional",
         "Sep 2005",
         "Osteoporosis",
         null
        ],
        [
         "NCT00170508",
         "National Institute of Allergy and Infectious Diseases (NIAID)",
         "Completed",
         "Jun 2005",
         "Aug 2005",
         "Interventional",
         "Sep 2005",
         "Influenza",
         null
        ],
        [
         "NCT00179543",
         "Beth Israel Deaconess Medical Center",
         "Completed",
         "Aug 2001",
         null,
         "Interventional",
         "Sep 2005",
         "Hypertension",
         null
        ],
        [
         "NCT00177216",
         "University of Pittsburgh",
         "Completed",
         "Feb 2002",
         "May 2008",
         "Interventional",
         "Sep 2005",
         "Sleep Initiation and Maintenance Disorders,Sleep Wake Disorders",
         "Zolpidem,Citalopram"
        ],
        [
         "NCT00176813",
         "University of Michigan Rogel Cancer Center",
         "Completed",
         "Mar 2003",
         "Nov 2006",
         "Interventional",
         "Sep 2005",
         "Pancreatic Neoplasms",
         "Gemcitabine,Celecoxib"
        ],
        [
         "NCT00170131",
         "Mayo Clinic",
         "Completed",
         "Sep 2002",
         "Jul 2007",
         "Observational",
         "Sep 2005",
         "Infections,Hepatitis C",
         null
        ],
        [
         "NCT00174551",
         "Rainier Associates",
         "Unknown status",
         "Nov 2003",
         "Nov 2005",
         "Interventional",
         "Sep 2005",
         "Stress Disorders",
         "Prazosin"
        ],
        [
         "NCT00170755",
         "Novartis",
         "Completed",
         "Apr 2002",
         "Jan 2005",
         "Interventional",
         "Sep 2005",
         "Urinary Bladder",
         "Darifenacin"
        ],
        [
         "NCT00174200",
         "Pfizer",
         "Completed",
         "Dec 2004",
         "May 2006",
         "Interventional",
         "Sep 2005",
         "Schizophrenia,Mental Disorders,Psychotic Disorders",
         "Risperidone"
        ],
        [
         "NCT00178698",
         "The University of Texas Health Science Center, Houston",
         "Unknown status",
         "Jul 2002",
         "Jun 2014",
         "Interventional",
         "Sep 2005",
         "Lung Neoplasms,Stomach Neoplasms,Small Cell Lung Carcinoma,Carcinoma",
         "Gemcitabine,Interferons"
        ],
        [
         "NCT00178516",
         "University of Rochester",
         "Completed",
         "Jun 2004",
         "Dec 2005",
         "Observational",
         "Sep 2005",
         "Infertility",
         null
        ],
        [
         "NCT00172289",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2004",
         "Dec 2006",
         "Observational",
         "Sep 2005",
         "Spinal Cord Injuries,Stroke,Wounds and Injuries",
         null
        ],
        [
         "NCT00172718",
         "National Taiwan University Hospital",
         "Unknown status",
         "Mar 2005",
         null,
         "Observational",
         "Sep 2005",
         "Jaw,Mouth",
         null
        ],
        [
         "NCT00174239",
         "Pfizer",
         "Terminated",
         "Jul 2004",
         "Sep 2005",
         "Interventional",
         "Sep 2005",
         "Parkinson Disease",
         "Levodopa,Carbidopa,Cabergoline"
        ],
        [
         "NCT00178620",
         "The University of Texas Health Science Center, Houston",
         "Completed",
         "Nov 2003",
         "Mar 2014",
         "Interventional",
         "Sep 2005",
         "Myocardial Infarction,Heart Diseases,Infarction",
         "Reteplase"
        ],
        [
         "NCT00177112",
         "University of Minnesota",
         "Completed",
         "Jun 2005",
         "Oct 2007",
         "Interventional",
         "Sep 2005",
         "Infections,Communicable Diseases,Urinary Tract Infections",
         null
        ],
        [
         "NCT00173108",
         "National Taiwan University Hospital",
         "Completed",
         "Jan 2006",
         "Oct 2010",
         "Interventional",
         "Sep 2005",
         "Premature Birth",
         null
        ],
        [
         "NCT00170404",
         "National Institute of Allergy and Infectious Diseases (NIAID)",
         "Completed",
         "Jun 2000",
         "Oct 2005",
         "Interventional",
         "Sep 2005",
         "Tuberculosis",
         "Vitamins,Folic Acid,Vitamin A,Thiamine,Selenium,Micronutrients,Trace Elements"
        ],
        [
         "NCT00176280",
         "University of Kentucky",
         "Withdrawn",
         "Sep 2005",
         null,
         "Interventional",
         "Sep 2005",
         "Carcinoma",
         "Dexamethasone,Sargramostim"
        ],
        [
         "NCT00175123",
         "University of Aarhus",
         "Unknown status",
         "May 2005",
         "Jun 2008",
         "Interventional",
         "Sep 2005",
         "Urinary Bladder,Meningomyelocele,Spina Bifida Cystica",
         "Botulinum Toxins,abobotulinumtoxinA"
        ],
        [
         "NCT00170924",
         "Novartis",
         "Completed",
         "Aug 2004",
         "Jun 2006",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Valsartan"
        ],
        [
         "NCT00170222",
         "Medical Center Alkmaar",
         "Completed",
         "Jul 2002",
         "Aug 2008",
         "Interventional",
         "Sep 2005",
         "Lung Diseases,Pulmonary Disease",
         "Doxycycline"
        ],
        [
         "NCT00172042",
         "Novartis Pharmaceuticals",
         "Completed",
         "Mar 2005",
         "Jun 2010",
         "Interventional",
         "Sep 2005",
         "Lung Neoplasms,Carcinoma,Neoplasm Metastasis",
         "Zoledronic Acid"
        ],
        [
         "NCT00170690",
         "North Eastern German Society of Gynaecological Oncology",
         "Completed",
         "Aug 2004",
         "Apr 2012",
         "Interventional",
         "Sep 2005",
         "Ovarian Neoplasms,Carcinoma",
         "Treosulfan,Busulfan"
        ],
        [
         "NCT00176904",
         "Masonic Cancer Center, University of Minnesota",
         "Completed",
         "Jan 1995",
         "Jun 2010",
         "Interventional",
         "Sep 2005",
         "Gaucher Disease,Adrenoleukodystrophy,Pick Disease of the Brain,Gangliosidoses,Leukodystrophy,Niemann-Pick Diseases,Niemann-Pick Disease,Neuronal Ceroid-Lipofuscinoses,Tay-Sachs Disease,Gangliosidosis,Sandhoff Disease,Fucosidosis,Metabolism,Wolman Disease",
         "Cyclophosphamide,Busulfan,Antilymphocyte Serum"
        ],
        [
         "NCT00178204",
         "University of Rochester",
         "Completed",
         "Nov 2004",
         "Dec 2011",
         "Observational",
         "Sep 2005",
         "Fatigue",
         null
        ],
        [
         "NCT00176345",
         "University of Leipzig",
         "Unknown status",
         "Jan 2001",
         null,
         "Interventional",
         "Sep 2005",
         "Coronary Artery Disease,Myocardial Ischemia,Coronary Disease",
         null
        ],
        [
         "NCT00178711",
         "The University of Texas Health Science Center, Houston",
         "Terminated",
         "Nov 2005",
         "Dec 2009",
         "Interventional",
         "Sep 2005",
         "Brain Injuries,Hypothermia,Wounds and Injuries",
         null
        ],
        [
         "NCT00173680",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         null,
         "Observational",
         "Sep 2005",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT00170417",
         "NHS Greater Glasgow and Clyde",
         "Completed",
         "Dec 2000",
         "May 2003",
         "Interventional",
         "Sep 2005",
         "Sleep Initiation and Maintenance Disorders",
         null
        ],
        [
         "NCT00173485",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         "Jun 2009",
         "Observational",
         "Sep 2005",
         "Peritonitis,Renal Insufficiency",
         null
        ],
        [
         "NCT00178269",
         "University of Rochester",
         "Completed",
         "Jan 2005",
         null,
         "Interventional",
         "Sep 2005",
         "Uterine Cervical Neoplasms",
         "Docetaxel"
        ],
        [
         "NCT00171301",
         "Novartis Pharmaceuticals",
         "Completed",
         "Jun 2005",
         "May 2008",
         "Interventional",
         "Sep 2005",
         "Thalassemia,beta-Thalassemia,Iron Overload,Hemosiderosis",
         "Deferasirox"
        ],
        [
         "NCT00171782",
         "Novartis",
         "Completed",
         "Feb 2004",
         "Dec 2004",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Valsartan,Hydrochlorothiazide"
        ],
        [
         "NCT00176566",
         "University of Medicine and Dentistry of New Jersey",
         "Terminated",
         "Sep 2003",
         "Nov 2006",
         "Interventional",
         "Sep 2005",
         "Leukoplakia",
         null
        ],
        [
         "NCT00170846",
         "Novartis Pharmaceuticals",
         "Completed",
         "Feb 2005",
         "Oct 2009",
         "Interventional",
         "Sep 2005",
         null,
         "Everolimus,Azathioprine,Calcineurin Inhibitors"
        ],
        [
         "NCT00173836",
         "National Taiwan University Hospital",
         "Completed",
         "Aug 2003",
         "Aug 2006",
         "Observational",
         "Sep 2005",
         "Nasopharyngeal Carcinoma,Nasopharyngeal Neoplasms",
         null
        ],
        [
         "NCT00174005",
         "National Taiwan University Hospital",
         "Unknown status",
         "Dec 1994",
         null,
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00176527",
         "University of Medicine and Dentistry of New Jersey",
         "Terminated",
         "Nov 2002",
         "Aug 2007",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms",
         "Interferons,Interferon-alpha,Interferon alpha-2,Docetaxel,Estramustine,Isotretinoin"
        ],
        [
         "NCT00171314",
         "Novartis Pharmaceuticals",
         "Completed",
         "Mar 2004",
         null,
         "Interventional",
         "Sep 2005",
         "Breast Neoplasms",
         "Zoledronic Acid,Letrozole"
        ],
        [
         "NCT00175409",
         "University of British Columbia",
         "Completed",
         "Jan 2008",
         "Jun 2010",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00177190",
         "University of Pittsburgh",
         "Completed",
         "Jun 2002",
         "Jan 2006",
         "Observational",
         "Sep 2005",
         "Mycoses,Lymphoma,Mycosis Fungoides,Sezary Syndrome",
         null
        ],
        [
         "NCT00179101",
         "Vanderbilt University",
         "Completed",
         "Apr 2004",
         "Nov 2005",
         "Observational",
         "Sep 2005",
         "Parkinson Disease,Depression",
         null
        ],
        [
         "NCT00175526",
         "University of British Columbia",
         "Completed",
         "Sep 2005",
         "Dec 2010",
         "Observational",
         "Sep 2005",
         "Toxemia,Sepsis",
         null
        ],
        [
         "NCT00176293",
         "University of Kentucky",
         "Terminated",
         "Oct 2005",
         "Feb 2007",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms",
         "Dexamethasone,Doxorubicin"
        ],
        [
         "NCT00178347",
         "University of Rochester",
         "Terminated",
         "Dec 2004",
         null,
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00171964",
         "Novartis Pharmaceuticals",
         "Completed",
         "May 2002",
         "Dec 2008",
         "Interventional",
         "Sep 2005",
         "Neoplasm Metastasis",
         "Zoledronic Acid"
        ],
        [
         "NCT00178945",
         "Vanderbilt University",
         "Completed",
         "Mar 2004",
         "Mar 2006",
         "Interventional",
         "Sep 2005",
         "Myofascial Pain Syndromes,Fibromyalgia,Dystonia,Dystonic Disorders,Syndrome,Torticollis",
         "Botulinum Toxins,abobotulinumtoxinA"
        ],
        [
         "NCT00172965",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2004",
         "Jun 2005",
         "Observational",
         "Sep 2005",
         "Mouth Neoplasms",
         null
        ],
        [
         "NCT00179764",
         "Ann & Robert H Lurie Children's Hospital of Chicago",
         "Completed",
         "Mar 2000",
         "Jan 2014",
         "Interventional",
         "Sep 2005",
         "Leukemia,Melanoma,Neoplasms,Hematologic Neoplasms,Precursor Cell Lymphoblastic Leukemia-Lymphoma",
         "Busulfan"
        ],
        [
         "NCT00170612",
         "University of Melbourne",
         "Completed",
         "Nov 2005",
         "Aug 2008",
         "Interventional",
         "Sep 2005",
         "Pneumococcal Infections",
         "Heptavalent Pneumococcal Conjugate Vaccine"
        ],
        [
         "NCT00172627",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2005",
         null,
         "Observational",
         "Sep 2005",
         "Stomach Neoplasms",
         null
        ],
        [
         "NCT00170872",
         "Novartis",
         "Completed",
         "Nov 2004",
         null,
         "Interventional",
         "Sep 2005",
         "Arthritis,Osteoarthritis",
         "Lumiracoxib"
        ],
        [
         "NCT00172770",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2004",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         "Schizophrenia",
         null
        ],
        [
         "NCT00173849",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2006",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         "Mouth Neoplasms",
         null
        ],
        [
         "NCT00175682",
         "University of British Columbia",
         "Completed",
         "Dec 2004",
         "Jul 2011",
         "Interventional",
         "Sep 2005",
         "Spinal Cord Injuries,Autonomic Dysreflexia",
         "Prazosin"
        ],
        [
         "NCT00179127",
         "Vanderbilt University Medical Center",
         "Completed",
         "Aug 2004",
         "Sep 2012",
         "Interventional",
         "Sep 2005",
         "Ketosis,Acidosis,Diabetic Ketoacidosis",
         "Insulin Glargine"
        ],
        [
         "NCT00178113",
         "University of Pittsburgh",
         "Completed",
         "Jul 2003",
         "Jul 2004",
         "Interventional",
         "Sep 2005",
         "Neoplasms,Carcinoma in Situ,Prostatic Intraepithelial Neoplasia",
         "Lycopene"
        ],
        [
         "NCT00170560",
         "National Institute of Allergy and Infectious Diseases (NIAID)",
         "Completed",
         "Oct 2001",
         null,
         "Observational",
         "Sep 2005",
         "Infections",
         null
        ],
        [
         "NCT00178022",
         "University of Pittsburgh",
         "Completed",
         "Feb 2005",
         "Sep 2006",
         "Interventional",
         "Sep 2005",
         "Brain Injuries,Wounds and Injuries,Depression,Anxiety Disorders",
         null
        ],
        [
         "NCT00178425",
         "University of Rochester",
         "Completed",
         "Jan 2005",
         "Jun 2006",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00178438",
         "University of Rochester",
         "Withdrawn",
         "Jun 2005",
         "Jun 2006",
         "Interventional",
         "Sep 2005",
         "Crohn Disease",
         null
        ],
        [
         "NCT00173173",
         "National Taiwan University Hospital",
         "Completed",
         "Aug 2003",
         "Jul 2004",
         "Observational",
         "Sep 2005",
         "Disease,Feeding and Eating Disorders",
         null
        ],
        [
         "NCT00177294",
         "University of Pittsburgh",
         "Completed",
         "Apr 2004",
         "Aug 2009",
         "Interventional",
         "Sep 2005",
         "Depression,Depressive Disorder",
         "Citalopram"
        ],
        [
         "NCT00175461",
         "University of British Columbia",
         "Completed",
         "Sep 2005",
         "Aug 2011",
         "Interventional",
         "Sep 2005",
         "Osteoarthritis",
         null
        ],
        [
         "NCT00179062",
         "Vanderbilt University",
         "Completed",
         "Feb 2000",
         "Jun 2007",
         "Interventional",
         "Sep 2005",
         "Disease,Schizophrenia,Depressive Disorder,Bipolar Disorder,Psychotic Disorders",
         "Olanzapine,Risperidone"
        ],
        [
         "NCT00173550",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2004",
         null,
         "Observational",
         "Sep 2005",
         "Premature Birth,Menopause,Primary Ovarian Insufficiency",
         null
        ],
        [
         "NCT00177385",
         "University of Pittsburgh",
         "Completed",
         "Jun 2003",
         "Sep 2011",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00171002",
         "Novartis",
         "Completed",
         "Nov 2004",
         "Jun 2005",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Amlodipine,Valsartan"
        ],
        [
         "NCT00177125",
         "University of Minnesota",
         "Completed",
         "Jan 2004",
         "Jan 2004",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms",
         null
        ],
        [
         "NCT00172861",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2005",
         null,
         "Observational",
         "Sep 2005",
         "Stomach Neoplasms",
         null
        ],
        [
         "NCT00174798",
         "Sanofi",
         "Completed",
         "May 2005",
         "May 2006",
         "Interventional",
         "Sep 2005",
         "Urinary Incontinence,Enuresis,Urinary Bladder",
         "Tolterodine Tartrate"
        ],
        [
         "NCT00177892",
         "National Institute on Aging (NIA)",
         "Unknown status",
         "Sep 2003",
         "Aug 2008",
         "Interventional",
         "Sep 2005",
         "Apnea,Sleep Apnea Syndromes,Sleep Apnea,Metabolic Syndrome,Syndrome",
         null
        ],
        [
         "NCT00176761",
         "University of Michigan Rogel Cancer Center",
         "Terminated",
         "Mar 2000",
         "May 2006",
         "Interventional",
         "Sep 2005",
         "Colorectal Neoplasms",
         "Interleukin-2"
        ],
        [
         "NCT00176319",
         "University of Leipzig",
         "Completed",
         "May 2005",
         null,
         "Interventional",
         "Sep 2005",
         "Heart Failure",
         null
        ],
        [
         "NCT00177203",
         "University of Pittsburgh",
         "Completed",
         "Jun 2003",
         "Jan 2009",
         "Interventional",
         "Sep 2005",
         "Sleep Initiation and Maintenance Disorders",
         null
        ],
        [
         "NCT00174993",
         "Takeda",
         "Completed",
         "May 2001",
         "Jan 2005",
         "Interventional",
         "Sep 2005",
         "Diabetes Mellitus",
         "Pioglitazone"
        ],
        [
         "NCT00177658",
         "University of Pittsburgh",
         "Completed",
         "Mar 2006",
         "Jun 2017",
         "Observational",
         "Sep 2005",
         "Salmonella Infections",
         null
        ],
        [
         "NCT00174928",
         "Takeda",
         "Completed",
         "May 2005",
         "Aug 2005",
         "Interventional",
         "Sep 2005",
         "Gastroesophageal Reflux,Esophagitis",
         "Lansoprazole,Dexlansoprazole"
        ],
        [
         "NCT00170677",
         "North Eastern German Society of Gynaecological Oncology",
         "Completed",
         "Sep 2005",
         "Jan 2013",
         "Interventional",
         "Sep 2005",
         "Ovarian Neoplasms,Carcinoma",
         "Topotecan"
        ],
        [
         "NCT00178295",
         "University of Rochester",
         "Completed",
         "Nov 1999",
         null,
         "Observational",
         "Sep 2005",
         "Brain Neoplasms,Trauma",
         null
        ],
        [
         "NCT00176449",
         "University of Maryland, Baltimore",
         "Completed",
         "Apr 2001",
         "Dec 2005",
         "Interventional",
         "Sep 2005",
         "Tobacco Use Disorder",
         "Bupropion"
        ],
        [
         "NCT00179751",
         "Celgene Corporation",
         "Terminated",
         "Apr 2005",
         "Aug 2006",
         "Interventional",
         "Sep 2005",
         "Pancreatic Neoplasms",
         "Gemcitabine,Lenalidomide"
        ],
        [
         "NCT00172744",
         "National Taiwan University Hospital",
         "Unknown status",
         "Apr 2005",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00177255",
         "University of Pittsburgh",
         "Terminated",
         "Apr 2005",
         "Dec 2008",
         "Interventional",
         "Sep 2005",
         null,
         "Docetaxel,Capecitabine"
        ],
        [
         "NCT00171925",
         "Novartis Pharmaceuticals",
         "Terminated",
         "Aug 2000",
         "Nov 2008",
         "Interventional",
         "Sep 2005",
         "Multiple Myeloma,Neoplasms",
         "Vitamin D,Zoledronic Acid,Calcium"
        ],
        [
         "NCT00177307",
         "University of Pittsburgh",
         "Completed",
         "Jan 2005",
         "Feb 2012",
         "Interventional",
         "Sep 2005",
         "Colorectal Neoplasms",
         "Bevacizumab,Capecitabine,Oxaliplatin"
        ],
        [
         "NCT00173862",
         "National Taiwan University Hospital",
         "Completed",
         "May 2000",
         "Jun 2006",
         "Interventional",
         "Jun 2005",
         "Carcinoma",
         "Gemcitabine,Ifosfamide"
        ],
        [
         "NCT00171990",
         "Novartis",
         "Completed",
         "Jan 2003",
         "Feb 2006",
         "Interventional",
         "Sep 2005",
         "Herpes Genitalis",
         "Famciclovir"
        ],
        [
         "NCT00177060",
         "Hordinsky, Maria K., MD",
         "Terminated",
         "Oct 2003",
         "May 2007",
         "Interventional",
         "Sep 2005",
         "Wounds and Injuries",
         "Hydromorphone"
        ],
        [
         "NCT00173043",
         "National Taiwan University Hospital",
         "Unknown status",
         "Oct 2004",
         "Aug 2005",
         "Observational",
         "Sep 2005",
         "Polycystic Ovary Syndrome,Insulin Resistance,Syndrome",
         null
        ],
        [
         "NCT00171769",
         "Novartis",
         "Completed",
         "Apr 2005",
         null,
         "Interventional",
         "Sep 2005",
         "Atrial Fibrillation",
         "Certoparin"
        ],
        [
         "NCT00171951",
         "Novartis Pharmaceuticals",
         "Completed",
         "Aug 2004",
         "Jul 2013",
         "Interventional",
         "Sep 2005",
         "ACTH-Secreting Pituitary Adenoma,Pituitary ACTH Hypersecretion",
         "Pasireotide"
        ],
        [
         "NCT00174850",
         "State University of New York - Upstate Medical University",
         "Completed",
         "Jul 2004",
         "May 2005",
         "Interventional",
         "Sep 2005",
         "Anxiety Disorders",
         null
        ],
        [
         "NCT00177970",
         "University of Pittsburgh",
         "Terminated",
         "Oct 2003",
         "Apr 2008",
         "Interventional",
         "Sep 2005",
         "Diarrhea",
         "Immunoglobulins,Antibodies,Immunoglobulin G,gamma-Globulins,Rho(D) Immune Globulin"
        ],
        [
         "NCT00171834",
         "Novartis Pharmaceuticals",
         "Completed",
         "Aug 2003",
         "Sep 2008",
         "Interventional",
         "Sep 2005",
         "Lung Neoplasms,Carcinoma",
         "Epothilones,Epothilone B"
        ],
        [
         "NCT00172601",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         null,
         "Interventional",
         "Sep 2005",
         "Bursitis",
         null
        ],
        [
         "NCT00176254",
         "Susanne Arnold",
         "Completed",
         "May 2000",
         "Oct 2012",
         "Interventional",
         "Sep 2005",
         "Carcinoma,Head and Neck Neoplasms",
         "Paclitaxel,Carboplatin"
        ],
        [
         "NCT00176553",
         "University of Medicine and Dentistry of New Jersey",
         "Terminated",
         "Mar 2003",
         "May 2007",
         "Interventional",
         "Sep 2005",
         "Neurotoxicity Syndromes",
         "Dextromethorphan"
        ],
        [
         "NCT00171405",
         "Novartis",
         "Completed",
         "Jun 2005",
         "Feb 2006",
         "Interventional",
         "Aug 2005",
         "Hypertension",
         null
        ],
        [
         "NCT00177814",
         "University of Pittsburgh",
         "Completed",
         "Sep 2005",
         "Jun 2017",
         "Observational",
         "Sep 2005",
         "Bacterial Infections,Gram-Negative Bacterial Infections",
         null
        ],
        [
         "NCT00174122",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jul 2005",
         "Jun 2006",
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00179608",
         "Celgene",
         "Completed",
         "Sep 2005",
         "Jun 2007",
         "Interventional",
         "Sep 2005",
         "Melanoma",
         "Lenalidomide"
        ],
        [
         "NCT00173394",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         "Dec 2008",
         "Observational",
         "Sep 2005",
         "Ovarian Neoplasms,Carcinoma",
         null
        ],
        [
         "NCT00170001",
         "Mayo Clinic",
         "Completed",
         "Apr 2005",
         "Aug 2006",
         "Interventional",
         "Sep 2005",
         "Gastroesophageal Reflux",
         "Esomeprazole"
        ],
        [
         "NCT00170963",
         "Novartis",
         "Completed",
         "Oct 2004",
         "Jun 2005",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Amlodipine,Valsartan"
        ],
        [
         "NCT00170365",
         "Hennepin Healthcare Research Institute",
         "Completed",
         "Jul 2004",
         "Mar 2005",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00173810",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         "Apr 2007",
         "Observational",
         "Sep 2005",
         "Stroke",
         null
        ],
        [
         "NCT00179335",
         "Albert Einstein College of Medicine",
         "Completed",
         "Aug 2003",
         "Sep 2006",
         "Observational",
         "Sep 2005",
         "HIV Infections",
         null
        ],
        [
         "NCT00178256",
         "University of Rochester",
         "Completed",
         "Jun 1998",
         "Dec 2012",
         "Interventional",
         "Sep 2005",
         "Carcinoma",
         "Paclitaxel"
        ],
        [
         "NCT00178035",
         "University of Pittsburgh",
         "Completed",
         "Dec 1999",
         "Aug 2003",
         "Interventional",
         "Sep 2005",
         "Depression,Depressive Disorder",
         "Paroxetine"
        ],
        [
         "NCT00177567",
         "University of Pittsburgh",
         "Completed",
         "Jul 2001",
         "Jan 2004",
         "Interventional",
         "Sep 2005",
         "Disease,Bipolar Disorder,Mood Disorders",
         "Lamotrigine,Valproic Acid,Olanzapine,Risperidone,Lithium Carbonate,Mirtazapine,Tranylcypromine,Bupropion,Paroxetine,Venlafaxine Hydrochloride"
        ],
        [
         "NCT00172666",
         "National Taiwan University Hospital",
         "Unknown status",
         "Aug 2005",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         "Arthritis,Lupus Erythematosus",
         null
        ],
        [
         "NCT00172731",
         "National Taiwan University Hospital",
         "Completed",
         "Mar 2005",
         "Jun 2005",
         "Observational",
         "Sep 2005",
         "Schizophrenia",
         null
        ],
        [
         "NCT00171873",
         "Carmen Schade-Brittinger",
         "Completed",
         "Sep 2001",
         "Dec 2013",
         "Interventional",
         "Sep 2005",
         "Neuroendocrine Tumors,Neoplasm Metastasis",
         "Octreotide"
        ],
        [
         "NCT00173355",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         "Aug 2005",
         "Observational",
         "Sep 2005",
         "Dermatofibrosarcoma,Soft Tissue Neoplasms",
         null
        ],
        [
         "NCT00176111",
         "Heidelberg University",
         "Terminated",
         "Jan 2004",
         "Jan 2005",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00170274",
         "Medtronic Bakken Research Center",
         "Completed",
         "Aug 2000",
         "Oct 2014",
         "Interventional",
         "Sep 2005",
         "Arrhythmias,Tachycardia",
         null
        ],
        [
         "NCT00172250",
         "National Taiwan University Hospital",
         "Completed",
         "Sep 2003",
         null,
         "Observational",
         "Sep 2005",
         "Coronary Artery Disease",
         null
        ],
        [
         "NCT00174356",
         "Pfizer",
         "Completed",
         "Dec 2002",
         "Oct 2005",
         "Interventional",
         "Sep 2005",
         "Carcinoma",
         "Paclitaxel,Carboplatin"
        ],
        [
         "NCT00170989",
         "Novartis",
         "Completed",
         "Sep 2004",
         "Jul 2005",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Valsartan,Hydrochlorothiazide"
        ],
        [
         "NCT00179569",
         "Beth Israel Deaconess Medical Center",
         "Completed",
         "Aug 2005",
         "Sep 2007",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00172796",
         "National Taiwan University Hospital",
         "Unknown status",
         "Apr 2005",
         null,
         "Observational",
         "Sep 2005",
         "Metabolic Syndrome,Prediabetic State",
         null
        ],
        [
         "NCT00178126",
         "University of Pittsburgh",
         "Completed",
         "Mar 2004",
         "Oct 2008",
         "Interventional",
         "Sep 2005",
         "Pressure Ulcer,Ulcer",
         null
        ],
        [
         "NCT00172029",
         "Novartis",
         "Completed",
         "Apr 2003",
         null,
         "Interventional",
         "Sep 2005",
         "Breast Neoplasms,Bone Diseases",
         "Zoledronic Acid"
        ],
        [
         "NCT00176696",
         "University of Medicine and Dentistry of New Jersey",
         "Terminated",
         "Aug 2005",
         "Apr 2007",
         "Observational",
         "Sep 2005",
         "Pain",
         "Anesthetics"
        ],
        [
         "NCT00177788",
         "University of Pittsburgh",
         "Completed",
         "Sep 2005",
         "Aug 2012",
         "Observational",
         "Sep 2005",
         "Mycoses,Fungemia",
         null
        ],
        [
         "NCT00171938",
         "Novartis",
         "Terminated",
         "Apr 2004",
         "Jun 2006",
         "Interventional",
         "Sep 2005",
         "Glioblastoma",
         "Imatinib Mesylate"
        ],
        [
         "NCT00177359",
         "University of Pittsburgh",
         "Completed",
         "Nov 2005",
         "Jun 2007",
         "Interventional",
         "Sep 2005",
         "Mobility Limitation",
         null
        ],
        [
         "NCT00171860",
         "Novartis Pharmaceuticals",
         "Terminated",
         "Sep 2002",
         null,
         "Interventional",
         "Sep 2005",
         "Hypereosinophilic Syndrome,Syndrome",
         "Imatinib Mesylate"
        ],
        [
         "NCT00171717",
         "Novartis",
         "Completed",
         "Feb 2004",
         "Dec 2005",
         "Interventional",
         "Sep 2005",
         "Diabetes Mellitus",
         "Cyclosporine,Cyclosporins"
        ],
        [
         "NCT00176748",
         "University of Michigan Rogel Cancer Center",
         "Completed",
         "Jul 2005",
         "Jun 2009",
         "Interventional",
         "Sep 2005",
         "Thyroid Neoplasms,Thyroid Diseases",
         null
        ],
        [
         "NCT00175084",
         "Tufts University",
         "Completed",
         "Oct 2004",
         "Dec 2012",
         "Interventional",
         "Sep 2005",
         "Cardiovascular Diseases,Metabolic Syndrome,Hyperlipidemias",
         null
        ],
        [
         "NCT00178334",
         "University of Rochester",
         "Completed",
         "Mar 2006",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         "Urinary Incontinence,Enuresis",
         null
        ],
        [
         "NCT00172822",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2003",
         "Jun 2005",
         "Observational",
         "Sep 2005",
         "Appendicitis",
         null
        ],
        [
         "NCT00170885",
         "Novartis",
         "Completed",
         "May 2005",
         "Jul 2007",
         "Interventional",
         "Sep 2005",
         null,
         "Everolimus"
        ],
        [
         "NCT00177684",
         "University of Pittsburgh",
         "Completed",
         "Sep 2004",
         "Sep 2005",
         "Interventional",
         "Sep 2005",
         "Mycoses",
         "Amphotericin B,Liposomal amphotericin B"
        ],
        [
         "NCT00178672",
         "The University of Texas Health Science Center, Houston",
         "Completed",
         "Nov 2002",
         "Aug 2007",
         "Interventional",
         "Sep 2005",
         "Carotid Stenosis,Carotid Artery Diseases,Stroke,Heart Diseases",
         null
        ],
        [
         "NCT00171080",
         "Novartis",
         "Completed",
         "Apr 2004",
         "Mar 2006",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Valsartan,Irbesartan"
        ],
        [
         "NCT00176891",
         "Masonic Cancer Center, University of Minnesota",
         "Completed",
         "Mar 2004",
         "Nov 2012",
         "Interventional",
         "Sep 2005",
         "Mucopolysaccharidoses,Mucopolysaccharidosis I,Syndrome",
         null
        ],
        [
         "NCT00172107",
         "Shire",
         "Completed",
         "May 1995",
         "Mar 1997",
         "Interventional",
         "Sep 2005",
         "Osteoporosis",
         "Parathyroid Hormone"
        ],
        [
         "NCT00177827",
         "University of Pittsburgh",
         "Completed",
         "Mar 2004",
         "Mar 2006",
         "Observational",
         "Sep 2005",
         "Aspergillosis",
         null
        ],
        [
         "NCT00177502",
         "University of Pittsburgh",
         "Completed",
         "Jan 2003",
         "Dec 2006",
         "Interventional",
         "Sep 2005",
         "Body Weight,Weight Loss,Weight Gain",
         null
        ],
        [
         "NCT00175045",
         "Takeda",
         "Completed",
         "Jun 2003",
         "Oct 2003",
         "Interventional",
         "Sep 2005",
         "Esophagitis",
         "Lansoprazole,Dexlansoprazole"
        ],
        [
         "NCT00175981",
         "Heidelberg University",
         "Completed",
         "Feb 2003",
         "Nov 2004",
         "Interventional",
         "Sep 2005",
         null,
         "Sildenafil Citrate,Fluvoxamine"
        ],
        [
         "NCT00177983",
         "University of Pittsburgh",
         "Completed",
         "Jan 2003",
         "Jan 2005",
         "Interventional",
         "Sep 2005",
         "Recurrence",
         null
        ],
        [
         "NCT00179699",
         "Celgene Corporation",
         "Terminated",
         "Sep 2005",
         "Nov 2006",
         "Interventional",
         "Sep 2005",
         "Lung Neoplasms,Carcinoma",
         "Pemetrexed,Lenalidomide"
        ],
        [
         "NCT00175383",
         "University of British Columbia",
         "Unknown status",
         "Jun 2004",
         "Dec 2013",
         "Interventional",
         "Sep 2005",
         "Prostatic Neoplasms",
         "Hormones,Prolactin Release-Inhibiting Factors"
        ],
        [
         "NCT00178230",
         "University of Rochester",
         "Completed",
         "Mar 1996",
         "Nov 2013",
         "Observational",
         "Sep 2005",
         "Lung Neoplasms",
         null
        ],
        [
         "NCT00170859",
         "Novartis Pharmaceuticals",
         "Completed",
         "Aug 2004",
         "Dec 2006",
         "Interventional",
         "Sep 2005",
         null,
         "Everolimus"
        ],
        [
         "NCT00179465",
         "Beth Israel Deaconess Medical Center",
         "Active, not recruiting",
         "Nov 2003",
         "Sep 2022",
         "Interventional",
         "Sep 2005",
         "Schizophrenia",
         "Tiagabine,Antipsychotic Agents"
        ],
        [
         "NCT00173732",
         "National Taiwan University Hospital",
         "Unknown status",
         "Sep 2005",
         null,
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00170976",
         "Novartis",
         "Completed",
         "Apr 2004",
         "Jun 2005",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Amlodipine,Valsartan"
        ],
        [
         "NCT00173641",
         "National Taiwan University Hospital",
         "Unknown status",
         "Sep 2005",
         "Aug 2006",
         "Observational",
         "Sep 2005",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT00173342",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         null,
         "Observational",
         "Sep 2005",
         "Bundle-Branch Block,Heart Block",
         null
        ],
        [
         "NCT00174148",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jul 2005",
         "Jul 2006",
         "Observational",
         "Sep 2005",
         "Neck Pain",
         null
        ],
        [
         "NCT00170144",
         "Mayo Clinic",
         "Completed",
         "Sep 2005",
         "Jun 2007",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00170469",
         "PharmAthene UK Limited",
         "Completed",
         "Mar 2005",
         "Feb 2007",
         "Interventional",
         "Sep 2005",
         "Anthrax",
         "Aluminum Hydroxide"
        ],
        [
         "NCT00179634",
         "Beth Israel Deaconess Medical Center",
         "Terminated",
         "Mar 2005",
         "Mar 2008",
         "Interventional",
         "Sep 2005",
         "Breast Neoplasms",
         null
        ],
        [
         "NCT00175318",
         "University of British Columbia",
         "Completed",
         "Apr 2005",
         "Feb 2011",
         "Interventional",
         "Sep 2005",
         "Dental Caries",
         null
        ],
        [
         "NCT00175812",
         "University of Bergen",
         "Completed",
         "Nov 2004",
         "Nov 2009",
         "Interventional",
         "Sep 2005",
         "Leukemia",
         "Tretinoin,Theophylline,Valproic Acid"
        ],
        [
         "NCT00178906",
         "Vanderbilt University",
         "Completed",
         "Dec 1999",
         "Apr 2008",
         "Observational",
         "Sep 2005",
         "Depression",
         null
        ],
        [
         "NCT00175448",
         "University of British Columbia",
         "Completed",
         "Sep 2005",
         "Dec 2007",
         "Interventional",
         "Sep 2005",
         "Arthritis",
         null
        ],
        [
         "NCT00173069",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2006",
         "Dec 2010",
         "Observational",
         "Sep 2005",
         "Schizophrenia",
         null
        ],
        [
         "NCT00176956",
         "Hordinsky, Maria K., MD",
         "Terminated",
         "Nov 2002",
         "Jan 2007",
         "Interventional",
         "Sep 2005",
         "Dermatitis,Skin Diseases",
         null
        ],
        [
         "NCT00173095",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2005",
         "Jan 2008",
         "Observational",
         "Sep 2005",
         "Subarachnoid Hemorrhage,Hemorrhage",
         null
        ],
        [
         "NCT00177424",
         "University of Pittsburgh",
         "Terminated",
         "Jul 2004",
         "Oct 2007",
         "Interventional",
         "Sep 2005",
         "Stroke,Depression,Depressive Disorder",
         "Sertraline"
        ],
        [
         "NCT00172783",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         "Dec 2005",
         "Observational",
         "Sep 2005",
         "Tuberculosis",
         null
        ],
        [
         "NCT00176917",
         "Masonic Cancer Center, University of Minnesota",
         "Completed",
         "May 1999",
         "May 2010",
         "Interventional",
         "Sep 2005",
         "Mucolipidoses,Mucopolysaccharidoses,Mucopolysaccharidosis I,Mannosidase Deficiency Diseases,alpha-Mannosidosis,Mucopolysaccharidosis VI",
         "Cyclophosphamide,Busulfan,Thymoglobulin"
        ],
        [
         "NCT00176839",
         "Masonic Cancer Center, University of Minnesota",
         "Terminated",
         "Jun 2000",
         "Feb 2012",
         "Interventional",
         "Sep 2005",
         "Neoplasms,Hematologic Neoplasms,Leukemia,Precursor Cell Lymphoblastic Leukemia-Lymphoma",
         "Cyclophosphamide,Melphalan,Busulfan,Antilymphocyte Serum,Lenograstim,Sargramostim"
        ],
        [
         "NCT00179322",
         "National Institute on Deafness and Other Communication Disorders (NIDCD)",
         "Completed",
         "Sep 2005",
         "Sep 2016",
         "Observational",
         "Sep 2005",
         "Sleep Deprivation",
         null
        ],
        [
         "NCT00170664",
         "North Eastern German Society of Gynaecological Oncology",
         "Completed",
         "Jan 1999",
         "Sep 2004",
         "Interventional",
         "Sep 2005",
         "Ovarian Neoplasms,Carcinoma",
         "Paclitaxel,Carboplatin"
        ],
        [
         "NCT00172003",
         "Novartis Pharmaceuticals",
         "Completed",
         "Sep 2004",
         "Jul 2009",
         "Interventional",
         "Sep 2005",
         "Neoplasm Metastasis,Neoplasms,Carcinoma",
         "Zoledronic Acid"
        ],
        [
         "NCT00170261",
         "Medtronic Bakken Research Center",
         "Completed",
         "Apr 2002",
         "Sep 2006",
         "Interventional",
         "Sep 2005",
         "Syncope",
         null
        ],
        [
         "NCT00179075",
         "Vanderbilt University",
         "Completed",
         "Apr 2003",
         "Apr 2008",
         "Observational",
         "Sep 2005",
         "Graft vs Host Disease",
         null
        ],
        [
         "NCT00179777",
         "University of Helsinki",
         "Completed",
         "May 2002",
         "Sep 2017",
         "Interventional",
         "Sep 2005",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT00174018",
         "National Taiwan University Hospital",
         "Completed",
         "Sep 1993",
         null,
         "Observational",
         "Sep 2005",
         "Shoulder Impingement Syndrome",
         null
        ],
        [
         "NCT00171535",
         "Novartis",
         "Completed",
         "Oct 2004",
         "Apr 2005",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Amlodipine,Valsartan"
        ],
        [
         "NCT00173914",
         "National Taiwan University Hospital",
         "Unknown status",
         "Mar 2003",
         null,
         "Observational",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00175825",
         "UCB Pharma",
         "Completed",
         "Nov 2005",
         "Jun 2006",
         "Interventional",
         "Sep 2005",
         "Epilepsy,Seizures",
         "Brivaracetam"
        ],
        [
         "NCT00172198",
         "National Taiwan University Hospital",
         "Unknown status",
         "Mar 2005",
         "Mar 2007",
         "Interventional",
         "Sep 2005",
         null,
         null
        ],
        [
         "NCT00171366",
         "Novartis",
         "Completed",
         "Jul 2004",
         "Jul 2005",
         "Interventional",
         "Sep 2005",
         "Hypertension",
         "Amlodipine,Benazepril"
        ],
        [
         "NCT00170287",
         "Medtronic Bakken Research Center",
         "Completed",
         "May 2002",
         "Aug 2011",
         "Interventional",
         "Sep 2005",
         "Tachycardia",
         null
        ],
        [
         "NCT00170729",
         "Novartis",
         "Completed",
         "Aug 2004",
         "Feb 2005",
         "Interventional",
         "Sep 2005",
         "Cataract,Capsule Opacification,Uveitis,Inflammation",
         "Prednisolone,Methylprednisolone Acetate,Methylprednisolone,Methylprednisolone Hemisuccinate,Prednisolone acetate,Prednisolone hemisuccinate,Prednisolone phosphate"
        ],
        [
         "NCT00173225",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         "Jun 2005",
         "Observational",
         "Sep 2005",
         "Asthma,Cough",
         null
        ],
        [
         "NCT00178100",
         "University of Pittsburgh",
         "Completed",
         "Mar 1999",
         "Aug 2005",
         "Interventional",
         "Sep 2005",
         "Depression,Depressive Disorder",
         "Paroxetine"
        ],
        [
         "NCT00176397",
         "University of Leipzig",
         "Unknown status",
         "Aug 2003",
         null,
         "Interventional",
         "Sep 2005",
         "Coronary Artery Disease,Myocardial Ischemia,Coronary Disease,Coronary Stenosis,Constriction",
         null
        ],
        [
         "NCT00177333",
         "University of Pittsburgh",
         "Completed",
         "Sep 2005",
         "May 2006",
         "Interventional",
         "Sep 2005",
         "Vomiting",
         "Doxycycline"
        ],
        [
         "NCT00175643",
         "University of British Columbia",
         "Completed",
         "Feb 2005",
         "Nov 2005",
         "Interventional",
         "Sep 2005",
         "Keratosis",
         "Imiquimod"
        ],
        [
         "NCT00172913",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         "Jul 2008",
         "Observational",
         "Sep 2005",
         "Myopia",
         null
        ],
        [
         "NCT00173628",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 1990",
         "Dec 2006",
         "Observational",
         "Sep 2005",
         "Diabetes Mellitus",
         null
        ],
        [
         "NCT00172757",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jan 2002",
         "Jun 2005",
         "Observational",
         "Sep 2005",
         "Colorectal Neoplasms,Diabetes Mellitus",
         null
        ],
        [
         "NCT00174512",
         "Pfizer",
         "Completed",
         "Mar 2005",
         "Jun 2006",
         "Interventional",
         "Sep 2005",
         "Heart Diseases,Myocardial Ischemia,Coronary Artery Disease",
         "Moxifloxacin"
        ],
        [
         "NCT00172939",
         "National Taiwan University Hospital",
         "Unknown status",
         "Jun 2005",
         "Jan 2008",
         "Interventional",
         "Sep 2005",
         "Vitiligo",
         null
        ],
        [
         "NCT00176995",
         "Hordinsky, Maria K., MD",
         "Completed",
         "Mar 1999",
         "Oct 2000",
         "Interventional",
         "Sep 2005",
         "Hair Diseases",
         "Eflornithine"
        ]
       ],
       "datasetInfos": [],
       "dbfsResultPath": null,
       "isJsonSchema": true,
       "metadata": {},
       "overflow": true,
       "plotOptions": {
        "customPlotOptions": {},
        "displayType": "table",
        "pivotAggregation": null,
        "pivotColumns": null,
        "xColumns": null,
        "yColumns": null
       },
       "removedWidgets": [],
       "schema": [
        {
         "metadata": "{}",
         "name": "Id",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Sponsor",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Status",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Start",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Completion",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Type",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Submission",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Conditions",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Interventions",
         "type": "\"string\""
        }
       ],
       "type": "table"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Taking a broad look at the clinical trial data\n",
    "clinical_df.display()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e5a05597-87a2-4e48-aa07-b42d877c20cb",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "##ANALYSING THE DATA"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "7fbc2504-0a50-42eb-9deb-547b7f35266c",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Problem Statement 1 - Obtaining the number of distinct studies in the dataset"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "807b22f6-224f-45d7-a6b5-aa7bbcbfdac7",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[9]: 387261"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[9]: 387261",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# Selecting the distinct rows and counting them\n",
    "no_of_distinct_studies = clinical_df.distinct().count()\n",
    "no_of_distinct_studies"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "0a659916-bd44-4fba-868a-bc5ba78d2699",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Problem Statement 2 - Listing all the types of studies in the data set along with their frequencies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "bcc2b18d-9388-4f4c-84ee-87c248f20182",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------------------+------+\n",
       "|Type                            |count |\n",
       "+--------------------------------+------+\n",
       "|Interventional                  |301472|\n",
       "|Observational                   |77540 |\n",
       "|Observational [Patient Registry]|8180  |\n",
       "|Expanded Access                 |69    |\n",
       "+--------------------------------+------+\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------------------+------+\n|Type                            |count |\n+--------------------------------+------+\n|Interventional                  |301472|\n|Observational                   |77540 |\n|Observational [Patient Registry]|8180  |\n|Expanded Access                 |69    |\n+--------------------------------+------+\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Grouping the data by trials, counting frequencies, then sorting from most frequent to least frequent\n",
    "types_list = clinical_df.groupBy('Type').count().sort('count', ascending=False)\n",
    "types_list.show(truncate = False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "b7b4d924-0d19-4117-89aa-c66f1830c4e6",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Problem Statement 3 - Displaying the top 5 conditions with their frequencies"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "54386f29-686b-497f-887a-58edb407f755",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------------------------------------------------------------------------------------------------+\n",
       "|Conditions                                                                                           |\n",
       "+-----------------------------------------------------------------------------------------------------+\n",
       "|null                                                                                                 |\n",
       "|Autistic Disorder,Autism Spectrum Disorder                                                           |\n",
       "|Diabetes Mellitus                                                                                    |\n",
       "|Tuberculosis,Lung Diseases,Pulmonary Disease                                                         |\n",
       "|Diverticular Diseases,Diverticulum,Diverticulosis                                                    |\n",
       "|Asthma                                                                                               |\n",
       "|Hypoventilation                                                                                      |\n",
       "|Lymphoma                                                                                             |\n",
       "|null                                                                                                 |\n",
       "|Myositis                                                                                             |\n",
       "|Diabetes Mellitus                                                                                    |\n",
       "|Hypertension                                                                                         |\n",
       "|Periodontal Diseases                                                                                 |\n",
       "|Diabetes Mellitus                                                                                    |\n",
       "|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones                             |\n",
       "|null                                                                                                 |\n",
       "|null                                                                                                 |\n",
       "|Hookworm Infections,Celiac Disease                                                                   |\n",
       "|Ascites                                                                                              |\n",
       "|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\n",
       "+-----------------------------------------------------------------------------------------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------------------------------------------------------------------------------------------------+\n|Conditions                                                                                           |\n+-----------------------------------------------------------------------------------------------------+\n|null                                                                                                 |\n|Autistic Disorder,Autism Spectrum Disorder                                                           |\n|Diabetes Mellitus                                                                                    |\n|Tuberculosis,Lung Diseases,Pulmonary Disease                                                         |\n|Diverticular Diseases,Diverticulum,Diverticulosis                                                    |\n|Asthma                                                                                               |\n|Hypoventilation                                                                                      |\n|Lymphoma                                                                                             |\n|null                                                                                                 |\n|Myositis                                                                                             |\n|Diabetes Mellitus                                                                                    |\n|Hypertension                                                                                         |\n|Periodontal Diseases                                                                                 |\n|Diabetes Mellitus                                                                                    |\n|Appendicitis,Stomach Ulcer,Cholecystolithiasis,Cholelithiasis,Gallstones                             |\n|null                                                                                                 |\n|null                                                                                                 |\n|Hookworm Infections,Celiac Disease                                                                   |\n|Ascites                                                                                              |\n|Chronic Pain,Substance-Related Disorders,Opioid-Related Disorders,Narcotic-Related Disorders,Behavior|\n+-----------------------------------------------------------------------------------------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#viewing the conditions column\n",
    "clinical_df.select(\"Conditions\").show(truncate = False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "b27464fe-aebd-485e-94f3-e7cd5e2a9c79",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|[Autistic Disorde...|                null|\n",
       "|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016| [Diabetes Mellitus]|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|[Tuberculosis, Lu...|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|[Diverticular Dis...|                null|\n",
       "|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|            [Asthma]|Fluticasone,Xhanc...|\n",
       "|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|   [Hypoventilation]|                null|\n",
       "|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|          [Lymphoma]|                null|\n",
       "|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n",
       "|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|          [Myositis]|                null|\n",
       "|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016| [Diabetes Mellitus]|Liraglutide,Xultophy|\n",
       "|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|      [Hypertension]|                null|\n",
       "|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|[Periodontal Dise...|                null|\n",
       "|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016| [Diabetes Mellitus]|Metformin,Empagli...|\n",
       "|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|[Appendicitis, St...|                null|\n",
       "|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n",
       "|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|[Hookworm Infecti...|                null|\n",
       "|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|           [Ascites]|                null|\n",
       "|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|[Chronic Pain, Su...|                null|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|[Autistic Disorde...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016| [Diabetes Mellitus]|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|[Tuberculosis, Lu...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|[Diverticular Dis...|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|            [Asthma]|Fluticasone,Xhanc...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|   [Hypoventilation]|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|          [Lymphoma]|                null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|          [Myositis]|                null|\n|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016| [Diabetes Mellitus]|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|      [Hypertension]|                null|\n|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|[Periodontal Dise...|                null|\n|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016| [Diabetes Mellitus]|Metformin,Empagli...|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|[Appendicitis, St...|                null|\n|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|[Hookworm Infecti...|                null|\n|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|           [Ascites]|                null|\n|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|[Chronic Pain, Su...|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#splitting the conditions column row by row in order for it to be exploded\n",
    "from pyspark.sql.functions import split\n",
    "splitDF = clinical_df.withColumn('Conditions', split(clinical_df[\"Conditions\"], \",\"))\n",
    "splitDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "cbaa6d64-3a8f-49d3-aa18-4248d00f28f8",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|   Autistic Disorder|                null|\n",
       "|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autism Spectrum D...|                null|\n",
       "|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|        Tuberculosis|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|       Lung Diseases|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|   Pulmonary Disease|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|        Diverticulum|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|      Diverticulosis|                null|\n",
       "|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n",
       "|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n",
       "|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n",
       "|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n",
       "|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n",
       "|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n",
       "|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n",
       "|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n",
       "|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|        Appendicitis|                null|\n",
       "|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|       Stomach Ulcer|                null|\n",
       "|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015| Cholecystolithiasis|                null|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|   Autistic Disorder|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autism Spectrum D...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|        Tuberculosis|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|       Lung Diseases|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|   Pulmonary Disease|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|        Diverticulum|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|      Diverticulosis|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|        Appendicitis|                null|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|       Stomach Ulcer|                null|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015| Cholecystolithiasis|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#exploding the split array\n",
    "from pyspark.sql.functions import explode\n",
    "explodedDF = splitDF.withColumn('Conditions', explode(splitDF[\"Conditions\"]))\n",
    "explodedDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "dd100eaf-c70f-44fb-add2-51a417799103",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------------+-----+\n",
       "|       Conditions|count|\n",
       "+-----------------+-----+\n",
       "|        Carcinoma|13389|\n",
       "|Diabetes Mellitus|11080|\n",
       "|        Neoplasms| 9371|\n",
       "| Breast Neoplasms| 8640|\n",
       "|         Syndrome| 8032|\n",
       "+-----------------+-----+\n",
       "only showing top 5 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------------+-----+\n|       Conditions|count|\n+-----------------+-----+\n|        Carcinoma|13389|\n|Diabetes Mellitus|11080|\n|        Neoplasms| 9371|\n| Breast Neoplasms| 8640|\n|         Syndrome| 8032|\n+-----------------+-----+\nonly showing top 5 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#grouping and counting the exploded conditions (and then displaying from most frequent to least frequent for better view)\n",
    "explodedDF.groupBy('Conditions').count().sort('count', ascending=False).show(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "9f695c10-65b7-4c65-be60-2b906c238a83",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Problem Statement 4 - The 5 most frequent roots"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "6c3c20f2-bdaf-41dc-a72d-b6728a4943a5",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "####Loading the Mesh Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "9d40e97d-6b0e-45f7-869b-5f02a9caf0fd",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Truncated to first 65536 bytes]\n",
       "Out[15]: 'term,tree\\r\\nCalcimycin,D03.633.100.221.173\\r\\nA-23187,D03.633.100.221.173\\r\\nTemefos,D02.705.400.625.800\\r\\nTemefos,D02.705.539.345.800\\r\\nTemefos,D02.886.300.692.800\\r\\nAbate,D02.705.400.625.800\\r\\nAbate,D02.705.539.345.800\\r\\nAbate,D02.886.300.692.800\\r\\nDifos,D02.705.400.625.800\\r\\nDifos,D02.705.539.345.800\\r\\nDifos,D02.886.300.692.800\\r\\nAbattoirs,J01.576.423.200.700.100\\r\\nAbattoirs,J03.540.020\\r\\nAbbreviations as Topic,L01.559.598.400.556.131\\r\\nAcronyms as Topic,L01.559.598.400.556.131\\r\\nAbdomen,A01.923.047\\r\\n\"Abdomen, Acute\",C23.888.592.612.054.200\\r\\n\"Abdomen, Acute\",C23.888.821.030.249\\r\\nAbdominal Injuries,C26.017\\r\\nAbdominal Neoplasms,C04.588.033\\r\\nAbdominal Muscles,A02.633.567.050\\r\\nCremaster Muscle,A02.633.567.050\\r\\nPyramidalis Muscle,A02.633.567.050\\r\\nQuadratus Abdominis,A02.633.567.050\\r\\nTransversus Abdominis,A02.633.567.050\\r\\nAbducens Nerve,A08.800.800.120.030\\r\\nAbelson murine leukemia virus,B04.613.807.375.525.020\\r\\nAbelson murine leukemia virus,B04.820.650.375.525.020\\r\\nAbetalipoproteinemia,C16.320.565.398.500.440.500\\r\\nAbetalipoproteinemia,C18.452.584.500.875.440.500\\r\\nAbetalipoproteinemia,C18.452.648.398.500.440.500\\r\\nCongenital Abnormalities,C16.131\\r\\nFetal Malformations,C16.131\\r\\nFetal Anomalies,C16.131\\r\\n\"Abnormalities, Drug-Induced\",C16.131.042\\r\\n\"Abnormalities, Multiple\",C16.131.077\\r\\n\"Abnormalities, Radiation-Induced\",C16.131.080\\r\\n\"Abnormalities, Radiation-Induced\",C26.733.031\\r\\n\"Abnormalities, Radiation-Induced\",G01.750.748.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031\\r\\nABO Blood-Group System,D23.050.301.290.031\\r\\nABO Blood-Group System,D23.050.705.230.031\\r\\nBlood Group H Type 1 Antigen,D23.050.301.290.031\\r\\nBlood Group H Type 1 Antigen,D23.050.705.230.031\\r\\nABO Factors,D23.050.301.290.031\\r\\nABO Factors,D23.050.705.230.031\\r\\nAbomasum,A13.869.106\\r\\nAbortifacient Agents,D27.505.696.875.131\\r\\nAbortifacient Agents,D27.505.954.705.131\\r\\nAbortifacient Effect,D27.505.696.875.131\\r\\nAbortifacient Effect,D27.505.954.705.131\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200\\r\\n\"Abortion, Spontaneous\",C13.703.039\\r\\n\"Abortion, Spontaneous\",G08.686.784.769.496.125\\r\\nEarly Pregnancy Loss,C13.703.039\\r\\nEarly Pregnancy Loss,G08.686.784.769.496.125\\r\\nMiscarriage,C13.703.039\\r\\nMiscarriage,G08.686.784.769.496.125\\r\\n\"Abortion, Tubal\",C13.703.039\\r\\n\"Abortion, Tubal\",G08.686.784.769.496.125\\r\\nAbortion Applicants,M01.050\\r\\n\"Abortion Seekers, Repeated\",M01.050\\r\\n\"Abortion Seekers, Refused\",M01.050\\r\\n\"Abortion, Criminal\",I01.198.240.089\\r\\n\"Abortion, Eugenic\",E04.520.050.050\\r\\n\"Abortion, Selective\",E04.520.050.050\\r\\n\"Abortion, Habitual\",C13.703.039.089\\r\\n\"Abortion, Incomplete\",C13.703.039.093\\r\\n\"Abortion, Induced\",E04.520.050\\r\\nAbortion Rate,E04.520.050\\r\\nAbortion Techniques,E04.520.050\\r\\n\"Abortion, Drug-Induced\",E04.520.050\\r\\nPrevious Abortion,E04.520.050\\r\\n\"Abortion, Saline-Solution\",E04.520.050\\r\\n\"Abortion, Soap-Solution\",E04.520.050\\r\\nAnti-Abortion Groups,E04.520.050\\r\\nEmbryotomy,E04.520.050\\r\\n\"Fertility Control, Postconception\",E04.520.050\\r\\nAbortion Failure,E04.520.050\\r\\n\"Abortion, Rivanol\",E04.520.050\\r\\n\"Abortion, Legal\",E04.520.050.055\\r\\nAbortion on Demand,E04.520.050.055\\r\\n\"Abortion, Missed\",C13.703.039.173\\r\\n\"Abortion, Septic\",C01.674.173\\r\\n\"Abortion, Septic\",C13.703.039.256\\r\\n\"Abortion, Septic\",C13.703.700.173\\r\\n\"Abortion, Therapeutic\",E04.520.050.060\\r\\n\"Abortion, Threatened\",C13.703.090\\r\\n\"Abortion, Veterinary\",C13.703.039.422\\r\\n\"Abortion, Veterinary\",C22.021\\r\\nAbreaction,F04.754.720.107\\r\\nAbrin,D08.811.277.450.430.700.750.111\\r\\nAbrin,D12.776.503.499.249\\r\\nAbrin,D12.776.765.678.906.111\\r\\nAbrin C,D08.811.277.450.430.700.750.111\\r\\nAbrin C,D12.776.503.499.249\\r\\nAbrin C,D12.776.765.678.906.111\\r\\nAbrin A,D08.811.277.450.430.700.750.111\\r\\nAbrin A,D12.776.503.499.249\\r\\nAbrin A,D12.776.765.678.906.111\\r\\nAbruptio Placentae,C13.703.420.078\\r\\nAbruptio Placentae,C13.703.590.132\\r\\nAbscess,C01.830.025\\r\\nAbscess,C23.550.470.756.100\\r\\nPeritonsillar Abscess,C01.748.561.750.500\\r\\nPeritonsillar Abscess,C01.830.025.675\\r\\nPeritonsillar Abscess,C07.550.781.750.500\\r\\nPeritonsillar Abscess,C08.730.561.750.500\\r\\nPeritonsillar Abscess,C09.775.649.750.500\\r\\nAbscisic Acid,D02.241.223.268.034\\r\\nAbscisic Acid,D02.455.326.271.665.202.061\\r\\nAbscisic Acid,D02.455.426.392.368.367.379.249.024\\r\\nAbscisic Acid,D02.455.849.131.061\\r\\nAbscisic Acid,D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500\\r\\nAbsenteeism,F02.784.692.107\\r\\nAbsorption,G01.015\\r\\nAbsorption,G02.010\\r\\nAbsorption,G03.015\\r\\nAbsorption,G03.787.024\\r\\nAbsorption,G07.690.725.015\\r\\nAbstracting and Indexing,L01.453.245.100\\r\\nIndexing,L01.453.245.100\\r\\nIndexes as Topic,L01.453.245.100\\r\\nAbstracting,L01.453.245.100\\r\\nDental Abutments,E06.780.346.500\\r\\nDental Abutments,E07.695.190.175\\r\\nAcacia,B01.650.940.800.575.912.250.401.025\\r\\nAcacia catechu,B01.650.940.800.575.912.250.401.025\\r\\nAcademic Medical Centers,N02.278.020\\r\\nAcademies and Institutes,N03.540.052\\r\\nInstitutes,N03.540.052\\r\\nResearch Institutes,N03.540.052\\r\\nAcademies,N03.540.052\\r\\nAcanthamoeba,B01.046.500.100.075.080\\r\\nAcanthocephala,B01.050.500.500.132\\r\\nAcanthocytes,A11.118.290.330.100\\r\\nAcanthocytes,A11.443.240.330.100\\r\\nAcanthocytes,A15.145.229.334.330.100\\r\\nAcantholysis,C17.800.865.070\\r\\nAcantholysis,C23.550.035\\r\\nAcanthosis Nigricans,C17.800.621.430.530.100\\r\\nAcari,B01.050.500.131.166.132\\r\\nAcceleration,G01.482.107\\r\\nAccessory Nerve,A08.800.800.120.060\\r\\nAccident Prevention,N06.850.135.060\\r\\nAccident Proneness,F01.145.015\\r\\nAccidental Falls,N06.850.135.122\\r\\nSlip and Fall,N06.850.135.122\\r\\nAccidents,N06.850.135\\r\\n\"Accidents, Aviation\",N06.850.135.185\\r\\n\"Accidents, Home\",N06.850.135.217\\r\\n\"Accidents, Occupational\",N06.850.135.240\\r\\n\"Accidents, Industrial\",N06.850.135.240\\r\\n\"Accidents, Traffic\",N06.850.135.392\\r\\nTraffic Collisions,N06.850.135.392\\r\\nTraffic Crashes,N06.850.135.392\\r\\nAcclimatization,G07.025.133\\r\\nAcclimatization,G16.012.500.133\\r\\n\"Accommodation, Ocular\",G14.010\\r\\n\"Accommodation, Lens\",G14.010\\r\\nAccounting,N03.219.463.030\\r\\nOil and Gas Industry,J01.576.655.875.750\\r\\nPetroleum Industry,J01.576.655.875.750\\r\\nOil Refinery,J01.576.655.875.750\\r\\nNatural Gas Industry,J01.576.655.875.750\\r\\nCoal Industry,J01.576.655.875.200\\r\\nDriving Under the Influence,F01.145.250.250\\r\\nDriving Under the Influence,F01.145.263.500\\r\\nDriving Under the Influence,I01.880.735.223.250\\r\\nDriving Under the Influence,I03.125.649\\r\\nDrinking and Driving,F01.145.250.250\\r\\nDrinking and Driving,F01.145.263.500\\r\\nDrinking and Driving,I01.880.735.223.250\\r\\nDrinking and Driving,I03.125.649\\r\\nHuman Embryonic Stem Cells,A11.872.700.250.750\\r\\nMouse Embryonic Stem Cells,A11.872.700.250.875\\r\\nEmbryonic Germ Cells,A11.497.124\\r\\nEmbryonic Germ Cells,A11.872.700.250.625\\r\\nWork Performance,I03.946.675\\r\\nJob Performance,I03.946.675\\r\\nCriminal Behavior,F01.145.250\\r\\nClinical Decision-Making,E01.055\\r\\nCognitive Aging,G07.345.124.260\\r\\nCognitive Neuroscience,F04.096.628.255.500\\r\\nCognitive Neuroscience,H01.158.610.030\\r\\nSocial Neuroscience,F04.096.628.255.500\\r\\nSocial Neuroscience,H01.158.610.030\\r\\nEmotional Adjustment,F01.058.144\\r\\nEmotional Adjustment,F01.752.543.500.250\\r\\nFacial Recognition,F02.463.593.524.250.500\\r\\nFacial Recognition,F02.463.593.524.500.500\\r\\nFacial Recognition,F02.463.593.932.622.500\\r\\nFacial Emotion Recognition,F02.463.593.524.250.500\\r\\nFacial Emotion Recognition,F02.463.593.524.500.500\\r\\nFacial Emotion Recognition,F02.463.593.932.622.500\\r\\nGrandparents,F01.829.263.403\\r\\nGrandparents,I01.880.853.150.452\\r\\nGrandparents,M01.264\\r\\nGrandmother,F01.829.263.403\\r\\nGrandmother,I01.880.853.150.452\\r\\nGrandmother,M01.264\\r\\nGrandfather,F01.829.263.403\\r\\nGrandfather,I01.880.853.150.452\\r\\nGrandfather,M01.264\\r\\nHelp-Seeking Behavior,F01.145.813.217\\r\\nHeuristics,F02.463.425.725.500\\r\\nHeuristics,F02.463.785.810.500\\r\\nIntimate Partner Violence,I01.198.240.856.575\\r\\nIntimate Partner Violence,I01.880.735.900.688\\r\\nDating Violence,I01.198.240.856.575\\r\\nDating Violence,I01.880.735.900.688\\r\\nNeurological Rehabilitation,E02.760.169.063.500.477\\r\\nNeurological Rehabilitation,E02.831.477\\r\\nNeurological Rehabilitation,H02.403.680.600.750\\r\\nNeurological Rehabilitation,N02.421.784.511\\r\\nPhysical Abuse,I01.198.240.856.688\\r\\nPhysical Abuse,I01.880.735.900.744\\r\\nProblem Behavior,F01.145.126.972\\r\\nProblem Behavior,F01.145.179.750\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.126.972\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.179.750\\r\\nDisruptive Behavior,F01.145.126.972\\r\\nDisruptive Behavior,F01.145.179.750\\r\\nUnderage Drinking,F01.145.022.750\\r\\nUnderage Drinking,F01.145.317.269.875\\r\\nUnderage Drinking,I01.880.735.878\\r\\nLegal Drinking Age,F01.145.022.750\\r\\nLegal Drinking Age,F01.145.317.269.875\\r\\nLegal Drinking Age,I01.880.735.878\\r\\nEctopic Gene Expression,G05.308.202\\r\\nCell Plasticity,G04.356.250\\r\\nCell Self Renewal,G04.144.220.235\\r\\nCell Self Renewal,G04.161.750.500.375\\r\\nCell Self Renewal,G05.113.415\\r\\nCell Self Renewal,G07.345.249.410.750.500.625\\r\\nStem Cell Self-Renewal,G04.144.220.235\\r\\nStem Cell Self-Renewal,G04.161.750.500.375\\r\\nStem Cell Self-Renewal,G05.113.415\\r\\nStem Cell Self-Renewal,G07.345.249.410.750.500.625\\r\\nRehabilitation Research,H01.770.644.145.472\\r\\nOrthodontists,M01.526.485.330.655\\r\\nOrthodontists,N02.360.330.655\\r\\nDentofacial Orthopedists,M01.526.485.330.655\\r\\nDentofacial Orthopedists,N02.360.330.655\\r\\nOral and Maxillofacial Surgeons,M01.526.485.330.483\\r\\nOral and Maxillofacial Surgeons,N02.360.330.483\\r\\nExodontists,M01.526.485.330.483\\r\\nExodontists,N02.360.330.483\\r\\nNeuroprotection,G11.561.645\\r\\n\"Diet, Food, and Nutrition\",G07.203\\r\\nTriticale,B01.650.940.800.575.912.250.822.906\\r\\nCritical Care Outcomes,N04.761.559.590.399.250\\r\\nCritical Care Outcomes,N05.715.360.575.575.399.250\\r\\nSimulation Training,I02.903.847\\r\\nInteractive Learning,I02.903.847\\r\\nMillets,B01.650.940.800.575.912.250.822.587\\r\\nBiobehavioral Sciences,H01.770.644.108.687\\r\\nProtein Corona,D12.776.642\\r\\nVegetarians,M01.928\\r\\nLacto-Ovo Vegetarians,M01.928\\r\\nVegans,M01.928.500\\r\\nAccounts Payable and Receivable,N03.219.463.030.080\\r\\nAccounts Payable,N03.219.463.030.080\\r\\nYouth Sports,I03.450.642.845.987\\r\\nOrganized Youth Sports,I03.450.642.845.987\\r\\nLiteracy,F01.145.209.429\\r\\nLiteracy,N01.824.196.500\\r\\nIlliteracy,F01.145.209.429\\r\\nIlliteracy,N01.824.196.500\\r\\nSevere Acute Malnutrition,C18.654.521.719\\r\\n\"Banking, Personal\",N03.219.463.030.100\\r\\nSavings Accounts,N03.219.463.030.100\\r\\nChecking Accounts,N03.219.463.030.100\\r\\nEvidence-Based Facility Design,N02.278.200.252\\r\\n\"Physical Appearance, Body\",E01.370.600.115.450\\r\\n\"Physical Appearance, Body\",G07.100.175\\r\\nFruit and Vegetable Juices,G07.203.100.606\\r\\nFruit and Vegetable Juices,J02.200.606\\r\\nVegetable Juices,G07.203.100.606\\r\\nVegetable Juices,J02.200.606\\r\\nFruit Juices,G07.203.100.606\\r\\nFruit Juices,J02.200.606\\r\\nGhee,D10.212.302.199.500\\r\\nGhee,G07.203.300.350.100.500\\r\\nGhee,G07.203.300.375.200.500\\r\\nGhee,J02.500.350.100.500\\r\\nGhee,J02.500.375.200.500\\r\\nHydraulic Fracking,J01.576.655.875.750.500\\r\\nPsychological Trauma,F03.950.750.375\\r\\nPeer Influence,F01.829.316.483.750\\r\\nPeer Pressure,F01.829.316.483.750\\r\\nVegetable Products,G07.203.300.850.450\\r\\nVegetable Products,J02.500.850.800\\r\\nDirect-to-Consumer Advertising,J01.219.687.274.500\\r\\nDirect-To-Consumer Screening and Testing,E01.370.398\\r\\nDirect-To-Consumer Screening and Testing,N02.421.726.233.166\\r\\nExtracellular Vesicles,A11.284.295.588\\r\\nExovesicles,A11.284.295.588\\r\\nApoptotic Bodies,A11.284.295.588\\r\\nFungal Viruses,B04.352\\r\\nTelocytes,A11.329.830.750\\r\\nExoskeleton Device,E07.341\\r\\nRobotic Exoskeleton,E07.341\\r\\nShellfish Hypersensitivity,C20.543.480.370.763\\r\\n\"Failure to Rescue, Health Care\",E01.789.800.760.500\\r\\n\"Failure to Rescue, Health Care\",H01.770.644.145.431.500\\r\\n\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500\\r\\n\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500\\r\\nPsychiatric Rehabilitation,H02.403.680.600.875\\r\\nPsychiatric Rehabilitation,N02.421.784.578\\r\\nPsychosocial Care,H02.403.680.600.875\\r\\nPsychosocial Care,N02.421.784.578\\r\\nSymptom Flare Up,C23.550.291.937.500\\r\\nSymptom Exacerbation,C23.550.291.937.500\\r\\nIsolated Heart Preparation,E05.519\\r\\nIsolated Heart Preparation,E05.598.750\\r\\nLangendorff Perfused Heart,E05.519\\r\\nLangendorff Perfused Heart,E05.598.750\\r\\nWorking Heart Preparation Technique,E05.519\\r\\nWorking Heart Preparation Technique,E05.598.750\\r\\nWorking Heart Preparation,E05.519\\r\\nWorking Heart Preparation,E05.598.750\\r\\nIsolated Heart Preparation Technique,E05.519\\r\\nIsolated Heart Preparation Technique,E05.598.750\\r\\n\"Diet, Vegan\",E02.642.249.300.750\\r\\n\"Diet, Vegan\",G07.203.650.240.300.750\\r\\nVeganism,E02.642.249.300.750\\r\\nVeganism,G07.203.650.240.300.750\\r\\nBehavior Observation Techniques,E05.796.112\\r\\nBehavior Observation Techniques,F04.669.112\\r\\nBehavior Rating Scale,F04.711.271\\r\\nBehavior Test,F04.711.271\\r\\nAlcohol Drinking in College,F01.145.317.269.625\\r\\n\"Obesity, Metabolically Benign\",C18.654.726.500.650\\r\\n\"Obesity, Metabolically Benign\",C23.888.144.699.500.250\\r\\n\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375\\r\\n\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375\\r\\nWhole Grains,G07.203.300.300.550.500\\r\\nWhole Grains,G07.203.300.775.500.500\\r\\nWhole Grains,J02.500.300.550.500\\r\\nWhole Grains,J02.500.775.500.500\\r\\nWhole Grain Cereals,G07.203.300.300.550.500\\r\\nWhole Grain Cereals,G07.203.300.775.500.500\\r\\nWhole Grain Cereals,J02.500.300.550.500\\r\\nWhole Grain Cereals,J02.500.775.500.500\\r\\nTransanal Endoscopic Surgery,E01.370.388.250.630.500\\r\\nTransanal Endoscopic Surgery,E04.210.240.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E01.370.388.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E04.210.240.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.630.500\\r\\nTransanal Endoscopic Microsurgery,E01.370.388.250.630.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.210.240.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.494.787\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.630.500.500\\r\\nCold Injury,C26.212\\r\\nPersonal Protective Equipment,E07.700.560\\r\\nPersonal Protective Equipment,J01.637.708.560\\r\\nNerve Agents,D27.720.599\\r\\nNerve Agents,D27.720.777.300.500\\r\\nNerve Gas,D27.720.599\\r\\nNerve Gas,D27.720.777.300.500\\r\\nWar-Related Injuries,C26.946\\r\\nWar-Related Injuries,I01.880.735.950.500.951.500\\r\\nWar-Related Injuries,N06.850.460.350.600.903.500\\r\\nWar-Related Trauma,C26.946\\r\\nWar-Related Trauma,I01.880.735.950.500.951.500\\r\\nWar-Related Trauma,N06.850.460.350.600.903.500\\r\\nAbnormal Involuntary Movement Scale,E01.370.600.550.162\\r\\nBlood Alcohol Content,D02.033.375.135\\r\\nSocial Communication Disorder,F03.625.374.250\\r\\nLegal Services,I01.880.604.583.482\\r\\nDefamation,I01.198.240.240\\r\\nDefamation,I01.880.735.191.051\\r\\nSlander,I01.198.240.240\\r\\nSlander,I01.880.735.191.051\\r\\nLibel,I01.198.240.240\\r\\nLibel,I01.880.735.191.051\\r\\nAnger Management Therapy,F04.754.137.087\\r\\n\"Psychology, Sports\",F04.096.628.914\\r\\nWar Exposure,I01.880.735.950.500.951\\r\\nWar Exposure,N06.850.460.350.600.903\\r\\nChildhood-Onset Fluency Disorder,F03.625.374.125\\r\\nNo-Show Patients,F01.100.150.750.500.600.750\\r\\nNo-Show Patients,F01.145.488.887.500.600.750\\r\\nNo-Show Patients,M01.643.550\\r\\nNo-Show Patients,N04.452.758.635.500\\r\\nNo-Show Patients,N05.300.150.800.500.600.750\\r\\nCellular Reprogramming Techniques,E05.200.500.380\\r\\nCellular Reprogramming Techniques,E05.242.378\\r\\nCellular Reprogramming Techniques,E05.393.085\\r\\nDirected Differentiation Techniques,E05.200.500.380\\r\\nDirected Differentiation Techniques,E05.242.378\\r\\nDirected Differentiation Techniques,E05.393.085\\r\\nDirect Cell Reprogramming Techniques,E05.200.500.380\\r\\nDirect Cell Reprogramming Techniques,E05.242.378\\r\\nDirect Cell Reprogramming Techniques,E05.393.085\\r\\nMetacognition,F02.463.188.756\\r\\nMetacognitive Awareness,F02.463.188.756\\r\\nMetacognitive Monitoring,F02.463.188.756\\r\\nMetacognitive Control,F02.463.188.756\\r\\nMetaemotion,F02.463.188.756\\r\\nMetamemory,F02.463.188.756\\r\\nPrescription Drug Overuse,E02.319.306.500.750\\r\\n\"Near Miss, Healthcare\",E02.319.529.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.500.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.550\\r\\n\"Near Miss, Healthcare\",N04.761.700.594\\r\\n\"Near Miss, Healthcare\",N05.700.513\\r\\nRNAi Therapeutics,E02.095.301.250\\r\\nDynamic Light Scattering,E05.196.822.325\\r\\nQuasi-Elastic Light Scattering (QELS),E05.196.822.325\\r\\n\"Time Out, Healthcare\",N04.761.700.635\\r\\n\"Time Out, Healthcare\",N05.700.739\\r\\nSurgical Time Out,N04.761.700.635\\r\\nSurgical Time Out,N05.700.739\\r\\nHealthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N04.452.871.715.400\\r\\nHealthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.505.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nFailure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nFailure Mode and Effect Analysis,N04.452.871.715.400\\r\\nFailure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nFailure Mode and Effect Analysis,N06.850.505.715.500\\r\\nFailure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nSpirit Possession,K01.844.619.500\\r\\n\"Crew Resource Management, Healthcare\",N04.590.254\\r\\nComputer Heuristics,L01.224.050.375.095\\r\\nAtaxins,D12.776.631.069\\r\\nAtaxins,D12.776.660.075\\r\\nAlarmins,D23.035\\r\\nDermal Fillers,D27.720.102.461\\r\\nAction Spectrum,E05.196.867.826.150\\r\\nDiplomacy,F01.829.316.171\\r\\nDiplomacy,F02.463.785.373.520.500\\r\\nDiplomacy,I01.738.305\\r\\nMutation Accumulation,G05.365.590.594\\r\\nSpontaneous Mutation Accumulation,G05.365.590.594\\r\\nInternal Ribosome Entry Sites,D13.444.735.790.878.942.250\\r\\nInternal Ribosome Entry Sites,G02.111.570.080.689.687.093\\r\\nInternal Ribosome Entry Sites,G05.360.080.689.687.093\\r\\nBiological Mimicry,G16.012.750\\r\\nBiological Camouflage,G16.012.750\\r\\nSpecific Learning Disorder,F03.625.562.700\\r\\nPotentially Inappropriate Medication List,N04.761.700.615\\r\\nPotentially Inappropriate Medication List,N05.700.594\\r\\nBeers Criteria,N04.761.700.615\\r\\nBeers Criteria,N05.700.594\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594\\r\\nMedication Appropriateness Index,N04.761.700.615\\r\\nMedication Appropriateness Index,N05.700.594\\r\\nLate Onset Disorders,C23.550.291.883\\r\\nPhakopsora pachyrhizi,B01.300.179.113\\r\\nFarmers,M01.526.390\\r\\nRanchers,M01.526.390\\r\\nCulturally Appropriate Technology,J01.897.052\\r\\nIntermediate Technology,J01.897.052\\r\\nSoft Technology,J01.897.052\\r\\nSocial Learning,F02.784.629.529.663\\r\\nFinancial Statements,N03.219.463.030.140\\r\\n\"Assets, Financial\",N03.219.463.030.140\\r\\nCash Flow Statement,N03.219.463.030.140\\r\\nBalance Sheet,N03.219.463.030.140\\r\\nExpense Statement,N03.219.463.030.140\\r\\nIncome Statement,N03.219.463.030.140\\r\\n\"Equity, Financial\",N03.219.463.030.140\\r\\n\"Liabilities, Financial\",N03.219.463.030.140\\r\\nMiners,M01.526.693\\r\\nChronopharmacokinetics,G07.690.725.249\\r\\n\"Administrative Claims, Healthcare\",N04.452.859.564.137\\r\\nChild Health,N01.400.225\\r\\nChild Well Being,N01.400.225\\r\\nInterleukin-33,D12.644.276.374.465.850\\r\\nInterleukin-33,D12.776.467.374.465.850\\r\\nInterleukin-33,D23.529.374.465.850\\r\\nS100A12 Protein,D12.776.157.125.750.875\\r\\nTelopodes,A11.284.180.900\\r\\nTelopodes,A11.329.830.750.500\\r\\nPodomers,A11.284.180.900\\r\\nPodomers,A11.329.830.750.500\\r\\nPodoms,A11.284.180.900\\r\\nPodoms,A11.329.830.750.500\\r\\nDrosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750\\r\\nOptimism,F01.100.787\\r\\nPositive Attitude,F01.100.787\\r\\nPositive Thinking,F01.100.787\\r\\nPessimism,F01.100.893\\r\\nAtaxin-1,D12.776.631.069.500\\r\\nAtaxin-1,D12.776.660.075.500\\r\\nAdolescent Health,N01.400.075\\r\\nAdolescent Well Being,N01.400.075\\r\\nAtaxin-2,D12.776.157.725.452.125\\r\\nAtaxin-2,D12.776.631.069.750\\r\\nAtaxin-2,D12.776.660.075.750\\r\\nAtaxin-2,D12.776.664.962.452.125\\r\\nAtaxin-3,D08.811.037.250\\r\\nAtaxin-3,D12.776.631.069.875\\r\\nAtaxin-3,D12.776.660.075.875\\r\\nPoint-of-Care Testing,N04.590.874.500\\r\\nBedside Testing,N04.590.874.500\\r\\nAtaxin-7,D12.776.631.069.901\\r\\nAtaxin-7,D12.776.660.075.900\\r\\nAtaxin-10,D12.776.631.069.950\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.695.021\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.750.360.100\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600\\r\\nReceptor for Advanced Glycation End Products,D12.776.543.750.615\\r\\nRNA Recognition Motif Proteins,D12.776.157.725.813\\r\\nRNA Recognition Motif Proteins,D12.776.664.962.813\\r\\nELAV-Like Protein 2,D12.776.157.725.813.500.500\\r\\nELAV-Like Protein 2,D12.776.631.520.500\\r\\nELAV-Like Protein 2,D12.776.664.962.813.500.500\\r\\nELAV-Like Protein 3,D12.776.157.725.813.500.750\\r\\nELAV-Like Protein 3,D12.776.631.520.750\\r\\nELAV-Like Protein 3,D12.776.664.962.813.500.750\\r\\nELAV-Like Protein 4,D12.776.157.725.813.500.875\\r\\nELAV-Like Protein 4,D12.776.631.520.875\\r\\nELAV-Like Protein 4,D12.776.664.962.813.500.875\\r\\nELAV-Like Protein 1,D12.776.157.725.813.500.250\\r\\nELAV-Like Protein 1,D12.776.664.962.813.500.250\\r\\nWhey,A12.790.760\\r\\nWhey,G07.203.100.700.750\\r\\nWhey,G07.203.300.350.525.760\\r\\nWhey,J02.200.700.750\\r\\nWhey,J02.500.350.525.760\\r\\nWhey Proteins,A12.790.520.500\\r\\nWhey Proteins,A12.790.760.500\\r\\nWhey Proteins,D12.776.256.159.750.816\\r\\nWhey Proteins,G07.203.300.350.525.760.500\\r\\nWhey Proteins,G07.203.300.428.159.812.500\\r\\nWhey Proteins,J02.500.350.525.520.500\\r\\nWhey Proteins,J02.500.350.525.760.500\\r\\nWhey Proteins,J02.500.428.159.750.500\\r\\nHoarding Disorder,F03.080.600.250\\r\\nObsessive Hoarding,F03.080.600.250\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692\\r\\nAutism Spectrum Disorder,F03.625.164.113\\r\\nCELF Proteins,D12.776.157.725.813.250\\r\\nCELF Proteins,D12.776.664.962.813.250\\r\\nCELF1 Protein,D12.776.157.725.813.250.500\\r\\nCELF1 Protein,D12.776.664.962.813.250.500\\r\\nIndustrial Development,I01.261.\n",
       "\n",
       "*** WARNING: max output size exceeded, skipping output. ***\n",
       "\n",
       "0\\r\\n\"Albuterol, Ipratropium Drug Combination\",D26.310.344\\r\\nCombivent Respimat,D02.033.100.291.057.125\\r\\nCombivent Respimat,D02.092.063.291.057.125\\r\\nCombivent Respimat,D02.092.471.683.061.125\\r\\nCombivent Respimat,D02.145.074.722.229.400.500\\r\\nCombivent Respimat,D03.132.760.180.572.400.500\\r\\nCombivent Respimat,D03.132.889.180.648.400.500\\r\\nCombivent Respimat,D03.605.084.500.722.229.400.500\\r\\nCombivent Respimat,D03.605.869.229.400.500\\r\\nCombivent Respimat,D26.310.344\\r\\nDey Combination,D02.033.100.291.057.125\\r\\nDey Combination,D02.092.063.291.057.125\\r\\nDey Combination,D02.092.471.683.061.125\\r\\nDey Combination,D02.145.074.722.229.400.500\\r\\nDey Combination,D03.132.760.180.572.400.500\\r\\nDey Combination,D03.132.889.180.648.400.500\\r\\nDey Combination,D03.605.084.500.722.229.400.500\\r\\nDey Combination,D03.605.869.229.400.500\\r\\nDey Combination,D26.310.344\\r\\nCombivent,D02.033.100.291.057.125\\r\\nCombivent,D02.092.063.291.057.125\\r\\nCombivent,D02.092.471.683.061.125\\r\\nCombivent,D02.145.074.722.229.400.500\\r\\nCombivent,D03.132.760.180.572.400.500\\r\\nCombivent,D03.132.889.180.648.400.500\\r\\nCombivent,D03.605.084.500.722.229.400.500\\r\\nCombivent,D03.605.869.229.400.500\\r\\nCombivent,D26.310.344\\r\\nDual Use Research,H01.770.644.217\\r\\nProfessionalism,K01.752.566.479.171.566\\r\\nProfessionalism,N05.350.340.581\\r\\nMedical Professionalism,K01.752.566.479.171.566\\r\\nMedical Professionalism,N05.350.340.581\\r\\nProfessionalism Education,K01.752.566.479.171.566\\r\\nProfessionalism Education,N05.350.340.581\\r\\nSurgical Professionalism,K01.752.566.479.171.566\\r\\nSurgical Professionalism,N05.350.340.581\\r\\nGenetic Background,G05.346\\r\\nSelective Breeding,E05.820.150.760\\r\\nSelective Breeding,G05.090.701\\r\\nLegendary Creatures,I01.076.201.450.515.500\\r\\nWerewolves,I01.076.201.450.515.500\\r\\nUnicorns,I01.076.201.450.515.500\\r\\n\"Yeti, Himalayan\",I01.076.201.450.515.500\\r\\nVampires,I01.076.201.450.515.500\\r\\nMermaids,I01.076.201.450.515.500\\r\\nMometasone Furoate,D04.210.500.745.432.719.526\\r\\nNasonex,D04.210.500.745.432.719.526\\r\\nMometasone Furoate Monohydrate,D04.210.500.745.432.719.526\\r\\nAsmanex Twisthaler,D04.210.500.745.432.719.526\\r\\nAsmanex,D04.210.500.745.432.719.526\\r\\nRinelon,D04.210.500.745.432.719.526\\r\\nElocon,D04.210.500.745.432.719.526\\r\\nSch 32088,D04.210.500.745.432.719.526\\r\\nMometasone,D04.210.500.745.432.719.526\\r\\nFallopia multiflora,B01.650.940.800.575.912.250.825.359.590\\r\\nSildenafil Citrate,D02.065.884.675\\r\\nSildenafil Citrate,D02.886.590.700.675\\r\\nSildenafil Citrate,D03.383.606.854\\r\\nSildenafil Citrate,D03.633.100.759.824\\r\\nNCX-911,D02.065.884.675\\r\\nNCX-911,D02.886.590.700.675\\r\\nNCX-911,D03.383.606.854\\r\\nNCX-911,D03.633.100.759.824\\r\\nRevatio,D02.065.884.675\\r\\nRevatio,D02.886.590.700.675\\r\\nRevatio,D03.383.606.854\\r\\nRevatio,D03.633.100.759.824\\r\\nSildenafil,D02.065.884.675\\r\\nSildenafil,D02.886.590.700.675\\r\\nSildenafil,D03.383.606.854\\r\\nSildenafil,D03.633.100.759.824\\r\\nUK 92480-10,D02.065.884.675\\r\\nUK 92480-10,D02.886.590.700.675\\r\\nUK 92480-10,D03.383.606.854\\r\\nUK 92480-10,D03.633.100.759.824\\r\\nHomosildenafil,D02.065.884.675\\r\\nHomosildenafil,D02.886.590.700.675\\r\\nHomosildenafil,D03.383.606.854\\r\\nHomosildenafil,D03.633.100.759.824\\r\\nHydroxyhomosildenafil,D02.065.884.675\\r\\nHydroxyhomosildenafil,D02.886.590.700.675\\r\\nHydroxyhomosildenafil,D03.383.606.854\\r\\nHydroxyhomosildenafil,D03.633.100.759.824\\r\\nViagra,D02.065.884.675\\r\\nViagra,D02.886.590.700.675\\r\\nViagra,D03.383.606.854\\r\\nViagra,D03.633.100.759.824\\r\\nAcetildenafil,D02.065.884.675\\r\\nAcetildenafil,D02.886.590.700.675\\r\\nAcetildenafil,D03.383.606.854\\r\\nAcetildenafil,D03.633.100.759.824\\r\\nSildenafil Lactate,D02.065.884.675\\r\\nSildenafil Lactate,D02.886.590.700.675\\r\\nSildenafil Lactate,D03.383.606.854\\r\\nSildenafil Lactate,D03.633.100.759.824\\r\\nSildenafil Nitrate,D02.065.884.675\\r\\nSildenafil Nitrate,D02.886.590.700.675\\r\\nSildenafil Nitrate,D03.383.606.854\\r\\nSildenafil Nitrate,D03.633.100.759.824\\r\\nDesmethyl Sildenafil,D02.065.884.675\\r\\nDesmethyl Sildenafil,D02.886.590.700.675\\r\\nDesmethyl Sildenafil,D03.383.606.854\\r\\nDesmethyl Sildenafil,D03.633.100.759.824\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.626.809.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.705.429.906.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.680.245.500.600.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.755.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.633.100.759.138.881.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D26.310.407\\r\\nComplera,D02.626.809.500\\r\\nComplera,D02.705.429.906.500\\r\\nComplera,D03.383.742.680.245.500.600.500\\r\\nComplera,D03.383.742.755.500\\r\\nComplera,D03.633.100.759.138.881.500\\r\\nComplera,D26.310.407\\r\\nEmtricitabine,D03.383.742.680.245.500.600\\r\\nEmtricitabine,D13.570.230.329.525\\r\\nEmtricitabine,D13.570.685.245.500.600\\r\\nCoviracil,D03.383.742.680.245.500.600\\r\\nCoviracil,D13.570.230.329.525\\r\\nCoviracil,D13.570.685.245.500.600\\r\\nEmtriva,D03.383.742.680.245.500.600\\r\\nEmtriva,D13.570.230.329.525\\r\\nEmtriva,D13.570.685.245.500.600\\r\\nRilpivirine,D02.626.809\\r\\nRilpivirine,D03.383.742.755\\r\\nRilpivirine Hydrochloride,D02.626.809\\r\\nRilpivirine Hydrochloride,D03.383.742.755\\r\\nR278474,D02.626.809\\r\\nR278474,D03.383.742.755\\r\\nTMC 278,D02.626.809\\r\\nTMC 278,D03.383.742.755\\r\\nTenofovir,D02.705.429.906\\r\\nTenofovir,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D03.633.100.759.138.881\\r\\nTenofovir Disoproxil Fumarate,D02.705.429.906\\r\\nTenofovir Disoproxil Fumarate,D03.633.100.759.138.881\\r\\nTenofovir Disoproxil,D02.705.429.906\\r\\nTenofovir Disoproxil,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D03.633.100.759.138.881\\r\\nViread,D02.705.429.906\\r\\nViread,D03.633.100.759.138.881\\r\\nGlatiramer Acetate,D12.644.219\\r\\nCopaxone,D12.644.219\\r\\nGlatiramer,D12.644.219\\r\\nTV 5010,D12.644.219\\r\\nRosuvastatin Calcium,D02.065.884.650\\r\\nRosuvastatin Calcium,D02.455.526.510.432.500\\r\\nRosuvastatin Calcium,D02.886.590.700.650\\r\\nRosuvastatin Calcium,D03.383.742.775\\r\\nCrestor,D02.065.884.650\\r\\nCrestor,D02.455.526.510.432.500\\r\\nCrestor,D02.886.590.700.650\\r\\nCrestor,D03.383.742.775\\r\\nRosuvastatin,D02.065.884.650\\r\\nRosuvastatin,D02.455.526.510.432.500\\r\\nRosuvastatin,D02.886.590.700.650\\r\\nRosuvastatin,D03.383.742.775\\r\\nZD4522,D02.065.884.650\\r\\nZD4522,D02.455.526.510.432.500\\r\\nZD4522,D02.886.590.700.650\\r\\nZD4522,D03.383.742.775\\r\\nDuloxetine Hydrochloride,D02.886.778.260\\r\\nDuloxetine Hydrochloride,D03.383.903.260\\r\\nLY 248686,D02.886.778.260\\r\\nLY 248686,D03.383.903.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D02.886.778.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D03.383.903.260\\r\\nLY 227942,D02.886.778.260\\r\\nLY 227942,D03.383.903.260\\r\\nDuloxetine,D02.886.778.260\\r\\nDuloxetine,D03.383.903.260\\r\\n\"Duloxetine, (+)-isomer\",D02.886.778.260\\r\\n\"Duloxetine, (+)-isomer\",D03.383.903.260\\r\\nCymbalta,D02.886.778.260\\r\\nCymbalta,D03.383.903.260\\r\\nTolterodine Tartrate,D02.033.100.624.706.750\\r\\nTolterodine Tartrate,D02.033.755.624.706.750\\r\\nTolterodine Tartrate,D02.092.063.624.706.800\\r\\nTolterodine Tartrate,D02.455.426.559.389.115.900\\r\\nTolterodine Tartrate,D02.455.426.559.389.657.239.756\\r\\nTolterodine,D02.033.100.624.706.750\\r\\nTolterodine,D02.033.755.624.706.750\\r\\nTolterodine,D02.092.063.624.706.800\\r\\nTolterodine,D02.455.426.559.389.115.900\\r\\nTolterodine,D02.455.426.559.389.657.239.756\\r\\nDetrol,D02.033.100.624.706.750\\r\\nDetrol,D02.033.755.624.706.750\\r\\nDetrol,D02.092.063.624.706.800\\r\\nDetrol,D02.455.426.559.389.115.900\\r\\nDetrol,D02.455.426.559.389.657.239.756\\r\\nDetrol LA,D02.033.100.624.706.750\\r\\nDetrol LA,D02.033.755.624.706.750\\r\\nDetrol LA,D02.092.063.624.706.800\\r\\nDetrol LA,D02.455.426.559.389.115.900\\r\\nDetrol LA,D02.455.426.559.389.657.239.756\\r\\nUrotrol,D02.033.100.624.706.750\\r\\nUrotrol,D02.033.755.624.706.750\\r\\nUrotrol,D02.092.063.624.706.800\\r\\nUrotrol,D02.455.426.559.389.115.900\\r\\nUrotrol,D02.455.426.559.389.657.239.756\\r\\nPHA-686464B,D02.033.100.624.706.750\\r\\nPHA-686464B,D02.033.755.624.706.750\\r\\nPHA-686464B,D02.092.063.624.706.800\\r\\nPHA-686464B,D02.455.426.559.389.115.900\\r\\nPHA-686464B,D02.455.426.559.389.657.239.756\\r\\nDetrusitol,D02.033.100.624.706.750\\r\\nDetrusitol,D02.033.755.624.706.750\\r\\nDetrusitol,D02.092.063.624.706.800\\r\\nDetrusitol,D02.455.426.559.389.115.900\\r\\nDetrusitol,D02.455.426.559.389.657.239.756\\r\\nUnidet,D02.033.100.624.706.750\\r\\nUnidet,D02.033.755.624.706.750\\r\\nUnidet,D02.092.063.624.706.800\\r\\nUnidet,D02.455.426.559.389.115.900\\r\\nUnidet,D02.455.426.559.389.657.239.756\\r\\nValsartan,D03.383.129.617.850\\r\\nValsartan,D12.125.070.950.550\\r\\nValsartan,D12.125.142.930.500\\r\\nDiovan,D03.383.129.617.850\\r\\nDiovan,D12.125.070.950.550\\r\\nDiovan,D12.125.142.930.500\\r\\nKalpress,D03.383.129.617.850\\r\\nKalpress,D12.125.070.950.550\\r\\nKalpress,D12.125.142.930.500\\r\\nTareg,D03.383.129.617.850\\r\\nTareg,D12.125.070.950.550\\r\\nTareg,D12.125.142.930.500\\r\\nNisis,D03.383.129.617.850\\r\\nNisis,D12.125.070.950.550\\r\\nNisis,D12.125.142.930.500\\r\\nProvas,D03.383.129.617.850\\r\\nProvas,D12.125.070.950.550\\r\\nProvas,D12.125.142.930.500\\r\\nVals,D03.383.129.617.850\\r\\nVals,D12.125.070.950.550\\r\\nVals,D12.125.142.930.500\\r\\nCGP 48933,D03.383.129.617.850\\r\\nCGP 48933,D12.125.070.950.550\\r\\nCGP 48933,D12.125.142.930.500\\r\\nMiten,D03.383.129.617.850\\r\\nMiten,D12.125.070.950.550\\r\\nMiten,D12.125.142.930.500\\r\\nOnonis,B01.650.940.800.575.912.250.401.604\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.033.100.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.092.063.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D04.210.500.745.432.719.526.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D26.310.469\\r\\nDulera,D02.033.100.291.425.500\\r\\nDulera,D02.092.063.291.425.500\\r\\nDulera,D04.210.500.745.432.719.526.500\\r\\nDulera,D26.310.469\\r\\nZenhale,D02.033.100.291.425.500\\r\\nZenhale,D02.092.063.291.425.500\\r\\nZenhale,D04.210.500.745.432.719.526.500\\r\\nZenhale,D26.310.469\\r\\nFormoterol Fumarate,D02.033.100.291.425\\r\\nFormoterol Fumarate,D02.092.063.291.425\\r\\nBD 40A,D02.033.100.291.425\\r\\nBD 40A,D02.092.063.291.425\\r\\nFormoterol,D02.033.100.291.425\\r\\nFormoterol,D02.092.063.291.425\\r\\nOxis,D02.033.100.291.425\\r\\nOxis,D02.092.063.291.425\\r\\nArformoterol,D02.033.100.291.425\\r\\nArformoterol,D02.092.063.291.425\\r\\nForadil,D02.033.100.291.425\\r\\nForadil,D02.092.063.291.425\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.562.437.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.625.600.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.696.577.600.693\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.696.277.350.500\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.954.427.210.350.500\\r\\nSleeping Pills,D27.505.696.277.350.500\\r\\nSleeping Pills,D27.505.954.427.210.350.500\\r\\nOrexin Receptor Antagonists,D27.505.519.625.663\\r\\nOrexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nOrexin Receptor Antagonists,D27.505.696.577.663\\r\\nOrexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.519.625.663\\r\\nDual Orexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.696.577.663\\r\\nDual Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nOrexins,D12.644.400.360\\r\\nOrexins,D12.776.631.650.363\\r\\nOrexin-B,D12.644.400.360\\r\\nOrexin-B,D12.776.631.650.363\\r\\nOrexin-A,D12.644.400.360\\r\\nOrexin-A,D12.776.631.650.363\\r\\nHoodia,B01.650.940.800.575.912.250.456.500.389\\r\\nHoodia gordonii,B01.650.940.800.575.912.250.456.500.389\\r\\nPrasugrel Hydrochloride,D02.886.778.600\\r\\nPrasugrel Hydrochloride,D03.383.606.800\\r\\nPrasugrel Hydrochloride,D03.383.903.600\\r\\nCS 747,D02.886.778.600\\r\\nCS 747,D03.383.606.800\\r\\nCS 747,D03.383.903.600\\r\\nPrasugrel,D02.886.778.600\\r\\nPrasugrel,D03.383.606.800\\r\\nPrasugrel,D03.383.903.600\\r\\nEfient,D02.886.778.600\\r\\nEfient,D03.383.606.800\\r\\nEfient,D03.383.903.600\\r\\nEffient,D02.886.778.600\\r\\nEffient,D03.383.606.800\\r\\nEffient,D03.383.903.600\\r\\nLY 640315,D02.886.778.600\\r\\nLY 640315,D03.383.606.800\\r\\nLY 640315,D03.383.903.600\\r\\nEtanercept,D12.644.541.500.697.624\\r\\nEtanercept,D12.776.124.486.485.538.500.624\\r\\nEtanercept,D12.776.124.486.485.680.697.624\\r\\nEtanercept,D12.776.124.790.651.538.500.624\\r\\nEtanercept,D12.776.124.790.651.680.660.624\\r\\nEtanercept,D12.776.377.715.548.538.500.624\\r\\nEtanercept,D12.776.377.715.548.680.660.624\\r\\nEtanercept,D12.776.543.750.705.852.760.232\\r\\nTNFR-Fc Fusion Protein,D12.644.541.500.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEtanercept-szzs,D12.644.541.500.697.624\\r\\nEtanercept-szzs,D12.776.124.486.485.538.500.624\\r\\nEtanercept-szzs,D12.776.124.486.485.680.697.624\\r\\nEtanercept-szzs,D12.776.124.790.651.538.500.624\\r\\nEtanercept-szzs,D12.776.124.790.651.680.660.624\\r\\nEtanercept-szzs,D12.776.377.715.548.538.500.624\\r\\nEtanercept-szzs,D12.776.377.715.548.680.660.624\\r\\nEtanercept-szzs,D12.776.543.750.705.852.760.232\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nErelzi,D12.644.541.500.697.624\\r\\nErelzi,D12.776.124.486.485.538.500.624\\r\\nErelzi,D12.776.124.486.485.680.697.624\\r\\nErelzi,D12.776.124.790.651.538.500.624\\r\\nErelzi,D12.776.124.790.651.680.660.624\\r\\nErelzi,D12.776.377.715.548.538.500.624\\r\\nErelzi,D12.776.377.715.548.680.660.624\\r\\nErelzi,D12.776.543.750.705.852.760.232\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEnbrel,D12.644.541.500.697.624\\r\\nEnbrel,D12.776.124.486.485.538.500.624\\r\\nEnbrel,D12.776.124.486.485.680.697.624\\r\\nEnbrel,D12.776.124.790.651.538.500.624\\r\\nEnbrel,D12.776.124.790.651.680.660.624\\r\\nEnbrel,D12.776.377.715.548.538.500.624\\r\\nEnbrel,D12.776.377.715.548.680.660.624\\r\\nEnbrel,D12.776.543.750.705.852.760.232\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.241.223.100.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.389.127.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.847.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D04.615.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D26.310.032\\r\\nEpiduo,D02.241.223.100.133.500\\r\\nEpiduo,D02.455.426.559.389.127.133.500\\r\\nEpiduo,D02.455.426.559.847.638.090.500\\r\\nEpiduo,D04.615.638.090.500\\r\\nEpiduo,D26.310.032\\r\\nAdapalene,D02.455.426.559.847.638.090\\r\\nAdapalene,D04.615.638.090\\r\\nCD 271,D02.455.426.559.847.638.090\\r\\nCD 271,D04.615.638.090\\r\\nAdaferin,D02.455.426.559.847.638.090\\r\\nAdaferin,D04.615.638.090\\r\\nDifferin,D02.455.426.559.847.638.090\\r\\nDifferin,D04.615.638.090\\r\\nEpoetin Alfa,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa,D12.776.395.240.150.750\\r\\nEpoetin Alfa,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa,D23.529.374.410.240.150.750\\r\\nEpoetin Alfa Hexal,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D12.776.395.240.150.750\\r\\nEpoetin Alfa Hexal,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D23.529.374.410.240.150.750\\r\\nEprex,D12.644.276.374.410.240.150.500\\r\\nEprex,D12.776.395.240.150.750\\r\\nEprex,D12.776.467.374.410.240.150.500\\r\\nEprex,D23.529.374.410.240.150.750\\r\\nHeberitro,D12.644.276.374.410.240.150.500\\r\\nHeberitro,D12.776.395.240.150.750\\r\\nHeberitro,D12.776.467.374.410.240.150.500\\r\\nHeberitro,D23.529.374.410.240.150.750\\r\\nProcrit,D12.644.276.374.410.240.150.500\\r\\nProcrit,D12.776.395.240.150.750\\r\\nProcrit,D12.776.467.374.410.240.150.500\\r\\nProcrit,D23.529.374.410.240.150.750\\r\\nBinocrit,D12.644.276.374.410.240.150.500\\r\\nBinocrit,D12.776.395.240.150.750\\r\\nBinocrit,D12.776.467.374.410.240.150.500\\r\\nBinocrit,D23.529.374.410.240.150.750\\r\\nHX575 Compound,D12.644.276.374.410.240.150.500\\r\\nHX575 Compound,D12.776.395.240.150.750\\r\\nHX575 Compound,D12.776.467.374.410.240.150.500\\r\\nHX575 Compound,D23.529.374.410.240.150.750\\r\\nEpogen,D12.644.276.374.410.240.150.500\\r\\nEpogen,D12.776.395.240.150.750\\r\\nEpogen,D12.776.467.374.410.240.150.500\\r\\nEpogen,D23.529.374.410.240.150.750\\r\\nHX575,D12.644.276.374.410.240.150.500\\r\\nHX575,D12.776.395.240.150.750\\r\\nHX575,D12.776.467.374.410.240.150.500\\r\\nHX575,D23.529.374.410.240.150.750\\r\\nCetuximab,D12.776.124.486.485.114.224.060.750\\r\\nCetuximab,D12.776.124.790.651.114.224.060.750\\r\\nCetuximab,D12.776.377.715.548.114.224.200.750\\r\\nErbitux,D12.776.124.486.485.114.224.060.750\\r\\nErbitux,D12.776.124.790.651.114.224.060.750\\r\\nErbitux,D12.776.377.715.548.114.224.200.750\\r\\nIMC C225,D12.776.124.486.485.114.224.060.750\\r\\nIMC C225,D12.776.124.790.651.114.224.060.750\\r\\nIMC C225,D12.776.377.715.548.114.224.200.750\\r\\nHyssopus Plant,B01.650.940.800.575.912.250.583.520.330\\r\\nHyssopus officinalis,B01.650.940.800.575.912.250.583.520.330\\r\\nRivastigmine,D02.241.081.251.583.899\\r\\nRivastigmineTartrate,D02.241.081.251.583.899\\r\\nExelon,D02.241.081.251.583.899\\r\\nENA 713,D02.241.081.251.583.899\\r\\nParmeliaceae,B01.300.107.685\\r\\nParmeliaceae,B01.300.340.458\\r\\nCetraria,B01.300.107.685\\r\\nCetraria,B01.300.340.458\\r\\nCetraria islandica,B01.300.107.685\\r\\nCetraria islandica,B01.300.340.458\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.129.617.850.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.725.203.065.750\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.070.950.550.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.142.930.500.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D26.310.094\\r\\nExforge,D03.383.129.617.850.500\\r\\nExforge,D03.383.725.203.065.750\\r\\nExforge,D12.125.070.950.550.500\\r\\nExforge,D12.125.142.930.500.500\\r\\nExforge,D26.310.094\\r\\nEugenia,B01.650.940.800.575.912.250.773.374\\r\\nEuginia uniflora,B01.650.940.800.575.912.250.773.374\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.899.498.500\\r\\nGardasil,D20.215.894.815.455\\r\\nGardasil,D20.215.894.899.498.500\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.899.498.500\\r\\nKombucha Tea,D20.215.784.844.500\\r\\nKombucha Tea,G07.203.100.831.500\\r\\nKombucha Tea,G07.203.200.625\\r\\nKombucha Tea,J02.200.831.500\\r\\nKombucha Tea,J02.350.625\\r\\nFingolimod Hydrochloride,D02.033.100.700.350\\r\\nFingolimod Hydrochloride,D02.033.455.706.431\\r\\nFingolimod Hydrochloride,D02.092.063.700.350\\r\\nFTY-720,D02.033.100.700.350\\r\\nFTY-720,D02.033.455.706.431\\r\\nFTY-720,D02.092.063.700.350\\r\\nGilenya,D02.033.100.700.350\\r\\nGilenya,D02.033.455.706.431\\r\\nGilenya,D02.092.063.700.350\\r\\nFingolimod,D02.033.100.700.350\\r\\nFingolimod,D02.033.455.706.431\\r\\nFingolimod,D02.092.063.700.350\\r\\nImatinib Mesylate,D02.065.277.456\\r\\nImatinib Mesylate,D02.241.223.100.100.435\\r\\nImatinib Mesylate,D02.455.426.559.389.127.085.465\\r\\nImatinib Mesylate,D03.383.606.405\\r\\nImatinib Mesylate,D03.383.742.349\\r\\nSTI571,D02.065.277.456\\r\\nSTI571,D02.241.223.100.100.435\\r\\nSTI571,D02.455.426.559.389.127.085.465\\r\\nSTI571,D03.383.606.405\\r\\nSTI571,D03.383.742.349\\r\\nGleevec,D02.065.277.456\\r\\nGleevec,D02.241.223.100.100.435\\r\\nGleevec,D02.455.426.559.389.127.085.465\\r\\nGleevec,D03.383.606.405\\r\\nGleevec,D03.383.742.349\\r\\nST 1571,D02.065.277.456\\r\\nST 1571,D02.241.223.100.100.435\\r\\nST 1571,D02.455.426.559.389.127.085.465\\r\\nST 1571,D03.383.606.405\\r\\nST 1571,D03.383.742.349\\r\\nCGP 57148,D02.065.277.456\\r\\nCGP 57148,D02.241.223.100.100.435\\r\\nCGP 57148,D02.455.426.559.389.127.085.465\\r\\nCGP 57148,D03.383.606.405\\r\\nCGP 57148,D03.383.742.349\\r\\nImatinib,D02.065.277.456\\r\\nImatinib,D02.241.223.100.100.435\\r\\nImatinib,D02.455.426.559.389.127.085.465\\r\\nImatinib,D03.383.606.405\\r\\nImatinib,D03.383.742.349\\r\\nTrastuzumab,D12.776.124.486.485.114.224.060.875\\r\\nTrastuzumab,D12.776.124.790.651.114.224.060.875\\r\\nTrastuzumab,D12.776.377.715.548.114.224.200.875\\r\\nHerceptin,D12.776.124.486.485.114.224.060.875\\r\\nHerceptin,D12.776.124.790.651.114.224.060.875\\r\\nHerceptin,D12.776.377.715.548.114.224.200.875\\r\\nTrazimera,D12.776.124.486.485.114.224.060.875\\r\\nTrazimera,D12.776.124.790.651.114.224.060.875\\r\\nTrazimera,D12.776.377.715.548.114.224.200.875\\r\\nAdalimumab,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab,D12.776.377.715.548.114.224.200.250\\r\\nHumira,D12.776.124.486.485.114.224.060.250\\r\\nHumira,D12.776.124.790.651.114.224.060.250\\r\\nHumira,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-adbm,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.377.715.548.114.224.200.250\\r\\nAmjevita,D12.776.124.486.485.114.224.060.250\\r\\nAmjevita,D12.776.124.790.651.114.224.060.250\\r\\nAmjevita,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-atto,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-atto,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-atto,D12.776.377.715.548.114.224.200.250\\r\\nCyltezo,D12.776.124.486.485.114.224.060.250\\r\\nCyltezo,D12.776.124.790.651.114.224.060.250\\r\\nCyltezo,D12.776.377.715.548.114.224.200.250\\r\\nD2E7 Antibody,D12.776.124.486.485.114.224.060.250\\r\\nD2E7 Antibody,D12.776.124.790.651.114.224.060.250\\r\\nD2E7 Antibody,D12.776.377.715.548.114.224.200.250\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.500.625.500.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.500.625.500.500\\r\\nHumulin N,D06.472.699.587.200.300.200.500\\r\\nHumulin N,D06.472.699.587.200.500.625.500.500\\r\\nHumulin N,D12.644.548.586.200.300.200.500\\r\\nHumulin N,D12.644.548.586.200.500.625.500.500\\r\\nNovolin N,D06.472.699.587.200.300.200.500\\r\\nNovolin N,D06.472.699.587.200.500.625.500.500\\r\\nNovolin N,D12.644.548.586.200.300.200.500\\r\\nNovolin N,D12.644.548.586.200.500.625.500.500\\r\\n\"Animals, Exotic\",B01.050.050.126\\r\\nExotic Pets,B01.050.050.126\\r\\nPaliperidone Palmitate,D03.383.129.385.650\\r\\nPaliperidone Palmitate,D03.383.742.592\\r\\nPaliperidone,D03.383.129.385.650\\r\\nPaliperidone,D03.383.742.592\\r\\nInvega,D03.383.129.385.650\\r\\nInvega,D03.383.742.592\\r\\nInvega Sustenna,D03.383.129.385.650\\r\\nInvega Sustenna,D03.383.742.592\\r\\nR 76477,D03.383.129.385.650\\r\\nR 76477,D03.383.742.592\\r\\nImmunosenescence,G07.345.124.390\\r\\nImmunosenescence,G12.460.500\\r\\nCanagliflozin,D02.886.778.075\\r\\nCanagliflozin,D03.383.903.075\\r\\nCanagliflozin,D09.408.348.113\\r\\nInvokana,D02.886.778.075\\r\\nInvokana,D03.383.903.075\\r\\nInvokana,D09.408.348.113\\r\\nCanagliflozin Hemihydrate,D02.886.778.075\\r\\nCanagliflozin Hemihydrate,D03.383.903.075\\r\\nCanagliflozin Hemihydrate,D09.408.348.113\\r\\n\"Canagliflozin, Anhydrous\",D02.886.778.075\\r\\n\"Canagliflozin, Anhydrous\",D03.383.903.075\\r\\n\"Canagliflozin, Anhydrous\",D09.408.348.113\\r\\nIridescence,G01.590.310\\r\\nOpalescence,G01.590.310\\r\\nRaltegravir Potassium,D03.383.773.812.752\\r\\nRaltegravir,D03.383.773.812.752\\r\\nMK 0518,D03.383.773.812.752\\r\\nIsentress'"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "[Truncated to first 65536 bytes]\nOut[15]: 'term,tree\\r\\nCalcimycin,D03.633.100.221.173\\r\\nA-23187,D03.633.100.221.173\\r\\nTemefos,D02.705.400.625.800\\r\\nTemefos,D02.705.539.345.800\\r\\nTemefos,D02.886.300.692.800\\r\\nAbate,D02.705.400.625.800\\r\\nAbate,D02.705.539.345.800\\r\\nAbate,D02.886.300.692.800\\r\\nDifos,D02.705.400.625.800\\r\\nDifos,D02.705.539.345.800\\r\\nDifos,D02.886.300.692.800\\r\\nAbattoirs,J01.576.423.200.700.100\\r\\nAbattoirs,J03.540.020\\r\\nAbbreviations as Topic,L01.559.598.400.556.131\\r\\nAcronyms as Topic,L01.559.598.400.556.131\\r\\nAbdomen,A01.923.047\\r\\n\"Abdomen, Acute\",C23.888.592.612.054.200\\r\\n\"Abdomen, Acute\",C23.888.821.030.249\\r\\nAbdominal Injuries,C26.017\\r\\nAbdominal Neoplasms,C04.588.033\\r\\nAbdominal Muscles,A02.633.567.050\\r\\nCremaster Muscle,A02.633.567.050\\r\\nPyramidalis Muscle,A02.633.567.050\\r\\nQuadratus Abdominis,A02.633.567.050\\r\\nTransversus Abdominis,A02.633.567.050\\r\\nAbducens Nerve,A08.800.800.120.030\\r\\nAbelson murine leukemia virus,B04.613.807.375.525.020\\r\\nAbelson murine leukemia virus,B04.820.650.375.525.020\\r\\nAbetalipoproteinemia,C16.320.565.398.500.440.500\\r\\nAbetalipoproteinemia,C18.452.584.500.875.440.500\\r\\nAbetalipoproteinemia,C18.452.648.398.500.440.500\\r\\nCongenital Abnormalities,C16.131\\r\\nFetal Malformations,C16.131\\r\\nFetal Anomalies,C16.131\\r\\n\"Abnormalities, Drug-Induced\",C16.131.042\\r\\n\"Abnormalities, Multiple\",C16.131.077\\r\\n\"Abnormalities, Radiation-Induced\",C16.131.080\\r\\n\"Abnormalities, Radiation-Induced\",C26.733.031\\r\\n\"Abnormalities, Radiation-Induced\",G01.750.748.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031\\r\\n\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031\\r\\nABO Blood-Group System,D23.050.301.290.031\\r\\nABO Blood-Group System,D23.050.705.230.031\\r\\nBlood Group H Type 1 Antigen,D23.050.301.290.031\\r\\nBlood Group H Type 1 Antigen,D23.050.705.230.031\\r\\nABO Factors,D23.050.301.290.031\\r\\nABO Factors,D23.050.705.230.031\\r\\nAbomasum,A13.869.106\\r\\nAbortifacient Agents,D27.505.696.875.131\\r\\nAbortifacient Agents,D27.505.954.705.131\\r\\nAbortifacient Effect,D27.505.696.875.131\\r\\nAbortifacient Effect,D27.505.954.705.131\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100\\r\\n\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200\\r\\n\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200\\r\\n\"Abortion, Spontaneous\",C13.703.039\\r\\n\"Abortion, Spontaneous\",G08.686.784.769.496.125\\r\\nEarly Pregnancy Loss,C13.703.039\\r\\nEarly Pregnancy Loss,G08.686.784.769.496.125\\r\\nMiscarriage,C13.703.039\\r\\nMiscarriage,G08.686.784.769.496.125\\r\\n\"Abortion, Tubal\",C13.703.039\\r\\n\"Abortion, Tubal\",G08.686.784.769.496.125\\r\\nAbortion Applicants,M01.050\\r\\n\"Abortion Seekers, Repeated\",M01.050\\r\\n\"Abortion Seekers, Refused\",M01.050\\r\\n\"Abortion, Criminal\",I01.198.240.089\\r\\n\"Abortion, Eugenic\",E04.520.050.050\\r\\n\"Abortion, Selective\",E04.520.050.050\\r\\n\"Abortion, Habitual\",C13.703.039.089\\r\\n\"Abortion, Incomplete\",C13.703.039.093\\r\\n\"Abortion, Induced\",E04.520.050\\r\\nAbortion Rate,E04.520.050\\r\\nAbortion Techniques,E04.520.050\\r\\n\"Abortion, Drug-Induced\",E04.520.050\\r\\nPrevious Abortion,E04.520.050\\r\\n\"Abortion, Saline-Solution\",E04.520.050\\r\\n\"Abortion, Soap-Solution\",E04.520.050\\r\\nAnti-Abortion Groups,E04.520.050\\r\\nEmbryotomy,E04.520.050\\r\\n\"Fertility Control, Postconception\",E04.520.050\\r\\nAbortion Failure,E04.520.050\\r\\n\"Abortion, Rivanol\",E04.520.050\\r\\n\"Abortion, Legal\",E04.520.050.055\\r\\nAbortion on Demand,E04.520.050.055\\r\\n\"Abortion, Missed\",C13.703.039.173\\r\\n\"Abortion, Septic\",C01.674.173\\r\\n\"Abortion, Septic\",C13.703.039.256\\r\\n\"Abortion, Septic\",C13.703.700.173\\r\\n\"Abortion, Therapeutic\",E04.520.050.060\\r\\n\"Abortion, Threatened\",C13.703.090\\r\\n\"Abortion, Veterinary\",C13.703.039.422\\r\\n\"Abortion, Veterinary\",C22.021\\r\\nAbreaction,F04.754.720.107\\r\\nAbrin,D08.811.277.450.430.700.750.111\\r\\nAbrin,D12.776.503.499.249\\r\\nAbrin,D12.776.765.678.906.111\\r\\nAbrin C,D08.811.277.450.430.700.750.111\\r\\nAbrin C,D12.776.503.499.249\\r\\nAbrin C,D12.776.765.678.906.111\\r\\nAbrin A,D08.811.277.450.430.700.750.111\\r\\nAbrin A,D12.776.503.499.249\\r\\nAbrin A,D12.776.765.678.906.111\\r\\nAbruptio Placentae,C13.703.420.078\\r\\nAbruptio Placentae,C13.703.590.132\\r\\nAbscess,C01.830.025\\r\\nAbscess,C23.550.470.756.100\\r\\nPeritonsillar Abscess,C01.748.561.750.500\\r\\nPeritonsillar Abscess,C01.830.025.675\\r\\nPeritonsillar Abscess,C07.550.781.750.500\\r\\nPeritonsillar Abscess,C08.730.561.750.500\\r\\nPeritonsillar Abscess,C09.775.649.750.500\\r\\nAbscisic Acid,D02.241.223.268.034\\r\\nAbscisic Acid,D02.455.326.271.665.202.061\\r\\nAbscisic Acid,D02.455.426.392.368.367.379.249.024\\r\\nAbscisic Acid,D02.455.849.131.061\\r\\nAbscisic Acid,D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061\\r\\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500\\r\\nAbsenteeism,F02.784.692.107\\r\\nAbsorption,G01.015\\r\\nAbsorption,G02.010\\r\\nAbsorption,G03.015\\r\\nAbsorption,G03.787.024\\r\\nAbsorption,G07.690.725.015\\r\\nAbstracting and Indexing,L01.453.245.100\\r\\nIndexing,L01.453.245.100\\r\\nIndexes as Topic,L01.453.245.100\\r\\nAbstracting,L01.453.245.100\\r\\nDental Abutments,E06.780.346.500\\r\\nDental Abutments,E07.695.190.175\\r\\nAcacia,B01.650.940.800.575.912.250.401.025\\r\\nAcacia catechu,B01.650.940.800.575.912.250.401.025\\r\\nAcademic Medical Centers,N02.278.020\\r\\nAcademies and Institutes,N03.540.052\\r\\nInstitutes,N03.540.052\\r\\nResearch Institutes,N03.540.052\\r\\nAcademies,N03.540.052\\r\\nAcanthamoeba,B01.046.500.100.075.080\\r\\nAcanthocephala,B01.050.500.500.132\\r\\nAcanthocytes,A11.118.290.330.100\\r\\nAcanthocytes,A11.443.240.330.100\\r\\nAcanthocytes,A15.145.229.334.330.100\\r\\nAcantholysis,C17.800.865.070\\r\\nAcantholysis,C23.550.035\\r\\nAcanthosis Nigricans,C17.800.621.430.530.100\\r\\nAcari,B01.050.500.131.166.132\\r\\nAcceleration,G01.482.107\\r\\nAccessory Nerve,A08.800.800.120.060\\r\\nAccident Prevention,N06.850.135.060\\r\\nAccident Proneness,F01.145.015\\r\\nAccidental Falls,N06.850.135.122\\r\\nSlip and Fall,N06.850.135.122\\r\\nAccidents,N06.850.135\\r\\n\"Accidents, Aviation\",N06.850.135.185\\r\\n\"Accidents, Home\",N06.850.135.217\\r\\n\"Accidents, Occupational\",N06.850.135.240\\r\\n\"Accidents, Industrial\",N06.850.135.240\\r\\n\"Accidents, Traffic\",N06.850.135.392\\r\\nTraffic Collisions,N06.850.135.392\\r\\nTraffic Crashes,N06.850.135.392\\r\\nAcclimatization,G07.025.133\\r\\nAcclimatization,G16.012.500.133\\r\\n\"Accommodation, Ocular\",G14.010\\r\\n\"Accommodation, Lens\",G14.010\\r\\nAccounting,N03.219.463.030\\r\\nOil and Gas Industry,J01.576.655.875.750\\r\\nPetroleum Industry,J01.576.655.875.750\\r\\nOil Refinery,J01.576.655.875.750\\r\\nNatural Gas Industry,J01.576.655.875.750\\r\\nCoal Industry,J01.576.655.875.200\\r\\nDriving Under the Influence,F01.145.250.250\\r\\nDriving Under the Influence,F01.145.263.500\\r\\nDriving Under the Influence,I01.880.735.223.250\\r\\nDriving Under the Influence,I03.125.649\\r\\nDrinking and Driving,F01.145.250.250\\r\\nDrinking and Driving,F01.145.263.500\\r\\nDrinking and Driving,I01.880.735.223.250\\r\\nDrinking and Driving,I03.125.649\\r\\nHuman Embryonic Stem Cells,A11.872.700.250.750\\r\\nMouse Embryonic Stem Cells,A11.872.700.250.875\\r\\nEmbryonic Germ Cells,A11.497.124\\r\\nEmbryonic Germ Cells,A11.872.700.250.625\\r\\nWork Performance,I03.946.675\\r\\nJob Performance,I03.946.675\\r\\nCriminal Behavior,F01.145.250\\r\\nClinical Decision-Making,E01.055\\r\\nCognitive Aging,G07.345.124.260\\r\\nCognitive Neuroscience,F04.096.628.255.500\\r\\nCognitive Neuroscience,H01.158.610.030\\r\\nSocial Neuroscience,F04.096.628.255.500\\r\\nSocial Neuroscience,H01.158.610.030\\r\\nEmotional Adjustment,F01.058.144\\r\\nEmotional Adjustment,F01.752.543.500.250\\r\\nFacial Recognition,F02.463.593.524.250.500\\r\\nFacial Recognition,F02.463.593.524.500.500\\r\\nFacial Recognition,F02.463.593.932.622.500\\r\\nFacial Emotion Recognition,F02.463.593.524.250.500\\r\\nFacial Emotion Recognition,F02.463.593.524.500.500\\r\\nFacial Emotion Recognition,F02.463.593.932.622.500\\r\\nGrandparents,F01.829.263.403\\r\\nGrandparents,I01.880.853.150.452\\r\\nGrandparents,M01.264\\r\\nGrandmother,F01.829.263.403\\r\\nGrandmother,I01.880.853.150.452\\r\\nGrandmother,M01.264\\r\\nGrandfather,F01.829.263.403\\r\\nGrandfather,I01.880.853.150.452\\r\\nGrandfather,M01.264\\r\\nHelp-Seeking Behavior,F01.145.813.217\\r\\nHeuristics,F02.463.425.725.500\\r\\nHeuristics,F02.463.785.810.500\\r\\nIntimate Partner Violence,I01.198.240.856.575\\r\\nIntimate Partner Violence,I01.880.735.900.688\\r\\nDating Violence,I01.198.240.856.575\\r\\nDating Violence,I01.880.735.900.688\\r\\nNeurological Rehabilitation,E02.760.169.063.500.477\\r\\nNeurological Rehabilitation,E02.831.477\\r\\nNeurological Rehabilitation,H02.403.680.600.750\\r\\nNeurological Rehabilitation,N02.421.784.511\\r\\nPhysical Abuse,I01.198.240.856.688\\r\\nPhysical Abuse,I01.880.735.900.744\\r\\nProblem Behavior,F01.145.126.972\\r\\nProblem Behavior,F01.145.179.750\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.126.972\\r\\n\"Dysfunctional Behavior, Psychology\",F01.145.179.750\\r\\nDisruptive Behavior,F01.145.126.972\\r\\nDisruptive Behavior,F01.145.179.750\\r\\nUnderage Drinking,F01.145.022.750\\r\\nUnderage Drinking,F01.145.317.269.875\\r\\nUnderage Drinking,I01.880.735.878\\r\\nLegal Drinking Age,F01.145.022.750\\r\\nLegal Drinking Age,F01.145.317.269.875\\r\\nLegal Drinking Age,I01.880.735.878\\r\\nEctopic Gene Expression,G05.308.202\\r\\nCell Plasticity,G04.356.250\\r\\nCell Self Renewal,G04.144.220.235\\r\\nCell Self Renewal,G04.161.750.500.375\\r\\nCell Self Renewal,G05.113.415\\r\\nCell Self Renewal,G07.345.249.410.750.500.625\\r\\nStem Cell Self-Renewal,G04.144.220.235\\r\\nStem Cell Self-Renewal,G04.161.750.500.375\\r\\nStem Cell Self-Renewal,G05.113.415\\r\\nStem Cell Self-Renewal,G07.345.249.410.750.500.625\\r\\nRehabilitation Research,H01.770.644.145.472\\r\\nOrthodontists,M01.526.485.330.655\\r\\nOrthodontists,N02.360.330.655\\r\\nDentofacial Orthopedists,M01.526.485.330.655\\r\\nDentofacial Orthopedists,N02.360.330.655\\r\\nOral and Maxillofacial Surgeons,M01.526.485.330.483\\r\\nOral and Maxillofacial Surgeons,N02.360.330.483\\r\\nExodontists,M01.526.485.330.483\\r\\nExodontists,N02.360.330.483\\r\\nNeuroprotection,G11.561.645\\r\\n\"Diet, Food, and Nutrition\",G07.203\\r\\nTriticale,B01.650.940.800.575.912.250.822.906\\r\\nCritical Care Outcomes,N04.761.559.590.399.250\\r\\nCritical Care Outcomes,N05.715.360.575.575.399.250\\r\\nSimulation Training,I02.903.847\\r\\nInteractive Learning,I02.903.847\\r\\nMillets,B01.650.940.800.575.912.250.822.587\\r\\nBiobehavioral Sciences,H01.770.644.108.687\\r\\nProtein Corona,D12.776.642\\r\\nVegetarians,M01.928\\r\\nLacto-Ovo Vegetarians,M01.928\\r\\nVegans,M01.928.500\\r\\nAccounts Payable and Receivable,N03.219.463.030.080\\r\\nAccounts Payable,N03.219.463.030.080\\r\\nYouth Sports,I03.450.642.845.987\\r\\nOrganized Youth Sports,I03.450.642.845.987\\r\\nLiteracy,F01.145.209.429\\r\\nLiteracy,N01.824.196.500\\r\\nIlliteracy,F01.145.209.429\\r\\nIlliteracy,N01.824.196.500\\r\\nSevere Acute Malnutrition,C18.654.521.719\\r\\n\"Banking, Personal\",N03.219.463.030.100\\r\\nSavings Accounts,N03.219.463.030.100\\r\\nChecking Accounts,N03.219.463.030.100\\r\\nEvidence-Based Facility Design,N02.278.200.252\\r\\n\"Physical Appearance, Body\",E01.370.600.115.450\\r\\n\"Physical Appearance, Body\",G07.100.175\\r\\nFruit and Vegetable Juices,G07.203.100.606\\r\\nFruit and Vegetable Juices,J02.200.606\\r\\nVegetable Juices,G07.203.100.606\\r\\nVegetable Juices,J02.200.606\\r\\nFruit Juices,G07.203.100.606\\r\\nFruit Juices,J02.200.606\\r\\nGhee,D10.212.302.199.500\\r\\nGhee,G07.203.300.350.100.500\\r\\nGhee,G07.203.300.375.200.500\\r\\nGhee,J02.500.350.100.500\\r\\nGhee,J02.500.375.200.500\\r\\nHydraulic Fracking,J01.576.655.875.750.500\\r\\nPsychological Trauma,F03.950.750.375\\r\\nPeer Influence,F01.829.316.483.750\\r\\nPeer Pressure,F01.829.316.483.750\\r\\nVegetable Products,G07.203.300.850.450\\r\\nVegetable Products,J02.500.850.800\\r\\nDirect-to-Consumer Advertising,J01.219.687.274.500\\r\\nDirect-To-Consumer Screening and Testing,E01.370.398\\r\\nDirect-To-Consumer Screening and Testing,N02.421.726.233.166\\r\\nExtracellular Vesicles,A11.284.295.588\\r\\nExovesicles,A11.284.295.588\\r\\nApoptotic Bodies,A11.284.295.588\\r\\nFungal Viruses,B04.352\\r\\nTelocytes,A11.329.830.750\\r\\nExoskeleton Device,E07.341\\r\\nRobotic Exoskeleton,E07.341\\r\\nShellfish Hypersensitivity,C20.543.480.370.763\\r\\n\"Failure to Rescue, Health Care\",E01.789.800.760.500\\r\\n\"Failure to Rescue, Health Care\",H01.770.644.145.431.500\\r\\n\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500\\r\\n\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500\\r\\nPsychiatric Rehabilitation,H02.403.680.600.875\\r\\nPsychiatric Rehabilitation,N02.421.784.578\\r\\nPsychosocial Care,H02.403.680.600.875\\r\\nPsychosocial Care,N02.421.784.578\\r\\nSymptom Flare Up,C23.550.291.937.500\\r\\nSymptom Exacerbation,C23.550.291.937.500\\r\\nIsolated Heart Preparation,E05.519\\r\\nIsolated Heart Preparation,E05.598.750\\r\\nLangendorff Perfused Heart,E05.519\\r\\nLangendorff Perfused Heart,E05.598.750\\r\\nWorking Heart Preparation Technique,E05.519\\r\\nWorking Heart Preparation Technique,E05.598.750\\r\\nWorking Heart Preparation,E05.519\\r\\nWorking Heart Preparation,E05.598.750\\r\\nIsolated Heart Preparation Technique,E05.519\\r\\nIsolated Heart Preparation Technique,E05.598.750\\r\\n\"Diet, Vegan\",E02.642.249.300.750\\r\\n\"Diet, Vegan\",G07.203.650.240.300.750\\r\\nVeganism,E02.642.249.300.750\\r\\nVeganism,G07.203.650.240.300.750\\r\\nBehavior Observation Techniques,E05.796.112\\r\\nBehavior Observation Techniques,F04.669.112\\r\\nBehavior Rating Scale,F04.711.271\\r\\nBehavior Test,F04.711.271\\r\\nAlcohol Drinking in College,F01.145.317.269.625\\r\\n\"Obesity, Metabolically Benign\",C18.654.726.500.650\\r\\n\"Obesity, Metabolically Benign\",C23.888.144.699.500.250\\r\\n\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375\\r\\n\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375\\r\\nWhole Grains,G07.203.300.300.550.500\\r\\nWhole Grains,G07.203.300.775.500.500\\r\\nWhole Grains,J02.500.300.550.500\\r\\nWhole Grains,J02.500.775.500.500\\r\\nWhole Grain Cereals,G07.203.300.300.550.500\\r\\nWhole Grain Cereals,G07.203.300.775.500.500\\r\\nWhole Grain Cereals,J02.500.300.550.500\\r\\nWhole Grain Cereals,J02.500.775.500.500\\r\\nTransanal Endoscopic Surgery,E01.370.388.250.630.500\\r\\nTransanal Endoscopic Surgery,E04.210.240.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Endoscopic Surgery,E04.502.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E01.370.388.250.630.500\\r\\nTransanal Minimally Invasive Surgery,E04.210.240.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.250.250.680.500\\r\\nTransanal Minimally Invasive Surgery,E04.502.250.630.500\\r\\nTransanal Endoscopic Microsurgery,E01.370.388.250.630.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.210.240.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.494.787\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500\\r\\nTransanal Endoscopic Microsurgery,E04.502.250.630.500.500\\r\\nCold Injury,C26.212\\r\\nPersonal Protective Equipment,E07.700.560\\r\\nPersonal Protective Equipment,J01.637.708.560\\r\\nNerve Agents,D27.720.599\\r\\nNerve Agents,D27.720.777.300.500\\r\\nNerve Gas,D27.720.599\\r\\nNerve Gas,D27.720.777.300.500\\r\\nWar-Related Injuries,C26.946\\r\\nWar-Related Injuries,I01.880.735.950.500.951.500\\r\\nWar-Related Injuries,N06.850.460.350.600.903.500\\r\\nWar-Related Trauma,C26.946\\r\\nWar-Related Trauma,I01.880.735.950.500.951.500\\r\\nWar-Related Trauma,N06.850.460.350.600.903.500\\r\\nAbnormal Involuntary Movement Scale,E01.370.600.550.162\\r\\nBlood Alcohol Content,D02.033.375.135\\r\\nSocial Communication Disorder,F03.625.374.250\\r\\nLegal Services,I01.880.604.583.482\\r\\nDefamation,I01.198.240.240\\r\\nDefamation,I01.880.735.191.051\\r\\nSlander,I01.198.240.240\\r\\nSlander,I01.880.735.191.051\\r\\nLibel,I01.198.240.240\\r\\nLibel,I01.880.735.191.051\\r\\nAnger Management Therapy,F04.754.137.087\\r\\n\"Psychology, Sports\",F04.096.628.914\\r\\nWar Exposure,I01.880.735.950.500.951\\r\\nWar Exposure,N06.850.460.350.600.903\\r\\nChildhood-Onset Fluency Disorder,F03.625.374.125\\r\\nNo-Show Patients,F01.100.150.750.500.600.750\\r\\nNo-Show Patients,F01.145.488.887.500.600.750\\r\\nNo-Show Patients,M01.643.550\\r\\nNo-Show Patients,N04.452.758.635.500\\r\\nNo-Show Patients,N05.300.150.800.500.600.750\\r\\nCellular Reprogramming Techniques,E05.200.500.380\\r\\nCellular Reprogramming Techniques,E05.242.378\\r\\nCellular Reprogramming Techniques,E05.393.085\\r\\nDirected Differentiation Techniques,E05.200.500.380\\r\\nDirected Differentiation Techniques,E05.242.378\\r\\nDirected Differentiation Techniques,E05.393.085\\r\\nDirect Cell Reprogramming Techniques,E05.200.500.380\\r\\nDirect Cell Reprogramming Techniques,E05.242.378\\r\\nDirect Cell Reprogramming Techniques,E05.393.085\\r\\nMetacognition,F02.463.188.756\\r\\nMetacognitive Awareness,F02.463.188.756\\r\\nMetacognitive Monitoring,F02.463.188.756\\r\\nMetacognitive Control,F02.463.188.756\\r\\nMetaemotion,F02.463.188.756\\r\\nMetamemory,F02.463.188.756\\r\\nPrescription Drug Overuse,E02.319.306.500.750\\r\\n\"Near Miss, Healthcare\",E02.319.529.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.500.750\\r\\n\"Near Miss, Healthcare\",N02.421.450.550\\r\\n\"Near Miss, Healthcare\",N04.761.700.594\\r\\n\"Near Miss, Healthcare\",N05.700.513\\r\\nRNAi Therapeutics,E02.095.301.250\\r\\nDynamic Light Scattering,E05.196.822.325\\r\\nQuasi-Elastic Light Scattering (QELS),E05.196.822.325\\r\\n\"Time Out, Healthcare\",N04.761.700.635\\r\\n\"Time Out, Healthcare\",N05.700.739\\r\\nSurgical Time Out,N04.761.700.635\\r\\nSurgical Time Out,N05.700.739\\r\\nHealthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N04.452.871.715.400\\r\\nHealthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.505.715.500\\r\\nHealthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nFailure Mode and Effect Analysis,E05.318.740.600.800.715.500\\r\\nFailure Mode and Effect Analysis,N04.452.871.715.400\\r\\nFailure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\\r\\nFailure Mode and Effect Analysis,N06.850.505.715.500\\r\\nFailure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\\r\\nSpirit Possession,K01.844.619.500\\r\\n\"Crew Resource Management, Healthcare\",N04.590.254\\r\\nComputer Heuristics,L01.224.050.375.095\\r\\nAtaxins,D12.776.631.069\\r\\nAtaxins,D12.776.660.075\\r\\nAlarmins,D23.035\\r\\nDermal Fillers,D27.720.102.461\\r\\nAction Spectrum,E05.196.867.826.150\\r\\nDiplomacy,F01.829.316.171\\r\\nDiplomacy,F02.463.785.373.520.500\\r\\nDiplomacy,I01.738.305\\r\\nMutation Accumulation,G05.365.590.594\\r\\nSpontaneous Mutation Accumulation,G05.365.590.594\\r\\nInternal Ribosome Entry Sites,D13.444.735.790.878.942.250\\r\\nInternal Ribosome Entry Sites,G02.111.570.080.689.687.093\\r\\nInternal Ribosome Entry Sites,G05.360.080.689.687.093\\r\\nBiological Mimicry,G16.012.750\\r\\nBiological Camouflage,G16.012.750\\r\\nSpecific Learning Disorder,F03.625.562.700\\r\\nPotentially Inappropriate Medication List,N04.761.700.615\\r\\nPotentially Inappropriate Medication List,N05.700.594\\r\\nBeers Criteria,N04.761.700.615\\r\\nBeers Criteria,N05.700.594\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615\\r\\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594\\r\\nMedication Appropriateness Index,N04.761.700.615\\r\\nMedication Appropriateness Index,N05.700.594\\r\\nLate Onset Disorders,C23.550.291.883\\r\\nPhakopsora pachyrhizi,B01.300.179.113\\r\\nFarmers,M01.526.390\\r\\nRanchers,M01.526.390\\r\\nCulturally Appropriate Technology,J01.897.052\\r\\nIntermediate Technology,J01.897.052\\r\\nSoft Technology,J01.897.052\\r\\nSocial Learning,F02.784.629.529.663\\r\\nFinancial Statements,N03.219.463.030.140\\r\\n\"Assets, Financial\",N03.219.463.030.140\\r\\nCash Flow Statement,N03.219.463.030.140\\r\\nBalance Sheet,N03.219.463.030.140\\r\\nExpense Statement,N03.219.463.030.140\\r\\nIncome Statement,N03.219.463.030.140\\r\\n\"Equity, Financial\",N03.219.463.030.140\\r\\n\"Liabilities, Financial\",N03.219.463.030.140\\r\\nMiners,M01.526.693\\r\\nChronopharmacokinetics,G07.690.725.249\\r\\n\"Administrative Claims, Healthcare\",N04.452.859.564.137\\r\\nChild Health,N01.400.225\\r\\nChild Well Being,N01.400.225\\r\\nInterleukin-33,D12.644.276.374.465.850\\r\\nInterleukin-33,D12.776.467.374.465.850\\r\\nInterleukin-33,D23.529.374.465.850\\r\\nS100A12 Protein,D12.776.157.125.750.875\\r\\nTelopodes,A11.284.180.900\\r\\nTelopodes,A11.329.830.750.500\\r\\nPodomers,A11.284.180.900\\r\\nPodomers,A11.329.830.750.500\\r\\nPodoms,A11.284.180.900\\r\\nPodoms,A11.329.830.750.500\\r\\nDrosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750\\r\\nOptimism,F01.100.787\\r\\nPositive Attitude,F01.100.787\\r\\nPositive Thinking,F01.100.787\\r\\nPessimism,F01.100.893\\r\\nAtaxin-1,D12.776.631.069.500\\r\\nAtaxin-1,D12.776.660.075.500\\r\\nAdolescent Health,N01.400.075\\r\\nAdolescent Well Being,N01.400.075\\r\\nAtaxin-2,D12.776.157.725.452.125\\r\\nAtaxin-2,D12.776.631.069.750\\r\\nAtaxin-2,D12.776.660.075.750\\r\\nAtaxin-2,D12.776.664.962.452.125\\r\\nAtaxin-3,D08.811.037.250\\r\\nAtaxin-3,D12.776.631.069.875\\r\\nAtaxin-3,D12.776.660.075.875\\r\\nPoint-of-Care Testing,N04.590.874.500\\r\\nBedside Testing,N04.590.874.500\\r\\nAtaxin-7,D12.776.631.069.901\\r\\nAtaxin-7,D12.776.660.075.900\\r\\nAtaxin-10,D12.776.631.069.950\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.695.021\\r\\nGlucagon-Like Peptide Receptors,D12.776.543.750.750.360.100\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500\\r\\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600\\r\\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600\\r\\nReceptor for Advanced Glycation End Products,D12.776.543.750.615\\r\\nRNA Recognition Motif Proteins,D12.776.157.725.813\\r\\nRNA Recognition Motif Proteins,D12.776.664.962.813\\r\\nELAV-Like Protein 2,D12.776.157.725.813.500.500\\r\\nELAV-Like Protein 2,D12.776.631.520.500\\r\\nELAV-Like Protein 2,D12.776.664.962.813.500.500\\r\\nELAV-Like Protein 3,D12.776.157.725.813.500.750\\r\\nELAV-Like Protein 3,D12.776.631.520.750\\r\\nELAV-Like Protein 3,D12.776.664.962.813.500.750\\r\\nELAV-Like Protein 4,D12.776.157.725.813.500.875\\r\\nELAV-Like Protein 4,D12.776.631.520.875\\r\\nELAV-Like Protein 4,D12.776.664.962.813.500.875\\r\\nELAV-Like Protein 1,D12.776.157.725.813.500.250\\r\\nELAV-Like Protein 1,D12.776.664.962.813.500.250\\r\\nWhey,A12.790.760\\r\\nWhey,G07.203.100.700.750\\r\\nWhey,G07.203.300.350.525.760\\r\\nWhey,J02.200.700.750\\r\\nWhey,J02.500.350.525.760\\r\\nWhey Proteins,A12.790.520.500\\r\\nWhey Proteins,A12.790.760.500\\r\\nWhey Proteins,D12.776.256.159.750.816\\r\\nWhey Proteins,G07.203.300.350.525.760.500\\r\\nWhey Proteins,G07.203.300.428.159.812.500\\r\\nWhey Proteins,J02.500.350.525.520.500\\r\\nWhey Proteins,J02.500.350.525.760.500\\r\\nWhey Proteins,J02.500.428.159.750.500\\r\\nHoarding Disorder,F03.080.600.250\\r\\nObsessive Hoarding,F03.080.600.250\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739\\r\\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692\\r\\nAutism Spectrum Disorder,F03.625.164.113\\r\\nCELF Proteins,D12.776.157.725.813.250\\r\\nCELF Proteins,D12.776.664.962.813.250\\r\\nCELF1 Protein,D12.776.157.725.813.250.500\\r\\nCELF1 Protein,D12.776.664.962.813.250.500\\r\\nIndustrial Development,I01.261.\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n0\\r\\n\"Albuterol, Ipratropium Drug Combination\",D26.310.344\\r\\nCombivent Respimat,D02.033.100.291.057.125\\r\\nCombivent Respimat,D02.092.063.291.057.125\\r\\nCombivent Respimat,D02.092.471.683.061.125\\r\\nCombivent Respimat,D02.145.074.722.229.400.500\\r\\nCombivent Respimat,D03.132.760.180.572.400.500\\r\\nCombivent Respimat,D03.132.889.180.648.400.500\\r\\nCombivent Respimat,D03.605.084.500.722.229.400.500\\r\\nCombivent Respimat,D03.605.869.229.400.500\\r\\nCombivent Respimat,D26.310.344\\r\\nDey Combination,D02.033.100.291.057.125\\r\\nDey Combination,D02.092.063.291.057.125\\r\\nDey Combination,D02.092.471.683.061.125\\r\\nDey Combination,D02.145.074.722.229.400.500\\r\\nDey Combination,D03.132.760.180.572.400.500\\r\\nDey Combination,D03.132.889.180.648.400.500\\r\\nDey Combination,D03.605.084.500.722.229.400.500\\r\\nDey Combination,D03.605.869.229.400.500\\r\\nDey Combination,D26.310.344\\r\\nCombivent,D02.033.100.291.057.125\\r\\nCombivent,D02.092.063.291.057.125\\r\\nCombivent,D02.092.471.683.061.125\\r\\nCombivent,D02.145.074.722.229.400.500\\r\\nCombivent,D03.132.760.180.572.400.500\\r\\nCombivent,D03.132.889.180.648.400.500\\r\\nCombivent,D03.605.084.500.722.229.400.500\\r\\nCombivent,D03.605.869.229.400.500\\r\\nCombivent,D26.310.344\\r\\nDual Use Research,H01.770.644.217\\r\\nProfessionalism,K01.752.566.479.171.566\\r\\nProfessionalism,N05.350.340.581\\r\\nMedical Professionalism,K01.752.566.479.171.566\\r\\nMedical Professionalism,N05.350.340.581\\r\\nProfessionalism Education,K01.752.566.479.171.566\\r\\nProfessionalism Education,N05.350.340.581\\r\\nSurgical Professionalism,K01.752.566.479.171.566\\r\\nSurgical Professionalism,N05.350.340.581\\r\\nGenetic Background,G05.346\\r\\nSelective Breeding,E05.820.150.760\\r\\nSelective Breeding,G05.090.701\\r\\nLegendary Creatures,I01.076.201.450.515.500\\r\\nWerewolves,I01.076.201.450.515.500\\r\\nUnicorns,I01.076.201.450.515.500\\r\\n\"Yeti, Himalayan\",I01.076.201.450.515.500\\r\\nVampires,I01.076.201.450.515.500\\r\\nMermaids,I01.076.201.450.515.500\\r\\nMometasone Furoate,D04.210.500.745.432.719.526\\r\\nNasonex,D04.210.500.745.432.719.526\\r\\nMometasone Furoate Monohydrate,D04.210.500.745.432.719.526\\r\\nAsmanex Twisthaler,D04.210.500.745.432.719.526\\r\\nAsmanex,D04.210.500.745.432.719.526\\r\\nRinelon,D04.210.500.745.432.719.526\\r\\nElocon,D04.210.500.745.432.719.526\\r\\nSch 32088,D04.210.500.745.432.719.526\\r\\nMometasone,D04.210.500.745.432.719.526\\r\\nFallopia multiflora,B01.650.940.800.575.912.250.825.359.590\\r\\nSildenafil Citrate,D02.065.884.675\\r\\nSildenafil Citrate,D02.886.590.700.675\\r\\nSildenafil Citrate,D03.383.606.854\\r\\nSildenafil Citrate,D03.633.100.759.824\\r\\nNCX-911,D02.065.884.675\\r\\nNCX-911,D02.886.590.700.675\\r\\nNCX-911,D03.383.606.854\\r\\nNCX-911,D03.633.100.759.824\\r\\nRevatio,D02.065.884.675\\r\\nRevatio,D02.886.590.700.675\\r\\nRevatio,D03.383.606.854\\r\\nRevatio,D03.633.100.759.824\\r\\nSildenafil,D02.065.884.675\\r\\nSildenafil,D02.886.590.700.675\\r\\nSildenafil,D03.383.606.854\\r\\nSildenafil,D03.633.100.759.824\\r\\nUK 92480-10,D02.065.884.675\\r\\nUK 92480-10,D02.886.590.700.675\\r\\nUK 92480-10,D03.383.606.854\\r\\nUK 92480-10,D03.633.100.759.824\\r\\nHomosildenafil,D02.065.884.675\\r\\nHomosildenafil,D02.886.590.700.675\\r\\nHomosildenafil,D03.383.606.854\\r\\nHomosildenafil,D03.633.100.759.824\\r\\nHydroxyhomosildenafil,D02.065.884.675\\r\\nHydroxyhomosildenafil,D02.886.590.700.675\\r\\nHydroxyhomosildenafil,D03.383.606.854\\r\\nHydroxyhomosildenafil,D03.633.100.759.824\\r\\nViagra,D02.065.884.675\\r\\nViagra,D02.886.590.700.675\\r\\nViagra,D03.383.606.854\\r\\nViagra,D03.633.100.759.824\\r\\nAcetildenafil,D02.065.884.675\\r\\nAcetildenafil,D02.886.590.700.675\\r\\nAcetildenafil,D03.383.606.854\\r\\nAcetildenafil,D03.633.100.759.824\\r\\nSildenafil Lactate,D02.065.884.675\\r\\nSildenafil Lactate,D02.886.590.700.675\\r\\nSildenafil Lactate,D03.383.606.854\\r\\nSildenafil Lactate,D03.633.100.759.824\\r\\nSildenafil Nitrate,D02.065.884.675\\r\\nSildenafil Nitrate,D02.886.590.700.675\\r\\nSildenafil Nitrate,D03.383.606.854\\r\\nSildenafil Nitrate,D03.633.100.759.824\\r\\nDesmethyl Sildenafil,D02.065.884.675\\r\\nDesmethyl Sildenafil,D02.886.590.700.675\\r\\nDesmethyl Sildenafil,D03.383.606.854\\r\\nDesmethyl Sildenafil,D03.633.100.759.824\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.626.809.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.705.429.906.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.680.245.500.600.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.755.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.633.100.759.138.881.500\\r\\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D26.310.407\\r\\nComplera,D02.626.809.500\\r\\nComplera,D02.705.429.906.500\\r\\nComplera,D03.383.742.680.245.500.600.500\\r\\nComplera,D03.383.742.755.500\\r\\nComplera,D03.633.100.759.138.881.500\\r\\nComplera,D26.310.407\\r\\nEmtricitabine,D03.383.742.680.245.500.600\\r\\nEmtricitabine,D13.570.230.329.525\\r\\nEmtricitabine,D13.570.685.245.500.600\\r\\nCoviracil,D03.383.742.680.245.500.600\\r\\nCoviracil,D13.570.230.329.525\\r\\nCoviracil,D13.570.685.245.500.600\\r\\nEmtriva,D03.383.742.680.245.500.600\\r\\nEmtriva,D13.570.230.329.525\\r\\nEmtriva,D13.570.685.245.500.600\\r\\nRilpivirine,D02.626.809\\r\\nRilpivirine,D03.383.742.755\\r\\nRilpivirine Hydrochloride,D02.626.809\\r\\nRilpivirine Hydrochloride,D03.383.742.755\\r\\nR278474,D02.626.809\\r\\nR278474,D03.383.742.755\\r\\nTMC 278,D02.626.809\\r\\nTMC 278,D03.383.742.755\\r\\nTenofovir,D02.705.429.906\\r\\nTenofovir,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D03.633.100.759.138.881\\r\\nTenofovir Disoproxil Fumarate,D02.705.429.906\\r\\nTenofovir Disoproxil Fumarate,D03.633.100.759.138.881\\r\\nTenofovir Disoproxil,D02.705.429.906\\r\\nTenofovir Disoproxil,D03.633.100.759.138.881\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D02.705.429.906\\r\\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D03.633.100.759.138.881\\r\\nViread,D02.705.429.906\\r\\nViread,D03.633.100.759.138.881\\r\\nGlatiramer Acetate,D12.644.219\\r\\nCopaxone,D12.644.219\\r\\nGlatiramer,D12.644.219\\r\\nTV 5010,D12.644.219\\r\\nRosuvastatin Calcium,D02.065.884.650\\r\\nRosuvastatin Calcium,D02.455.526.510.432.500\\r\\nRosuvastatin Calcium,D02.886.590.700.650\\r\\nRosuvastatin Calcium,D03.383.742.775\\r\\nCrestor,D02.065.884.650\\r\\nCrestor,D02.455.526.510.432.500\\r\\nCrestor,D02.886.590.700.650\\r\\nCrestor,D03.383.742.775\\r\\nRosuvastatin,D02.065.884.650\\r\\nRosuvastatin,D02.455.526.510.432.500\\r\\nRosuvastatin,D02.886.590.700.650\\r\\nRosuvastatin,D03.383.742.775\\r\\nZD4522,D02.065.884.650\\r\\nZD4522,D02.455.526.510.432.500\\r\\nZD4522,D02.886.590.700.650\\r\\nZD4522,D03.383.742.775\\r\\nDuloxetine Hydrochloride,D02.886.778.260\\r\\nDuloxetine Hydrochloride,D03.383.903.260\\r\\nLY 248686,D02.886.778.260\\r\\nLY 248686,D03.383.903.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D02.886.778.260\\r\\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D03.383.903.260\\r\\nLY 227942,D02.886.778.260\\r\\nLY 227942,D03.383.903.260\\r\\nDuloxetine,D02.886.778.260\\r\\nDuloxetine,D03.383.903.260\\r\\n\"Duloxetine, (+)-isomer\",D02.886.778.260\\r\\n\"Duloxetine, (+)-isomer\",D03.383.903.260\\r\\nCymbalta,D02.886.778.260\\r\\nCymbalta,D03.383.903.260\\r\\nTolterodine Tartrate,D02.033.100.624.706.750\\r\\nTolterodine Tartrate,D02.033.755.624.706.750\\r\\nTolterodine Tartrate,D02.092.063.624.706.800\\r\\nTolterodine Tartrate,D02.455.426.559.389.115.900\\r\\nTolterodine Tartrate,D02.455.426.559.389.657.239.756\\r\\nTolterodine,D02.033.100.624.706.750\\r\\nTolterodine,D02.033.755.624.706.750\\r\\nTolterodine,D02.092.063.624.706.800\\r\\nTolterodine,D02.455.426.559.389.115.900\\r\\nTolterodine,D02.455.426.559.389.657.239.756\\r\\nDetrol,D02.033.100.624.706.750\\r\\nDetrol,D02.033.755.624.706.750\\r\\nDetrol,D02.092.063.624.706.800\\r\\nDetrol,D02.455.426.559.389.115.900\\r\\nDetrol,D02.455.426.559.389.657.239.756\\r\\nDetrol LA,D02.033.100.624.706.750\\r\\nDetrol LA,D02.033.755.624.706.750\\r\\nDetrol LA,D02.092.063.624.706.800\\r\\nDetrol LA,D02.455.426.559.389.115.900\\r\\nDetrol LA,D02.455.426.559.389.657.239.756\\r\\nUrotrol,D02.033.100.624.706.750\\r\\nUrotrol,D02.033.755.624.706.750\\r\\nUrotrol,D02.092.063.624.706.800\\r\\nUrotrol,D02.455.426.559.389.115.900\\r\\nUrotrol,D02.455.426.559.389.657.239.756\\r\\nPHA-686464B,D02.033.100.624.706.750\\r\\nPHA-686464B,D02.033.755.624.706.750\\r\\nPHA-686464B,D02.092.063.624.706.800\\r\\nPHA-686464B,D02.455.426.559.389.115.900\\r\\nPHA-686464B,D02.455.426.559.389.657.239.756\\r\\nDetrusitol,D02.033.100.624.706.750\\r\\nDetrusitol,D02.033.755.624.706.750\\r\\nDetrusitol,D02.092.063.624.706.800\\r\\nDetrusitol,D02.455.426.559.389.115.900\\r\\nDetrusitol,D02.455.426.559.389.657.239.756\\r\\nUnidet,D02.033.100.624.706.750\\r\\nUnidet,D02.033.755.624.706.750\\r\\nUnidet,D02.092.063.624.706.800\\r\\nUnidet,D02.455.426.559.389.115.900\\r\\nUnidet,D02.455.426.559.389.657.239.756\\r\\nValsartan,D03.383.129.617.850\\r\\nValsartan,D12.125.070.950.550\\r\\nValsartan,D12.125.142.930.500\\r\\nDiovan,D03.383.129.617.850\\r\\nDiovan,D12.125.070.950.550\\r\\nDiovan,D12.125.142.930.500\\r\\nKalpress,D03.383.129.617.850\\r\\nKalpress,D12.125.070.950.550\\r\\nKalpress,D12.125.142.930.500\\r\\nTareg,D03.383.129.617.850\\r\\nTareg,D12.125.070.950.550\\r\\nTareg,D12.125.142.930.500\\r\\nNisis,D03.383.129.617.850\\r\\nNisis,D12.125.070.950.550\\r\\nNisis,D12.125.142.930.500\\r\\nProvas,D03.383.129.617.850\\r\\nProvas,D12.125.070.950.550\\r\\nProvas,D12.125.142.930.500\\r\\nVals,D03.383.129.617.850\\r\\nVals,D12.125.070.950.550\\r\\nVals,D12.125.142.930.500\\r\\nCGP 48933,D03.383.129.617.850\\r\\nCGP 48933,D12.125.070.950.550\\r\\nCGP 48933,D12.125.142.930.500\\r\\nMiten,D03.383.129.617.850\\r\\nMiten,D12.125.070.950.550\\r\\nMiten,D12.125.142.930.500\\r\\nOnonis,B01.650.940.800.575.912.250.401.604\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.033.100.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.092.063.291.425.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D04.210.500.745.432.719.526.500\\r\\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D26.310.469\\r\\nDulera,D02.033.100.291.425.500\\r\\nDulera,D02.092.063.291.425.500\\r\\nDulera,D04.210.500.745.432.719.526.500\\r\\nDulera,D26.310.469\\r\\nZenhale,D02.033.100.291.425.500\\r\\nZenhale,D02.092.063.291.425.500\\r\\nZenhale,D04.210.500.745.432.719.526.500\\r\\nZenhale,D26.310.469\\r\\nFormoterol Fumarate,D02.033.100.291.425\\r\\nFormoterol Fumarate,D02.092.063.291.425\\r\\nBD 40A,D02.033.100.291.425\\r\\nBD 40A,D02.092.063.291.425\\r\\nFormoterol,D02.033.100.291.425\\r\\nFormoterol,D02.092.063.291.425\\r\\nOxis,D02.033.100.291.425\\r\\nOxis,D02.092.063.291.425\\r\\nArformoterol,D02.033.100.291.425\\r\\nArformoterol,D02.092.063.291.425\\r\\nForadil,D02.033.100.291.425\\r\\nForadil,D02.092.063.291.425\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.562.437.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.625.600.693\\r\\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.696.577.600.693\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.696.277.350.500\\r\\n\"Sleep Aids, Pharmaceutical\",D27.505.954.427.210.350.500\\r\\nSleeping Pills,D27.505.696.277.350.500\\r\\nSleeping Pills,D27.505.954.427.210.350.500\\r\\nOrexin Receptor Antagonists,D27.505.519.625.663\\r\\nOrexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nOrexin Receptor Antagonists,D27.505.696.577.663\\r\\nOrexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.519.625.663\\r\\nDual Orexin Receptor Antagonists,D27.505.696.277.350.500.500\\r\\nDual Orexin Receptor Antagonists,D27.505.696.577.663\\r\\nDual Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\\r\\nOrexins,D12.644.400.360\\r\\nOrexins,D12.776.631.650.363\\r\\nOrexin-B,D12.644.400.360\\r\\nOrexin-B,D12.776.631.650.363\\r\\nOrexin-A,D12.644.400.360\\r\\nOrexin-A,D12.776.631.650.363\\r\\nHoodia,B01.650.940.800.575.912.250.456.500.389\\r\\nHoodia gordonii,B01.650.940.800.575.912.250.456.500.389\\r\\nPrasugrel Hydrochloride,D02.886.778.600\\r\\nPrasugrel Hydrochloride,D03.383.606.800\\r\\nPrasugrel Hydrochloride,D03.383.903.600\\r\\nCS 747,D02.886.778.600\\r\\nCS 747,D03.383.606.800\\r\\nCS 747,D03.383.903.600\\r\\nPrasugrel,D02.886.778.600\\r\\nPrasugrel,D03.383.606.800\\r\\nPrasugrel,D03.383.903.600\\r\\nEfient,D02.886.778.600\\r\\nEfient,D03.383.606.800\\r\\nEfient,D03.383.903.600\\r\\nEffient,D02.886.778.600\\r\\nEffient,D03.383.606.800\\r\\nEffient,D03.383.903.600\\r\\nLY 640315,D02.886.778.600\\r\\nLY 640315,D03.383.606.800\\r\\nLY 640315,D03.383.903.600\\r\\nEtanercept,D12.644.541.500.697.624\\r\\nEtanercept,D12.776.124.486.485.538.500.624\\r\\nEtanercept,D12.776.124.486.485.680.697.624\\r\\nEtanercept,D12.776.124.790.651.538.500.624\\r\\nEtanercept,D12.776.124.790.651.680.660.624\\r\\nEtanercept,D12.776.377.715.548.538.500.624\\r\\nEtanercept,D12.776.377.715.548.680.660.624\\r\\nEtanercept,D12.776.543.750.705.852.760.232\\r\\nTNFR-Fc Fusion Protein,D12.644.541.500.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNFR-Fc Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNFR-Fc Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEtanercept-szzs,D12.644.541.500.697.624\\r\\nEtanercept-szzs,D12.776.124.486.485.538.500.624\\r\\nEtanercept-szzs,D12.776.124.486.485.680.697.624\\r\\nEtanercept-szzs,D12.776.124.790.651.538.500.624\\r\\nEtanercept-szzs,D12.776.124.790.651.680.660.624\\r\\nEtanercept-szzs,D12.776.377.715.548.538.500.624\\r\\nEtanercept-szzs,D12.776.377.715.548.680.660.624\\r\\nEtanercept-szzs,D12.776.543.750.705.852.760.232\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nTNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nErelzi,D12.644.541.500.697.624\\r\\nErelzi,D12.776.124.486.485.538.500.624\\r\\nErelzi,D12.776.124.486.485.680.697.624\\r\\nErelzi,D12.776.124.790.651.538.500.624\\r\\nErelzi,D12.776.124.790.651.680.660.624\\r\\nErelzi,D12.776.377.715.548.538.500.624\\r\\nErelzi,D12.776.377.715.548.680.660.624\\r\\nErelzi,D12.776.543.750.705.852.760.232\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\\r\\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\\r\\nEnbrel,D12.644.541.500.697.624\\r\\nEnbrel,D12.776.124.486.485.538.500.624\\r\\nEnbrel,D12.776.124.486.485.680.697.624\\r\\nEnbrel,D12.776.124.790.651.538.500.624\\r\\nEnbrel,D12.776.124.790.651.680.660.624\\r\\nEnbrel,D12.776.377.715.548.538.500.624\\r\\nEnbrel,D12.776.377.715.548.680.660.624\\r\\nEnbrel,D12.776.543.750.705.852.760.232\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.241.223.100.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.389.127.133.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.847.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D04.615.638.090.500\\r\\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D26.310.032\\r\\nEpiduo,D02.241.223.100.133.500\\r\\nEpiduo,D02.455.426.559.389.127.133.500\\r\\nEpiduo,D02.455.426.559.847.638.090.500\\r\\nEpiduo,D04.615.638.090.500\\r\\nEpiduo,D26.310.032\\r\\nAdapalene,D02.455.426.559.847.638.090\\r\\nAdapalene,D04.615.638.090\\r\\nCD 271,D02.455.426.559.847.638.090\\r\\nCD 271,D04.615.638.090\\r\\nAdaferin,D02.455.426.559.847.638.090\\r\\nAdaferin,D04.615.638.090\\r\\nDifferin,D02.455.426.559.847.638.090\\r\\nDifferin,D04.615.638.090\\r\\nEpoetin Alfa,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa,D12.776.395.240.150.750\\r\\nEpoetin Alfa,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa,D23.529.374.410.240.150.750\\r\\nEpoetin Alfa Hexal,D12.644.276.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D12.776.395.240.150.750\\r\\nEpoetin Alfa Hexal,D12.776.467.374.410.240.150.500\\r\\nEpoetin Alfa Hexal,D23.529.374.410.240.150.750\\r\\nEprex,D12.644.276.374.410.240.150.500\\r\\nEprex,D12.776.395.240.150.750\\r\\nEprex,D12.776.467.374.410.240.150.500\\r\\nEprex,D23.529.374.410.240.150.750\\r\\nHeberitro,D12.644.276.374.410.240.150.500\\r\\nHeberitro,D12.776.395.240.150.750\\r\\nHeberitro,D12.776.467.374.410.240.150.500\\r\\nHeberitro,D23.529.374.410.240.150.750\\r\\nProcrit,D12.644.276.374.410.240.150.500\\r\\nProcrit,D12.776.395.240.150.750\\r\\nProcrit,D12.776.467.374.410.240.150.500\\r\\nProcrit,D23.529.374.410.240.150.750\\r\\nBinocrit,D12.644.276.374.410.240.150.500\\r\\nBinocrit,D12.776.395.240.150.750\\r\\nBinocrit,D12.776.467.374.410.240.150.500\\r\\nBinocrit,D23.529.374.410.240.150.750\\r\\nHX575 Compound,D12.644.276.374.410.240.150.500\\r\\nHX575 Compound,D12.776.395.240.150.750\\r\\nHX575 Compound,D12.776.467.374.410.240.150.500\\r\\nHX575 Compound,D23.529.374.410.240.150.750\\r\\nEpogen,D12.644.276.374.410.240.150.500\\r\\nEpogen,D12.776.395.240.150.750\\r\\nEpogen,D12.776.467.374.410.240.150.500\\r\\nEpogen,D23.529.374.410.240.150.750\\r\\nHX575,D12.644.276.374.410.240.150.500\\r\\nHX575,D12.776.395.240.150.750\\r\\nHX575,D12.776.467.374.410.240.150.500\\r\\nHX575,D23.529.374.410.240.150.750\\r\\nCetuximab,D12.776.124.486.485.114.224.060.750\\r\\nCetuximab,D12.776.124.790.651.114.224.060.750\\r\\nCetuximab,D12.776.377.715.548.114.224.200.750\\r\\nErbitux,D12.776.124.486.485.114.224.060.750\\r\\nErbitux,D12.776.124.790.651.114.224.060.750\\r\\nErbitux,D12.776.377.715.548.114.224.200.750\\r\\nIMC C225,D12.776.124.486.485.114.224.060.750\\r\\nIMC C225,D12.776.124.790.651.114.224.060.750\\r\\nIMC C225,D12.776.377.715.548.114.224.200.750\\r\\nHyssopus Plant,B01.650.940.800.575.912.250.583.520.330\\r\\nHyssopus officinalis,B01.650.940.800.575.912.250.583.520.330\\r\\nRivastigmine,D02.241.081.251.583.899\\r\\nRivastigmineTartrate,D02.241.081.251.583.899\\r\\nExelon,D02.241.081.251.583.899\\r\\nENA 713,D02.241.081.251.583.899\\r\\nParmeliaceae,B01.300.107.685\\r\\nParmeliaceae,B01.300.340.458\\r\\nCetraria,B01.300.107.685\\r\\nCetraria,B01.300.340.458\\r\\nCetraria islandica,B01.300.107.685\\r\\nCetraria islandica,B01.300.340.458\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.129.617.850.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D03.383.725.203.065.750\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.070.950.550.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D12.125.142.930.500.500\\r\\n\"Amlodipine, Valsartan Drug Combination\",D26.310.094\\r\\nExforge,D03.383.129.617.850.500\\r\\nExforge,D03.383.725.203.065.750\\r\\nExforge,D12.125.070.950.550.500\\r\\nExforge,D12.125.142.930.500.500\\r\\nExforge,D26.310.094\\r\\nEugenia,B01.650.940.800.575.912.250.773.374\\r\\nEuginia uniflora,B01.650.940.800.575.912.250.773.374\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.899.498.500\\r\\nGardasil,D20.215.894.815.455\\r\\nGardasil,D20.215.894.899.498.500\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.815.455\\r\\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.899.498.500\\r\\nKombucha Tea,D20.215.784.844.500\\r\\nKombucha Tea,G07.203.100.831.500\\r\\nKombucha Tea,G07.203.200.625\\r\\nKombucha Tea,J02.200.831.500\\r\\nKombucha Tea,J02.350.625\\r\\nFingolimod Hydrochloride,D02.033.100.700.350\\r\\nFingolimod Hydrochloride,D02.033.455.706.431\\r\\nFingolimod Hydrochloride,D02.092.063.700.350\\r\\nFTY-720,D02.033.100.700.350\\r\\nFTY-720,D02.033.455.706.431\\r\\nFTY-720,D02.092.063.700.350\\r\\nGilenya,D02.033.100.700.350\\r\\nGilenya,D02.033.455.706.431\\r\\nGilenya,D02.092.063.700.350\\r\\nFingolimod,D02.033.100.700.350\\r\\nFingolimod,D02.033.455.706.431\\r\\nFingolimod,D02.092.063.700.350\\r\\nImatinib Mesylate,D02.065.277.456\\r\\nImatinib Mesylate,D02.241.223.100.100.435\\r\\nImatinib Mesylate,D02.455.426.559.389.127.085.465\\r\\nImatinib Mesylate,D03.383.606.405\\r\\nImatinib Mesylate,D03.383.742.349\\r\\nSTI571,D02.065.277.456\\r\\nSTI571,D02.241.223.100.100.435\\r\\nSTI571,D02.455.426.559.389.127.085.465\\r\\nSTI571,D03.383.606.405\\r\\nSTI571,D03.383.742.349\\r\\nGleevec,D02.065.277.456\\r\\nGleevec,D02.241.223.100.100.435\\r\\nGleevec,D02.455.426.559.389.127.085.465\\r\\nGleevec,D03.383.606.405\\r\\nGleevec,D03.383.742.349\\r\\nST 1571,D02.065.277.456\\r\\nST 1571,D02.241.223.100.100.435\\r\\nST 1571,D02.455.426.559.389.127.085.465\\r\\nST 1571,D03.383.606.405\\r\\nST 1571,D03.383.742.349\\r\\nCGP 57148,D02.065.277.456\\r\\nCGP 57148,D02.241.223.100.100.435\\r\\nCGP 57148,D02.455.426.559.389.127.085.465\\r\\nCGP 57148,D03.383.606.405\\r\\nCGP 57148,D03.383.742.349\\r\\nImatinib,D02.065.277.456\\r\\nImatinib,D02.241.223.100.100.435\\r\\nImatinib,D02.455.426.559.389.127.085.465\\r\\nImatinib,D03.383.606.405\\r\\nImatinib,D03.383.742.349\\r\\nTrastuzumab,D12.776.124.486.485.114.224.060.875\\r\\nTrastuzumab,D12.776.124.790.651.114.224.060.875\\r\\nTrastuzumab,D12.776.377.715.548.114.224.200.875\\r\\nHerceptin,D12.776.124.486.485.114.224.060.875\\r\\nHerceptin,D12.776.124.790.651.114.224.060.875\\r\\nHerceptin,D12.776.377.715.548.114.224.200.875\\r\\nTrazimera,D12.776.124.486.485.114.224.060.875\\r\\nTrazimera,D12.776.124.790.651.114.224.060.875\\r\\nTrazimera,D12.776.377.715.548.114.224.200.875\\r\\nAdalimumab,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab,D12.776.377.715.548.114.224.200.250\\r\\nHumira,D12.776.124.486.485.114.224.060.250\\r\\nHumira,D12.776.124.790.651.114.224.060.250\\r\\nHumira,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-adbm,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-adbm,D12.776.377.715.548.114.224.200.250\\r\\nAmjevita,D12.776.124.486.485.114.224.060.250\\r\\nAmjevita,D12.776.124.790.651.114.224.060.250\\r\\nAmjevita,D12.776.377.715.548.114.224.200.250\\r\\nAdalimumab-atto,D12.776.124.486.485.114.224.060.250\\r\\nAdalimumab-atto,D12.776.124.790.651.114.224.060.250\\r\\nAdalimumab-atto,D12.776.377.715.548.114.224.200.250\\r\\nCyltezo,D12.776.124.486.485.114.224.060.250\\r\\nCyltezo,D12.776.124.790.651.114.224.060.250\\r\\nCyltezo,D12.776.377.715.548.114.224.200.250\\r\\nD2E7 Antibody,D12.776.124.486.485.114.224.060.250\\r\\nD2E7 Antibody,D12.776.124.790.651.114.224.060.250\\r\\nD2E7 Antibody,D12.776.377.715.548.114.224.200.250\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D06.472.699.587.200.500.625.500.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.300.200.500\\r\\n\"Isophane Insulin, Human\",D12.644.548.586.200.500.625.500.500\\r\\nHumulin N,D06.472.699.587.200.300.200.500\\r\\nHumulin N,D06.472.699.587.200.500.625.500.500\\r\\nHumulin N,D12.644.548.586.200.300.200.500\\r\\nHumulin N,D12.644.548.586.200.500.625.500.500\\r\\nNovolin N,D06.472.699.587.200.300.200.500\\r\\nNovolin N,D06.472.699.587.200.500.625.500.500\\r\\nNovolin N,D12.644.548.586.200.300.200.500\\r\\nNovolin N,D12.644.548.586.200.500.625.500.500\\r\\n\"Animals, Exotic\",B01.050.050.126\\r\\nExotic Pets,B01.050.050.126\\r\\nPaliperidone Palmitate,D03.383.129.385.650\\r\\nPaliperidone Palmitate,D03.383.742.592\\r\\nPaliperidone,D03.383.129.385.650\\r\\nPaliperidone,D03.383.742.592\\r\\nInvega,D03.383.129.385.650\\r\\nInvega,D03.383.742.592\\r\\nInvega Sustenna,D03.383.129.385.650\\r\\nInvega Sustenna,D03.383.742.592\\r\\nR 76477,D03.383.129.385.650\\r\\nR 76477,D03.383.742.592\\r\\nImmunosenescence,G07.345.124.390\\r\\nImmunosenescence,G12.460.500\\r\\nCanagliflozin,D02.886.778.075\\r\\nCanagliflozin,D03.383.903.075\\r\\nCanagliflozin,D09.408.348.113\\r\\nInvokana,D02.886.778.075\\r\\nInvokana,D03.383.903.075\\r\\nInvokana,D09.408.348.113\\r\\nCanagliflozin Hemihydrate,D02.886.778.075\\r\\nCanagliflozin Hemihydrate,D03.383.903.075\\r\\nCanagliflozin Hemihydrate,D09.408.348.113\\r\\n\"Canagliflozin, Anhydrous\",D02.886.778.075\\r\\n\"Canagliflozin, Anhydrous\",D03.383.903.075\\r\\n\"Canagliflozin, Anhydrous\",D09.408.348.113\\r\\nIridescence,G01.590.310\\r\\nOpalescence,G01.590.310\\r\\nRaltegravir Potassium,D03.383.773.812.752\\r\\nRaltegravir,D03.383.773.812.752\\r\\nMK 0518,D03.383.773.812.752\\r\\nIsentress'",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#viwing the first few lines \n",
    "dbutils.fs.head(\"/FileStore/tables/mesh.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "f950be22-560a-4ead-8a64-af2abb23364c",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Truncated to first 65536 bytes]\n",
       "term,tree\n",
       "Calcimycin,D03.633.100.221.173\n",
       "A-23187,D03.633.100.221.173\n",
       "Temefos,D02.705.400.625.800\n",
       "Temefos,D02.705.539.345.800\n",
       "Temefos,D02.886.300.692.800\n",
       "Abate,D02.705.400.625.800\n",
       "Abate,D02.705.539.345.800\n",
       "Abate,D02.886.300.692.800\n",
       "Difos,D02.705.400.625.800\n",
       "Difos,D02.705.539.345.800\n",
       "Difos,D02.886.300.692.800\n",
       "Abattoirs,J01.576.423.200.700.100\n",
       "Abattoirs,J03.540.020\n",
       "Abbreviations as Topic,L01.559.598.400.556.131\n",
       "Acronyms as Topic,L01.559.598.400.556.131\n",
       "Abdomen,A01.923.047\n",
       "\"Abdomen, Acute\",C23.888.592.612.054.200\n",
       "\"Abdomen, Acute\",C23.888.821.030.249\n",
       "Abdominal Injuries,C26.017\n",
       "Abdominal Neoplasms,C04.588.033\n",
       "Abdominal Muscles,A02.633.567.050\n",
       "Cremaster Muscle,A02.633.567.050\n",
       "Pyramidalis Muscle,A02.633.567.050\n",
       "Quadratus Abdominis,A02.633.567.050\n",
       "Transversus Abdominis,A02.633.567.050\n",
       "Abducens Nerve,A08.800.800.120.030\n",
       "Abelson murine leukemia virus,B04.613.807.375.525.020\n",
       "Abelson murine leukemia virus,B04.820.650.375.525.020\n",
       "Abetalipoproteinemia,C16.320.565.398.500.440.500\n",
       "Abetalipoproteinemia,C18.452.584.500.875.440.500\n",
       "Abetalipoproteinemia,C18.452.648.398.500.440.500\n",
       "Congenital Abnormalities,C16.131\n",
       "Fetal Malformations,C16.131\n",
       "Fetal Anomalies,C16.131\n",
       "\"Abnormalities, Drug-Induced\",C16.131.042\n",
       "\"Abnormalities, Multiple\",C16.131.077\n",
       "\"Abnormalities, Radiation-Induced\",C16.131.080\n",
       "\"Abnormalities, Radiation-Induced\",C26.733.031\n",
       "\"Abnormalities, Radiation-Induced\",G01.750.748.500.031\n",
       "\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031\n",
       "\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031\n",
       "ABO Blood-Group System,D23.050.301.290.031\n",
       "ABO Blood-Group System,D23.050.705.230.031\n",
       "Blood Group H Type 1 Antigen,D23.050.301.290.031\n",
       "Blood Group H Type 1 Antigen,D23.050.705.230.031\n",
       "ABO Factors,D23.050.301.290.031\n",
       "ABO Factors,D23.050.705.230.031\n",
       "Abomasum,A13.869.106\n",
       "Abortifacient Agents,D27.505.696.875.131\n",
       "Abortifacient Agents,D27.505.954.705.131\n",
       "Abortifacient Effect,D27.505.696.875.131\n",
       "Abortifacient Effect,D27.505.954.705.131\n",
       "\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100\n",
       "\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100\n",
       "\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200\n",
       "\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200\n",
       "\"Abortion, Spontaneous\",C13.703.039\n",
       "\"Abortion, Spontaneous\",G08.686.784.769.496.125\n",
       "Early Pregnancy Loss,C13.703.039\n",
       "Early Pregnancy Loss,G08.686.784.769.496.125\n",
       "Miscarriage,C13.703.039\n",
       "Miscarriage,G08.686.784.769.496.125\n",
       "\"Abortion, Tubal\",C13.703.039\n",
       "\"Abortion, Tubal\",G08.686.784.769.496.125\n",
       "Abortion Applicants,M01.050\n",
       "\"Abortion Seekers, Repeated\",M01.050\n",
       "\"Abortion Seekers, Refused\",M01.050\n",
       "\"Abortion, Criminal\",I01.198.240.089\n",
       "\"Abortion, Eugenic\",E04.520.050.050\n",
       "\"Abortion, Selective\",E04.520.050.050\n",
       "\"Abortion, Habitual\",C13.703.039.089\n",
       "\"Abortion, Incomplete\",C13.703.039.093\n",
       "\"Abortion, Induced\",E04.520.050\n",
       "Abortion Rate,E04.520.050\n",
       "Abortion Techniques,E04.520.050\n",
       "\"Abortion, Drug-Induced\",E04.520.050\n",
       "Previous Abortion,E04.520.050\n",
       "\"Abortion, Saline-Solution\",E04.520.050\n",
       "\"Abortion, Soap-Solution\",E04.520.050\n",
       "Anti-Abortion Groups,E04.520.050\n",
       "Embryotomy,E04.520.050\n",
       "\"Fertility Control, Postconception\",E04.520.050\n",
       "Abortion Failure,E04.520.050\n",
       "\"Abortion, Rivanol\",E04.520.050\n",
       "\"Abortion, Legal\",E04.520.050.055\n",
       "Abortion on Demand,E04.520.050.055\n",
       "\"Abortion, Missed\",C13.703.039.173\n",
       "\"Abortion, Septic\",C01.674.173\n",
       "\"Abortion, Septic\",C13.703.039.256\n",
       "\"Abortion, Septic\",C13.703.700.173\n",
       "\"Abortion, Therapeutic\",E04.520.050.060\n",
       "\"Abortion, Threatened\",C13.703.090\n",
       "\"Abortion, Veterinary\",C13.703.039.422\n",
       "\"Abortion, Veterinary\",C22.021\n",
       "Abreaction,F04.754.720.107\n",
       "Abrin,D08.811.277.450.430.700.750.111\n",
       "Abrin,D12.776.503.499.249\n",
       "Abrin,D12.776.765.678.906.111\n",
       "Abrin C,D08.811.277.450.430.700.750.111\n",
       "Abrin C,D12.776.503.499.249\n",
       "Abrin C,D12.776.765.678.906.111\n",
       "Abrin A,D08.811.277.450.430.700.750.111\n",
       "Abrin A,D12.776.503.499.249\n",
       "Abrin A,D12.776.765.678.906.111\n",
       "Abruptio Placentae,C13.703.420.078\n",
       "Abruptio Placentae,C13.703.590.132\n",
       "Abscess,C01.830.025\n",
       "Abscess,C23.550.470.756.100\n",
       "Peritonsillar Abscess,C01.748.561.750.500\n",
       "Peritonsillar Abscess,C01.830.025.675\n",
       "Peritonsillar Abscess,C07.550.781.750.500\n",
       "Peritonsillar Abscess,C08.730.561.750.500\n",
       "Peritonsillar Abscess,C09.775.649.750.500\n",
       "Abscisic Acid,D02.241.223.268.034\n",
       "Abscisic Acid,D02.455.326.271.665.202.061\n",
       "Abscisic Acid,D02.455.426.392.368.367.379.249.024\n",
       "Abscisic Acid,D02.455.849.131.061\n",
       "Abscisic Acid,D02.455.849.765.521.500\n",
       "\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034\n",
       "\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061\n",
       "\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\n",
       "\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061\n",
       "\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500\n",
       "\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034\n",
       "\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061\n",
       "\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024\n",
       "\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061\n",
       "\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500\n",
       "\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034\n",
       "\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061\n",
       "\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\n",
       "\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061\n",
       "\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500\n",
       "\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034\n",
       "\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061\n",
       "\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\n",
       "\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061\n",
       "\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500\n",
       "\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034\n",
       "\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061\n",
       "\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\n",
       "\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061\n",
       "\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500\n",
       "\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034\n",
       "\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061\n",
       "\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024\n",
       "\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061\n",
       "\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500\n",
       "Absenteeism,F02.784.692.107\n",
       "Absorption,G01.015\n",
       "Absorption,G02.010\n",
       "Absorption,G03.015\n",
       "Absorption,G03.787.024\n",
       "Absorption,G07.690.725.015\n",
       "Abstracting and Indexing,L01.453.245.100\n",
       "Indexing,L01.453.245.100\n",
       "Indexes as Topic,L01.453.245.100\n",
       "Abstracting,L01.453.245.100\n",
       "Dental Abutments,E06.780.346.500\n",
       "Dental Abutments,E07.695.190.175\n",
       "Acacia,B01.650.940.800.575.912.250.401.025\n",
       "Acacia catechu,B01.650.940.800.575.912.250.401.025\n",
       "Academic Medical Centers,N02.278.020\n",
       "Academies and Institutes,N03.540.052\n",
       "Institutes,N03.540.052\n",
       "Research Institutes,N03.540.052\n",
       "Academies,N03.540.052\n",
       "Acanthamoeba,B01.046.500.100.075.080\n",
       "Acanthocephala,B01.050.500.500.132\n",
       "Acanthocytes,A11.118.290.330.100\n",
       "Acanthocytes,A11.443.240.330.100\n",
       "Acanthocytes,A15.145.229.334.330.100\n",
       "Acantholysis,C17.800.865.070\n",
       "Acantholysis,C23.550.035\n",
       "Acanthosis Nigricans,C17.800.621.430.530.100\n",
       "Acari,B01.050.500.131.166.132\n",
       "Acceleration,G01.482.107\n",
       "Accessory Nerve,A08.800.800.120.060\n",
       "Accident Prevention,N06.850.135.060\n",
       "Accident Proneness,F01.145.015\n",
       "Accidental Falls,N06.850.135.122\n",
       "Slip and Fall,N06.850.135.122\n",
       "Accidents,N06.850.135\n",
       "\"Accidents, Aviation\",N06.850.135.185\n",
       "\"Accidents, Home\",N06.850.135.217\n",
       "\"Accidents, Occupational\",N06.850.135.240\n",
       "\"Accidents, Industrial\",N06.850.135.240\n",
       "\"Accidents, Traffic\",N06.850.135.392\n",
       "Traffic Collisions,N06.850.135.392\n",
       "Traffic Crashes,N06.850.135.392\n",
       "Acclimatization,G07.025.133\n",
       "Acclimatization,G16.012.500.133\n",
       "\"Accommodation, Ocular\",G14.010\n",
       "\"Accommodation, Lens\",G14.010\n",
       "Accounting,N03.219.463.030\n",
       "Oil and Gas Industry,J01.576.655.875.750\n",
       "Petroleum Industry,J01.576.655.875.750\n",
       "Oil Refinery,J01.576.655.875.750\n",
       "Natural Gas Industry,J01.576.655.875.750\n",
       "Coal Industry,J01.576.655.875.200\n",
       "Driving Under the Influence,F01.145.250.250\n",
       "Driving Under the Influence,F01.145.263.500\n",
       "Driving Under the Influence,I01.880.735.223.250\n",
       "Driving Under the Influence,I03.125.649\n",
       "Drinking and Driving,F01.145.250.250\n",
       "Drinking and Driving,F01.145.263.500\n",
       "Drinking and Driving,I01.880.735.223.250\n",
       "Drinking and Driving,I03.125.649\n",
       "Human Embryonic Stem Cells,A11.872.700.250.750\n",
       "Mouse Embryonic Stem Cells,A11.872.700.250.875\n",
       "Embryonic Germ Cells,A11.497.124\n",
       "Embryonic Germ Cells,A11.872.700.250.625\n",
       "Work Performance,I03.946.675\n",
       "Job Performance,I03.946.675\n",
       "Criminal Behavior,F01.145.250\n",
       "Clinical Decision-Making,E01.055\n",
       "Cognitive Aging,G07.345.124.260\n",
       "Cognitive Neuroscience,F04.096.628.255.500\n",
       "Cognitive Neuroscience,H01.158.610.030\n",
       "Social Neuroscience,F04.096.628.255.500\n",
       "Social Neuroscience,H01.158.610.030\n",
       "Emotional Adjustment,F01.058.144\n",
       "Emotional Adjustment,F01.752.543.500.250\n",
       "Facial Recognition,F02.463.593.524.250.500\n",
       "Facial Recognition,F02.463.593.524.500.500\n",
       "Facial Recognition,F02.463.593.932.622.500\n",
       "Facial Emotion Recognition,F02.463.593.524.250.500\n",
       "Facial Emotion Recognition,F02.463.593.524.500.500\n",
       "Facial Emotion Recognition,F02.463.593.932.622.500\n",
       "Grandparents,F01.829.263.403\n",
       "Grandparents,I01.880.853.150.452\n",
       "Grandparents,M01.264\n",
       "Grandmother,F01.829.263.403\n",
       "Grandmother,I01.880.853.150.452\n",
       "Grandmother,M01.264\n",
       "Grandfather,F01.829.263.403\n",
       "Grandfather,I01.880.853.150.452\n",
       "Grandfather,M01.264\n",
       "Help-Seeking Behavior,F01.145.813.217\n",
       "Heuristics,F02.463.425.725.500\n",
       "Heuristics,F02.463.785.810.500\n",
       "Intimate Partner Violence,I01.198.240.856.575\n",
       "Intimate Partner Violence,I01.880.735.900.688\n",
       "Dating Violence,I01.198.240.856.575\n",
       "Dating Violence,I01.880.735.900.688\n",
       "Neurological Rehabilitation,E02.760.169.063.500.477\n",
       "Neurological Rehabilitation,E02.831.477\n",
       "Neurological Rehabilitation,H02.403.680.600.750\n",
       "Neurological Rehabilitation,N02.421.784.511\n",
       "Physical Abuse,I01.198.240.856.688\n",
       "Physical Abuse,I01.880.735.900.744\n",
       "Problem Behavior,F01.145.126.972\n",
       "Problem Behavior,F01.145.179.750\n",
       "\"Dysfunctional Behavior, Psychology\",F01.145.126.972\n",
       "\"Dysfunctional Behavior, Psychology\",F01.145.179.750\n",
       "Disruptive Behavior,F01.145.126.972\n",
       "Disruptive Behavior,F01.145.179.750\n",
       "Underage Drinking,F01.145.022.750\n",
       "Underage Drinking,F01.145.317.269.875\n",
       "Underage Drinking,I01.880.735.878\n",
       "Legal Drinking Age,F01.145.022.750\n",
       "Legal Drinking Age,F01.145.317.269.875\n",
       "Legal Drinking Age,I01.880.735.878\n",
       "Ectopic Gene Expression,G05.308.202\n",
       "Cell Plasticity,G04.356.250\n",
       "Cell Self Renewal,G04.144.220.235\n",
       "Cell Self Renewal,G04.161.750.500.375\n",
       "Cell Self Renewal,G05.113.415\n",
       "Cell Self Renewal,G07.345.249.410.750.500.625\n",
       "Stem Cell Self-Renewal,G04.144.220.235\n",
       "Stem Cell Self-Renewal,G04.161.750.500.375\n",
       "Stem Cell Self-Renewal,G05.113.415\n",
       "Stem Cell Self-Renewal,G07.345.249.410.750.500.625\n",
       "Rehabilitation Research,H01.770.644.145.472\n",
       "Orthodontists,M01.526.485.330.655\n",
       "Orthodontists,N02.360.330.655\n",
       "Dentofacial Orthopedists,M01.526.485.330.655\n",
       "Dentofacial Orthopedists,N02.360.330.655\n",
       "Oral and Maxillofacial Surgeons,M01.526.485.330.483\n",
       "Oral and Maxillofacial Surgeons,N02.360.330.483\n",
       "Exodontists,M01.526.485.330.483\n",
       "Exodontists,N02.360.330.483\n",
       "Neuroprotection,G11.561.645\n",
       "\"Diet, Food, and Nutrition\",G07.203\n",
       "Triticale,B01.650.940.800.575.912.250.822.906\n",
       "Critical Care Outcomes,N04.761.559.590.399.250\n",
       "Critical Care Outcomes,N05.715.360.575.575.399.250\n",
       "Simulation Training,I02.903.847\n",
       "Interactive Learning,I02.903.847\n",
       "Millets,B01.650.940.800.575.912.250.822.587\n",
       "Biobehavioral Sciences,H01.770.644.108.687\n",
       "Protein Corona,D12.776.642\n",
       "Vegetarians,M01.928\n",
       "Lacto-Ovo Vegetarians,M01.928\n",
       "Vegans,M01.928.500\n",
       "Accounts Payable and Receivable,N03.219.463.030.080\n",
       "Accounts Payable,N03.219.463.030.080\n",
       "Youth Sports,I03.450.642.845.987\n",
       "Organized Youth Sports,I03.450.642.845.987\n",
       "Literacy,F01.145.209.429\n",
       "Literacy,N01.824.196.500\n",
       "Illiteracy,F01.145.209.429\n",
       "Illiteracy,N01.824.196.500\n",
       "Severe Acute Malnutrition,C18.654.521.719\n",
       "\"Banking, Personal\",N03.219.463.030.100\n",
       "Savings Accounts,N03.219.463.030.100\n",
       "Checking Accounts,N03.219.463.030.100\n",
       "Evidence-Based Facility Design,N02.278.200.252\n",
       "\"Physical Appearance, Body\",E01.370.600.115.450\n",
       "\"Physical Appearance, Body\",G07.100.175\n",
       "Fruit and Vegetable Juices,G07.203.100.606\n",
       "Fruit and Vegetable Juices,J02.200.606\n",
       "Vegetable Juices,G07.203.100.606\n",
       "Vegetable Juices,J02.200.606\n",
       "Fruit Juices,G07.203.100.606\n",
       "Fruit Juices,J02.200.606\n",
       "Ghee,D10.212.302.199.500\n",
       "Ghee,G07.203.300.350.100.500\n",
       "Ghee,G07.203.300.375.200.500\n",
       "Ghee,J02.500.350.100.500\n",
       "Ghee,J02.500.375.200.500\n",
       "Hydraulic Fracking,J01.576.655.875.750.500\n",
       "Psychological Trauma,F03.950.750.375\n",
       "Peer Influence,F01.829.316.483.750\n",
       "Peer Pressure,F01.829.316.483.750\n",
       "Vegetable Products,G07.203.300.850.450\n",
       "Vegetable Products,J02.500.850.800\n",
       "Direct-to-Consumer Advertising,J01.219.687.274.500\n",
       "Direct-To-Consumer Screening and Testing,E01.370.398\n",
       "Direct-To-Consumer Screening and Testing,N02.421.726.233.166\n",
       "Extracellular Vesicles,A11.284.295.588\n",
       "Exovesicles,A11.284.295.588\n",
       "Apoptotic Bodies,A11.284.295.588\n",
       "Fungal Viruses,B04.352\n",
       "Telocytes,A11.329.830.750\n",
       "Exoskeleton Device,E07.341\n",
       "Robotic Exoskeleton,E07.341\n",
       "Shellfish Hypersensitivity,C20.543.480.370.763\n",
       "\"Failure to Rescue, Health Care\",E01.789.800.760.500\n",
       "\"Failure to Rescue, Health Care\",H01.770.644.145.431.500\n",
       "\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500\n",
       "\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500\n",
       "Psychiatric Rehabilitation,H02.403.680.600.875\n",
       "Psychiatric Rehabilitation,N02.421.784.578\n",
       "Psychosocial Care,H02.403.680.600.875\n",
       "Psychosocial Care,N02.421.784.578\n",
       "Symptom Flare Up,C23.550.291.937.500\n",
       "Symptom Exacerbation,C23.550.291.937.500\n",
       "Isolated Heart Preparation,E05.519\n",
       "Isolated Heart Preparation,E05.598.750\n",
       "Langendorff Perfused Heart,E05.519\n",
       "Langendorff Perfused Heart,E05.598.750\n",
       "Working Heart Preparation Technique,E05.519\n",
       "Working Heart Preparation Technique,E05.598.750\n",
       "Working Heart Preparation,E05.519\n",
       "Working Heart Preparation,E05.598.750\n",
       "Isolated Heart Preparation Technique,E05.519\n",
       "Isolated Heart Preparation Technique,E05.598.750\n",
       "\"Diet, Vegan\",E02.642.249.300.750\n",
       "\"Diet, Vegan\",G07.203.650.240.300.750\n",
       "Veganism,E02.642.249.300.750\n",
       "Veganism,G07.203.650.240.300.750\n",
       "Behavior Observation Techniques,E05.796.112\n",
       "Behavior Observation Techniques,F04.669.112\n",
       "Behavior Rating Scale,F04.711.271\n",
       "Behavior Test,F04.711.271\n",
       "Alcohol Drinking in College,F01.145.317.269.625\n",
       "\"Obesity, Metabolically Benign\",C18.654.726.500.650\n",
       "\"Obesity, Metabolically Benign\",C23.888.144.699.500.250\n",
       "\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375\n",
       "\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375\n",
       "Whole Grains,G07.203.300.300.550.500\n",
       "Whole Grains,G07.203.300.775.500.500\n",
       "Whole Grains,J02.500.300.550.500\n",
       "Whole Grains,J02.500.775.500.500\n",
       "Whole Grain Cereals,G07.203.300.300.550.500\n",
       "Whole Grain Cereals,G07.203.300.775.500.500\n",
       "Whole Grain Cereals,J02.500.300.550.500\n",
       "Whole Grain Cereals,J02.500.775.500.500\n",
       "Transanal Endoscopic Surgery,E01.370.388.250.630.500\n",
       "Transanal Endoscopic Surgery,E04.210.240.250.680.500\n",
       "Transanal Endoscopic Surgery,E04.502.250.250.250.680.500\n",
       "Transanal Endoscopic Surgery,E04.502.250.630.500\n",
       "Transanal Minimally Invasive Surgery,E01.370.388.250.630.500\n",
       "Transanal Minimally Invasive Surgery,E04.210.240.250.680.500\n",
       "Transanal Minimally Invasive Surgery,E04.502.250.250.250.680.500\n",
       "Transanal Minimally Invasive Surgery,E04.502.250.630.500\n",
       "Transanal Endoscopic Microsurgery,E01.370.388.250.630.500.500\n",
       "Transanal Endoscopic Microsurgery,E04.210.240.250.680.500.500\n",
       "Transanal Endoscopic Microsurgery,E04.494.787\n",
       "Transanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500\n",
       "Transanal Endoscopic Microsurgery,E04.502.250.630.500.500\n",
       "Cold Injury,C26.212\n",
       "Personal Protective Equipment,E07.700.560\n",
       "Personal Protective Equipment,J01.637.708.560\n",
       "Nerve Agents,D27.720.599\n",
       "Nerve Agents,D27.720.777.300.500\n",
       "Nerve Gas,D27.720.599\n",
       "Nerve Gas,D27.720.777.300.500\n",
       "War-Related Injuries,C26.946\n",
       "War-Related Injuries,I01.880.735.950.500.951.500\n",
       "War-Related Injuries,N06.850.460.350.600.903.500\n",
       "War-Related Trauma,C26.946\n",
       "War-Related Trauma,I01.880.735.950.500.951.500\n",
       "War-Related Trauma,N06.850.460.350.600.903.500\n",
       "Abnormal Involuntary Movement Scale,E01.370.600.550.162\n",
       "Blood Alcohol Content,D02.033.375.135\n",
       "Social Communication Disorder,F03.625.374.250\n",
       "Legal Services,I01.880.604.583.482\n",
       "Defamation,I01.198.240.240\n",
       "Defamation,I01.880.735.191.051\n",
       "Slander,I01.198.240.240\n",
       "Slander,I01.880.735.191.051\n",
       "Libel,I01.198.240.240\n",
       "Libel,I01.880.735.191.051\n",
       "Anger Management Therapy,F04.754.137.087\n",
       "\"Psychology, Sports\",F04.096.628.914\n",
       "War Exposure,I01.880.735.950.500.951\n",
       "War Exposure,N06.850.460.350.600.903\n",
       "Childhood-Onset Fluency Disorder,F03.625.374.125\n",
       "No-Show Patients,F01.100.150.750.500.600.750\n",
       "No-Show Patients,F01.145.488.887.500.600.750\n",
       "No-Show Patients,M01.643.550\n",
       "No-Show Patients,N04.452.758.635.500\n",
       "No-Show Patients,N05.300.150.800.500.600.750\n",
       "Cellular Reprogramming Techniques,E05.200.500.380\n",
       "Cellular Reprogramming Techniques,E05.242.378\n",
       "Cellular Reprogramming Techniques,E05.393.085\n",
       "Directed Differentiation Techniques,E05.200.500.380\n",
       "Directed Differentiation Techniques,E05.242.378\n",
       "Directed Differentiation Techniques,E05.393.085\n",
       "Direct Cell Reprogramming Techniques,E05.200.500.380\n",
       "Direct Cell Reprogramming Techniques,E05.242.378\n",
       "Direct Cell Reprogramming Techniques,E05.393.085\n",
       "Metacognition,F02.463.188.756\n",
       "Metacognitive Awareness,F02.463.188.756\n",
       "Metacognitive Monitoring,F02.463.188.756\n",
       "Metacognitive Control,F02.463.188.756\n",
       "Metaemotion,F02.463.188.756\n",
       "Metamemory,F02.463.188.756\n",
       "Prescription Drug Overuse,E02.319.306.500.750\n",
       "\"Near Miss, Healthcare\",E02.319.529.750\n",
       "\"Near Miss, Healthcare\",N02.421.450.500.750\n",
       "\"Near Miss, Healthcare\",N02.421.450.550\n",
       "\"Near Miss, Healthcare\",N04.761.700.594\n",
       "\"Near Miss, Healthcare\",N05.700.513\n",
       "RNAi Therapeutics,E02.095.301.250\n",
       "Dynamic Light Scattering,E05.196.822.325\n",
       "Quasi-Elastic Light Scattering (QELS),E05.196.822.325\n",
       "\"Time Out, Healthcare\",N04.761.700.635\n",
       "\"Time Out, Healthcare\",N05.700.739\n",
       "Surgical Time Out,N04.761.700.635\n",
       "Surgical Time Out,N05.700.739\n",
       "Healthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\n",
       "Healthcare Failure Mode and Effect Analysis,N04.452.871.715.400\n",
       "Healthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\n",
       "Healthcare Failure Mode and Effect Analysis,N06.850.505.715.500\n",
       "Healthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\n",
       "Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\n",
       "Failure Mode and Effect Analysis,N04.452.871.715.400\n",
       "Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\n",
       "Failure Mode and Effect Analysis,N06.850.505.715.500\n",
       "Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\n",
       "Spirit Possession,K01.844.619.500\n",
       "\"Crew Resource Management, Healthcare\",N04.590.254\n",
       "Computer Heuristics,L01.224.050.375.095\n",
       "Ataxins,D12.776.631.069\n",
       "Ataxins,D12.776.660.075\n",
       "Alarmins,D23.035\n",
       "Dermal Fillers,D27.720.102.461\n",
       "Action Spectrum,E05.196.867.826.150\n",
       "Diplomacy,F01.829.316.171\n",
       "Diplomacy,F02.463.785.373.520.500\n",
       "Diplomacy,I01.738.305\n",
       "Mutation Accumulation,G05.365.590.594\n",
       "Spontaneous Mutation Accumulation,G05.365.590.594\n",
       "Internal Ribosome Entry Sites,D13.444.735.790.878.942.250\n",
       "Internal Ribosome Entry Sites,G02.111.570.080.689.687.093\n",
       "Internal Ribosome Entry Sites,G05.360.080.689.687.093\n",
       "Biological Mimicry,G16.012.750\n",
       "Biological Camouflage,G16.012.750\n",
       "Specific Learning Disorder,F03.625.562.700\n",
       "Potentially Inappropriate Medication List,N04.761.700.615\n",
       "Potentially Inappropriate Medication List,N05.700.594\n",
       "Beers Criteria,N04.761.700.615\n",
       "Beers Criteria,N05.700.594\n",
       "STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615\n",
       "STOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594\n",
       "Medication Appropriateness Index,N04.761.700.615\n",
       "Medication Appropriateness Index,N05.700.594\n",
       "Late Onset Disorders,C23.550.291.883\n",
       "Phakopsora pachyrhizi,B01.300.179.113\n",
       "Farmers,M01.526.390\n",
       "Ranchers,M01.526.390\n",
       "Culturally Appropriate Technology,J01.897.052\n",
       "Intermediate Technology,J01.897.052\n",
       "Soft Technology,J01.897.052\n",
       "Social Learning,F02.784.629.529.663\n",
       "Financial Statements,N03.219.463.030.140\n",
       "\"Assets, Financial\",N03.219.463.030.140\n",
       "Cash Flow Statement,N03.219.463.030.140\n",
       "Balance Sheet,N03.219.463.030.140\n",
       "Expense Statement,N03.219.463.030.140\n",
       "Income Statement,N03.219.463.030.140\n",
       "\"Equity, Financial\",N03.219.463.030.140\n",
       "\"Liabilities, Financial\",N03.219.463.030.140\n",
       "Miners,M01.526.693\n",
       "Chronopharmacokinetics,G07.690.725.249\n",
       "\"Administrative Claims, Healthcare\",N04.452.859.564.137\n",
       "Child Health,N01.400.225\n",
       "Child Well Being,N01.400.225\n",
       "Interleukin-33,D12.644.276.374.465.850\n",
       "Interleukin-33,D12.776.467.374.465.850\n",
       "Interleukin-33,D23.529.374.465.850\n",
       "S100A12 Protein,D12.776.157.125.750.875\n",
       "Telopodes,A11.284.180.900\n",
       "Telopodes,A11.329.830.750.500\n",
       "Podomers,A11.284.180.900\n",
       "Podomers,A11.329.830.750.500\n",
       "Podoms,A11.284.180.900\n",
       "Podoms,A11.329.830.750.500\n",
       "Drosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750\n",
       "Optimism,F01.100.787\n",
       "Positive Attitude,F01.100.787\n",
       "Positive Thinking,F01.100.787\n",
       "Pessimism,F01.100.893\n",
       "Ataxin-1,D12.776.631.069.500\n",
       "Ataxin-1,D12.776.660.075.500\n",
       "Adolescent Health,N01.400.075\n",
       "Adolescent Well Being,N01.400.075\n",
       "Ataxin-2,D12.776.157.725.452.125\n",
       "Ataxin-2,D12.776.631.069.750\n",
       "Ataxin-2,D12.776.660.075.750\n",
       "Ataxin-2,D12.776.664.962.452.125\n",
       "Ataxin-3,D08.811.037.250\n",
       "Ataxin-3,D12.776.631.069.875\n",
       "Ataxin-3,D12.776.660.075.875\n",
       "Point-of-Care Testing,N04.590.874.500\n",
       "Bedside Testing,N04.590.874.500\n",
       "Ataxin-7,D12.776.631.069.901\n",
       "Ataxin-7,D12.776.660.075.900\n",
       "Ataxin-10,D12.776.631.069.950\n",
       "Glucagon-Like Peptide Receptors,D12.776.543.750.695.021\n",
       "Glucagon-Like Peptide Receptors,D12.776.543.750.750.360.100\n",
       "Glucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500\n",
       "Glucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500\n",
       "Glucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600\n",
       "Glucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600\n",
       "Receptor for Advanced Glycation End Products,D12.776.543.750.615\n",
       "RNA Recognition Motif Proteins,D12.776.157.725.813\n",
       "RNA Recognition Motif Proteins,D12.776.664.962.813\n",
       "ELAV-Like Protein 2,D12.776.157.725.813.500.500\n",
       "ELAV-Like Protein 2,D12.776.631.520.500\n",
       "ELAV-Like Protein 2,D12.776.664.962.813.500.500\n",
       "ELAV-Like Protein 3,D12.776.157.725.813.500.750\n",
       "ELAV-Like Protein 3,D12.776.631.520.750\n",
       "ELAV-Like Protein 3,D12.776.664.962.813.500.750\n",
       "ELAV-Like Protein 4,D12.776.157.725.813.500.875\n",
       "ELAV-Like Protein 4,D12.776.631.520.875\n",
       "ELAV-Like Protein 4,D12.776.664.962.813.500.875\n",
       "ELAV-Like Protein 1,D12.776.157.725.813.500.250\n",
       "ELAV-Like Protein 1,D12.776.664.962.813.500.250\n",
       "Whey,A12.790.760\n",
       "Whey,G07.203.100.700.750\n",
       "Whey,G07.203.300.350.525.760\n",
       "Whey,J02.200.700.750\n",
       "Whey,J02.500.350.525.760\n",
       "Whey Proteins,A12.790.520.500\n",
       "Whey Proteins,A12.790.760.500\n",
       "Whey Proteins,D12.776.256.159.750.816\n",
       "Whey Proteins,G07.203.300.350.525.760.500\n",
       "Whey Proteins,G07.203.300.428.159.812.500\n",
       "Whey Proteins,J02.500.350.525.520.500\n",
       "Whey Proteins,J02.500.350.525.760.500\n",
       "Whey Proteins,J02.500.428.159.750.500\n",
       "Hoarding Disorder,F03.080.600.250\n",
       "Obsessive Hoarding,F03.080.600.250\n",
       "Poly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739\n",
       "Poly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692\n",
       "Autism Spectrum Disorder,F03.625.164.113\n",
       "CELF Proteins,D12.776.157.725.813.250\n",
       "CELF Proteins,D12.776.664.962.813.250\n",
       "CELF1 Protein,D12.776.157.725.813.250.500\n",
       "CELF1 Protein,D12.776.664.962.813.250.500\n",
       "Industrial Development,I01.261.262.500\n",
       "Industrial Development,J01.576.519\n",
       "Technology Development,I01.261.262.500\n",
       "Technology Development,J01.576.519\n",
       "Industrialization,I01.261.262.500\n",
       "Industrialization,J01.576.519\n",
       "Cloud Computing,L01.224.097\n",
       "Natural Resources,G16.500.275.553\n",
       "Natural Resources,J01.728\n",
       "Natural Resources,N06.230.350\n",
       "Land Supply,G16.500.275.553\n",
       "Land Supply,J01.728\n",
       "Land Supply,N06.230.350\n",
       "Glycemic Load,G07.203.650.660.750\n",
       "Glycemic Load,J01.576.423.850.730.750.750\n",
       "Glycemic Load,N06.850.601.750.750\n",
       "Adenylyl Cyclase Inhibitors,D27.505.519.389.108\n",
       "RAW 264.7 Cells,A11.251.210.172.875\n",
       "RAW 264.7 Cells,A11.733.397.815\n",
       "Accreditation,N03.706.110.070\n",
       "Accreditation,N05.700.200.100\n",
       "Clostridiales,B03.353.625\n",
       "Graphic Novel,V02.700.415\n",
       "Comic Book,V02.700.415\n",
       "South Sudan,Z01.058.290.120.745\n",
       "Motor Disorders,F03.608\n",
       "Maternal Health,N01.400.900.500\n",
       "Seed Bank,N02.278.065.650\n",
       "Germplasm Bank,N02.278.065.650\n",
       "Trauma and Stressor Related Disorders,F03.950\n",
       "Maternal-Child Health Services,N02.421.143.130.660\n",
       "Maternal-Child Health Services,N02.421.143.620.275\n",
       "Serine-Arginine Splicing Factors,D12.776.157.725.829.500\n",
       "Serine-Arginine Splicing Factors,D12.776.664.962.829.500\n",
       "Infant Health,N01.400.388\n",
       "Newborn Health,N01.400.388\n",
       "Bipolar and Related Disorders,F03.084\n",
       "Gender Dysphoria,F03.835.550\n",
       "Formative Feedback,F02.784.629.529.223\n",
       "Aripiprazole,D03.383.606.170\n",
       "Aripiprazole,D03.633.100.810.835.122\n",
       "Abilify,D03.383.606.170\n",
       "Abilify,D03.633.100.810.835.122\n",
       "OPC 14597,D03.383.606.170\n",
       "OPC 14597,D03.633.100.810.835.122\n",
       "Prunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500\n",
       "Almonds,B01.650.940.800.575.912.250.859.937.500.625.500\n",
       "Albumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500\n",
       "Albumin-Bound Paclitaxel,D02.455.849.291.850.777.500\n",
       "Albumin-Bound Paclitaxel,D12.776.034.073\n",
       "Abraxane,D02\n",
       "\n",
       "*** WARNING: max output size exceeded, skipping output. ***\n",
       "\n",
       "80.604.238\n",
       "\"Censorship, Research\",K01.752.566.479.173.200\n",
       "\"Censorship, Research\",N05.350.670.250\n",
       "Data Accuracy,E05.318.308.028\n",
       "Data Accuracy,E05.318.370.725.250\n",
       "Data Accuracy,L01.399.250.202\n",
       "Data Accuracy,N05.715.360.300.202\n",
       "Data Accuracy,N05.715.360.325.685.250\n",
       "Data Quality,E05.318.308.028\n",
       "Data Quality,E05.318.370.725.250\n",
       "Data Quality,L01.399.250.202\n",
       "Data Quality,N05.715.360.300.202\n",
       "Data Quality,N05.715.360.325.685.250\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500\n",
       "\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312\n",
       "Combigan,D02.033.100.624.915.500\n",
       "Combigan,D02.033.755.624.915.500\n",
       "Combigan,D02.092.063.624.915.500\n",
       "Combigan,D02.886.675.867.768.500\n",
       "Combigan,D03.383.129.708.867.768.500\n",
       "Combigan,D03.633.100.857.070.500\n",
       "Combigan,D26.310.312\n",
       "\"Albuterol, Ipratropium Drug Combination\",D02.033.100.291.057.125\n",
       "\"Albuterol, Ipratropium Drug Combination\",D02.092.063.291.057.125\n",
       "\"Albuterol, Ipratropium Drug Combination\",D02.092.471.683.061.125\n",
       "\"Albuterol, Ipratropium Drug Combination\",D02.145.074.722.229.400.500\n",
       "\"Albuterol, Ipratropium Drug Combination\",D03.132.760.180.572.400.500\n",
       "\"Albuterol, Ipratropium Drug Combination\",D03.132.889.180.648.400.500\n",
       "\"Albuterol, Ipratropium Drug Combination\",D03.605.084.500.722.229.400.500\n",
       "\"Albuterol, Ipratropium Drug Combination\",D03.605.869.229.400.500\n",
       "\"Albuterol, Ipratropium Drug Combination\",D26.310.344\n",
       "Combivent Respimat,D02.033.100.291.057.125\n",
       "Combivent Respimat,D02.092.063.291.057.125\n",
       "Combivent Respimat,D02.092.471.683.061.125\n",
       "Combivent Respimat,D02.145.074.722.229.400.500\n",
       "Combivent Respimat,D03.132.760.180.572.400.500\n",
       "Combivent Respimat,D03.132.889.180.648.400.500\n",
       "Combivent Respimat,D03.605.084.500.722.229.400.500\n",
       "Combivent Respimat,D03.605.869.229.400.500\n",
       "Combivent Respimat,D26.310.344\n",
       "Dey Combination,D02.033.100.291.057.125\n",
       "Dey Combination,D02.092.063.291.057.125\n",
       "Dey Combination,D02.092.471.683.061.125\n",
       "Dey Combination,D02.145.074.722.229.400.500\n",
       "Dey Combination,D03.132.760.180.572.400.500\n",
       "Dey Combination,D03.132.889.180.648.400.500\n",
       "Dey Combination,D03.605.084.500.722.229.400.500\n",
       "Dey Combination,D03.605.869.229.400.500\n",
       "Dey Combination,D26.310.344\n",
       "Combivent,D02.033.100.291.057.125\n",
       "Combivent,D02.092.063.291.057.125\n",
       "Combivent,D02.092.471.683.061.125\n",
       "Combivent,D02.145.074.722.229.400.500\n",
       "Combivent,D03.132.760.180.572.400.500\n",
       "Combivent,D03.132.889.180.648.400.500\n",
       "Combivent,D03.605.084.500.722.229.400.500\n",
       "Combivent,D03.605.869.229.400.500\n",
       "Combivent,D26.310.344\n",
       "Dual Use Research,H01.770.644.217\n",
       "Professionalism,K01.752.566.479.171.566\n",
       "Professionalism,N05.350.340.581\n",
       "Medical Professionalism,K01.752.566.479.171.566\n",
       "Medical Professionalism,N05.350.340.581\n",
       "Professionalism Education,K01.752.566.479.171.566\n",
       "Professionalism Education,N05.350.340.581\n",
       "Surgical Professionalism,K01.752.566.479.171.566\n",
       "Surgical Professionalism,N05.350.340.581\n",
       "Genetic Background,G05.346\n",
       "Selective Breeding,E05.820.150.760\n",
       "Selective Breeding,G05.090.701\n",
       "Legendary Creatures,I01.076.201.450.515.500\n",
       "Werewolves,I01.076.201.450.515.500\n",
       "Unicorns,I01.076.201.450.515.500\n",
       "\"Yeti, Himalayan\",I01.076.201.450.515.500\n",
       "Vampires,I01.076.201.450.515.500\n",
       "Mermaids,I01.076.201.450.515.500\n",
       "Mometasone Furoate,D04.210.500.745.432.719.526\n",
       "Nasonex,D04.210.500.745.432.719.526\n",
       "Mometasone Furoate Monohydrate,D04.210.500.745.432.719.526\n",
       "Asmanex Twisthaler,D04.210.500.745.432.719.526\n",
       "Asmanex,D04.210.500.745.432.719.526\n",
       "Rinelon,D04.210.500.745.432.719.526\n",
       "Elocon,D04.210.500.745.432.719.526\n",
       "Sch 32088,D04.210.500.745.432.719.526\n",
       "Mometasone,D04.210.500.745.432.719.526\n",
       "Fallopia multiflora,B01.650.940.800.575.912.250.825.359.590\n",
       "Sildenafil Citrate,D02.065.884.675\n",
       "Sildenafil Citrate,D02.886.590.700.675\n",
       "Sildenafil Citrate,D03.383.606.854\n",
       "Sildenafil Citrate,D03.633.100.759.824\n",
       "NCX-911,D02.065.884.675\n",
       "NCX-911,D02.886.590.700.675\n",
       "NCX-911,D03.383.606.854\n",
       "NCX-911,D03.633.100.759.824\n",
       "Revatio,D02.065.884.675\n",
       "Revatio,D02.886.590.700.675\n",
       "Revatio,D03.383.606.854\n",
       "Revatio,D03.633.100.759.824\n",
       "Sildenafil,D02.065.884.675\n",
       "Sildenafil,D02.886.590.700.675\n",
       "Sildenafil,D03.383.606.854\n",
       "Sildenafil,D03.633.100.759.824\n",
       "UK 92480-10,D02.065.884.675\n",
       "UK 92480-10,D02.886.590.700.675\n",
       "UK 92480-10,D03.383.606.854\n",
       "UK 92480-10,D03.633.100.759.824\n",
       "Homosildenafil,D02.065.884.675\n",
       "Homosildenafil,D02.886.590.700.675\n",
       "Homosildenafil,D03.383.606.854\n",
       "Homosildenafil,D03.633.100.759.824\n",
       "Hydroxyhomosildenafil,D02.065.884.675\n",
       "Hydroxyhomosildenafil,D02.886.590.700.675\n",
       "Hydroxyhomosildenafil,D03.383.606.854\n",
       "Hydroxyhomosildenafil,D03.633.100.759.824\n",
       "Viagra,D02.065.884.675\n",
       "Viagra,D02.886.590.700.675\n",
       "Viagra,D03.383.606.854\n",
       "Viagra,D03.633.100.759.824\n",
       "Acetildenafil,D02.065.884.675\n",
       "Acetildenafil,D02.886.590.700.675\n",
       "Acetildenafil,D03.383.606.854\n",
       "Acetildenafil,D03.633.100.759.824\n",
       "Sildenafil Lactate,D02.065.884.675\n",
       "Sildenafil Lactate,D02.886.590.700.675\n",
       "Sildenafil Lactate,D03.383.606.854\n",
       "Sildenafil Lactate,D03.633.100.759.824\n",
       "Sildenafil Nitrate,D02.065.884.675\n",
       "Sildenafil Nitrate,D02.886.590.700.675\n",
       "Sildenafil Nitrate,D03.383.606.854\n",
       "Sildenafil Nitrate,D03.633.100.759.824\n",
       "Desmethyl Sildenafil,D02.065.884.675\n",
       "Desmethyl Sildenafil,D02.886.590.700.675\n",
       "Desmethyl Sildenafil,D03.383.606.854\n",
       "Desmethyl Sildenafil,D03.633.100.759.824\n",
       "\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.626.809.500\n",
       "\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.705.429.906.500\n",
       "\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.680.245.500.600.500\n",
       "\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.755.500\n",
       "\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.633.100.759.138.881.500\n",
       "\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D26.310.407\n",
       "Complera,D02.626.809.500\n",
       "Complera,D02.705.429.906.500\n",
       "Complera,D03.383.742.680.245.500.600.500\n",
       "Complera,D03.383.742.755.500\n",
       "Complera,D03.633.100.759.138.881.500\n",
       "Complera,D26.310.407\n",
       "Emtricitabine,D03.383.742.680.245.500.600\n",
       "Emtricitabine,D13.570.230.329.525\n",
       "Emtricitabine,D13.570.685.245.500.600\n",
       "Coviracil,D03.383.742.680.245.500.600\n",
       "Coviracil,D13.570.230.329.525\n",
       "Coviracil,D13.570.685.245.500.600\n",
       "Emtriva,D03.383.742.680.245.500.600\n",
       "Emtriva,D13.570.230.329.525\n",
       "Emtriva,D13.570.685.245.500.600\n",
       "Rilpivirine,D02.626.809\n",
       "Rilpivirine,D03.383.742.755\n",
       "Rilpivirine Hydrochloride,D02.626.809\n",
       "Rilpivirine Hydrochloride,D03.383.742.755\n",
       "R278474,D02.626.809\n",
       "R278474,D03.383.742.755\n",
       "TMC 278,D02.626.809\n",
       "TMC 278,D03.383.742.755\n",
       "Tenofovir,D02.705.429.906\n",
       "Tenofovir,D03.633.100.759.138.881\n",
       "\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D02.705.429.906\n",
       "\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D03.633.100.759.138.881\n",
       "\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D02.705.429.906\n",
       "\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D03.633.100.759.138.881\n",
       "Tenofovir Disoproxil Fumarate,D02.705.429.906\n",
       "Tenofovir Disoproxil Fumarate,D03.633.100.759.138.881\n",
       "Tenofovir Disoproxil,D02.705.429.906\n",
       "Tenofovir Disoproxil,D03.633.100.759.138.881\n",
       "\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D02.705.429.906\n",
       "\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D03.633.100.759.138.881\n",
       "Viread,D02.705.429.906\n",
       "Viread,D03.633.100.759.138.881\n",
       "Glatiramer Acetate,D12.644.219\n",
       "Copaxone,D12.644.219\n",
       "Glatiramer,D12.644.219\n",
       "TV 5010,D12.644.219\n",
       "Rosuvastatin Calcium,D02.065.884.650\n",
       "Rosuvastatin Calcium,D02.455.526.510.432.500\n",
       "Rosuvastatin Calcium,D02.886.590.700.650\n",
       "Rosuvastatin Calcium,D03.383.742.775\n",
       "Crestor,D02.065.884.650\n",
       "Crestor,D02.455.526.510.432.500\n",
       "Crestor,D02.886.590.700.650\n",
       "Crestor,D03.383.742.775\n",
       "Rosuvastatin,D02.065.884.650\n",
       "Rosuvastatin,D02.455.526.510.432.500\n",
       "Rosuvastatin,D02.886.590.700.650\n",
       "Rosuvastatin,D03.383.742.775\n",
       "ZD4522,D02.065.884.650\n",
       "ZD4522,D02.455.526.510.432.500\n",
       "ZD4522,D02.886.590.700.650\n",
       "ZD4522,D03.383.742.775\n",
       "Duloxetine Hydrochloride,D02.886.778.260\n",
       "Duloxetine Hydrochloride,D03.383.903.260\n",
       "LY 248686,D02.886.778.260\n",
       "LY 248686,D03.383.903.260\n",
       "\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D02.886.778.260\n",
       "\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D03.383.903.260\n",
       "LY 227942,D02.886.778.260\n",
       "LY 227942,D03.383.903.260\n",
       "Duloxetine,D02.886.778.260\n",
       "Duloxetine,D03.383.903.260\n",
       "\"Duloxetine, (+)-isomer\",D02.886.778.260\n",
       "\"Duloxetine, (+)-isomer\",D03.383.903.260\n",
       "Cymbalta,D02.886.778.260\n",
       "Cymbalta,D03.383.903.260\n",
       "Tolterodine Tartrate,D02.033.100.624.706.750\n",
       "Tolterodine Tartrate,D02.033.755.624.706.750\n",
       "Tolterodine Tartrate,D02.092.063.624.706.800\n",
       "Tolterodine Tartrate,D02.455.426.559.389.115.900\n",
       "Tolterodine Tartrate,D02.455.426.559.389.657.239.756\n",
       "Tolterodine,D02.033.100.624.706.750\n",
       "Tolterodine,D02.033.755.624.706.750\n",
       "Tolterodine,D02.092.063.624.706.800\n",
       "Tolterodine,D02.455.426.559.389.115.900\n",
       "Tolterodine,D02.455.426.559.389.657.239.756\n",
       "Detrol,D02.033.100.624.706.750\n",
       "Detrol,D02.033.755.624.706.750\n",
       "Detrol,D02.092.063.624.706.800\n",
       "Detrol,D02.455.426.559.389.115.900\n",
       "Detrol,D02.455.426.559.389.657.239.756\n",
       "Detrol LA,D02.033.100.624.706.750\n",
       "Detrol LA,D02.033.755.624.706.750\n",
       "Detrol LA,D02.092.063.624.706.800\n",
       "Detrol LA,D02.455.426.559.389.115.900\n",
       "Detrol LA,D02.455.426.559.389.657.239.756\n",
       "Urotrol,D02.033.100.624.706.750\n",
       "Urotrol,D02.033.755.624.706.750\n",
       "Urotrol,D02.092.063.624.706.800\n",
       "Urotrol,D02.455.426.559.389.115.900\n",
       "Urotrol,D02.455.426.559.389.657.239.756\n",
       "PHA-686464B,D02.033.100.624.706.750\n",
       "PHA-686464B,D02.033.755.624.706.750\n",
       "PHA-686464B,D02.092.063.624.706.800\n",
       "PHA-686464B,D02.455.426.559.389.115.900\n",
       "PHA-686464B,D02.455.426.559.389.657.239.756\n",
       "Detrusitol,D02.033.100.624.706.750\n",
       "Detrusitol,D02.033.755.624.706.750\n",
       "Detrusitol,D02.092.063.624.706.800\n",
       "Detrusitol,D02.455.426.559.389.115.900\n",
       "Detrusitol,D02.455.426.559.389.657.239.756\n",
       "Unidet,D02.033.100.624.706.750\n",
       "Unidet,D02.033.755.624.706.750\n",
       "Unidet,D02.092.063.624.706.800\n",
       "Unidet,D02.455.426.559.389.115.900\n",
       "Unidet,D02.455.426.559.389.657.239.756\n",
       "Valsartan,D03.383.129.617.850\n",
       "Valsartan,D12.125.070.950.550\n",
       "Valsartan,D12.125.142.930.500\n",
       "Diovan,D03.383.129.617.850\n",
       "Diovan,D12.125.070.950.550\n",
       "Diovan,D12.125.142.930.500\n",
       "Kalpress,D03.383.129.617.850\n",
       "Kalpress,D12.125.070.950.550\n",
       "Kalpress,D12.125.142.930.500\n",
       "Tareg,D03.383.129.617.850\n",
       "Tareg,D12.125.070.950.550\n",
       "Tareg,D12.125.142.930.500\n",
       "Nisis,D03.383.129.617.850\n",
       "Nisis,D12.125.070.950.550\n",
       "Nisis,D12.125.142.930.500\n",
       "Provas,D03.383.129.617.850\n",
       "Provas,D12.125.070.950.550\n",
       "Provas,D12.125.142.930.500\n",
       "Vals,D03.383.129.617.850\n",
       "Vals,D12.125.070.950.550\n",
       "Vals,D12.125.142.930.500\n",
       "CGP 48933,D03.383.129.617.850\n",
       "CGP 48933,D12.125.070.950.550\n",
       "CGP 48933,D12.125.142.930.500\n",
       "Miten,D03.383.129.617.850\n",
       "Miten,D12.125.070.950.550\n",
       "Miten,D12.125.142.930.500\n",
       "Ononis,B01.650.940.800.575.912.250.401.604\n",
       "\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.033.100.291.425.500\n",
       "\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.092.063.291.425.500\n",
       "\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D04.210.500.745.432.719.526.500\n",
       "\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D26.310.469\n",
       "Dulera,D02.033.100.291.425.500\n",
       "Dulera,D02.092.063.291.425.500\n",
       "Dulera,D04.210.500.745.432.719.526.500\n",
       "Dulera,D26.310.469\n",
       "Zenhale,D02.033.100.291.425.500\n",
       "Zenhale,D02.092.063.291.425.500\n",
       "Zenhale,D04.210.500.745.432.719.526.500\n",
       "Zenhale,D26.310.469\n",
       "Formoterol Fumarate,D02.033.100.291.425\n",
       "Formoterol Fumarate,D02.092.063.291.425\n",
       "BD 40A,D02.033.100.291.425\n",
       "BD 40A,D02.092.063.291.425\n",
       "Formoterol,D02.033.100.291.425\n",
       "Formoterol,D02.092.063.291.425\n",
       "Oxis,D02.033.100.291.425\n",
       "Oxis,D02.092.063.291.425\n",
       "Arformoterol,D02.033.100.291.425\n",
       "Arformoterol,D02.092.063.291.425\n",
       "Foradil,D02.033.100.291.425\n",
       "Foradil,D02.092.063.291.425\n",
       "Serotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.562.437.693\n",
       "Serotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.625.600.693\n",
       "Serotonin and Noradrenaline Reuptake Inhibitors,D27.505.696.577.600.693\n",
       "\"Sleep Aids, Pharmaceutical\",D27.505.696.277.350.500\n",
       "\"Sleep Aids, Pharmaceutical\",D27.505.954.427.210.350.500\n",
       "Sleeping Pills,D27.505.696.277.350.500\n",
       "Sleeping Pills,D27.505.954.427.210.350.500\n",
       "Orexin Receptor Antagonists,D27.505.519.625.663\n",
       "Orexin Receptor Antagonists,D27.505.696.277.350.500.500\n",
       "Orexin Receptor Antagonists,D27.505.696.577.663\n",
       "Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\n",
       "Dual Orexin Receptor Antagonists,D27.505.519.625.663\n",
       "Dual Orexin Receptor Antagonists,D27.505.696.277.350.500.500\n",
       "Dual Orexin Receptor Antagonists,D27.505.696.577.663\n",
       "Dual Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\n",
       "Orexins,D12.644.400.360\n",
       "Orexins,D12.776.631.650.363\n",
       "Orexin-B,D12.644.400.360\n",
       "Orexin-B,D12.776.631.650.363\n",
       "Orexin-A,D12.644.400.360\n",
       "Orexin-A,D12.776.631.650.363\n",
       "Hoodia,B01.650.940.800.575.912.250.456.500.389\n",
       "Hoodia gordonii,B01.650.940.800.575.912.250.456.500.389\n",
       "Prasugrel Hydrochloride,D02.886.778.600\n",
       "Prasugrel Hydrochloride,D03.383.606.800\n",
       "Prasugrel Hydrochloride,D03.383.903.600\n",
       "CS 747,D02.886.778.600\n",
       "CS 747,D03.383.606.800\n",
       "CS 747,D03.383.903.600\n",
       "Prasugrel,D02.886.778.600\n",
       "Prasugrel,D03.383.606.800\n",
       "Prasugrel,D03.383.903.600\n",
       "Efient,D02.886.778.600\n",
       "Efient,D03.383.606.800\n",
       "Efient,D03.383.903.600\n",
       "Effient,D02.886.778.600\n",
       "Effient,D03.383.606.800\n",
       "Effient,D03.383.903.600\n",
       "LY 640315,D02.886.778.600\n",
       "LY 640315,D03.383.606.800\n",
       "LY 640315,D03.383.903.600\n",
       "Etanercept,D12.644.541.500.697.624\n",
       "Etanercept,D12.776.124.486.485.538.500.624\n",
       "Etanercept,D12.776.124.486.485.680.697.624\n",
       "Etanercept,D12.776.124.790.651.538.500.624\n",
       "Etanercept,D12.776.124.790.651.680.660.624\n",
       "Etanercept,D12.776.377.715.548.538.500.624\n",
       "Etanercept,D12.776.377.715.548.680.660.624\n",
       "Etanercept,D12.776.543.750.705.852.760.232\n",
       "TNFR-Fc Fusion Protein,D12.644.541.500.697.624\n",
       "TNFR-Fc Fusion Protein,D12.776.124.486.485.538.500.624\n",
       "TNFR-Fc Fusion Protein,D12.776.124.486.485.680.697.624\n",
       "TNFR-Fc Fusion Protein,D12.776.124.790.651.538.500.624\n",
       "TNFR-Fc Fusion Protein,D12.776.124.790.651.680.660.624\n",
       "TNFR-Fc Fusion Protein,D12.776.377.715.548.538.500.624\n",
       "TNFR-Fc Fusion Protein,D12.776.377.715.548.680.660.624\n",
       "TNFR-Fc Fusion Protein,D12.776.543.750.705.852.760.232\n",
       "Etanercept-szzs,D12.644.541.500.697.624\n",
       "Etanercept-szzs,D12.776.124.486.485.538.500.624\n",
       "Etanercept-szzs,D12.776.124.486.485.680.697.624\n",
       "Etanercept-szzs,D12.776.124.790.651.538.500.624\n",
       "Etanercept-szzs,D12.776.124.790.651.680.660.624\n",
       "Etanercept-szzs,D12.776.377.715.548.538.500.624\n",
       "Etanercept-szzs,D12.776.377.715.548.680.660.624\n",
       "Etanercept-szzs,D12.776.543.750.705.852.760.232\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\n",
       "TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\n",
       "Erelzi,D12.644.541.500.697.624\n",
       "Erelzi,D12.776.124.486.485.538.500.624\n",
       "Erelzi,D12.776.124.486.485.680.697.624\n",
       "Erelzi,D12.776.124.790.651.538.500.624\n",
       "Erelzi,D12.776.124.790.651.680.660.624\n",
       "Erelzi,D12.776.377.715.548.538.500.624\n",
       "Erelzi,D12.776.377.715.548.680.660.624\n",
       "Erelzi,D12.776.543.750.705.852.760.232\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\n",
       "Recombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\n",
       "Enbrel,D12.644.541.500.697.624\n",
       "Enbrel,D12.776.124.486.485.538.500.624\n",
       "Enbrel,D12.776.124.486.485.680.697.624\n",
       "Enbrel,D12.776.124.790.651.538.500.624\n",
       "Enbrel,D12.776.124.790.651.680.660.624\n",
       "Enbrel,D12.776.377.715.548.538.500.624\n",
       "Enbrel,D12.776.377.715.548.680.660.624\n",
       "Enbrel,D12.776.543.750.705.852.760.232\n",
       "\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.241.223.100.133.500\n",
       "\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.389.127.133.500\n",
       "\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.847.638.090.500\n",
       "\"Adapalene, Benzoyl Peroxide Drug Combination\",D04.615.638.090.500\n",
       "\"Adapalene, Benzoyl Peroxide Drug Combination\",D26.310.032\n",
       "Epiduo,D02.241.223.100.133.500\n",
       "Epiduo,D02.455.426.559.389.127.133.500\n",
       "Epiduo,D02.455.426.559.847.638.090.500\n",
       "Epiduo,D04.615.638.090.500\n",
       "Epiduo,D26.310.032\n",
       "Adapalene,D02.455.426.559.847.638.090\n",
       "Adapalene,D04.615.638.090\n",
       "CD 271,D02.455.426.559.847.638.090\n",
       "CD 271,D04.615.638.090\n",
       "Adaferin,D02.455.426.559.847.638.090\n",
       "Adaferin,D04.615.638.090\n",
       "Differin,D02.455.426.559.847.638.090\n",
       "Differin,D04.615.638.090\n",
       "Epoetin Alfa,D12.644.276.374.410.240.150.500\n",
       "Epoetin Alfa,D12.776.395.240.150.750\n",
       "Epoetin Alfa,D12.776.467.374.410.240.150.500\n",
       "Epoetin Alfa,D23.529.374.410.240.150.750\n",
       "Epoetin Alfa Hexal,D12.644.276.374.410.240.150.500\n",
       "Epoetin Alfa Hexal,D12.776.395.240.150.750\n",
       "Epoetin Alfa Hexal,D12.776.467.374.410.240.150.500\n",
       "Epoetin Alfa Hexal,D23.529.374.410.240.150.750\n",
       "Eprex,D12.644.276.374.410.240.150.500\n",
       "Eprex,D12.776.395.240.150.750\n",
       "Eprex,D12.776.467.374.410.240.150.500\n",
       "Eprex,D23.529.374.410.240.150.750\n",
       "Heberitro,D12.644.276.374.410.240.150.500\n",
       "Heberitro,D12.776.395.240.150.750\n",
       "Heberitro,D12.776.467.374.410.240.150.500\n",
       "Heberitro,D23.529.374.410.240.150.750\n",
       "Procrit,D12.644.276.374.410.240.150.500\n",
       "Procrit,D12.776.395.240.150.750\n",
       "Procrit,D12.776.467.374.410.240.150.500\n",
       "Procrit,D23.529.374.410.240.150.750\n",
       "Binocrit,D12.644.276.374.410.240.150.500\n",
       "Binocrit,D12.776.395.240.150.750\n",
       "Binocrit,D12.776.467.374.410.240.150.500\n",
       "Binocrit,D23.529.374.410.240.150.750\n",
       "HX575 Compound,D12.644.276.374.410.240.150.500\n",
       "HX575 Compound,D12.776.395.240.150.750\n",
       "HX575 Compound,D12.776.467.374.410.240.150.500\n",
       "HX575 Compound,D23.529.374.410.240.150.750\n",
       "Epogen,D12.644.276.374.410.240.150.500\n",
       "Epogen,D12.776.395.240.150.750\n",
       "Epogen,D12.776.467.374.410.240.150.500\n",
       "Epogen,D23.529.374.410.240.150.750\n",
       "HX575,D12.644.276.374.410.240.150.500\n",
       "HX575,D12.776.395.240.150.750\n",
       "HX575,D12.776.467.374.410.240.150.500\n",
       "HX575,D23.529.374.410.240.150.750\n",
       "Cetuximab,D12.776.124.486.485.114.224.060.750\n",
       "Cetuximab,D12.776.124.790.651.114.224.060.750\n",
       "Cetuximab,D12.776.377.715.548.114.224.200.750\n",
       "Erbitux,D12.776.124.486.485.114.224.060.750\n",
       "Erbitux,D12.776.124.790.651.114.224.060.750\n",
       "Erbitux,D12.776.377.715.548.114.224.200.750\n",
       "IMC C225,D12.776.124.486.485.114.224.060.750\n",
       "IMC C225,D12.776.124.790.651.114.224.060.750\n",
       "IMC C225,D12.776.377.715.548.114.224.200.750\n",
       "Hyssopus Plant,B01.650.940.800.575.912.250.583.520.330\n",
       "Hyssopus officinalis,B01.650.940.800.575.912.250.583.520.330\n",
       "Rivastigmine,D02.241.081.251.583.899\n",
       "RivastigmineTartrate,D02.241.081.251.583.899\n",
       "Exelon,D02.241.081.251.583.899\n",
       "ENA 713,D02.241.081.251.583.899\n",
       "Parmeliaceae,B01.300.107.685\n",
       "Parmeliaceae,B01.300.340.458\n",
       "Cetraria,B01.300.107.685\n",
       "Cetraria,B01.300.340.458\n",
       "Cetraria islandica,B01.300.107.685\n",
       "Cetraria islandica,B01.300.340.458\n",
       "\"Amlodipine, Valsartan Drug Combination\",D03.383.129.617.850.500\n",
       "\"Amlodipine, Valsartan Drug Combination\",D03.383.725.203.065.750\n",
       "\"Amlodipine, Valsartan Drug Combination\",D12.125.070.950.550.500\n",
       "\"Amlodipine, Valsartan Drug Combination\",D12.125.142.930.500.500\n",
       "\"Amlodipine, Valsartan Drug Combination\",D26.310.094\n",
       "Exforge,D03.383.129.617.850.500\n",
       "Exforge,D03.383.725.203.065.750\n",
       "Exforge,D12.125.070.950.550.500\n",
       "Exforge,D12.125.142.930.500.500\n",
       "Exforge,D26.310.094\n",
       "Eugenia,B01.650.940.800.575.912.250.773.374\n",
       "Euginia uniflora,B01.650.940.800.575.912.250.773.374\n",
       "\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.815.455\n",
       "\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.899.498.500\n",
       "Gardasil,D20.215.894.815.455\n",
       "Gardasil,D20.215.894.899.498.500\n",
       "\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.815.455\n",
       "\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.899.498.500\n",
       "Kombucha Tea,D20.215.784.844.500\n",
       "Kombucha Tea,G07.203.100.831.500\n",
       "Kombucha Tea,G07.203.200.625\n",
       "Kombucha Tea,J02.200.831.500\n",
       "Kombucha Tea,J02.350.625\n",
       "Fingolimod Hydrochloride,D02.033.100.700.350\n",
       "Fingolimod Hydrochloride,D02.033.455.706.431\n",
       "Fingolimod Hydrochloride,D02.092.063.700.350\n",
       "FTY-720,D02.033.100.700.350\n",
       "FTY-720,D02.033.455.706.431\n",
       "FTY-720,D02.092.063.700.350\n",
       "Gilenya,D02.033.100.700.350\n",
       "Gilenya,D02.033.455.706.431\n",
       "Gilenya,D02.092.063.700.350\n",
       "Fingolimod,D02.033.100.700.350\n",
       "Fingolimod,D02.033.455.706.431\n",
       "Fingolimod,D02.092.063.700.350\n",
       "Imatinib Mesylate,D02.065.277.456\n",
       "Imatinib Mesylate,D02.241.223.100.100.435\n",
       "Imatinib Mesylate,D02.455.426.559.389.127.085.465\n",
       "Imatinib Mesylate,D03.383.606.405\n",
       "Imatinib Mesylate,D03.383.742.349\n",
       "STI571,D02.065.277.456\n",
       "STI571,D02.241.223.100.100.435\n",
       "STI571,D02.455.426.559.389.127.085.465\n",
       "STI571,D03.383.606.405\n",
       "STI571,D03.383.742.349\n",
       "Gleevec,D02.065.277.456\n",
       "Gleevec,D02.241.223.100.100.435\n",
       "Gleevec,D02.455.426.559.389.127.085.465\n",
       "Gleevec,D03.383.606.405\n",
       "Gleevec,D03.383.742.349\n",
       "ST 1571,D02.065.277.456\n",
       "ST 1571,D02.241.223.100.100.435\n",
       "ST 1571,D02.455.426.559.389.127.085.465\n",
       "ST 1571,D03.383.606.405\n",
       "ST 1571,D03.383.742.349\n",
       "CGP 57148,D02.065.277.456\n",
       "CGP 57148,D02.241.223.100.100.435\n",
       "CGP 57148,D02.455.426.559.389.127.085.465\n",
       "CGP 57148,D03.383.606.405\n",
       "CGP 57148,D03.383.742.349\n",
       "Imatinib,D02.065.277.456\n",
       "Imatinib,D02.241.223.100.100.435\n",
       "Imatinib,D02.455.426.559.389.127.085.465\n",
       "Imatinib,D03.383.606.405\n",
       "Imatinib,D03.383.742.349\n",
       "Trastuzumab,D12.776.124.486.485.114.224.060.875\n",
       "Trastuzumab,D12.776.124.790.651.114.224.060.875\n",
       "Trastuzumab,D12.776.377.715.548.114.224.200.875\n",
       "Herceptin,D12.776.124.486.485.114.224.060.875\n",
       "Herceptin,D12.776.124.790.651.114.224.060.875\n",
       "Herceptin,D12.776.377.715.548.114.224.200.875\n",
       "Trazimera,D12.776.124.486.485.114.224.060.875\n",
       "Trazimera,D12.776.124.790.651.114.224.060.875\n",
       "Trazimera,D12.776.377.715.548.114.224.200.875\n",
       "Adalimumab,D12.776.124.486.485.114.224.060.250\n",
       "Adalimumab,D12.776.124.790.651.114.224.060.250\n",
       "Adalimumab,D12.776.377.715.548.114.224.200.250\n",
       "Humira,D12.776.124.486.485.114.224.060.250\n",
       "Humira,D12.776.124.790.651.114.224.060.250\n",
       "Humira,D12.776.377.715.548.114.224.200.250\n",
       "Adalimumab-adbm,D12.776.124.486.485.114.224.060.250\n",
       "Adalimumab-adbm,D12.776.124.790.651.114.224.060.250\n",
       "Adalimumab-adbm,D12.776.377.715.548.114.224.200.250\n",
       "Amjevita,D12.776.124.486.485.114.224.060.250\n",
       "Amjevita,D12.776.124.790.651.114.224.060.250\n",
       "Amjevita,D12.776.377.715.548.114.224.200.250\n",
       "Adalimumab-atto,D12.776.124.486.485.114.224.060.250\n",
       "Adalimumab-atto,D12.776.124.790.651.114.224.060.250\n",
       "Adalimumab-atto,D12.776.377.715.548.114.224.200.250\n",
       "Cyltezo,D12.776.124.486.485.114.224.060.250\n",
       "Cyltezo,D12.776.124.790.651.114.224.060.250\n",
       "Cyltezo,D12.776.377.715.548.114.224.200.250\n",
       "D2E7 Antibody,D12.776.124.486.485.114.224.060.250\n",
       "D2E7 Antibody,D12.776.124.790.651.114.224.060.250\n",
       "D2E7 Antibody,D12.776.377.715.548.114.224.200.250\n",
       "\"Isophane Insulin, Human\",D06.472.699.587.200.300.200.500\n",
       "\"Isophane Insulin, Human\",D06.472.699.587.200.500.625.500.500\n",
       "\"Isophane Insulin, Human\",D12.644.548.586.200.300.200.500\n",
       "\"Isophane Insulin, Human\",D12.644.548.586.200.500.625.500.500\n",
       "Humulin N,D06.472.699.587.200.300.200.500\n",
       "Humulin N,D06.472.699.587.200.500.625.500.500\n",
       "Humulin N,D12.644.548.586.200.300.200.500\n",
       "Humulin N,D12.644.548.586.200.500.625.500.500\n",
       "Novolin N,D06.472.699.587.200.300.200.500\n",
       "Novolin N,D06.472.699.587.200.500.625.500.500\n",
       "Novolin N,D12.644.548.586.200.300.200.500\n",
       "Novolin N,D12.644.548.586.200.500.625.500.500\n",
       "\"Animals, Exotic\",B01.050.050.126\n",
       "Exotic Pets,B01.050.050.126\n",
       "Paliperidone Palmitate,D03.383.129.385.650\n",
       "Paliperidone Palmitate,D03.383.742.592\n",
       "Paliperidone,D03.383.129.385.650\n",
       "Paliperidone,D03.383.742.592\n",
       "Invega,D03.383.129.385.650\n",
       "Invega,D03.383.742.592\n",
       "Invega Sustenna,D03.383.129.385.650\n",
       "Invega Sustenna,D03.383.742.592\n",
       "R 76477,D03.383.129.385.650\n",
       "R 76477,D03.383.742.592\n",
       "Immunosenescence,G07.345.124.390\n",
       "Immunosenescence,G12.460.500\n",
       "Canagliflozin,D02.886.778.075\n",
       "Canagliflozin,D03.383.903.075\n",
       "Canagliflozin,D09.408.348.113\n",
       "Invokana,D02.886.778.075\n",
       "Invokana,D03.383.903.075\n",
       "Invokana,D09.408.348.113\n",
       "Canagliflozin Hemihydrate,D02.886.778.075\n",
       "Canagliflozin Hemihydrate,D03.383.903.075\n",
       "Canagliflozin Hemihydrate,D09.408.348.113\n",
       "\"Canagliflozin, Anhydrous\",D02.886.778.075\n",
       "\"Canagliflozin, Anhydrous\",D03.383.903.075\n",
       "\"Canagliflozin, Anhydrous\",D09.408.348.113\n",
       "Iridescence,G01.590.310\n",
       "Opalescence,G01.590.310\n",
       "Raltegravir Potassium,D03.383.773.812.752\n",
       "Raltegravir,D03.383.773.812.752\n",
       "MK 0518,D03.383.773.812.752\n",
       "Isentress\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "[Truncated to first 65536 bytes]\nterm,tree\nCalcimycin,D03.633.100.221.173\nA-23187,D03.633.100.221.173\nTemefos,D02.705.400.625.800\nTemefos,D02.705.539.345.800\nTemefos,D02.886.300.692.800\nAbate,D02.705.400.625.800\nAbate,D02.705.539.345.800\nAbate,D02.886.300.692.800\nDifos,D02.705.400.625.800\nDifos,D02.705.539.345.800\nDifos,D02.886.300.692.800\nAbattoirs,J01.576.423.200.700.100\nAbattoirs,J03.540.020\nAbbreviations as Topic,L01.559.598.400.556.131\nAcronyms as Topic,L01.559.598.400.556.131\nAbdomen,A01.923.047\n\"Abdomen, Acute\",C23.888.592.612.054.200\n\"Abdomen, Acute\",C23.888.821.030.249\nAbdominal Injuries,C26.017\nAbdominal Neoplasms,C04.588.033\nAbdominal Muscles,A02.633.567.050\nCremaster Muscle,A02.633.567.050\nPyramidalis Muscle,A02.633.567.050\nQuadratus Abdominis,A02.633.567.050\nTransversus Abdominis,A02.633.567.050\nAbducens Nerve,A08.800.800.120.030\nAbelson murine leukemia virus,B04.613.807.375.525.020\nAbelson murine leukemia virus,B04.820.650.375.525.020\nAbetalipoproteinemia,C16.320.565.398.500.440.500\nAbetalipoproteinemia,C18.452.584.500.875.440.500\nAbetalipoproteinemia,C18.452.648.398.500.440.500\nCongenital Abnormalities,C16.131\nFetal Malformations,C16.131\nFetal Anomalies,C16.131\n\"Abnormalities, Drug-Induced\",C16.131.042\n\"Abnormalities, Multiple\",C16.131.077\n\"Abnormalities, Radiation-Induced\",C16.131.080\n\"Abnormalities, Radiation-Induced\",C26.733.031\n\"Abnormalities, Radiation-Induced\",G01.750.748.500.031\n\"Abnormalities, Radiation-Induced\",N06.850.460.350.850.500.031\n\"Abnormalities, Radiation-Induced\",N06.850.810.300.360.031\nABO Blood-Group System,D23.050.301.290.031\nABO Blood-Group System,D23.050.705.230.031\nBlood Group H Type 1 Antigen,D23.050.301.290.031\nBlood Group H Type 1 Antigen,D23.050.705.230.031\nABO Factors,D23.050.301.290.031\nABO Factors,D23.050.705.230.031\nAbomasum,A13.869.106\nAbortifacient Agents,D27.505.696.875.131\nAbortifacient Agents,D27.505.954.705.131\nAbortifacient Effect,D27.505.696.875.131\nAbortifacient Effect,D27.505.954.705.131\n\"Abortifacient Agents, Nonsteroidal\",D27.505.696.875.131.100\n\"Abortifacient Agents, Nonsteroidal\",D27.505.954.705.131.100\n\"Abortifacient Agents, Steroidal\",D27.505.696.875.131.200\n\"Abortifacient Agents, Steroidal\",D27.505.954.705.131.200\n\"Abortion, Spontaneous\",C13.703.039\n\"Abortion, Spontaneous\",G08.686.784.769.496.125\nEarly Pregnancy Loss,C13.703.039\nEarly Pregnancy Loss,G08.686.784.769.496.125\nMiscarriage,C13.703.039\nMiscarriage,G08.686.784.769.496.125\n\"Abortion, Tubal\",C13.703.039\n\"Abortion, Tubal\",G08.686.784.769.496.125\nAbortion Applicants,M01.050\n\"Abortion Seekers, Repeated\",M01.050\n\"Abortion Seekers, Refused\",M01.050\n\"Abortion, Criminal\",I01.198.240.089\n\"Abortion, Eugenic\",E04.520.050.050\n\"Abortion, Selective\",E04.520.050.050\n\"Abortion, Habitual\",C13.703.039.089\n\"Abortion, Incomplete\",C13.703.039.093\n\"Abortion, Induced\",E04.520.050\nAbortion Rate,E04.520.050\nAbortion Techniques,E04.520.050\n\"Abortion, Drug-Induced\",E04.520.050\nPrevious Abortion,E04.520.050\n\"Abortion, Saline-Solution\",E04.520.050\n\"Abortion, Soap-Solution\",E04.520.050\nAnti-Abortion Groups,E04.520.050\nEmbryotomy,E04.520.050\n\"Fertility Control, Postconception\",E04.520.050\nAbortion Failure,E04.520.050\n\"Abortion, Rivanol\",E04.520.050\n\"Abortion, Legal\",E04.520.050.055\nAbortion on Demand,E04.520.050.055\n\"Abortion, Missed\",C13.703.039.173\n\"Abortion, Septic\",C01.674.173\n\"Abortion, Septic\",C13.703.039.256\n\"Abortion, Septic\",C13.703.700.173\n\"Abortion, Therapeutic\",E04.520.050.060\n\"Abortion, Threatened\",C13.703.090\n\"Abortion, Veterinary\",C13.703.039.422\n\"Abortion, Veterinary\",C22.021\nAbreaction,F04.754.720.107\nAbrin,D08.811.277.450.430.700.750.111\nAbrin,D12.776.503.499.249\nAbrin,D12.776.765.678.906.111\nAbrin C,D08.811.277.450.430.700.750.111\nAbrin C,D12.776.503.499.249\nAbrin C,D12.776.765.678.906.111\nAbrin A,D08.811.277.450.430.700.750.111\nAbrin A,D12.776.503.499.249\nAbrin A,D12.776.765.678.906.111\nAbruptio Placentae,C13.703.420.078\nAbruptio Placentae,C13.703.590.132\nAbscess,C01.830.025\nAbscess,C23.550.470.756.100\nPeritonsillar Abscess,C01.748.561.750.500\nPeritonsillar Abscess,C01.830.025.675\nPeritonsillar Abscess,C07.550.781.750.500\nPeritonsillar Abscess,C08.730.561.750.500\nPeritonsillar Abscess,C09.775.649.750.500\nAbscisic Acid,D02.241.223.268.034\nAbscisic Acid,D02.455.326.271.665.202.061\nAbscisic Acid,D02.455.426.392.368.367.379.249.024\nAbscisic Acid,D02.455.849.131.061\nAbscisic Acid,D02.455.849.765.521.500\n\"Abscisic Acid, (+,-)-Isomer\",D02.241.223.268.034\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.326.271.665.202.061\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.131.061\n\"Abscisic Acid, (+,-)-Isomer\",D02.455.849.765.521.500\n\"Abscisic Acid, (Z,E)-Isomer\",D02.241.223.268.034\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.326.271.665.202.061\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.426.392.368.367.379.249.024\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.131.061\n\"Abscisic Acid, (Z,E)-Isomer\",D02.455.849.765.521.500\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.241.223.268.034\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.326.271.665.202.061\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.426.392.368.367.379.249.024\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.131.061\n\"Abscisic Acid, (E,Z)-(+,-)-Isomer\",D02.455.849.765.521.500\n\"Abscisic Acid, (R)-Isomer\",D02.241.223.268.034\n\"Abscisic Acid, (R)-Isomer\",D02.455.326.271.665.202.061\n\"Abscisic Acid, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.131.061\n\"Abscisic Acid, (R)-Isomer\",D02.455.849.765.521.500\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.241.223.268.034\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.326.271.665.202.061\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.426.392.368.367.379.249.024\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.131.061\n\"Abscisic Acid Monoammonium Salt, (R)-Isomer\",D02.455.849.765.521.500\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.241.223.268.034\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.326.271.665.202.061\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.426.392.368.367.379.249.024\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.131.061\n\"Abscisic Acid, (E,E)-(+-)-Isomer\",D02.455.849.765.521.500\nAbsenteeism,F02.784.692.107\nAbsorption,G01.015\nAbsorption,G02.010\nAbsorption,G03.015\nAbsorption,G03.787.024\nAbsorption,G07.690.725.015\nAbstracting and Indexing,L01.453.245.100\nIndexing,L01.453.245.100\nIndexes as Topic,L01.453.245.100\nAbstracting,L01.453.245.100\nDental Abutments,E06.780.346.500\nDental Abutments,E07.695.190.175\nAcacia,B01.650.940.800.575.912.250.401.025\nAcacia catechu,B01.650.940.800.575.912.250.401.025\nAcademic Medical Centers,N02.278.020\nAcademies and Institutes,N03.540.052\nInstitutes,N03.540.052\nResearch Institutes,N03.540.052\nAcademies,N03.540.052\nAcanthamoeba,B01.046.500.100.075.080\nAcanthocephala,B01.050.500.500.132\nAcanthocytes,A11.118.290.330.100\nAcanthocytes,A11.443.240.330.100\nAcanthocytes,A15.145.229.334.330.100\nAcantholysis,C17.800.865.070\nAcantholysis,C23.550.035\nAcanthosis Nigricans,C17.800.621.430.530.100\nAcari,B01.050.500.131.166.132\nAcceleration,G01.482.107\nAccessory Nerve,A08.800.800.120.060\nAccident Prevention,N06.850.135.060\nAccident Proneness,F01.145.015\nAccidental Falls,N06.850.135.122\nSlip and Fall,N06.850.135.122\nAccidents,N06.850.135\n\"Accidents, Aviation\",N06.850.135.185\n\"Accidents, Home\",N06.850.135.217\n\"Accidents, Occupational\",N06.850.135.240\n\"Accidents, Industrial\",N06.850.135.240\n\"Accidents, Traffic\",N06.850.135.392\nTraffic Collisions,N06.850.135.392\nTraffic Crashes,N06.850.135.392\nAcclimatization,G07.025.133\nAcclimatization,G16.012.500.133\n\"Accommodation, Ocular\",G14.010\n\"Accommodation, Lens\",G14.010\nAccounting,N03.219.463.030\nOil and Gas Industry,J01.576.655.875.750\nPetroleum Industry,J01.576.655.875.750\nOil Refinery,J01.576.655.875.750\nNatural Gas Industry,J01.576.655.875.750\nCoal Industry,J01.576.655.875.200\nDriving Under the Influence,F01.145.250.250\nDriving Under the Influence,F01.145.263.500\nDriving Under the Influence,I01.880.735.223.250\nDriving Under the Influence,I03.125.649\nDrinking and Driving,F01.145.250.250\nDrinking and Driving,F01.145.263.500\nDrinking and Driving,I01.880.735.223.250\nDrinking and Driving,I03.125.649\nHuman Embryonic Stem Cells,A11.872.700.250.750\nMouse Embryonic Stem Cells,A11.872.700.250.875\nEmbryonic Germ Cells,A11.497.124\nEmbryonic Germ Cells,A11.872.700.250.625\nWork Performance,I03.946.675\nJob Performance,I03.946.675\nCriminal Behavior,F01.145.250\nClinical Decision-Making,E01.055\nCognitive Aging,G07.345.124.260\nCognitive Neuroscience,F04.096.628.255.500\nCognitive Neuroscience,H01.158.610.030\nSocial Neuroscience,F04.096.628.255.500\nSocial Neuroscience,H01.158.610.030\nEmotional Adjustment,F01.058.144\nEmotional Adjustment,F01.752.543.500.250\nFacial Recognition,F02.463.593.524.250.500\nFacial Recognition,F02.463.593.524.500.500\nFacial Recognition,F02.463.593.932.622.500\nFacial Emotion Recognition,F02.463.593.524.250.500\nFacial Emotion Recognition,F02.463.593.524.500.500\nFacial Emotion Recognition,F02.463.593.932.622.500\nGrandparents,F01.829.263.403\nGrandparents,I01.880.853.150.452\nGrandparents,M01.264\nGrandmother,F01.829.263.403\nGrandmother,I01.880.853.150.452\nGrandmother,M01.264\nGrandfather,F01.829.263.403\nGrandfather,I01.880.853.150.452\nGrandfather,M01.264\nHelp-Seeking Behavior,F01.145.813.217\nHeuristics,F02.463.425.725.500\nHeuristics,F02.463.785.810.500\nIntimate Partner Violence,I01.198.240.856.575\nIntimate Partner Violence,I01.880.735.900.688\nDating Violence,I01.198.240.856.575\nDating Violence,I01.880.735.900.688\nNeurological Rehabilitation,E02.760.169.063.500.477\nNeurological Rehabilitation,E02.831.477\nNeurological Rehabilitation,H02.403.680.600.750\nNeurological Rehabilitation,N02.421.784.511\nPhysical Abuse,I01.198.240.856.688\nPhysical Abuse,I01.880.735.900.744\nProblem Behavior,F01.145.126.972\nProblem Behavior,F01.145.179.750\n\"Dysfunctional Behavior, Psychology\",F01.145.126.972\n\"Dysfunctional Behavior, Psychology\",F01.145.179.750\nDisruptive Behavior,F01.145.126.972\nDisruptive Behavior,F01.145.179.750\nUnderage Drinking,F01.145.022.750\nUnderage Drinking,F01.145.317.269.875\nUnderage Drinking,I01.880.735.878\nLegal Drinking Age,F01.145.022.750\nLegal Drinking Age,F01.145.317.269.875\nLegal Drinking Age,I01.880.735.878\nEctopic Gene Expression,G05.308.202\nCell Plasticity,G04.356.250\nCell Self Renewal,G04.144.220.235\nCell Self Renewal,G04.161.750.500.375\nCell Self Renewal,G05.113.415\nCell Self Renewal,G07.345.249.410.750.500.625\nStem Cell Self-Renewal,G04.144.220.235\nStem Cell Self-Renewal,G04.161.750.500.375\nStem Cell Self-Renewal,G05.113.415\nStem Cell Self-Renewal,G07.345.249.410.750.500.625\nRehabilitation Research,H01.770.644.145.472\nOrthodontists,M01.526.485.330.655\nOrthodontists,N02.360.330.655\nDentofacial Orthopedists,M01.526.485.330.655\nDentofacial Orthopedists,N02.360.330.655\nOral and Maxillofacial Surgeons,M01.526.485.330.483\nOral and Maxillofacial Surgeons,N02.360.330.483\nExodontists,M01.526.485.330.483\nExodontists,N02.360.330.483\nNeuroprotection,G11.561.645\n\"Diet, Food, and Nutrition\",G07.203\nTriticale,B01.650.940.800.575.912.250.822.906\nCritical Care Outcomes,N04.761.559.590.399.250\nCritical Care Outcomes,N05.715.360.575.575.399.250\nSimulation Training,I02.903.847\nInteractive Learning,I02.903.847\nMillets,B01.650.940.800.575.912.250.822.587\nBiobehavioral Sciences,H01.770.644.108.687\nProtein Corona,D12.776.642\nVegetarians,M01.928\nLacto-Ovo Vegetarians,M01.928\nVegans,M01.928.500\nAccounts Payable and Receivable,N03.219.463.030.080\nAccounts Payable,N03.219.463.030.080\nYouth Sports,I03.450.642.845.987\nOrganized Youth Sports,I03.450.642.845.987\nLiteracy,F01.145.209.429\nLiteracy,N01.824.196.500\nIlliteracy,F01.145.209.429\nIlliteracy,N01.824.196.500\nSevere Acute Malnutrition,C18.654.521.719\n\"Banking, Personal\",N03.219.463.030.100\nSavings Accounts,N03.219.463.030.100\nChecking Accounts,N03.219.463.030.100\nEvidence-Based Facility Design,N02.278.200.252\n\"Physical Appearance, Body\",E01.370.600.115.450\n\"Physical Appearance, Body\",G07.100.175\nFruit and Vegetable Juices,G07.203.100.606\nFruit and Vegetable Juices,J02.200.606\nVegetable Juices,G07.203.100.606\nVegetable Juices,J02.200.606\nFruit Juices,G07.203.100.606\nFruit Juices,J02.200.606\nGhee,D10.212.302.199.500\nGhee,G07.203.300.350.100.500\nGhee,G07.203.300.375.200.500\nGhee,J02.500.350.100.500\nGhee,J02.500.375.200.500\nHydraulic Fracking,J01.576.655.875.750.500\nPsychological Trauma,F03.950.750.375\nPeer Influence,F01.829.316.483.750\nPeer Pressure,F01.829.316.483.750\nVegetable Products,G07.203.300.850.450\nVegetable Products,J02.500.850.800\nDirect-to-Consumer Advertising,J01.219.687.274.500\nDirect-To-Consumer Screening and Testing,E01.370.398\nDirect-To-Consumer Screening and Testing,N02.421.726.233.166\nExtracellular Vesicles,A11.284.295.588\nExovesicles,A11.284.295.588\nApoptotic Bodies,A11.284.295.588\nFungal Viruses,B04.352\nTelocytes,A11.329.830.750\nExoskeleton Device,E07.341\nRobotic Exoskeleton,E07.341\nShellfish Hypersensitivity,C20.543.480.370.763\n\"Failure to Rescue, Health Care\",E01.789.800.760.500\n\"Failure to Rescue, Health Care\",H01.770.644.145.431.500\n\"Failure to Rescue, Health Care\",N04.761.559.590.800.760.500\n\"Failure to Rescue, Health Care\",N05.715.360.575.575.800.760.500\nPsychiatric Rehabilitation,H02.403.680.600.875\nPsychiatric Rehabilitation,N02.421.784.578\nPsychosocial Care,H02.403.680.600.875\nPsychosocial Care,N02.421.784.578\nSymptom Flare Up,C23.550.291.937.500\nSymptom Exacerbation,C23.550.291.937.500\nIsolated Heart Preparation,E05.519\nIsolated Heart Preparation,E05.598.750\nLangendorff Perfused Heart,E05.519\nLangendorff Perfused Heart,E05.598.750\nWorking Heart Preparation Technique,E05.519\nWorking Heart Preparation Technique,E05.598.750\nWorking Heart Preparation,E05.519\nWorking Heart Preparation,E05.598.750\nIsolated Heart Preparation Technique,E05.519\nIsolated Heart Preparation Technique,E05.598.750\n\"Diet, Vegan\",E02.642.249.300.750\n\"Diet, Vegan\",G07.203.650.240.300.750\nVeganism,E02.642.249.300.750\nVeganism,G07.203.650.240.300.750\nBehavior Observation Techniques,E05.796.112\nBehavior Observation Techniques,F04.669.112\nBehavior Rating Scale,F04.711.271\nBehavior Test,F04.711.271\nAlcohol Drinking in College,F01.145.317.269.625\n\"Obesity, Metabolically Benign\",C18.654.726.500.650\n\"Obesity, Metabolically Benign\",C23.888.144.699.500.250\n\"Obesity, Metabolically Benign\",E01.370.600.115.100.160.120.699.500.375\n\"Obesity, Metabolically Benign\",G07.100.100.160.120.699.500.375\nWhole Grains,G07.203.300.300.550.500\nWhole Grains,G07.203.300.775.500.500\nWhole Grains,J02.500.300.550.500\nWhole Grains,J02.500.775.500.500\nWhole Grain Cereals,G07.203.300.300.550.500\nWhole Grain Cereals,G07.203.300.775.500.500\nWhole Grain Cereals,J02.500.300.550.500\nWhole Grain Cereals,J02.500.775.500.500\nTransanal Endoscopic Surgery,E01.370.388.250.630.500\nTransanal Endoscopic Surgery,E04.210.240.250.680.500\nTransanal Endoscopic Surgery,E04.502.250.250.250.680.500\nTransanal Endoscopic Surgery,E04.502.250.630.500\nTransanal Minimally Invasive Surgery,E01.370.388.250.630.500\nTransanal Minimally Invasive Surgery,E04.210.240.250.680.500\nTransanal Minimally Invasive Surgery,E04.502.250.250.250.680.500\nTransanal Minimally Invasive Surgery,E04.502.250.630.500\nTransanal Endoscopic Microsurgery,E01.370.388.250.630.500.500\nTransanal Endoscopic Microsurgery,E04.210.240.250.680.500.500\nTransanal Endoscopic Microsurgery,E04.494.787\nTransanal Endoscopic Microsurgery,E04.502.250.250.250.680.500.500\nTransanal Endoscopic Microsurgery,E04.502.250.630.500.500\nCold Injury,C26.212\nPersonal Protective Equipment,E07.700.560\nPersonal Protective Equipment,J01.637.708.560\nNerve Agents,D27.720.599\nNerve Agents,D27.720.777.300.500\nNerve Gas,D27.720.599\nNerve Gas,D27.720.777.300.500\nWar-Related Injuries,C26.946\nWar-Related Injuries,I01.880.735.950.500.951.500\nWar-Related Injuries,N06.850.460.350.600.903.500\nWar-Related Trauma,C26.946\nWar-Related Trauma,I01.880.735.950.500.951.500\nWar-Related Trauma,N06.850.460.350.600.903.500\nAbnormal Involuntary Movement Scale,E01.370.600.550.162\nBlood Alcohol Content,D02.033.375.135\nSocial Communication Disorder,F03.625.374.250\nLegal Services,I01.880.604.583.482\nDefamation,I01.198.240.240\nDefamation,I01.880.735.191.051\nSlander,I01.198.240.240\nSlander,I01.880.735.191.051\nLibel,I01.198.240.240\nLibel,I01.880.735.191.051\nAnger Management Therapy,F04.754.137.087\n\"Psychology, Sports\",F04.096.628.914\nWar Exposure,I01.880.735.950.500.951\nWar Exposure,N06.850.460.350.600.903\nChildhood-Onset Fluency Disorder,F03.625.374.125\nNo-Show Patients,F01.100.150.750.500.600.750\nNo-Show Patients,F01.145.488.887.500.600.750\nNo-Show Patients,M01.643.550\nNo-Show Patients,N04.452.758.635.500\nNo-Show Patients,N05.300.150.800.500.600.750\nCellular Reprogramming Techniques,E05.200.500.380\nCellular Reprogramming Techniques,E05.242.378\nCellular Reprogramming Techniques,E05.393.085\nDirected Differentiation Techniques,E05.200.500.380\nDirected Differentiation Techniques,E05.242.378\nDirected Differentiation Techniques,E05.393.085\nDirect Cell Reprogramming Techniques,E05.200.500.380\nDirect Cell Reprogramming Techniques,E05.242.378\nDirect Cell Reprogramming Techniques,E05.393.085\nMetacognition,F02.463.188.756\nMetacognitive Awareness,F02.463.188.756\nMetacognitive Monitoring,F02.463.188.756\nMetacognitive Control,F02.463.188.756\nMetaemotion,F02.463.188.756\nMetamemory,F02.463.188.756\nPrescription Drug Overuse,E02.319.306.500.750\n\"Near Miss, Healthcare\",E02.319.529.750\n\"Near Miss, Healthcare\",N02.421.450.500.750\n\"Near Miss, Healthcare\",N02.421.450.550\n\"Near Miss, Healthcare\",N04.761.700.594\n\"Near Miss, Healthcare\",N05.700.513\nRNAi Therapeutics,E02.095.301.250\nDynamic Light Scattering,E05.196.822.325\nQuasi-Elastic Light Scattering (QELS),E05.196.822.325\n\"Time Out, Healthcare\",N04.761.700.635\n\"Time Out, Healthcare\",N05.700.739\nSurgical Time Out,N04.761.700.635\nSurgical Time Out,N05.700.739\nHealthcare Failure Mode and Effect Analysis,E05.318.740.600.800.715.500\nHealthcare Failure Mode and Effect Analysis,N04.452.871.715.400\nHealthcare Failure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\nHealthcare Failure Mode and Effect Analysis,N06.850.505.715.500\nHealthcare Failure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\nFailure Mode and Effect Analysis,E05.318.740.600.800.715.500\nFailure Mode and Effect Analysis,N04.452.871.715.400\nFailure Mode and Effect Analysis,N05.715.360.750.625.700.690.400\nFailure Mode and Effect Analysis,N06.850.505.715.500\nFailure Mode and Effect Analysis,N06.850.520.830.600.800.715.500\nSpirit Possession,K01.844.619.500\n\"Crew Resource Management, Healthcare\",N04.590.254\nComputer Heuristics,L01.224.050.375.095\nAtaxins,D12.776.631.069\nAtaxins,D12.776.660.075\nAlarmins,D23.035\nDermal Fillers,D27.720.102.461\nAction Spectrum,E05.196.867.826.150\nDiplomacy,F01.829.316.171\nDiplomacy,F02.463.785.373.520.500\nDiplomacy,I01.738.305\nMutation Accumulation,G05.365.590.594\nSpontaneous Mutation Accumulation,G05.365.590.594\nInternal Ribosome Entry Sites,D13.444.735.790.878.942.250\nInternal Ribosome Entry Sites,G02.111.570.080.689.687.093\nInternal Ribosome Entry Sites,G05.360.080.689.687.093\nBiological Mimicry,G16.012.750\nBiological Camouflage,G16.012.750\nSpecific Learning Disorder,F03.625.562.700\nPotentially Inappropriate Medication List,N04.761.700.615\nPotentially Inappropriate Medication List,N05.700.594\nBeers Criteria,N04.761.700.615\nBeers Criteria,N05.700.594\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N04.761.700.615\nSTOPP (Screening Tool of Older Persons Potentially Inappropriate Prescriptions),N05.700.594\nMedication Appropriateness Index,N04.761.700.615\nMedication Appropriateness Index,N05.700.594\nLate Onset Disorders,C23.550.291.883\nPhakopsora pachyrhizi,B01.300.179.113\nFarmers,M01.526.390\nRanchers,M01.526.390\nCulturally Appropriate Technology,J01.897.052\nIntermediate Technology,J01.897.052\nSoft Technology,J01.897.052\nSocial Learning,F02.784.629.529.663\nFinancial Statements,N03.219.463.030.140\n\"Assets, Financial\",N03.219.463.030.140\nCash Flow Statement,N03.219.463.030.140\nBalance Sheet,N03.219.463.030.140\nExpense Statement,N03.219.463.030.140\nIncome Statement,N03.219.463.030.140\n\"Equity, Financial\",N03.219.463.030.140\n\"Liabilities, Financial\",N03.219.463.030.140\nMiners,M01.526.693\nChronopharmacokinetics,G07.690.725.249\n\"Administrative Claims, Healthcare\",N04.452.859.564.137\nChild Health,N01.400.225\nChild Well Being,N01.400.225\nInterleukin-33,D12.644.276.374.465.850\nInterleukin-33,D12.776.467.374.465.850\nInterleukin-33,D23.529.374.465.850\nS100A12 Protein,D12.776.157.125.750.875\nTelopodes,A11.284.180.900\nTelopodes,A11.329.830.750.500\nPodomers,A11.284.180.900\nPodomers,A11.329.830.750.500\nPodoms,A11.284.180.900\nPodoms,A11.329.830.750.500\nDrosophila simulans,B01.050.500.131.617.720.500.500.750.310.250.750\nOptimism,F01.100.787\nPositive Attitude,F01.100.787\nPositive Thinking,F01.100.787\nPessimism,F01.100.893\nAtaxin-1,D12.776.631.069.500\nAtaxin-1,D12.776.660.075.500\nAdolescent Health,N01.400.075\nAdolescent Well Being,N01.400.075\nAtaxin-2,D12.776.157.725.452.125\nAtaxin-2,D12.776.631.069.750\nAtaxin-2,D12.776.660.075.750\nAtaxin-2,D12.776.664.962.452.125\nAtaxin-3,D08.811.037.250\nAtaxin-3,D12.776.631.069.875\nAtaxin-3,D12.776.660.075.875\nPoint-of-Care Testing,N04.590.874.500\nBedside Testing,N04.590.874.500\nAtaxin-7,D12.776.631.069.901\nAtaxin-7,D12.776.660.075.900\nAtaxin-10,D12.776.631.069.950\nGlucagon-Like Peptide Receptors,D12.776.543.750.695.021\nGlucagon-Like Peptide Receptors,D12.776.543.750.750.360.100\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.695.021.500\nGlucagon-Like Peptide-1 Receptor,D12.776.543.750.750.360.100.500\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.695.021.600\nGlucagon-Like Peptide-2 Receptor,D12.776.543.750.750.360.100.600\nReceptor for Advanced Glycation End Products,D12.776.543.750.615\nRNA Recognition Motif Proteins,D12.776.157.725.813\nRNA Recognition Motif Proteins,D12.776.664.962.813\nELAV-Like Protein 2,D12.776.157.725.813.500.500\nELAV-Like Protein 2,D12.776.631.520.500\nELAV-Like Protein 2,D12.776.664.962.813.500.500\nELAV-Like Protein 3,D12.776.157.725.813.500.750\nELAV-Like Protein 3,D12.776.631.520.750\nELAV-Like Protein 3,D12.776.664.962.813.500.750\nELAV-Like Protein 4,D12.776.157.725.813.500.875\nELAV-Like Protein 4,D12.776.631.520.875\nELAV-Like Protein 4,D12.776.664.962.813.500.875\nELAV-Like Protein 1,D12.776.157.725.813.500.250\nELAV-Like Protein 1,D12.776.664.962.813.500.250\nWhey,A12.790.760\nWhey,G07.203.100.700.750\nWhey,G07.203.300.350.525.760\nWhey,J02.200.700.750\nWhey,J02.500.350.525.760\nWhey Proteins,A12.790.520.500\nWhey Proteins,A12.790.760.500\nWhey Proteins,D12.776.256.159.750.816\nWhey Proteins,G07.203.300.350.525.760.500\nWhey Proteins,G07.203.300.428.159.812.500\nWhey Proteins,J02.500.350.525.520.500\nWhey Proteins,J02.500.350.525.760.500\nWhey Proteins,J02.500.428.159.750.500\nHoarding Disorder,F03.080.600.250\nObsessive Hoarding,F03.080.600.250\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.519.389.739\nPoly(ADP-ribose) Polymerase Inhibitors,D27.505.954.248.692\nAutism Spectrum Disorder,F03.625.164.113\nCELF Proteins,D12.776.157.725.813.250\nCELF Proteins,D12.776.664.962.813.250\nCELF1 Protein,D12.776.157.725.813.250.500\nCELF1 Protein,D12.776.664.962.813.250.500\nIndustrial Development,I01.261.262.500\nIndustrial Development,J01.576.519\nTechnology Development,I01.261.262.500\nTechnology Development,J01.576.519\nIndustrialization,I01.261.262.500\nIndustrialization,J01.576.519\nCloud Computing,L01.224.097\nNatural Resources,G16.500.275.553\nNatural Resources,J01.728\nNatural Resources,N06.230.350\nLand Supply,G16.500.275.553\nLand Supply,J01.728\nLand Supply,N06.230.350\nGlycemic Load,G07.203.650.660.750\nGlycemic Load,J01.576.423.850.730.750.750\nGlycemic Load,N06.850.601.750.750\nAdenylyl Cyclase Inhibitors,D27.505.519.389.108\nRAW 264.7 Cells,A11.251.210.172.875\nRAW 264.7 Cells,A11.733.397.815\nAccreditation,N03.706.110.070\nAccreditation,N05.700.200.100\nClostridiales,B03.353.625\nGraphic Novel,V02.700.415\nComic Book,V02.700.415\nSouth Sudan,Z01.058.290.120.745\nMotor Disorders,F03.608\nMaternal Health,N01.400.900.500\nSeed Bank,N02.278.065.650\nGermplasm Bank,N02.278.065.650\nTrauma and Stressor Related Disorders,F03.950\nMaternal-Child Health Services,N02.421.143.130.660\nMaternal-Child Health Services,N02.421.143.620.275\nSerine-Arginine Splicing Factors,D12.776.157.725.829.500\nSerine-Arginine Splicing Factors,D12.776.664.962.829.500\nInfant Health,N01.400.388\nNewborn Health,N01.400.388\nBipolar and Related Disorders,F03.084\nGender Dysphoria,F03.835.550\nFormative Feedback,F02.784.629.529.223\nAripiprazole,D03.383.606.170\nAripiprazole,D03.633.100.810.835.122\nAbilify,D03.383.606.170\nAbilify,D03.633.100.810.835.122\nOPC 14597,D03.383.606.170\nOPC 14597,D03.633.100.810.835.122\nPrunus dulcis,B01.650.940.800.575.912.250.859.937.500.625.500\nAlmonds,B01.650.940.800.575.912.250.859.937.500.625.500\nAlbumin-Bound Paclitaxel,D02.455.426.392.368.242.888.777.500\nAlbumin-Bound Paclitaxel,D02.455.849.291.850.777.500\nAlbumin-Bound Paclitaxel,D12.776.034.073\nAbraxane,D02\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n80.604.238\n\"Censorship, Research\",K01.752.566.479.173.200\n\"Censorship, Research\",N05.350.670.250\nData Accuracy,E05.318.308.028\nData Accuracy,E05.318.370.725.250\nData Accuracy,L01.399.250.202\nData Accuracy,N05.715.360.300.202\nData Accuracy,N05.715.360.325.685.250\nData Quality,E05.318.308.028\nData Quality,E05.318.370.725.250\nData Quality,L01.399.250.202\nData Quality,N05.715.360.300.202\nData Quality,N05.715.360.325.685.250\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.100.624.915.500\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.033.755.624.915.500\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.092.063.624.915.500\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D02.886.675.867.768.500\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.383.129.708.867.768.500\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D03.633.100.857.070.500\n\"Brimonidine Tartrate, Timolol Maleate Drug Combination\",D26.310.312\nCombigan,D02.033.100.624.915.500\nCombigan,D02.033.755.624.915.500\nCombigan,D02.092.063.624.915.500\nCombigan,D02.886.675.867.768.500\nCombigan,D03.383.129.708.867.768.500\nCombigan,D03.633.100.857.070.500\nCombigan,D26.310.312\n\"Albuterol, Ipratropium Drug Combination\",D02.033.100.291.057.125\n\"Albuterol, Ipratropium Drug Combination\",D02.092.063.291.057.125\n\"Albuterol, Ipratropium Drug Combination\",D02.092.471.683.061.125\n\"Albuterol, Ipratropium Drug Combination\",D02.145.074.722.229.400.500\n\"Albuterol, Ipratropium Drug Combination\",D03.132.760.180.572.400.500\n\"Albuterol, Ipratropium Drug Combination\",D03.132.889.180.648.400.500\n\"Albuterol, Ipratropium Drug Combination\",D03.605.084.500.722.229.400.500\n\"Albuterol, Ipratropium Drug Combination\",D03.605.869.229.400.500\n\"Albuterol, Ipratropium Drug Combination\",D26.310.344\nCombivent Respimat,D02.033.100.291.057.125\nCombivent Respimat,D02.092.063.291.057.125\nCombivent Respimat,D02.092.471.683.061.125\nCombivent Respimat,D02.145.074.722.229.400.500\nCombivent Respimat,D03.132.760.180.572.400.500\nCombivent Respimat,D03.132.889.180.648.400.500\nCombivent Respimat,D03.605.084.500.722.229.400.500\nCombivent Respimat,D03.605.869.229.400.500\nCombivent Respimat,D26.310.344\nDey Combination,D02.033.100.291.057.125\nDey Combination,D02.092.063.291.057.125\nDey Combination,D02.092.471.683.061.125\nDey Combination,D02.145.074.722.229.400.500\nDey Combination,D03.132.760.180.572.400.500\nDey Combination,D03.132.889.180.648.400.500\nDey Combination,D03.605.084.500.722.229.400.500\nDey Combination,D03.605.869.229.400.500\nDey Combination,D26.310.344\nCombivent,D02.033.100.291.057.125\nCombivent,D02.092.063.291.057.125\nCombivent,D02.092.471.683.061.125\nCombivent,D02.145.074.722.229.400.500\nCombivent,D03.132.760.180.572.400.500\nCombivent,D03.132.889.180.648.400.500\nCombivent,D03.605.084.500.722.229.400.500\nCombivent,D03.605.869.229.400.500\nCombivent,D26.310.344\nDual Use Research,H01.770.644.217\nProfessionalism,K01.752.566.479.171.566\nProfessionalism,N05.350.340.581\nMedical Professionalism,K01.752.566.479.171.566\nMedical Professionalism,N05.350.340.581\nProfessionalism Education,K01.752.566.479.171.566\nProfessionalism Education,N05.350.340.581\nSurgical Professionalism,K01.752.566.479.171.566\nSurgical Professionalism,N05.350.340.581\nGenetic Background,G05.346\nSelective Breeding,E05.820.150.760\nSelective Breeding,G05.090.701\nLegendary Creatures,I01.076.201.450.515.500\nWerewolves,I01.076.201.450.515.500\nUnicorns,I01.076.201.450.515.500\n\"Yeti, Himalayan\",I01.076.201.450.515.500\nVampires,I01.076.201.450.515.500\nMermaids,I01.076.201.450.515.500\nMometasone Furoate,D04.210.500.745.432.719.526\nNasonex,D04.210.500.745.432.719.526\nMometasone Furoate Monohydrate,D04.210.500.745.432.719.526\nAsmanex Twisthaler,D04.210.500.745.432.719.526\nAsmanex,D04.210.500.745.432.719.526\nRinelon,D04.210.500.745.432.719.526\nElocon,D04.210.500.745.432.719.526\nSch 32088,D04.210.500.745.432.719.526\nMometasone,D04.210.500.745.432.719.526\nFallopia multiflora,B01.650.940.800.575.912.250.825.359.590\nSildenafil Citrate,D02.065.884.675\nSildenafil Citrate,D02.886.590.700.675\nSildenafil Citrate,D03.383.606.854\nSildenafil Citrate,D03.633.100.759.824\nNCX-911,D02.065.884.675\nNCX-911,D02.886.590.700.675\nNCX-911,D03.383.606.854\nNCX-911,D03.633.100.759.824\nRevatio,D02.065.884.675\nRevatio,D02.886.590.700.675\nRevatio,D03.383.606.854\nRevatio,D03.633.100.759.824\nSildenafil,D02.065.884.675\nSildenafil,D02.886.590.700.675\nSildenafil,D03.383.606.854\nSildenafil,D03.633.100.759.824\nUK 92480-10,D02.065.884.675\nUK 92480-10,D02.886.590.700.675\nUK 92480-10,D03.383.606.854\nUK 92480-10,D03.633.100.759.824\nHomosildenafil,D02.065.884.675\nHomosildenafil,D02.886.590.700.675\nHomosildenafil,D03.383.606.854\nHomosildenafil,D03.633.100.759.824\nHydroxyhomosildenafil,D02.065.884.675\nHydroxyhomosildenafil,D02.886.590.700.675\nHydroxyhomosildenafil,D03.383.606.854\nHydroxyhomosildenafil,D03.633.100.759.824\nViagra,D02.065.884.675\nViagra,D02.886.590.700.675\nViagra,D03.383.606.854\nViagra,D03.633.100.759.824\nAcetildenafil,D02.065.884.675\nAcetildenafil,D02.886.590.700.675\nAcetildenafil,D03.383.606.854\nAcetildenafil,D03.633.100.759.824\nSildenafil Lactate,D02.065.884.675\nSildenafil Lactate,D02.886.590.700.675\nSildenafil Lactate,D03.383.606.854\nSildenafil Lactate,D03.633.100.759.824\nSildenafil Nitrate,D02.065.884.675\nSildenafil Nitrate,D02.886.590.700.675\nSildenafil Nitrate,D03.383.606.854\nSildenafil Nitrate,D03.633.100.759.824\nDesmethyl Sildenafil,D02.065.884.675\nDesmethyl Sildenafil,D02.886.590.700.675\nDesmethyl Sildenafil,D03.383.606.854\nDesmethyl Sildenafil,D03.633.100.759.824\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.626.809.500\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D02.705.429.906.500\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.680.245.500.600.500\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.383.742.755.500\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D03.633.100.759.138.881.500\n\"Emtricitabine, Rilpivirine, Tenofovir Drug Combination\",D26.310.407\nComplera,D02.626.809.500\nComplera,D02.705.429.906.500\nComplera,D03.383.742.680.245.500.600.500\nComplera,D03.383.742.755.500\nComplera,D03.633.100.759.138.881.500\nComplera,D26.310.407\nEmtricitabine,D03.383.742.680.245.500.600\nEmtricitabine,D13.570.230.329.525\nEmtricitabine,D13.570.685.245.500.600\nCoviracil,D03.383.742.680.245.500.600\nCoviracil,D13.570.230.329.525\nCoviracil,D13.570.685.245.500.600\nEmtriva,D03.383.742.680.245.500.600\nEmtriva,D13.570.230.329.525\nEmtriva,D13.570.685.245.500.600\nRilpivirine,D02.626.809\nRilpivirine,D03.383.742.755\nRilpivirine Hydrochloride,D02.626.809\nRilpivirine Hydrochloride,D03.383.742.755\nR278474,D02.626.809\nR278474,D03.383.742.755\nTMC 278,D02.626.809\nTMC 278,D03.383.742.755\nTenofovir,D02.705.429.906\nTenofovir,D03.633.100.759.138.881\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D02.705.429.906\n\"9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer\",D03.633.100.759.138.881\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D02.705.429.906\n\"9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer\",D03.633.100.759.138.881\nTenofovir Disoproxil Fumarate,D02.705.429.906\nTenofovir Disoproxil Fumarate,D03.633.100.759.138.881\nTenofovir Disoproxil,D02.705.429.906\nTenofovir Disoproxil,D03.633.100.759.138.881\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D02.705.429.906\n\"9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098\",D03.633.100.759.138.881\nViread,D02.705.429.906\nViread,D03.633.100.759.138.881\nGlatiramer Acetate,D12.644.219\nCopaxone,D12.644.219\nGlatiramer,D12.644.219\nTV 5010,D12.644.219\nRosuvastatin Calcium,D02.065.884.650\nRosuvastatin Calcium,D02.455.526.510.432.500\nRosuvastatin Calcium,D02.886.590.700.650\nRosuvastatin Calcium,D03.383.742.775\nCrestor,D02.065.884.650\nCrestor,D02.455.526.510.432.500\nCrestor,D02.886.590.700.650\nCrestor,D03.383.742.775\nRosuvastatin,D02.065.884.650\nRosuvastatin,D02.455.526.510.432.500\nRosuvastatin,D02.886.590.700.650\nRosuvastatin,D03.383.742.775\nZD4522,D02.065.884.650\nZD4522,D02.455.526.510.432.500\nZD4522,D02.886.590.700.650\nZD4522,D03.383.742.775\nDuloxetine Hydrochloride,D02.886.778.260\nDuloxetine Hydrochloride,D03.383.903.260\nLY 248686,D02.886.778.260\nLY 248686,D03.383.903.260\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D02.886.778.260\n\"Duloxetine Ethanedioate (1:1), (+-)-isomer - T353987\",D03.383.903.260\nLY 227942,D02.886.778.260\nLY 227942,D03.383.903.260\nDuloxetine,D02.886.778.260\nDuloxetine,D03.383.903.260\n\"Duloxetine, (+)-isomer\",D02.886.778.260\n\"Duloxetine, (+)-isomer\",D03.383.903.260\nCymbalta,D02.886.778.260\nCymbalta,D03.383.903.260\nTolterodine Tartrate,D02.033.100.624.706.750\nTolterodine Tartrate,D02.033.755.624.706.750\nTolterodine Tartrate,D02.092.063.624.706.800\nTolterodine Tartrate,D02.455.426.559.389.115.900\nTolterodine Tartrate,D02.455.426.559.389.657.239.756\nTolterodine,D02.033.100.624.706.750\nTolterodine,D02.033.755.624.706.750\nTolterodine,D02.092.063.624.706.800\nTolterodine,D02.455.426.559.389.115.900\nTolterodine,D02.455.426.559.389.657.239.756\nDetrol,D02.033.100.624.706.750\nDetrol,D02.033.755.624.706.750\nDetrol,D02.092.063.624.706.800\nDetrol,D02.455.426.559.389.115.900\nDetrol,D02.455.426.559.389.657.239.756\nDetrol LA,D02.033.100.624.706.750\nDetrol LA,D02.033.755.624.706.750\nDetrol LA,D02.092.063.624.706.800\nDetrol LA,D02.455.426.559.389.115.900\nDetrol LA,D02.455.426.559.389.657.239.756\nUrotrol,D02.033.100.624.706.750\nUrotrol,D02.033.755.624.706.750\nUrotrol,D02.092.063.624.706.800\nUrotrol,D02.455.426.559.389.115.900\nUrotrol,D02.455.426.559.389.657.239.756\nPHA-686464B,D02.033.100.624.706.750\nPHA-686464B,D02.033.755.624.706.750\nPHA-686464B,D02.092.063.624.706.800\nPHA-686464B,D02.455.426.559.389.115.900\nPHA-686464B,D02.455.426.559.389.657.239.756\nDetrusitol,D02.033.100.624.706.750\nDetrusitol,D02.033.755.624.706.750\nDetrusitol,D02.092.063.624.706.800\nDetrusitol,D02.455.426.559.389.115.900\nDetrusitol,D02.455.426.559.389.657.239.756\nUnidet,D02.033.100.624.706.750\nUnidet,D02.033.755.624.706.750\nUnidet,D02.092.063.624.706.800\nUnidet,D02.455.426.559.389.115.900\nUnidet,D02.455.426.559.389.657.239.756\nValsartan,D03.383.129.617.850\nValsartan,D12.125.070.950.550\nValsartan,D12.125.142.930.500\nDiovan,D03.383.129.617.850\nDiovan,D12.125.070.950.550\nDiovan,D12.125.142.930.500\nKalpress,D03.383.129.617.850\nKalpress,D12.125.070.950.550\nKalpress,D12.125.142.930.500\nTareg,D03.383.129.617.850\nTareg,D12.125.070.950.550\nTareg,D12.125.142.930.500\nNisis,D03.383.129.617.850\nNisis,D12.125.070.950.550\nNisis,D12.125.142.930.500\nProvas,D03.383.129.617.850\nProvas,D12.125.070.950.550\nProvas,D12.125.142.930.500\nVals,D03.383.129.617.850\nVals,D12.125.070.950.550\nVals,D12.125.142.930.500\nCGP 48933,D03.383.129.617.850\nCGP 48933,D12.125.070.950.550\nCGP 48933,D12.125.142.930.500\nMiten,D03.383.129.617.850\nMiten,D12.125.070.950.550\nMiten,D12.125.142.930.500\nOnonis,B01.650.940.800.575.912.250.401.604\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.033.100.291.425.500\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D02.092.063.291.425.500\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D04.210.500.745.432.719.526.500\n\"Mometasone Furoate, Formoterol Fumarate Drug Combination\",D26.310.469\nDulera,D02.033.100.291.425.500\nDulera,D02.092.063.291.425.500\nDulera,D04.210.500.745.432.719.526.500\nDulera,D26.310.469\nZenhale,D02.033.100.291.425.500\nZenhale,D02.092.063.291.425.500\nZenhale,D04.210.500.745.432.719.526.500\nZenhale,D26.310.469\nFormoterol Fumarate,D02.033.100.291.425\nFormoterol Fumarate,D02.092.063.291.425\nBD 40A,D02.033.100.291.425\nBD 40A,D02.092.063.291.425\nFormoterol,D02.033.100.291.425\nFormoterol,D02.092.063.291.425\nOxis,D02.033.100.291.425\nOxis,D02.092.063.291.425\nArformoterol,D02.033.100.291.425\nArformoterol,D02.092.063.291.425\nForadil,D02.033.100.291.425\nForadil,D02.092.063.291.425\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.562.437.693\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.519.625.600.693\nSerotonin and Noradrenaline Reuptake Inhibitors,D27.505.696.577.600.693\n\"Sleep Aids, Pharmaceutical\",D27.505.696.277.350.500\n\"Sleep Aids, Pharmaceutical\",D27.505.954.427.210.350.500\nSleeping Pills,D27.505.696.277.350.500\nSleeping Pills,D27.505.954.427.210.350.500\nOrexin Receptor Antagonists,D27.505.519.625.663\nOrexin Receptor Antagonists,D27.505.696.277.350.500.500\nOrexin Receptor Antagonists,D27.505.696.577.663\nOrexin Receptor Antagonists,D27.505.954.427.210.350.500.500\nDual Orexin Receptor Antagonists,D27.505.519.625.663\nDual Orexin Receptor Antagonists,D27.505.696.277.350.500.500\nDual Orexin Receptor Antagonists,D27.505.696.577.663\nDual Orexin Receptor Antagonists,D27.505.954.427.210.350.500.500\nOrexins,D12.644.400.360\nOrexins,D12.776.631.650.363\nOrexin-B,D12.644.400.360\nOrexin-B,D12.776.631.650.363\nOrexin-A,D12.644.400.360\nOrexin-A,D12.776.631.650.363\nHoodia,B01.650.940.800.575.912.250.456.500.389\nHoodia gordonii,B01.650.940.800.575.912.250.456.500.389\nPrasugrel Hydrochloride,D02.886.778.600\nPrasugrel Hydrochloride,D03.383.606.800\nPrasugrel Hydrochloride,D03.383.903.600\nCS 747,D02.886.778.600\nCS 747,D03.383.606.800\nCS 747,D03.383.903.600\nPrasugrel,D02.886.778.600\nPrasugrel,D03.383.606.800\nPrasugrel,D03.383.903.600\nEfient,D02.886.778.600\nEfient,D03.383.606.800\nEfient,D03.383.903.600\nEffient,D02.886.778.600\nEffient,D03.383.606.800\nEffient,D03.383.903.600\nLY 640315,D02.886.778.600\nLY 640315,D03.383.606.800\nLY 640315,D03.383.903.600\nEtanercept,D12.644.541.500.697.624\nEtanercept,D12.776.124.486.485.538.500.624\nEtanercept,D12.776.124.486.485.680.697.624\nEtanercept,D12.776.124.790.651.538.500.624\nEtanercept,D12.776.124.790.651.680.660.624\nEtanercept,D12.776.377.715.548.538.500.624\nEtanercept,D12.776.377.715.548.680.660.624\nEtanercept,D12.776.543.750.705.852.760.232\nTNFR-Fc Fusion Protein,D12.644.541.500.697.624\nTNFR-Fc Fusion Protein,D12.776.124.486.485.538.500.624\nTNFR-Fc Fusion Protein,D12.776.124.486.485.680.697.624\nTNFR-Fc Fusion Protein,D12.776.124.790.651.538.500.624\nTNFR-Fc Fusion Protein,D12.776.124.790.651.680.660.624\nTNFR-Fc Fusion Protein,D12.776.377.715.548.538.500.624\nTNFR-Fc Fusion Protein,D12.776.377.715.548.680.660.624\nTNFR-Fc Fusion Protein,D12.776.543.750.705.852.760.232\nEtanercept-szzs,D12.644.541.500.697.624\nEtanercept-szzs,D12.776.124.486.485.538.500.624\nEtanercept-szzs,D12.776.124.486.485.680.697.624\nEtanercept-szzs,D12.776.124.790.651.538.500.624\nEtanercept-szzs,D12.776.124.790.651.680.660.624\nEtanercept-szzs,D12.776.377.715.548.538.500.624\nEtanercept-szzs,D12.776.377.715.548.680.660.624\nEtanercept-szzs,D12.776.543.750.705.852.760.232\nTNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\nTNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\nErelzi,D12.644.541.500.697.624\nErelzi,D12.776.124.486.485.538.500.624\nErelzi,D12.776.124.486.485.680.697.624\nErelzi,D12.776.124.790.651.538.500.624\nErelzi,D12.776.124.790.651.680.660.624\nErelzi,D12.776.377.715.548.538.500.624\nErelzi,D12.776.377.715.548.680.660.624\nErelzi,D12.776.543.750.705.852.760.232\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.644.541.500.697.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.538.500.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.486.485.680.697.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.538.500.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.124.790.651.680.660.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.538.500.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.377.715.548.680.660.624\nRecombinant Human Dimeric TNF Receptor Type II-IgG Fusion Protein,D12.776.543.750.705.852.760.232\nEnbrel,D12.644.541.500.697.624\nEnbrel,D12.776.124.486.485.538.500.624\nEnbrel,D12.776.124.486.485.680.697.624\nEnbrel,D12.776.124.790.651.538.500.624\nEnbrel,D12.776.124.790.651.680.660.624\nEnbrel,D12.776.377.715.548.538.500.624\nEnbrel,D12.776.377.715.548.680.660.624\nEnbrel,D12.776.543.750.705.852.760.232\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.241.223.100.133.500\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.389.127.133.500\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D02.455.426.559.847.638.090.500\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D04.615.638.090.500\n\"Adapalene, Benzoyl Peroxide Drug Combination\",D26.310.032\nEpiduo,D02.241.223.100.133.500\nEpiduo,D02.455.426.559.389.127.133.500\nEpiduo,D02.455.426.559.847.638.090.500\nEpiduo,D04.615.638.090.500\nEpiduo,D26.310.032\nAdapalene,D02.455.426.559.847.638.090\nAdapalene,D04.615.638.090\nCD 271,D02.455.426.559.847.638.090\nCD 271,D04.615.638.090\nAdaferin,D02.455.426.559.847.638.090\nAdaferin,D04.615.638.090\nDifferin,D02.455.426.559.847.638.090\nDifferin,D04.615.638.090\nEpoetin Alfa,D12.644.276.374.410.240.150.500\nEpoetin Alfa,D12.776.395.240.150.750\nEpoetin Alfa,D12.776.467.374.410.240.150.500\nEpoetin Alfa,D23.529.374.410.240.150.750\nEpoetin Alfa Hexal,D12.644.276.374.410.240.150.500\nEpoetin Alfa Hexal,D12.776.395.240.150.750\nEpoetin Alfa Hexal,D12.776.467.374.410.240.150.500\nEpoetin Alfa Hexal,D23.529.374.410.240.150.750\nEprex,D12.644.276.374.410.240.150.500\nEprex,D12.776.395.240.150.750\nEprex,D12.776.467.374.410.240.150.500\nEprex,D23.529.374.410.240.150.750\nHeberitro,D12.644.276.374.410.240.150.500\nHeberitro,D12.776.395.240.150.750\nHeberitro,D12.776.467.374.410.240.150.500\nHeberitro,D23.529.374.410.240.150.750\nProcrit,D12.644.276.374.410.240.150.500\nProcrit,D12.776.395.240.150.750\nProcrit,D12.776.467.374.410.240.150.500\nProcrit,D23.529.374.410.240.150.750\nBinocrit,D12.644.276.374.410.240.150.500\nBinocrit,D12.776.395.240.150.750\nBinocrit,D12.776.467.374.410.240.150.500\nBinocrit,D23.529.374.410.240.150.750\nHX575 Compound,D12.644.276.374.410.240.150.500\nHX575 Compound,D12.776.395.240.150.750\nHX575 Compound,D12.776.467.374.410.240.150.500\nHX575 Compound,D23.529.374.410.240.150.750\nEpogen,D12.644.276.374.410.240.150.500\nEpogen,D12.776.395.240.150.750\nEpogen,D12.776.467.374.410.240.150.500\nEpogen,D23.529.374.410.240.150.750\nHX575,D12.644.276.374.410.240.150.500\nHX575,D12.776.395.240.150.750\nHX575,D12.776.467.374.410.240.150.500\nHX575,D23.529.374.410.240.150.750\nCetuximab,D12.776.124.486.485.114.224.060.750\nCetuximab,D12.776.124.790.651.114.224.060.750\nCetuximab,D12.776.377.715.548.114.224.200.750\nErbitux,D12.776.124.486.485.114.224.060.750\nErbitux,D12.776.124.790.651.114.224.060.750\nErbitux,D12.776.377.715.548.114.224.200.750\nIMC C225,D12.776.124.486.485.114.224.060.750\nIMC C225,D12.776.124.790.651.114.224.060.750\nIMC C225,D12.776.377.715.548.114.224.200.750\nHyssopus Plant,B01.650.940.800.575.912.250.583.520.330\nHyssopus officinalis,B01.650.940.800.575.912.250.583.520.330\nRivastigmine,D02.241.081.251.583.899\nRivastigmineTartrate,D02.241.081.251.583.899\nExelon,D02.241.081.251.583.899\nENA 713,D02.241.081.251.583.899\nParmeliaceae,B01.300.107.685\nParmeliaceae,B01.300.340.458\nCetraria,B01.300.107.685\nCetraria,B01.300.340.458\nCetraria islandica,B01.300.107.685\nCetraria islandica,B01.300.340.458\n\"Amlodipine, Valsartan Drug Combination\",D03.383.129.617.850.500\n\"Amlodipine, Valsartan Drug Combination\",D03.383.725.203.065.750\n\"Amlodipine, Valsartan Drug Combination\",D12.125.070.950.550.500\n\"Amlodipine, Valsartan Drug Combination\",D12.125.142.930.500.500\n\"Amlodipine, Valsartan Drug Combination\",D26.310.094\nExforge,D03.383.129.617.850.500\nExforge,D03.383.725.203.065.750\nExforge,D12.125.070.950.550.500\nExforge,D12.125.142.930.500.500\nExforge,D26.310.094\nEugenia,B01.650.940.800.575.912.250.773.374\nEuginia uniflora,B01.650.940.800.575.912.250.773.374\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.815.455\n\"Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18\",D20.215.894.899.498.500\nGardasil,D20.215.894.815.455\nGardasil,D20.215.894.899.498.500\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.815.455\n\"Human Papillomavirus Vaccine L1, Type 6,11,16,18\",D20.215.894.899.498.500\nKombucha Tea,D20.215.784.844.500\nKombucha Tea,G07.203.100.831.500\nKombucha Tea,G07.203.200.625\nKombucha Tea,J02.200.831.500\nKombucha Tea,J02.350.625\nFingolimod Hydrochloride,D02.033.100.700.350\nFingolimod Hydrochloride,D02.033.455.706.431\nFingolimod Hydrochloride,D02.092.063.700.350\nFTY-720,D02.033.100.700.350\nFTY-720,D02.033.455.706.431\nFTY-720,D02.092.063.700.350\nGilenya,D02.033.100.700.350\nGilenya,D02.033.455.706.431\nGilenya,D02.092.063.700.350\nFingolimod,D02.033.100.700.350\nFingolimod,D02.033.455.706.431\nFingolimod,D02.092.063.700.350\nImatinib Mesylate,D02.065.277.456\nImatinib Mesylate,D02.241.223.100.100.435\nImatinib Mesylate,D02.455.426.559.389.127.085.465\nImatinib Mesylate,D03.383.606.405\nImatinib Mesylate,D03.383.742.349\nSTI571,D02.065.277.456\nSTI571,D02.241.223.100.100.435\nSTI571,D02.455.426.559.389.127.085.465\nSTI571,D03.383.606.405\nSTI571,D03.383.742.349\nGleevec,D02.065.277.456\nGleevec,D02.241.223.100.100.435\nGleevec,D02.455.426.559.389.127.085.465\nGleevec,D03.383.606.405\nGleevec,D03.383.742.349\nST 1571,D02.065.277.456\nST 1571,D02.241.223.100.100.435\nST 1571,D02.455.426.559.389.127.085.465\nST 1571,D03.383.606.405\nST 1571,D03.383.742.349\nCGP 57148,D02.065.277.456\nCGP 57148,D02.241.223.100.100.435\nCGP 57148,D02.455.426.559.389.127.085.465\nCGP 57148,D03.383.606.405\nCGP 57148,D03.383.742.349\nImatinib,D02.065.277.456\nImatinib,D02.241.223.100.100.435\nImatinib,D02.455.426.559.389.127.085.465\nImatinib,D03.383.606.405\nImatinib,D03.383.742.349\nTrastuzumab,D12.776.124.486.485.114.224.060.875\nTrastuzumab,D12.776.124.790.651.114.224.060.875\nTrastuzumab,D12.776.377.715.548.114.224.200.875\nHerceptin,D12.776.124.486.485.114.224.060.875\nHerceptin,D12.776.124.790.651.114.224.060.875\nHerceptin,D12.776.377.715.548.114.224.200.875\nTrazimera,D12.776.124.486.485.114.224.060.875\nTrazimera,D12.776.124.790.651.114.224.060.875\nTrazimera,D12.776.377.715.548.114.224.200.875\nAdalimumab,D12.776.124.486.485.114.224.060.250\nAdalimumab,D12.776.124.790.651.114.224.060.250\nAdalimumab,D12.776.377.715.548.114.224.200.250\nHumira,D12.776.124.486.485.114.224.060.250\nHumira,D12.776.124.790.651.114.224.060.250\nHumira,D12.776.377.715.548.114.224.200.250\nAdalimumab-adbm,D12.776.124.486.485.114.224.060.250\nAdalimumab-adbm,D12.776.124.790.651.114.224.060.250\nAdalimumab-adbm,D12.776.377.715.548.114.224.200.250\nAmjevita,D12.776.124.486.485.114.224.060.250\nAmjevita,D12.776.124.790.651.114.224.060.250\nAmjevita,D12.776.377.715.548.114.224.200.250\nAdalimumab-atto,D12.776.124.486.485.114.224.060.250\nAdalimumab-atto,D12.776.124.790.651.114.224.060.250\nAdalimumab-atto,D12.776.377.715.548.114.224.200.250\nCyltezo,D12.776.124.486.485.114.224.060.250\nCyltezo,D12.776.124.790.651.114.224.060.250\nCyltezo,D12.776.377.715.548.114.224.200.250\nD2E7 Antibody,D12.776.124.486.485.114.224.060.250\nD2E7 Antibody,D12.776.124.790.651.114.224.060.250\nD2E7 Antibody,D12.776.377.715.548.114.224.200.250\n\"Isophane Insulin, Human\",D06.472.699.587.200.300.200.500\n\"Isophane Insulin, Human\",D06.472.699.587.200.500.625.500.500\n\"Isophane Insulin, Human\",D12.644.548.586.200.300.200.500\n\"Isophane Insulin, Human\",D12.644.548.586.200.500.625.500.500\nHumulin N,D06.472.699.587.200.300.200.500\nHumulin N,D06.472.699.587.200.500.625.500.500\nHumulin N,D12.644.548.586.200.300.200.500\nHumulin N,D12.644.548.586.200.500.625.500.500\nNovolin N,D06.472.699.587.200.300.200.500\nNovolin N,D06.472.699.587.200.500.625.500.500\nNovolin N,D12.644.548.586.200.300.200.500\nNovolin N,D12.644.548.586.200.500.625.500.500\n\"Animals, Exotic\",B01.050.050.126\nExotic Pets,B01.050.050.126\nPaliperidone Palmitate,D03.383.129.385.650\nPaliperidone Palmitate,D03.383.742.592\nPaliperidone,D03.383.129.385.650\nPaliperidone,D03.383.742.592\nInvega,D03.383.129.385.650\nInvega,D03.383.742.592\nInvega Sustenna,D03.383.129.385.650\nInvega Sustenna,D03.383.742.592\nR 76477,D03.383.129.385.650\nR 76477,D03.383.742.592\nImmunosenescence,G07.345.124.390\nImmunosenescence,G12.460.500\nCanagliflozin,D02.886.778.075\nCanagliflozin,D03.383.903.075\nCanagliflozin,D09.408.348.113\nInvokana,D02.886.778.075\nInvokana,D03.383.903.075\nInvokana,D09.408.348.113\nCanagliflozin Hemihydrate,D02.886.778.075\nCanagliflozin Hemihydrate,D03.383.903.075\nCanagliflozin Hemihydrate,D09.408.348.113\n\"Canagliflozin, Anhydrous\",D02.886.778.075\n\"Canagliflozin, Anhydrous\",D03.383.903.075\n\"Canagliflozin, Anhydrous\",D09.408.348.113\nIridescence,G01.590.310\nOpalescence,G01.590.310\nRaltegravir Potassium,D03.383.773.812.752\nRaltegravir,D03.383.773.812.752\nMK 0518,D03.383.773.812.752\nIsentress\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#looking at the data more clearly\n",
    "for line in dbutils.fs.head(\"/FileStore/tables/mesh.csv\").splitlines():\n",
    "    print(line)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "a976ae1c-c9d4-4e35-bb3c-2f0c54ac1b96",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+----------+-------------------+\n",
       "|      term|               tree|\n",
       "+----------+-------------------+\n",
       "|Calcimycin|D03.633.100.221.173|\n",
       "|   A-23187|D03.633.100.221.173|\n",
       "|   Temefos|D02.705.400.625.800|\n",
       "|   Temefos|D02.705.539.345.800|\n",
       "|   Temefos|D02.886.300.692.800|\n",
       "|     Abate|D02.705.400.625.800|\n",
       "|     Abate|D02.705.539.345.800|\n",
       "|     Abate|D02.886.300.692.800|\n",
       "|     Difos|D02.705.400.625.800|\n",
       "|     Difos|D02.705.539.345.800|\n",
       "+----------+-------------------+\n",
       "only showing top 10 rows\n",
       "\n",
       "root\n",
       " |-- term: string (nullable = true)\n",
       " |-- tree: string (nullable = true)\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+----------+-------------------+\n|      term|               tree|\n+----------+-------------------+\n|Calcimycin|D03.633.100.221.173|\n|   A-23187|D03.633.100.221.173|\n|   Temefos|D02.705.400.625.800|\n|   Temefos|D02.705.539.345.800|\n|   Temefos|D02.886.300.692.800|\n|     Abate|D02.705.400.625.800|\n|     Abate|D02.705.539.345.800|\n|     Abate|D02.886.300.692.800|\n|     Difos|D02.705.400.625.800|\n|     Difos|D02.705.539.345.800|\n+----------+-------------------+\nonly showing top 10 rows\n\nroot\n |-- term: string (nullable = true)\n |-- tree: string (nullable = true)\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# reading the mesh data into a dataframe and checking to see if it was read in correctly\n",
    "mesh_df = spark.read.option(\"delimiter\", \",\").csv( \"/FileStore/tables/mesh.csv\", header = True , inferSchema = True)\n",
    "mesh_df.show(10)\n",
    "mesh_df.printSchema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "30dfce7f-ef9e-416d-97be-3cf468e55f3c",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+--------------------+----+\n",
       "|                term|                tree|root|\n",
       "+--------------------+--------------------+----+\n",
       "|          Calcimycin| D03.633.100.221.173| D03|\n",
       "|             A-23187| D03.633.100.221.173| D03|\n",
       "|             Temefos| D02.705.400.625.800| D02|\n",
       "|             Temefos| D02.705.539.345.800| D02|\n",
       "|             Temefos| D02.886.300.692.800| D02|\n",
       "|               Abate| D02.705.400.625.800| D02|\n",
       "|               Abate| D02.705.539.345.800| D02|\n",
       "|               Abate| D02.886.300.692.800| D02|\n",
       "|               Difos| D02.705.400.625.800| D02|\n",
       "|               Difos| D02.705.539.345.800| D02|\n",
       "|               Difos| D02.886.300.692.800| D02|\n",
       "|           Abattoirs|J01.576.423.200.7...| J01|\n",
       "|           Abattoirs|         J03.540.020| J03|\n",
       "|Abbreviations as ...|L01.559.598.400.5...| L01|\n",
       "|   Acronyms as Topic|L01.559.598.400.5...| L01|\n",
       "|             Abdomen|         A01.923.047| A01|\n",
       "|      Abdomen, Acute|C23.888.592.612.0...| C23|\n",
       "|      Abdomen, Acute| C23.888.821.030.249| C23|\n",
       "|  Abdominal Injuries|             C26.017| C26|\n",
       "| Abdominal Neoplasms|         C04.588.033| C04|\n",
       "+--------------------+--------------------+----+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+--------------------+----+\n|                term|                tree|root|\n+--------------------+--------------------+----+\n|          Calcimycin| D03.633.100.221.173| D03|\n|             A-23187| D03.633.100.221.173| D03|\n|             Temefos| D02.705.400.625.800| D02|\n|             Temefos| D02.705.539.345.800| D02|\n|             Temefos| D02.886.300.692.800| D02|\n|               Abate| D02.705.400.625.800| D02|\n|               Abate| D02.705.539.345.800| D02|\n|               Abate| D02.886.300.692.800| D02|\n|               Difos| D02.705.400.625.800| D02|\n|               Difos| D02.705.539.345.800| D02|\n|               Difos| D02.886.300.692.800| D02|\n|           Abattoirs|J01.576.423.200.7...| J01|\n|           Abattoirs|         J03.540.020| J03|\n|Abbreviations as ...|L01.559.598.400.5...| L01|\n|   Acronyms as Topic|L01.559.598.400.5...| L01|\n|             Abdomen|         A01.923.047| A01|\n|      Abdomen, Acute|C23.888.592.612.0...| C23|\n|      Abdomen, Acute| C23.888.821.030.249| C23|\n|  Abdominal Injuries|             C26.017| C26|\n| Abdominal Neoplasms|         C04.588.033| C04|\n+--------------------+--------------------+----+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#extracting the root from the tree using substring to create root column\n",
    "meshrootDF = mesh_df.withColumn(\"root\", mesh_df.tree.substr(1,3))\n",
    "meshrootDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "bf6ba582-8497-4ed8-84b0-af36a4119de0",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+----+\n",
       "|                term|root|\n",
       "+--------------------+----+\n",
       "|          Calcimycin| D03|\n",
       "|             A-23187| D03|\n",
       "|             Temefos| D02|\n",
       "|             Temefos| D02|\n",
       "|             Temefos| D02|\n",
       "|               Abate| D02|\n",
       "|               Abate| D02|\n",
       "|               Abate| D02|\n",
       "|               Difos| D02|\n",
       "|               Difos| D02|\n",
       "|               Difos| D02|\n",
       "|           Abattoirs| J01|\n",
       "|           Abattoirs| J03|\n",
       "|Abbreviations as ...| L01|\n",
       "|   Acronyms as Topic| L01|\n",
       "|             Abdomen| A01|\n",
       "|      Abdomen, Acute| C23|\n",
       "|      Abdomen, Acute| C23|\n",
       "|  Abdominal Injuries| C26|\n",
       "| Abdominal Neoplasms| C04|\n",
       "+--------------------+----+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+----+\n|                term|root|\n+--------------------+----+\n|          Calcimycin| D03|\n|             A-23187| D03|\n|             Temefos| D02|\n|             Temefos| D02|\n|             Temefos| D02|\n|               Abate| D02|\n|               Abate| D02|\n|               Abate| D02|\n|               Difos| D02|\n|               Difos| D02|\n|               Difos| D02|\n|           Abattoirs| J01|\n|           Abattoirs| J03|\n|Abbreviations as ...| L01|\n|   Acronyms as Topic| L01|\n|             Abdomen| A01|\n|      Abdomen, Acute| C23|\n|      Abdomen, Acute| C23|\n|  Abdominal Injuries| C26|\n| Abdominal Neoplasms| C04|\n+--------------------+----+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#creating a dataframe containing the columns needed from the mesh data for problem analysis\n",
    "termrootDF = meshrootDF.select(\"term\" , \"root\")\n",
    "termrootDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "1b3bdc48-cec6-4519-b469-901fdc3bf833",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+\n",
       "|          Conditions|\n",
       "+--------------------+\n",
       "|   Autistic Disorder|\n",
       "|Autism Spectrum D...|\n",
       "|   Diabetes Mellitus|\n",
       "|        Tuberculosis|\n",
       "|       Lung Diseases|\n",
       "|   Pulmonary Disease|\n",
       "|Diverticular Dise...|\n",
       "|        Diverticulum|\n",
       "|      Diverticulosis|\n",
       "|              Asthma|\n",
       "|     Hypoventilation|\n",
       "|            Lymphoma|\n",
       "|            Myositis|\n",
       "|   Diabetes Mellitus|\n",
       "|        Hypertension|\n",
       "|Periodontal Diseases|\n",
       "|   Diabetes Mellitus|\n",
       "|        Appendicitis|\n",
       "|       Stomach Ulcer|\n",
       "| Cholecystolithiasis|\n",
       "+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+\n|          Conditions|\n+--------------------+\n|   Autistic Disorder|\n|Autism Spectrum D...|\n|   Diabetes Mellitus|\n|        Tuberculosis|\n|       Lung Diseases|\n|   Pulmonary Disease|\n|Diverticular Dise...|\n|        Diverticulum|\n|      Diverticulosis|\n|              Asthma|\n|     Hypoventilation|\n|            Lymphoma|\n|            Myositis|\n|   Diabetes Mellitus|\n|        Hypertension|\n|Periodontal Diseases|\n|   Diabetes Mellitus|\n|        Appendicitis|\n|       Stomach Ulcer|\n| Cholecystolithiasis|\n+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#creating a dataframe containing the columns needed from the clinical trial data for problem analysis\n",
    "explodedConditions = explodedDF.select('Conditions')\n",
    "explodedConditions.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "4d8833d4-2a3d-4270-8059-46a964a8a38e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+--------------------+----+\n",
       "|          Conditions|                term|root|\n",
       "+--------------------+--------------------+----+\n",
       "|   Autistic Disorder|   Autistic Disorder| F03|\n",
       "|Autism Spectrum D...|Autism Spectrum D...| F03|\n",
       "|   Diabetes Mellitus|   Diabetes Mellitus| C19|\n",
       "|   Diabetes Mellitus|   Diabetes Mellitus| C18|\n",
       "|        Tuberculosis|        Tuberculosis| C01|\n",
       "|       Lung Diseases|       Lung Diseases| C08|\n",
       "|Diverticular Dise...|Diverticular Dise...| C06|\n",
       "|        Diverticulum|        Diverticulum| C23|\n",
       "|        Diverticulum|        Diverticulum| C06|\n",
       "|      Diverticulosis|      Diverticulosis| C23|\n",
       "|      Diverticulosis|      Diverticulosis| C06|\n",
       "|              Asthma|              Asthma| C20|\n",
       "|              Asthma|              Asthma| C08|\n",
       "|              Asthma|              Asthma| C08|\n",
       "|              Asthma|              Asthma| C08|\n",
       "|     Hypoventilation|     Hypoventilation| C23|\n",
       "|     Hypoventilation|     Hypoventilation| C08|\n",
       "|            Lymphoma|            Lymphoma| C20|\n",
       "|            Lymphoma|            Lymphoma| C15|\n",
       "|            Lymphoma|            Lymphoma| C04|\n",
       "+--------------------+--------------------+----+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+--------------------+----+\n|          Conditions|                term|root|\n+--------------------+--------------------+----+\n|   Autistic Disorder|   Autistic Disorder| F03|\n|Autism Spectrum D...|Autism Spectrum D...| F03|\n|   Diabetes Mellitus|   Diabetes Mellitus| C19|\n|   Diabetes Mellitus|   Diabetes Mellitus| C18|\n|        Tuberculosis|        Tuberculosis| C01|\n|       Lung Diseases|       Lung Diseases| C08|\n|Diverticular Dise...|Diverticular Dise...| C06|\n|        Diverticulum|        Diverticulum| C23|\n|        Diverticulum|        Diverticulum| C06|\n|      Diverticulosis|      Diverticulosis| C23|\n|      Diverticulosis|      Diverticulosis| C06|\n|              Asthma|              Asthma| C20|\n|              Asthma|              Asthma| C08|\n|              Asthma|              Asthma| C08|\n|              Asthma|              Asthma| C08|\n|     Hypoventilation|     Hypoventilation| C23|\n|     Hypoventilation|     Hypoventilation| C08|\n|            Lymphoma|            Lymphoma| C20|\n|            Lymphoma|            Lymphoma| C15|\n|            Lymphoma|            Lymphoma| C04|\n+--------------------+--------------------+----+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Joining the two dataframes using inner join\n",
    "joinedDF = explodedConditions.join(termrootDF,explodedConditions.Conditions == termrootDF.term)\n",
    "joinedDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "657d3c87-dcd1-46be-ab46-58179bec62be",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+----+------+\n",
       "|root| count|\n",
       "+----+------+\n",
       "| C04|143994|\n",
       "| C23|136079|\n",
       "| C01|106674|\n",
       "| C14| 94523|\n",
       "| C10| 92310|\n",
       "+----+------+\n",
       "only showing top 5 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+----+------+\n|root| count|\n+----+------+\n| C04|143994|\n| C23|136079|\n| C01|106674|\n| C14| 94523|\n| C10| 92310|\n+----+------+\nonly showing top 5 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Grouping by the root column, counting and sorting \n",
    "frequentroots = joinedDF.groupBy('root').count().sort('count', ascending=False)\n",
    "frequentroots.show(5)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "8131996c-fca6-476a-9de4-e44bdae3cdfb",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Problem Statement 5 - Ten most common sponsors that are not pharmacetical companies"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "0ead3f35-74bf-45da-9f87-6c9cd316b2df",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "####Loading the Pharma Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "94eaa0ac-e79a-4304-b979-331a30712cec",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Truncated to first 65536 bytes]\n",
       "Out[23]: '\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech\n",
       "\n",
       "*** WARNING: max output size exceeded, skipping output. ***\n",
       "\n",
       "$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon\\'s illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company\\'s industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo\\'s marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage\\'s corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company\\'s drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex\\'s conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company\\'s guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi\\'s acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to'"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "[Truncated to first 65536 bytes]\nOut[23]: '\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company\\'s carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP\\'s executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company\\'s unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children\\'s liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen\\'s Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation\\'s Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services\\' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company\\'s alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon\\'s illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company\\'s industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo\\'s marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage\\'s corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company\\'s drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex\\'s conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company\\'s guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi\\'s acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to'",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#checking the head of the file \n",
    "dbutils.fs.head(\"/FileStore/tables/pharma.csv\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "546451f1-4c38-4259-bc89-293d429f2db4",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "[Truncated to first 65536 bytes]\n",
       "\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\n",
       "\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\n",
       "\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\n",
       "\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\n",
       "\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n",
       "\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\n",
       "\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\n",
       "\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\n",
       "\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\n",
       "\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\n",
       "\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n",
       "\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company's unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\n",
       "\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\n",
       "\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\n",
       "\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children's liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\n",
       "\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n",
       "\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\n",
       "\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen's Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\n",
       "\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\n",
       "\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\n",
       "\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\n",
       "\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation's Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\n",
       "\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\n",
       "\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\n",
       "\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\n",
       "\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\n",
       "\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\n",
       "\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\n",
       "\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\n",
       "\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company's alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\n",
       "\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech company and three former executives for misleadi\n",
       "\n",
       "*** WARNING: max output size exceeded, skipping output. ***\n",
       "\n",
       " Inc.\",\"Teva Pharmaceutical Industries\",\"$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon's illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\n",
       "\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\n",
       "\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\n",
       "\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\n",
       "\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\n",
       "\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\n",
       "\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\n",
       "\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\n",
       "\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\n",
       "\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\n",
       "\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\n",
       "\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\n",
       "\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\n",
       "\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\n",
       "\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\n",
       "\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\n",
       "\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\n",
       "\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\n",
       "\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\n",
       "\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\n",
       "\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company's industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\n",
       "\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\n",
       "\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo's marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\n",
       "\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage's corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\n",
       "\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\n",
       "\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex's conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\n",
       "\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n",
       "\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\n",
       "\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company's guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\n",
       "\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\n",
       "\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\n",
       "\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\n",
       "\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\n",
       "\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi's acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "[Truncated to first 65536 bytes]\n\"Company\",\"Parent_Company\",\"Penalty_Amount\",\"Subtraction_From_Penalty\",\"Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting\",\"Penalty_Year\",\"Penalty_Date\",\"Offense_Group\",\"Primary_Offense\",\"Secondary_Offense\",\"Description\",\"Level_of_Government\",\"Action_Type\",\"Agency\",\"Civil/Criminal\",\"Prosecution_Agreement\",\"Court\",\"Case_ID\",\"Private_Litigation_Case_Title\",\"Lawsuit_Resolution\",\"Facility_State\",\"City\",\"Address\",\"Zip\",\"NAICS_Code\",\"NAICS_Translation\",\"HQ_Country_of_Parent\",\"HQ_State_of_Parent\",\"Ownership_Structure\",\"Parent_Company_Stock_Ticker\",\"Major_Industry_of_Parent\",\"Specific_Industry_of_Parent\",\"Info_Source\",\"Notes\"\n\"Abbott Laboratories\",\"Abbott Laboratories\",\"$5,475,000\",\"$0\",\"$5,475,000\",\"2013\",\"20131227\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Abbott Laboratories agreed to $5.475 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce doctors to implant the company's carotid, biliary and peripheral vascular products.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/abbott-laboratories-pays-us-5475-million-settle-claims-company-paid-kickbacks-physicians\",\"\"\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$1,500,000,000\",\"$0\",\"$1,500,000,000\",\"2012\",\"20120507\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Global Health Care Company Abbott Laboratories Inc. has pleaded guilty and agreed to pay $1.5 billion to resolve its criminal and civil liability arising from the company's unlawful promotion of the prescription drug Depakote for uses not approved as safe and effective by the Food and Drug Administration. The resolution - the second largest payment by a drug company - includes a criminal fine and forfeiture totaling $700 million and civil settlements with the federal government and the states totaling $800 million. Abbott also will be subject to court-supervised probation and reporting obligations for Abbotts CEO and Board of Directors.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/abbott-labs-pay-15-billion-resolve-criminal-civil-investigations-label-promotion-depakote\",\"\"\n\"Abbott Laboratories Inc.\",\"AbbVie\",\"$126,500,000\",\"$0\",\"$126,500,000\",\"2010\",\"20101207\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Abbott Laboratories Inc., B. Braun Medical Inc. and Roxane Laboratories Inc. n/k/a Boehringer Ingelheim Roxane Inc. and affiliated entities agreed to pay $421 million to settle False Claims Act allegations, that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products knowing that federal healthcare programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturers-pay-4212-million-settle-false-claims-act-cases\",\"\"\n\"Abbott Laboratories Puerto Rico, Inc.\",\"Abbott Laboratories\",\"$49,045\",\"$0\",\"$49,045\",\"2009\",\"20090305\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1527129\",\"\",\"\",\"Puerto Rico\",\"San Juan\",\"\",\"\",\"423450\",\"423450: Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Acclarent Inc.\",\"Johnson & Johnson\",\"$18,000,000\",\"$0\",\"$18,000,000\",\"2016\",\"20160722\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"California-based medical device manufacturer Acclarent Inc., a subsidiary of Johnson & Johnson, agreed to pay $18 million to resolve allegations that the company caused health care providers to submit false claims to Medicare and other federal health care programs by marketing and distributing its sinus spacer product for use as a drug delivery device without Food and Drug Administration approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/johnson-johnson-subsidiary-acclarent-inc-pays-government-18-million-settle-false-claims-act\",\"\"\n\"Advanced Medical Optics\",\"Abbott Laboratories\",\"$16,800\",\"$0\",\"$16,800\",\"2004\",\"20040412\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"21-CA-36104-001\",\"\",\"\",\"California\",\"Irvine\",\"\",\"92606\",\"333314\",\"333314: Optical Instrument and Lens Manufacturing\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\n\"Advanced Neuromodulation Systems, Inc.\",\"Abbott Laboratories\",\"$2,950,000\",\"$0\",\"$2,950,000\",\"2007\",\"20070702\",\"healthcare-related offenses\",\"HHS civil monetary penalties\",\"kickbacks and bribery\",\"The HHS Inspector General announced that Advanced Neuromodulation Systems, Inc.,  a medical device manufacturer specializing in spinal cord stimulation used for pain management, agreed to pay $2.95 million to settle allegations that it paid kickbacks to physicians in violation of the Civil Monetary Penalties Law (CMPL). The company also entered into a 3-year Corporate Integrity Agreement.\",\"federal\",\"agency action\",\"Health & Human Services Department Office of Inspector General\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://oig.hhs.gov/publications/docs/press/2007/ANS%20Press%20Release.pdf\",\"\"\n\"Advanced Sterilization Products\",\"Johnson & Johnson\",\"$136,800\",\"$0\",\"$136,800\",\"2014\",\"20140520\",\"environment-related offenses\",\"environmental violation\",\"\",\"The U.S. Environmental Protection Agency announced that an Irvine, Calif. company, Advanced Sterilization Products, has agreed to pay a $136,800 penalty for the sale and distribution of unregistered and misbranded pesticides to veterinary clinics and laboratories nationwide.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/8e820317c86e4c5685257cde00717855.html\",\"\"\n\"Advanced Sterilization Products, a division of Ethicon Inc.\",\"Johnson & Johnson\",\"$1,200,000\",\"$0\",\"$1,200,000\",\"2013\",\"20131204\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Settlement of a civil money penalty action against Advanced Sterilization Products, a division of Ethicon Inc., a Johnson & Johnson company, and two of ASP's executives alleging that ASP manufactured and distributed adulterated and misbranded sterilization monitoring products.\",\"federal\",\"agency action\",\"Food and Drug Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"California\",\"Irvine\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"JNJ\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm377588.htm\",\"\"\n\"Alere San Diego Inc.\",\"Abbott Laboratories\",\"$10,572\",\"$0\",\"$10,572\",\"2017\",\"20170309\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1813371\",\"\",\"\",\"California\",\"Pomona\",\"828 Towne Center Dr.\",\"91767\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABT\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Allergan Inc.\",\"AbbVie\",\"$600,000,000\",\"$0\",\"$600,000,000\",\"2010\",\"20100901\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"American pharmaceutical manufacturer Allergan Inc. has agreed to plead guilty and pay $600 million to resolve its criminal and civil liability arising from the company's unlawful promotion of its biological product, Botox Therapeutic, for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a criminal fine and forfeiture totaling $375 million and a civil settlement with the federal government and the states of $225 million.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/allergan-agrees-plead-guilty-and-pay-600-million-resolve-allegations-label-promotion-botox\",\"\"\n\"Allergan Inc.\",\"AbbVie\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2017\",\"20170117\",\"financial offenses\",\"investor protection violation\",\"\",\"Allergan Inc. admitted securities law violations and agreed to pay a $15 million penalty for disclosure failures in the wake of a hostile takeover bid.\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/news/pressrelease/2017-16.html\",\"\"\n\"Alpharma Inc.\",\"Pfizer\",\"$42,500,000\",\"$0\",\"$42,500,000\",\"2010\",\"20100316\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Alpharma Inc. agreed to pay $42.5 million to resolve False Claims Act allegations in connection with the marketing of the morphine-based drug Kadian. The settlement resolved allegations that between January 1, 2000 and December 29, 2008 Alpharma paid health care providers to induce them to promote or prescribe Kadian, and made misrepresentations about the safety and efficacy of the drug. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/alpharma-pay-425-million-resolve-false-claims-act-allegations-connection-promotion-drug\",\"\"\n\"Alpharma, Inc.\",\"Pfizer\",\"$2,500,000\",\"$0\",\"$2,500,000\",\"2004\",\"20040812\",\"competition-related offenses\",\"price-fixing or anti-competitive practices\",\"consumer protection violation\",\"Generic drug manufacturers Alpharma Inc. and Perrigo Company agreed to give up a total of $6.25 million in illegal profits to settle Federal Trade Commission allegations that their agreement to limit competition for over-the-counter store-brand children's liquid ibuprofen drove up prices and violated federal law.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"PFE\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2004/08/generic-drug-marketers-settle-ftc-charges\",\"\"\n\"American Pharmaceutical Partners, Inc.\",\"Bristol-Myers Squibb\",\"$160,203\",\"$0\",\"$160,203\",\"2004\",\"20041226\",\"employment-related offenses\",\"wage and hour violation\",\"Fair Labor Standards Act\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1379241\",\"\",\"\",\"New York\",\"Grand Island\",\"\",\"14072\",\"32541\",\"32541: Pharmaceutical and Medicine Manufacturing\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"March 7, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Amgen Inc.\",\"Amgen\",\"$762,000,000\",\"$0\",\"$762,000,000\",\"2012\",\"20121219\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"U.S. District Judge Sterling Johnson, Jr. accepted a guilty plea by American biotechnology giant Amgen Inc. for illegally introducing a misbranded drug into interstate commerce. The plea is part of a global settlement with the United States in which Amgen agreed to pay $762 million to resolve criminal and civil liability arising from its sale and promotion of certain drugs.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/amgen-inc-pleads-guilty-federal-charge-brooklyn-ny-pays-762-million-resolve-criminal\",\"\"\n\"Amgen Inc.\",\"Amgen\",\"$24,900,000\",\"$0\",\"$24,900,000\",\"2013\",\"20130416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Amgen Inc. agreed to pay the United States $24.9 million to settle allegations that it violated the False Claims Act. The company was accused of paying kickbacks  to long-term care pharmacy providers Omnicare Inc., PharMerica Corporation and Kindred Healthcare Inc. in return for implementing \"\"therapeutic interchange\"\" programs that were designed to switch Medicare and Medicaid beneficiaries from a competitor drug to Amgen's Aranesp.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/amgen-pay-us-249-million-resolve-false-claims-act-allegations\",\"\"\n\"Amgen, Inc.\",\"Amgen\",\"$40,000\",\"$0\",\"$40,000\",\"2011\",\"20110302\",\"employment-related offenses\",\"labor relations violation\",\"\",\"back pay award in unfair labor practices case\",\"federal\",\"agency action\",\"National Labor Relations Board\",\"civil\",\"\",\"\",\"14-CA-30273-001\",\"\",\"\",\"Missouri\",\"St. Louis\",\"\",\"63130\",\"541720\",\"541720: Research and Development in the Social Sciences and Humanities\",\"USA\",\"California\",\"publicly traded\",\"AMGN\",\"pharmaceuticals\",\"pharmaceuticals\",\"Extracted from an NLRB dataset covering 1999-2011 downloaded at https://catalog.data.gov/dataset/nlrb-cats-final-c-case-data-bulk-19990101-20110930-in-xml\",\"\"\n\"Amneal Pharmaceuticals of NY, LLC\",\"Amneal Pharmaceuticals\",\"$99,000\",\"$0\",\"$99,000\",\"2015\",\"20150930\",\"employment-related offenses\",\"employment discrimination\",\"\",\"\",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"AMRX\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/ofccp/foia/files/AmnealPharmaceuticalsCA_Redacted.pdf\",\"\"\n\"Astellas Pharma US Inc.\",\"Astellas Pharma\",\"$7,300,000\",\"$0\",\"$7,300,000\",\"2014\",\"20140416\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"off-label or unapproved promotion of medical products\",\"Astellas Pharma US Inc. agreed to pay $7.3 million to resolve allegations that it violated the False Claims Act in connection with its marketing and promotion of the drug Mycamine for pediatric use, which had not received FDA approval.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astellas-pharma-us-inc-pay-73-million-resolve-false-claims-act-allegations-relating-marketing\",\"\"\n\"AstraZeneca\",\"AstraZeneca\",\"$250,000\",\"$0\",\"$250,000\",\"2011\",\"20110606\",\"employment-related offenses\",\"employment discrimination\",\"\",\"AstraZeneca agreed to pay $250,000 to 124 women who allegedly were subjected to pay discrimination while working at the corporation's Philadelphia Business Center in Wayne, Pa. The action resolved a lawsuit filed by the U.S. Department of Labor in May 2010 alleging that the company discriminated against female sales specialists by paying them salaries that were, on average, $1,700 less than their male counterparts. \",\"federal\",\"agency action\",\"Office of Federal Contract Compliance Programs\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"Wayne\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.dol.gov/opa/media/press/ofccp/OFCCP20110829.htm\",\"\"\n\"AstraZeneca LP\",\"AstraZeneca\",\"$520,000,000\",\"$0\",\"$520,000,000\",\"2010\",\"20100427\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"AstraZeneca LP and AstraZeneca Pharmaceuticals LP will pay $520 million to resolve allegations that AstraZeneca illegally marketed the anti-psychotic drug Seroquel for uses not approved as safe and effective by the Food and Drug Administration, the Departments of Justice and Health and Human Services' Health Care Fraud Enforcement Action Team.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-giant-astrazeneca-pay-520-million-label-drug-marketing\",\"\"\n\"AstraZeneca LP\",\"AstraZeneca\",\"$46,500,000\",\"$0\",\"$46,500,000\",\"2015\",\"20150706\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca LP agreed to pay the United States and participating states a total of $46.5 million, plus interest, to resolve allegations that it knowingly underpaid rebates owed under the Medicaid Drug Rebate Program.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-and-cephalon-pay-465-million-and-75-million-respectively-allegedly-underpaying\",\"\"\n\"AstraZeneca LP\",\"AstraZeneca\",\"$7,900,000\",\"$0\",\"$7,900,000\",\"2015\",\"20150211\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"AstraZeneca LP, a pharmaceutical manufacturer based in Delaware, agreed to pay the government $7.9 million to settle allegations that it engaged in a kickback scheme in violation of the False Claims Act.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/astrazeneca-pay-79-million-resolve-kickback-allegations\",\"\"\n\"AstraZeneca Pharmaceuticals\",\"AstraZeneca\",\"$2,600,000\",\"$0\",\"$2,600,000\",\"2009\",\"20091019\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Mylan Pharmaceuticals, UDL Laboratories, AstraZeneca Pharmaceuticals and Ortho McNeil Pharmaceutical entered into settlement agreements for a total of $124 million to resolve claims that they violated the False Claims Act by failing to pay appropriate rebates to state Medicaid programs for drugs paid for by those programs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid\",\"\"\n\"AstraZeneca Pharmaceuticals LP\",\"AstraZeneca\",\"$354,900,000\",\"$0\",\"$354,900,000\",\"2003\",\"20030620\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"AstraZeneca Pharmaceuticals LP pleaded guilty in federal district court in Wilmington, Delaware and agreed to pay $354.9 million to resolve criminal charges and civil liabilities in connection with its drug pricing and marketing practices with regard to Zoladex, a drug used primarily for the treatment of prostate cancer. AstraZeneca agreed to pay a criminal fine of $63.9 million as part of pleaded guilty to conspiring to violate the Prescription Drug Marketing Act by causing to be submitted claims for payment for the prescription of Zoladex which had been provided as free samples to urologists. AstraZeneca agreed to settle its federal civil False Claim Act liabilities and to pay the U.S. government $266.1 million to resolve allegations it caused false and fraudulent claims to be filed with the Medicare; another $24.9 million was to be paid to states to resolve similar claims concerning Medicaid.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_371.htm\",\"\"\n\"AstraZeneca PLC\",\"AstraZeneca\",\"$5,522,000\",\"$0\",\"$5,522,000\",\"2016\",\"20160830\",\"competition-related offenses\",\"kickbacks and bribery\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"United Kingdom\",\"\",\"publicly traded\",\"LSE: AZN\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2016/34-78730.pdf\",\"\"\n\"Aventis Pharmaceutical Inc.\",\"Sanofi\",\"$95,500,000\",\"$0\",\"$95,500,000\",\"2009\",\"20090528\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Aventis Pharmaceutical Inc. agreed to pay the United States $95.5 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/aventis-pharmaceutical-pay-us-955-million-settle-false-claims-act-allegations\",\"\"\n\"Aventis Pharmaceuticals Inc.\",\"Sanofi\",\"$190,000,000\",\"$0\",\"$190,000,000\",\"2007\",\"20070910\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Aventis Pharmaceuticals Inc. paid the United States and a number of states, as well as the District of Columbia, over $190 million to resolve allegations that the company caused false claims to be filed with Medicare and other federal health programs as a result of the company's alleged fraudulent pricing and marketing of drugs. Aventis, which changed its name to Sanofi-Aventis,  agreed to settle False Claims Act allegations concerning its pricing and marketing of Anzemet, an antiemetic drug used primarily in conjunction with oncology and radiation treatment to prevent nausea and vomiting. \",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2007/September/07_civ_694.html\",\"\"\n\"AVEO Pharmaceuticals Inc.\",\"AVEO Pharmaceuticals\",\"$4,000,000\",\"$0\",\"$4,000,000\",\"2016\",\"20160329\",\"financial offenses\",\"investor protection violation\",\"\",\"The SEC announced fraud charges against a Massachusetts-based biotech company and three former executives for misleadi\n\n*** WARNING: max output size exceeded, skipping output. ***\n\n Inc.\",\"Teva Pharmaceutical Industries\",\"$1,200,000,000\",\"$0\",\"$1,200,000,000\",\"2015\",\"20150528\",\"consumer-protection-related offenses\",\"consumer protection violation\",\"price-fixing or anti-competitive practices\",\"The Federal Trade Commission reached a settlement resolving a suit accusing Cephalon, Inc. of illegally blocking generic competition to its blockbuster sleep-disorder drug Provigil. The settlement ensures that Teva Pharmaceutical Industries, Ltd., which acquired Cephalon in 2012, will make a total of $1.2 billion available to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid because of Cephalon's illegal conduct.\",\"federal\",\"agency action\",\"Federal Trade Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Israel\",\"\",\"publicly traded\",\"TEVA\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.ftc.gov/news-events/press-releases/2015/05/ftc-settlement-cephalon-pay-delay-case-ensures-12-billion-ill\",\"\"\n\"CHEROKEE PHARMACEUTICALS LLC\",\"Merck\",\"$10,001\",\"$0\",\"$10,001\",\"2011\",\"20110613\",\"employment-related offenses\",\"benefit plan administrator violation\",\"\",\"Deficient Filer\",\"federal\",\"agency action\",\"Employee Benefits Security Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Pennsylvania\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"MRK\",\"pharmaceuticals\",\"pharmaceuticals\",\"Included in a dataset downloaded at https://enforcedata.dol.gov/views/data_summary.php\",\"Company is plan administrator. Penalty amount reported in range of $10,001 to $50,000. \"\n\"Chiron Corporation Ltd\",\"Novartis\",\"$168,500\",\"$0\",\"$168,500\",\"2004\",\"20040604\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/06042004.pdf\",\"\"\n\"Cypress Pharmaceutical Inc.\",\"Currax Pharmaceuticals\",\"$2,800,000\",\"$0\",\"$2,800,000\",\"2012\",\"20120328\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Mississippi-based Cypress Pharmaceutical Inc., its subsidiary Hawthorn Pharmaceuticals Inc. and its CEO, Max Draughn, have agreed to pay $2.8 million to resolve civil allegations under the False Claims Act, the Justice Department announced. The government alleged that between 2003 and 2009, Cypress, Hawthorn and Draughn were responsible for marketing three pharmaceutical products that were not approved as safe and effective by the Food and Drug Administration (FDA). The products were Hylira, a gel used for the treatment of dry skin, Zaclir, an acne treatment and Zacare, another acne treatment.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/mississippi-pharmaceutical-firm-and-ceo-pay-28-million-resolve-allegations-illegal-marketing\",\"\"\n\"Daiichi Sankyo Inc.\",\"Daiichi Sankyo\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20150109\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Daiichi Sankyo Inc., a global pharmaceutical company with its U.S. headquarters in New Jersey, agreed to pay the United States and state Medicaid programs $39 million to resolve allegations that it violated the False Claims Act by paying kickbacks to induce physicians to prescribe Daiichi drugs.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/daiichi-sankyo-inc-agrees-pay-39-million-settle-kickback-allegations-under-false-claims-act\",\"\"\n\"Dava Pharmaceuticals Inc.\",\"Endo International\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2012\",\"20120208\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dava Pharmaceuticals Inc. agreed to pay the United States $11 million to settle allegations that it violated the False Claims Act by misreporting drug prices in order to reduce its Medicaid Drug Rebate obligations.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/dava-pharmaceuticals-pay-us-11-million-settle-false-claims-act-allegations\",\"\"\n\"Dey Inc.\",\"Viatris\",\"$280,000,000\",\"$0\",\"$280,000,000\",\"2010\",\"20101220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Dey Inc., Dey Pharma L.P. and Dey L.P. Inc. agreed to pay $280 million to settle False Claims Act allegations that they engaged in a scheme to report false and inflated prices for numerous pharmaceutical products, knowing that federal health care programs relied on those reported prices to set payment rates.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-manufacturer-pay-280-million-settle-false-claims-act-case\",\"\"\n\"Dey, Inc.\",\"Viatris\",\"$18,500,000\",\"$0\",\"$18,500,000\",\"2003\",\"20030611\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"fraud\",\"Dey, Inc., a manufacturer of prescription drugs for the treatment of allergies and respiratory diseases, agreed to pay the United States and the state of Texas $18.5 million to settle allegations of health care fraud.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Pennsylvania\",\"publicly traded\",\"VTRS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2003/June/03_civ_350.htm\",\"\"\n\"DuPont Pharmaceuticals Company\",\"Bristol-Myers Squibb\",\"$6,600\",\"$0\",\"$6,600\",\"2004\",\"20040806\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"BMY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/08062004.pdf\",\"\"\n\"Eisai Inc.\",\"Eisai\",\"$11,000,000\",\"$0\",\"$11,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Japan\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\n\"Elan Pharmaceuticals Inc.\",\"Perrigo\",\"$31,000\",\"$0\",\"$31,000\",\"2005\",\"20050620\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"FOIA204\",\"Source document obtained through a Freedom of Information Act request to the agency.\"\n\"Elan Corporation PLC\",\"Perrigo\",\"$203,000,000\",\"$0\",\"$203,000,000\",\"2010\",\"20101215\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Irish pharmaceutical manufacturer Elan Corporation PLC and its U.S. subsidiary Elan Pharmaceuticals Inc. agreed to pay more than $203 million to resolve criminal and civil liability arising from the illegal promotion of the epilepsy drug Zonegran. In a separate civil settlement, Japanese drug marketer Eisai Inc., which purchased the drug from Elan, will pay $11 million to resolve civil liability for off-label marketing of Zonegran.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/pharmaceutical-companies-pay-2145-million-resolve-allegations-label-promotion-zonegran\",\"\"\n\"Elan Corporation, plc\",\"Perrigo\",\"$15,000,000\",\"$0\",\"$15,000,000\",\"2005\",\"20050208\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"PRGO\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/litreleases/lr19066.htm\",\"\"\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$1,415,000,000\",\"$0\",\"$1,415,000,000\",\"2009\",\"20090115\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration. This resolution included a criminal fine of $515 million, the forfeiture of $100 million in assets, and up to $800 million in a civil settlement with the federal government and the states.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eli-lilly-and-company-agrees-pay-1415-billion-resolve-allegations-label-promotion-zyprexa\",\"\"\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$36,000,000\",\"$0\",\"$36,000,000\",\"2005\",\"20051221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Eli Lilly and Company agreed to plead guilty and to pay $36 million in connection with its illegal promotion of its pharmaceutical drug Evista.\",\"federal\",\"agency action\",\"Justice Department Criminal Division\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/archive/opa/pr/2005/December/05_civ_685.html\",\"\"\n\"Eli Lilly and Company\",\"Eli Lilly\",\"$29,398,734\",\"$0\",\"$29,398,734\",\"2012\",\"20121220\",\"competition-related offenses\",\"Foreign Corrupt Practices Act\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Indiana\",\"publicly traded\",\"LLY\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/News/PressRelease/Detail/PressRelease/1365171487116\",\"\"\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$13,170\",\"$0\",\"$13,170\",\"2004\",\"20041229\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2004-0250-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2005-pdf\",\"\"\n\"EMD CHEMICALS INCORPORATED\",\"Merck KGaA (EMD)\",\"$7,614\",\"$0\",\"$7,614\",\"2006\",\"20060523\",\"safety-related offenses\",\"motor vehicle safety violation\",\"\",\"OH-2006-0107-US0482\",\"federal\",\"agency action\",\"Federal Motor Carrier Safety Administration\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Ohio\",\"CINCINNATI\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.fmcsa.dot.gov/regulations/enforcement/national-listing-enforcement-cases-subject-name-closed-fiscal-year-2006-pdf\",\"Year is fiscal year. Date is closing date.\"\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$8,250\",\"$0\",\"$8,250\",\"2007\",\"20070202\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/02022007.pdf\",\"\"\n\"EMD Chemicals, Inc.\",\"Merck KGaA (EMD)\",\"$44,000\",\"$0\",\"$44,000\",\"2007\",\"20070309\",\"competition-related offenses\",\"export control violation\",\"\",\"\",\"federal\",\"agency action\",\"Bureau of Industry and Security\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://efoia.bis.doc.gov/index.php/component/docman/?task=doc_download&gid=341&Itemid=\",\"\"\n\"EMD Millipore Corp.\",\"Merck KGaA (EMD)\",\"$385,000\",\"$0\",\"$385,000\",\"2017\",\"20170206\",\"environment-related offenses\",\"environmental violation\",\"\",\"Under the terms of a Consent Decree lodged in federal court, EMD Millipore Corp. of Jaffrey, N.H., agreed to upgrade its on-site wastewater treatment system to comply with the terms of the company's industrial wastewater discharge permit and prevent pretreatment violations of the federal Clean Water Act (CWA). The company also agreed to pay a civil penalty of $385,000 for alleged violations of the CWA.\",\"federal\",\"agency action\",\"Environmental Protection Agency referral to the Justice Department\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"New Hampshire\",\"Jaffrey\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.epa.gov/enforcement/reference-news-release-jaffrey-nh-facility-upgrade-its-wastewater-treatment-systems\",\"\"\n\"EMD Millipore Corporation\",\"Merck KGaA (EMD)\",\"$2,681,500\",\"$0\",\"$2,681,500\",\"2013\",\"20130731\",\"environment-related offenses\",\"environmental violation\",\"\",\"EMD Millipore Corporation, of Billerica, Mass., has agreed to pay $2,681,500 in civil penalties to settle EPA allegations that it violated the federal pesticide law and regulations on numerous instances over many years.\",\"federal\",\"agency action\",\"Environmental Protection Agency\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"Massachusetts\",\"Billerica\",\"\",\"\",\"\",\"\",\"Germany\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://archive.epa.gov/epapages/newsroom_archive/newsreleases/ce0d13ac337fe52685257bb900603f21.html\",\"\"\n\"Endo Health Solutions Inc.\",\"Endo International\",\"$192,700,000\",\"$0\",\"$192,700,000\",\"2014\",\"20140221\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Pharmaceutical company Endo Health Solutions Inc. and its subsidiary Endo Pharmaceuticals Inc. agreed to pay $192.7 million to resolve criminal and civil liability arising from Endo's marketing of the prescription drug Lidoderm for uses not approved as safe and effective by the Food and Drug Administration. The resolution included a deferred prosecution agreement and forfeiture totaling $20.8 million and civil false claims settlements with the federal government and the states and the District of Columbia totaling $171.9 million. \",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"deferred prosecution agreement\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/endo-pharmaceuticals-and-endo-health-solutions-pay-1927-million-resolve-criminal-and-civil\",\"\"\n\"Endo Pharmaceuticals Inc. and Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals\",\"Endo International\",\"$39,000,000\",\"$0\",\"$39,000,000\",\"2015\",\"20151216\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"fraud\",\"The United States Attorney for the Southern District of New York and the Office of Inspector General for the Department of Health and Human Services announced a $39 million settlement against Vintage Pharmaceuticals, LLC d/b/a Qualitest Pharmaceuticals and  Vintage's corporate parent Endo Pharmaceuticals, Inc. in a civil fraud lawsuit.\",\"federal\",\"agency action\",\"U.S. Attorney-Southern District of New York\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Ireland\",\"\",\"publicly traded\",\"ENDP\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/usao-sdny/pr/manhattan-us-attorney-announces-39-million-civil-fraud-settlement-against-qualitest\",\"\"\n\"Eon Labs Inc.\",\"Novartis\",\"$3,500,000\",\"$0\",\"$3,500,000\",\"2010\",\"20100222\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Eon Labs Inc. agreed to pay the United States $3.5 million to resolve False Claims Act allegations relating to the company's drug Nitroglycerin Sustained Release (SR) capsules.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"NYSE: NVS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/eon-labs-pays-us-35-million-settle-allegations-submitting-false-claims-medicaid\",\"\"\n\"Ethex Corporation\",\"KV Pharmaceutical\",\"$27,600,000\",\"$0\",\"$27,600,000\",\"2010\",\"20100302\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Ethex Corporation, a wholly owned subsidiary of St. Louis-based drug manufacturer, KV Pharmaceutical Company, pleaded guilty to two felonies and was sentenced in connection with the manufacturing of oversized prescription drug tablets. The government had charged that, despite having knowledge that the two drugs did not meet required specifications, Ethex violated the law by intentionally withholding this information from the Food and Drug Administration (FDA). Given the seriousness of Ethex's conduct and the risk it posed to consumers of its drugs, the Justice Department pursued felony charges. According to charges presented in U.S. District Court in St. Louis, Ethex failed to submit required \"\"field alert reports\"\" to the FDA in 2008 concerning two drugs, propafenone and dextroamphetamine sulfate.  Following the recommendations of a plea agreement, Judge E. Richard Webber sentenced Ethex to pay a fine of more than $23.4 million, pay approximately $2.3 million in restitution to Medicare and Medicaid for their approximate losses, and forfeit nearly $1.8 million to the United States.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Missouri\",\"out of business\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/kv-pharmaceutical-subsidiary-pleads-guilty-two-felonies-regarding-oversized-drugs\",\"\"\n\"ExecuPharm, Inc.\",\"Parexel International\",\"$5,900\",\"$0\",\"$5,900\",\"2017\",\"20170401\",\"employment-related offenses\",\"Family and Medical Leave Act\",\"\",\"\",\"federal\",\"agency action\",\"Labor Department Wage and Hour Division\",\"civil\",\"\",\"\",\"1808162\",\"\",\"\",\"Pennsylvania\",\"King of Prussia\",\"610 Freedom Business Center Suite 200\",\"19406\",\"\",\"\",\"USA\",\"Massachusetts\",\"privately held\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"July 23, 2017 download of a dataset posted by the Wage and Hour Division at https://enforcedata.dol.gov/views/data_summary.php\",\"Date and year are the Findings End Date in the dataset posted by the Wage and Hour Division, which does not provide case opening or closing dates. The company name is the Legal Name provided by the dataset unless that field is blank, in which case the Trade Name is used. The dataset provides only one address and does not indicate whether it is the company headquarters address or the establishment address. The penalty amount is the total of civil monetary penalties and mandated back wages. The original dataset provides a breakdown.\"\n\"Forest Laboratories and Forest Pharmaceuticals\",\"AbbVie\",\"$38,000,000\",\"$0\",\"$38,000,000\",\"2016\",\"20161215\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"kickbacks and bribery\",\"Forest Laboratories LLC, located in New York, New York, and its subsidiary, Forest Pharmaceuticals Inc., agreed to pay $38 million to resolve allegations that they violated the False Claims Act by paying kickbacks to induce physicians to prescribe the drugs Bystolic, Savella, and Namenda.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/forest-laboratories-and-forest-pharmaceuticals-pay-38-million-resolve-kickback-allegations\",\"\"\n\"Forest Pharmaceuticals Inc.\",\"AbbVie\",\"$164,000,000\",\"$0\",\"$164,000,000\",\"2011\",\"20110302\",\"healthcare-related offenses\",\"off-label or unapproved promotion of medical products\",\"\",\"Drug manufacturer Forest Pharmaceuticals Inc. was sentenced by U.S. District Judge Nancy Gertner to pay a criminal fine of $150 million and forfeit assets of $14 million following the company's guilty plea in November 2010 to one felony count of obstructing justice, one misdemeanor count of distributing an unapproved new drug in interstate commerce and one misdemeanor count of distributing a misbranded drug in interstate commerce, the Justice Department announced. The company, a subsidiary of New York City-based Forest Laboratories Inc., pleaded guilty to charges related to obstruction of an FDA regulatory inspection, to the distribution of Levothroid, which at the time was an unapproved new drug, and to the illegal promotion of the anti-depressant drug Celexa for use in treating children and adolescents.\",\"federal\",\"agency action\",\"Food and Drug Administration referral to the Justice Department\",\"civil and criminal\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"Illinois\",\"publicly traded\",\"ABBV\",\"pharmaceuticals\",\"pharmaceuticals\",\"http://www.justice.gov/opa/pr/forest-pharmaceuticals-sentenced-pay-164-million-criminal-violations\",\"\"\n\"Fort Dodge Animal Health\",\"Zoetis\",\"$26,956\",\"$0\",\"$26,956\",\"2004\",\"20041105\",\"financial offenses\",\"economic sanction violation\",\"\",\"\",\"federal\",\"agency action\",\"Office of Foreign Assets Control\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New Jersey\",\"publicly traded\",\"ZTS\",\"pharmaceuticals\",\"animal health products\",\"https://www.treasury.gov/resource-center/sanctions/OFAC-Enforcement/Documents/11052004.pdf\",\"\"\n\"Galena Biopharma, Inc.\",\"SELLAS Life Sciences Group\",\"$200,000\",\"$0\",\"$200,000\",\"2017\",\"20170410\",\"financial offenses\",\"accounting fraud or deficiencies\",\"\",\"\",\"federal\",\"agency action\",\"Securities and Exchange Commission\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"USA\",\"New York\",\"publicly traded\",\"SLS\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.sec.gov/litigation/admin/2017/33-10337.pdf\",\"\"\n\"Genentech Inc.\",\"Roche\",\"$33,500,000\",\"$0\",\"$33,500,000\",\"2016\",\"20160606\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Pharmaceutical companies Genentech Inc. and OSI Pharmaceuticals LLC agreed to pay $67 million to resolve False Claims Act allegations that they made misleading statements about the effectiveness of the drug Tarceva to treat non-small cell lung cancer. The announcement did not indicate how much each company would pay. Here we assume the total was split evenly between them.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"Switzerland\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/pharmaceutical-companies-pay-67-million-resolve-false-claims-act-allegations-relating-tarceva\",\"\"\n\"Genzyme Corp.\",\"Sanofi\",\"$22,280,000\",\"$0\",\"$22,280,000\",\"2013\",\"20131220\",\"government-contracting-related offenses\",\"False Claims Act and related\",\"\",\"Genzyme Corp. agreed to pay $22.28 million to resolve allegations that it marketed, and caused false claims to be submitted to federal and state health care programs for use of, a \"\"slurry\"\" version of its Seprafilm adhesion barrier.\",\"federal\",\"agency action\",\"Justice Department Civil Division\",\"civil\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"\",\"France\",\"\",\"publicly traded\",\"\",\"pharmaceuticals\",\"pharmaceuticals\",\"https://www.justice.gov/opa/pr/genzyme-corp-pay-2228-million-resolve-false-claims-allegations-related-slurry-used-patients\",\"\"\n\"Genzyme Corporation\",\"Sanofi\",\"$32,587,439\",\"$0\",\"$32,587,439\",\"2015\",\"20150903\",\"safety-related offenses\",\"drug or medical equipment safety violation\",\"\",\"Genzyme Corporation, a wholly-owned biotechnology subsidiary of French pharmaceutical company Sanofi, agreed to resolve criminal charges that it violated the federal Food, Drug and Cosmetic Act with regard to the unlawful distribution of Seprafilm, a surgical device it marketed and promoted. As part of the agreed resolution, the department filed a two-count criminal information in the U.S. District Court for the Middle District of Florida charging that between 2005 and 2010, Genzyme caused a medical device to become adulterated and misbranded while being held for sale.  The conduct occurred prior to Sanofi's acquisition of Genzyme, based in Cambridge, Massachusetts, in 2011.  To resolve these charges, Genzyme agreed to\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Taking a look at the first few lines clearly\n",
    "for line in dbutils.fs.head(\"/FileStore/tables/pharma.csv\").splitlines():\n",
    "    print(line)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "c1390664-1422-4571-a78e-5d7cd9f46ce5",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n",
       "|             Company|     Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|       Offense_Group|     Primary_Offense|   Secondary_Offense|         Description|Level_of_Government|  Action_Type|              Agency|    Civil/Criminal|Prosecution_Agreement|Court|        Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|    City|             Address|  Zip|NAICS_Code|   NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|         Info_Source|               Notes|\n",
       "+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n",
       "| Abbott Laboratories|Abbott Laboratories|    $5,475,000|                      $0|                                               $5,475,000|        2013|    20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n",
       "|Abbott Laboratori...|             AbbVie|$1,500,000,000|                      $0|                                           $1,500,000,000|        2012|    20120507|healthcare-relate...|off-label or unap...|                null|Global Health Car...|            federal|agency action|Food and Drug Adm...|civil and criminal|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|http://www.justic...|                null|\n",
       "|Abbott Laboratori...|             AbbVie|  $126,500,000|                      $0|                                             $126,500,000|        2010|    20101207|government-contra...|False Claims Act ...|                null|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n",
       "|Abbott Laboratori...|Abbott Laboratories|       $49,045|                      $0|                                                  $49,045|        2009|    20090305|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1527129|                         null|              null|   Puerto Rico|San Juan|                null| null|    423450|423450: Medical, ...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|March 7, 2017 dow...|Date and year are...|\n",
       "|      Acclarent Inc.|  Johnson & Johnson|   $18,000,000|                      $0|                                              $18,000,000|        2016|    20160722|government-contra...|False Claims Act ...|                null|California-based ...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n",
       "|Advanced Medical ...|Abbott Laboratories|       $16,800|                      $0|                                                  $16,800|        2004|    20040412|employment-relate...|labor relations v...|                null|back pay award in...|            federal|agency action|National Labor Re...|             civil|                 null| null|21-CA-36104-001|                         null|              null|    California|  Irvine|                null|92606|    333314|333314: Optical I...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|Extracted from an...|                null|\n",
       "|Advanced Neuromod...|Abbott Laboratories|    $2,950,000|                      $0|                                               $2,950,000|        2007|    20070702|healthcare-relate...|HHS civil monetar...|kickbacks and bri...|The HHS Inspector...|            federal|agency action|Health & Human Se...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://oig.hhs.g...|                null|\n",
       "|Advanced Steriliz...|  Johnson & Johnson|      $136,800|                      $0|                                                 $136,800|        2014|    20140520|environment-relat...|environmental vio...|                null|The U.S. Environm...|            federal|agency action|Environmental Pro...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://archive.e...|                null|\n",
       "|Advanced Steriliz...|  Johnson & Johnson|    $1,200,000|                      $0|                                               $1,200,000|        2013|    20131204|safety-related of...|drug or medical e...|                null|Settlement of a c...|            federal|agency action|Food and Drug Adm...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|http://www.fda.go...|                null|\n",
       "|Alere San Diego Inc.|Abbott Laboratories|       $10,572|                      $0|                                                  $10,572|        2017|    20170309|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1813371|                         null|              null|    California|  Pomona|828 Towne Center Dr.|91767|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|July 23, 2017 dow...|Date and year are...|\n",
       "+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n",
       "only showing top 10 rows\n",
       "\n",
       "root\n",
       " |-- Company: string (nullable = true)\n",
       " |-- Parent_Company: string (nullable = true)\n",
       " |-- Penalty_Amount: string (nullable = true)\n",
       " |-- Subtraction_From_Penalty: string (nullable = true)\n",
       " |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n",
       " |-- Penalty_Year: integer (nullable = true)\n",
       " |-- Penalty_Date: integer (nullable = true)\n",
       " |-- Offense_Group: string (nullable = true)\n",
       " |-- Primary_Offense: string (nullable = true)\n",
       " |-- Secondary_Offense: string (nullable = true)\n",
       " |-- Description: string (nullable = true)\n",
       " |-- Level_of_Government: string (nullable = true)\n",
       " |-- Action_Type: string (nullable = true)\n",
       " |-- Agency: string (nullable = true)\n",
       " |-- Civil/Criminal: string (nullable = true)\n",
       " |-- Prosecution_Agreement: string (nullable = true)\n",
       " |-- Court: string (nullable = true)\n",
       " |-- Case_ID: string (nullable = true)\n",
       " |-- Private_Litigation_Case_Title: string (nullable = true)\n",
       " |-- Lawsuit_Resolution: string (nullable = true)\n",
       " |-- Facility_State: string (nullable = true)\n",
       " |-- City: string (nullable = true)\n",
       " |-- Address: string (nullable = true)\n",
       " |-- Zip: string (nullable = true)\n",
       " |-- NAICS_Code: integer (nullable = true)\n",
       " |-- NAICS_Translation: string (nullable = true)\n",
       " |-- HQ_Country_of_Parent: string (nullable = true)\n",
       " |-- HQ_State_of_Parent: string (nullable = true)\n",
       " |-- Ownership_Structure: string (nullable = true)\n",
       " |-- Parent_Company_Stock_Ticker: string (nullable = true)\n",
       " |-- Major_Industry_of_Parent: string (nullable = true)\n",
       " |-- Specific_Industry_of_Parent: string (nullable = true)\n",
       " |-- Info_Source: string (nullable = true)\n",
       " |-- Notes: string (nullable = true)\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n|             Company|     Parent_Company|Penalty_Amount|Subtraction_From_Penalty|Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting|Penalty_Year|Penalty_Date|       Offense_Group|     Primary_Offense|   Secondary_Offense|         Description|Level_of_Government|  Action_Type|              Agency|    Civil/Criminal|Prosecution_Agreement|Court|        Case_ID|Private_Litigation_Case_Title|Lawsuit_Resolution|Facility_State|    City|             Address|  Zip|NAICS_Code|   NAICS_Translation|HQ_Country_of_Parent|HQ_State_of_Parent|Ownership_Structure|Parent_Company_Stock_Ticker|Major_Industry_of_Parent|Specific_Industry_of_Parent|         Info_Source|               Notes|\n+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\n| Abbott Laboratories|Abbott Laboratories|    $5,475,000|                      $0|                                               $5,475,000|        2013|    20131227|government-contra...|False Claims Act ...|kickbacks and bri...|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Abbott Laboratori...|             AbbVie|$1,500,000,000|                      $0|                                           $1,500,000,000|        2012|    20120507|healthcare-relate...|off-label or unap...|                null|Global Health Car...|            federal|agency action|Food and Drug Adm...|civil and criminal|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|http://www.justic...|                null|\n|Abbott Laboratori...|             AbbVie|  $126,500,000|                      $0|                                             $126,500,000|        2010|    20101207|government-contra...|False Claims Act ...|                null|Abbott Laboratori...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                       ABBV|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Abbott Laboratori...|Abbott Laboratories|       $49,045|                      $0|                                                  $49,045|        2009|    20090305|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1527129|                         null|              null|   Puerto Rico|San Juan|                null| null|    423450|423450: Medical, ...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|March 7, 2017 dow...|Date and year are...|\n|      Acclarent Inc.|  Johnson & Johnson|   $18,000,000|                      $0|                                              $18,000,000|        2016|    20160722|government-contra...|False Claims Act ...|                null|California-based ...|            federal|agency action|Justice Departmen...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://www.justi...|                null|\n|Advanced Medical ...|Abbott Laboratories|       $16,800|                      $0|                                                  $16,800|        2004|    20040412|employment-relate...|labor relations v...|                null|back pay award in...|            federal|agency action|National Labor Re...|             civil|                 null| null|21-CA-36104-001|                         null|              null|    California|  Irvine|                null|92606|    333314|333314: Optical I...|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|Extracted from an...|                null|\n|Advanced Neuromod...|Abbott Laboratories|    $2,950,000|                      $0|                                               $2,950,000|        2007|    20070702|healthcare-relate...|HHS civil monetar...|kickbacks and bri...|The HHS Inspector...|            federal|agency action|Health & Human Se...|             civil|                 null| null|           null|                         null|              null|          null|    null|                null| null|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|https://oig.hhs.g...|                null|\n|Advanced Steriliz...|  Johnson & Johnson|      $136,800|                      $0|                                                 $136,800|        2014|    20140520|environment-relat...|environmental vio...|                null|The U.S. Environm...|            federal|agency action|Environmental Pro...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|https://archive.e...|                null|\n|Advanced Steriliz...|  Johnson & Johnson|    $1,200,000|                      $0|                                               $1,200,000|        2013|    20131204|safety-related of...|drug or medical e...|                null|Settlement of a c...|            federal|agency action|Food and Drug Adm...|             civil|                 null| null|           null|                         null|              null|    California|  Irvine|                null| null|      null|                null|                 USA|        New Jersey|    publicly traded|                        JNJ|         pharmaceuticals|            pharmaceuticals|http://www.fda.go...|                null|\n|Alere San Diego Inc.|Abbott Laboratories|       $10,572|                      $0|                                                  $10,572|        2017|    20170309|employment-relate...|wage and hour vio...|Fair Labor Standa...|                null|            federal|agency action|Labor Department ...|             civil|                 null| null|        1813371|                         null|              null|    California|  Pomona|828 Towne Center Dr.|91767|      null|                null|                 USA|          Illinois|    publicly traded|                        ABT|         pharmaceuticals|            pharmaceuticals|July 23, 2017 dow...|Date and year are...|\n+--------------------+-------------------+--------------+------------------------+---------------------------------------------------------+------------+------------+--------------------+--------------------+--------------------+--------------------+-------------------+-------------+--------------------+------------------+---------------------+-----+---------------+-----------------------------+------------------+--------------+--------+--------------------+-----+----------+--------------------+--------------------+------------------+-------------------+---------------------------+------------------------+---------------------------+--------------------+--------------------+\nonly showing top 10 rows\n\nroot\n |-- Company: string (nullable = true)\n |-- Parent_Company: string (nullable = true)\n |-- Penalty_Amount: string (nullable = true)\n |-- Subtraction_From_Penalty: string (nullable = true)\n |-- Penalty_Amount_Adjusted_For_Eliminating_Multiple_Counting: string (nullable = true)\n |-- Penalty_Year: integer (nullable = true)\n |-- Penalty_Date: integer (nullable = true)\n |-- Offense_Group: string (nullable = true)\n |-- Primary_Offense: string (nullable = true)\n |-- Secondary_Offense: string (nullable = true)\n |-- Description: string (nullable = true)\n |-- Level_of_Government: string (nullable = true)\n |-- Action_Type: string (nullable = true)\n |-- Agency: string (nullable = true)\n |-- Civil/Criminal: string (nullable = true)\n |-- Prosecution_Agreement: string (nullable = true)\n |-- Court: string (nullable = true)\n |-- Case_ID: string (nullable = true)\n |-- Private_Litigation_Case_Title: string (nullable = true)\n |-- Lawsuit_Resolution: string (nullable = true)\n |-- Facility_State: string (nullable = true)\n |-- City: string (nullable = true)\n |-- Address: string (nullable = true)\n |-- Zip: string (nullable = true)\n |-- NAICS_Code: integer (nullable = true)\n |-- NAICS_Translation: string (nullable = true)\n |-- HQ_Country_of_Parent: string (nullable = true)\n |-- HQ_State_of_Parent: string (nullable = true)\n |-- Ownership_Structure: string (nullable = true)\n |-- Parent_Company_Stock_Ticker: string (nullable = true)\n |-- Major_Industry_of_Parent: string (nullable = true)\n |-- Specific_Industry_of_Parent: string (nullable = true)\n |-- Info_Source: string (nullable = true)\n |-- Notes: string (nullable = true)\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "# reading the pharma data into a dataframe and checking to see if it was read in correctly\n",
    "pharma_df = spark.read.option(\"delimiter\", \",\").csv( \"/FileStore/tables/pharma.csv\", header = True , inferSchema = True)\n",
    "pharma_df.show(10)\n",
    "pharma_df.printSchema()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "6a407a52-8290-4716-8f0d-192d27ec0b66",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+\n",
       "|      Parent_Company|\n",
       "+--------------------+\n",
       "| Abbott Laboratories|\n",
       "|              AbbVie|\n",
       "|              AbbVie|\n",
       "| Abbott Laboratories|\n",
       "|   Johnson & Johnson|\n",
       "| Abbott Laboratories|\n",
       "| Abbott Laboratories|\n",
       "|   Johnson & Johnson|\n",
       "|   Johnson & Johnson|\n",
       "| Abbott Laboratories|\n",
       "|              AbbVie|\n",
       "|              AbbVie|\n",
       "|              Pfizer|\n",
       "|              Pfizer|\n",
       "|Bristol-Myers Squibb|\n",
       "|               Amgen|\n",
       "|               Amgen|\n",
       "|               Amgen|\n",
       "|Amneal Pharmaceut...|\n",
       "|     Astellas Pharma|\n",
       "+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+\n|      Parent_Company|\n+--------------------+\n| Abbott Laboratories|\n|              AbbVie|\n|              AbbVie|\n| Abbott Laboratories|\n|   Johnson & Johnson|\n| Abbott Laboratories|\n| Abbott Laboratories|\n|   Johnson & Johnson|\n|   Johnson & Johnson|\n| Abbott Laboratories|\n|              AbbVie|\n|              AbbVie|\n|              Pfizer|\n|              Pfizer|\n|Bristol-Myers Squibb|\n|               Amgen|\n|               Amgen|\n|               Amgen|\n|Amneal Pharmaceut...|\n|     Astellas Pharma|\n+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Selecting the column needed from pharma data for analysis\n",
    "ParentCompanyDF = pharma_df.select(\"Parent_Company\")\n",
    "ParentCompanyDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "4bcca6ae-0617-4c57-bf4c-ea3c8783bea0",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+\n",
       "|             Sponsor|\n",
       "+--------------------+\n",
       "|The University of...|\n",
       "|     Duke University|\n",
       "|Universidade Fede...|\n",
       "|Istanbul Medeniye...|\n",
       "|University of Rom...|\n",
       "|Consorzio Futuro ...|\n",
       "|   Ankara University|\n",
       "|     Ruijin Hospital|\n",
       "|Washington Univer...|\n",
       "|           Orphazyme|\n",
       "|    Novo Nordisk A/S|\n",
       "|Daniel Alexandre ...|\n",
       "|Bulent Ecevit Uni...|\n",
       "|Institut für Phar...|\n",
       "|The Third Xiangya...|\n",
       "|Tel Aviv Medical ...|\n",
       "|Medicines for Mal...|\n",
       "|James Cook Univer...|\n",
       "|Soonchunhyang Uni...|\n",
       "|Member Companies ...|\n",
       "+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+\n|             Sponsor|\n+--------------------+\n|The University of...|\n|     Duke University|\n|Universidade Fede...|\n|Istanbul Medeniye...|\n|University of Rom...|\n|Consorzio Futuro ...|\n|   Ankara University|\n|     Ruijin Hospital|\n|Washington Univer...|\n|           Orphazyme|\n|    Novo Nordisk A/S|\n|Daniel Alexandre ...|\n|Bulent Ecevit Uni...|\n|Institut für Phar...|\n|The Third Xiangya...|\n|Tel Aviv Medical ...|\n|Medicines for Mal...|\n|James Cook Univer...|\n|Soonchunhyang Uni...|\n|Member Companies ...|\n+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Selecting the column needed from clinical trial data for analysis\n",
    "SponsorsDF = clinical_df.select(\"Sponsor\")\n",
    "SponsorsDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "edc10c90-48fd-4597-b2d7-11bb8bbbec81",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<style scoped>\n",
       "  .table-result-container {\n",
       "    max-height: 300px;\n",
       "    overflow: auto;\n",
       "  }\n",
       "  table, th, td {\n",
       "    border: 1px solid black;\n",
       "    border-collapse: collapse;\n",
       "  }\n",
       "  th, td {\n",
       "    padding: 5px;\n",
       "  }\n",
       "  th {\n",
       "    text-align: left;\n",
       "  }\n",
       "</style><div class='table-result-container'><table class='table-result'><thead style='background-color: white'><tr><th>Sponsor</th><th>Parent_Company</th></tr></thead><tbody><tr><td>The University of Hong Kong</td><td>null</td></tr><tr><td>Duke University</td><td>null</td></tr><tr><td>Universidade Federal do Rio de Janeiro</td><td>null</td></tr><tr><td>Istanbul Medeniyet University</td><td>null</td></tr><tr><td>University of Roma La Sapienza</td><td>null</td></tr><tr><td>Consorzio Futuro in Ricerca</td><td>null</td></tr><tr><td>Ankara University</td><td>null</td></tr><tr><td>Ruijin Hospital</td><td>null</td></tr><tr><td>Washington University School of Medicine</td><td>null</td></tr><tr><td>Orphazyme</td><td>null</td></tr><tr><td>Novo Nordisk A/S</td><td>null</td></tr><tr><td>Daniel Alexandre Bottino</td><td>null</td></tr><tr><td>Bulent Ecevit University</td><td>null</td></tr><tr><td>Institut für Pharmakologie und Präventive Medizin</td><td>null</td></tr><tr><td>The Third Xiangya Hospital of Central South University</td><td>null</td></tr><tr><td>Tel Aviv Medical Center</td><td>null</td></tr><tr><td>Medicines for Malaria Venture</td><td>null</td></tr><tr><td>James Cook University, Queensland, Australia</td><td>null</td></tr><tr><td>Soonchunhyang University Hospital</td><td>null</td></tr><tr><td>Member Companies of the Opioid PMR Consortium</td><td>null</td></tr><tr><td>Marmara University</td><td>null</td></tr><tr><td>Cycle Pharmaceuticals Ltd.</td><td>null</td></tr><tr><td>Yonsei University</td><td>null</td></tr><tr><td>Cutera Inc.</td><td>null</td></tr><tr><td>University of Zurich</td><td>null</td></tr><tr><td>Guangdong Association of Clinical Trials</td><td>null</td></tr><tr><td>Ruijin Hospital</td><td>null</td></tr><tr><td>The Cleveland Clinic</td><td>null</td></tr><tr><td>St. Justine's Hospital</td><td>null</td></tr><tr><td>Alcresta Therapeutics, Inc.</td><td>null</td></tr><tr><td>Iron Horse Diagnostics, Inc.</td><td>null</td></tr><tr><td>VA Puget Sound Health Care System</td><td>null</td></tr><tr><td>University of Colorado, Denver</td><td>null</td></tr><tr><td>H. Lundbeck A/S</td><td>null</td></tr><tr><td>Ospedale San Giovanni Bellinzona</td><td>null</td></tr><tr><td>Dong-A ST Co., Ltd.</td><td>null</td></tr><tr><td>The University of Texas Health Science Center, Houston</td><td>null</td></tr><tr><td>Gilead Sciences</td><td>Gilead Sciences</td></tr><tr><td>Gilead Sciences</td><td>Gilead Sciences</td></tr><tr><td>Gilead Sciences</td><td>Gilead Sciences</td></tr><tr><td>Gilead Sciences</td><td>Gilead Sciences</td></tr><tr><td>Laval University</td><td>null</td></tr><tr><td>Children's Hospital of Eastern Ontario</td><td>null</td></tr><tr><td>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</td><td>null</td></tr><tr><td>The Skin Center Dermatology Group</td><td>null</td></tr><tr><td>Mert Özcan</td><td>null</td></tr><tr><td>Instituto de Investigación Hospital Universitario La Paz</td><td>null</td></tr><tr><td>University Hospital, Grenoble</td><td>null</td></tr><tr><td>Foisor Orthopedics Clinical Hospital</td><td>null</td></tr><tr><td>Institute of Cancer Research, United Kingdom</td><td>null</td></tr><tr><td>VU University Medical Center</td><td>null</td></tr><tr><td>NantBioScience, Inc.</td><td>null</td></tr><tr><td>University of Campania Luigi Vanvitelli</td><td>null</td></tr><tr><td>Lawson Health Research Institute</td><td>null</td></tr><tr><td>Merck Sharp & Dohme Corp.</td><td>null</td></tr><tr><td>Sharda University</td><td>null</td></tr><tr><td>Holland Bloorview Kids Rehabilitation Hospital</td><td>null</td></tr><tr><td>Niğde State Hospital</td><td>null</td></tr><tr><td>Spectrum Health Hospitals</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>Hospices Civils de Lyon</td><td>null</td></tr><tr><td>Università Politecnica delle Marche</td><td>null</td></tr><tr><td>Biogen</td><td>null</td></tr><tr><td>University of Liege</td><td>null</td></tr><tr><td>Sumitomo Dainippon Pharma Co., Ltd.</td><td>null</td></tr><tr><td>Mayo Clinic</td><td>null</td></tr><tr><td>University of British Columbia</td><td>null</td></tr><tr><td>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</td><td>null</td></tr><tr><td>Medical University of Graz</td><td>null</td></tr><tr><td>Hippocration General Hospital</td><td>null</td></tr><tr><td>Beijing Anzhen Hospital</td><td>null</td></tr><tr><td>Medtronic BRC</td><td>null</td></tr><tr><td>Samsung Medical Center</td><td>null</td></tr><tr><td>Washington University School of Medicine</td><td>null</td></tr><tr><td>University of Modena and Reggio Emilia</td><td>null</td></tr><tr><td>Samsung Medical Center</td><td>null</td></tr><tr><td>University of Michigan</td><td>null</td></tr><tr><td>Tel Hai College</td><td>null</td></tr><tr><td>University of Arizona</td><td>null</td></tr><tr><td>Rigshospitalet, Denmark</td><td>null</td></tr><tr><td>Astellas Pharma Inc</td><td>null</td></tr><tr><td>Texas A&M University</td><td>null</td></tr><tr><td>Kevin Farrell</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Merck Sharp & Dohme Corp.</td><td>null</td></tr><tr><td>Massachusetts General Hospital</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Adil Bharucha</td><td>null</td></tr><tr><td>University of California, San Diego</td><td>null</td></tr><tr><td>medac GmbH</td><td>null</td></tr><tr><td>Millennium Pharmaceuticals, Inc.</td><td>null</td></tr><tr><td>Rush University Medical Center</td><td>null</td></tr><tr><td>Harvard School of Public Health (HSPH)</td><td>null</td></tr><tr><td>Aarhus University Hospital</td><td>null</td></tr><tr><td>Royal Devon and Exeter NHS Foundation Trust</td><td>null</td></tr><tr><td>Samsung Bioepis Co., Ltd.</td><td>null</td></tr><tr><td>Martin-Luther-Universität Halle-Wittenberg</td><td>null</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Samsung Medical Center</td><td>null</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>Boehringer Ingelheim</td><td>Boehringer Ingelheim</td></tr><tr><td>University of Bologna</td><td>null</td></tr><tr><td>Chongqing Medical University</td><td>null</td></tr><tr><td>Charite University, Berlin, Germany</td><td>null</td></tr><tr><td>Cutera Inc.</td><td>null</td></tr><tr><td>Kahramanmaras Sutcu Imam University</td><td>null</td></tr><tr><td>Rush University Medical Center</td><td>null</td></tr><tr><td>Brown, Theodore R., M.D., MPH</td><td>null</td></tr><tr><td>NYU Langone Health</td><td>null</td></tr><tr><td>Eli Lilly and Company</td><td>null</td></tr><tr><td>Anavex Life Sciences Corp.</td><td>null</td></tr><tr><td>Konkuk University Medical Center</td><td>null</td></tr><tr><td>University of Colorado, Denver</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Peking University People's Hospital</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Asan Medical Center</td><td>null</td></tr><tr><td>Hospices Civils de Lyon</td><td>null</td></tr><tr><td>Marienhospital Osnabrück</td><td>null</td></tr><tr><td>Peking Union Medical College Hospital</td><td>null</td></tr><tr><td>Northwell Health</td><td>null</td></tr><tr><td>Eisai Inc.</td><td>null</td></tr><tr><td>Charite University, Berlin, Germany</td><td>null</td></tr><tr><td>Tata Memorial Centre</td><td>null</td></tr><tr><td>M.D. Anderson Cancer Center</td><td>null</td></tr><tr><td>Magrabi Eye & Ear Hospital</td><td>null</td></tr><tr><td>Shaare Zedek Medical Center</td><td>null</td></tr><tr><td>Holland Bloorview Kids Rehabilitation Hospital</td><td>null</td></tr><tr><td>Umeå University</td><td>null</td></tr><tr><td>Oregon Health and Science University</td><td>null</td></tr><tr><td>Duke University</td><td>null</td></tr><tr><td>University of East Anglia</td><td>null</td></tr><tr><td>Leiden University</td><td>null</td></tr><tr><td>Washington State University</td><td>null</td></tr><tr><td>Fraser Orthopaedic Research Society</td><td>null</td></tr><tr><td>Cycle Pharmaceuticals Ltd.</td><td>null</td></tr><tr><td>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</td><td>null</td></tr><tr><td>Dartmouth-Hitchcock Medical Center</td><td>null</td></tr><tr><td>European Respiratory Society</td><td>null</td></tr><tr><td>Istanbul University</td><td>null</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Lara McKenzie</td><td>null</td></tr><tr><td>Nabriva Therapeutics AG</td><td>null</td></tr><tr><td>University Health Network, Toronto</td><td>null</td></tr><tr><td>Valtari Bio</td><td>null</td></tr><tr><td>Virginia Polytechnic Institute and State University</td><td>null</td></tr><tr><td>Centre hospitalier de Ville-Evrard, France</td><td>null</td></tr><tr><td>Lancaster General Hospital</td><td>null</td></tr><tr><td>University Hospital Inselspital, Berne</td><td>null</td></tr><tr><td>Marmara University</td><td>null</td></tr><tr><td>Medtronic Cardiac Rhythm and Heart Failure</td><td>null</td></tr><tr><td>University Hospital, Caen</td><td>null</td></tr><tr><td>Florian Lordick, MD</td><td>null</td></tr><tr><td>Astellas Pharma Europe B.V.</td><td>null</td></tr><tr><td>Rabih A. Chaer</td><td>null</td></tr><tr><td>Eco Fusion</td><td>null</td></tr><tr><td>Shanghai Cingularbio Co. Ltd</td><td>null</td></tr><tr><td>Novartis Pharmaceuticals</td><td>null</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Amgen</td><td>Amgen</td></tr><tr><td>Skane University Hospital</td><td>null</td></tr><tr><td>Aesculap AG</td><td>null</td></tr><tr><td>King's College London</td><td>null</td></tr><tr><td>STZ eyetrial</td><td>null</td></tr><tr><td>Medtronic - MITG</td><td>null</td></tr><tr><td>Nils Hoyer</td><td>null</td></tr><tr><td>Sheba Medical Center</td><td>null</td></tr><tr><td>Hospices Civils de Lyon</td><td>null</td></tr><tr><td>Parc de Salut Mar</td><td>null</td></tr><tr><td>Universidad de Valparaiso</td><td>null</td></tr><tr><td>Mundipharma Research Limited</td><td>null</td></tr><tr><td>Inova Health Care Services</td><td>null</td></tr><tr><td>Sana Klinikum Offenbach</td><td>null</td></tr><tr><td>Tampere University Hospital</td><td>null</td></tr><tr><td>Southern Methodist University</td><td>null</td></tr><tr><td>Peter Bader</td><td>null</td></tr><tr><td>M.D. Anderson Cancer Center</td><td>null</td></tr><tr><td>University of Nebraska</td><td>null</td></tr><tr><td>Haukeland University Hospital</td><td>null</td></tr><tr><td>Lawson Health Research Institute</td><td>null</td></tr><tr><td>RWTH Aachen University</td><td>null</td></tr><tr><td>Guy's and St Thomas' NHS Foundation Trust</td><td>null</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>Wuerzburg University Hospital</td><td>null</td></tr><tr><td>Nobelpharma</td><td>null</td></tr><tr><td>Dong-A ST Co., Ltd.</td><td>null</td></tr><tr><td>Stanford University</td><td>null</td></tr><tr><td>Fondazione Salvatore Maugeri</td><td>null</td></tr><tr><td>University of British Columbia</td><td>null</td></tr><tr><td>Burnasyan Federal Medical Biophysical Center</td><td>null</td></tr><tr><td>National Taiwan University Hospital</td><td>null</td></tr><tr><td>Atridia Pty Ltd.</td><td>null</td></tr><tr><td>The University of Texas Medical Branch, Galveston</td><td>null</td></tr><tr><td>Kasr El Aini Hospital</td><td>null</td></tr><tr><td>University of California, San Francisco</td><td>null</td></tr><tr><td>Arkansas Heart Hospital</td><td>null</td></tr><tr><td>JSI Research & Training Institute, Inc.</td><td>null</td></tr><tr><td>Yale University</td><td>null</td></tr><tr><td>All India Institute of Medical Sciences, New Delhi</td><td>null</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Pfizer</td><td>Pfizer</td></tr><tr><td>Riyadh Colleges of Dentistry and Pharmacy</td><td>null</td></tr><tr><td>University of Roma La Sapienza</td><td>null</td></tr><tr><td>Eli Lilly and Company</td><td>null</td></tr><tr><td>Nova Scotia Health Authority</td><td>null</td></tr><tr><td>Assiut University</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Penn State University</td><td>null</td></tr><tr><td>Electrical Geodesics, Inc.</td><td>null</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Sanofi</td><td>Sanofi</td></tr><tr><td>Konkuk University Medical Center</td><td>null</td></tr><tr><td>Vanderbilt University</td><td>null</td></tr><tr><td>Gachon University Gil Medical Center</td><td>null</td></tr><tr><td>Tel Hai College</td><td>null</td></tr><tr><td>Rigshospitalet, Denmark</td><td>null</td></tr><tr><td>University of California, Davis</td><td>null</td></tr><tr><td>Merck Sharp & Dohme Corp.</td><td>null</td></tr><tr><td>Medstar Health Research Institute</td><td>null</td></tr><tr><td>Haukeland University Hospital</td><td>null</td></tr><tr><td>Northwell Health</td><td>null</td></tr><tr><td>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</td><td>null</td></tr><tr><td>Mayo Clinic</td><td>null</td></tr><tr><td>South East Asia Research Collaboration with Hawaii</td><td>null</td></tr><tr><td>Danube Hospital</td><td>null</td></tr><tr><td>Seoul National University Hospital</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>Indonesia University</td><td>null</td></tr><tr><td>University of Zurich</td><td>null</td></tr><tr><td>Lawson Health Research Institute</td><td>null</td></tr><tr><td>Montreal General Hospital</td><td>null</td></tr><tr><td>Instituto Mexicano del Seguro Social</td><td>null</td></tr><tr><td>Brigham and Women's Hospital</td><td>null</td></tr><tr><td>Massachusetts General Hospital</td><td>null</td></tr><tr><td>Johns Hopkins University</td><td>null</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>Bristol-Myers Squibb</td><td>Bristol-Myers Squibb</td></tr><tr><td>New York University</td><td>null</td></tr><tr><td>Alcon, a Novartis Company</td><td>null</td></tr><tr><td>Modarres Hospital</td><td>null</td></tr><tr><td>Queen Mary University of London</td><td>null</td></tr><tr><td>RedHill Biopharma Limited</td><td>null</td></tr><tr><td>Ina-Respond</td><td>null</td></tr><tr><td>University Hospital, Angers</td><td>null</td></tr><tr><td>Washington University Early Recognition Center</td><td>null</td></tr><tr><td>Memorial Sloan Kettering Cancer Center</td><td>null</td></tr><tr><td>Mayne Pharma International Pty Ltd</td><td>null</td></tr><tr><td>Dr. Orit Hamiel</td><td>null</td></tr><tr><td>Imperial College London</td><td>null</td></tr><tr><td>Shiraz University of Medical Sciences</td><td>null</td></tr><tr><td>Universidad Iberoamericana A.C., Mexico</td><td>null</td></tr><tr><td>Federal University of São Paulo</td><td>null</td></tr><tr><td>Groupe Francophone des Myelodysplasies</td><td>null</td></tr><tr><td>Bnai Zion Medical Center</td><td>null</td></tr><tr><td>MCM Vaccines B.V.</td><td>null</td></tr><tr><td>Washington University School of Medicine</td><td>null</td></tr><tr><td>Mayo Clinic</td><td>null</td></tr><tr><td>Kaohsiung Veterans General Hospital.</td><td>null</td></tr><tr><td>Washington University School of Medicine</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>Tanta University</td><td>null</td></tr><tr><td>Alliance for Clinical Trials in Oncology</td><td>null</td></tr><tr><td>New York State Psychiatric Institute</td><td>null</td></tr><tr><td>Laborie Medical Technologies Inc.</td><td>null</td></tr><tr><td>University of California, San Francisco</td><td>null</td></tr><tr><td>The University of Hong Kong</td><td>null</td></tr><tr><td>University Medical Center Groningen</td><td>null</td></tr><tr><td>Vinita Takiar</td><td>null</td></tr><tr><td>Boston Urogynecology Associates</td><td>null</td></tr><tr><td>Federal University of São Paulo</td><td>null</td></tr><tr><td>University Health Network, Toronto</td><td>null</td></tr><tr><td>Jiangsu Hansoh Pharmaceutical Co., Ltd.</td><td>null</td></tr><tr><td>University Hospital Schleswig-Holstein</td><td>null</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>Odense University Hospital</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>Seoul National University Hospital</td><td>null</td></tr><tr><td>Beijing Tiantan Hospital</td><td>null</td></tr><tr><td>Eli Lilly and Company</td><td>null</td></tr><tr><td>University of Limerick</td><td>null</td></tr><tr><td>Sidney Kimmel Cancer Center at Thomas Jefferson University</td><td>null</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>AbbVie</td><td>AbbVie</td></tr><tr><td>Pieris Pharmaceuticals GmbH</td><td>null</td></tr><tr><td>Shockwave Medical, Inc.</td><td>null</td></tr><tr><td>The University of Hong Kong</td><td>null</td></tr><tr><td>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</td><td>null</td></tr><tr><td>Dana-Farber Cancer Institute</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>Fudan University</td><td>null</td></tr><tr><td>Azienda Ospedaliera Bolognini di Seriate Bergamo</td><td>null</td></tr><tr><td>Biocad</td><td>null</td></tr><tr><td>NYU Langone Health</td><td>null</td></tr><tr><td>Tata Medical Center</td><td>null</td></tr><tr><td>University Hospital, Lille</td><td>null</td></tr><tr><td>Novartis Pharmaceuticals</td><td>null</td></tr><tr><td>IRCCS Policlinico S. Matteo</td><td>null</td></tr><tr><td>Fox Chase Cancer Center</td><td>null</td></tr><tr><td>Centre National de la Recherche Scientifique, France</td><td>null</td></tr><tr><td>Konkuk University Medical Center</td><td>null</td></tr><tr><td>Biotronik, Inc.</td><td>null</td></tr><tr><td>The Hospital for Sick Children</td><td>null</td></tr><tr><td>University of Colorado, Denver</td><td>null</td></tr><tr><td>Washington University School of Medicine</td><td>null</td></tr><tr><td>Eli Lilly and Company</td><td>null</td></tr><tr><td>Hospices Civils de Lyon</td><td>null</td></tr><tr><td>Catharina Ziekenhuis Eindhoven</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>RenJi Hospital</td><td>null</td></tr><tr><td>Jonsson Comprehensive Cancer Center</td><td>null</td></tr><tr><td>Karolinska Institutet</td><td>null</td></tr><tr><td>Chulalongkorn University</td><td>null</td></tr><tr><td>Ankara University</td><td>null</td></tr><tr><td>Jena University Hospital</td><td>null</td></tr><tr><td>ESM Technologies, LLC</td><td>null</td></tr><tr><td>National Institute on Drug Abuse (NIDA)</td><td>null</td></tr><tr><td>Samuel Lunenfeld Research Institute, Mount Sinai Hospital</td><td>null</td></tr><tr><td>Ágata Sofia da Silva Vieira</td><td>null</td></tr><tr><td>Pennington Biomedical Research Center</td><td>null</td></tr><tr><td>Uppsala University</td><td>null</td></tr><tr><td>HaEmek Medical Center, Israel</td><td>null</td></tr><tr><td>United States Naval Medical Center, San Diego</td><td>null</td></tr><tr><td>Dana-Farber Cancer Institute</td><td>null</td></tr><tr><td>Verifomics LLC</td><td>null</td></tr><tr><td>Central Hospital, Nancy, France</td><td>null</td></tr><tr><td>Eli Lilly and Company</td><td>null</td></tr><tr><td>Seoul National University Hospital</td><td>null</td></tr><tr><td>Ottawa Hospital Research Institute</td><td>null</td></tr><tr><td>University of Sao Paulo</td><td>null</td></tr><tr><td>Azienda Ospedaliera Bolognini di Seriate Bergamo</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>The Queen Elizabeth Hospital</td><td>null</td></tr><tr><td>University of Nove de Julho</td><td>null</td></tr><tr><td>University of British Columbia</td><td>null</td></tr><tr><td>Meyer Children's Hospital</td><td>null</td></tr><tr><td>Centre hospitalier de l'Université de Montréal (CHUM)</td><td>null</td></tr><tr><td>The Cleveland Clinic</td><td>null</td></tr><tr><td>Medical University of South Carolina</td><td>null</td></tr><tr><td>Università Politecnica delle Marche</td><td>null</td></tr><tr><td>Michigan State University</td><td>null</td></tr><tr><td>Bloodworks</td><td>null</td></tr><tr><td>Royal Marsden NHS Foundation Trust</td><td>null</td></tr><tr><td>Weill Medical College of Cornell University</td><td>null</td></tr><tr><td>Medtronic Cardiovascular</td><td>null</td></tr><tr><td>M.D. Anderson Cancer Center</td><td>null</td></tr><tr><td>Fred Hutchinson Cancer Research Center</td><td>null</td></tr><tr><td>Universitat Jaume I</td><td>null</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>AstraZeneca</td><td>AstraZeneca</td></tr><tr><td>Massachusetts General Hospital</td><td>null</td></tr><tr><td>Sheffield Teaching Hospitals NHS Foundation Trust</td><td>null</td></tr><tr><td>Institut de Cancérologie de Lorraine</td><td>null</td></tr><tr><td>University of Pittsburgh</td><td>null</td></tr><tr><td>NHS Greater Glasgow and Clyde</td><td>null</td></tr><tr><td>Third Military Medical University</td><td>null</td></tr><tr><td>University of California, Davis</td><td>null</td></tr><tr><td>Sanofi Pasteur, a Sanofi Company</td><td>null</td></tr><tr><td>University Hospital, Bordeaux</td><td>null</td></tr><tr><td>University of Bergen</td><td>null</td></tr><tr><td>High Point University</td><td>null</td></tr><tr><td>Assistance Publique Hopitaux De Marseille</td><td>null</td></tr><tr><td>Abramson Cancer Center of the University of Pennsylvania</td><td>null</td></tr><tr><td>Royal Brompton & Harefield NHS Foundation Trust</td><td>null</td></tr><tr><td>Rennes University Hospital</td><td>null</td></tr><tr><td>University of British Columbia</td><td>null</td></tr><tr><td>Centre Hospitalier Universitaire de Nice</td><td>null</td></tr><tr><td>University of Rochester</td><td>null</td></tr><tr><td>Abbott Nutrition</td><td>null</td></tr><tr><td>Mclean Hospital</td><td>null</td></tr><tr><td>Guy's and St Thomas' NHS Foundation Trust</td><td>null</td></tr><tr><td>University of California, San Francisco</td><td>null</td></tr><tr><td>AnalyticsPlus, Inc.</td><td>null</td></tr><tr><td>University of Tromso</td><td>null</td></tr><tr><td>European Association of Urology Research Foundation</td><td>null</td></tr><tr><td>All India Institute of Medical Sciences, New Delhi</td><td>null</td></tr><tr><td>Charite University, Berlin, Germany</td><td>null</td></tr><tr><td>The Baruch Padeh Medical Center, Poriya</td><td>null</td></tr><tr><td>Isfahan University of Medical Sciences</td><td>null</td></tr><tr><td>Ospedale Generale Di Zona Moriggia-Pelascini</td><td>null</td></tr><tr><td>Massachusetts General Hospital</td><td>null</td></tr><tr><td>Cochlear</td><td>null</td></tr><tr><td>Penn State University</td><td>null</td></tr><tr><td>University Hospital, Grenoble</td><td>null</td></tr><tr><td>Brown University</td><td>null</td></tr><tr><td>Janssen Research & Development, LLC</td><td>null</td></tr><tr><td>Clene Nanomedicine</td><td>null</td></tr><tr><td>Boston Medical Center</td><td>null</td></tr><tr><td>Royal Marsden NHS Foundation Trust</td><td>null</td></tr><tr><td>Assistance Publique - Hôpitaux de Paris</td><td>null</td></tr><tr><td>Taipei Medical University WanFang Hospital</td><td>null</td></tr><tr><td>Armata Pharmaceuticals, Inc.</td><td>null</td></tr><tr><td>University of New Mexico</td><td>null</td></tr><tr><td>University of Luebeck</td><td>null</td></tr><tr><td>Hospital Central Dr. Luis Ortega</td><td>null</td></tr><tr><td>McGill University</td><td>null</td></tr><tr><td>F-star Therapeutics, Inc.</td><td>null</td></tr><tr><td>Dartmouth-Hitchcock Medical Center</td><td>null</td></tr><tr><td>Global Protection Corp.</td><td>null</td></tr><tr><td>Peking University People's Hospital</td><td>null</td></tr><tr><td>Radboud University</td><td>null</td></tr><tr><td>Bayer</td><td>null</td></tr><tr><td>National Jewish Health</td><td>null</td></tr><tr><td>University of Wisconsin, Madison</td><td>null</td></tr><tr><td>Federal University of São Paulo</td><td>null</td></tr><tr><td>University of Sheffield</td><td>null</td></tr><tr><td>Teesside University</td><td>null</td></tr><tr><td>KK Women's and Children's Hospital</td><td>null</td></tr><tr><td>University of Brasilia</td><td>null</td></tr><tr><td>Paul Finn</td><td>null</td></tr><tr><td>University Hospital, Lille</td><td>null</td></tr><tr><td>University of Texas Southwestern Medical Center</td><td>null</td></tr><tr><td>Tampere University Hospital</td><td>null</td></tr><tr><td>National Institute of Allergy and Infectious Diseases (NIAID)</td><td>null</td></tr><tr><td>University of Nottingham</td><td>null</td></tr><tr><td>Chung Shan Medical University</td><td>null</td></tr><tr><td>Xuanwu Hospital, Beijing</td><td>null</td></tr><tr><td>University of Pennsylvania</td><td>null</td></tr><tr><td>Baylor Research Institute</td><td>null</td></tr><tr><td>Health Decisions</td><td>null</td></tr><tr><td>Dr. Soetomo General Hospital</td><td>null</td></tr><tr><td>University of New Mexico</td><td>null</td></tr><tr><td>Liverpool Women's NHS Foundation Trust</td><td>null</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr><tr><td>GlaxoSmithKline</td><td>GlaxoSmithKline</td></tr></tbody></table>Showing the first 1000 rows.</div>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "aggData": [],
       "aggError": "",
       "aggOverflow": false,
       "aggSchema": [],
       "aggSeriesLimitReached": false,
       "aggType": "",
       "arguments": {},
       "columnCustomDisplayInfos": {},
       "data": [
        [
         "The University of Hong Kong",
         null
        ],
        [
         "Duke University",
         null
        ],
        [
         "Universidade Federal do Rio de Janeiro",
         null
        ],
        [
         "Istanbul Medeniyet University",
         null
        ],
        [
         "University of Roma La Sapienza",
         null
        ],
        [
         "Consorzio Futuro in Ricerca",
         null
        ],
        [
         "Ankara University",
         null
        ],
        [
         "Ruijin Hospital",
         null
        ],
        [
         "Washington University School of Medicine",
         null
        ],
        [
         "Orphazyme",
         null
        ],
        [
         "Novo Nordisk A/S",
         null
        ],
        [
         "Daniel Alexandre Bottino",
         null
        ],
        [
         "Bulent Ecevit University",
         null
        ],
        [
         "Institut für Pharmakologie und Präventive Medizin",
         null
        ],
        [
         "The Third Xiangya Hospital of Central South University",
         null
        ],
        [
         "Tel Aviv Medical Center",
         null
        ],
        [
         "Medicines for Malaria Venture",
         null
        ],
        [
         "James Cook University, Queensland, Australia",
         null
        ],
        [
         "Soonchunhyang University Hospital",
         null
        ],
        [
         "Member Companies of the Opioid PMR Consortium",
         null
        ],
        [
         "Marmara University",
         null
        ],
        [
         "Cycle Pharmaceuticals Ltd.",
         null
        ],
        [
         "Yonsei University",
         null
        ],
        [
         "Cutera Inc.",
         null
        ],
        [
         "University of Zurich",
         null
        ],
        [
         "Guangdong Association of Clinical Trials",
         null
        ],
        [
         "Ruijin Hospital",
         null
        ],
        [
         "The Cleveland Clinic",
         null
        ],
        [
         "St. Justine's Hospital",
         null
        ],
        [
         "Alcresta Therapeutics, Inc.",
         null
        ],
        [
         "Iron Horse Diagnostics, Inc.",
         null
        ],
        [
         "VA Puget Sound Health Care System",
         null
        ],
        [
         "University of Colorado, Denver",
         null
        ],
        [
         "H. Lundbeck A/S",
         null
        ],
        [
         "Ospedale San Giovanni Bellinzona",
         null
        ],
        [
         "Dong-A ST Co., Ltd.",
         null
        ],
        [
         "The University of Texas Health Science Center, Houston",
         null
        ],
        [
         "Gilead Sciences",
         "Gilead Sciences"
        ],
        [
         "Gilead Sciences",
         "Gilead Sciences"
        ],
        [
         "Gilead Sciences",
         "Gilead Sciences"
        ],
        [
         "Gilead Sciences",
         "Gilead Sciences"
        ],
        [
         "Laval University",
         null
        ],
        [
         "Children's Hospital of Eastern Ontario",
         null
        ],
        [
         "Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",
         null
        ],
        [
         "The Skin Center Dermatology Group",
         null
        ],
        [
         "Mert Özcan",
         null
        ],
        [
         "Instituto de Investigación Hospital Universitario La Paz",
         null
        ],
        [
         "University Hospital, Grenoble",
         null
        ],
        [
         "Foisor Orthopedics Clinical Hospital",
         null
        ],
        [
         "Institute of Cancer Research, United Kingdom",
         null
        ],
        [
         "VU University Medical Center",
         null
        ],
        [
         "NantBioScience, Inc.",
         null
        ],
        [
         "University of Campania Luigi Vanvitelli",
         null
        ],
        [
         "Lawson Health Research Institute",
         null
        ],
        [
         "Merck Sharp & Dohme Corp.",
         null
        ],
        [
         "Sharda University",
         null
        ],
        [
         "Holland Bloorview Kids Rehabilitation Hospital",
         null
        ],
        [
         "Niğde State Hospital",
         null
        ],
        [
         "Spectrum Health Hospitals",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "Hospices Civils de Lyon",
         null
        ],
        [
         "Università Politecnica delle Marche",
         null
        ],
        [
         "Biogen",
         null
        ],
        [
         "University of Liege",
         null
        ],
        [
         "Sumitomo Dainippon Pharma Co., Ltd.",
         null
        ],
        [
         "Mayo Clinic",
         null
        ],
        [
         "University of British Columbia",
         null
        ],
        [
         "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",
         null
        ],
        [
         "Medical University of Graz",
         null
        ],
        [
         "Hippocration General Hospital",
         null
        ],
        [
         "Beijing Anzhen Hospital",
         null
        ],
        [
         "Medtronic BRC",
         null
        ],
        [
         "Samsung Medical Center",
         null
        ],
        [
         "Washington University School of Medicine",
         null
        ],
        [
         "University of Modena and Reggio Emilia",
         null
        ],
        [
         "Samsung Medical Center",
         null
        ],
        [
         "University of Michigan",
         null
        ],
        [
         "Tel Hai College",
         null
        ],
        [
         "University of Arizona",
         null
        ],
        [
         "Rigshospitalet, Denmark",
         null
        ],
        [
         "Astellas Pharma Inc",
         null
        ],
        [
         "Texas A&M University",
         null
        ],
        [
         "Kevin Farrell",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "Merck Sharp & Dohme Corp.",
         null
        ],
        [
         "Massachusetts General Hospital",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "Adil Bharucha",
         null
        ],
        [
         "University of California, San Diego",
         null
        ],
        [
         "medac GmbH",
         null
        ],
        [
         "Millennium Pharmaceuticals, Inc.",
         null
        ],
        [
         "Rush University Medical Center",
         null
        ],
        [
         "Harvard School of Public Health (HSPH)",
         null
        ],
        [
         "Aarhus University Hospital",
         null
        ],
        [
         "Royal Devon and Exeter NHS Foundation Trust",
         null
        ],
        [
         "Samsung Bioepis Co., Ltd.",
         null
        ],
        [
         "Martin-Luther-Universität Halle-Wittenberg",
         null
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Samsung Medical Center",
         null
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "Boehringer Ingelheim",
         "Boehringer Ingelheim"
        ],
        [
         "University of Bologna",
         null
        ],
        [
         "Chongqing Medical University",
         null
        ],
        [
         "Charite University, Berlin, Germany",
         null
        ],
        [
         "Cutera Inc.",
         null
        ],
        [
         "Kahramanmaras Sutcu Imam University",
         null
        ],
        [
         "Rush University Medical Center",
         null
        ],
        [
         "Brown, Theodore R., M.D., MPH",
         null
        ],
        [
         "NYU Langone Health",
         null
        ],
        [
         "Eli Lilly and Company",
         null
        ],
        [
         "Anavex Life Sciences Corp.",
         null
        ],
        [
         "Konkuk University Medical Center",
         null
        ],
        [
         "University of Colorado, Denver",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "Peking University People's Hospital",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "Asan Medical Center",
         null
        ],
        [
         "Hospices Civils de Lyon",
         null
        ],
        [
         "Marienhospital Osnabrück",
         null
        ],
        [
         "Peking Union Medical College Hospital",
         null
        ],
        [
         "Northwell Health",
         null
        ],
        [
         "Eisai Inc.",
         null
        ],
        [
         "Charite University, Berlin, Germany",
         null
        ],
        [
         "Tata Memorial Centre",
         null
        ],
        [
         "M.D. Anderson Cancer Center",
         null
        ],
        [
         "Magrabi Eye & Ear Hospital",
         null
        ],
        [
         "Shaare Zedek Medical Center",
         null
        ],
        [
         "Holland Bloorview Kids Rehabilitation Hospital",
         null
        ],
        [
         "Umeå University",
         null
        ],
        [
         "Oregon Health and Science University",
         null
        ],
        [
         "Duke University",
         null
        ],
        [
         "University of East Anglia",
         null
        ],
        [
         "Leiden University",
         null
        ],
        [
         "Washington State University",
         null
        ],
        [
         "Fraser Orthopaedic Research Society",
         null
        ],
        [
         "Cycle Pharmaceuticals Ltd.",
         null
        ],
        [
         "Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine",
         null
        ],
        [
         "Dartmouth-Hitchcock Medical Center",
         null
        ],
        [
         "European Respiratory Society",
         null
        ],
        [
         "Istanbul University",
         null
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Bayer",
         null
        ],
        [
         "Lara McKenzie",
         null
        ],
        [
         "Nabriva Therapeutics AG",
         null
        ],
        [
         "University Health Network, Toronto",
         null
        ],
        [
         "Valtari Bio",
         null
        ],
        [
         "Virginia Polytechnic Institute and State University",
         null
        ],
        [
         "Centre hospitalier de Ville-Evrard, France",
         null
        ],
        [
         "Lancaster General Hospital",
         null
        ],
        [
         "University Hospital Inselspital, Berne",
         null
        ],
        [
         "Marmara University",
         null
        ],
        [
         "Medtronic Cardiac Rhythm and Heart Failure",
         null
        ],
        [
         "University Hospital, Caen",
         null
        ],
        [
         "Florian Lordick, MD",
         null
        ],
        [
         "Astellas Pharma Europe B.V.",
         null
        ],
        [
         "Rabih A. Chaer",
         null
        ],
        [
         "Eco Fusion",
         null
        ],
        [
         "Shanghai Cingularbio Co. Ltd",
         null
        ],
        [
         "Novartis Pharmaceuticals",
         null
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Amgen",
         "Amgen"
        ],
        [
         "Skane University Hospital",
         null
        ],
        [
         "Aesculap AG",
         null
        ],
        [
         "King's College London",
         null
        ],
        [
         "STZ eyetrial",
         null
        ],
        [
         "Medtronic - MITG",
         null
        ],
        [
         "Nils Hoyer",
         null
        ],
        [
         "Sheba Medical Center",
         null
        ],
        [
         "Hospices Civils de Lyon",
         null
        ],
        [
         "Parc de Salut Mar",
         null
        ],
        [
         "Universidad de Valparaiso",
         null
        ],
        [
         "Mundipharma Research Limited",
         null
        ],
        [
         "Inova Health Care Services",
         null
        ],
        [
         "Sana Klinikum Offenbach",
         null
        ],
        [
         "Tampere University Hospital",
         null
        ],
        [
         "Southern Methodist University",
         null
        ],
        [
         "Peter Bader",
         null
        ],
        [
         "M.D. Anderson Cancer Center",
         null
        ],
        [
         "University of Nebraska",
         null
        ],
        [
         "Haukeland University Hospital",
         null
        ],
        [
         "Lawson Health Research Institute",
         null
        ],
        [
         "RWTH Aachen University",
         null
        ],
        [
         "Guy's and St Thomas' NHS Foundation Trust",
         null
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "Wuerzburg University Hospital",
         null
        ],
        [
         "Nobelpharma",
         null
        ],
        [
         "Dong-A ST Co., Ltd.",
         null
        ],
        [
         "Stanford University",
         null
        ],
        [
         "Fondazione Salvatore Maugeri",
         null
        ],
        [
         "University of British Columbia",
         null
        ],
        [
         "Burnasyan Federal Medical Biophysical Center",
         null
        ],
        [
         "National Taiwan University Hospital",
         null
        ],
        [
         "Atridia Pty Ltd.",
         null
        ],
        [
         "The University of Texas Medical Branch, Galveston",
         null
        ],
        [
         "Kasr El Aini Hospital",
         null
        ],
        [
         "University of California, San Francisco",
         null
        ],
        [
         "Arkansas Heart Hospital",
         null
        ],
        [
         "JSI Research & Training Institute, Inc.",
         null
        ],
        [
         "Yale University",
         null
        ],
        [
         "All India Institute of Medical Sciences, New Delhi",
         null
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Pfizer",
         "Pfizer"
        ],
        [
         "Riyadh Colleges of Dentistry and Pharmacy",
         null
        ],
        [
         "University of Roma La Sapienza",
         null
        ],
        [
         "Eli Lilly and Company",
         null
        ],
        [
         "Nova Scotia Health Authority",
         null
        ],
        [
         "Assiut University",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "Penn State University",
         null
        ],
        [
         "Electrical Geodesics, Inc.",
         null
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Sanofi",
         "Sanofi"
        ],
        [
         "Konkuk University Medical Center",
         null
        ],
        [
         "Vanderbilt University",
         null
        ],
        [
         "Gachon University Gil Medical Center",
         null
        ],
        [
         "Tel Hai College",
         null
        ],
        [
         "Rigshospitalet, Denmark",
         null
        ],
        [
         "University of California, Davis",
         null
        ],
        [
         "Merck Sharp & Dohme Corp.",
         null
        ],
        [
         "Medstar Health Research Institute",
         null
        ],
        [
         "Haukeland University Hospital",
         null
        ],
        [
         "Northwell Health",
         null
        ],
        [
         "Samuel Lunenfeld Research Institute, Mount Sinai Hospital",
         null
        ],
        [
         "Mayo Clinic",
         null
        ],
        [
         "South East Asia Research Collaboration with Hawaii",
         null
        ],
        [
         "Danube Hospital",
         null
        ],
        [
         "Seoul National University Hospital",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "Indonesia University",
         null
        ],
        [
         "University of Zurich",
         null
        ],
        [
         "Lawson Health Research Institute",
         null
        ],
        [
         "Montreal General Hospital",
         null
        ],
        [
         "Instituto Mexicano del Seguro Social",
         null
        ],
        [
         "Brigham and Women's Hospital",
         null
        ],
        [
         "Massachusetts General Hospital",
         null
        ],
        [
         "Johns Hopkins University",
         null
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "Bristol-Myers Squibb",
         "Bristol-Myers Squibb"
        ],
        [
         "New York University",
         null
        ],
        [
         "Alcon, a Novartis Company",
         null
        ],
        [
         "Modarres Hospital",
         null
        ],
        [
         "Queen Mary University of London",
         null
        ],
        [
         "RedHill Biopharma Limited",
         null
        ],
        [
         "Ina-Respond",
         null
        ],
        [
         "University Hospital, Angers",
         null
        ],
        [
         "Washington University Early Recognition Center",
         null
        ],
        [
         "Memorial Sloan Kettering Cancer Center",
         null
        ],
        [
         "Mayne Pharma International Pty Ltd",
         null
        ],
        [
         "Dr. Orit Hamiel",
         null
        ],
        [
         "Imperial College London",
         null
        ],
        [
         "Shiraz University of Medical Sciences",
         null
        ],
        [
         "Universidad Iberoamericana A.C., Mexico",
         null
        ],
        [
         "Federal University of São Paulo",
         null
        ],
        [
         "Groupe Francophone des Myelodysplasies",
         null
        ],
        [
         "Bnai Zion Medical Center",
         null
        ],
        [
         "MCM Vaccines B.V.",
         null
        ],
        [
         "Washington University School of Medicine",
         null
        ],
        [
         "Mayo Clinic",
         null
        ],
        [
         "Kaohsiung Veterans General Hospital.",
         null
        ],
        [
         "Washington University School of Medicine",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "Tanta University",
         null
        ],
        [
         "Alliance for Clinical Trials in Oncology",
         null
        ],
        [
         "New York State Psychiatric Institute",
         null
        ],
        [
         "Laborie Medical Technologies Inc.",
         null
        ],
        [
         "University of California, San Francisco",
         null
        ],
        [
         "The University of Hong Kong",
         null
        ],
        [
         "University Medical Center Groningen",
         null
        ],
        [
         "Vinita Takiar",
         null
        ],
        [
         "Boston Urogynecology Associates",
         null
        ],
        [
         "Federal University of São Paulo",
         null
        ],
        [
         "University Health Network, Toronto",
         null
        ],
        [
         "Jiangsu Hansoh Pharmaceutical Co., Ltd.",
         null
        ],
        [
         "University Hospital Schleswig-Holstein",
         null
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "Odense University Hospital",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "Seoul National University Hospital",
         null
        ],
        [
         "Beijing Tiantan Hospital",
         null
        ],
        [
         "Eli Lilly and Company",
         null
        ],
        [
         "University of Limerick",
         null
        ],
        [
         "Sidney Kimmel Cancer Center at Thomas Jefferson University",
         null
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "AbbVie",
         "AbbVie"
        ],
        [
         "Pieris Pharmaceuticals GmbH",
         null
        ],
        [
         "Shockwave Medical, Inc.",
         null
        ],
        [
         "The University of Hong Kong",
         null
        ],
        [
         "Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau",
         null
        ],
        [
         "Dana-Farber Cancer Institute",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "Fudan University",
         null
        ],
        [
         "Azienda Ospedaliera Bolognini di Seriate Bergamo",
         null
        ],
        [
         "Biocad",
         null
        ],
        [
         "NYU Langone Health",
         null
        ],
        [
         "Tata Medical Center",
         null
        ],
        [
         "University Hospital, Lille",
         null
        ],
        [
         "Novartis Pharmaceuticals",
         null
        ],
        [
         "IRCCS Policlinico S. Matteo",
         null
        ],
        [
         "Fox Chase Cancer Center",
         null
        ],
        [
         "Centre National de la Recherche Scientifique, France",
         null
        ],
        [
         "Konkuk University Medical Center",
         null
        ],
        [
         "Biotronik, Inc.",
         null
        ],
        [
         "The Hospital for Sick Children",
         null
        ],
        [
         "University of Colorado, Denver",
         null
        ],
        [
         "Washington University School of Medicine",
         null
        ],
        [
         "Eli Lilly and Company",
         null
        ],
        [
         "Hospices Civils de Lyon",
         null
        ],
        [
         "Catharina Ziekenhuis Eindhoven",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "RenJi Hospital",
         null
        ],
        [
         "Jonsson Comprehensive Cancer Center",
         null
        ],
        [
         "Karolinska Institutet",
         null
        ],
        [
         "Chulalongkorn University",
         null
        ],
        [
         "Ankara University",
         null
        ],
        [
         "Jena University Hospital",
         null
        ],
        [
         "ESM Technologies, LLC",
         null
        ],
        [
         "National Institute on Drug Abuse (NIDA)",
         null
        ],
        [
         "Samuel Lunenfeld Research Institute, Mount Sinai Hospital",
         null
        ],
        [
         "Ágata Sofia da Silva Vieira",
         null
        ],
        [
         "Pennington Biomedical Research Center",
         null
        ],
        [
         "Uppsala University",
         null
        ],
        [
         "HaEmek Medical Center, Israel",
         null
        ],
        [
         "United States Naval Medical Center, San Diego",
         null
        ],
        [
         "Dana-Farber Cancer Institute",
         null
        ],
        [
         "Verifomics LLC",
         null
        ],
        [
         "Central Hospital, Nancy, France",
         null
        ],
        [
         "Eli Lilly and Company",
         null
        ],
        [
         "Seoul National University Hospital",
         null
        ],
        [
         "Ottawa Hospital Research Institute",
         null
        ],
        [
         "University of Sao Paulo",
         null
        ],
        [
         "Azienda Ospedaliera Bolognini di Seriate Bergamo",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "The Queen Elizabeth Hospital",
         null
        ],
        [
         "University of Nove de Julho",
         null
        ],
        [
         "University of British Columbia",
         null
        ],
        [
         "Meyer Children's Hospital",
         null
        ],
        [
         "Centre hospitalier de l'Université de Montréal (CHUM)",
         null
        ],
        [
         "The Cleveland Clinic",
         null
        ],
        [
         "Medical University of South Carolina",
         null
        ],
        [
         "Università Politecnica delle Marche",
         null
        ],
        [
         "Michigan State University",
         null
        ],
        [
         "Bloodworks",
         null
        ],
        [
         "Royal Marsden NHS Foundation Trust",
         null
        ],
        [
         "Weill Medical College of Cornell University",
         null
        ],
        [
         "Medtronic Cardiovascular",
         null
        ],
        [
         "M.D. Anderson Cancer Center",
         null
        ],
        [
         "Fred Hutchinson Cancer Research Center",
         null
        ],
        [
         "Universitat Jaume I",
         null
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "AstraZeneca",
         "AstraZeneca"
        ],
        [
         "Massachusetts General Hospital",
         null
        ],
        [
         "Sheffield Teaching Hospitals NHS Foundation Trust",
         null
        ],
        [
         "Institut de Cancérologie de Lorraine",
         null
        ],
        [
         "University of Pittsburgh",
         null
        ],
        [
         "NHS Greater Glasgow and Clyde",
         null
        ],
        [
         "Third Military Medical University",
         null
        ],
        [
         "University of California, Davis",
         null
        ],
        [
         "Sanofi Pasteur, a Sanofi Company",
         null
        ],
        [
         "University Hospital, Bordeaux",
         null
        ],
        [
         "University of Bergen",
         null
        ],
        [
         "High Point University",
         null
        ],
        [
         "Assistance Publique Hopitaux De Marseille",
         null
        ],
        [
         "Abramson Cancer Center of the University of Pennsylvania",
         null
        ],
        [
         "Royal Brompton & Harefield NHS Foundation Trust",
         null
        ],
        [
         "Rennes University Hospital",
         null
        ],
        [
         "University of British Columbia",
         null
        ],
        [
         "Centre Hospitalier Universitaire de Nice",
         null
        ],
        [
         "University of Rochester",
         null
        ],
        [
         "Abbott Nutrition",
         null
        ],
        [
         "Mclean Hospital",
         null
        ],
        [
         "Guy's and St Thomas' NHS Foundation Trust",
         null
        ],
        [
         "University of California, San Francisco",
         null
        ],
        [
         "AnalyticsPlus, Inc.",
         null
        ],
        [
         "University of Tromso",
         null
        ],
        [
         "European Association of Urology Research Foundation",
         null
        ],
        [
         "All India Institute of Medical Sciences, New Delhi",
         null
        ],
        [
         "Charite University, Berlin, Germany",
         null
        ],
        [
         "The Baruch Padeh Medical Center, Poriya",
         null
        ],
        [
         "Isfahan University of Medical Sciences",
         null
        ],
        [
         "Ospedale Generale Di Zona Moriggia-Pelascini",
         null
        ],
        [
         "Massachusetts General Hospital",
         null
        ],
        [
         "Cochlear",
         null
        ],
        [
         "Penn State University",
         null
        ],
        [
         "University Hospital, Grenoble",
         null
        ],
        [
         "Brown University",
         null
        ],
        [
         "Janssen Research & Development, LLC",
         null
        ],
        [
         "Clene Nanomedicine",
         null
        ],
        [
         "Boston Medical Center",
         null
        ],
        [
         "Royal Marsden NHS Foundation Trust",
         null
        ],
        [
         "Assistance Publique - Hôpitaux de Paris",
         null
        ],
        [
         "Taipei Medical University WanFang Hospital",
         null
        ],
        [
         "Armata Pharmaceuticals, Inc.",
         null
        ],
        [
         "University of New Mexico",
         null
        ],
        [
         "University of Luebeck",
         null
        ],
        [
         "Hospital Central Dr. Luis Ortega",
         null
        ],
        [
         "McGill University",
         null
        ],
        [
         "F-star Therapeutics, Inc.",
         null
        ],
        [
         "Dartmouth-Hitchcock Medical Center",
         null
        ],
        [
         "Global Protection Corp.",
         null
        ],
        [
         "Peking University People's Hospital",
         null
        ],
        [
         "Radboud University",
         null
        ],
        [
         "Bayer",
         null
        ],
        [
         "National Jewish Health",
         null
        ],
        [
         "University of Wisconsin, Madison",
         null
        ],
        [
         "Federal University of São Paulo",
         null
        ],
        [
         "University of Sheffield",
         null
        ],
        [
         "Teesside University",
         null
        ],
        [
         "KK Women's and Children's Hospital",
         null
        ],
        [
         "University of Brasilia",
         null
        ],
        [
         "Paul Finn",
         null
        ],
        [
         "University Hospital, Lille",
         null
        ],
        [
         "University of Texas Southwestern Medical Center",
         null
        ],
        [
         "Tampere University Hospital",
         null
        ],
        [
         "National Institute of Allergy and Infectious Diseases (NIAID)",
         null
        ],
        [
         "University of Nottingham",
         null
        ],
        [
         "Chung Shan Medical University",
         null
        ],
        [
         "Xuanwu Hospital, Beijing",
         null
        ],
        [
         "University of Pennsylvania",
         null
        ],
        [
         "Baylor Research Institute",
         null
        ],
        [
         "Health Decisions",
         null
        ],
        [
         "Dr. Soetomo General Hospital",
         null
        ],
        [
         "University of New Mexico",
         null
        ],
        [
         "Liverpool Women's NHS Foundation Trust",
         null
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ],
        [
         "GlaxoSmithKline",
         "GlaxoSmithKline"
        ]
       ],
       "datasetInfos": [],
       "dbfsResultPath": null,
       "isJsonSchema": true,
       "metadata": {},
       "overflow": true,
       "plotOptions": {
        "customPlotOptions": {},
        "displayType": "table",
        "pivotAggregation": null,
        "pivotColumns": null,
        "xColumns": null,
        "yColumns": null
       },
       "removedWidgets": [],
       "schema": [
        {
         "metadata": "{}",
         "name": "Sponsor",
         "type": "\"string\""
        },
        {
         "metadata": "{}",
         "name": "Parent_Company",
         "type": "\"string\""
        }
       ],
       "type": "table"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Joining the two dataframes using left join\n",
    "joinedpharmaDF = SponsorsDF.join(ParentCompanyDF,SponsorsDF.Sponsor == ParentCompanyDF.Parent_Company, \"left\")\n",
    "joinedpharmaDF.display()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "aee435dd-9bb1-44e3-912f-7d99a75d4c7a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+--------------------+--------------+\n",
       "|             Sponsor|Parent_Company|\n",
       "+--------------------+--------------+\n",
       "|The University of...|          null|\n",
       "|     Duke University|          null|\n",
       "|Universidade Fede...|          null|\n",
       "|Istanbul Medeniye...|          null|\n",
       "|University of Rom...|          null|\n",
       "|Consorzio Futuro ...|          null|\n",
       "|   Ankara University|          null|\n",
       "|     Ruijin Hospital|          null|\n",
       "|Washington Univer...|          null|\n",
       "|           Orphazyme|          null|\n",
       "|    Novo Nordisk A/S|          null|\n",
       "|Daniel Alexandre ...|          null|\n",
       "|Bulent Ecevit Uni...|          null|\n",
       "|Institut für Phar...|          null|\n",
       "|The Third Xiangya...|          null|\n",
       "|Tel Aviv Medical ...|          null|\n",
       "|Medicines for Mal...|          null|\n",
       "|James Cook Univer...|          null|\n",
       "|Soonchunhyang Uni...|          null|\n",
       "|Member Companies ...|          null|\n",
       "+--------------------+--------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+--------------------+--------------+\n|             Sponsor|Parent_Company|\n+--------------------+--------------+\n|The University of...|          null|\n|     Duke University|          null|\n|Universidade Fede...|          null|\n|Istanbul Medeniye...|          null|\n|University of Rom...|          null|\n|Consorzio Futuro ...|          null|\n|   Ankara University|          null|\n|     Ruijin Hospital|          null|\n|Washington Univer...|          null|\n|           Orphazyme|          null|\n|    Novo Nordisk A/S|          null|\n|Daniel Alexandre ...|          null|\n|Bulent Ecevit Uni...|          null|\n|Institut für Phar...|          null|\n|The Third Xiangya...|          null|\n|Tel Aviv Medical ...|          null|\n|Medicines for Mal...|          null|\n|James Cook Univer...|          null|\n|Soonchunhyang Uni...|          null|\n|Member Companies ...|          null|\n+--------------------+--------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Extracting the rows that have null values in the joined dataframe, grouping and \n",
    "nonpharma_Sponsors = joinedpharmaDF.where(\"Parent_Company is null\")\n",
    "nonpharma_Sponsors.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e071ff1d-b6a2-4b94-856f-f617f7a53da8",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+---------------------------------------+-----+\n",
       "|Sponsor                                |count|\n",
       "+---------------------------------------+-----+\n",
       "|National Cancer Institute (NCI)        |3218 |\n",
       "|M.D. Anderson Cancer Center            |2414 |\n",
       "|Assistance Publique - Hôpitaux de Paris|2369 |\n",
       "|Mayo Clinic                            |2300 |\n",
       "|Merck Sharp & Dohme Corp.              |2243 |\n",
       "|Assiut University                      |2154 |\n",
       "|Novartis Pharmaceuticals               |2088 |\n",
       "|Massachusetts General Hospital         |1971 |\n",
       "|Cairo University                       |1928 |\n",
       "|Hoffmann-La Roche                      |1828 |\n",
       "+---------------------------------------+-----+\n",
       "only showing top 10 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+---------------------------------------+-----+\n|Sponsor                                |count|\n+---------------------------------------+-----+\n|National Cancer Institute (NCI)        |3218 |\n|M.D. Anderson Cancer Center            |2414 |\n|Assistance Publique - Hôpitaux de Paris|2369 |\n|Mayo Clinic                            |2300 |\n|Merck Sharp & Dohme Corp.              |2243 |\n|Assiut University                      |2154 |\n|Novartis Pharmaceuticals               |2088 |\n|Massachusetts General Hospital         |1971 |\n|Cairo University                       |1928 |\n|Hoffmann-La Roche                      |1828 |\n+---------------------------------------+-----+\nonly showing top 10 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#grouping, counting and sorting\n",
    "common_nonpharma_Sponsors = nonpharma_Sponsors.groupBy('Sponsor').count().sort('count', ascending=False)\n",
    "common_nonpharma_Sponsors.show(10, truncate = False)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "ca4ef00b-183d-4a31-b84a-427308f73b66",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Problem 6 - Number of Completed Studies In A Given Year"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e6616a9b-e239-4090-804d-bad931b99102",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n",
       "|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n",
       "|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n",
       "|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n",
       "|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n",
       "|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n",
       "|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n",
       "|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n",
       "|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n",
       "|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n",
       "|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n",
       "|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|Appendicitis,Stom...|                null|\n",
       "|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n",
       "|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|Hookworm Infectio...|                null|\n",
       "|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|             Ascites|                null|\n",
       "|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|Chronic Pain,Subs...|                null|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|Fluticasone,Xhanc...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|            Vitamins|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|Liraglutide,Xultophy|\n|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|Metformin,Empagli...|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|Appendicitis,Stom...|                null|\n|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|Hookworm Infectio...|                null|\n|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|             Ascites|                null|\n|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|Chronic Pain,Subs...|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Viewing the clinical trial dataframe again\n",
    "clinical_df.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "a0ac635e-4019-4002-bd14-6f6a0e4d06ae",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+----------+---------+\n",
       "|Completion|   Status|\n",
       "+----------+---------+\n",
       "|  Jul 2020|Completed|\n",
       "|  Jan 2018|Completed|\n",
       "|  Dec 2014|Completed|\n",
       "|  Jan 2018|Completed|\n",
       "|  Jul 2017|Completed|\n",
       "|  Jan 2021|Completed|\n",
       "|  Oct 2016|Completed|\n",
       "|  Dec 2015|Completed|\n",
       "|  Mar 2016|Completed|\n",
       "|  May 2019|Completed|\n",
       "|  Oct 2019|Completed|\n",
       "|  Apr 2015|Completed|\n",
       "|  Jan 2016|Completed|\n",
       "|      null|Completed|\n",
       "|  Apr 2017|Completed|\n",
       "|  Nov 2020|Completed|\n",
       "|  Jul 2017|Completed|\n",
       "|  Jun 2021|Completed|\n",
       "|  Mar 2017|Completed|\n",
       "|  Apr 2018|Completed|\n",
       "+----------+---------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+----------+---------+\n|Completion|   Status|\n+----------+---------+\n|  Jul 2020|Completed|\n|  Jan 2018|Completed|\n|  Dec 2014|Completed|\n|  Jan 2018|Completed|\n|  Jul 2017|Completed|\n|  Jan 2021|Completed|\n|  Oct 2016|Completed|\n|  Dec 2015|Completed|\n|  Mar 2016|Completed|\n|  May 2019|Completed|\n|  Oct 2019|Completed|\n|  Apr 2015|Completed|\n|  Jan 2016|Completed|\n|      null|Completed|\n|  Apr 2017|Completed|\n|  Nov 2020|Completed|\n|  Jul 2017|Completed|\n|  Jun 2021|Completed|\n|  Mar 2017|Completed|\n|  Apr 2018|Completed|\n+----------+---------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Extracting studies that have been completed\n",
    "CompletedStudies = clinical_df.select(\"Completion\", \"Status\")\\\n",
    "                                .filter(clinical_df.Status == \"Completed\")\n",
    "CompletedStudies.show()\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "fd81203a-48cd-459d-a7b6-23ba5f26c1c4",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+----------+---------+-----+----+\n",
       "|Completion|   Status|Month|Year|\n",
       "+----------+---------+-----+----+\n",
       "|  Jul 2020|Completed|  Jul|2020|\n",
       "|  Jan 2018|Completed|  Jan|2018|\n",
       "|  Dec 2014|Completed|  Dec|2014|\n",
       "|  Jan 2018|Completed|  Jan|2018|\n",
       "|  Jul 2017|Completed|  Jul|2017|\n",
       "|  Jan 2021|Completed|  Jan|2021|\n",
       "|  Oct 2016|Completed|  Oct|2016|\n",
       "|  Dec 2015|Completed|  Dec|2015|\n",
       "|  Mar 2016|Completed|  Mar|2016|\n",
       "|  May 2019|Completed|  May|2019|\n",
       "|  Oct 2019|Completed|  Oct|2019|\n",
       "|  Apr 2015|Completed|  Apr|2015|\n",
       "|  Jan 2016|Completed|  Jan|2016|\n",
       "|      null|Completed| null|null|\n",
       "|  Apr 2017|Completed|  Apr|2017|\n",
       "|  Nov 2020|Completed|  Nov|2020|\n",
       "|  Jul 2017|Completed|  Jul|2017|\n",
       "|  Jun 2021|Completed|  Jun|2021|\n",
       "|  Mar 2017|Completed|  Mar|2017|\n",
       "|  Apr 2018|Completed|  Apr|2018|\n",
       "+----------+---------+-----+----+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+----------+---------+-----+----+\n|Completion|   Status|Month|Year|\n+----------+---------+-----+----+\n|  Jul 2020|Completed|  Jul|2020|\n|  Jan 2018|Completed|  Jan|2018|\n|  Dec 2014|Completed|  Dec|2014|\n|  Jan 2018|Completed|  Jan|2018|\n|  Jul 2017|Completed|  Jul|2017|\n|  Jan 2021|Completed|  Jan|2021|\n|  Oct 2016|Completed|  Oct|2016|\n|  Dec 2015|Completed|  Dec|2015|\n|  Mar 2016|Completed|  Mar|2016|\n|  May 2019|Completed|  May|2019|\n|  Oct 2019|Completed|  Oct|2019|\n|  Apr 2015|Completed|  Apr|2015|\n|  Jan 2016|Completed|  Jan|2016|\n|      null|Completed| null|null|\n|  Apr 2017|Completed|  Apr|2017|\n|  Nov 2020|Completed|  Nov|2020|\n|  Jul 2017|Completed|  Jul|2017|\n|  Jun 2021|Completed|  Jun|2021|\n|  Mar 2017|Completed|  Mar|2017|\n|  Apr 2018|Completed|  Apr|2018|\n+----------+---------+-----+----+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Seperating the month and the year into two seperate columns\n",
    "split_completedstudies = CompletedStudies.withColumn(\"Month\", CompletedStudies.Completion.substr(1,3))\\\n",
    "                                         .withColumn(\"Year\", CompletedStudies.Completion.substr(5,8))\n",
    "split_completedstudies.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "354aea74-c404-467c-86df-f04f7777cb9b",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----+----+\n",
       "|Month|Year|\n",
       "+-----+----+\n",
       "|  Jan|2021|\n",
       "|  Jun|2021|\n",
       "|  Mar|2021|\n",
       "|  Jan|2021|\n",
       "|  May|2021|\n",
       "|  Feb|2021|\n",
       "|  Feb|2021|\n",
       "|  May|2021|\n",
       "|  Aug|2021|\n",
       "|  May|2021|\n",
       "|  Mar|2021|\n",
       "|  Feb|2021|\n",
       "|  May|2021|\n",
       "|  May|2021|\n",
       "|  May|2021|\n",
       "|  Apr|2021|\n",
       "|  Apr|2021|\n",
       "|  Aug|2021|\n",
       "|  Feb|2021|\n",
       "|  Apr|2021|\n",
       "+-----+----+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----+----+\n|Month|Year|\n+-----+----+\n|  Jan|2021|\n|  Jun|2021|\n|  Mar|2021|\n|  Jan|2021|\n|  May|2021|\n|  Feb|2021|\n|  Feb|2021|\n|  May|2021|\n|  Aug|2021|\n|  May|2021|\n|  Mar|2021|\n|  Feb|2021|\n|  May|2021|\n|  May|2021|\n|  May|2021|\n|  Apr|2021|\n|  Apr|2021|\n|  Aug|2021|\n|  Feb|2021|\n|  Apr|2021|\n+-----+----+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Extracting column needed and filtering for concerned year\n",
    "CompletedStudies_year = split_completedstudies.select(\"Month\" , \"Year\")\\\n",
    "                                              .filter(split_completedstudies.Year == year)\n",
    "CompletedStudies_year.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e905b4d8-a4a6-494a-b2c0-1755e435af51",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----+-----+\n",
       "|Month|count|\n",
       "+-----+-----+\n",
       "|  Oct|  187|\n",
       "|  Sep|  528|\n",
       "|  Aug|  700|\n",
       "|  Jul|  819|\n",
       "|  Feb|  934|\n",
       "|  Apr|  967|\n",
       "|  May|  984|\n",
       "|  Jun| 1094|\n",
       "|  Jan| 1131|\n",
       "|  Mar| 1227|\n",
       "+-----+-----+\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----+-----+\n|Month|count|\n+-----+-----+\n|  Oct|  187|\n|  Sep|  528|\n|  Aug|  700|\n|  Jul|  819|\n|  Feb|  934|\n|  Apr|  967|\n|  May|  984|\n|  Jun| 1094|\n|  Jan| 1131|\n|  Mar| 1227|\n+-----+-----+\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "Monthly_CompletedStudies = CompletedStudies_year.groupby('Month').count().sort(\"count\")\n",
    "Monthly_CompletedStudies.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "89e661aa-52ec-45d6-ace6-4e4dbc1f52a2",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "from pyspark.sql.functions import col, when\n",
    "\n",
    "Ordered_Monthly_CompletedStudies = Monthly_CompletedStudies.orderBy(when(col(\"Month\") == \"Jan\", 1)\n",
    "           .when(col(\"Month\") == \"Feb\", 2)\n",
    "           .when(col(\"Month\") == \"Mar\", 3)\n",
    "           .when(col(\"Month\") == \"Apr\", 4)\n",
    "           .when(col(\"Month\") == \"May\", 5)\n",
    "           .when(col(\"Month\") == \"Jun\", 6)\n",
    "           .when(col(\"Month\") == \"Jul\", 7)\n",
    "           .when(col(\"Month\") == \"Aug\", 8)\n",
    "           .when(col(\"Month\") == \"Sep\", 9)\n",
    "           .when(col(\"Month\") == \"Oct\", 10)\n",
    "           .when(col(\"Month\") == \"Nov\", 11)\n",
    "           .when(col(\"Month\") == \"Dec\", 12)\n",
    "           )"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "9309132d-2fb7-4e4d-8ea0-002689943bb9",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----+-----+\n",
       "|Month|count|\n",
       "+-----+-----+\n",
       "|  Jan| 1131|\n",
       "|  Feb|  934|\n",
       "|  Mar| 1227|\n",
       "|  Apr|  967|\n",
       "|  May|  984|\n",
       "|  Jun| 1094|\n",
       "|  Jul|  819|\n",
       "|  Aug|  700|\n",
       "|  Sep|  528|\n",
       "|  Oct|  187|\n",
       "+-----+-----+\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----+-----+\n|Month|count|\n+-----+-----+\n|  Jan| 1131|\n|  Feb|  934|\n|  Mar| 1227|\n|  Apr|  967|\n|  May|  984|\n|  Jun| 1094|\n|  Jul|  819|\n|  Aug|  700|\n|  Sep|  528|\n|  Oct|  187|\n+-----+-----+\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "Ordered_Monthly_CompletedStudies.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "7363fbd6-1ec1-49f6-86d2-bbc2e8117d34",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "##VISUALIZATIONS"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "9fac0adf-fbb4-4b06-a439-07cdbc3281b0",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "#converting the pyspark dataframe to pandas dataframe to aid plotting\n",
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "726eff69-4c3d-4b17-bd3b-1937dd5f9af3",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Using Bokeh"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "d38d7203-83ef-49ac-85f5-0bed67b3b9e5",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "Months = list(Ordered_Monthly_CompletedStudies.toPandas()['Month'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "47e15788-eb6a-4a83-89a1-1d01f569f01a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[40]: ['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct']"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[40]: ['Jan', 'Feb', 'Mar', 'Apr', 'May', 'Jun', 'Jul', 'Aug', 'Sep', 'Oct']",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "Months"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "824d27cd-992c-42d2-b556-4c17095ba727",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "count = list(Ordered_Monthly_CompletedStudies.toPandas()['count'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e41076f1-cb1d-4735-8e61-eb49a121bc5d",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[42]: [1131, 934, 1227, 967, 984, 1094, 819, 700, 528, 187]"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[42]: [1131, 934, 1227, 967, 984, 1094, 819, 700, 528, 187]",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "count"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "245d971b-a832-4880-bc11-2719c349da59",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "\n",
       "\n",
       "\n",
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "  \n",
       "  <head>\n",
       "    \n",
       "      <meta charset=\"utf-8\">\n",
       "      <title>Completed Studies each month for year 2021</title>\n",
       "      \n",
       "      \n",
       "        \n",
       "          \n",
       "        \n",
       "        \n",
       "          \n",
       "        <script type=\"text/javascript\" src=\"https://cdn.bokeh.org/bokeh/release/bokeh-2.4.2.min.js\"></script>\n",
       "        <script type=\"text/javascript\">\n",
       "            Bokeh.set_log_level(\"info\");\n",
       "        </script>\n",
       "        \n",
       "      \n",
       "      \n",
       "    \n",
       "  </head>\n",
       "  \n",
       "  \n",
       "  <body>\n",
       "    \n",
       "      \n",
       "        \n",
       "          \n",
       "          \n",
       "            \n",
       "              <div class=\"bk-root\" id=\"43b2f6a3-14b0-4aa4-97c7-073bc87f62d8\" data-root-id=\"1002\"></div>\n",
       "            \n",
       "          \n",
       "        \n",
       "      \n",
       "      \n",
       "        <script type=\"application/json\" id=\"1172\">\n",
       "          {\"5f090383-e1f8-4587-8865-892a284a2f3b\":{\"defs\":[],\"roots\":{\"references\":[{\"attributes\":{},\"id\":\"1025\",\"type\":\"HelpTool\"},{\"attributes\":{},\"id\":\"1047\",\"type\":\"CategoricalTickFormatter\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1044\"},\"group\":null,\"major_label_policy\":{\"id\":\"1045\"},\"ticker\":{\"id\":\"1017\"}},\"id\":\"1016\",\"type\":\"LinearAxis\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.2},\"fill_color\":{\"field\":\"fill_color\"},\"hatch_alpha\":{\"value\":0.2},\"hatch_color\":{\"field\":\"hatch_color\"},\"line_alpha\":{\"value\":0.2},\"line_color\":{\"field\":\"line_color\"},\"top\":{\"field\":\"top\"},\"width\":{\"value\":0.9},\"x\":{\"field\":\"x\"}},\"id\":\"1039\",\"type\":\"VBar\"},{\"attributes\":{},\"id\":\"1050\",\"type\":\"Selection\"},{\"attributes\":{},\"id\":\"1017\",\"type\":\"BasicTicker\"},{\"attributes\":{\"tools\":[{\"id\":\"1020\"},{\"id\":\"1021\"},{\"id\":\"1022\"},{\"id\":\"1023\"},{\"id\":\"1024\"},{\"id\":\"1025\"},{\"id\":\"1027\"}]},\"id\":\"1028\",\"type\":\"Toolbar\"},{\"attributes\":{\"callback\":null,\"tooltips\":[[\"Month\",\"@x\"],[\"Count\",\"@top\"]]},\"id\":\"1027\",\"type\":\"HoverTool\"},{\"attributes\":{\"coordinates\":null,\"data_source\":{\"id\":\"1036\"},\"glyph\":{\"id\":\"1037\"},\"group\":null,\"hover_glyph\":null,\"muted_glyph\":{\"id\":\"1039\"},\"nonselection_glyph\":{\"id\":\"1038\"},\"view\":{\"id\":\"1041\"}},\"id\":\"1040\",\"type\":\"GlyphRenderer\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.1},\"fill_color\":{\"field\":\"fill_color\"},\"hatch_alpha\":{\"value\":0.1},\"hatch_color\":{\"field\":\"hatch_color\"},\"line_alpha\":{\"value\":0.1},\"line_color\":{\"field\":\"line_color\"},\"top\":{\"field\":\"top\"},\"width\":{\"value\":0.9},\"x\":{\"field\":\"x\"}},\"id\":\"1038\",\"type\":\"VBar\"},{\"attributes\":{},\"id\":\"1021\",\"type\":\"WheelZoomTool\"},{\"attributes\":{},\"id\":\"1020\",\"type\":\"PanTool\"},{\"attributes\":{\"overlay\":{\"id\":\"1026\"}},\"id\":\"1022\",\"type\":\"BoxZoomTool\"},{\"attributes\":{\"source\":{\"id\":\"1036\"}},\"id\":\"1041\",\"type\":\"CDSView\"},{\"attributes\":{\"below\":[{\"id\":\"1013\"}],\"center\":[{\"id\":\"1015\"},{\"id\":\"1019\"}],\"height\":400,\"left\":[{\"id\":\"1016\"}],\"renderers\":[{\"id\":\"1040\"}],\"title\":{\"id\":\"1003\"},\"toolbar\":{\"id\":\"1028\"},\"toolbar_location\":null,\"x_range\":{\"id\":\"1005\"},\"x_scale\":{\"id\":\"1009\"},\"y_range\":{\"id\":\"1007\"},\"y_scale\":{\"id\":\"1011\"}},\"id\":\"1002\",\"subtype\":\"Figure\",\"type\":\"Plot\"},{\"attributes\":{},\"id\":\"1023\",\"type\":\"SaveTool\"},{\"attributes\":{},\"id\":\"1044\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{},\"id\":\"1024\",\"type\":\"ResetTool\"},{\"attributes\":{},\"id\":\"1045\",\"type\":\"AllLabels\"},{\"attributes\":{},\"id\":\"1014\",\"type\":\"CategoricalTicker\"},{\"attributes\":{\"bottom_units\":\"screen\",\"coordinates\":null,\"fill_alpha\":0.5,\"fill_color\":\"lightgrey\",\"group\":null,\"left_units\":\"screen\",\"level\":\"overlay\",\"line_alpha\":1.0,\"line_color\":\"black\",\"line_dash\":[4,4],\"line_width\":2,\"right_units\":\"screen\",\"syncable\":false,\"top_units\":\"screen\"},\"id\":\"1026\",\"type\":\"BoxAnnotation\"},{\"attributes\":{\"factors\":[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\"]},\"id\":\"1005\",\"type\":\"FactorRange\"},{\"attributes\":{},\"id\":\"1048\",\"type\":\"AllLabels\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.75},\"fill_color\":{\"field\":\"fill_color\"},\"hatch_color\":{\"field\":\"hatch_color\"},\"line_color\":{\"field\":\"line_color\"},\"top\":{\"field\":\"top\"},\"width\":{\"value\":0.9},\"x\":{\"field\":\"x\"}},\"id\":\"1037\",\"type\":\"VBar\"},{\"attributes\":{\"coordinates\":null,\"group\":null,\"text\":\"Completed Studies each month for year 2021\"},\"id\":\"1003\",\"type\":\"Title\"},{\"attributes\":{\"data\":{\"fill_color\":[\"#2A768E\",\"#74D054\",\"#6BCD59\",\"#39B976\",\"#2BB17D\",\"#277C8E\",\"#433B83\",\"#C2DF22\",\"#33608D\",\"#1F968B\"],\"hatch_color\":[\"#2A768E\",\"#74D054\",\"#6BCD59\",\"#39B976\",\"#2BB17D\",\"#277C8E\",\"#433B83\",\"#C2DF22\",\"#33608D\",\"#1F968B\"],\"line_color\":[\"#2A768E\",\"#74D054\",\"#6BCD59\",\"#39B976\",\"#2BB17D\",\"#277C8E\",\"#433B83\",\"#C2DF22\",\"#33608D\",\"#1F968B\"],\"top\":[1131,934,1227,967,984,1094,819,700,528,187],\"x\":[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\"]},\"selected\":{\"id\":\"1050\"},\"selection_policy\":{\"id\":\"1049\"}},\"id\":\"1036\",\"type\":\"ColumnDataSource\"},{\"attributes\":{\"axis\":{\"id\":\"1016\"},\"coordinates\":null,\"dimension\":1,\"group\":null,\"ticker\":null},\"id\":\"1019\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1009\",\"type\":\"CategoricalScale\"},{\"attributes\":{},\"id\":\"1049\",\"type\":\"UnionRenderers\"},{\"attributes\":{\"axis\":{\"id\":\"1013\"},\"coordinates\":null,\"grid_line_color\":null,\"group\":null,\"ticker\":null},\"id\":\"1015\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1011\",\"type\":\"LinearScale\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1047\"},\"group\":null,\"major_label_policy\":{\"id\":\"1048\"},\"ticker\":{\"id\":\"1014\"}},\"id\":\"1013\",\"type\":\"CategoricalAxis\"},{\"attributes\":{\"start\":0},\"id\":\"1007\",\"type\":\"DataRange1d\"}],\"root_ids\":[\"1002\"]},\"title\":\"Bokeh Application\",\"version\":\"2.4.2\"}}\n",
       "        </script>\n",
       "        <script type=\"text/javascript\">\n",
       "          (function() {\n",
       "            const fn = function() {\n",
       "              Bokeh.safely(function() {\n",
       "                (function(root) {\n",
       "                  function embed_document(root) {\n",
       "                    \n",
       "                  const docs_json = document.getElementById('1172').textContent;\n",
       "                  const render_items = [{\"docid\":\"5f090383-e1f8-4587-8865-892a284a2f3b\",\"root_ids\":[\"1002\"],\"roots\":{\"1002\":\"43b2f6a3-14b0-4aa4-97c7-073bc87f62d8\"}}];\n",
       "                  root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "                \n",
       "                  }\n",
       "                  if (root.Bokeh !== undefined) {\n",
       "                    embed_document(root);\n",
       "                  } else {\n",
       "                    let attempts = 0;\n",
       "                    const timer = setInterval(function(root) {\n",
       "                      if (root.Bokeh !== undefined) {\n",
       "                        clearInterval(timer);\n",
       "                        embed_document(root);\n",
       "                      } else {\n",
       "                        attempts++;\n",
       "                        if (attempts > 100) {\n",
       "                          clearInterval(timer);\n",
       "                          console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "                        }\n",
       "                      }\n",
       "                    }, 10, root)\n",
       "                  }\n",
       "                })(window);\n",
       "              });\n",
       "            };\n",
       "            if (document.readyState != \"loading\") fn();\n",
       "            else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "          })();\n",
       "        </script>\n",
       "    \n",
       "  </body>\n",
       "  \n",
       "</html>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "\n\n\n\n<!DOCTYPE html>\n<html lang=\"en\">\n  \n  <head>\n    \n      <meta charset=\"utf-8\">\n      <title>Completed Studies each month for year 2021</title>\n      \n      \n        \n          \n        \n        \n          \n        <script type=\"text/javascript\" src=\"https://cdn.bokeh.org/bokeh/release/bokeh-2.4.2.min.js\"></script>\n        <script type=\"text/javascript\">\n            Bokeh.set_log_level(\"info\");\n        </script>\n        \n      \n      \n    \n  </head>\n  \n  \n  <body>\n    \n      \n        \n          \n          \n            \n              <div class=\"bk-root\" id=\"43b2f6a3-14b0-4aa4-97c7-073bc87f62d8\" data-root-id=\"1002\"></div>\n            \n          \n        \n      \n      \n        <script type=\"application/json\" id=\"1172\">\n          {\"5f090383-e1f8-4587-8865-892a284a2f3b\":{\"defs\":[],\"roots\":{\"references\":[{\"attributes\":{},\"id\":\"1025\",\"type\":\"HelpTool\"},{\"attributes\":{},\"id\":\"1047\",\"type\":\"CategoricalTickFormatter\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1044\"},\"group\":null,\"major_label_policy\":{\"id\":\"1045\"},\"ticker\":{\"id\":\"1017\"}},\"id\":\"1016\",\"type\":\"LinearAxis\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.2},\"fill_color\":{\"field\":\"fill_color\"},\"hatch_alpha\":{\"value\":0.2},\"hatch_color\":{\"field\":\"hatch_color\"},\"line_alpha\":{\"value\":0.2},\"line_color\":{\"field\":\"line_color\"},\"top\":{\"field\":\"top\"},\"width\":{\"value\":0.9},\"x\":{\"field\":\"x\"}},\"id\":\"1039\",\"type\":\"VBar\"},{\"attributes\":{},\"id\":\"1050\",\"type\":\"Selection\"},{\"attributes\":{},\"id\":\"1017\",\"type\":\"BasicTicker\"},{\"attributes\":{\"tools\":[{\"id\":\"1020\"},{\"id\":\"1021\"},{\"id\":\"1022\"},{\"id\":\"1023\"},{\"id\":\"1024\"},{\"id\":\"1025\"},{\"id\":\"1027\"}]},\"id\":\"1028\",\"type\":\"Toolbar\"},{\"attributes\":{\"callback\":null,\"tooltips\":[[\"Month\",\"@x\"],[\"Count\",\"@top\"]]},\"id\":\"1027\",\"type\":\"HoverTool\"},{\"attributes\":{\"coordinates\":null,\"data_source\":{\"id\":\"1036\"},\"glyph\":{\"id\":\"1037\"},\"group\":null,\"hover_glyph\":null,\"muted_glyph\":{\"id\":\"1039\"},\"nonselection_glyph\":{\"id\":\"1038\"},\"view\":{\"id\":\"1041\"}},\"id\":\"1040\",\"type\":\"GlyphRenderer\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.1},\"fill_color\":{\"field\":\"fill_color\"},\"hatch_alpha\":{\"value\":0.1},\"hatch_color\":{\"field\":\"hatch_color\"},\"line_alpha\":{\"value\":0.1},\"line_color\":{\"field\":\"line_color\"},\"top\":{\"field\":\"top\"},\"width\":{\"value\":0.9},\"x\":{\"field\":\"x\"}},\"id\":\"1038\",\"type\":\"VBar\"},{\"attributes\":{},\"id\":\"1021\",\"type\":\"WheelZoomTool\"},{\"attributes\":{},\"id\":\"1020\",\"type\":\"PanTool\"},{\"attributes\":{\"overlay\":{\"id\":\"1026\"}},\"id\":\"1022\",\"type\":\"BoxZoomTool\"},{\"attributes\":{\"source\":{\"id\":\"1036\"}},\"id\":\"1041\",\"type\":\"CDSView\"},{\"attributes\":{\"below\":[{\"id\":\"1013\"}],\"center\":[{\"id\":\"1015\"},{\"id\":\"1019\"}],\"height\":400,\"left\":[{\"id\":\"1016\"}],\"renderers\":[{\"id\":\"1040\"}],\"title\":{\"id\":\"1003\"},\"toolbar\":{\"id\":\"1028\"},\"toolbar_location\":null,\"x_range\":{\"id\":\"1005\"},\"x_scale\":{\"id\":\"1009\"},\"y_range\":{\"id\":\"1007\"},\"y_scale\":{\"id\":\"1011\"}},\"id\":\"1002\",\"subtype\":\"Figure\",\"type\":\"Plot\"},{\"attributes\":{},\"id\":\"1023\",\"type\":\"SaveTool\"},{\"attributes\":{},\"id\":\"1044\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{},\"id\":\"1024\",\"type\":\"ResetTool\"},{\"attributes\":{},\"id\":\"1045\",\"type\":\"AllLabels\"},{\"attributes\":{},\"id\":\"1014\",\"type\":\"CategoricalTicker\"},{\"attributes\":{\"bottom_units\":\"screen\",\"coordinates\":null,\"fill_alpha\":0.5,\"fill_color\":\"lightgrey\",\"group\":null,\"left_units\":\"screen\",\"level\":\"overlay\",\"line_alpha\":1.0,\"line_color\":\"black\",\"line_dash\":[4,4],\"line_width\":2,\"right_units\":\"screen\",\"syncable\":false,\"top_units\":\"screen\"},\"id\":\"1026\",\"type\":\"BoxAnnotation\"},{\"attributes\":{\"factors\":[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\"]},\"id\":\"1005\",\"type\":\"FactorRange\"},{\"attributes\":{},\"id\":\"1048\",\"type\":\"AllLabels\"},{\"attributes\":{\"fill_alpha\":{\"value\":0.75},\"fill_color\":{\"field\":\"fill_color\"},\"hatch_color\":{\"field\":\"hatch_color\"},\"line_color\":{\"field\":\"line_color\"},\"top\":{\"field\":\"top\"},\"width\":{\"value\":0.9},\"x\":{\"field\":\"x\"}},\"id\":\"1037\",\"type\":\"VBar\"},{\"attributes\":{\"coordinates\":null,\"group\":null,\"text\":\"Completed Studies each month for year 2021\"},\"id\":\"1003\",\"type\":\"Title\"},{\"attributes\":{\"data\":{\"fill_color\":[\"#2A768E\",\"#74D054\",\"#6BCD59\",\"#39B976\",\"#2BB17D\",\"#277C8E\",\"#433B83\",\"#C2DF22\",\"#33608D\",\"#1F968B\"],\"hatch_color\":[\"#2A768E\",\"#74D054\",\"#6BCD59\",\"#39B976\",\"#2BB17D\",\"#277C8E\",\"#433B83\",\"#C2DF22\",\"#33608D\",\"#1F968B\"],\"line_color\":[\"#2A768E\",\"#74D054\",\"#6BCD59\",\"#39B976\",\"#2BB17D\",\"#277C8E\",\"#433B83\",\"#C2DF22\",\"#33608D\",\"#1F968B\"],\"top\":[1131,934,1227,967,984,1094,819,700,528,187],\"x\":[\"Jan\",\"Feb\",\"Mar\",\"Apr\",\"May\",\"Jun\",\"Jul\",\"Aug\",\"Sep\",\"Oct\"]},\"selected\":{\"id\":\"1050\"},\"selection_policy\":{\"id\":\"1049\"}},\"id\":\"1036\",\"type\":\"ColumnDataSource\"},{\"attributes\":{\"axis\":{\"id\":\"1016\"},\"coordinates\":null,\"dimension\":1,\"group\":null,\"ticker\":null},\"id\":\"1019\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1009\",\"type\":\"CategoricalScale\"},{\"attributes\":{},\"id\":\"1049\",\"type\":\"UnionRenderers\"},{\"attributes\":{\"axis\":{\"id\":\"1013\"},\"coordinates\":null,\"grid_line_color\":null,\"group\":null,\"ticker\":null},\"id\":\"1015\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1011\",\"type\":\"LinearScale\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1047\"},\"group\":null,\"major_label_policy\":{\"id\":\"1048\"},\"ticker\":{\"id\":\"1014\"}},\"id\":\"1013\",\"type\":\"CategoricalAxis\"},{\"attributes\":{\"start\":0},\"id\":\"1007\",\"type\":\"DataRange1d\"}],\"root_ids\":[\"1002\"]},\"title\":\"Bokeh Application\",\"version\":\"2.4.2\"}}\n        </script>\n        <script type=\"text/javascript\">\n          (function() {\n            const fn = function() {\n              Bokeh.safely(function() {\n                (function(root) {\n                  function embed_document(root) {\n                    \n                  const docs_json = document.getElementById('1172').textContent;\n                  const render_items = [{\"docid\":\"5f090383-e1f8-4587-8865-892a284a2f3b\",\"root_ids\":[\"1002\"],\"roots\":{\"1002\":\"43b2f6a3-14b0-4aa4-97c7-073bc87f62d8\"}}];\n                  root.Bokeh.embed.embed_items(docs_json, render_items);\n                \n                  }\n                  if (root.Bokeh !== undefined) {\n                    embed_document(root);\n                  } else {\n                    let attempts = 0;\n                    const timer = setInterval(function(root) {\n                      if (root.Bokeh !== undefined) {\n                        clearInterval(timer);\n                        embed_document(root);\n                      } else {\n                        attempts++;\n                        if (attempts > 100) {\n                          clearInterval(timer);\n                          console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n                        }\n                      }\n                    }, 10, root)\n                  }\n                })(window);\n              });\n            };\n            if (document.readyState != \"loading\") fn();\n            else document.addEventListener(\"DOMContentLoaded\", fn);\n          })();\n        </script>\n    \n  </body>\n  \n</html>",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "textData": null,
       "type": "htmlSandbox"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import random\n",
    "from bokeh.io import output_file, show\n",
    "from bokeh.plotting import figure\n",
    "from bokeh.embed import components, file_html\n",
    "from bokeh.resources import CDN\n",
    "from bokeh.palettes import Viridis256\n",
    "\n",
    "output_file(\"Monthly_completed_studies.html\")\n",
    "\n",
    "p = figure(x_range= Months, height=400, title=\"Completed Studies each month for year 2021\", \n",
    "           toolbar_location=None ,tooltips = [(\"Month\",  \"@x\"), (\"Count\" , \"@top\")])\n",
    "\n",
    "p.vbar(x=Months, top=count, width=0.9,color = random.sample(Viridis256,10), fill_alpha=.75)\n",
    "\n",
    "p.xgrid.grid_line_color = None\n",
    "p.y_range.start = 0\n",
    "\n",
    "html = file_html(p, CDN, \"Completed Studies each month for year 2021\")\n",
    "displayHTML(html)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "ace03ba6-b643-41bf-8667-13225bba2f05",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "###Using Matplotlib"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e1e9b155-af31-4d65-bedf-a61d29b16ce4",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n"
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "data:image/png;base64,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\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "image"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "import matplotlib.pyplot as plt\n",
    "\n",
    "Ordered_Monthly_CompletedStudies.toPandas().plot(x=\"Month\", y=\"count\", kind='line',  marker='*', color='red', ms=10\n",
    "                                                ,title=\"Number of Completed Studies each month - Year 2021\", figsize=(15, 6))\n",
    "\n",
    "plt.show()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "dac55ae7-9756-4a0e-8263-9848010e41dc",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "#FURTHER ANALYSIS"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "85e9a264-09fd-4416-89fb-6416b4562198",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "##Exploring the top Interventions"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "b5ebd80e-33f0-4e16-97d3-d4fce6e037cf",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+----------------------------------------------------------------------+\n",
       "|Interventions                                                         |\n",
       "+----------------------------------------------------------------------+\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate|\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|Vitamins                                                              |\n",
       "|null                                                                  |\n",
       "|Liraglutide,Xultophy                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|Metformin,Empagliflozin,Linagliptin                                   |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "|null                                                                  |\n",
       "+----------------------------------------------------------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+----------------------------------------------------------------------+\n|Interventions                                                         |\n+----------------------------------------------------------------------+\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n|Fluticasone,Xhance,Budesonide,Formoterol Fumarate,Salmeterol Xinafoate|\n|null                                                                  |\n|null                                                                  |\n|Vitamins                                                              |\n|null                                                                  |\n|Liraglutide,Xultophy                                                  |\n|null                                                                  |\n|null                                                                  |\n|Metformin,Empagliflozin,Linagliptin                                   |\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n|null                                                                  |\n+----------------------------------------------------------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#viewing the interventions column\n",
    "clinical_df.select(\"Interventions\").show(truncate = False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "e383ce6d-caa4-4b24-a55c-41cd87889172",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n",
       "|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n",
       "|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n",
       "|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n",
       "|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|[Fluticasone, Xha...|\n",
       "|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n",
       "|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n",
       "|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|          [Vitamins]|\n",
       "|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n",
       "|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|[Liraglutide, Xul...|\n",
       "|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n",
       "|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n",
       "|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|[Metformin, Empag...|\n",
       "|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|Appendicitis,Stom...|                null|\n",
       "|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n",
       "|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n",
       "|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|Hookworm Infectio...|                null|\n",
       "|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|             Ascites|                null|\n",
       "|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|Chronic Pain,Subs...|                null|\n",
       "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|         Id|             Sponsor|              Status|   Start|Completion|                Type|Submission|          Conditions|       Interventions|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\n|NCT02758028|The University of...|          Recruiting|Aug 2005|  Nov 2021|      Interventional|  Apr 2016|                null|                null|\n|NCT02751957|     Duke University|           Completed|Jul 2016|  Jul 2020|      Interventional|  Apr 2016|Autistic Disorder...|                null|\n|NCT02758483|Universidade Fede...|           Completed|Mar 2017|  Jan 2018|      Interventional|  Apr 2016|   Diabetes Mellitus|                null|\n|NCT02759848|Istanbul Medeniye...|           Completed|Jan 2012|  Dec 2014|       Observational|  May 2016|Tuberculosis,Lung...|                null|\n|NCT02758860|University of Rom...|Active, not recru...|Jun 2016|  Sep 2020|Observational [Pa...|  Apr 2016|Diverticular Dise...|                null|\n|NCT02757209|Consorzio Futuro ...|           Completed|Apr 2016|  Jan 2018|      Interventional|  Apr 2016|              Asthma|[Fluticasone, Xha...|\n|NCT02752438|   Ankara University|      Unknown status|May 2016|  Jul 2017|Observational [Pa...|  Apr 2016|     Hypoventilation|                null|\n|NCT02753543|     Ruijin Hospital|      Unknown status|Nov 2015|  Nov 2019|      Interventional|  Apr 2016|            Lymphoma|                null|\n|NCT02757508|Washington Univer...|           Completed|Mar 2016|  Jul 2017|      Interventional|  Apr 2016|                null|          [Vitamins]|\n|NCT02753530|           Orphazyme|           Completed|Aug 2017|  Jan 2021|      Interventional|  Apr 2016|            Myositis|                null|\n|NCT02754817|    Novo Nordisk A/S|           Completed|Apr 2016|  Oct 2016|       Observational|  Apr 2016|   Diabetes Mellitus|[Liraglutide, Xul...|\n|NCT02759276|Daniel Alexandre ...|           Completed|May 2015|  Dec 2015|       Observational|  Apr 2016|        Hypertension|                null|\n|NCT02750956|Bulent Ecevit Uni...|           Completed|Jun 2015|  Mar 2016|       Observational|  Apr 2016|Periodontal Diseases|                null|\n|NCT02752113|Institut für Phar...|           Completed|Apr 2016|  May 2019|      Interventional|  Apr 2016|   Diabetes Mellitus|[Metformin, Empag...|\n|NCT02752698|The Third Xiangya...|Active, not recru...|Jan 2015|  Dec 2021|      Interventional|  Jun 2015|Appendicitis,Stom...|                null|\n|NCT02755779|Tel Aviv Medical ...|      Unknown status|Jun 2016|  Jun 2017|       Observational|  Apr 2016|                null|                null|\n|NCT02750384|Medicines for Mal...|          Terminated|May 2016|  Jul 2016|      Interventional|  Apr 2016|                null|                null|\n|NCT02754609|James Cook Univer...|           Completed|Sep 2016|  Oct 2019|      Interventional|  Apr 2016|Hookworm Infectio...|                null|\n|NCT02755701|Soonchunhyang Uni...|      Unknown status|Jul 2016|  Dec 2018|      Interventional|  Apr 2016|             Ascites|                null|\n|NCT02751762|Member Companies ...|          Recruiting|Nov 2017|  Oct 2022|       Observational|  Apr 2016|Chronic Pain,Subs...|                null|\n+-----------+--------------------+--------------------+--------+----------+--------------------+----------+--------------------+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#splitting the conditions column row by row in order for it to be exploded\n",
    "from pyspark.sql.functions import split\n",
    "splitinterventionsDF = clinical_df.withColumn('Interventions', split(clinical_df[\"Interventions\"], \",\"))\n",
    "splitinterventionsDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "d2a50d10-4b61-4009-ab67-83268ca4d265",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-----------+--------------------+--------------+--------+----------+--------------+----------+-----------------+--------------------+\n",
       "|         Id|             Sponsor|        Status|   Start|Completion|          Type|Submission|       Conditions|       Interventions|\n",
       "+-----------+--------------------+--------------+--------+----------+--------------+----------+-----------------+--------------------+\n",
       "|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|         Fluticasone|\n",
       "|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|              Xhance|\n",
       "|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|          Budesonide|\n",
       "|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma| Formoterol Fumarate|\n",
       "|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|Salmeterol Xinafoate|\n",
       "|NCT02757508|Washington Univer...|     Completed|Mar 2016|  Jul 2017|Interventional|  Apr 2016|             null|            Vitamins|\n",
       "|NCT02754817|    Novo Nordisk A/S|     Completed|Apr 2016|  Oct 2016| Observational|  Apr 2016|Diabetes Mellitus|         Liraglutide|\n",
       "|NCT02754817|    Novo Nordisk A/S|     Completed|Apr 2016|  Oct 2016| Observational|  Apr 2016|Diabetes Mellitus|            Xultophy|\n",
       "|NCT02752113|Institut für Phar...|     Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|Diabetes Mellitus|           Metformin|\n",
       "|NCT02752113|Institut für Phar...|     Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|Diabetes Mellitus|       Empagliflozin|\n",
       "|NCT02752113|Institut für Phar...|     Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|Diabetes Mellitus|         Linagliptin|\n",
       "|NCT02750709|Cycle Pharmaceuti...|     Completed|Oct 2015|  Jan 2016|Interventional|  Apr 2016|     Tyrosinemias|          Nitisinone|\n",
       "|NCT02755298|University of Zurich|     Completed|Oct 2016|  Nov 2020|Interventional|  Mar 2016|     Hypertension|       Acetazolamide|\n",
       "|NCT02759614|Guangdong Associa...|Unknown status|Apr 2016|  Jun 2019|Interventional|  Mar 2016|        Carcinoma|         Bevacizumab|\n",
       "|NCT02759614|Guangdong Associa...|Unknown status|Apr 2016|  Jun 2019|Interventional|  Mar 2016|        Carcinoma|Erlotinib Hydroch...|\n",
       "|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|          Prednisone|\n",
       "|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|    Cyclophosphamide|\n",
       "|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|           Rituximab|\n",
       "|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|         Vincristine|\n",
       "|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|          Epirubicin|\n",
       "+-----------+--------------------+--------------+--------+----------+--------------+----------+-----------------+--------------------+\n",
       "only showing top 20 rows\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-----------+--------------------+--------------+--------+----------+--------------+----------+-----------------+--------------------+\n|         Id|             Sponsor|        Status|   Start|Completion|          Type|Submission|       Conditions|       Interventions|\n+-----------+--------------------+--------------+--------+----------+--------------+----------+-----------------+--------------------+\n|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|         Fluticasone|\n|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|              Xhance|\n|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|          Budesonide|\n|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma| Formoterol Fumarate|\n|NCT02757209|Consorzio Futuro ...|     Completed|Apr 2016|  Jan 2018|Interventional|  Apr 2016|           Asthma|Salmeterol Xinafoate|\n|NCT02757508|Washington Univer...|     Completed|Mar 2016|  Jul 2017|Interventional|  Apr 2016|             null|            Vitamins|\n|NCT02754817|    Novo Nordisk A/S|     Completed|Apr 2016|  Oct 2016| Observational|  Apr 2016|Diabetes Mellitus|         Liraglutide|\n|NCT02754817|    Novo Nordisk A/S|     Completed|Apr 2016|  Oct 2016| Observational|  Apr 2016|Diabetes Mellitus|            Xultophy|\n|NCT02752113|Institut für Phar...|     Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|Diabetes Mellitus|           Metformin|\n|NCT02752113|Institut für Phar...|     Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|Diabetes Mellitus|       Empagliflozin|\n|NCT02752113|Institut für Phar...|     Completed|Apr 2016|  May 2019|Interventional|  Apr 2016|Diabetes Mellitus|         Linagliptin|\n|NCT02750709|Cycle Pharmaceuti...|     Completed|Oct 2015|  Jan 2016|Interventional|  Apr 2016|     Tyrosinemias|          Nitisinone|\n|NCT02755298|University of Zurich|     Completed|Oct 2016|  Nov 2020|Interventional|  Mar 2016|     Hypertension|       Acetazolamide|\n|NCT02759614|Guangdong Associa...|Unknown status|Apr 2016|  Jun 2019|Interventional|  Mar 2016|        Carcinoma|         Bevacizumab|\n|NCT02759614|Guangdong Associa...|Unknown status|Apr 2016|  Jun 2019|Interventional|  Mar 2016|        Carcinoma|Erlotinib Hydroch...|\n|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|          Prednisone|\n|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|    Cyclophosphamide|\n|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|           Rituximab|\n|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|         Vincristine|\n|NCT02752815|     Ruijin Hospital|Unknown status|Apr 2016|  Jun 2020|Interventional|  Apr 2016|         Lymphoma|          Epirubicin|\n+-----------+--------------------+--------------+--------+----------+--------------+----------+-----------------+--------------------+\nonly showing top 20 rows\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#exploding the split array\n",
    "from pyspark.sql.functions import explode\n",
    "explodedinterventionsDF = splitinterventionsDF.withColumn('Interventions', explode(splitinterventionsDF[\"Interventions\"]))\n",
    "explodedinterventionsDF.show()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "b81ba8d6-1368-4443-a826-82a2a1fe9e1a",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "completedinterventions = explodedinterventionsDF.filter(clinical_df.Status == 'Completed')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "d5047633-a201-4905-bea5-905abff62212",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "interventions_list = list(completedinterventions.toPandas()['Interventions'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "94a3277c-dc92-4cb5-9c87-213ad5455402",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[50]: ['Fluticasone',\n",
       " 'Xhance',\n",
       " 'Budesonide',\n",
       " 'Formoterol Fumarate',\n",
       " 'Salmeterol Xinafoate',\n",
       " 'Vitamins',\n",
       " 'Liraglutide',\n",
       " 'Xultophy',\n",
       " 'Metformin',\n",
       " 'Empagliflozin',\n",
       " 'Linagliptin',\n",
       " 'Nitisinone',\n",
       " 'Acetazolamide',\n",
       " 'Ketamine',\n",
       " 'Methohexital',\n",
       " 'Micronutrients',\n",
       " 'Trace Elements',\n",
       " 'Pioglitazone',\n",
       " 'Etoricoxib',\n",
       " 'Lornoxicam',\n",
       " 'Lidocaine',\n",
       " 'Tedizolid phosphate',\n",
       " 'Tedizolid',\n",
       " 'Oxazolidinones',\n",
       " 'Dextrans',\n",
       " 'Povidone',\n",
       " 'Ophthalmic Solutions',\n",
       " 'Lubricant Eye Drops',\n",
       " 'Tafenoquine',\n",
       " 'Acetaminophen',\n",
       " 'Ketamine',\n",
       " 'Pravastatin',\n",
       " 'Caffeine',\n",
       " 'Sunscreening Agents',\n",
       " 'Erythromycin',\n",
       " 'Erythromycin Estolate',\n",
       " 'Erythromycin Ethylsuccinate',\n",
       " 'Erythromycin stearate',\n",
       " 'Erythromycin lactobionate',\n",
       " 'Aminolevulinic Acid',\n",
       " 'Fulvestrant',\n",
       " 'Sufentanil',\n",
       " 'Dsuvia',\n",
       " 'Propofol',\n",
       " 'Paclitaxel',\n",
       " 'Bevacizumab',\n",
       " 'Carboplatin',\n",
       " 'Empagliflozin',\n",
       " 'Linagliptin',\n",
       " 'Hyaluronic Acid',\n",
       " 'BI 836826',\n",
       " 'Celecoxib',\n",
       " 'Golimumab',\n",
       " 'Propofol',\n",
       " 'Sevoflurane',\n",
       " 'Pilocarpine',\n",
       " 'Sunscreening Agents',\n",
       " 'Magnesium Sulfate',\n",
       " 'Bupivacaine',\n",
       " 'Nitisinone',\n",
       " 'Insulin',\n",
       " 'Metformin',\n",
       " 'Insulin Glargine',\n",
       " 'Lixisenatide',\n",
       " 'Tazobactam',\n",
       " 'Piperacillin',\n",
       " 'Fosfomycin',\n",
       " 'Insulin',\n",
       " 'Mirabegron',\n",
       " 'Interferons',\n",
       " 'Ritonavir',\n",
       " 'Ribavirin',\n",
       " 'Interferon-alpha',\n",
       " 'Interferon alpha-2',\n",
       " 'Sofosbuvir',\n",
       " 'Peginterferon alfa-2a',\n",
       " 'Ledipasvir',\n",
       " 'Simeprevir',\n",
       " 'Fluticasone',\n",
       " 'Xhance',\n",
       " 'Formoterol Fumarate',\n",
       " 'Aminolevulinic Acid',\n",
       " 'Melatonin',\n",
       " 'Betaine',\n",
       " 'Dexmedetomidine',\n",
       " 'Dulaglutide',\n",
       " 'Insulin',\n",
       " 'Insulin Glargine',\n",
       " 'Lixisenatide',\n",
       " 'Hypoglycemic Agents',\n",
       " 'Propofol',\n",
       " 'Desflurane',\n",
       " 'Suvorexant',\n",
       " 'Azithromycin',\n",
       " 'Metronidazole',\n",
       " 'Doxycycline',\n",
       " 'Tenofovir',\n",
       " 'Lamivudine',\n",
       " 'Efavirenz',\n",
       " 'Telmisartan',\n",
       " 'Itraconazole',\n",
       " 'Terlipressin',\n",
       " 'Pantoprazole',\n",
       " 'Somatostatin',\n",
       " 'Fluorides',\n",
       " 'Tin Fluorides',\n",
       " 'Fluorophosphate',\n",
       " 'Pembrolizumab',\n",
       " 'Dulaglutide',\n",
       " 'Tirzepatide',\n",
       " 'Adalimumab',\n",
       " 'Fluorides',\n",
       " 'Glatiramer Acetate',\n",
       " 'Mannitol',\n",
       " '(T',\n",
       " 'Naltrexone',\n",
       " 'Fentanyl',\n",
       " 'Bupivacaine',\n",
       " 'Fluorides',\n",
       " 'Tin Fluorides',\n",
       " 'Nicotine',\n",
       " 'Vaccines',\n",
       " 'Chlorhexidine',\n",
       " 'Acetazolamide',\n",
       " 'Methazolamide',\n",
       " 'Doxycycline',\n",
       " 'Cholecalciferol',\n",
       " 'Metformin',\n",
       " 'Clozapine',\n",
       " 'Diclofenac',\n",
       " 'Bupivacaine',\n",
       " 'Tenofovir',\n",
       " 'Prednisone',\n",
       " 'AZD7624',\n",
       " 'Tetracaine',\n",
       " 'Nitrous Oxide',\n",
       " 'Bromides',\n",
       " 'Ipratropium',\n",
       " 'Acetazolamide',\n",
       " 'Cytarabine',\n",
       " 'Cyclosporine',\n",
       " 'Mycophenolic Acid',\n",
       " 'Sirolimus',\n",
       " 'Fludarabine',\n",
       " 'Fludarabine phosphate',\n",
       " 'Melphalan',\n",
       " 'Mechlorethamine',\n",
       " 'Mitoxantrone',\n",
       " 'Nitrogen Mustard Compounds',\n",
       " 'Cladribine',\n",
       " '2-chloro-3-deoxyadenosine',\n",
       " 'Cyclosporins',\n",
       " 'Lenograstim',\n",
       " 'Fluorides',\n",
       " 'Tin Fluorides',\n",
       " 'Fluorophosphate',\n",
       " 'Plasminogen',\n",
       " 'Tissue Plasminogen Activator',\n",
       " 'Valsartan',\n",
       " 'Sacubitril and valsartan sodium hydrate drug combination',\n",
       " 'Salicylic Acid',\n",
       " 'Adapalene',\n",
       " 'Salicylates',\n",
       " 'Nitisinone',\n",
       " 'Bupivacaine',\n",
       " 'Lidocaine',\n",
       " 'Ondansetron',\n",
       " 'Sirolimus',\n",
       " 'Alogliptin',\n",
       " 'Gemcitabine',\n",
       " 'Dexamethasone',\n",
       " 'Obinutuzumab',\n",
       " 'Fentanyl',\n",
       " 'Ketorolac',\n",
       " 'Nepafenac',\n",
       " 'Citric Acid',\n",
       " 'Sodium Citrate',\n",
       " 'Celecoxib',\n",
       " 'Dronabinol',\n",
       " 'Cannabidiol',\n",
       " 'Vaccines',\n",
       " 'Azilsartan medoxomil',\n",
       " 'Telavancin',\n",
       " 'Misoprostol',\n",
       " 'Cetirizine',\n",
       " 'Tamsulosin',\n",
       " 'Mirabegron',\n",
       " 'Dexmedetomidine',\n",
       " 'Irsogladine',\n",
       " 'Lafutidine',\n",
       " 'Cannabidiol',\n",
       " 'Allopurinol',\n",
       " 'Febuxostat',\n",
       " 'Anesthetics',\n",
       " 'Vaccines',\n",
       " 'Hydrogen Peroxide',\n",
       " 'Doxorubicin',\n",
       " 'Liposomal doxorubicin',\n",
       " 'Pembrolizumab',\n",
       " 'Ixekizumab',\n",
       " 'Melatonin',\n",
       " 'Vitamin D',\n",
       " 'Vaccines',\n",
       " 'Phosphocreatine',\n",
       " 'Anesthetics',\n",
       " 'Fluorodeoxyglucose F18',\n",
       " 'Hydroxychloroquine',\n",
       " 'Hydrocortisone',\n",
       " 'Cyclophosphamide',\n",
       " 'Dronabinol',\n",
       " 'Dapagliflozin',\n",
       " 'Acetaminophen',\n",
       " 'Tramadol',\n",
       " 'Codeine',\n",
       " 'Micronutrients',\n",
       " 'Trace Elements',\n",
       " 'Leucovorin',\n",
       " 'Bevacizumab',\n",
       " 'Fluorouracil',\n",
       " 'Irinotecan',\n",
       " 'Carboxymethylcellulose Sodium',\n",
       " 'Ophthalmic Solutions',\n",
       " 'Lubricant Eye Drops',\n",
       " 'Botulinum Toxins',\n",
       " 'Olanzapine',\n",
       " 'Tenofovir',\n",
       " 'Doxorubicin',\n",
       " 'Liposomal doxorubicin',\n",
       " 'Maytansine',\n",
       " 'Sunscreening Agents',\n",
       " 'Insulin',\n",
       " 'Azacitidine',\n",
       " 'Salmeterol Xinafoate',\n",
       " 'Montelukast',\n",
       " 'Lansoprazole',\n",
       " 'Dexlansoprazole',\n",
       " 'Rebamipide',\n",
       " 'Atropine',\n",
       " 'Epinephrine',\n",
       " 'Fentanyl',\n",
       " 'Bupivacaine',\n",
       " 'Neostigmine',\n",
       " 'Rituximab',\n",
       " 'Chlorhexidine',\n",
       " 'Chlorhexidine gluconate',\n",
       " 'Cetylpyridinium',\n",
       " 'Esomeprazole',\n",
       " 'Sirolimus',\n",
       " 'Dexamethasone',\n",
       " 'Lenalidomide',\n",
       " 'Dronedarone',\n",
       " 'Gefitinib',\n",
       " 'Insulin',\n",
       " 'Insulin Glargine',\n",
       " 'Insulin glulisine',\n",
       " 'Fludarabine',\n",
       " 'Fludarabine phosphate',\n",
       " 'Busulfan',\n",
       " 'Antilymphocyte Serum',\n",
       " 'Methylphenidate',\n",
       " 'Amlodipine',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Alendronate',\n",
       " 'Febuxostat',\n",
       " 'Valsartan',\n",
       " 'Gemcitabine',\n",
       " 'Docetaxel',\n",
       " 'Olanzapine',\n",
       " 'Clozapine',\n",
       " 'Valsartan',\n",
       " 'Simvastatin',\n",
       " 'Zolpidem',\n",
       " 'Citalopram',\n",
       " 'Gemcitabine',\n",
       " 'Celecoxib',\n",
       " 'Darifenacin',\n",
       " 'Risperidone',\n",
       " 'Reteplase',\n",
       " 'Vitamins',\n",
       " 'Folic Acid',\n",
       " 'Vitamin A',\n",
       " 'Thiamine',\n",
       " 'Selenium',\n",
       " 'Micronutrients',\n",
       " 'Trace Elements',\n",
       " 'Valsartan',\n",
       " 'Doxycycline',\n",
       " 'Zoledronic Acid',\n",
       " 'Treosulfan',\n",
       " 'Busulfan',\n",
       " 'Cyclophosphamide',\n",
       " 'Busulfan',\n",
       " 'Antilymphocyte Serum',\n",
       " 'Docetaxel',\n",
       " 'Deferasirox',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Everolimus',\n",
       " 'Azathioprine',\n",
       " 'Calcineurin Inhibitors',\n",
       " 'Zoledronic Acid',\n",
       " 'Letrozole',\n",
       " 'Zoledronic Acid',\n",
       " 'Botulinum Toxins',\n",
       " 'abobotulinumtoxinA',\n",
       " 'Busulfan',\n",
       " 'Heptavalent Pneumococcal Conjugate Vaccine',\n",
       " 'Lumiracoxib',\n",
       " 'Prazosin',\n",
       " 'Insulin Glargine',\n",
       " 'Lycopene',\n",
       " 'Citalopram',\n",
       " 'Olanzapine',\n",
       " 'Risperidone',\n",
       " 'Amlodipine',\n",
       " 'Valsartan',\n",
       " 'Tolterodine Tartrate',\n",
       " 'Pioglitazone',\n",
       " 'Lansoprazole',\n",
       " 'Dexlansoprazole',\n",
       " 'Topotecan',\n",
       " 'Bupropion',\n",
       " 'Bevacizumab',\n",
       " 'Capecitabine',\n",
       " 'Oxaliplatin',\n",
       " 'Gemcitabine',\n",
       " 'Ifosfamide',\n",
       " 'Famciclovir',\n",
       " 'Certoparin',\n",
       " 'Pasireotide',\n",
       " 'Epothilones',\n",
       " 'Epothilone B',\n",
       " 'Paclitaxel',\n",
       " 'Carboplatin',\n",
       " 'Lenalidomide',\n",
       " 'Esomeprazole',\n",
       " 'Amlodipine',\n",
       " 'Valsartan',\n",
       " 'Paclitaxel',\n",
       " 'Paroxetine',\n",
       " 'Lamotrigine',\n",
       " 'Valproic Acid',\n",
       " 'Olanzapine',\n",
       " 'Risperidone',\n",
       " 'Lithium Carbonate',\n",
       " 'Mirtazapine',\n",
       " 'Tranylcypromine',\n",
       " 'Bupropion',\n",
       " 'Paroxetine',\n",
       " 'Venlafaxine Hydrochloride',\n",
       " 'Octreotide',\n",
       " 'Paclitaxel',\n",
       " 'Carboplatin',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Zoledronic Acid',\n",
       " 'Cyclosporine',\n",
       " 'Cyclosporins',\n",
       " 'Everolimus',\n",
       " 'Amphotericin B',\n",
       " 'Liposomal amphotericin B',\n",
       " 'Valsartan',\n",
       " 'Irbesartan',\n",
       " 'Parathyroid Hormone',\n",
       " 'Lansoprazole',\n",
       " 'Dexlansoprazole',\n",
       " 'Sildenafil Citrate',\n",
       " 'Fluvoxamine',\n",
       " 'Everolimus',\n",
       " 'Amlodipine',\n",
       " 'Valsartan',\n",
       " 'Aluminum Hydroxide',\n",
       " 'Tretinoin',\n",
       " 'Theophylline',\n",
       " 'Valproic Acid',\n",
       " 'Cyclophosphamide',\n",
       " 'Busulfan',\n",
       " 'Thymoglobulin',\n",
       " 'Paclitaxel',\n",
       " 'Carboplatin',\n",
       " 'Zoledronic Acid',\n",
       " 'Amlodipine',\n",
       " 'Valsartan',\n",
       " 'Brivaracetam',\n",
       " 'Amlodipine',\n",
       " 'Benazepril',\n",
       " 'Prednisolone',\n",
       " 'Methylprednisolone Acetate',\n",
       " 'Methylprednisolone',\n",
       " 'Methylprednisolone Hemisuccinate',\n",
       " 'Prednisolone acetate',\n",
       " 'Prednisolone hemisuccinate',\n",
       " 'Prednisolone phosphate',\n",
       " 'Paroxetine',\n",
       " 'Doxycycline',\n",
       " 'Imiquimod',\n",
       " 'Moxifloxacin',\n",
       " 'Eflornithine',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Duloxetine Hydrochloride',\n",
       " 'Donepezil',\n",
       " 'Citalopram',\n",
       " 'Venlafaxine Hydrochloride',\n",
       " 'Codeine',\n",
       " 'Tirapazamine',\n",
       " 'Pioglitazone',\n",
       " 'Deferasirox',\n",
       " 'Valsartan',\n",
       " 'Lisinopril',\n",
       " 'Rifampin',\n",
       " 'Isoniazid',\n",
       " 'Gemcitabine',\n",
       " 'Cisplatin',\n",
       " 'Docetaxel',\n",
       " 'Allopurinol',\n",
       " 'Febuxostat',\n",
       " 'Pravastatin',\n",
       " 'Mycophenolic Acid',\n",
       " 'Thalidomide',\n",
       " 'Carboplatin',\n",
       " 'Baclofen',\n",
       " 'Botulinum Toxins',\n",
       " 'abobotulinumtoxinA',\n",
       " 'Valsartan',\n",
       " 'Interferons',\n",
       " 'Interferon-alpha',\n",
       " 'Interferon alpha-2',\n",
       " 'Peginterferon alfa-2a',\n",
       " 'Vatalanib',\n",
       " 'Ciclesonide',\n",
       " 'Diclofenac',\n",
       " 'Carboplatin',\n",
       " 'Brivaracetam',\n",
       " 'Docetaxel',\n",
       " 'Modafinil',\n",
       " 'Tacrolimus',\n",
       " 'Lumiracoxib',\n",
       " 'Mupirocin',\n",
       " 'Sodium Hypochlorite',\n",
       " 'Eusol',\n",
       " 'Petrolatum',\n",
       " 'Aripiprazole',\n",
       " 'Cyclosporine',\n",
       " 'Mycophenolic Acid',\n",
       " 'Fludarabine',\n",
       " 'Melphalan',\n",
       " 'Alemtuzumab',\n",
       " 'Cyclosporins',\n",
       " 'Antilymphocyte Serum',\n",
       " 'Immunoglobulins',\n",
       " 'Antibodies',\n",
       " 'gamma-Globulins',\n",
       " 'Rho(D) Immune Globulin',\n",
       " 'Deferasirox',\n",
       " 'Imatinib Mesylate',\n",
       " 'Voriconazole',\n",
       " 'Modafinil',\n",
       " 'SR 31747',\n",
       " 'Vidarabine',\n",
       " 'Cyclophosphamide',\n",
       " 'Busulfan',\n",
       " 'Fludarabine',\n",
       " 'Fludarabine phosphate',\n",
       " 'Alemtuzumab',\n",
       " 'Antilymphocyte Serum',\n",
       " 'Sargramostim',\n",
       " 'Lenograstim',\n",
       " 'Misoprostol',\n",
       " 'Mifepristone',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Docetaxel',\n",
       " 'Sargramostim',\n",
       " 'Octreotide',\n",
       " 'Clopidogrel',\n",
       " 'Nicotine',\n",
       " 'Ziprasidone',\n",
       " 'Natriuretic Peptide',\n",
       " 'Vaccines',\n",
       " 'Furosemide',\n",
       " 'Mannitol',\n",
       " 'Sertraline',\n",
       " 'Certolizumab Pegol',\n",
       " 'Lenalidomide',\n",
       " 'Fluconazole',\n",
       " 'Bupivacaine',\n",
       " 'Sertraline',\n",
       " 'Venlafaxine Hydrochloride',\n",
       " 'Lamotrigine',\n",
       " 'Eletriptan',\n",
       " 'Pasireotide',\n",
       " 'Cyclosporine',\n",
       " 'Tacrolimus',\n",
       " 'Cyclosporins',\n",
       " 'Leucovorin',\n",
       " 'Fluorouracil',\n",
       " 'Irinotecan',\n",
       " 'Tetrathiomolybdate',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Everolimus',\n",
       " 'Topotecan',\n",
       " 'Gefitinib',\n",
       " 'Valacyclovir',\n",
       " 'Cyclophosphamide',\n",
       " 'Etoposide',\n",
       " 'Topotecan',\n",
       " 'Lenalidomide',\n",
       " 'Tegaserod',\n",
       " 'Rosuvastatin Calcium',\n",
       " 'Letrozole',\n",
       " 'Teduglutide',\n",
       " 'Ipilimumab',\n",
       " 'Leuprolide',\n",
       " 'Goserelin',\n",
       " 'Bicalutamide',\n",
       " 'Flutamide',\n",
       " 'Capecitabine',\n",
       " 'Oxaliplatin',\n",
       " 'Celecoxib',\n",
       " 'Diclofenac',\n",
       " 'Midazolam',\n",
       " 'Anastrozole',\n",
       " 'Rivastigmine',\n",
       " 'Allopurinol',\n",
       " 'Febuxostat',\n",
       " 'Telithromycin',\n",
       " 'Octreotide',\n",
       " 'Zoledronic Acid',\n",
       " 'Everolimus',\n",
       " 'Trimethaphan',\n",
       " 'Pseudoephedrine',\n",
       " 'Ephedrine',\n",
       " 'Trimethaphan camsylate',\n",
       " 'Valsartan',\n",
       " 'Febuxostat',\n",
       " 'Valproic Acid',\n",
       " 'Anticonvulsants',\n",
       " 'Risperidone',\n",
       " 'Antipsychotic Agents',\n",
       " 'Ciclesonide',\n",
       " 'Imatinib Mesylate',\n",
       " 'Cyclophosphamide',\n",
       " 'Docetaxel',\n",
       " 'Doxorubicin',\n",
       " 'Liposomal doxorubicin',\n",
       " 'Calcium',\n",
       " 'Parathyroid Hormone',\n",
       " 'Capsaicin',\n",
       " 'Drotrecogin alfa activated',\n",
       " 'Protein C',\n",
       " 'Diclofenac',\n",
       " 'Lenalidomide',\n",
       " 'Cyclosporine',\n",
       " 'Cyclosporins',\n",
       " 'Fluticasone',\n",
       " 'Levetiracetam',\n",
       " 'Liposomal doxorubicin',\n",
       " 'Atenolol',\n",
       " 'Valsartan',\n",
       " 'Prednisone',\n",
       " 'Darifenacin',\n",
       " 'Rosiglitazone',\n",
       " 'Bexarotene',\n",
       " 'Belotecan',\n",
       " 'Diclofenac',\n",
       " 'Cyclosporine',\n",
       " 'Cyclosporins',\n",
       " 'Olanzapine',\n",
       " 'Risperidone',\n",
       " 'Quetiapine Fumarate',\n",
       " 'Aripiprazole',\n",
       " 'Ziprasidone',\n",
       " 'Antipsychotic Agents',\n",
       " 'Insulin',\n",
       " 'Insulin Glargine',\n",
       " 'Ezetimibe',\n",
       " 'Bupivacaine',\n",
       " 'Valsartan',\n",
       " 'Tegaserod',\n",
       " 'Lumiracoxib',\n",
       " 'Everolimus',\n",
       " 'Minoxidil',\n",
       " 'Spironolactone',\n",
       " 'Insulin',\n",
       " 'Metformin',\n",
       " 'Insulin Glargine',\n",
       " 'Insulin glulisine',\n",
       " 'Secretagogues',\n",
       " 'Sertraline',\n",
       " 'Insulin Glargine',\n",
       " 'Galantamine',\n",
       " 'Enoxaparin',\n",
       " 'Diclofenac',\n",
       " 'Oxaliplatin',\n",
       " 'Vaccines',\n",
       " 'Zoledronic Acid',\n",
       " 'Imiquimod',\n",
       " 'Aspirin',\n",
       " 'Hydroxyurea',\n",
       " 'Bupropion',\n",
       " 'Sertraline',\n",
       " 'Cisplatin',\n",
       " 'Docetaxel',\n",
       " 'Botulinum Toxins',\n",
       " 'abobotulinumtoxinA',\n",
       " 'Atorvastatin',\n",
       " 'Valsartan',\n",
       " 'Imatinib Mesylate',\n",
       " 'Paclitaxel',\n",
       " 'Sunitinib',\n",
       " 'Olanzapine',\n",
       " 'Asenapine',\n",
       " 'Imatinib Mesylate',\n",
       " 'Amlodipine',\n",
       " 'Atorvastatin',\n",
       " 'Amphotericin B',\n",
       " 'Liposomal amphotericin B',\n",
       " 'Vancomycin',\n",
       " 'Mycophenolic Acid',\n",
       " 'Tadalafil',\n",
       " 'Alemtuzumab',\n",
       " 'Imatinib Mesylate',\n",
       " 'Lenalidomide',\n",
       " 'Immunoglobulins',\n",
       " 'Antibodies',\n",
       " 'gamma-Globulins',\n",
       " 'Rho(D) Immune Globulin',\n",
       " 'Polyethylene glycol 3350',\n",
       " 'Tegaserod',\n",
       " 'Aripiprazole',\n",
       " 'Viscum album peptide',\n",
       " 'Levofloxacin',\n",
       " 'Ofloxacin',\n",
       " 'Methadone',\n",
       " 'Heroin',\n",
       " 'Tegaserod',\n",
       " 'Bupropion',\n",
       " 'Interferons',\n",
       " 'Interferon-alpha',\n",
       " 'Interferon alpha-2',\n",
       " 'Peginterferon alfa-2b',\n",
       " 'Colchicine',\n",
       " 'Leucovorin',\n",
       " 'Cytarabine',\n",
       " 'Dexamethasone',\n",
       " 'Hydrocortisone',\n",
       " 'Cyclophosphamide',\n",
       " 'Methotrexate',\n",
       " 'Vincristine',\n",
       " 'Asparaginase',\n",
       " 'Mercaptopurine',\n",
       " 'Thioguanine',\n",
       " 'Daunorubicin',\n",
       " 'Aminopterin',\n",
       " 'Levetiracetam',\n",
       " 'Tamoxifen',\n",
       " 'Letrozole',\n",
       " 'Lenalidomide',\n",
       " 'Darifenacin',\n",
       " 'Deferasirox',\n",
       " 'Paroxetine',\n",
       " 'Buspirone',\n",
       " 'Atomoxetine Hydrochloride',\n",
       " 'Aluminum Hydroxide',\n",
       " 'Cyclophosphamide',\n",
       " 'Docetaxel',\n",
       " 'Methotrexate',\n",
       " 'Amlodipine',\n",
       " 'Atorvastatin',\n",
       " 'Hydrocortisone',\n",
       " 'Trimethaphan',\n",
       " 'Trimethaphan camsylate',\n",
       " 'Brivaracetam',\n",
       " 'Aspirin',\n",
       " 'Hydroxychloroquine',\n",
       " 'Cyclophosphamide',\n",
       " 'Melphalan',\n",
       " 'Sargramostim',\n",
       " 'Lenograstim',\n",
       " 'Insulin Glargine',\n",
       " 'Zoledronic Acid',\n",
       " 'Letrozole',\n",
       " 'Paclitaxel',\n",
       " 'Carboplatin',\n",
       " 'Tetrathiomolybdate',\n",
       " 'Diclofenac',\n",
       " 'Zoledronic Acid',\n",
       " 'Valsartan',\n",
       " 'Lisinopril',\n",
       " 'Buspirone',\n",
       " 'Imatinib Mesylate',\n",
       " 'Imiquimod',\n",
       " 'Atenolol',\n",
       " 'Valsartan',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Carbamazepine',\n",
       " 'Levetiracetam',\n",
       " 'Valproic Acid',\n",
       " 'Venlafaxine Hydrochloride',\n",
       " 'Exemestane',\n",
       " 'Tegaserod',\n",
       " 'Interferons',\n",
       " 'Interferon-beta',\n",
       " 'Interferon beta-1a',\n",
       " 'Oxybutynin',\n",
       " 'Darifenacin',\n",
       " 'Alfuzosin',\n",
       " 'Budesonide',\n",
       " 'Aspirin',\n",
       " 'Celecoxib',\n",
       " 'Naproxen',\n",
       " 'Lansoprazole',\n",
       " 'Dexlansoprazole',\n",
       " 'Azelaic acid',\n",
       " 'Propofol',\n",
       " 'Desflurane',\n",
       " 'Montelukast',\n",
       " 'Lubiprostone',\n",
       " 'Paromomycin',\n",
       " 'Pentamidine',\n",
       " 'Palonosetron',\n",
       " 'Efinaconazole',\n",
       " 'Calcipotriene',\n",
       " 'Factor VIII',\n",
       " 'Avasopasem manganese',\n",
       " 'Darunavir',\n",
       " 'Dolutegravir',\n",
       " 'Cobicistat',\n",
       " 'Triamcinolone',\n",
       " 'Triamcinolone Acetonide',\n",
       " 'Triamcinolone hexacetonide',\n",
       " 'Triamcinolone diacetate',\n",
       " 'Loteprednol Etabonate',\n",
       " 'Aspirin',\n",
       " 'Daratumumab',\n",
       " 'Vitamin D',\n",
       " 'Cholecalciferol',\n",
       " 'Docetaxel',\n",
       " 'Irinotecan',\n",
       " 'Carbidopa',\n",
       " 'Empagliflozin',\n",
       " 'Insulin',\n",
       " 'Apremilast',\n",
       " 'Dexmedetomidine',\n",
       " 'Propofol',\n",
       " 'XL647',\n",
       " 'Ticagrelor',\n",
       " 'Immunoglobulins',\n",
       " 'Antibodies',\n",
       " 'Dexmedetomidine',\n",
       " 'Rifamycins',\n",
       " 'Rifamycin SV',\n",
       " 'Anti-Anxiety Agents',\n",
       " 'Antipsychotic Agents',\n",
       " 'Antidepressive Agents',\n",
       " 'Insulin',\n",
       " 'Insulin Lispro',\n",
       " 'Grazoprevir',\n",
       " 'Anesthetics',\n",
       " 'Tinzaparin',\n",
       " 'Heparin',\n",
       " 'Dalteparin',\n",
       " 'Prednisone',\n",
       " 'Tiotropium Bromide',\n",
       " 'Ixekizumab',\n",
       " 'Resveratrol',\n",
       " 'Vitamin D',\n",
       " 'Cholecalciferol',\n",
       " 'Ergocalciferols',\n",
       " 'Methicillin',\n",
       " 'Ramipril',\n",
       " 'Capecitabine',\n",
       " 'Ropivacaine',\n",
       " 'Ferric Oxide',\n",
       " 'Methyltestosterone',\n",
       " 'Testosterone',\n",
       " 'Testosterone undecanoate',\n",
       " 'Testosterone enanthate',\n",
       " 'Testosterone 17 beta-cypionate',\n",
       " 'Hypoglycemic Agents',\n",
       " 'Paclitaxel',\n",
       " 'Vinblastine',\n",
       " 'Carboplatin',\n",
       " 'Petrolatum',\n",
       " 'Lenabasum',\n",
       " 'Puerarin',\n",
       " 'Bupivacaine',\n",
       " 'Anesthetics',\n",
       " 'Menthol',\n",
       " 'Insulin Glargine',\n",
       " 'Levodopa',\n",
       " 'Benserazide',\n",
       " 'Resveratrol',\n",
       " 'Nivolumab',\n",
       " 'Daratumumab',\n",
       " 'Evolocumab',\n",
       " 'Avasopasem manganese',\n",
       " 'Anti-Infective Agents',\n",
       " 'Tetracycline',\n",
       " 'Anti-Bacterial Agents',\n",
       " 'Citric Acid',\n",
       " 'Sodium Citrate',\n",
       " 'Sufentanil',\n",
       " 'Dexmedetomidine',\n",
       " 'Remifentanil',\n",
       " 'Dsuvia',\n",
       " 'Nalmefene',\n",
       " 'Pancrelipase',\n",
       " 'Naloxone',\n",
       " 'Metronidazole',\n",
       " 'Irinotecan',\n",
       " 'Topotecan',\n",
       " 'Dinutuximab',\n",
       " 'Atomoxetine Hydrochloride',\n",
       " 'Interferons',\n",
       " 'Ribavirin',\n",
       " 'Aspirin',\n",
       " 'Apremilast',\n",
       " 'Paclitaxel',\n",
       " 'Carboplatin',\n",
       " 'Resveratrol',\n",
       " 'Medroxyprogesterone Acetate',\n",
       " 'Medroxyprogesterone',\n",
       " 'Estrogens',\n",
       " 'Lidocaine',\n",
       " 'Amoxicillin',\n",
       " 'Sirolimus',\n",
       " 'Dimethyl Fumarate',\n",
       " 'Vitamin K',\n",
       " 'Lorazepam',\n",
       " 'Physostigmine',\n",
       " 'Erenumab',\n",
       " 'KHK4083',\n",
       " 'Menotropins',\n",
       " 'Propofol',\n",
       " 'Sevoflurane',\n",
       " 'Nicotine',\n",
       " 'Bacitracin zinc',\n",
       " 'Sunitinib',\n",
       " 'Ribavirin',\n",
       " 'Diclofenac',\n",
       " 'Grazoprevir',\n",
       " 'Buprenorphine',\n",
       " 'Methadone',\n",
       " 'Albuterol',\n",
       " 'Resveratrol',\n",
       " 'Benserazide',\n",
       " 'Antimicrobial Cationic Peptides',\n",
       " 'Metronidazole',\n",
       " 'Praliciguat',\n",
       " 'Drospirenone',\n",
       " 'Ethinyl Estradiol',\n",
       " 'Mycophenolic Acid',\n",
       " 'Prednisone',\n",
       " 'Methylprednisolone',\n",
       " 'Tacrolimus',\n",
       " 'Thymoglobulin',\n",
       " 'Antilymphocyte Serum',\n",
       " 'Immunoglobulins',\n",
       " 'Antibodies',\n",
       " 'Dolutegravir',\n",
       " 'Benserazide',\n",
       " 'Esketamine',\n",
       " 'Menthol',\n",
       " 'Caffeine',\n",
       " 'Caffeine citrate',\n",
       " 'Ranibizumab',\n",
       " 'Glucagon',\n",
       " 'Glucagon-Like Peptide 1',\n",
       " 'Elvitegravir',\n",
       " 'Emtricitabine tenofovir alafenamide',\n",
       " 'Pirfenidone',\n",
       " 'Petrolatum',\n",
       " 'Esomeprazole',\n",
       " 'Omeprazole',\n",
       " 'Rabeprazole',\n",
       " 'Pantoprazole',\n",
       " 'Lansoprazole',\n",
       " 'Dexlansoprazole',\n",
       " 'Proton Pump Inhibitors',\n",
       " 'Tiotropium Bromide',\n",
       " 'Zinc',\n",
       " 'Zinc Sulfate',\n",
       " 'Vaccines',\n",
       " 'Remifentanil',\n",
       " 'Propofol',\n",
       " 'Sevoflurane',\n",
       " 'Letrozole',\n",
       " 'Goserelin',\n",
       " 'Naproxen',\n",
       " 'Esomeprazole',\n",
       " 'Insulin',\n",
       " 'Insulin Glargine',\n",
       " 'Chlorthalidone',\n",
       " 'Bumetanide',\n",
       " 'Pregabalin',\n",
       " 'Methoxyflurane',\n",
       " 'Hydrochlorothiazide',\n",
       " 'Perindopril',\n",
       " 'Antibodies',\n",
       " 'Atezolizumab',\n",
       " 'Magrolimab',\n",
       " 'Midazolam',\n",
       " 'Atorvastatin',\n",
       " 'Simvastatin',\n",
       " 'Metformin',\n",
       " 'Ticagrelor',\n",
       " 'Remifentanil',\n",
       " 'Propofol',\n",
       " 'Lorecivivint',\n",
       " 'Bacitracin',\n",
       " 'Eplerenone',\n",
       " 'Dolutegravir',\n",
       " 'Itraconazole',\n",
       " 'Sertraline',\n",
       " 'Venlafaxine Hydrochloride',\n",
       " 'Dexamethasone',\n",
       " 'Dexamethasone acetate',\n",
       " 'BB 1101',\n",
       " 'Denosumab',\n",
       " 'Ophthalmic Solutions',\n",
       " 'Metformin',\n",
       " 'Sitagliptin Phosphate',\n",
       " 'Dexmedetomidine',\n",
       " 'Aspirin',\n",
       " 'Rifampin',\n",
       " 'Linezolid',\n",
       " 'Dexamethasone',\n",
       " 'BMS-986165',\n",
       " 'abobotulinumtoxinA',\n",
       " 'Botulinum Toxins',\n",
       " 'Antihypertensive Agents',\n",
       " 'Citalopram',\n",
       " 'Bupropion',\n",
       " 'Propofol',\n",
       " 'Fentanyl',\n",
       " 'Propofol',\n",
       " 'Vitamins',\n",
       " 'Vitamin B Complex',\n",
       " 'Fluticasone',\n",
       " 'Xhance',\n",
       " 'Vitamin D',\n",
       " 'Cholecalciferol',\n",
       " 'Fluconazole',\n",
       " 'Heptavalent Pneumococcal Conjugate Vaccine',\n",
       " 'Granisetron',\n",
       " 'Serotonin',\n",
       " 'Anesthetics',\n",
       " 'Dexmedetomidine',\n",
       " 'Remifentanil',\n",
       " 'Propofol',\n",
       " 'Aflutinib',\n",
       " 'Mirtazapine',\n",
       " 'Nafithromycin',\n",
       " 'Bupropion',\n",
       " 'Itraconazole',\n",
       " 'Rifampin',\n",
       " 'Calcium',\n",
       " 'Benralizumab',\n",
       " 'Oxytocin',\n",
       " 'Citalopram',\n",
       " 'Ropivacaine',\n",
       " 'Topiramate',\n",
       " 'Phentermine',\n",
       " 'Warfarin',\n",
       " 'Rivaroxaban',\n",
       " 'Insulin',\n",
       " 'Risdiplam',\n",
       " 'Vitamin D',\n",
       " 'Ergocalciferols',\n",
       " 'Cholecalciferol',\n",
       " 'Vitamins',\n",
       " 'Hyaluronic Acid',\n",
       " 'Anti-Bacterial Agents',\n",
       " 'Vancomycin',\n",
       " 'Tobramycin',\n",
       " 'Cholecalciferol',\n",
       " 'Varenicline',\n",
       " 'Anesthetics',\n",
       " 'Prednisone',\n",
       " 'Asparaginase',\n",
       " 'Prilocaine',\n",
       " 'Asunaprevir',\n",
       " 'Trastuzumab',\n",
       " 'Ado-Trastuzumab Emtansine',\n",
       " 'Maytansine',\n",
       " 'Eslicarbazepine acetate',\n",
       " 'Bupivacaine',\n",
       " 'Radium Ra 223 dichloride',\n",
       " 'Carvedilol',\n",
       " 'Isoproterenol',\n",
       " 'Cytarabine',\n",
       " 'Daunorubicin',\n",
       " 'Atomoxetine Hydrochloride',\n",
       " 'Rivaroxaban',\n",
       " 'Atorvastatin',\n",
       " 'Glimepiride',\n",
       " ...]"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[50]: ['Fluticasone',\n 'Xhance',\n 'Budesonide',\n 'Formoterol Fumarate',\n 'Salmeterol Xinafoate',\n 'Vitamins',\n 'Liraglutide',\n 'Xultophy',\n 'Metformin',\n 'Empagliflozin',\n 'Linagliptin',\n 'Nitisinone',\n 'Acetazolamide',\n 'Ketamine',\n 'Methohexital',\n 'Micronutrients',\n 'Trace Elements',\n 'Pioglitazone',\n 'Etoricoxib',\n 'Lornoxicam',\n 'Lidocaine',\n 'Tedizolid phosphate',\n 'Tedizolid',\n 'Oxazolidinones',\n 'Dextrans',\n 'Povidone',\n 'Ophthalmic Solutions',\n 'Lubricant Eye Drops',\n 'Tafenoquine',\n 'Acetaminophen',\n 'Ketamine',\n 'Pravastatin',\n 'Caffeine',\n 'Sunscreening Agents',\n 'Erythromycin',\n 'Erythromycin Estolate',\n 'Erythromycin Ethylsuccinate',\n 'Erythromycin stearate',\n 'Erythromycin lactobionate',\n 'Aminolevulinic Acid',\n 'Fulvestrant',\n 'Sufentanil',\n 'Dsuvia',\n 'Propofol',\n 'Paclitaxel',\n 'Bevacizumab',\n 'Carboplatin',\n 'Empagliflozin',\n 'Linagliptin',\n 'Hyaluronic Acid',\n 'BI 836826',\n 'Celecoxib',\n 'Golimumab',\n 'Propofol',\n 'Sevoflurane',\n 'Pilocarpine',\n 'Sunscreening Agents',\n 'Magnesium Sulfate',\n 'Bupivacaine',\n 'Nitisinone',\n 'Insulin',\n 'Metformin',\n 'Insulin Glargine',\n 'Lixisenatide',\n 'Tazobactam',\n 'Piperacillin',\n 'Fosfomycin',\n 'Insulin',\n 'Mirabegron',\n 'Interferons',\n 'Ritonavir',\n 'Ribavirin',\n 'Interferon-alpha',\n 'Interferon alpha-2',\n 'Sofosbuvir',\n 'Peginterferon alfa-2a',\n 'Ledipasvir',\n 'Simeprevir',\n 'Fluticasone',\n 'Xhance',\n 'Formoterol Fumarate',\n 'Aminolevulinic Acid',\n 'Melatonin',\n 'Betaine',\n 'Dexmedetomidine',\n 'Dulaglutide',\n 'Insulin',\n 'Insulin Glargine',\n 'Lixisenatide',\n 'Hypoglycemic Agents',\n 'Propofol',\n 'Desflurane',\n 'Suvorexant',\n 'Azithromycin',\n 'Metronidazole',\n 'Doxycycline',\n 'Tenofovir',\n 'Lamivudine',\n 'Efavirenz',\n 'Telmisartan',\n 'Itraconazole',\n 'Terlipressin',\n 'Pantoprazole',\n 'Somatostatin',\n 'Fluorides',\n 'Tin Fluorides',\n 'Fluorophosphate',\n 'Pembrolizumab',\n 'Dulaglutide',\n 'Tirzepatide',\n 'Adalimumab',\n 'Fluorides',\n 'Glatiramer Acetate',\n 'Mannitol',\n '(T',\n 'Naltrexone',\n 'Fentanyl',\n 'Bupivacaine',\n 'Fluorides',\n 'Tin Fluorides',\n 'Nicotine',\n 'Vaccines',\n 'Chlorhexidine',\n 'Acetazolamide',\n 'Methazolamide',\n 'Doxycycline',\n 'Cholecalciferol',\n 'Metformin',\n 'Clozapine',\n 'Diclofenac',\n 'Bupivacaine',\n 'Tenofovir',\n 'Prednisone',\n 'AZD7624',\n 'Tetracaine',\n 'Nitrous Oxide',\n 'Bromides',\n 'Ipratropium',\n 'Acetazolamide',\n 'Cytarabine',\n 'Cyclosporine',\n 'Mycophenolic Acid',\n 'Sirolimus',\n 'Fludarabine',\n 'Fludarabine phosphate',\n 'Melphalan',\n 'Mechlorethamine',\n 'Mitoxantrone',\n 'Nitrogen Mustard Compounds',\n 'Cladribine',\n '2-chloro-3-deoxyadenosine',\n 'Cyclosporins',\n 'Lenograstim',\n 'Fluorides',\n 'Tin Fluorides',\n 'Fluorophosphate',\n 'Plasminogen',\n 'Tissue Plasminogen Activator',\n 'Valsartan',\n 'Sacubitril and valsartan sodium hydrate drug combination',\n 'Salicylic Acid',\n 'Adapalene',\n 'Salicylates',\n 'Nitisinone',\n 'Bupivacaine',\n 'Lidocaine',\n 'Ondansetron',\n 'Sirolimus',\n 'Alogliptin',\n 'Gemcitabine',\n 'Dexamethasone',\n 'Obinutuzumab',\n 'Fentanyl',\n 'Ketorolac',\n 'Nepafenac',\n 'Citric Acid',\n 'Sodium Citrate',\n 'Celecoxib',\n 'Dronabinol',\n 'Cannabidiol',\n 'Vaccines',\n 'Azilsartan medoxomil',\n 'Telavancin',\n 'Misoprostol',\n 'Cetirizine',\n 'Tamsulosin',\n 'Mirabegron',\n 'Dexmedetomidine',\n 'Irsogladine',\n 'Lafutidine',\n 'Cannabidiol',\n 'Allopurinol',\n 'Febuxostat',\n 'Anesthetics',\n 'Vaccines',\n 'Hydrogen Peroxide',\n 'Doxorubicin',\n 'Liposomal doxorubicin',\n 'Pembrolizumab',\n 'Ixekizumab',\n 'Melatonin',\n 'Vitamin D',\n 'Vaccines',\n 'Phosphocreatine',\n 'Anesthetics',\n 'Fluorodeoxyglucose F18',\n 'Hydroxychloroquine',\n 'Hydrocortisone',\n 'Cyclophosphamide',\n 'Dronabinol',\n 'Dapagliflozin',\n 'Acetaminophen',\n 'Tramadol',\n 'Codeine',\n 'Micronutrients',\n 'Trace Elements',\n 'Leucovorin',\n 'Bevacizumab',\n 'Fluorouracil',\n 'Irinotecan',\n 'Carboxymethylcellulose Sodium',\n 'Ophthalmic Solutions',\n 'Lubricant Eye Drops',\n 'Botulinum Toxins',\n 'Olanzapine',\n 'Tenofovir',\n 'Doxorubicin',\n 'Liposomal doxorubicin',\n 'Maytansine',\n 'Sunscreening Agents',\n 'Insulin',\n 'Azacitidine',\n 'Salmeterol Xinafoate',\n 'Montelukast',\n 'Lansoprazole',\n 'Dexlansoprazole',\n 'Rebamipide',\n 'Atropine',\n 'Epinephrine',\n 'Fentanyl',\n 'Bupivacaine',\n 'Neostigmine',\n 'Rituximab',\n 'Chlorhexidine',\n 'Chlorhexidine gluconate',\n 'Cetylpyridinium',\n 'Esomeprazole',\n 'Sirolimus',\n 'Dexamethasone',\n 'Lenalidomide',\n 'Dronedarone',\n 'Gefitinib',\n 'Insulin',\n 'Insulin Glargine',\n 'Insulin glulisine',\n 'Fludarabine',\n 'Fludarabine phosphate',\n 'Busulfan',\n 'Antilymphocyte Serum',\n 'Methylphenidate',\n 'Amlodipine',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Alendronate',\n 'Febuxostat',\n 'Valsartan',\n 'Gemcitabine',\n 'Docetaxel',\n 'Olanzapine',\n 'Clozapine',\n 'Valsartan',\n 'Simvastatin',\n 'Zolpidem',\n 'Citalopram',\n 'Gemcitabine',\n 'Celecoxib',\n 'Darifenacin',\n 'Risperidone',\n 'Reteplase',\n 'Vitamins',\n 'Folic Acid',\n 'Vitamin A',\n 'Thiamine',\n 'Selenium',\n 'Micronutrients',\n 'Trace Elements',\n 'Valsartan',\n 'Doxycycline',\n 'Zoledronic Acid',\n 'Treosulfan',\n 'Busulfan',\n 'Cyclophosphamide',\n 'Busulfan',\n 'Antilymphocyte Serum',\n 'Docetaxel',\n 'Deferasirox',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Everolimus',\n 'Azathioprine',\n 'Calcineurin Inhibitors',\n 'Zoledronic Acid',\n 'Letrozole',\n 'Zoledronic Acid',\n 'Botulinum Toxins',\n 'abobotulinumtoxinA',\n 'Busulfan',\n 'Heptavalent Pneumococcal Conjugate Vaccine',\n 'Lumiracoxib',\n 'Prazosin',\n 'Insulin Glargine',\n 'Lycopene',\n 'Citalopram',\n 'Olanzapine',\n 'Risperidone',\n 'Amlodipine',\n 'Valsartan',\n 'Tolterodine Tartrate',\n 'Pioglitazone',\n 'Lansoprazole',\n 'Dexlansoprazole',\n 'Topotecan',\n 'Bupropion',\n 'Bevacizumab',\n 'Capecitabine',\n 'Oxaliplatin',\n 'Gemcitabine',\n 'Ifosfamide',\n 'Famciclovir',\n 'Certoparin',\n 'Pasireotide',\n 'Epothilones',\n 'Epothilone B',\n 'Paclitaxel',\n 'Carboplatin',\n 'Lenalidomide',\n 'Esomeprazole',\n 'Amlodipine',\n 'Valsartan',\n 'Paclitaxel',\n 'Paroxetine',\n 'Lamotrigine',\n 'Valproic Acid',\n 'Olanzapine',\n 'Risperidone',\n 'Lithium Carbonate',\n 'Mirtazapine',\n 'Tranylcypromine',\n 'Bupropion',\n 'Paroxetine',\n 'Venlafaxine Hydrochloride',\n 'Octreotide',\n 'Paclitaxel',\n 'Carboplatin',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Zoledronic Acid',\n 'Cyclosporine',\n 'Cyclosporins',\n 'Everolimus',\n 'Amphotericin B',\n 'Liposomal amphotericin B',\n 'Valsartan',\n 'Irbesartan',\n 'Parathyroid Hormone',\n 'Lansoprazole',\n 'Dexlansoprazole',\n 'Sildenafil Citrate',\n 'Fluvoxamine',\n 'Everolimus',\n 'Amlodipine',\n 'Valsartan',\n 'Aluminum Hydroxide',\n 'Tretinoin',\n 'Theophylline',\n 'Valproic Acid',\n 'Cyclophosphamide',\n 'Busulfan',\n 'Thymoglobulin',\n 'Paclitaxel',\n 'Carboplatin',\n 'Zoledronic Acid',\n 'Amlodipine',\n 'Valsartan',\n 'Brivaracetam',\n 'Amlodipine',\n 'Benazepril',\n 'Prednisolone',\n 'Methylprednisolone Acetate',\n 'Methylprednisolone',\n 'Methylprednisolone Hemisuccinate',\n 'Prednisolone acetate',\n 'Prednisolone hemisuccinate',\n 'Prednisolone phosphate',\n 'Paroxetine',\n 'Doxycycline',\n 'Imiquimod',\n 'Moxifloxacin',\n 'Eflornithine',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Duloxetine Hydrochloride',\n 'Donepezil',\n 'Citalopram',\n 'Venlafaxine Hydrochloride',\n 'Codeine',\n 'Tirapazamine',\n 'Pioglitazone',\n 'Deferasirox',\n 'Valsartan',\n 'Lisinopril',\n 'Rifampin',\n 'Isoniazid',\n 'Gemcitabine',\n 'Cisplatin',\n 'Docetaxel',\n 'Allopurinol',\n 'Febuxostat',\n 'Pravastatin',\n 'Mycophenolic Acid',\n 'Thalidomide',\n 'Carboplatin',\n 'Baclofen',\n 'Botulinum Toxins',\n 'abobotulinumtoxinA',\n 'Valsartan',\n 'Interferons',\n 'Interferon-alpha',\n 'Interferon alpha-2',\n 'Peginterferon alfa-2a',\n 'Vatalanib',\n 'Ciclesonide',\n 'Diclofenac',\n 'Carboplatin',\n 'Brivaracetam',\n 'Docetaxel',\n 'Modafinil',\n 'Tacrolimus',\n 'Lumiracoxib',\n 'Mupirocin',\n 'Sodium Hypochlorite',\n 'Eusol',\n 'Petrolatum',\n 'Aripiprazole',\n 'Cyclosporine',\n 'Mycophenolic Acid',\n 'Fludarabine',\n 'Melphalan',\n 'Alemtuzumab',\n 'Cyclosporins',\n 'Antilymphocyte Serum',\n 'Immunoglobulins',\n 'Antibodies',\n 'gamma-Globulins',\n 'Rho(D) Immune Globulin',\n 'Deferasirox',\n 'Imatinib Mesylate',\n 'Voriconazole',\n 'Modafinil',\n 'SR 31747',\n 'Vidarabine',\n 'Cyclophosphamide',\n 'Busulfan',\n 'Fludarabine',\n 'Fludarabine phosphate',\n 'Alemtuzumab',\n 'Antilymphocyte Serum',\n 'Sargramostim',\n 'Lenograstim',\n 'Misoprostol',\n 'Mifepristone',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Docetaxel',\n 'Sargramostim',\n 'Octreotide',\n 'Clopidogrel',\n 'Nicotine',\n 'Ziprasidone',\n 'Natriuretic Peptide',\n 'Vaccines',\n 'Furosemide',\n 'Mannitol',\n 'Sertraline',\n 'Certolizumab Pegol',\n 'Lenalidomide',\n 'Fluconazole',\n 'Bupivacaine',\n 'Sertraline',\n 'Venlafaxine Hydrochloride',\n 'Lamotrigine',\n 'Eletriptan',\n 'Pasireotide',\n 'Cyclosporine',\n 'Tacrolimus',\n 'Cyclosporins',\n 'Leucovorin',\n 'Fluorouracil',\n 'Irinotecan',\n 'Tetrathiomolybdate',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Everolimus',\n 'Topotecan',\n 'Gefitinib',\n 'Valacyclovir',\n 'Cyclophosphamide',\n 'Etoposide',\n 'Topotecan',\n 'Lenalidomide',\n 'Tegaserod',\n 'Rosuvastatin Calcium',\n 'Letrozole',\n 'Teduglutide',\n 'Ipilimumab',\n 'Leuprolide',\n 'Goserelin',\n 'Bicalutamide',\n 'Flutamide',\n 'Capecitabine',\n 'Oxaliplatin',\n 'Celecoxib',\n 'Diclofenac',\n 'Midazolam',\n 'Anastrozole',\n 'Rivastigmine',\n 'Allopurinol',\n 'Febuxostat',\n 'Telithromycin',\n 'Octreotide',\n 'Zoledronic Acid',\n 'Everolimus',\n 'Trimethaphan',\n 'Pseudoephedrine',\n 'Ephedrine',\n 'Trimethaphan camsylate',\n 'Valsartan',\n 'Febuxostat',\n 'Valproic Acid',\n 'Anticonvulsants',\n 'Risperidone',\n 'Antipsychotic Agents',\n 'Ciclesonide',\n 'Imatinib Mesylate',\n 'Cyclophosphamide',\n 'Docetaxel',\n 'Doxorubicin',\n 'Liposomal doxorubicin',\n 'Calcium',\n 'Parathyroid Hormone',\n 'Capsaicin',\n 'Drotrecogin alfa activated',\n 'Protein C',\n 'Diclofenac',\n 'Lenalidomide',\n 'Cyclosporine',\n 'Cyclosporins',\n 'Fluticasone',\n 'Levetiracetam',\n 'Liposomal doxorubicin',\n 'Atenolol',\n 'Valsartan',\n 'Prednisone',\n 'Darifenacin',\n 'Rosiglitazone',\n 'Bexarotene',\n 'Belotecan',\n 'Diclofenac',\n 'Cyclosporine',\n 'Cyclosporins',\n 'Olanzapine',\n 'Risperidone',\n 'Quetiapine Fumarate',\n 'Aripiprazole',\n 'Ziprasidone',\n 'Antipsychotic Agents',\n 'Insulin',\n 'Insulin Glargine',\n 'Ezetimibe',\n 'Bupivacaine',\n 'Valsartan',\n 'Tegaserod',\n 'Lumiracoxib',\n 'Everolimus',\n 'Minoxidil',\n 'Spironolactone',\n 'Insulin',\n 'Metformin',\n 'Insulin Glargine',\n 'Insulin glulisine',\n 'Secretagogues',\n 'Sertraline',\n 'Insulin Glargine',\n 'Galantamine',\n 'Enoxaparin',\n 'Diclofenac',\n 'Oxaliplatin',\n 'Vaccines',\n 'Zoledronic Acid',\n 'Imiquimod',\n 'Aspirin',\n 'Hydroxyurea',\n 'Bupropion',\n 'Sertraline',\n 'Cisplatin',\n 'Docetaxel',\n 'Botulinum Toxins',\n 'abobotulinumtoxinA',\n 'Atorvastatin',\n 'Valsartan',\n 'Imatinib Mesylate',\n 'Paclitaxel',\n 'Sunitinib',\n 'Olanzapine',\n 'Asenapine',\n 'Imatinib Mesylate',\n 'Amlodipine',\n 'Atorvastatin',\n 'Amphotericin B',\n 'Liposomal amphotericin B',\n 'Vancomycin',\n 'Mycophenolic Acid',\n 'Tadalafil',\n 'Alemtuzumab',\n 'Imatinib Mesylate',\n 'Lenalidomide',\n 'Immunoglobulins',\n 'Antibodies',\n 'gamma-Globulins',\n 'Rho(D) Immune Globulin',\n 'Polyethylene glycol 3350',\n 'Tegaserod',\n 'Aripiprazole',\n 'Viscum album peptide',\n 'Levofloxacin',\n 'Ofloxacin',\n 'Methadone',\n 'Heroin',\n 'Tegaserod',\n 'Bupropion',\n 'Interferons',\n 'Interferon-alpha',\n 'Interferon alpha-2',\n 'Peginterferon alfa-2b',\n 'Colchicine',\n 'Leucovorin',\n 'Cytarabine',\n 'Dexamethasone',\n 'Hydrocortisone',\n 'Cyclophosphamide',\n 'Methotrexate',\n 'Vincristine',\n 'Asparaginase',\n 'Mercaptopurine',\n 'Thioguanine',\n 'Daunorubicin',\n 'Aminopterin',\n 'Levetiracetam',\n 'Tamoxifen',\n 'Letrozole',\n 'Lenalidomide',\n 'Darifenacin',\n 'Deferasirox',\n 'Paroxetine',\n 'Buspirone',\n 'Atomoxetine Hydrochloride',\n 'Aluminum Hydroxide',\n 'Cyclophosphamide',\n 'Docetaxel',\n 'Methotrexate',\n 'Amlodipine',\n 'Atorvastatin',\n 'Hydrocortisone',\n 'Trimethaphan',\n 'Trimethaphan camsylate',\n 'Brivaracetam',\n 'Aspirin',\n 'Hydroxychloroquine',\n 'Cyclophosphamide',\n 'Melphalan',\n 'Sargramostim',\n 'Lenograstim',\n 'Insulin Glargine',\n 'Zoledronic Acid',\n 'Letrozole',\n 'Paclitaxel',\n 'Carboplatin',\n 'Tetrathiomolybdate',\n 'Diclofenac',\n 'Zoledronic Acid',\n 'Valsartan',\n 'Lisinopril',\n 'Buspirone',\n 'Imatinib Mesylate',\n 'Imiquimod',\n 'Atenolol',\n 'Valsartan',\n 'Hydrochlorothiazide',\n 'Carbamazepine',\n 'Levetiracetam',\n 'Valproic Acid',\n 'Venlafaxine Hydrochloride',\n 'Exemestane',\n 'Tegaserod',\n 'Interferons',\n 'Interferon-beta',\n 'Interferon beta-1a',\n 'Oxybutynin',\n 'Darifenacin',\n 'Alfuzosin',\n 'Budesonide',\n 'Aspirin',\n 'Celecoxib',\n 'Naproxen',\n 'Lansoprazole',\n 'Dexlansoprazole',\n 'Azelaic acid',\n 'Propofol',\n 'Desflurane',\n 'Montelukast',\n 'Lubiprostone',\n 'Paromomycin',\n 'Pentamidine',\n 'Palonosetron',\n 'Efinaconazole',\n 'Calcipotriene',\n 'Factor VIII',\n 'Avasopasem manganese',\n 'Darunavir',\n 'Dolutegravir',\n 'Cobicistat',\n 'Triamcinolone',\n 'Triamcinolone Acetonide',\n 'Triamcinolone hexacetonide',\n 'Triamcinolone diacetate',\n 'Loteprednol Etabonate',\n 'Aspirin',\n 'Daratumumab',\n 'Vitamin D',\n 'Cholecalciferol',\n 'Docetaxel',\n 'Irinotecan',\n 'Carbidopa',\n 'Empagliflozin',\n 'Insulin',\n 'Apremilast',\n 'Dexmedetomidine',\n 'Propofol',\n 'XL647',\n 'Ticagrelor',\n 'Immunoglobulins',\n 'Antibodies',\n 'Dexmedetomidine',\n 'Rifamycins',\n 'Rifamycin SV',\n 'Anti-Anxiety Agents',\n 'Antipsychotic Agents',\n 'Antidepressive Agents',\n 'Insulin',\n 'Insulin Lispro',\n 'Grazoprevir',\n 'Anesthetics',\n 'Tinzaparin',\n 'Heparin',\n 'Dalteparin',\n 'Prednisone',\n 'Tiotropium Bromide',\n 'Ixekizumab',\n 'Resveratrol',\n 'Vitamin D',\n 'Cholecalciferol',\n 'Ergocalciferols',\n 'Methicillin',\n 'Ramipril',\n 'Capecitabine',\n 'Ropivacaine',\n 'Ferric Oxide',\n 'Methyltestosterone',\n 'Testosterone',\n 'Testosterone undecanoate',\n 'Testosterone enanthate',\n 'Testosterone 17 beta-cypionate',\n 'Hypoglycemic Agents',\n 'Paclitaxel',\n 'Vinblastine',\n 'Carboplatin',\n 'Petrolatum',\n 'Lenabasum',\n 'Puerarin',\n 'Bupivacaine',\n 'Anesthetics',\n 'Menthol',\n 'Insulin Glargine',\n 'Levodopa',\n 'Benserazide',\n 'Resveratrol',\n 'Nivolumab',\n 'Daratumumab',\n 'Evolocumab',\n 'Avasopasem manganese',\n 'Anti-Infective Agents',\n 'Tetracycline',\n 'Anti-Bacterial Agents',\n 'Citric Acid',\n 'Sodium Citrate',\n 'Sufentanil',\n 'Dexmedetomidine',\n 'Remifentanil',\n 'Dsuvia',\n 'Nalmefene',\n 'Pancrelipase',\n 'Naloxone',\n 'Metronidazole',\n 'Irinotecan',\n 'Topotecan',\n 'Dinutuximab',\n 'Atomoxetine Hydrochloride',\n 'Interferons',\n 'Ribavirin',\n 'Aspirin',\n 'Apremilast',\n 'Paclitaxel',\n 'Carboplatin',\n 'Resveratrol',\n 'Medroxyprogesterone Acetate',\n 'Medroxyprogesterone',\n 'Estrogens',\n 'Lidocaine',\n 'Amoxicillin',\n 'Sirolimus',\n 'Dimethyl Fumarate',\n 'Vitamin K',\n 'Lorazepam',\n 'Physostigmine',\n 'Erenumab',\n 'KHK4083',\n 'Menotropins',\n 'Propofol',\n 'Sevoflurane',\n 'Nicotine',\n 'Bacitracin zinc',\n 'Sunitinib',\n 'Ribavirin',\n 'Diclofenac',\n 'Grazoprevir',\n 'Buprenorphine',\n 'Methadone',\n 'Albuterol',\n 'Resveratrol',\n 'Benserazide',\n 'Antimicrobial Cationic Peptides',\n 'Metronidazole',\n 'Praliciguat',\n 'Drospirenone',\n 'Ethinyl Estradiol',\n 'Mycophenolic Acid',\n 'Prednisone',\n 'Methylprednisolone',\n 'Tacrolimus',\n 'Thymoglobulin',\n 'Antilymphocyte Serum',\n 'Immunoglobulins',\n 'Antibodies',\n 'Dolutegravir',\n 'Benserazide',\n 'Esketamine',\n 'Menthol',\n 'Caffeine',\n 'Caffeine citrate',\n 'Ranibizumab',\n 'Glucagon',\n 'Glucagon-Like Peptide 1',\n 'Elvitegravir',\n 'Emtricitabine tenofovir alafenamide',\n 'Pirfenidone',\n 'Petrolatum',\n 'Esomeprazole',\n 'Omeprazole',\n 'Rabeprazole',\n 'Pantoprazole',\n 'Lansoprazole',\n 'Dexlansoprazole',\n 'Proton Pump Inhibitors',\n 'Tiotropium Bromide',\n 'Zinc',\n 'Zinc Sulfate',\n 'Vaccines',\n 'Remifentanil',\n 'Propofol',\n 'Sevoflurane',\n 'Letrozole',\n 'Goserelin',\n 'Naproxen',\n 'Esomeprazole',\n 'Insulin',\n 'Insulin Glargine',\n 'Chlorthalidone',\n 'Bumetanide',\n 'Pregabalin',\n 'Methoxyflurane',\n 'Hydrochlorothiazide',\n 'Perindopril',\n 'Antibodies',\n 'Atezolizumab',\n 'Magrolimab',\n 'Midazolam',\n 'Atorvastatin',\n 'Simvastatin',\n 'Metformin',\n 'Ticagrelor',\n 'Remifentanil',\n 'Propofol',\n 'Lorecivivint',\n 'Bacitracin',\n 'Eplerenone',\n 'Dolutegravir',\n 'Itraconazole',\n 'Sertraline',\n 'Venlafaxine Hydrochloride',\n 'Dexamethasone',\n 'Dexamethasone acetate',\n 'BB 1101',\n 'Denosumab',\n 'Ophthalmic Solutions',\n 'Metformin',\n 'Sitagliptin Phosphate',\n 'Dexmedetomidine',\n 'Aspirin',\n 'Rifampin',\n 'Linezolid',\n 'Dexamethasone',\n 'BMS-986165',\n 'abobotulinumtoxinA',\n 'Botulinum Toxins',\n 'Antihypertensive Agents',\n 'Citalopram',\n 'Bupropion',\n 'Propofol',\n 'Fentanyl',\n 'Propofol',\n 'Vitamins',\n 'Vitamin B Complex',\n 'Fluticasone',\n 'Xhance',\n 'Vitamin D',\n 'Cholecalciferol',\n 'Fluconazole',\n 'Heptavalent Pneumococcal Conjugate Vaccine',\n 'Granisetron',\n 'Serotonin',\n 'Anesthetics',\n 'Dexmedetomidine',\n 'Remifentanil',\n 'Propofol',\n 'Aflutinib',\n 'Mirtazapine',\n 'Nafithromycin',\n 'Bupropion',\n 'Itraconazole',\n 'Rifampin',\n 'Calcium',\n 'Benralizumab',\n 'Oxytocin',\n 'Citalopram',\n 'Ropivacaine',\n 'Topiramate',\n 'Phentermine',\n 'Warfarin',\n 'Rivaroxaban',\n 'Insulin',\n 'Risdiplam',\n 'Vitamin D',\n 'Ergocalciferols',\n 'Cholecalciferol',\n 'Vitamins',\n 'Hyaluronic Acid',\n 'Anti-Bacterial Agents',\n 'Vancomycin',\n 'Tobramycin',\n 'Cholecalciferol',\n 'Varenicline',\n 'Anesthetics',\n 'Prednisone',\n 'Asparaginase',\n 'Prilocaine',\n 'Asunaprevir',\n 'Trastuzumab',\n 'Ado-Trastuzumab Emtansine',\n 'Maytansine',\n 'Eslicarbazepine acetate',\n 'Bupivacaine',\n 'Radium Ra 223 dichloride',\n 'Carvedilol',\n 'Isoproterenol',\n 'Cytarabine',\n 'Daunorubicin',\n 'Atomoxetine Hydrochloride',\n 'Rivaroxaban',\n 'Atorvastatin',\n 'Glimepiride',\n ...]",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "interventions_list"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "cd4ec7ed-5375-47a0-925d-7faf72fda0b4",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "image/png": "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\n"
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "data:image/png;base64,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\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "image"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#converting the list to a dictionary with values and its occurences\n",
    "from wordcloud import WordCloud, STOPWORDS, ImageColorGenerator\n",
    "from collections import Counter\n",
    "word_could_dict=Counter(interventions_list)\n",
    "wordcloud = WordCloud(width = 1000, height = 500).generate_from_frequencies(word_could_dict)\n",
    "\n",
    "plt.figure(figsize=(15,8))\n",
    "plt.imshow(wordcloud)\n",
    "plt.axis(\"off\")\n",
    "plt.show()\n",
    "plt.savefig('yourfile.png', bbox_inches='tight')\n",
    "plt.close()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "6ec30dff-f471-458b-b03f-30d0b8eb6880",
     "showTitle": false,
     "title": ""
    }
   },
   "source": [
    "## Visualizing the status of clinical trials"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "266e6027-743a-483b-bfa0-7f3929f984dc",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "+-------------------------+------+\n",
       "|Status                   |count |\n",
       "+-------------------------+------+\n",
       "|Completed                |209749|\n",
       "|Recruiting               |60950 |\n",
       "|Unknown status           |44608 |\n",
       "|Terminated               |22285 |\n",
       "|Active, not recruiting   |17848 |\n",
       "|Not yet recruiting       |16499 |\n",
       "|Withdrawn                |9973  |\n",
       "|Enrolling by invitation  |3682  |\n",
       "|Suspended                |1598  |\n",
       "|No longer available      |39    |\n",
       "|Approved for marketing   |24    |\n",
       "|Available                |5     |\n",
       "|Temporarily not available|1     |\n",
       "+-------------------------+------+\n",
       "\n"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "+-------------------------+------+\n|Status                   |count |\n+-------------------------+------+\n|Completed                |209749|\n|Recruiting               |60950 |\n|Unknown status           |44608 |\n|Terminated               |22285 |\n|Active, not recruiting   |17848 |\n|Not yet recruiting       |16499 |\n|Withdrawn                |9973  |\n|Enrolling by invitation  |3682  |\n|Suspended                |1598  |\n|No longer available      |39    |\n|Approved for marketing   |24    |\n|Available                |5     |\n|Temporarily not available|1     |\n+-------------------------+------+\n\n",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "#Grouping the data by trials, counting frequencies, then sorting from most frequent to least frequent\n",
    "status_list = clinical_df.groupBy('Status').count().sort('count', ascending=False)\n",
    "status_list.show(truncate = False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "87b79694-d6e4-4bf8-bc1d-2d785123805e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "df = status_list.toPandas()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "73441f77-6f21-499a-87c8-334fac281ae9",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Status</th>\n",
       "      <th>count</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>Completed</td>\n",
       "      <td>209749</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>Recruiting</td>\n",
       "      <td>60950</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>Unknown status</td>\n",
       "      <td>44608</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>Terminated</td>\n",
       "      <td>22285</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>Active, not recruiting</td>\n",
       "      <td>17848</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>Not yet recruiting</td>\n",
       "      <td>16499</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>Withdrawn</td>\n",
       "      <td>9973</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>7</th>\n",
       "      <td>Enrolling by invitation</td>\n",
       "      <td>3682</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>Suspended</td>\n",
       "      <td>1598</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>9</th>\n",
       "      <td>No longer available</td>\n",
       "      <td>39</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>Approved for marketing</td>\n",
       "      <td>24</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>11</th>\n",
       "      <td>Available</td>\n",
       "      <td>5</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>Temporarily not available</td>\n",
       "      <td>1</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "<div>\n<style scoped>\n    .dataframe tbody tr th:only-of-type {\n        vertical-align: middle;\n    }\n\n    .dataframe tbody tr th {\n        vertical-align: top;\n    }\n\n    .dataframe thead th {\n        text-align: right;\n    }\n</style>\n<table border=\"1\" class=\"dataframe\">\n  <thead>\n    <tr style=\"text-align: right;\">\n      <th></th>\n      <th>Status</th>\n      <th>count</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <th>0</th>\n      <td>Completed</td>\n      <td>209749</td>\n    </tr>\n    <tr>\n      <th>1</th>\n      <td>Recruiting</td>\n      <td>60950</td>\n    </tr>\n    <tr>\n      <th>2</th>\n      <td>Unknown status</td>\n      <td>44608</td>\n    </tr>\n    <tr>\n      <th>3</th>\n      <td>Terminated</td>\n      <td>22285</td>\n    </tr>\n    <tr>\n      <th>4</th>\n      <td>Active, not recruiting</td>\n      <td>17848</td>\n    </tr>\n    <tr>\n      <th>5</th>\n      <td>Not yet recruiting</td>\n      <td>16499</td>\n    </tr>\n    <tr>\n      <th>6</th>\n      <td>Withdrawn</td>\n      <td>9973</td>\n    </tr>\n    <tr>\n      <th>7</th>\n      <td>Enrolling by invitation</td>\n      <td>3682</td>\n    </tr>\n    <tr>\n      <th>8</th>\n      <td>Suspended</td>\n      <td>1598</td>\n    </tr>\n    <tr>\n      <th>9</th>\n      <td>No longer available</td>\n      <td>39</td>\n    </tr>\n    <tr>\n      <th>10</th>\n      <td>Approved for marketing</td>\n      <td>24</td>\n    </tr>\n    <tr>\n      <th>11</th>\n      <td>Available</td>\n      <td>5</td>\n    </tr>\n    <tr>\n      <th>12</th>\n      <td>Temporarily not available</td>\n      <td>1</td>\n    </tr>\n  </tbody>\n</table>\n</div>",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "textData": null,
       "type": "htmlSandbox"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "a30b0ee2-475b-4cbe-b688-241b433ea9f3",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "Status = list(status_list.toPandas()['Status'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "5190b0e9-f382-428a-aefe-4428967f42d3",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[56]: ['Completed',\n",
       " 'Recruiting',\n",
       " 'Unknown status',\n",
       " 'Terminated',\n",
       " 'Active, not recruiting',\n",
       " 'Not yet recruiting',\n",
       " 'Withdrawn',\n",
       " 'Enrolling by invitation',\n",
       " 'Suspended',\n",
       " 'No longer available',\n",
       " 'Approved for marketing',\n",
       " 'Available',\n",
       " 'Temporarily not available']"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[56]: ['Completed',\n 'Recruiting',\n 'Unknown status',\n 'Terminated',\n 'Active, not recruiting',\n 'Not yet recruiting',\n 'Withdrawn',\n 'Enrolling by invitation',\n 'Suspended',\n 'No longer available',\n 'Approved for marketing',\n 'Available',\n 'Temporarily not available']",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "Status"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "ecf3c580-f98a-48ff-8799-be1f69cac49e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "Frequency = list(status_list.toPandas()['count'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "ab637eae-c87d-4f66-9ea4-966911620e22",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[58]: [209749, 60950, 44608, 22285, 17848, 16499, 9973, 3682, 1598, 39, 24, 5, 1]"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[58]: [209749, 60950, 44608, 22285, 17848, 16499, 9973, 3682, 1598, 39, 24, 5, 1]",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "Frequency"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "7452129c-2cfe-451c-ac3f-8dd66e260743",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": [
    "my_dict = dict(zip(Status, Frequency))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "71935abd-ae24-4046-8e98-c83d2120257e",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "Out[60]: {'Completed': 209749,\n",
       " 'Recruiting': 60950,\n",
       " 'Unknown status': 44608,\n",
       " 'Terminated': 22285,\n",
       " 'Active, not recruiting': 17848,\n",
       " 'Not yet recruiting': 16499,\n",
       " 'Withdrawn': 9973,\n",
       " 'Enrolling by invitation': 3682,\n",
       " 'Suspended': 1598,\n",
       " 'No longer available': 39,\n",
       " 'Approved for marketing': 24,\n",
       " 'Available': 5,\n",
       " 'Temporarily not available': 1}"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "Out[60]: {'Completed': 209749,\n 'Recruiting': 60950,\n 'Unknown status': 44608,\n 'Terminated': 22285,\n 'Active, not recruiting': 17848,\n 'Not yet recruiting': 16499,\n 'Withdrawn': 9973,\n 'Enrolling by invitation': 3682,\n 'Suspended': 1598,\n 'No longer available': 39,\n 'Approved for marketing': 24,\n 'Available': 5,\n 'Temporarily not available': 1}",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "type": "ansi"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "my_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "b63f4549-29a7-4fca-a023-9e88214ad489",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "\n",
       "\n",
       "\n",
       "\n",
       "<!DOCTYPE html>\n",
       "<html lang=\"en\">\n",
       "  \n",
       "  <head>\n",
       "    \n",
       "      <meta charset=\"utf-8\">\n",
       "      <title>Status of Clinical Trials</title>\n",
       "      \n",
       "      \n",
       "        \n",
       "          \n",
       "        \n",
       "        \n",
       "          \n",
       "        <script type=\"text/javascript\" src=\"https://cdn.bokeh.org/bokeh/release/bokeh-2.4.2.min.js\"></script>\n",
       "        <script type=\"text/javascript\">\n",
       "            Bokeh.set_log_level(\"info\");\n",
       "        </script>\n",
       "        \n",
       "      \n",
       "      \n",
       "    \n",
       "  </head>\n",
       "  \n",
       "  \n",
       "  <body>\n",
       "    \n",
       "      \n",
       "        \n",
       "          \n",
       "          \n",
       "            \n",
       "              <div class=\"bk-root\" id=\"4273641a-70bb-41f1-8245-30a57a1b12d7\" data-root-id=\"1173\"></div>\n",
       "            \n",
       "          \n",
       "        \n",
       "      \n",
       "      \n",
       "        <script type=\"application/json\" id=\"1332\">\n",
       "          {\"972348d4-23a5-4bf9-a2b1-d7137f06ad02\":{\"defs\":[],\"roots\":{\"references\":[{\"attributes\":{},\"id\":\"1189\",\"type\":\"BasicTicker\"},{\"attributes\":{},\"id\":\"1206\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1206\"},\"group\":null,\"major_label_policy\":{\"id\":\"1207\"},\"ticker\":{\"id\":\"1189\"},\"visible\":false},\"id\":\"1188\",\"type\":\"LinearAxis\"},{\"attributes\":{\"end_angle\":{\"expr\":{\"id\":\"1196\"}},\"fill_alpha\":{\"value\":0.2},\"fill_color\":{\"field\":\"color\"},\"hatch_alpha\":{\"value\":0.2},\"line_alpha\":{\"value\":0.2},\"line_color\":{\"value\":\"white\"},\"radius\":{\"value\":0.4},\"start_angle\":{\"expr\":{\"id\":\"1195\"}},\"x\":{\"value\":0},\"y\":{\"value\":1}},\"id\":\"1201\",\"type\":\"Wedge\"},{\"attributes\":{\"coordinates\":null,\"group\":null,\"items\":[{\"id\":\"1214\"}]},\"id\":\"1213\",\"type\":\"Legend\"},{\"attributes\":{\"label\":{\"field\":\"Status\"},\"renderers\":[{\"id\":\"1202\"}]},\"id\":\"1214\",\"type\":\"LegendItem\"},{\"attributes\":{\"tools\":[{\"id\":\"1192\"}]},\"id\":\"1193\",\"type\":\"Toolbar\"},{\"attributes\":{\"axis\":{\"id\":\"1184\"},\"coordinates\":null,\"grid_line_color\":null,\"group\":null,\"ticker\":null},\"id\":\"1187\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1209\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{},\"id\":\"1211\",\"type\":\"UnionRenderers\"},{\"attributes\":{\"axis\":{\"id\":\"1188\"},\"coordinates\":null,\"dimension\":1,\"grid_line_color\":null,\"group\":null,\"ticker\":null},\"id\":\"1191\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1212\",\"type\":\"Selection\"},{\"attributes\":{},\"id\":\"1180\",\"type\":\"LinearScale\"},{\"attributes\":{\"end_angle\":{\"expr\":{\"id\":\"1196\"}},\"fill_alpha\":{\"value\":0.1},\"fill_color\":{\"field\":\"color\"},\"hatch_alpha\":{\"value\":0.1},\"line_alpha\":{\"value\":0.1},\"line_color\":{\"value\":\"white\"},\"radius\":{\"value\":0.4},\"start_angle\":{\"expr\":{\"id\":\"1195\"}},\"x\":{\"value\":0},\"y\":{\"value\":1}},\"id\":\"1200\",\"type\":\"Wedge\"},{\"attributes\":{\"end_angle\":{\"expr\":{\"id\":\"1196\"}},\"fill_color\":{\"field\":\"color\"},\"line_color\":{\"value\":\"white\"},\"radius\":{\"value\":0.4},\"start_angle\":{\"expr\":{\"id\":\"1195\"}},\"x\":{\"value\":0},\"y\":{\"value\":1}},\"id\":\"1199\",\"type\":\"Wedge\"},{\"attributes\":{\"source\":{\"id\":\"1197\"}},\"id\":\"1203\",\"type\":\"CDSView\"},{\"attributes\":{},\"id\":\"1210\",\"type\":\"AllLabels\"},{\"attributes\":{\"field\":\"angle\"},\"id\":\"1196\",\"type\":\"CumSum\"},{\"attributes\":{\"coordinates\":null,\"group\":null,\"text\":\"Pie Chart showing status of clinical trials\"},\"id\":\"1174\",\"type\":\"Title\"},{\"attributes\":{\"start\":-0.5},\"id\":\"1176\",\"type\":\"Range1d\"},{\"attributes\":{},\"id\":\"1178\",\"type\":\"DataRange1d\"},{\"attributes\":{\"below\":[{\"id\":\"1184\"}],\"center\":[{\"id\":\"1187\"},{\"id\":\"1191\"},{\"id\":\"1213\"}],\"height\":350,\"left\":[{\"id\":\"1188\"}],\"renderers\":[{\"id\":\"1202\"}],\"title\":{\"id\":\"1174\"},\"toolbar\":{\"id\":\"1193\"},\"toolbar_location\":null,\"x_range\":{\"id\":\"1176\"},\"x_scale\":{\"id\":\"1180\"},\"y_range\":{\"id\":\"1178\"},\"y_scale\":{\"id\":\"1182\"}},\"id\":\"1173\",\"subtype\":\"Figure\",\"type\":\"Plot\"},{\"attributes\":{\"callback\":null,\"tooltips\":[[\"Status\",\"@Status\"],[\"Count\",\"@value\"],[\"Percentage\",\"@percent{0.2f} %\"]]},\"id\":\"1192\",\"type\":\"HoverTool\"},{\"attributes\":{\"field\":\"angle\",\"include_zero\":true},\"id\":\"1195\",\"type\":\"CumSum\"},{\"attributes\":{},\"id\":\"1185\",\"type\":\"BasicTicker\"},{\"attributes\":{},\"id\":\"1182\",\"type\":\"LinearScale\"},{\"attributes\":{\"coordinates\":null,\"data_source\":{\"id\":\"1197\"},\"glyph\":{\"id\":\"1199\"},\"group\":null,\"hover_glyph\":null,\"muted_glyph\":{\"id\":\"1201\"},\"nonselection_glyph\":{\"id\":\"1200\"},\"view\":{\"id\":\"1203\"}},\"id\":\"1202\",\"type\":\"GlyphRenderer\"},{\"attributes\":{},\"id\":\"1207\",\"type\":\"AllLabels\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1209\"},\"group\":null,\"major_label_policy\":{\"id\":\"1210\"},\"ticker\":{\"id\":\"1185\"},\"visible\":false},\"id\":\"1184\",\"type\":\"LinearAxis\"},{\"attributes\":{\"data\":{\"Status\":[\"Completed\",\"Recruiting\",\"Unknown status\",\"Terminated\",\"Active, not recruiting\",\"Not yet recruiting\",\"Withdrawn\",\"Enrolling by invitation\",\"Suspended\",\"No longer available\",\"Approved for marketing\",\"Available\",\"Temporarily not available\"],\"angle\":{\"__ndarray__\":\"ikrNzpE5C0CGbvRhBaXvPzXTFb72KOc/XPzgxOkj1z8AKKBwcojSP8KR+FLZIdE/EE1C7iW2xD/4NZ8sJZauP0pDH/mdjJo/TlPQDv+7RD9Ntewl64Q5P8BBRUoZRBU/M86dbkcD8T4=\",\"dtype\":\"float64\",\"order\":\"little\",\"shape\":[13]},\"color\":[\"#3182bd\",\"#6baed6\",\"#9ecae1\",\"#c6dbef\",\"#e6550d\",\"#fd8d3c\",\"#fdae6b\",\"#fdd0a2\",\"#31a354\",\"#74c476\",\"#a1d99b\",\"#c7e9c0\",\"#756bb1\"],\"index\":[0,1,2,3,4,5,6,7,8,9,10,11,12],\"percent\":{\"__ndarray__\":\"WiSvUMIUS0DqxIgQPHovQIcRWj6mCSdAuP9cGaAEF0Cf3PuDY28SQHDsy0GvChFAkNuP8SSaBEC4kOIaymzuP+bb9lO4aNo/f07dKfafhD/YESQMamJ5PzNkc19YJ1U/kLbCskbsMD8=\",\"dtype\":\"float64\",\"order\":\"little\",\"shape\":[13]},\"value\":[209749,60950,44608,22285,17848,16499,9973,3682,1598,39,24,5,1]},\"selected\":{\"id\":\"1212\"},\"selection_policy\":{\"id\":\"1211\"}},\"id\":\"1197\",\"type\":\"ColumnDataSource\"}],\"root_ids\":[\"1173\"]},\"title\":\"Bokeh Application\",\"version\":\"2.4.2\"}}\n",
       "        </script>\n",
       "        <script type=\"text/javascript\">\n",
       "          (function() {\n",
       "            const fn = function() {\n",
       "              Bokeh.safely(function() {\n",
       "                (function(root) {\n",
       "                  function embed_document(root) {\n",
       "                    \n",
       "                  const docs_json = document.getElementById('1332').textContent;\n",
       "                  const render_items = [{\"docid\":\"972348d4-23a5-4bf9-a2b1-d7137f06ad02\",\"root_ids\":[\"1173\"],\"roots\":{\"1173\":\"4273641a-70bb-41f1-8245-30a57a1b12d7\"}}];\n",
       "                  root.Bokeh.embed.embed_items(docs_json, render_items);\n",
       "                \n",
       "                  }\n",
       "                  if (root.Bokeh !== undefined) {\n",
       "                    embed_document(root);\n",
       "                  } else {\n",
       "                    let attempts = 0;\n",
       "                    const timer = setInterval(function(root) {\n",
       "                      if (root.Bokeh !== undefined) {\n",
       "                        clearInterval(timer);\n",
       "                        embed_document(root);\n",
       "                      } else {\n",
       "                        attempts++;\n",
       "                        if (attempts > 100) {\n",
       "                          clearInterval(timer);\n",
       "                          console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n",
       "                        }\n",
       "                      }\n",
       "                    }, 10, root)\n",
       "                  }\n",
       "                })(window);\n",
       "              });\n",
       "            };\n",
       "            if (document.readyState != \"loading\") fn();\n",
       "            else document.addEventListener(\"DOMContentLoaded\", fn);\n",
       "          })();\n",
       "        </script>\n",
       "    \n",
       "  </body>\n",
       "  \n",
       "</html>"
      ]
     },
     "metadata": {
      "application/vnd.databricks.v1+output": {
       "addedWidgets": {},
       "arguments": {},
       "data": "\n\n\n\n<!DOCTYPE html>\n<html lang=\"en\">\n  \n  <head>\n    \n      <meta charset=\"utf-8\">\n      <title>Status of Clinical Trials</title>\n      \n      \n        \n          \n        \n        \n          \n        <script type=\"text/javascript\" src=\"https://cdn.bokeh.org/bokeh/release/bokeh-2.4.2.min.js\"></script>\n        <script type=\"text/javascript\">\n            Bokeh.set_log_level(\"info\");\n        </script>\n        \n      \n      \n    \n  </head>\n  \n  \n  <body>\n    \n      \n        \n          \n          \n            \n              <div class=\"bk-root\" id=\"4273641a-70bb-41f1-8245-30a57a1b12d7\" data-root-id=\"1173\"></div>\n            \n          \n        \n      \n      \n        <script type=\"application/json\" id=\"1332\">\n          {\"972348d4-23a5-4bf9-a2b1-d7137f06ad02\":{\"defs\":[],\"roots\":{\"references\":[{\"attributes\":{},\"id\":\"1189\",\"type\":\"BasicTicker\"},{\"attributes\":{},\"id\":\"1206\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1206\"},\"group\":null,\"major_label_policy\":{\"id\":\"1207\"},\"ticker\":{\"id\":\"1189\"},\"visible\":false},\"id\":\"1188\",\"type\":\"LinearAxis\"},{\"attributes\":{\"end_angle\":{\"expr\":{\"id\":\"1196\"}},\"fill_alpha\":{\"value\":0.2},\"fill_color\":{\"field\":\"color\"},\"hatch_alpha\":{\"value\":0.2},\"line_alpha\":{\"value\":0.2},\"line_color\":{\"value\":\"white\"},\"radius\":{\"value\":0.4},\"start_angle\":{\"expr\":{\"id\":\"1195\"}},\"x\":{\"value\":0},\"y\":{\"value\":1}},\"id\":\"1201\",\"type\":\"Wedge\"},{\"attributes\":{\"coordinates\":null,\"group\":null,\"items\":[{\"id\":\"1214\"}]},\"id\":\"1213\",\"type\":\"Legend\"},{\"attributes\":{\"label\":{\"field\":\"Status\"},\"renderers\":[{\"id\":\"1202\"}]},\"id\":\"1214\",\"type\":\"LegendItem\"},{\"attributes\":{\"tools\":[{\"id\":\"1192\"}]},\"id\":\"1193\",\"type\":\"Toolbar\"},{\"attributes\":{\"axis\":{\"id\":\"1184\"},\"coordinates\":null,\"grid_line_color\":null,\"group\":null,\"ticker\":null},\"id\":\"1187\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1209\",\"type\":\"BasicTickFormatter\"},{\"attributes\":{},\"id\":\"1211\",\"type\":\"UnionRenderers\"},{\"attributes\":{\"axis\":{\"id\":\"1188\"},\"coordinates\":null,\"dimension\":1,\"grid_line_color\":null,\"group\":null,\"ticker\":null},\"id\":\"1191\",\"type\":\"Grid\"},{\"attributes\":{},\"id\":\"1212\",\"type\":\"Selection\"},{\"attributes\":{},\"id\":\"1180\",\"type\":\"LinearScale\"},{\"attributes\":{\"end_angle\":{\"expr\":{\"id\":\"1196\"}},\"fill_alpha\":{\"value\":0.1},\"fill_color\":{\"field\":\"color\"},\"hatch_alpha\":{\"value\":0.1},\"line_alpha\":{\"value\":0.1},\"line_color\":{\"value\":\"white\"},\"radius\":{\"value\":0.4},\"start_angle\":{\"expr\":{\"id\":\"1195\"}},\"x\":{\"value\":0},\"y\":{\"value\":1}},\"id\":\"1200\",\"type\":\"Wedge\"},{\"attributes\":{\"end_angle\":{\"expr\":{\"id\":\"1196\"}},\"fill_color\":{\"field\":\"color\"},\"line_color\":{\"value\":\"white\"},\"radius\":{\"value\":0.4},\"start_angle\":{\"expr\":{\"id\":\"1195\"}},\"x\":{\"value\":0},\"y\":{\"value\":1}},\"id\":\"1199\",\"type\":\"Wedge\"},{\"attributes\":{\"source\":{\"id\":\"1197\"}},\"id\":\"1203\",\"type\":\"CDSView\"},{\"attributes\":{},\"id\":\"1210\",\"type\":\"AllLabels\"},{\"attributes\":{\"field\":\"angle\"},\"id\":\"1196\",\"type\":\"CumSum\"},{\"attributes\":{\"coordinates\":null,\"group\":null,\"text\":\"Pie Chart showing status of clinical trials\"},\"id\":\"1174\",\"type\":\"Title\"},{\"attributes\":{\"start\":-0.5},\"id\":\"1176\",\"type\":\"Range1d\"},{\"attributes\":{},\"id\":\"1178\",\"type\":\"DataRange1d\"},{\"attributes\":{\"below\":[{\"id\":\"1184\"}],\"center\":[{\"id\":\"1187\"},{\"id\":\"1191\"},{\"id\":\"1213\"}],\"height\":350,\"left\":[{\"id\":\"1188\"}],\"renderers\":[{\"id\":\"1202\"}],\"title\":{\"id\":\"1174\"},\"toolbar\":{\"id\":\"1193\"},\"toolbar_location\":null,\"x_range\":{\"id\":\"1176\"},\"x_scale\":{\"id\":\"1180\"},\"y_range\":{\"id\":\"1178\"},\"y_scale\":{\"id\":\"1182\"}},\"id\":\"1173\",\"subtype\":\"Figure\",\"type\":\"Plot\"},{\"attributes\":{\"callback\":null,\"tooltips\":[[\"Status\",\"@Status\"],[\"Count\",\"@value\"],[\"Percentage\",\"@percent{0.2f} %\"]]},\"id\":\"1192\",\"type\":\"HoverTool\"},{\"attributes\":{\"field\":\"angle\",\"include_zero\":true},\"id\":\"1195\",\"type\":\"CumSum\"},{\"attributes\":{},\"id\":\"1185\",\"type\":\"BasicTicker\"},{\"attributes\":{},\"id\":\"1182\",\"type\":\"LinearScale\"},{\"attributes\":{\"coordinates\":null,\"data_source\":{\"id\":\"1197\"},\"glyph\":{\"id\":\"1199\"},\"group\":null,\"hover_glyph\":null,\"muted_glyph\":{\"id\":\"1201\"},\"nonselection_glyph\":{\"id\":\"1200\"},\"view\":{\"id\":\"1203\"}},\"id\":\"1202\",\"type\":\"GlyphRenderer\"},{\"attributes\":{},\"id\":\"1207\",\"type\":\"AllLabels\"},{\"attributes\":{\"coordinates\":null,\"formatter\":{\"id\":\"1209\"},\"group\":null,\"major_label_policy\":{\"id\":\"1210\"},\"ticker\":{\"id\":\"1185\"},\"visible\":false},\"id\":\"1184\",\"type\":\"LinearAxis\"},{\"attributes\":{\"data\":{\"Status\":[\"Completed\",\"Recruiting\",\"Unknown status\",\"Terminated\",\"Active, not recruiting\",\"Not yet recruiting\",\"Withdrawn\",\"Enrolling by invitation\",\"Suspended\",\"No longer available\",\"Approved for marketing\",\"Available\",\"Temporarily not available\"],\"angle\":{\"__ndarray__\":\"ikrNzpE5C0CGbvRhBaXvPzXTFb72KOc/XPzgxOkj1z8AKKBwcojSP8KR+FLZIdE/EE1C7iW2xD/4NZ8sJZauP0pDH/mdjJo/TlPQDv+7RD9Ntewl64Q5P8BBRUoZRBU/M86dbkcD8T4=\",\"dtype\":\"float64\",\"order\":\"little\",\"shape\":[13]},\"color\":[\"#3182bd\",\"#6baed6\",\"#9ecae1\",\"#c6dbef\",\"#e6550d\",\"#fd8d3c\",\"#fdae6b\",\"#fdd0a2\",\"#31a354\",\"#74c476\",\"#a1d99b\",\"#c7e9c0\",\"#756bb1\"],\"index\":[0,1,2,3,4,5,6,7,8,9,10,11,12],\"percent\":{\"__ndarray__\":\"WiSvUMIUS0DqxIgQPHovQIcRWj6mCSdAuP9cGaAEF0Cf3PuDY28SQHDsy0GvChFAkNuP8SSaBEC4kOIaymzuP+bb9lO4aNo/f07dKfafhD/YESQMamJ5PzNkc19YJ1U/kLbCskbsMD8=\",\"dtype\":\"float64\",\"order\":\"little\",\"shape\":[13]},\"value\":[209749,60950,44608,22285,17848,16499,9973,3682,1598,39,24,5,1]},\"selected\":{\"id\":\"1212\"},\"selection_policy\":{\"id\":\"1211\"}},\"id\":\"1197\",\"type\":\"ColumnDataSource\"}],\"root_ids\":[\"1173\"]},\"title\":\"Bokeh Application\",\"version\":\"2.4.2\"}}\n        </script>\n        <script type=\"text/javascript\">\n          (function() {\n            const fn = function() {\n              Bokeh.safely(function() {\n                (function(root) {\n                  function embed_document(root) {\n                    \n                  const docs_json = document.getElementById('1332').textContent;\n                  const render_items = [{\"docid\":\"972348d4-23a5-4bf9-a2b1-d7137f06ad02\",\"root_ids\":[\"1173\"],\"roots\":{\"1173\":\"4273641a-70bb-41f1-8245-30a57a1b12d7\"}}];\n                  root.Bokeh.embed.embed_items(docs_json, render_items);\n                \n                  }\n                  if (root.Bokeh !== undefined) {\n                    embed_document(root);\n                  } else {\n                    let attempts = 0;\n                    const timer = setInterval(function(root) {\n                      if (root.Bokeh !== undefined) {\n                        clearInterval(timer);\n                        embed_document(root);\n                      } else {\n                        attempts++;\n                        if (attempts > 100) {\n                          clearInterval(timer);\n                          console.log(\"Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing\");\n                        }\n                      }\n                    }, 10, root)\n                  }\n                })(window);\n              });\n            };\n            if (document.readyState != \"loading\") fn();\n            else document.addEventListener(\"DOMContentLoaded\", fn);\n          })();\n        </script>\n    \n  </body>\n  \n</html>",
       "datasetInfos": [],
       "metadata": {},
       "removedWidgets": [],
       "textData": null,
       "type": "htmlSandbox"
      }
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "from math import pi\n",
    "\n",
    "import pandas as pd\n",
    "\n",
    "from bokeh.palettes import Category20c\n",
    "from bokeh.plotting import figure, show\n",
    "from bokeh.transform import cumsum\n",
    "\n",
    "\n",
    "data = pd.Series(my_dict).reset_index(name='value').rename(columns={'index': 'Status'})\n",
    "data['angle'] = data['value']/data['value'].sum() * 2*pi\n",
    "data['color'] = Category20c[len(my_dict)]\n",
    "data['percent'] = data['value'] / sum(my_dict.values()) * 100\n",
    "\n",
    "p = figure(height=350, title=\"Pie Chart showing status of clinical trials\", toolbar_location=None,\n",
    "           tools=\"hover\", tooltips=[(\"Status\" ,\"@Status\") ,(\"Count\" , \"@value\") , (\"Percentage\" , \"@percent{0.2f} %\")], x_range=(-0.5, 1.0))\n",
    "\n",
    "p.wedge(x=0, y=1, radius=0.4,\n",
    "        start_angle=cumsum('angle', include_zero=True), end_angle=cumsum('angle'),\n",
    "        line_color=\"white\", fill_color='color', legend_field='Status', source=data)\n",
    "\n",
    "p.axis.axis_label = None\n",
    "p.axis.visible = False\n",
    "p.grid.grid_line_color = None\n",
    "\n",
    "html = file_html(p, CDN, \"Status of Clinical Trials\")\n",
    "displayHTML(html)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 0,
   "metadata": {
    "application/vnd.databricks.v1+cell": {
     "inputWidgets": {},
     "nuid": "cc8fbb26-cc6f-45f1-86a2-f8b3ded4451d",
     "showTitle": false,
     "title": ""
    }
   },
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "application/vnd.databricks.v1+notebook": {
   "dashboards": [],
   "language": "python",
   "notebookMetadata": {
    "pythonIndentUnit": 4
   },
   "notebookName": "Dataframe Implementation",
   "notebookOrigID": 1119975640154742,
   "widgets": {}
  },
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.9.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
